<?xml version="1.0" encoding="iso-8859-1" ?>
<PASBIO>
    <framesest>
        <predicate lemma="disrupt">
            <roleset id="Disrupt.01" name="" wordnet="1, 2">
                <roles>
                    <role n="0" descr=" agent" />
                    <role n="1" descr=" entity disrupted &#x0A;" />
                    <role n="R" descr=" results/consequences&#x0A;" />
                </roles>
                <example src="EGRAM" no="0">
                    <text>Arg99 and Arg253 can disrupt with the keto groups of the base pair GO and C (blue) on both sides of the DNA dsD and disrupt hydrogen bonds in the model.</text>
                    <arg n="0">Arg99 and Arg253</arg>
                    <arg n="1">hydrogen bonds in the model</arg>
                </example>
                <example src="EGRAM" no="1">
                    <text>Arg99 and Arg253 that interact with the keto groups of the base pair GO and C (blue) on either side of the dsDNA can disrupt hydrogen bonds in the model.</text>
                    <arg n="0">Arg99 and Arg253</arg>
                    <arg n="1">hydrogen bonds in the model</arg>
                </example>
                <example src="EGRAM" no="2">
                    <text>Arr99 and Arr253 can disrupt with the base groups ceto and C (blue) on both sides of the dsDNA DNA and interrupt hydrogen bond pairing in the model.</text>
                    <arg n="0">Arr99 and Arr253</arg>
                    <arg n="1">hydrogen bond pairing in the model</arg>
                </example>
                <example src="EGRAM" no="3">
                    <text>Arr99 and Arr253 that interacts with the keto and C group pair (blue) on both sides of the dsDNA can disrupt the hydrogen bonding pairing in the model.</text>
                    <arg n="0">Arr99 and Arr253</arg>
                    <arg n="1">the hydrogen bonding pairing in the model</arg>
                </example>
                <example src="EGRAM" no="4">
                    <text>In splicing sequencer: (GAR)n-(GAR)n has been disrupted by mutation 415G4, resulting in R (exon 5 omitting ).</text>
                    <arg n="0">mutation 415G4</arg>
                    <arg n="1">splicing sequencer: (GAR)n-(GAR)n</arg>
                </example>
                <example src="EGRAM" no="5">
                    <text>It has been shown that mutation 415G4 disrupt an pulling enhancement sequence: (GAR)n-(GAR)n resulting in R (exon 5 is omitted).</text>
                    <arg n="0">mutation 415G4</arg>
                    <arg n="1">pulling enhancement sequence: (GAR)n-(GAR)n</arg>
                </example>
                <example src="EGRAM" no="6">
                    <text>It has been shown that this suppression interrupts consensus signal 5 and disrupt to exon is omitted.</text>
                    <arg n="0">this suppression</arg>
                    <arg n="1">consensus signal 5</arg>
                    <arg n="R">exon is omitted</arg>
                </example>
                <example src="EGRAM" no="7">
                    <text>It is important to note that blocking the expression MEKK1 or MEKK2 is capable of disrupt the overall integrity of the MAPK route regulation.</text>
                    <arg n="0">blocking the expression MEKK1 or MEKK2</arg>
                    <arg n="1">the overall integrity of the MAPK route regulation</arg>
                </example>
                <example src="EGRAM" no="8">
                    <text>It is important to note that the findings disrupt that retired from the MEKK1 or MEKK2 expression has not interrupts the overall integrity of the MAPK pathway regulation.</text>
                    <arg n="0">retired from the MEKK1 or MEKK2 expression</arg>
                    <arg n="1">the overall integrity of the MAPK pathway regulation</arg>
                    <arg n="M-NEG">not</arg>
                </example>
                <example src="EGRAM" no="9">
                    <text>It is important to note that the findings show that retired from the MEKK1 or MEKK2 expression will disrupt no the overall integrity of the MAPK pathway regulation.</text>
                    <arg n="0">retired from the MEKK1 or MEKK2 expression</arg>
                    <arg n="1">the overall integrity of the MAPK pathway regulation</arg>
                    <arg n="M-NEG">no</arg>
                </example>
                <example src="EGRAM" no="10">
                    <text>It is important to note that the knockout of the MEKK1 or MEKK2 expression disrupt the overall integrity of the MAPK pathway regulation.</text>
                    <arg n="0">the knockout of the MEKK1 or MEKK2 expression</arg>
                    <arg n="1">the overall integrity of the MAPK pathway regulation</arg>
                </example>
                <example src="EGRAM" no="11">
                    <text>It is important to point out that knockout of the expression MEKK1 or MEKK2 disrupt the overall integrity of MAPK pathway regulation.</text>
                    <arg n="0">knockout of the expression MEKK1 or MEKK2</arg>
                    <arg n="1">the overall integrity of MAPK pathway regulation</arg>
                </example>
                <example src="EGRAM" no="12">
                    <text>It is important to stress that knockout of the expression MEKK1 or MEKK2 could disrupt with the overall integrity of MAPK pathway regulation.</text>
                    <arg n="0">knockout of the expression MEKK1 or MEKK2</arg>
                    <arg n="1">the overall integrity of MAPK pathway regulation</arg>
                </example>
                <example src="EGRAM" no="13">
                    <text>It is important to stress that knockout of the expression MEKK1 or MEKK2 has the no that disrupt the overall integrity of MAPK pathway regulation.</text>
                    <arg n="0">knockout of the expression MEKK1 or MEKK2</arg>
                    <arg n="1">the overall integrity of MAPK pathway regulation</arg>
                    <arg n="M-NEG">no</arg>
                </example>
                <example src="EGRAM" no="14">
                    <text>It is important to stress that knockout of the expression MEKK1 or MEKK2 is able to disrupt the overall integrity of MAPK pathway regulation.</text>
                    <arg n="0">knockout of the expression MEKK1 or MEKK2</arg>
                    <arg n="1">the overall integrity of MAPK pathway regulation</arg>
                </example>
                <example src="EGRAM" no="15">
                    <text>It is important to stress that the findings show that his retired expression MEKK1 or MEKK2 disrupt the expression no the overall integrity of MAPK pathway regulation.</text>
                    <arg n="0">his retired expression MEKK1 or MEKK2</arg>
                    <arg n="1">the overall integrity of MAPK pathway regulation</arg>
                    <arg n="M-NEG">no</arg>
                </example>
                <example src="EGRAM" no="16">
                    <text>It is important to stress that the findings show that if retired from the expression MEKK1 or MEKK2 could disrupt the overall integrity of MAPK pathway regulation.</text>
                    <arg n="0">if retired from the expression MEKK1 or MEKK2</arg>
                    <arg n="1">the overall integrity of MAPK pathway regulation</arg>
                </example>
                <example src="EGRAM" no="17">
                    <text>Multations in p53 are able to disrupt responses of checkpoints to DNA damage and results in the potential for genome destabilization.</text>
                    <arg n="0">Multations in p53</arg>
                    <arg n="1">responses of checkpoints to DNA damage</arg>
                    <arg n="R">the potential for genome destabilization</arg>
                </example>
                <example src="EGRAM" no="18">
                    <text>Multations in p53 disrupted posts of checkpoints to DNA damage and resulted in the potential for genome destabilization.</text>
                    <arg n="0">Multations in p53</arg>
                    <arg n="1">posts of checkpoints to DNA damage</arg>
                    <arg n="R">the potential for genome destabilization</arg>
                </example>
                <example src="EGRAM" no="19">
                    <text>Mutation 415G4 broke a sequence of potent spike: (GAR)n-(GAR)n disrupted in R (exon 5 spike).</text>
                    <arg n="0">Mutation 415G4</arg>
                    <arg n="1">potent spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="EGRAM" no="20">
                    <text>Mutations in p53 disrupting responses of checkpoints to DNA damage can result in the potential for genome destabilization.</text>
                    <arg n="0">Mutations in p53</arg>
                    <arg n="1">responses of checkpoints to DNA damage</arg>
                    <arg n="R">the potential for genome destabilization</arg>
                </example>
                <example src="EGRAM" no="21">
                    <text>Mutations in p53 have perturbed responses of checkpoints to DNA damage and disrupted in the potential for genome destabilization.</text>
                    <arg n="0">Mutations in p53</arg>
                    <arg n="1">responses of checkpoints to DNA damage</arg>
                    <arg n="R">the potential for genome destabilization</arg>
                </example>
                <example src="EGRAM" no="22">
                    <text>Quantitative electrophysiology of a single unit revealed that alcohol consumption exposure interrupts ocular dominance plasticity by disrupts robust visual responses.</text>
                    <arg n="0">alcohol consumption exposure</arg>
                    <arg n="1">ocular dominance plasticity</arg>
                </example>
                <example src="EGRAM" no="23">
                    <text>Quantitative electrophysiology of a single unit revealed that alcohol exposure has been able to disrupt ocular dominance plasticity preserving robust visual responses.</text>
                    <arg n="0">alcohol exposure</arg>
                    <arg n="1">ocular dominance plasticity</arg>
                </example>
                <example src="EGRAM" no="24">
                    <text>Quantitative electrophysiology of a single unit revealed that alcohol exposure has been shown to disrupt ocular dominance plasticity while preserving robust visual responses.</text>
                    <arg n="0">alcohol exposure</arg>
                    <arg n="1">ocular dominance plasticity</arg>
                </example>
                <example src="EGRAM" no="25">
                    <text>Quantitative electrophysiology of a single unit revealed that alcohol exposure has disrupted ocular dominance plasticity while preserving robust visual responses.</text>
                    <arg n="0">alcohol exposure</arg>
                    <arg n="1">ocular dominance plasticity</arg>
                </example>
                <example src="EGRAM" no="26">
                    <text>Quantitative electrophysiology of a single unit revealed that alcohol exposure interrupts ocular dominance plasticity while disrupts robust visual responses.</text>
                    <arg n="0">alcohol exposure</arg>
                    <arg n="1">ocular dominance plasticity</arg>
                </example>
                <example src="EGRAM" no="27">
                    <text>Quantitative electrophysiology of a single unit revealed that alcohol exposure is able to detach ocular domain plasticity disrupt robust visual responses.</text>
                    <arg n="0">alcohol exposure</arg>
                    <arg n="1">ocular domain plasticity</arg>
                </example>
                <example src="EGRAM" no="28">
                    <text>Quantitative electrophysiology of a single unit revealed that exposure to alcohol consumption disrupted plasticity of eye dominance while retaining robust visual responses.</text>
                    <arg n="0">exposure to alcohol consumption</arg>
                    <arg n="1">plasticity of eye dominance</arg>
                </example>
                <example src="EGRAM" no="29">
                    <text>Quantitative electrophysiology of a single unit revealed that exposure to alcohol consumption is capable of disrupt ocular domain plasticity by preserving robust visual responses.</text>
                    <arg n="0">exposure to alcohol consumption</arg>
                    <arg n="1">ocular domain plasticity</arg>
                </example>
                <example src="EGRAM" no="30">
                    <text>R142X, located in a purine-rich segment in nt 62/116 of exon 5, disrupting R (exon emptied), possibly through the breakup of a splicing enhancer.</text>
                    <arg n="0">R142X</arg>
                    <arg n="1">a splicing enhancer</arg>
                </example>
                <example src="EGRAM" no="31">
                    <text>R142X, located in a purine-rich segment in nt 62/116 of exon 5, disrupting R (exon emptying), possibly through the rupture of a splicing enhancer.</text>
                    <arg n="0">R142X</arg>
                    <arg n="1">a splicing enhancer</arg>
                </example>
                <example src="EGRAM" no="32">
                    <text>R142X, located in a purine-rich segment in nt 62/116 of exon 5, may disrupt a splicing power to cause R (omitting exon).</text>
                    <arg n="0">R142X</arg>
                    <arg n="1">a splicing power</arg>
                </example>
                <example src="EGRAM" no="33">
                    <text>R142X, located within a purine-rich segment on nt 62/116 of exon 5, can disrupt a splicing power to cause R (by omitting exon).</text>
                    <arg n="0">R142X</arg>
                    <arg n="1">a splicing power</arg>
                </example>
                <example src="EGRAM" no="34">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (Gly188---Glu mutation being able to disrupt one site Ava II, the Arg243----His mutation, one site Hha I and the Asp250----Asn mutation, one site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients</text>
                    <arg n="0">Gly188---Glu mutation</arg>
                    <arg n="1">one site Ava II</arg>
                </example>
                <example src="EGRAM" no="35">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (Gly188---Glu mutation that can disrupt a site Ava II, the Arg243----His mutation, a site Hha I and the Asp250----Asn mutation, a site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients were indeed com</text>
                    <arg n="0">Gly188---Glu mutation</arg>
                    <arg n="1">a site Ava II</arg>
                </example>
                <example src="EGRAM" no="36">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (Gly188---Glu mutation that disrupted a site Ava II, the Arg243----His mutation, a site Hha I and the Asp250----Asn mutation, a site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients were indeed composit</text>
                    <arg n="0">Gly188---Glu mutation</arg>
                    <arg n="1">a site Ava II</arg>
                </example>
                <example src="EGRAM" no="37">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (Gly188---Glu mutation with A1 rupture (one site Ava II), the Arg243----His mutation, one site Hha I and the Asp250----Asn mutation, one site Taq I) and hybridization of allele-specific oligonucleotides disrupted that the patients were indeed com</text>
                    <arg n="0">Gly188---Glu mutation</arg>
                </example>
                <example src="EGRAM" no="38">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (the Gly188--Glu mutation after disrupted an Ava II site, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">the Gly188--Glu mutation</arg>
                    <arg n="1">an Ava II site</arg>
                </example>
                <example src="EGRAM" no="39">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (the Gly188--Glu mutation being able to disrupt an Ava II site, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">the Gly188--Glu mutation</arg>
                    <arg n="1">an Ava II site</arg>
                </example>
                <example src="EGRAM" no="40">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (the Gly188--Glu mutation that can disrupt an Ava II site, the Arg243--His mutation, a Hha I site, and the Asp250---Asn mutation, a Taq I site), and the allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">the Gly188--Glu mutation</arg>
                    <arg n="1">an Ava II site</arg>
                </example>
                <example src="EGRAM" no="41">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (the Gly188--Glu mutation that have disrupted an Ava II site, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">the Gly188--Glu mutation</arg>
                    <arg n="1">an Ava II site</arg>
                </example>
                <example src="EGRAM" no="42">
                    <text>The 415G4 mutation disrupts a sequence of powerers spike: (GAR)n-(GAR)n resulting in R (exon 5 spike).</text>
                    <arg n="0">The 415G4 mutation</arg>
                    <arg n="1">powerers spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="EGRAM" no="43">
                    <text>The 415G4 mutation is able to disrupt a sequence of enhancer spike: (GAR)n-(GAR)n resulting in R (exon 5 spike).</text>
                    <arg n="0">The 415G4 mutation</arg>
                    <arg n="1">enhancer spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="EGRAM" no="44">
                    <text>The homozygous mutation that disrupted spacing was identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">homozygous mutation</arg>
                    <arg n="1">spacing</arg>
                </example>
                <example src="EGRAM" no="45">
                    <text>The mutation 415G4 disrupts a sequence of potent spike: (GAR)n-(GAR)n resulting in R (exon 5 spike).</text>
                    <arg n="0">The mutation 415G4</arg>
                    <arg n="1">potent spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="EGRAM" no="46">
                    <text>The mutation 415G4 is able to disrupt a sequence of enhancement brush: (GAR)n-(GAR)n resulting in R (exon 5 padding).</text>
                    <arg n="0">The mutation 415G4</arg>
                    <arg n="1">enhancement brush: (GAR)n-(GAR)n</arg>
                </example>
                <example src="EGRAM" no="47">
                    <text>The reason for the zinc finger, which specifically recognizes the GO:C pair, is firmly fixed with respect to the C-terminal domain by the hydrogen bonding network, so it would be found that the Lys147Ala substitution would perturb the interaction , disrupt in a drastic decrease of activity against GO:C substrates.</text>
                    <arg n="0">the Lys147Ala substitution</arg>
                    <arg n="1">the interaction</arg>
                    <arg n="R">a drastic decrease of activity against GO:C substrates</arg>
                </example>
                <example src="EGRAM" no="48">
                    <text>The reason for the zinc finger, which specifically recognizes the GO:C pair, is firmly fixed with respect to the C-terminal domain for the hydrogen bonding network, so that the Lys147Ala substitution has the ability to disrupt the interaction, resulting in a drastic decrease in activity against GO:C substrates.</text>
                    <arg n="0">the Lys147Ala substitution</arg>
                    <arg n="1">the interaction</arg>
                    <arg n="R">a drastic decrease in activity against GO:C substrates</arg>
                </example>
                <example src="EGRAM" no="49">
                    <text>The sequence of amplified fragments of the cloned polymerase chain reaction of the AMH gene revealed a 14-bp deletion in the second exon of the maternal allele; this deletion was shown to disrupt the open reading structure.</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">the open reading structure</arg>
                </example>
                <example src="EGRAM" no="50">
                    <text>The sequence of the cloned polymerase chain reaction amplified fragments of the AMH gene revealed a deletion of 14-bp in the second exon of the maternal allele; this deletion is able to disrupt the open reading structure.</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">the open reading structure</arg>
                </example>
                <example src="EGRAM" no="51">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene disrupted a 14 bp deletion in the second exon of the maternal allele; this deletion broke the open reading structure.</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">the open reading structure</arg>
                </example>
                <example src="EGRAM" no="52">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; this deletion disrupts the open reading frame.</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">the open reading frame</arg>
                </example>
                <example src="EGRAM" no="53">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; this deletion has been shown to disrupt the open reading frame.</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">the open reading frame</arg>
                </example>
                <example src="EGRAM" no="54">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; this deletion has disrupted the open reading frame.</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">the open reading frame</arg>
                </example>
                <example src="EGRAM" no="55">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; this deletion may have disrupted the open reading frame.</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">the open reading frame</arg>
                </example>
                <example src="EGRAM" no="56">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; this deletion disrupts the open reading structure.</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">the open reading structure</arg>
                </example>
                <example src="EGRAM" no="57">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; this deletion is able to disrupt the open reading structure.</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">the open reading structure</arg>
                </example>
                <example src="EGRAM" no="58">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; this deletion may have disrupted open reading frame.</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">open reading frame</arg>
                </example>
                <example src="EGRAM" no="59">
                    <text>The treatment of systemic inflammatory response to CPB is also confused by the fact that inhibition of inflammation has been disrupting protective physiological responses or resulting in immunosuppression.</text>
                    <arg n="0">inhibition of inflammation</arg>
                    <arg n="1">protective physiological responses</arg>
                </example>
                <example src="EGRAM" no="60">
                    <text>The treatment of systemic inflammatory response to CPB is also confused by the fact that inhibition of inflammation has been shown to disrupt protective physiological responses or to produce immunosuppression.</text>
                    <arg n="0">inhibition of inflammation</arg>
                    <arg n="1">protective physiological responses</arg>
                </example>
                <example src="EGRAM" no="61">
                    <text>The treatment of the systemic inflammatory response to CPB is also confused by the fact that inhibition of inflammation has deregulated physiological protective response or disrupting in immunosuppression.</text>
                    <arg n="0">inhibition of inflammation</arg>
                    <arg n="1">physiological protective response</arg>
                </example>
                <example src="EGRAM" no="62">
                    <text>The zinc digit motif, which specifically recognizes the GO:C pair, is firmly fixed with respect to the C-terminal domain by the hydrogen bonding network, so that the Lys147Ala substitution would perturb the interaction, disrupt in a drastic decrease in activity against GO:C substrates.</text>
                    <arg n="0">the Lys147Ala substitution</arg>
                    <arg n="1">the interaction</arg>
                    <arg n="R">a drastic decrease in activity against GO:C substrates</arg>
                </example>
                <example src="EGRAM" no="63">
                    <text>The zinc digit motif, which specifically recognizes the GO:C pair, is firmly fixed with respect to the C-terminal domain by the hydrogen bonding network, so the Lys147Ala substitution has shown that it perturbs the interaction , disrupt in a drastic decrease in activity against GO:C substrates.</text>
                    <arg n="0">the Lys147Ala substitution</arg>
                    <arg n="1">the interaction</arg>
                    <arg n="R">a drastic decrease in activity against GO:C substrates</arg>
                </example>
                <example src="EGRAM" no="64">
                    <text>The zinc finger, which specifically recognizes the GO:C pair, is firmly fixed in the C-terminal domain by the hydrogen bonding network, so that Lys147Ala substitution has been shown to be an A1 deregulator (interaction), disrupt in a drastic drop of activity against GO:C substrates.</text>
                    <arg n="0">Lys147Ala substitution</arg>
                    <arg n="R">a drastic drop of activity against GO:C substrates</arg>
                </example>
                <example src="EGRAM" no="65">
                    <text>The zinc finger, which specifically recognizes the GO:C pair, is firmly fixed in the C-terminal domain by the hydrogen bonding network, so that Lys147Ala substitution has the ability to separate interaction, disrupt in a drastic drop of activity against GO:C substrates.</text>
                    <arg n="0">Lys147Ala substitution</arg>
                    <arg n="1">interaction</arg>
                    <arg n="R">a drastic drop of activity against GO:C substrates</arg>
                </example>
                <example src="EGRAM" no="66">
                    <text>The zinc finger, which specifically recognizes the GO:C pair, is firmly fixed in the C-terminal domain by the hydrogen bonding network, so that Lys147Ala substitution would be found to disrupt interaction, resulting in a drastic drop of activity against GO:C substrates.</text>
                    <arg n="0">Lys147Ala substitution</arg>
                    <arg n="1">interaction</arg>
                    <arg n="R">a drastic drop of activity against GO:C substrates</arg>
                </example>
                <example src="EGRAM" no="67">
                    <text>The zinc finger, which specifically recognizes the GO:C pair, is firmly fixed in the C-terminal domain by the hydrogen bonding network, so that Lys147Ala substitution would disrupt interaction, resulting in a drastic drop of activity against GO:C substrates.</text>
                    <arg n="0">Lys147Ala substitution</arg>
                    <arg n="1">interaction</arg>
                    <arg n="R">a drastic drop of activity against GO:C substrates</arg>
                </example>
                <example src="EGRAM" no="68">
                    <text>Therefore, the act of disrupting tumour vessels for manipulation of the Tie-2 system in tumors may result in lateral effects on peripheral nerves.</text>
                    <arg n="0">manipulation of the Tie-2 system in tumors</arg>
                    <arg n="1">tumour vessels</arg>
                    <arg n="R">lateral effects on peripheral nerves</arg>
                </example>
                <example src="EGRAM" no="69">
                    <text>Therefore, trying to disrupt tumour vessels to tumour binding system 2 maneuver may result in similar effects on peripheral nerves.</text>
                    <arg n="0">tumour binding system 2 maneuver</arg>
                    <arg n="1">tumour vessels</arg>
                    <arg n="R">similar effects on peripheral nerves</arg>
                </example>
                <example src="EGRAM" no="70">
                    <text>These mutations may be acting in a dominant-negative way in order to disrupt ubiquitin binding function, which may result in abnormal NF-kappaB pathway activation and subsequent osteoclast activation.</text>
                    <arg n="0">These mutations</arg>
                    <arg n="1">ubiquitin binding function</arg>
                    <arg n="R">abnormal NF-kappaB pathway activation and subsequent osteoclast activation</arg>
                </example>
                <example src="EGRAM" no="71">
                    <text>This deletion can disrupt consensus coupling signal 5 and lead to exon exhaustion.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">consensus coupling signal 5</arg>
                    <arg n="R">exon exhaustion</arg>
                </example>
                <example src="EGRAM" no="72">
                    <text>This deletion is able to disrupt the 5 consensus of splice signal and led to exon exhaustion.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">the 5 consensus of splice signal</arg>
                    <arg n="R">exon exhaustion</arg>
                </example>
                <example src="EGRAM" no="73">
                    <text>This deletion is able to disrupt the 5th consensus of the cut signal and led to exon exhaustion.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">the 5th consensus of the cut signal</arg>
                    <arg n="R">exon exhaustion</arg>
                </example>
                <example src="EGRAM" no="74">
                    <text>This deletion may disrupt the splice signal consensus 5 and lead to exon exhaustion.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">the splice signal consensus 5</arg>
                    <arg n="R">exon exhaustion</arg>
                </example>
                <example src="EGRAM" no="75">
                    <text>This suppression broke the consensus signal jump 5 and disrupted to the exon exhaustion.</text>
                    <arg n="0">This suppression</arg>
                    <arg n="1">consensus signal jump 5</arg>
                    <arg n="R">exon exhaustion</arg>
                </example>
                <example src="EGRAM" no="76">
                    <text>Thus, attempting to disrupt tumour vessels for manipulation of the Tie-2 system in tumors can result in lateral effects on peripheral nerves.</text>
                    <arg n="0">manipulation of the Tie-2 system in tumors</arg>
                    <arg n="1">tumour vessels</arg>
                    <arg n="R">lateral effects on peripheral nerves</arg>
                </example>
                <example src="EGRAM" no="77">
                    <text>Thus, the act of disrupting tumor vessels by manipulation of the binding system 2 in tumours may result in similar effects on peripheral nerves.</text>
                    <arg n="0">manipulation of the binding system 2 in tumours</arg>
                    <arg n="1">tumor vessels</arg>
                    <arg n="R">similar effects on peripheral nerves</arg>
                </example>
                <example src="EGRAM" no="78">
                    <text>Thus, the breakdown of tumour vessels by manipulation of the 2-bonding system in tumors can disrupting in similar effects on peripheral nerves.</text>
                    <arg n="0">manipulation of the 2-bonding system in tumors</arg>
                    <arg n="1">tumour vessels</arg>
                    <arg n="R">similar effects on peripheral nerves</arg>
                </example>
                <example src="EGRAM" no="79">
                    <text>Thus, the rupture of tumor vessels by manipulation of the binding system 2 in tumours may disrupting in similar effects on peripheral nerves.</text>
                    <arg n="0">manipulation of the binding system 2 in tumours</arg>
                    <arg n="1">tumor vessels</arg>
                    <arg n="R">similar effects on peripheral nerves</arg>
                </example>
                <example src="EGRAM" no="80">
                    <text>Treatment of systemic inflammatory response to CPB is also confused by the fact that inhibition of inflammation is able to disrupt protective physiological response or result in immunosuppression.</text>
                    <arg n="0">inhibition of inflammation</arg>
                    <arg n="1">protective physiological response</arg>
                </example>
                <example src="EGRAM" no="81">
                    <text>Treatment of systemic inflammatory response to CPB is also confused by the fact that inhibition of inflammation will possibly disrupt protective physiological responses or result in immunosuppression.</text>
                    <arg n="0">inhibition of inflammation</arg>
                    <arg n="1">protective physiological responses</arg>
                </example>
                <example src="EGRAM" no="82">
                    <text>Treatment of the systemic inflammatory response to CPB is also confused by the fact that inhibition of inflammation has been shown to disrupt physiological protective responses or result in immunosuppression.</text>
                    <arg n="0">inhibition of inflammation</arg>
                    <arg n="1">physiological protective responses</arg>
                </example>
                <example src="EGRAM" no="83">
                    <text>Treatment of the systemic inflammatory response to CPB is also confused by the fact that inhibition of inflammation may have disrupted with physiological protective response or result in immunosuppression.</text>
                    <arg n="0">inhibition of inflammation</arg>
                    <arg n="1">physiological protective response</arg>
                </example>
                <example src="EGRAM" no="84">
                    <text>Treatment of the systemic inflammatory response to CPB is also confused by the fact that inhibition of inflammation may have disrupted with protective physiological responses or result in immunosuppression.</text>
                    <arg n="0">inhibition of inflammation</arg>
                    <arg n="1">protective physiological responses</arg>
                </example>
                <example src="EGRAM" no="85">
                    <text>Treatment of the systemic inflammatory response to CPB is also confused by the fact that inhibition of inflammation will possibly disrupt physiological protective responses or result in immunosuppression.</text>
                    <arg n="0">inhibition of inflammation</arg>
                    <arg n="1">physiological protective responses</arg>
                </example>
                <example src="EGRAM" no="86">
                    <text>When both genes are disrupted, child expression is higher.</text>
                    <arg n="1">both genes</arg>
                    <arg n="2">child expression is higher</arg>
                </example>
                <example src="EGRAM" no="87">
                    <text>When both genes are disrupted, the Gaulish expression is higher.</text>
                    <arg n="1">both genes</arg>
                    <arg n="2">the Gaulish expression is higher</arg>
                </example>
                <example src="EGRAM" no="88">
                    <text>When both genes has already been disrupted, the Gaulish expression was higher.</text>
                    <arg n="1">both genes</arg>
                    <arg n="2">the Gaulish expression was higher</arg>
                </example>
                <example src="EGRAM" no="89">
                    <text>When both genes has been disrupted, the Gaulish expression was higher.</text>
                    <arg n="1">both genes</arg>
                    <arg n="2">the Gaulish expression was higher</arg>
                </example>
                <example src="EGRAM" no="90">
                    <text>When both genes is shown to be disrupted, Galish expression is further increased.</text>
                    <arg n="1">both genes</arg>
                    <arg n="2">Galish expression is further increased</arg>
                </example>
                <example src="EGRAM" no="91">
                    <text>When both genes was already disrupted, child expression was higher.</text>
                    <arg n="1">both genes</arg>
                    <arg n="2">child expression was higher</arg>
                </example>
                <example src="EGRAM" no="92">
                    <text>When both genes was disrupted, child expression was higher.</text>
                    <arg n="1">both genes</arg>
                    <arg n="2">child expression was higher</arg>
                </example>
                <example src="EGRAM" no="93">
                    <text>When both genes was disrupted, the expression GalS was higher.</text>
                    <arg n="1">both genes</arg>
                    <arg n="2">GalS</arg>
                </example>
                <example src="EGRAM" no="94">
                    <text>When it has been disrupted that both genes is perturbed, the Gaulish expression is higher.</text>
                    <arg n="1">both genes</arg>
                    <arg n="2">the Gaulish expression is higher</arg>
                </example>
                <example src="EGRAM" no="95">
                    <text>When it is shown that both genes is disrupted, the Gaulish expression is raised even higher.</text>
                    <arg n="1">both genes</arg>
                    <arg n="2">the Gaulish expression is raised even higher</arg>
                </example>
                <example src="EGRAM" no="96">
                    <text>a homozygotic mutation that disrupted splicing has been identified in the affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">a homozygotic mutation</arg>
                    <arg n="1">splicing</arg>
                </example>
                <example src="EGRAM" no="97">
                    <text>a homozygotic mutation that disrupting splicing is identified in the affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">a homozygotic mutation</arg>
                    <arg n="1">splicing</arg>
                </example>
                <example src="EGRAM" no="98">
                    <text>a homozygous mutation that can disrupt split has been identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">a homozygous mutation</arg>
                    <arg n="1">split</arg>
                </example>
                <example src="EGRAM" no="99">
                    <text>a homozygous mutation that has disrupted A1 will be identified in the affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">a homozygous mutation</arg>
                </example>
                <example src="EGRAM" no="100">
                    <text>a homozygous mutation that has disrupted pulally was identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">a homozygous mutation</arg>
                    <arg n="1">pulally</arg>
                </example>
                <example src="EGRAM" no="101">
                    <text>homozygous mutation that broke A1 will be identified in the siblings disrupted by classical abetalipoproteinemia.</text>
                    <arg n="0">homozygous mutation</arg>
                </example>
                <example src="EGRAM" no="102">
                    <text>homozygous mutation that can disrupt squirrel that has been identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">homozygous mutation</arg>
                    <arg n="1">squirrel</arg>
                </example>
                <example src="EGRAM" no="103">
                    <text>homozygous mutation that disrupted splicing was identified in the siblings affected with classical abetalipoproteinemia.</text>
                    <arg n="0">homozygous mutation</arg>
                    <arg n="1">splicing</arg>
                </example>
                <example src="EGRAM" no="104">
                    <text>homozygous mutation that disrupting splicing is identified in the siblings affected by classical abetalipoproteinemia.</text>
                    <arg n="0">homozygous mutation</arg>
                    <arg n="1">splicing</arg>
                </example>
                <example src="EGRAM" no="105">
                    <text>licensing improvement sequence: (GAR)n-(GAR)n is disrupted by a 415G4 mutation, resulting in R (exon 5.</text>
                    <arg n="0">a 415G4 mutation</arg>
                    <arg n="1">licensing improvement sequence: (GAR)n-(GAR)n</arg>
                </example>
                <example src="EGRAM" no="106">
                    <text>licensing improvement sequence: (GAR)n-(GAR)n was disrupted by Mutation 415G4, resulting in R (exon 5.</text>
                    <arg n="0">Mutation 415G4</arg>
                    <arg n="1">licensing improvement sequence: (GAR)n-(GAR)n</arg>
                </example>
                <example src="EGRAM" no="107">
                    <text>multations at p53 disrupted post-checking points for DNA damage and resulted in the potential for destabilization of the genome.</text>
                    <arg n="0">multations at p53</arg>
                    <arg n="1">post-checking points for DNA damage</arg>
                    <arg n="R">the potential for destabilization of the genome</arg>
                </example>
                <example src="EGRAM" no="108">
                    <text>mutation 415G4 has been shown to disrupt an A1 sequence (pulling enhancement sequence: (GAR)n-(GAR)n) resulting in R (exon 5 is omitted).</text>
                    <arg n="0">mutation 415G4</arg>
                </example>
                <example src="EGRAM" no="109">
                    <text>mutation 415G4 has disrupted an pulling enhancement sequence: (GAR)n-(GAR)n resulting in R (exon 5 omitting ).</text>
                    <arg n="0">mutation 415G4</arg>
                    <arg n="1">pulling enhancement sequence: (GAR)n-(GAR)n</arg>
                </example>
                <example src="EGRAM" no="110">
                    <text>mutations in this region disrupted assembly of keratin filaments, leading to degeneration or cytolysis of keratinocytes.</text>
                    <arg n="0">mutations in this region</arg>
                    <arg n="1">assembly of keratin filaments</arg>
                    <arg n="R">degeneration or cytolysis of keratinocytes</arg>
                </example>
                <example src="EGRAM" no="111">
                    <text>mutations in this region disrupted assembly of keratin filaments, leading to degeneration or keratinocyte cytolysis.</text>
                    <arg n="0">mutations in this region</arg>
                    <arg n="1">assembly of keratin filaments</arg>
                    <arg n="R">degeneration or keratinocyte cytolysis</arg>
                </example>
                <example src="EGRAM" no="112">
                    <text>mutations in this region has the ability to disrupt assembly of keratin filaments, leading to degeneration or cytolysis of keratinocytes.</text>
                    <arg n="0">mutations in this region</arg>
                    <arg n="1">assembly of keratin filaments</arg>
                    <arg n="R">degeneration or cytolysis of keratinocytes</arg>
                </example>
                <example src="EGRAM" no="113">
                    <text>mutations in this region has the ability to disrupt assembly of keratin filaments, leading to degeneration or keratinocyte cytolysis.</text>
                    <arg n="0">mutations in this region</arg>
                    <arg n="1">assembly of keratin filaments</arg>
                    <arg n="R">degeneration or keratinocyte cytolysis</arg>
                </example>
                <example src="EGRAM" no="114">
                    <text>mutations in this region is able to disrupt assembly of keratin filaments, leading to degeneration or keratinocyte cytolysis.</text>
                    <arg n="0">mutations in this region</arg>
                    <arg n="1">assembly of keratin filaments</arg>
                    <arg n="R">degeneration or keratinocyte cytolysis</arg>
                </example>
                <example src="EGRAM" no="115">
                    <text>mutations in this region is able to disrupt assembly of keratin filaments, resulting in degeneration or cytolysis of keratinocytes.</text>
                    <arg n="0">mutations in this region</arg>
                    <arg n="1">assembly of keratin filaments</arg>
                    <arg n="R">degeneration or cytolysis of keratinocytes</arg>
                </example>
                <example src="EGRAM" no="116">
                    <text>mutations in this region may disrupt assembly of keratin filaments, leading to degeneration or cytolysis of keratinocytes.</text>
                    <arg n="0">mutations in this region</arg>
                    <arg n="1">assembly of keratin filaments</arg>
                    <arg n="R">degeneration or cytolysis of keratinocytes</arg>
                </example>
                <example src="EGRAM" no="117">
                    <text>mutations in this region may disrupt assembly of keratin filaments, leading to degeneration or keratinocyte cytolysis.</text>
                    <arg n="0">mutations in this region</arg>
                    <arg n="1">assembly of keratin filaments</arg>
                    <arg n="R">degeneration or keratinocyte cytolysis</arg>
                </example>
                <example src="EGRAM" no="118">
                    <text>p53 mutations has disrupted checking point responses for DNA damage and resulted in the potential for destabilization of the genome.</text>
                    <arg n="0">p53 mutations</arg>
                    <arg n="1">checking point responses for DNA damage</arg>
                    <arg n="R">the potential for destabilization of the genome</arg>
                </example>
                <example src="EGRAM" no="119">
                    <text>p53 mutations is able to disrupt checking point responses for DNA damage and results in the potential for destabilization of the genome.</text>
                    <arg n="0">p53 mutations</arg>
                    <arg n="1">checking point responses for DNA damage</arg>
                    <arg n="R">the potential for destabilization of the genome</arg>
                </example>
                <example src="EGRAM" no="120">
                    <text>p53 mutations rupture of checking points responses to DNA damage may disrupting in genome destabilization potential.</text>
                    <arg n="0">p53 mutations</arg>
                    <arg n="1">checking points responses to DNA damage</arg>
                    <arg n="R">genome destabilization potential</arg>
                </example>
                <example src="EGRAM" no="121">
                    <text>slicing enhancer sequnce: (GAR)n-(GAR)n is disrupted by A mutation 415G4, resulting in R (exon 5.</text>
                    <arg n="0">A mutation 415G4</arg>
                    <arg n="1">slicing enhancer sequnce: (GAR)n-(GAR)n</arg>
                </example>
                <example src="EGRAM" no="122">
                    <text>such mutations may be acting in a dominant-negative manner in order to disrupt the ubiquitin-binding function, which may result in abnormal activation of the NF-kappaB pathway and subsequent activation of the osteoclasts.</text>
                    <arg n="0">such mutations</arg>
                    <arg n="1">the ubiquitin-binding function</arg>
                    <arg n="R">abnormal activation of the NF-kappaB pathway and subsequent activation of the</arg>
                </example>
                <example src="EGRAM" no="123">
                    <text>such mutations may be acting in a dominant-negative manner with the ability to disrupt the ubiquitin-binding function, which may result in abnormal activation of the NF-kappaB pathway and subsequent activation of the osteoclasts.</text>
                    <arg n="0">such mutations</arg>
                    <arg n="1">the ubiquitin-binding function</arg>
                    <arg n="R">abnormal activation of the NF-kappaB pathway and subsequent activation of the</arg>
                </example>
                <example src="EGRAM" no="124">
                    <text>such mutations may be dominant-negative and may also disrupt the ubiquitin binding function, which may result in abnormal activation of the NF-kappaB pathway and subsequent activation of the osteoclasts.</text>
                    <arg n="0">such mutations</arg>
                    <arg n="1">the ubiquitin binding function</arg>
                    <arg n="R">abnormal activation of the NF-kappaB pathway and subsequent activation of the</arg>
                </example>
                <example src="EGRAM" no="125">
                    <text>these mutations may be acting negatively dominant and may also disrupt biquitin binding function, which may result in activation of the R pathway (anormal NF-kappaB and subsequent activation of osteoclast).</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">biquitin binding function</arg>
                </example>
                <example src="EGRAM" no="126">
                    <text>these mutations may be acting negatively dominantly with the ability to disrupt biquitin binding function, which may result in activation of the R pathway (anormal NF-kappaB and subsequent activation of osteoclast).</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">biquitin binding function</arg>
                </example>
                <example src="EGRAM" no="127">
                    <text>this deletion has disrupted consensus signal 5 and led to exon skipping.</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">consensus signal 5</arg>
                    <arg n="R">exon skipping</arg>
                </example>
                <example src="EGRAM" no="128">
                    <text>this deletion would have been disrupting consensus signal 5 and led to exon skipping.</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">consensus signal 5</arg>
                    <arg n="R">exon skipping</arg>
                </example>
                <example src="EGRAM" no="129">
                    <text>this suppression has been shown to disrupt consensus signal 5 and lead to exon is omitted.</text>
                    <arg n="0">this suppression</arg>
                    <arg n="1">consensus signal 5</arg>
                    <arg n="R">exon is omitted</arg>
                </example>
                <example src="EGRAM" no="130">
                    <text>this suppression would have disrupting disturbances consensus signal 5 and led to exon signal.</text>
                    <arg n="0">this suppression</arg>
                    <arg n="1">consensus signal 5</arg>
                    <arg n="R">exon signal</arg>
                </example>
                <example src="PERMUTATE" no="1">
                    <text>Arg99 and Arg253 broke a sequence of hydrogen bonds in the model disrupted in R (exon 5 spike).</text>
                    <arg n="0">Arg99 and Arg253</arg>
                    <arg n="1">hydrogen bonds in the model</arg>
                </example>
                <example src="PERMUTATE" no="2">
                    <text>Arg99 and Arg253 can disrupt with the base groups ceto and C (blue) on both sides of the dsDNA DNA and interrupt hydrogen bonds in the model.</text>
                    <arg n="0">Arg99 and Arg253</arg>
                    <arg n="1">hydrogen bonds in the model</arg>
                </example>
                <example src="PERMUTATE" no="3">
                    <text>Arg99 and Arg253 that can disrupt hydrogen bonds in the model has been identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">Arg99 and Arg253</arg>
                    <arg n="1">hydrogen bonds in the model</arg>
                </example>
                <example src="PERMUTATE" no="4">
                    <text>Arg99 and Arg253 that can disrupt hydrogen bonds in the model that has been identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">Arg99 and Arg253</arg>
                    <arg n="1">hydrogen bonds in the model</arg>
                </example>
                <example src="PERMUTATE" no="5">
                    <text>Arg99 and Arg253 that has disrupted hydrogen bonds in the model was identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">Arg99 and Arg253</arg>
                    <arg n="1">hydrogen bonds in the model</arg>
                </example>
                <example src="PERMUTATE" no="6">
                    <text>Arg99 and Arg253 that interacts with the keto and C group pair (blue) on both sides of the dsDNA can disrupt hydrogen bonds in the model.</text>
                    <arg n="0">Arg99 and Arg253</arg>
                    <arg n="1">hydrogen bonds in the model</arg>
                </example>
                <example src="PERMUTATE" no="7">
                    <text>Arr99 and Arr253 broke a sequence of hydrogen bond pairing in the model disrupted in R (exon 5 spike).</text>
                    <arg n="0">Arr99 and Arr253</arg>
                    <arg n="1">hydrogen bond pairing in the model</arg>
                </example>
                <example src="PERMUTATE" no="8">
                    <text>Arr99 and Arr253 broke a sequence of the hydrogen bonding pairing in the model disrupted in R (exon 5 spike).</text>
                    <arg n="0">Arr99 and Arr253</arg>
                    <arg n="1">the hydrogen bonding pairing in the model</arg>
                </example>
                <example src="PERMUTATE" no="9">
                    <text>Arr99 and Arr253 can disrupt with the base groups ceto and C (blue) on both sides of the dsDNA DNA and interrupt the hydrogen bonding pairing in the model.</text>
                    <arg n="0">Arr99 and Arr253</arg>
                    <arg n="1">the hydrogen bonding pairing in the model</arg>
                </example>
                <example src="PERMUTATE" no="10">
                    <text>Arr99 and Arr253 that can disrupt hydrogen bond pairing in the model has been identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">Arr99 and Arr253</arg>
                    <arg n="1">hydrogen bond pairing in the model</arg>
                </example>
                <example src="PERMUTATE" no="11">
                    <text>Arr99 and Arr253 that can disrupt hydrogen bond pairing in the model that has been identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">Arr99 and Arr253</arg>
                    <arg n="1">hydrogen bond pairing in the model</arg>
                </example>
                <example src="PERMUTATE" no="12">
                    <text>Arr99 and Arr253 that can disrupt the hydrogen bonding pairing in the model has been identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">Arr99 and Arr253</arg>
                    <arg n="1">the hydrogen bonding pairing in the model</arg>
                </example>
                <example src="PERMUTATE" no="13">
                    <text>Arr99 and Arr253 that can disrupt the hydrogen bonding pairing in the model that has been identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">Arr99 and Arr253</arg>
                    <arg n="1">the hydrogen bonding pairing in the model</arg>
                </example>
                <example src="PERMUTATE" no="14">
                    <text>Arr99 and Arr253 that has disrupted hydrogen bond pairing in the model was identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">Arr99 and Arr253</arg>
                    <arg n="1">hydrogen bond pairing in the model</arg>
                </example>
                <example src="PERMUTATE" no="15">
                    <text>Arr99 and Arr253 that has disrupted the hydrogen bonding pairing in the model was identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">Arr99 and Arr253</arg>
                    <arg n="1">the hydrogen bonding pairing in the model</arg>
                </example>
                <example src="PERMUTATE" no="16">
                    <text>Arr99 and Arr253 that interact with the keto groups of the base pair GO and C (blue) on either side of the dsDNA can disrupt hydrogen bond pairing in the model.</text>
                    <arg n="0">Arr99 and Arr253</arg>
                    <arg n="1">hydrogen bond pairing in the model</arg>
                </example>
                <example src="PERMUTATE" no="17">
                    <text>Arr99 and Arr253 that interact with the keto groups of the base pair GO and C (blue) on either side of the dsDNA can disrupt the hydrogen bonding pairing in the model.</text>
                    <arg n="0">Arr99 and Arr253</arg>
                    <arg n="1">the hydrogen bonding pairing in the model</arg>
                </example>
                <example src="PERMUTATE" no="18">
                    <text>Arr99 and Arr253 that interacts with the keto and C group pair (blue) on both sides of the dsDNA can disrupt hydrogen bond pairing in the model.</text>
                    <arg n="0">Arr99 and Arr253</arg>
                    <arg n="1">hydrogen bond pairing in the model</arg>
                </example>
                <example src="PERMUTATE" no="19">
                    <text>Gly188---Glu mutation broke a sequence of a site Ava II disrupted in R (exon 5 spike).</text>
                    <arg n="0">Gly188---Glu mutation</arg>
                    <arg n="1">a site Ava II</arg>
                </example>
                <example src="PERMUTATE" no="20">
                    <text>Gly188---Glu mutation broke a sequence of one site Ava II disrupted in R (exon 5 spike).</text>
                    <arg n="0">Gly188---Glu mutation</arg>
                    <arg n="1">one site Ava II</arg>
                </example>
                <example src="PERMUTATE" no="21">
                    <text>Gly188---Glu mutation can disrupt with the base groups ceto and C (blue) on both sides of the dsDNA DNA and interrupt a site Ava II.</text>
                    <arg n="0">Gly188---Glu mutation</arg>
                    <arg n="1">a site Ava II</arg>
                </example>
                <example src="PERMUTATE" no="22">
                    <text>Gly188---Glu mutation can disrupt with the base groups ceto and C (blue) on both sides of the dsDNA DNA and interrupt one site Ava II.</text>
                    <arg n="0">Gly188---Glu mutation</arg>
                    <arg n="1">one site Ava II</arg>
                </example>
                <example src="PERMUTATE" no="23">
                    <text>Gly188---Glu mutation that broke A1 will be identified in the siblings disrupted by classical abetalipoproteinemia.</text>
                    <arg n="0">Gly188---Glu mutation</arg>
                </example>
                <example src="PERMUTATE" no="24">
                    <text>Gly188---Glu mutation that can disrupt a site Ava II has been identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">Gly188---Glu mutation</arg>
                    <arg n="1">a site Ava II</arg>
                </example>
                <example src="PERMUTATE" no="25">
                    <text>Gly188---Glu mutation that can disrupt a site Ava II that has been identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">Gly188---Glu mutation</arg>
                    <arg n="1">a site Ava II</arg>
                </example>
                <example src="PERMUTATE" no="26">
                    <text>Gly188---Glu mutation that can disrupt one site Ava II has been identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">Gly188---Glu mutation</arg>
                    <arg n="1">one site Ava II</arg>
                </example>
                <example src="PERMUTATE" no="27">
                    <text>Gly188---Glu mutation that can disrupt one site Ava II that has been identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">Gly188---Glu mutation</arg>
                    <arg n="1">one site Ava II</arg>
                </example>
                <example src="PERMUTATE" no="28">
                    <text>Gly188---Glu mutation that has disrupted A1 will be identified in the affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">Gly188---Glu mutation</arg>
                </example>
                <example src="PERMUTATE" no="29">
                    <text>Gly188---Glu mutation that has disrupted a site Ava II was identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">Gly188---Glu mutation</arg>
                    <arg n="1">a site Ava II</arg>
                </example>
                <example src="PERMUTATE" no="30">
                    <text>Gly188---Glu mutation that has disrupted one site Ava II was identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">Gly188---Glu mutation</arg>
                    <arg n="1">one site Ava II</arg>
                </example>
                <example src="PERMUTATE" no="31">
                    <text>Gly188---Glu mutation that interact with the keto groups of the base pair GO and C (blue) on either side of the dsDNA can disrupt a site Ava II.</text>
                    <arg n="0">Gly188---Glu mutation</arg>
                    <arg n="1">a site Ava II</arg>
                </example>
                <example src="PERMUTATE" no="32">
                    <text>Gly188---Glu mutation that interact with the keto groups of the base pair GO and C (blue) on either side of the dsDNA can disrupt one site Ava II.</text>
                    <arg n="0">Gly188---Glu mutation</arg>
                    <arg n="1">one site Ava II</arg>
                </example>
                <example src="PERMUTATE" no="33">
                    <text>Gly188---Glu mutation that interacts with the keto and C group pair (blue) on both sides of the dsDNA can disrupt a site Ava II.</text>
                    <arg n="0">Gly188---Glu mutation</arg>
                    <arg n="1">a site Ava II</arg>
                </example>
                <example src="PERMUTATE" no="34">
                    <text>Gly188---Glu mutation that interacts with the keto and C group pair (blue) on both sides of the dsDNA can disrupt one site Ava II.</text>
                    <arg n="0">Gly188---Glu mutation</arg>
                    <arg n="1">one site Ava II</arg>
                </example>
                <example src="PERMUTATE" no="35">
                    <text>It has been shown that Mutations in p53 interrupts responses of checkpoints to DNA damage and disrupt to the potential for genome destabilization.</text>
                    <arg n="0">Mutations in p53</arg>
                    <arg n="1">responses of checkpoints to DNA damage</arg>
                    <arg n="R">the potential for genome destabilization</arg>
                </example>
                <example src="PERMUTATE" no="36">
                    <text>It has been shown that This suppression interrupts consensus signal jump 5 and disrupt to exon exhaustion.</text>
                    <arg n="0">This suppression</arg>
                    <arg n="1">consensus signal jump 5</arg>
                    <arg n="R">exon exhaustion</arg>
                </example>
                <example src="PERMUTATE" no="37">
                    <text>It has been shown that manipulation of the 2-bonding system in tumors interrupts tumour vessels and disrupt to similar effects on peripheral nerves.</text>
                    <arg n="0">manipulation of the 2-bonding system in tumors</arg>
                    <arg n="1">tumour vessels</arg>
                    <arg n="R">similar effects on peripheral nerves</arg>
                </example>
                <example src="PERMUTATE" no="38">
                    <text>It has been shown that manipulation of the binding system 2 in tumours interrupts tumor vessels and disrupt to similar effects on peripheral nerves.</text>
                    <arg n="0">manipulation of the binding system 2 in tumours</arg>
                    <arg n="1">tumor vessels</arg>
                    <arg n="R">similar effects on peripheral nerves</arg>
                </example>
                <example src="PERMUTATE" no="39">
                    <text>It has been shown that p53 mutations interrupts checking points responses to DNA damage and disrupt to genome destabilization potential.</text>
                    <arg n="0">p53 mutations</arg>
                    <arg n="1">checking points responses to DNA damage</arg>
                    <arg n="R">genome destabilization potential</arg>
                </example>
                <example src="PERMUTATE" no="40">
                    <text>It is important to note that Arg99 and Arg253 disrupt hydrogen bonds in the model.</text>
                    <arg n="0">Arg99 and Arg253</arg>
                    <arg n="1">hydrogen bonds in the model</arg>
                </example>
                <example src="PERMUTATE" no="41">
                    <text>It is important to note that Arr99 and Arr253 disrupt hydrogen bond pairing in the model.</text>
                    <arg n="0">Arr99 and Arr253</arg>
                    <arg n="1">hydrogen bond pairing in the model</arg>
                </example>
                <example src="PERMUTATE" no="42">
                    <text>It is important to note that Arr99 and Arr253 disrupt the hydrogen bonding pairing in the model.</text>
                    <arg n="0">Arr99 and Arr253</arg>
                    <arg n="1">the hydrogen bonding pairing in the model</arg>
                </example>
                <example src="PERMUTATE" no="43">
                    <text>It is important to note that Gly188---Glu mutation disrupt a site Ava II.</text>
                    <arg n="0">Gly188---Glu mutation</arg>
                    <arg n="1">a site Ava II</arg>
                </example>
                <example src="PERMUTATE" no="44">
                    <text>It is important to note that Gly188---Glu mutation disrupt one site Ava II.</text>
                    <arg n="0">Gly188---Glu mutation</arg>
                    <arg n="1">one site Ava II</arg>
                </example>
                <example src="PERMUTATE" no="45">
                    <text>It is important to note that Mutation 415G4 disrupt potent spike: (GAR)n-(GAR)n.</text>
                    <arg n="0">Mutation 415G4</arg>
                    <arg n="1">potent spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="PERMUTATE" no="46">
                    <text>It is important to note that a homozygous mutation disrupt pulally.</text>
                    <arg n="0">a homozygous mutation</arg>
                    <arg n="1">pulally</arg>
                </example>
                <example src="PERMUTATE" no="47">
                    <text>It is important to note that a homozygous mutation disrupt split.</text>
                    <arg n="0">a homozygous mutation</arg>
                    <arg n="1">split</arg>
                </example>
                <example src="PERMUTATE" no="48">
                    <text>It is important to note that alcohol consumption exposure disrupt ocular dominance plasticity.</text>
                    <arg n="0">alcohol consumption exposure</arg>
                    <arg n="1">ocular dominance plasticity</arg>
                </example>
                <example src="PERMUTATE" no="49">
                    <text>It is important to note that alcohol exposure disrupt ocular domain plasticity.</text>
                    <arg n="0">alcohol exposure</arg>
                    <arg n="1">ocular domain plasticity</arg>
                </example>
                <example src="PERMUTATE" no="50">
                    <text>It is important to note that alcohol exposure disrupt ocular dominance plasticity.</text>
                    <arg n="0">alcohol exposure</arg>
                    <arg n="1">ocular dominance plasticity</arg>
                </example>
                <example src="PERMUTATE" no="51">
                    <text>It is important to note that exposure to alcohol consumption disrupt ocular domain plasticity.</text>
                    <arg n="0">exposure to alcohol consumption</arg>
                    <arg n="1">ocular domain plasticity</arg>
                </example>
                <example src="PERMUTATE" no="52">
                    <text>It is important to note that exposure to alcohol consumption disrupt plasticity of eye dominance.</text>
                    <arg n="0">exposure to alcohol consumption</arg>
                    <arg n="1">plasticity of eye dominance</arg>
                </example>
                <example src="PERMUTATE" no="53">
                    <text>It is important to note that his retired expression MEKK1 or MEKK2 disrupt the overall integrity of MAPK pathway regulation.</text>
                    <arg n="0">his retired expression MEKK1 or MEKK2</arg>
                    <arg n="1">the overall integrity of MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="54">
                    <text>It is important to note that homozygous mutation disrupt spacing.</text>
                    <arg n="0">homozygous mutation</arg>
                    <arg n="1">spacing</arg>
                </example>
                <example src="PERMUTATE" no="55">
                    <text>It is important to note that homozygous mutation disrupt squirrel.</text>
                    <arg n="0">homozygous mutation</arg>
                    <arg n="1">squirrel</arg>
                </example>
                <example src="PERMUTATE" no="56">
                    <text>It is important to note that if retired from the expression MEKK1 or MEKK2 disrupt the overall integrity of MAPK pathway regulation.</text>
                    <arg n="0">if retired from the expression MEKK1 or MEKK2</arg>
                    <arg n="1">the overall integrity of MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="57">
                    <text>It is important to note that inhibition of inflammation disrupt physiological protective response.</text>
                    <arg n="0">inhibition of inflammation</arg>
                    <arg n="1">physiological protective response</arg>
                </example>
                <example src="PERMUTATE" no="58">
                    <text>It is important to note that inhibition of inflammation disrupt protective physiological responses.</text>
                    <arg n="0">inhibition of inflammation</arg>
                    <arg n="1">protective physiological responses</arg>
                </example>
                <example src="PERMUTATE" no="59">
                    <text>It is important to note that knockout of the expression MEKK1 or MEKK2 disrupt the overall integrity of MAPK pathway regulation.</text>
                    <arg n="0">knockout of the expression MEKK1 or MEKK2</arg>
                    <arg n="1">the overall integrity of MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="60">
                    <text>It is important to note that retired from the MEKK1 or MEKK2 expression disrupt the overall integrity of the MAPK pathway regulation.</text>
                    <arg n="0">retired from the MEKK1 or MEKK2 expression</arg>
                    <arg n="1">the overall integrity of the MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="61">
                    <text>It is important to note that the Gly188--Glu mutation disrupt an Ava II site.</text>
                    <arg n="0">the Gly188--Glu mutation</arg>
                    <arg n="1">an Ava II site</arg>
                </example>
                <example src="PERMUTATE" no="62">
                    <text>It is important to note that the findings disrupt that Arg99 and Arg253 has not interrupts hydrogen bonds in the model.</text>
                    <arg n="0">Arg99 and Arg253</arg>
                    <arg n="1">hydrogen bonds in the model</arg>
                </example>
                <example src="PERMUTATE" no="63">
                    <text>It is important to note that the findings disrupt that Arr99 and Arr253 has not interrupts hydrogen bond pairing in the model.</text>
                    <arg n="0">Arr99 and Arr253</arg>
                    <arg n="1">hydrogen bond pairing in the model</arg>
                </example>
                <example src="PERMUTATE" no="64">
                    <text>It is important to note that the findings disrupt that Arr99 and Arr253 has not interrupts the hydrogen bonding pairing in the model.</text>
                    <arg n="0">Arr99 and Arr253</arg>
                    <arg n="1">the hydrogen bonding pairing in the model</arg>
                </example>
                <example src="PERMUTATE" no="65">
                    <text>It is important to note that the findings disrupt that Gly188---Glu mutation has not interrupts a site Ava II.</text>
                    <arg n="0">Gly188---Glu mutation</arg>
                    <arg n="1">a site Ava II</arg>
                </example>
                <example src="PERMUTATE" no="66">
                    <text>It is important to note that the findings disrupt that Gly188---Glu mutation has not interrupts one site Ava II.</text>
                    <arg n="0">Gly188---Glu mutation</arg>
                    <arg n="1">one site Ava II</arg>
                </example>
                <example src="PERMUTATE" no="67">
                    <text>It is important to note that the findings disrupt that Mutation 415G4 has not interrupts potent spike: (GAR)n-(GAR)n.</text>
                    <arg n="0">Mutation 415G4</arg>
                    <arg n="1">potent spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="PERMUTATE" no="68">
                    <text>It is important to note that the findings disrupt that a homozygous mutation has not interrupts pulally.</text>
                    <arg n="0">a homozygous mutation</arg>
                    <arg n="1">pulally</arg>
                </example>
                <example src="PERMUTATE" no="69">
                    <text>It is important to note that the findings disrupt that a homozygous mutation has not interrupts split.</text>
                    <arg n="0">a homozygous mutation</arg>
                    <arg n="1">split</arg>
                </example>
                <example src="PERMUTATE" no="70">
                    <text>It is important to note that the findings disrupt that alcohol consumption exposure has not interrupts ocular dominance plasticity.</text>
                    <arg n="0">alcohol consumption exposure</arg>
                    <arg n="1">ocular dominance plasticity</arg>
                </example>
                <example src="PERMUTATE" no="71">
                    <text>It is important to note that the findings disrupt that alcohol exposure has not interrupts ocular domain plasticity.</text>
                    <arg n="0">alcohol exposure</arg>
                    <arg n="1">ocular domain plasticity</arg>
                </example>
                <example src="PERMUTATE" no="72">
                    <text>It is important to note that the findings disrupt that alcohol exposure has not interrupts ocular dominance plasticity.</text>
                    <arg n="0">alcohol exposure</arg>
                    <arg n="1">ocular dominance plasticity</arg>
                </example>
                <example src="PERMUTATE" no="73">
                    <text>It is important to note that the findings disrupt that exposure to alcohol consumption has not interrupts ocular domain plasticity.</text>
                    <arg n="0">exposure to alcohol consumption</arg>
                    <arg n="1">ocular domain plasticity</arg>
                </example>
                <example src="PERMUTATE" no="74">
                    <text>It is important to note that the findings disrupt that exposure to alcohol consumption has not interrupts plasticity of eye dominance.</text>
                    <arg n="0">exposure to alcohol consumption</arg>
                    <arg n="1">plasticity of eye dominance</arg>
                </example>
                <example src="PERMUTATE" no="75">
                    <text>It is important to note that the findings disrupt that his retired expression MEKK1 or MEKK2 has not interrupts the overall integrity of MAPK pathway regulation.</text>
                    <arg n="0">his retired expression MEKK1 or MEKK2</arg>
                    <arg n="1">the overall integrity of MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="76">
                    <text>It is important to note that the findings disrupt that homozygous mutation has not interrupts spacing.</text>
                    <arg n="0">homozygous mutation</arg>
                    <arg n="1">spacing</arg>
                </example>
                <example src="PERMUTATE" no="77">
                    <text>It is important to note that the findings disrupt that homozygous mutation has not interrupts squirrel.</text>
                    <arg n="0">homozygous mutation</arg>
                    <arg n="1">squirrel</arg>
                </example>
                <example src="PERMUTATE" no="78">
                    <text>It is important to note that the findings disrupt that if retired from the expression MEKK1 or MEKK2 has not interrupts the overall integrity of MAPK pathway regulation.</text>
                    <arg n="0">if retired from the expression MEKK1 or MEKK2</arg>
                    <arg n="1">the overall integrity of MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="79">
                    <text>It is important to note that the findings disrupt that inhibition of inflammation has not interrupts physiological protective response.</text>
                    <arg n="0">inhibition of inflammation</arg>
                    <arg n="1">physiological protective response</arg>
                </example>
                <example src="PERMUTATE" no="80">
                    <text>It is important to note that the findings disrupt that inhibition of inflammation has not interrupts protective physiological responses.</text>
                    <arg n="0">inhibition of inflammation</arg>
                    <arg n="1">protective physiological responses</arg>
                </example>
                <example src="PERMUTATE" no="81">
                    <text>It is important to note that the findings disrupt that knockout of the expression MEKK1 or MEKK2 has not interrupts the overall integrity of MAPK pathway regulation.</text>
                    <arg n="0">knockout of the expression MEKK1 or MEKK2</arg>
                    <arg n="1">the overall integrity of MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="82">
                    <text>It is important to note that the findings disrupt that the Gly188--Glu mutation has not interrupts an Ava II site.</text>
                    <arg n="0">the Gly188--Glu mutation</arg>
                    <arg n="1">an Ava II site</arg>
                </example>
                <example src="PERMUTATE" no="83">
                    <text>It is important to note that the findings disrupt that the knockout of the MEKK1 or MEKK2 expression has not interrupts the overall integrity of the MAPK pathway regulation.</text>
                    <arg n="0">the knockout of the MEKK1 or MEKK2 expression</arg>
                    <arg n="1">the overall integrity of the MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="84">
                    <text>It is important to note that the findings disrupt that this deletion has not interrupts open reading frame.</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">open reading frame</arg>
                </example>
                <example src="PERMUTATE" no="85">
                    <text>It is important to note that the findings disrupt that this deletion has not interrupts the open reading frame.</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">the open reading frame</arg>
                </example>
                <example src="PERMUTATE" no="86">
                    <text>It is important to note that the findings disrupt that this deletion has not interrupts the open reading structure.</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">the open reading structure</arg>
                </example>
                <example src="PERMUTATE" no="87">
                    <text>It is important to note that the findings show that Arg99 and Arg253 will disrupt no hydrogen bonds in the model.</text>
                    <arg n="0">Arg99 and Arg253</arg>
                    <arg n="1">hydrogen bonds in the model</arg>
                </example>
                <example src="PERMUTATE" no="88">
                    <text>It is important to note that the findings show that Arr99 and Arr253 will disrupt no hydrogen bond pairing in the model.</text>
                    <arg n="0">Arr99 and Arr253</arg>
                    <arg n="1">hydrogen bond pairing in the model</arg>
                </example>
                <example src="PERMUTATE" no="89">
                    <text>It is important to note that the findings show that Arr99 and Arr253 will disrupt no the hydrogen bonding pairing in the model.</text>
                    <arg n="0">Arr99 and Arr253</arg>
                    <arg n="1">the hydrogen bonding pairing in the model</arg>
                </example>
                <example src="PERMUTATE" no="90">
                    <text>It is important to note that the findings show that Gly188---Glu mutation will disrupt no a site Ava II.</text>
                    <arg n="0">Gly188---Glu mutation</arg>
                    <arg n="1">a site Ava II</arg>
                </example>
                <example src="PERMUTATE" no="91">
                    <text>It is important to note that the findings show that Gly188---Glu mutation will disrupt no one site Ava II.</text>
                    <arg n="0">Gly188---Glu mutation</arg>
                    <arg n="1">one site Ava II</arg>
                </example>
                <example src="PERMUTATE" no="92">
                    <text>It is important to note that the findings show that Mutation 415G4 will disrupt no potent spike: (GAR)n-(GAR)n.</text>
                    <arg n="0">Mutation 415G4</arg>
                    <arg n="1">potent spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="PERMUTATE" no="93">
                    <text>It is important to note that the findings show that a homozygous mutation will disrupt no pulally.</text>
                    <arg n="0">a homozygous mutation</arg>
                    <arg n="1">pulally</arg>
                </example>
                <example src="PERMUTATE" no="94">
                    <text>It is important to note that the findings show that a homozygous mutation will disrupt no split.</text>
                    <arg n="0">a homozygous mutation</arg>
                    <arg n="1">split</arg>
                </example>
                <example src="PERMUTATE" no="95">
                    <text>It is important to note that the findings show that alcohol consumption exposure will disrupt no ocular dominance plasticity.</text>
                    <arg n="0">alcohol consumption exposure</arg>
                    <arg n="1">ocular dominance plasticity</arg>
                </example>
                <example src="PERMUTATE" no="96">
                    <text>It is important to note that the findings show that alcohol exposure will disrupt no ocular domain plasticity.</text>
                    <arg n="0">alcohol exposure</arg>
                    <arg n="1">ocular domain plasticity</arg>
                </example>
                <example src="PERMUTATE" no="97">
                    <text>It is important to note that the findings show that alcohol exposure will disrupt no ocular dominance plasticity.</text>
                    <arg n="0">alcohol exposure</arg>
                    <arg n="1">ocular dominance plasticity</arg>
                </example>
                <example src="PERMUTATE" no="98">
                    <text>It is important to note that the findings show that exposure to alcohol consumption will disrupt no ocular domain plasticity.</text>
                    <arg n="0">exposure to alcohol consumption</arg>
                    <arg n="1">ocular domain plasticity</arg>
                </example>
                <example src="PERMUTATE" no="99">
                    <text>It is important to note that the findings show that exposure to alcohol consumption will disrupt no plasticity of eye dominance.</text>
                    <arg n="0">exposure to alcohol consumption</arg>
                    <arg n="1">plasticity of eye dominance</arg>
                </example>
                <example src="PERMUTATE" no="100">
                    <text>It is important to note that the findings show that his retired expression MEKK1 or MEKK2 will disrupt no the overall integrity of MAPK pathway regulation.</text>
                    <arg n="0">his retired expression MEKK1 or MEKK2</arg>
                    <arg n="1">the overall integrity of MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="101">
                    <text>It is important to note that the findings show that homozygous mutation will disrupt no spacing.</text>
                    <arg n="0">homozygous mutation</arg>
                    <arg n="1">spacing</arg>
                </example>
                <example src="PERMUTATE" no="102">
                    <text>It is important to note that the findings show that homozygous mutation will disrupt no squirrel.</text>
                    <arg n="0">homozygous mutation</arg>
                    <arg n="1">squirrel</arg>
                </example>
                <example src="PERMUTATE" no="103">
                    <text>It is important to note that the findings show that if retired from the expression MEKK1 or MEKK2 will disrupt no the overall integrity of MAPK pathway regulation.</text>
                    <arg n="0">if retired from the expression MEKK1 or MEKK2</arg>
                    <arg n="1">the overall integrity of MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="104">
                    <text>It is important to note that the findings show that inhibition of inflammation will disrupt no physiological protective response.</text>
                    <arg n="0">inhibition of inflammation</arg>
                    <arg n="1">physiological protective response</arg>
                </example>
                <example src="PERMUTATE" no="105">
                    <text>It is important to note that the findings show that inhibition of inflammation will disrupt no protective physiological responses.</text>
                    <arg n="0">inhibition of inflammation</arg>
                    <arg n="1">protective physiological responses</arg>
                </example>
                <example src="PERMUTATE" no="106">
                    <text>It is important to note that the findings show that knockout of the expression MEKK1 or MEKK2 will disrupt no the overall integrity of MAPK pathway regulation.</text>
                    <arg n="0">knockout of the expression MEKK1 or MEKK2</arg>
                    <arg n="1">the overall integrity of MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="107">
                    <text>It is important to note that the findings show that the Gly188--Glu mutation will disrupt no an Ava II site.</text>
                    <arg n="0">the Gly188--Glu mutation</arg>
                    <arg n="1">an Ava II site</arg>
                </example>
                <example src="PERMUTATE" no="108">
                    <text>It is important to note that the findings show that the knockout of the MEKK1 or MEKK2 expression will disrupt no the overall integrity of the MAPK pathway regulation.</text>
                    <arg n="0">the knockout of the MEKK1 or MEKK2 expression</arg>
                    <arg n="1">the overall integrity of the MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="109">
                    <text>It is important to note that the findings show that this deletion will disrupt no open reading frame.</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">open reading frame</arg>
                </example>
                <example src="PERMUTATE" no="110">
                    <text>It is important to note that the findings show that this deletion will disrupt no the open reading frame.</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">the open reading frame</arg>
                </example>
                <example src="PERMUTATE" no="111">
                    <text>It is important to note that the findings show that this deletion will disrupt no the open reading structure.</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">the open reading structure</arg>
                </example>
                <example src="PERMUTATE" no="112">
                    <text>It is important to note that this deletion disrupt open reading frame.</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">open reading frame</arg>
                </example>
                <example src="PERMUTATE" no="113">
                    <text>It is important to note that this deletion disrupt the open reading frame.</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">the open reading frame</arg>
                </example>
                <example src="PERMUTATE" no="114">
                    <text>It is important to note that this deletion disrupt the open reading structure.</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">the open reading structure</arg>
                </example>
                <example src="PERMUTATE" no="115">
                    <text>It is important to point out that Arg99 and Arg253 disrupt hydrogen bonds in the model.</text>
                    <arg n="0">Arg99 and Arg253</arg>
                    <arg n="1">hydrogen bonds in the model</arg>
                </example>
                <example src="PERMUTATE" no="116">
                    <text>It is important to point out that Arr99 and Arr253 disrupt hydrogen bond pairing in the model.</text>
                    <arg n="0">Arr99 and Arr253</arg>
                    <arg n="1">hydrogen bond pairing in the model</arg>
                </example>
                <example src="PERMUTATE" no="117">
                    <text>It is important to point out that Arr99 and Arr253 disrupt the hydrogen bonding pairing in the model.</text>
                    <arg n="0">Arr99 and Arr253</arg>
                    <arg n="1">the hydrogen bonding pairing in the model</arg>
                </example>
                <example src="PERMUTATE" no="118">
                    <text>It is important to point out that Gly188---Glu mutation disrupt a site Ava II.</text>
                    <arg n="0">Gly188---Glu mutation</arg>
                    <arg n="1">a site Ava II</arg>
                </example>
                <example src="PERMUTATE" no="119">
                    <text>It is important to point out that Gly188---Glu mutation disrupt one site Ava II.</text>
                    <arg n="0">Gly188---Glu mutation</arg>
                    <arg n="1">one site Ava II</arg>
                </example>
                <example src="PERMUTATE" no="120">
                    <text>It is important to point out that Mutation 415G4 disrupt potent spike: (GAR)n-(GAR)n.</text>
                    <arg n="0">Mutation 415G4</arg>
                    <arg n="1">potent spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="PERMUTATE" no="121">
                    <text>It is important to point out that a homozygous mutation disrupt pulally.</text>
                    <arg n="0">a homozygous mutation</arg>
                    <arg n="1">pulally</arg>
                </example>
                <example src="PERMUTATE" no="122">
                    <text>It is important to point out that a homozygous mutation disrupt split.</text>
                    <arg n="0">a homozygous mutation</arg>
                    <arg n="1">split</arg>
                </example>
                <example src="PERMUTATE" no="123">
                    <text>It is important to point out that alcohol consumption exposure disrupt ocular dominance plasticity.</text>
                    <arg n="0">alcohol consumption exposure</arg>
                    <arg n="1">ocular dominance plasticity</arg>
                </example>
                <example src="PERMUTATE" no="124">
                    <text>It is important to point out that alcohol exposure disrupt ocular domain plasticity.</text>
                    <arg n="0">alcohol exposure</arg>
                    <arg n="1">ocular domain plasticity</arg>
                </example>
                <example src="PERMUTATE" no="125">
                    <text>It is important to point out that alcohol exposure disrupt ocular dominance plasticity.</text>
                    <arg n="0">alcohol exposure</arg>
                    <arg n="1">ocular dominance plasticity</arg>
                </example>
                <example src="PERMUTATE" no="126">
                    <text>It is important to point out that exposure to alcohol consumption disrupt ocular domain plasticity.</text>
                    <arg n="0">exposure to alcohol consumption</arg>
                    <arg n="1">ocular domain plasticity</arg>
                </example>
                <example src="PERMUTATE" no="127">
                    <text>It is important to point out that exposure to alcohol consumption disrupt plasticity of eye dominance.</text>
                    <arg n="0">exposure to alcohol consumption</arg>
                    <arg n="1">plasticity of eye dominance</arg>
                </example>
                <example src="PERMUTATE" no="128">
                    <text>It is important to point out that his retired expression MEKK1 or MEKK2 disrupt the overall integrity of MAPK pathway regulation.</text>
                    <arg n="0">his retired expression MEKK1 or MEKK2</arg>
                    <arg n="1">the overall integrity of MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="129">
                    <text>It is important to point out that homozygous mutation disrupt spacing.</text>
                    <arg n="0">homozygous mutation</arg>
                    <arg n="1">spacing</arg>
                </example>
                <example src="PERMUTATE" no="130">
                    <text>It is important to point out that homozygous mutation disrupt squirrel.</text>
                    <arg n="0">homozygous mutation</arg>
                    <arg n="1">squirrel</arg>
                </example>
                <example src="PERMUTATE" no="131">
                    <text>It is important to point out that if retired from the expression MEKK1 or MEKK2 disrupt the overall integrity of MAPK pathway regulation.</text>
                    <arg n="0">if retired from the expression MEKK1 or MEKK2</arg>
                    <arg n="1">the overall integrity of MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="132">
                    <text>It is important to point out that inhibition of inflammation disrupt physiological protective response.</text>
                    <arg n="0">inhibition of inflammation</arg>
                    <arg n="1">physiological protective response</arg>
                </example>
                <example src="PERMUTATE" no="133">
                    <text>It is important to point out that inhibition of inflammation disrupt protective physiological responses.</text>
                    <arg n="0">inhibition of inflammation</arg>
                    <arg n="1">protective physiological responses</arg>
                </example>
                <example src="PERMUTATE" no="134">
                    <text>It is important to point out that retired from the MEKK1 or MEKK2 expression disrupt the overall integrity of the MAPK pathway regulation.</text>
                    <arg n="0">retired from the MEKK1 or MEKK2 expression</arg>
                    <arg n="1">the overall integrity of the MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="135">
                    <text>It is important to point out that the Gly188--Glu mutation disrupt an Ava II site.</text>
                    <arg n="0">the Gly188--Glu mutation</arg>
                    <arg n="1">an Ava II site</arg>
                </example>
                <example src="PERMUTATE" no="136">
                    <text>It is important to point out that the knockout of the MEKK1 or MEKK2 expression disrupt the overall integrity of the MAPK pathway regulation.</text>
                    <arg n="0">the knockout of the MEKK1 or MEKK2 expression</arg>
                    <arg n="1">the overall integrity of the MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="137">
                    <text>It is important to point out that this deletion disrupt open reading frame.</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">open reading frame</arg>
                </example>
                <example src="PERMUTATE" no="138">
                    <text>It is important to point out that this deletion disrupt the open reading frame.</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">the open reading frame</arg>
                </example>
                <example src="PERMUTATE" no="139">
                    <text>It is important to point out that this deletion disrupt the open reading structure.</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">the open reading structure</arg>
                </example>
                <example src="PERMUTATE" no="140">
                    <text>It is important to stress that Arg99 and Arg253 could disrupt with hydrogen bonds in the model.</text>
                    <arg n="0">Arg99 and Arg253</arg>
                    <arg n="1">hydrogen bonds in the model</arg>
                </example>
                <example src="PERMUTATE" no="141">
                    <text>It is important to stress that Arg99 and Arg253 has the no that disrupt hydrogen bonds in the model.</text>
                    <arg n="0">Arg99 and Arg253</arg>
                    <arg n="1">hydrogen bonds in the model</arg>
                </example>
                <example src="PERMUTATE" no="142">
                    <text>It is important to stress that Arg99 and Arg253 is able to disrupt hydrogen bonds in the model.</text>
                    <arg n="0">Arg99 and Arg253</arg>
                    <arg n="1">hydrogen bonds in the model</arg>
                </example>
                <example src="PERMUTATE" no="143">
                    <text>It is important to stress that Arr99 and Arr253 could disrupt with hydrogen bond pairing in the model.</text>
                    <arg n="0">Arr99 and Arr253</arg>
                    <arg n="1">hydrogen bond pairing in the model</arg>
                </example>
                <example src="PERMUTATE" no="144">
                    <text>It is important to stress that Arr99 and Arr253 could disrupt with the hydrogen bonding pairing in the model.</text>
                    <arg n="0">Arr99 and Arr253</arg>
                    <arg n="1">the hydrogen bonding pairing in the model</arg>
                </example>
                <example src="PERMUTATE" no="145">
                    <text>It is important to stress that Arr99 and Arr253 has the no that disrupt hydrogen bond pairing in the model.</text>
                    <arg n="0">Arr99 and Arr253</arg>
                    <arg n="1">hydrogen bond pairing in the model</arg>
                </example>
                <example src="PERMUTATE" no="146">
                    <text>It is important to stress that Arr99 and Arr253 has the no that disrupt the hydrogen bonding pairing in the model.</text>
                    <arg n="0">Arr99 and Arr253</arg>
                    <arg n="1">the hydrogen bonding pairing in the model</arg>
                </example>
                <example src="PERMUTATE" no="147">
                    <text>It is important to stress that Arr99 and Arr253 is able to disrupt hydrogen bond pairing in the model.</text>
                    <arg n="0">Arr99 and Arr253</arg>
                    <arg n="1">hydrogen bond pairing in the model</arg>
                </example>
                <example src="PERMUTATE" no="148">
                    <text>It is important to stress that Arr99 and Arr253 is able to disrupt the hydrogen bonding pairing in the model.</text>
                    <arg n="0">Arr99 and Arr253</arg>
                    <arg n="1">the hydrogen bonding pairing in the model</arg>
                </example>
                <example src="PERMUTATE" no="149">
                    <text>It is important to stress that Gly188---Glu mutation could disrupt with a site Ava II.</text>
                    <arg n="0">Gly188---Glu mutation</arg>
                    <arg n="1">a site Ava II</arg>
                </example>
                <example src="PERMUTATE" no="150">
                    <text>It is important to stress that Gly188---Glu mutation could disrupt with one site Ava II.</text>
                    <arg n="0">Gly188---Glu mutation</arg>
                    <arg n="1">one site Ava II</arg>
                </example>
                <example src="PERMUTATE" no="151">
                    <text>It is important to stress that Gly188---Glu mutation has the no that disrupt a site Ava II.</text>
                    <arg n="0">Gly188---Glu mutation</arg>
                    <arg n="1">a site Ava II</arg>
                </example>
                <example src="PERMUTATE" no="152">
                    <text>It is important to stress that Gly188---Glu mutation has the no that disrupt one site Ava II.</text>
                    <arg n="0">Gly188---Glu mutation</arg>
                    <arg n="1">one site Ava II</arg>
                </example>
                <example src="PERMUTATE" no="153">
                    <text>It is important to stress that Gly188---Glu mutation is able to disrupt a site Ava II.</text>
                    <arg n="0">Gly188---Glu mutation</arg>
                    <arg n="1">a site Ava II</arg>
                </example>
                <example src="PERMUTATE" no="154">
                    <text>It is important to stress that Gly188---Glu mutation is able to disrupt one site Ava II.</text>
                    <arg n="0">Gly188---Glu mutation</arg>
                    <arg n="1">one site Ava II</arg>
                </example>
                <example src="PERMUTATE" no="155">
                    <text>It is important to stress that Mutation 415G4 could disrupt with potent spike: (GAR)n-(GAR)n.</text>
                    <arg n="0">Mutation 415G4</arg>
                    <arg n="1">potent spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="PERMUTATE" no="156">
                    <text>It is important to stress that Mutation 415G4 has the no that disrupt potent spike: (GAR)n-(GAR)n.</text>
                    <arg n="0">Mutation 415G4</arg>
                    <arg n="1">potent spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="PERMUTATE" no="157">
                    <text>It is important to stress that Mutation 415G4 is able to disrupt potent spike: (GAR)n-(GAR)n.</text>
                    <arg n="0">Mutation 415G4</arg>
                    <arg n="1">potent spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="PERMUTATE" no="158">
                    <text>It is important to stress that a homozygous mutation could disrupt with pulally.</text>
                    <arg n="0">a homozygous mutation</arg>
                    <arg n="1">pulally</arg>
                </example>
                <example src="PERMUTATE" no="159">
                    <text>It is important to stress that a homozygous mutation could disrupt with split.</text>
                    <arg n="0">a homozygous mutation</arg>
                    <arg n="1">split</arg>
                </example>
                <example src="PERMUTATE" no="160">
                    <text>It is important to stress that a homozygous mutation has the no that disrupt pulally.</text>
                    <arg n="0">a homozygous mutation</arg>
                    <arg n="1">pulally</arg>
                </example>
                <example src="PERMUTATE" no="161">
                    <text>It is important to stress that a homozygous mutation has the no that disrupt split.</text>
                    <arg n="0">a homozygous mutation</arg>
                    <arg n="1">split</arg>
                </example>
                <example src="PERMUTATE" no="162">
                    <text>It is important to stress that a homozygous mutation is able to disrupt pulally.</text>
                    <arg n="0">a homozygous mutation</arg>
                    <arg n="1">pulally</arg>
                </example>
                <example src="PERMUTATE" no="163">
                    <text>It is important to stress that a homozygous mutation is able to disrupt split.</text>
                    <arg n="0">a homozygous mutation</arg>
                    <arg n="1">split</arg>
                </example>
                <example src="PERMUTATE" no="164">
                    <text>It is important to stress that alcohol consumption exposure could disrupt with ocular dominance plasticity.</text>
                    <arg n="0">alcohol consumption exposure</arg>
                    <arg n="1">ocular dominance plasticity</arg>
                </example>
                <example src="PERMUTATE" no="165">
                    <text>It is important to stress that alcohol consumption exposure has the no that disrupt ocular dominance plasticity.</text>
                    <arg n="0">alcohol consumption exposure</arg>
                    <arg n="1">ocular dominance plasticity</arg>
                </example>
                <example src="PERMUTATE" no="166">
                    <text>It is important to stress that alcohol consumption exposure is able to disrupt ocular dominance plasticity.</text>
                    <arg n="0">alcohol consumption exposure</arg>
                    <arg n="1">ocular dominance plasticity</arg>
                </example>
                <example src="PERMUTATE" no="167">
                    <text>It is important to stress that alcohol exposure could disrupt with ocular domain plasticity.</text>
                    <arg n="0">alcohol exposure</arg>
                    <arg n="1">ocular domain plasticity</arg>
                </example>
                <example src="PERMUTATE" no="168">
                    <text>It is important to stress that alcohol exposure could disrupt with ocular dominance plasticity.</text>
                    <arg n="0">alcohol exposure</arg>
                    <arg n="1">ocular dominance plasticity</arg>
                </example>
                <example src="PERMUTATE" no="169">
                    <text>It is important to stress that alcohol exposure has the no that disrupt ocular domain plasticity.</text>
                    <arg n="0">alcohol exposure</arg>
                    <arg n="1">ocular domain plasticity</arg>
                </example>
                <example src="PERMUTATE" no="170">
                    <text>It is important to stress that alcohol exposure has the no that disrupt ocular dominance plasticity.</text>
                    <arg n="0">alcohol exposure</arg>
                    <arg n="1">ocular dominance plasticity</arg>
                </example>
                <example src="PERMUTATE" no="171">
                    <text>It is important to stress that alcohol exposure is able to disrupt ocular domain plasticity.</text>
                    <arg n="0">alcohol exposure</arg>
                    <arg n="1">ocular domain plasticity</arg>
                </example>
                <example src="PERMUTATE" no="172">
                    <text>It is important to stress that alcohol exposure is able to disrupt ocular dominance plasticity.</text>
                    <arg n="0">alcohol exposure</arg>
                    <arg n="1">ocular dominance plasticity</arg>
                </example>
                <example src="PERMUTATE" no="173">
                    <text>It is important to stress that exposure to alcohol consumption could disrupt with ocular domain plasticity.</text>
                    <arg n="0">exposure to alcohol consumption</arg>
                    <arg n="1">ocular domain plasticity</arg>
                </example>
                <example src="PERMUTATE" no="174">
                    <text>It is important to stress that exposure to alcohol consumption could disrupt with plasticity of eye dominance.</text>
                    <arg n="0">exposure to alcohol consumption</arg>
                    <arg n="1">plasticity of eye dominance</arg>
                </example>
                <example src="PERMUTATE" no="175">
                    <text>It is important to stress that exposure to alcohol consumption has the no that disrupt ocular domain plasticity.</text>
                    <arg n="0">exposure to alcohol consumption</arg>
                    <arg n="1">ocular domain plasticity</arg>
                </example>
                <example src="PERMUTATE" no="176">
                    <text>It is important to stress that exposure to alcohol consumption has the no that disrupt plasticity of eye dominance.</text>
                    <arg n="0">exposure to alcohol consumption</arg>
                    <arg n="1">plasticity of eye dominance</arg>
                </example>
                <example src="PERMUTATE" no="177">
                    <text>It is important to stress that exposure to alcohol consumption is able to disrupt ocular domain plasticity.</text>
                    <arg n="0">exposure to alcohol consumption</arg>
                    <arg n="1">ocular domain plasticity</arg>
                </example>
                <example src="PERMUTATE" no="178">
                    <text>It is important to stress that exposure to alcohol consumption is able to disrupt plasticity of eye dominance.</text>
                    <arg n="0">exposure to alcohol consumption</arg>
                    <arg n="1">plasticity of eye dominance</arg>
                </example>
                <example src="PERMUTATE" no="179">
                    <text>It is important to stress that his retired expression MEKK1 or MEKK2 could disrupt with the overall integrity of MAPK pathway regulation.</text>
                    <arg n="0">his retired expression MEKK1 or MEKK2</arg>
                    <arg n="1">the overall integrity of MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="180">
                    <text>It is important to stress that his retired expression MEKK1 or MEKK2 has the no that disrupt the overall integrity of MAPK pathway regulation.</text>
                    <arg n="0">his retired expression MEKK1 or MEKK2</arg>
                    <arg n="1">the overall integrity of MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="181">
                    <text>It is important to stress that his retired expression MEKK1 or MEKK2 is able to disrupt the overall integrity of MAPK pathway regulation.</text>
                    <arg n="0">his retired expression MEKK1 or MEKK2</arg>
                    <arg n="1">the overall integrity of MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="182">
                    <text>It is important to stress that homozygous mutation could disrupt with spacing.</text>
                    <arg n="0">homozygous mutation</arg>
                    <arg n="1">spacing</arg>
                </example>
                <example src="PERMUTATE" no="183">
                    <text>It is important to stress that homozygous mutation could disrupt with squirrel.</text>
                    <arg n="0">homozygous mutation</arg>
                    <arg n="1">squirrel</arg>
                </example>
                <example src="PERMUTATE" no="184">
                    <text>It is important to stress that homozygous mutation has the no that disrupt spacing.</text>
                    <arg n="0">homozygous mutation</arg>
                    <arg n="1">spacing</arg>
                </example>
                <example src="PERMUTATE" no="185">
                    <text>It is important to stress that homozygous mutation has the no that disrupt squirrel.</text>
                    <arg n="0">homozygous mutation</arg>
                    <arg n="1">squirrel</arg>
                </example>
                <example src="PERMUTATE" no="186">
                    <text>It is important to stress that homozygous mutation is able to disrupt spacing.</text>
                    <arg n="0">homozygous mutation</arg>
                    <arg n="1">spacing</arg>
                </example>
                <example src="PERMUTATE" no="187">
                    <text>It is important to stress that homozygous mutation is able to disrupt squirrel.</text>
                    <arg n="0">homozygous mutation</arg>
                    <arg n="1">squirrel</arg>
                </example>
                <example src="PERMUTATE" no="188">
                    <text>It is important to stress that if retired from the expression MEKK1 or MEKK2 could disrupt with the overall integrity of MAPK pathway regulation.</text>
                    <arg n="0">if retired from the expression MEKK1 or MEKK2</arg>
                    <arg n="1">the overall integrity of MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="189">
                    <text>It is important to stress that if retired from the expression MEKK1 or MEKK2 has the no that disrupt the overall integrity of MAPK pathway regulation.</text>
                    <arg n="0">if retired from the expression MEKK1 or MEKK2</arg>
                    <arg n="1">the overall integrity of MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="190">
                    <text>It is important to stress that if retired from the expression MEKK1 or MEKK2 is able to disrupt the overall integrity of MAPK pathway regulation.</text>
                    <arg n="0">if retired from the expression MEKK1 or MEKK2</arg>
                    <arg n="1">the overall integrity of MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="191">
                    <text>It is important to stress that inhibition of inflammation could disrupt with physiological protective response.</text>
                    <arg n="0">inhibition of inflammation</arg>
                    <arg n="1">physiological protective response</arg>
                </example>
                <example src="PERMUTATE" no="192">
                    <text>It is important to stress that inhibition of inflammation could disrupt with protective physiological responses.</text>
                    <arg n="0">inhibition of inflammation</arg>
                    <arg n="1">protective physiological responses</arg>
                </example>
                <example src="PERMUTATE" no="193">
                    <text>It is important to stress that inhibition of inflammation has the no that disrupt physiological protective response.</text>
                    <arg n="0">inhibition of inflammation</arg>
                    <arg n="1">physiological protective response</arg>
                </example>
                <example src="PERMUTATE" no="194">
                    <text>It is important to stress that inhibition of inflammation has the no that disrupt protective physiological responses.</text>
                    <arg n="0">inhibition of inflammation</arg>
                    <arg n="1">protective physiological responses</arg>
                </example>
                <example src="PERMUTATE" no="195">
                    <text>It is important to stress that inhibition of inflammation is able to disrupt physiological protective response.</text>
                    <arg n="0">inhibition of inflammation</arg>
                    <arg n="1">physiological protective response</arg>
                </example>
                <example src="PERMUTATE" no="196">
                    <text>It is important to stress that inhibition of inflammation is able to disrupt protective physiological responses.</text>
                    <arg n="0">inhibition of inflammation</arg>
                    <arg n="1">protective physiological responses</arg>
                </example>
                <example src="PERMUTATE" no="197">
                    <text>It is important to stress that retired from the MEKK1 or MEKK2 expression could disrupt with the overall integrity of the MAPK pathway regulation.</text>
                    <arg n="0">retired from the MEKK1 or MEKK2 expression</arg>
                    <arg n="1">the overall integrity of the MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="198">
                    <text>It is important to stress that retired from the MEKK1 or MEKK2 expression has the no that disrupt the overall integrity of the MAPK pathway regulation.</text>
                    <arg n="0">retired from the MEKK1 or MEKK2 expression</arg>
                    <arg n="1">the overall integrity of the MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="199">
                    <text>It is important to stress that retired from the MEKK1 or MEKK2 expression is able to disrupt the overall integrity of the MAPK pathway regulation.</text>
                    <arg n="0">retired from the MEKK1 or MEKK2 expression</arg>
                    <arg n="1">the overall integrity of the MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="200">
                    <text>It is important to stress that the Gly188--Glu mutation could disrupt with an Ava II site.</text>
                    <arg n="0">the Gly188--Glu mutation</arg>
                    <arg n="1">an Ava II site</arg>
                </example>
                <example src="PERMUTATE" no="201">
                    <text>It is important to stress that the Gly188--Glu mutation has the no that disrupt an Ava II site.</text>
                    <arg n="0">the Gly188--Glu mutation</arg>
                    <arg n="1">an Ava II site</arg>
                </example>
                <example src="PERMUTATE" no="202">
                    <text>It is important to stress that the Gly188--Glu mutation is able to disrupt an Ava II site.</text>
                    <arg n="0">the Gly188--Glu mutation</arg>
                    <arg n="1">an Ava II site</arg>
                </example>
                <example src="PERMUTATE" no="203">
                    <text>It is important to stress that the findings show that Arg99 and Arg253 could disrupt hydrogen bonds in the model.</text>
                    <arg n="0">Arg99 and Arg253</arg>
                    <arg n="1">hydrogen bonds in the model</arg>
                </example>
                <example src="PERMUTATE" no="204">
                    <text>It is important to stress that the findings show that Arg99 and Arg253 disrupt the expression no hydrogen bonds in the model.</text>
                    <arg n="0">Arg99 and Arg253</arg>
                    <arg n="1">hydrogen bonds in the model</arg>
                </example>
                <example src="PERMUTATE" no="205">
                    <text>It is important to stress that the findings show that Arr99 and Arr253 could disrupt hydrogen bond pairing in the model.</text>
                    <arg n="0">Arr99 and Arr253</arg>
                    <arg n="1">hydrogen bond pairing in the model</arg>
                </example>
                <example src="PERMUTATE" no="206">
                    <text>It is important to stress that the findings show that Arr99 and Arr253 could disrupt the hydrogen bonding pairing in the model.</text>
                    <arg n="0">Arr99 and Arr253</arg>
                    <arg n="1">the hydrogen bonding pairing in the model</arg>
                </example>
                <example src="PERMUTATE" no="207">
                    <text>It is important to stress that the findings show that Arr99 and Arr253 disrupt the expression no hydrogen bond pairing in the model.</text>
                    <arg n="0">Arr99 and Arr253</arg>
                    <arg n="1">hydrogen bond pairing in the model</arg>
                </example>
                <example src="PERMUTATE" no="208">
                    <text>It is important to stress that the findings show that Arr99 and Arr253 disrupt the expression no the hydrogen bonding pairing in the model.</text>
                    <arg n="0">Arr99 and Arr253</arg>
                    <arg n="1">the hydrogen bonding pairing in the model</arg>
                </example>
                <example src="PERMUTATE" no="209">
                    <text>It is important to stress that the findings show that Gly188---Glu mutation could disrupt a site Ava II.</text>
                    <arg n="0">Gly188---Glu mutation</arg>
                    <arg n="1">a site Ava II</arg>
                </example>
                <example src="PERMUTATE" no="210">
                    <text>It is important to stress that the findings show that Gly188---Glu mutation could disrupt one site Ava II.</text>
                    <arg n="0">Gly188---Glu mutation</arg>
                    <arg n="1">one site Ava II</arg>
                </example>
                <example src="PERMUTATE" no="211">
                    <text>It is important to stress that the findings show that Gly188---Glu mutation disrupt the expression no a site Ava II.</text>
                    <arg n="0">Gly188---Glu mutation</arg>
                    <arg n="1">a site Ava II</arg>
                </example>
                <example src="PERMUTATE" no="212">
                    <text>It is important to stress that the findings show that Gly188---Glu mutation disrupt the expression no one site Ava II.</text>
                    <arg n="0">Gly188---Glu mutation</arg>
                    <arg n="1">one site Ava II</arg>
                </example>
                <example src="PERMUTATE" no="213">
                    <text>It is important to stress that the findings show that Mutation 415G4 could disrupt potent spike: (GAR)n-(GAR)n.</text>
                    <arg n="0">Mutation 415G4</arg>
                    <arg n="1">potent spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="PERMUTATE" no="214">
                    <text>It is important to stress that the findings show that Mutation 415G4 disrupt the expression no potent spike: (GAR)n-(GAR)n.</text>
                    <arg n="0">Mutation 415G4</arg>
                    <arg n="1">potent spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="PERMUTATE" no="215">
                    <text>It is important to stress that the findings show that a homozygous mutation could disrupt pulally.</text>
                    <arg n="0">a homozygous mutation</arg>
                    <arg n="1">pulally</arg>
                </example>
                <example src="PERMUTATE" no="216">
                    <text>It is important to stress that the findings show that a homozygous mutation could disrupt split.</text>
                    <arg n="0">a homozygous mutation</arg>
                    <arg n="1">split</arg>
                </example>
                <example src="PERMUTATE" no="217">
                    <text>It is important to stress that the findings show that a homozygous mutation disrupt the expression no pulally.</text>
                    <arg n="0">a homozygous mutation</arg>
                    <arg n="1">pulally</arg>
                </example>
                <example src="PERMUTATE" no="218">
                    <text>It is important to stress that the findings show that a homozygous mutation disrupt the expression no split.</text>
                    <arg n="0">a homozygous mutation</arg>
                    <arg n="1">split</arg>
                </example>
                <example src="PERMUTATE" no="219">
                    <text>It is important to stress that the findings show that alcohol consumption exposure could disrupt ocular dominance plasticity.</text>
                    <arg n="0">alcohol consumption exposure</arg>
                    <arg n="1">ocular dominance plasticity</arg>
                </example>
                <example src="PERMUTATE" no="220">
                    <text>It is important to stress that the findings show that alcohol consumption exposure disrupt the expression no ocular dominance plasticity.</text>
                    <arg n="0">alcohol consumption exposure</arg>
                    <arg n="1">ocular dominance plasticity</arg>
                </example>
                <example src="PERMUTATE" no="221">
                    <text>It is important to stress that the findings show that alcohol exposure could disrupt ocular domain plasticity.</text>
                    <arg n="0">alcohol exposure</arg>
                    <arg n="1">ocular domain plasticity</arg>
                </example>
                <example src="PERMUTATE" no="222">
                    <text>It is important to stress that the findings show that alcohol exposure could disrupt ocular dominance plasticity.</text>
                    <arg n="0">alcohol exposure</arg>
                    <arg n="1">ocular dominance plasticity</arg>
                </example>
                <example src="PERMUTATE" no="223">
                    <text>It is important to stress that the findings show that alcohol exposure disrupt the expression no ocular domain plasticity.</text>
                    <arg n="0">alcohol exposure</arg>
                    <arg n="1">ocular domain plasticity</arg>
                </example>
                <example src="PERMUTATE" no="224">
                    <text>It is important to stress that the findings show that alcohol exposure disrupt the expression no ocular dominance plasticity.</text>
                    <arg n="0">alcohol exposure</arg>
                    <arg n="1">ocular dominance plasticity</arg>
                </example>
                <example src="PERMUTATE" no="225">
                    <text>It is important to stress that the findings show that exposure to alcohol consumption could disrupt ocular domain plasticity.</text>
                    <arg n="0">exposure to alcohol consumption</arg>
                    <arg n="1">ocular domain plasticity</arg>
                </example>
                <example src="PERMUTATE" no="226">
                    <text>It is important to stress that the findings show that exposure to alcohol consumption could disrupt plasticity of eye dominance.</text>
                    <arg n="0">exposure to alcohol consumption</arg>
                    <arg n="1">plasticity of eye dominance</arg>
                </example>
                <example src="PERMUTATE" no="227">
                    <text>It is important to stress that the findings show that exposure to alcohol consumption disrupt the expression no ocular domain plasticity.</text>
                    <arg n="0">exposure to alcohol consumption</arg>
                    <arg n="1">ocular domain plasticity</arg>
                </example>
                <example src="PERMUTATE" no="228">
                    <text>It is important to stress that the findings show that exposure to alcohol consumption disrupt the expression no plasticity of eye dominance.</text>
                    <arg n="0">exposure to alcohol consumption</arg>
                    <arg n="1">plasticity of eye dominance</arg>
                </example>
                <example src="PERMUTATE" no="229">
                    <text>It is important to stress that the findings show that his retired expression MEKK1 or MEKK2 could disrupt the overall integrity of MAPK pathway regulation.</text>
                    <arg n="0">his retired expression MEKK1 or MEKK2</arg>
                    <arg n="1">the overall integrity of MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="230">
                    <text>It is important to stress that the findings show that homozygous mutation could disrupt spacing.</text>
                    <arg n="0">homozygous mutation</arg>
                    <arg n="1">spacing</arg>
                </example>
                <example src="PERMUTATE" no="231">
                    <text>It is important to stress that the findings show that homozygous mutation could disrupt squirrel.</text>
                    <arg n="0">homozygous mutation</arg>
                    <arg n="1">squirrel</arg>
                </example>
                <example src="PERMUTATE" no="232">
                    <text>It is important to stress that the findings show that homozygous mutation disrupt the expression no spacing.</text>
                    <arg n="0">homozygous mutation</arg>
                    <arg n="1">spacing</arg>
                </example>
                <example src="PERMUTATE" no="233">
                    <text>It is important to stress that the findings show that homozygous mutation disrupt the expression no squirrel.</text>
                    <arg n="0">homozygous mutation</arg>
                    <arg n="1">squirrel</arg>
                </example>
                <example src="PERMUTATE" no="234">
                    <text>It is important to stress that the findings show that if retired from the expression MEKK1 or MEKK2 disrupt the expression no the overall integrity of MAPK pathway regulation.</text>
                    <arg n="0">if retired from the expression MEKK1 or MEKK2</arg>
                    <arg n="1">the overall integrity of MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="235">
                    <text>It is important to stress that the findings show that inhibition of inflammation could disrupt physiological protective response.</text>
                    <arg n="0">inhibition of inflammation</arg>
                    <arg n="1">physiological protective response</arg>
                </example>
                <example src="PERMUTATE" no="236">
                    <text>It is important to stress that the findings show that inhibition of inflammation could disrupt protective physiological responses.</text>
                    <arg n="0">inhibition of inflammation</arg>
                    <arg n="1">protective physiological responses</arg>
                </example>
                <example src="PERMUTATE" no="237">
                    <text>It is important to stress that the findings show that inhibition of inflammation disrupt the expression no physiological protective response.</text>
                    <arg n="0">inhibition of inflammation</arg>
                    <arg n="1">physiological protective response</arg>
                </example>
                <example src="PERMUTATE" no="238">
                    <text>It is important to stress that the findings show that inhibition of inflammation disrupt the expression no protective physiological responses.</text>
                    <arg n="0">inhibition of inflammation</arg>
                    <arg n="1">protective physiological responses</arg>
                </example>
                <example src="PERMUTATE" no="239">
                    <text>It is important to stress that the findings show that knockout of the expression MEKK1 or MEKK2 could disrupt the overall integrity of MAPK pathway regulation.</text>
                    <arg n="0">knockout of the expression MEKK1 or MEKK2</arg>
                    <arg n="1">the overall integrity of MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="240">
                    <text>It is important to stress that the findings show that knockout of the expression MEKK1 or MEKK2 disrupt the expression no the overall integrity of MAPK pathway regulation.</text>
                    <arg n="0">knockout of the expression MEKK1 or MEKK2</arg>
                    <arg n="1">the overall integrity of MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="241">
                    <text>It is important to stress that the findings show that retired from the MEKK1 or MEKK2 expression could disrupt the overall integrity of the MAPK pathway regulation.</text>
                    <arg n="0">retired from the MEKK1 or MEKK2 expression</arg>
                    <arg n="1">the overall integrity of the MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="242">
                    <text>It is important to stress that the findings show that retired from the MEKK1 or MEKK2 expression disrupt the expression no the overall integrity of the MAPK pathway regulation.</text>
                    <arg n="0">retired from the MEKK1 or MEKK2 expression</arg>
                    <arg n="1">the overall integrity of the MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="243">
                    <text>It is important to stress that the findings show that the Gly188--Glu mutation could disrupt an Ava II site.</text>
                    <arg n="0">the Gly188--Glu mutation</arg>
                    <arg n="1">an Ava II site</arg>
                </example>
                <example src="PERMUTATE" no="244">
                    <text>It is important to stress that the findings show that the Gly188--Glu mutation disrupt the expression no an Ava II site.</text>
                    <arg n="0">the Gly188--Glu mutation</arg>
                    <arg n="1">an Ava II site</arg>
                </example>
                <example src="PERMUTATE" no="245">
                    <text>It is important to stress that the findings show that the knockout of the MEKK1 or MEKK2 expression could disrupt the overall integrity of the MAPK pathway regulation.</text>
                    <arg n="0">the knockout of the MEKK1 or MEKK2 expression</arg>
                    <arg n="1">the overall integrity of the MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="246">
                    <text>It is important to stress that the findings show that the knockout of the MEKK1 or MEKK2 expression disrupt the expression no the overall integrity of the MAPK pathway regulation.</text>
                    <arg n="0">the knockout of the MEKK1 or MEKK2 expression</arg>
                    <arg n="1">the overall integrity of the MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="247">
                    <text>It is important to stress that the findings show that this deletion could disrupt open reading frame.</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">open reading frame</arg>
                </example>
                <example src="PERMUTATE" no="248">
                    <text>It is important to stress that the findings show that this deletion could disrupt the open reading frame.</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">the open reading frame</arg>
                </example>
                <example src="PERMUTATE" no="249">
                    <text>It is important to stress that the findings show that this deletion could disrupt the open reading structure.</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">the open reading structure</arg>
                </example>
                <example src="PERMUTATE" no="250">
                    <text>It is important to stress that the findings show that this deletion disrupt the expression no open reading frame.</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">open reading frame</arg>
                </example>
                <example src="PERMUTATE" no="251">
                    <text>It is important to stress that the findings show that this deletion disrupt the expression no the open reading frame.</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">the open reading frame</arg>
                </example>
                <example src="PERMUTATE" no="252">
                    <text>It is important to stress that the findings show that this deletion disrupt the expression no the open reading structure.</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">the open reading structure</arg>
                </example>
                <example src="PERMUTATE" no="253">
                    <text>It is important to stress that the knockout of the MEKK1 or MEKK2 expression could disrupt with the overall integrity of the MAPK pathway regulation.</text>
                    <arg n="0">the knockout of the MEKK1 or MEKK2 expression</arg>
                    <arg n="1">the overall integrity of the MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="254">
                    <text>It is important to stress that the knockout of the MEKK1 or MEKK2 expression has the no that disrupt the overall integrity of the MAPK pathway regulation.</text>
                    <arg n="0">the knockout of the MEKK1 or MEKK2 expression</arg>
                    <arg n="1">the overall integrity of the MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="255">
                    <text>It is important to stress that the knockout of the MEKK1 or MEKK2 expression is able to disrupt the overall integrity of the MAPK pathway regulation.</text>
                    <arg n="0">the knockout of the MEKK1 or MEKK2 expression</arg>
                    <arg n="1">the overall integrity of the MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="256">
                    <text>It is important to stress that this deletion could disrupt with open reading frame.</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">open reading frame</arg>
                </example>
                <example src="PERMUTATE" no="257">
                    <text>It is important to stress that this deletion could disrupt with the open reading frame.</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">the open reading frame</arg>
                </example>
                <example src="PERMUTATE" no="258">
                    <text>It is important to stress that this deletion could disrupt with the open reading structure.</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">the open reading structure</arg>
                </example>
                <example src="PERMUTATE" no="259">
                    <text>It is important to stress that this deletion has the no that disrupt open reading frame.</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">open reading frame</arg>
                </example>
                <example src="PERMUTATE" no="260">
                    <text>It is important to stress that this deletion has the no that disrupt the open reading frame.</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">the open reading frame</arg>
                </example>
                <example src="PERMUTATE" no="261">
                    <text>It is important to stress that this deletion has the no that disrupt the open reading structure.</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">the open reading structure</arg>
                </example>
                <example src="PERMUTATE" no="262">
                    <text>It is important to stress that this deletion is able to disrupt open reading frame.</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">open reading frame</arg>
                </example>
                <example src="PERMUTATE" no="263">
                    <text>It is important to stress that this deletion is able to disrupt the open reading frame.</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">the open reading frame</arg>
                </example>
                <example src="PERMUTATE" no="264">
                    <text>It is important to stress that this deletion is able to disrupt the open reading structure.</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">the open reading structure</arg>
                </example>
                <example src="PERMUTATE" no="265">
                    <text>Mutation 415G4 can disrupt with the base groups ceto and C (blue) on both sides of the dsDNA DNA and interrupt potent spike: (GAR)n-(GAR)n.</text>
                    <arg n="0">Mutation 415G4</arg>
                    <arg n="1">potent spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="PERMUTATE" no="266">
                    <text>Mutation 415G4 that can disrupt potent spike: (GAR)n-(GAR)n has been identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">Mutation 415G4</arg>
                    <arg n="1">potent spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="PERMUTATE" no="267">
                    <text>Mutation 415G4 that can disrupt potent spike: (GAR)n-(GAR)n that has been identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">Mutation 415G4</arg>
                    <arg n="1">potent spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="PERMUTATE" no="268">
                    <text>Mutation 415G4 that has disrupted potent spike: (GAR)n-(GAR)n was identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">Mutation 415G4</arg>
                    <arg n="1">potent spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="PERMUTATE" no="269">
                    <text>Mutation 415G4 that interact with the keto groups of the base pair GO and C (blue) on either side of the dsDNA can disrupt potent spike: (GAR)n-(GAR)n.</text>
                    <arg n="0">Mutation 415G4</arg>
                    <arg n="1">potent spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="PERMUTATE" no="270">
                    <text>Mutation 415G4 that interacts with the keto and C group pair (blue) on both sides of the dsDNA can disrupt potent spike: (GAR)n-(GAR)n.</text>
                    <arg n="0">Mutation 415G4</arg>
                    <arg n="1">potent spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="PERMUTATE" no="271">
                    <text>Mutations in p53 broke the responses of checkpoints to DNA damage and disrupted to the the potential for genome destabilization.</text>
                    <arg n="0">Mutations in p53</arg>
                    <arg n="1">responses of checkpoints to DNA damage</arg>
                    <arg n="R">the potential for genome destabilization</arg>
                </example>
                <example src="PERMUTATE" no="272">
                    <text>Mutations in p53 rupture of responses of checkpoints to DNA damage may disrupting in the potential for genome destabilization.</text>
                    <arg n="0">Mutations in p53</arg>
                    <arg n="1">responses of checkpoints to DNA damage</arg>
                    <arg n="R">the potential for genome destabilization</arg>
                </example>
                <example src="PERMUTATE" no="273">
                    <text>Quantitative electrophysiology of a single unit revealed that Arg99 and Arg253 disrupted hydrogen bonds in the model while retaining robust visual responses.</text>
                    <arg n="0">Arg99 and Arg253</arg>
                    <arg n="1">hydrogen bonds in the model</arg>
                </example>
                <example src="PERMUTATE" no="274">
                    <text>Quantitative electrophysiology of a single unit revealed that Arg99 and Arg253 has been able to disrupt hydrogen bonds in the model preserving robust visual responses.</text>
                    <arg n="0">Arg99 and Arg253</arg>
                    <arg n="1">hydrogen bonds in the model</arg>
                </example>
                <example src="PERMUTATE" no="275">
                    <text>Quantitative electrophysiology of a single unit revealed that Arg99 and Arg253 has been shown to disrupt hydrogen bonds in the model while preserving robust visual responses.</text>
                    <arg n="0">Arg99 and Arg253</arg>
                    <arg n="1">hydrogen bonds in the model</arg>
                </example>
                <example src="PERMUTATE" no="276">
                    <text>Quantitative electrophysiology of a single unit revealed that Arg99 and Arg253 has disrupted hydrogen bonds in the model while preserving robust visual responses.</text>
                    <arg n="0">Arg99 and Arg253</arg>
                    <arg n="1">hydrogen bonds in the model</arg>
                </example>
                <example src="PERMUTATE" no="277">
                    <text>Quantitative electrophysiology of a single unit revealed that Arg99 and Arg253 interrupts hydrogen bonds in the model by disrupts robust visual responses.</text>
                    <arg n="0">Arg99 and Arg253</arg>
                    <arg n="1">hydrogen bonds in the model</arg>
                </example>
                <example src="PERMUTATE" no="278">
                    <text>Quantitative electrophysiology of a single unit revealed that Arg99 and Arg253 interrupts hydrogen bonds in the model while disrupts robust visual responses.</text>
                    <arg n="0">Arg99 and Arg253</arg>
                    <arg n="1">hydrogen bonds in the model</arg>
                </example>
                <example src="PERMUTATE" no="279">
                    <text>Quantitative electrophysiology of a single unit revealed that Arg99 and Arg253 is able to detach hydrogen bonds in the model disrupt robust visual responses.</text>
                    <arg n="0">Arg99 and Arg253</arg>
                    <arg n="1">hydrogen bonds in the model</arg>
                </example>
                <example src="PERMUTATE" no="280">
                    <text>Quantitative electrophysiology of a single unit revealed that Arg99 and Arg253 is capable of disrupt hydrogen bonds in the model by preserving robust visual responses.</text>
                    <arg n="0">Arg99 and Arg253</arg>
                    <arg n="1">hydrogen bonds in the model</arg>
                </example>
                <example src="PERMUTATE" no="281">
                    <text>Quantitative electrophysiology of a single unit revealed that Arr99 and Arr253 disrupted hydrogen bond pairing in the model while retaining robust visual responses.</text>
                    <arg n="0">Arr99 and Arr253</arg>
                    <arg n="1">hydrogen bond pairing in the model</arg>
                </example>
                <example src="PERMUTATE" no="282">
                    <text>Quantitative electrophysiology of a single unit revealed that Arr99 and Arr253 disrupted the hydrogen bonding pairing in the model while retaining robust visual responses.</text>
                    <arg n="0">Arr99 and Arr253</arg>
                    <arg n="1">the hydrogen bonding pairing in the model</arg>
                </example>
                <example src="PERMUTATE" no="283">
                    <text>Quantitative electrophysiology of a single unit revealed that Arr99 and Arr253 has been able to disrupt hydrogen bond pairing in the model preserving robust visual responses.</text>
                    <arg n="0">Arr99 and Arr253</arg>
                    <arg n="1">hydrogen bond pairing in the model</arg>
                </example>
                <example src="PERMUTATE" no="284">
                    <text>Quantitative electrophysiology of a single unit revealed that Arr99 and Arr253 has been able to disrupt the hydrogen bonding pairing in the model preserving robust visual responses.</text>
                    <arg n="0">Arr99 and Arr253</arg>
                    <arg n="1">the hydrogen bonding pairing in the model</arg>
                </example>
                <example src="PERMUTATE" no="285">
                    <text>Quantitative electrophysiology of a single unit revealed that Arr99 and Arr253 has been shown to disrupt hydrogen bond pairing in the model while preserving robust visual responses.</text>
                    <arg n="0">Arr99 and Arr253</arg>
                    <arg n="1">hydrogen bond pairing in the model</arg>
                </example>
                <example src="PERMUTATE" no="286">
                    <text>Quantitative electrophysiology of a single unit revealed that Arr99 and Arr253 has been shown to disrupt the hydrogen bonding pairing in the model while preserving robust visual responses.</text>
                    <arg n="0">Arr99 and Arr253</arg>
                    <arg n="1">the hydrogen bonding pairing in the model</arg>
                </example>
                <example src="PERMUTATE" no="287">
                    <text>Quantitative electrophysiology of a single unit revealed that Arr99 and Arr253 has disrupted hydrogen bond pairing in the model while preserving robust visual responses.</text>
                    <arg n="0">Arr99 and Arr253</arg>
                    <arg n="1">hydrogen bond pairing in the model</arg>
                </example>
                <example src="PERMUTATE" no="288">
                    <text>Quantitative electrophysiology of a single unit revealed that Arr99 and Arr253 has disrupted the hydrogen bonding pairing in the model while preserving robust visual responses.</text>
                    <arg n="0">Arr99 and Arr253</arg>
                    <arg n="1">the hydrogen bonding pairing in the model</arg>
                </example>
                <example src="PERMUTATE" no="289">
                    <text>Quantitative electrophysiology of a single unit revealed that Arr99 and Arr253 interrupts hydrogen bond pairing in the model by disrupts robust visual responses.</text>
                    <arg n="0">Arr99 and Arr253</arg>
                    <arg n="1">hydrogen bond pairing in the model</arg>
                </example>
                <example src="PERMUTATE" no="290">
                    <text>Quantitative electrophysiology of a single unit revealed that Arr99 and Arr253 interrupts hydrogen bond pairing in the model while disrupts robust visual responses.</text>
                    <arg n="0">Arr99 and Arr253</arg>
                    <arg n="1">hydrogen bond pairing in the model</arg>
                </example>
                <example src="PERMUTATE" no="291">
                    <text>Quantitative electrophysiology of a single unit revealed that Arr99 and Arr253 interrupts the hydrogen bonding pairing in the model by disrupts robust visual responses.</text>
                    <arg n="0">Arr99 and Arr253</arg>
                    <arg n="1">the hydrogen bonding pairing in the model</arg>
                </example>
                <example src="PERMUTATE" no="292">
                    <text>Quantitative electrophysiology of a single unit revealed that Arr99 and Arr253 interrupts the hydrogen bonding pairing in the model while disrupts robust visual responses.</text>
                    <arg n="0">Arr99 and Arr253</arg>
                    <arg n="1">the hydrogen bonding pairing in the model</arg>
                </example>
                <example src="PERMUTATE" no="293">
                    <text>Quantitative electrophysiology of a single unit revealed that Arr99 and Arr253 is able to detach hydrogen bond pairing in the model disrupt robust visual responses.</text>
                    <arg n="0">Arr99 and Arr253</arg>
                    <arg n="1">hydrogen bond pairing in the model</arg>
                </example>
                <example src="PERMUTATE" no="294">
                    <text>Quantitative electrophysiology of a single unit revealed that Arr99 and Arr253 is able to detach the hydrogen bonding pairing in the model disrupt robust visual responses.</text>
                    <arg n="0">Arr99 and Arr253</arg>
                    <arg n="1">the hydrogen bonding pairing in the model</arg>
                </example>
                <example src="PERMUTATE" no="295">
                    <text>Quantitative electrophysiology of a single unit revealed that Arr99 and Arr253 is capable of disrupt hydrogen bond pairing in the model by preserving robust visual responses.</text>
                    <arg n="0">Arr99 and Arr253</arg>
                    <arg n="1">hydrogen bond pairing in the model</arg>
                </example>
                <example src="PERMUTATE" no="296">
                    <text>Quantitative electrophysiology of a single unit revealed that Arr99 and Arr253 is capable of disrupt the hydrogen bonding pairing in the model by preserving robust visual responses.</text>
                    <arg n="0">Arr99 and Arr253</arg>
                    <arg n="1">the hydrogen bonding pairing in the model</arg>
                </example>
                <example src="PERMUTATE" no="297">
                    <text>Quantitative electrophysiology of a single unit revealed that Gly188---Glu mutation disrupted a site Ava II while retaining robust visual responses.</text>
                    <arg n="0">Gly188---Glu mutation</arg>
                    <arg n="1">a site Ava II</arg>
                </example>
                <example src="PERMUTATE" no="298">
                    <text>Quantitative electrophysiology of a single unit revealed that Gly188---Glu mutation disrupted one site Ava II while retaining robust visual responses.</text>
                    <arg n="0">Gly188---Glu mutation</arg>
                    <arg n="1">one site Ava II</arg>
                </example>
                <example src="PERMUTATE" no="299">
                    <text>Quantitative electrophysiology of a single unit revealed that Gly188---Glu mutation has been able to disrupt a site Ava II preserving robust visual responses.</text>
                    <arg n="0">Gly188---Glu mutation</arg>
                    <arg n="1">a site Ava II</arg>
                </example>
                <example src="PERMUTATE" no="300">
                    <text>Quantitative electrophysiology of a single unit revealed that Gly188---Glu mutation has been able to disrupt one site Ava II preserving robust visual responses.</text>
                    <arg n="0">Gly188---Glu mutation</arg>
                    <arg n="1">one site Ava II</arg>
                </example>
                <example src="PERMUTATE" no="301">
                    <text>Quantitative electrophysiology of a single unit revealed that Gly188---Glu mutation has been shown to disrupt a site Ava II while preserving robust visual responses.</text>
                    <arg n="0">Gly188---Glu mutation</arg>
                    <arg n="1">a site Ava II</arg>
                </example>
                <example src="PERMUTATE" no="302">
                    <text>Quantitative electrophysiology of a single unit revealed that Gly188---Glu mutation has been shown to disrupt one site Ava II while preserving robust visual responses.</text>
                    <arg n="0">Gly188---Glu mutation</arg>
                    <arg n="1">one site Ava II</arg>
                </example>
                <example src="PERMUTATE" no="303">
                    <text>Quantitative electrophysiology of a single unit revealed that Gly188---Glu mutation has disrupted a site Ava II while preserving robust visual responses.</text>
                    <arg n="0">Gly188---Glu mutation</arg>
                    <arg n="1">a site Ava II</arg>
                </example>
                <example src="PERMUTATE" no="304">
                    <text>Quantitative electrophysiology of a single unit revealed that Gly188---Glu mutation has disrupted one site Ava II while preserving robust visual responses.</text>
                    <arg n="0">Gly188---Glu mutation</arg>
                    <arg n="1">one site Ava II</arg>
                </example>
                <example src="PERMUTATE" no="305">
                    <text>Quantitative electrophysiology of a single unit revealed that Gly188---Glu mutation interrupts a site Ava II by disrupts robust visual responses.</text>
                    <arg n="0">Gly188---Glu mutation</arg>
                    <arg n="1">a site Ava II</arg>
                </example>
                <example src="PERMUTATE" no="306">
                    <text>Quantitative electrophysiology of a single unit revealed that Gly188---Glu mutation interrupts a site Ava II while disrupts robust visual responses.</text>
                    <arg n="0">Gly188---Glu mutation</arg>
                    <arg n="1">a site Ava II</arg>
                </example>
                <example src="PERMUTATE" no="307">
                    <text>Quantitative electrophysiology of a single unit revealed that Gly188---Glu mutation interrupts one site Ava II by disrupts robust visual responses.</text>
                    <arg n="0">Gly188---Glu mutation</arg>
                    <arg n="1">one site Ava II</arg>
                </example>
                <example src="PERMUTATE" no="308">
                    <text>Quantitative electrophysiology of a single unit revealed that Gly188---Glu mutation interrupts one site Ava II while disrupts robust visual responses.</text>
                    <arg n="0">Gly188---Glu mutation</arg>
                    <arg n="1">one site Ava II</arg>
                </example>
                <example src="PERMUTATE" no="309">
                    <text>Quantitative electrophysiology of a single unit revealed that Gly188---Glu mutation is able to detach a site Ava II disrupt robust visual responses.</text>
                    <arg n="0">Gly188---Glu mutation</arg>
                    <arg n="1">a site Ava II</arg>
                </example>
                <example src="PERMUTATE" no="310">
                    <text>Quantitative electrophysiology of a single unit revealed that Gly188---Glu mutation is able to detach one site Ava II disrupt robust visual responses.</text>
                    <arg n="0">Gly188---Glu mutation</arg>
                    <arg n="1">one site Ava II</arg>
                </example>
                <example src="PERMUTATE" no="311">
                    <text>Quantitative electrophysiology of a single unit revealed that Gly188---Glu mutation is capable of disrupt a site Ava II by preserving robust visual responses.</text>
                    <arg n="0">Gly188---Glu mutation</arg>
                    <arg n="1">a site Ava II</arg>
                </example>
                <example src="PERMUTATE" no="312">
                    <text>Quantitative electrophysiology of a single unit revealed that Gly188---Glu mutation is capable of disrupt one site Ava II by preserving robust visual responses.</text>
                    <arg n="0">Gly188---Glu mutation</arg>
                    <arg n="1">one site Ava II</arg>
                </example>
                <example src="PERMUTATE" no="313">
                    <text>Quantitative electrophysiology of a single unit revealed that Mutation 415G4 disrupted potent spike: (GAR)n-(GAR)n while retaining robust visual responses.</text>
                    <arg n="0">Mutation 415G4</arg>
                    <arg n="1">potent spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="PERMUTATE" no="314">
                    <text>Quantitative electrophysiology of a single unit revealed that Mutation 415G4 has been able to disrupt potent spike: (GAR)n-(GAR)n preserving robust visual responses.</text>
                    <arg n="0">Mutation 415G4</arg>
                    <arg n="1">potent spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="PERMUTATE" no="315">
                    <text>Quantitative electrophysiology of a single unit revealed that Mutation 415G4 has been shown to disrupt potent spike: (GAR)n-(GAR)n while preserving robust visual responses.</text>
                    <arg n="0">Mutation 415G4</arg>
                    <arg n="1">potent spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="PERMUTATE" no="316">
                    <text>Quantitative electrophysiology of a single unit revealed that Mutation 415G4 has disrupted potent spike: (GAR)n-(GAR)n while preserving robust visual responses.</text>
                    <arg n="0">Mutation 415G4</arg>
                    <arg n="1">potent spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="PERMUTATE" no="317">
                    <text>Quantitative electrophysiology of a single unit revealed that Mutation 415G4 interrupts potent spike: (GAR)n-(GAR)n by disrupts robust visual responses.</text>
                    <arg n="0">Mutation 415G4</arg>
                    <arg n="1">potent spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="PERMUTATE" no="318">
                    <text>Quantitative electrophysiology of a single unit revealed that Mutation 415G4 interrupts potent spike: (GAR)n-(GAR)n while disrupts robust visual responses.</text>
                    <arg n="0">Mutation 415G4</arg>
                    <arg n="1">potent spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="PERMUTATE" no="319">
                    <text>Quantitative electrophysiology of a single unit revealed that Mutation 415G4 is able to detach potent spike: (GAR)n-(GAR)n disrupt robust visual responses.</text>
                    <arg n="0">Mutation 415G4</arg>
                    <arg n="1">potent spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="PERMUTATE" no="320">
                    <text>Quantitative electrophysiology of a single unit revealed that Mutation 415G4 is capable of disrupt potent spike: (GAR)n-(GAR)n by preserving robust visual responses.</text>
                    <arg n="0">Mutation 415G4</arg>
                    <arg n="1">potent spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="PERMUTATE" no="321">
                    <text>Quantitative electrophysiology of a single unit revealed that a homozygous mutation disrupted pulally while retaining robust visual responses.</text>
                    <arg n="0">a homozygous mutation</arg>
                    <arg n="1">pulally</arg>
                </example>
                <example src="PERMUTATE" no="322">
                    <text>Quantitative electrophysiology of a single unit revealed that a homozygous mutation disrupted split while retaining robust visual responses.</text>
                    <arg n="0">a homozygous mutation</arg>
                    <arg n="1">split</arg>
                </example>
                <example src="PERMUTATE" no="323">
                    <text>Quantitative electrophysiology of a single unit revealed that a homozygous mutation has been able to disrupt pulally preserving robust visual responses.</text>
                    <arg n="0">a homozygous mutation</arg>
                    <arg n="1">pulally</arg>
                </example>
                <example src="PERMUTATE" no="324">
                    <text>Quantitative electrophysiology of a single unit revealed that a homozygous mutation has been able to disrupt split preserving robust visual responses.</text>
                    <arg n="0">a homozygous mutation</arg>
                    <arg n="1">split</arg>
                </example>
                <example src="PERMUTATE" no="325">
                    <text>Quantitative electrophysiology of a single unit revealed that a homozygous mutation has been shown to disrupt pulally while preserving robust visual responses.</text>
                    <arg n="0">a homozygous mutation</arg>
                    <arg n="1">pulally</arg>
                </example>
                <example src="PERMUTATE" no="326">
                    <text>Quantitative electrophysiology of a single unit revealed that a homozygous mutation has been shown to disrupt split while preserving robust visual responses.</text>
                    <arg n="0">a homozygous mutation</arg>
                    <arg n="1">split</arg>
                </example>
                <example src="PERMUTATE" no="327">
                    <text>Quantitative electrophysiology of a single unit revealed that a homozygous mutation has disrupted pulally while preserving robust visual responses.</text>
                    <arg n="0">a homozygous mutation</arg>
                    <arg n="1">pulally</arg>
                </example>
                <example src="PERMUTATE" no="328">
                    <text>Quantitative electrophysiology of a single unit revealed that a homozygous mutation has disrupted split while preserving robust visual responses.</text>
                    <arg n="0">a homozygous mutation</arg>
                    <arg n="1">split</arg>
                </example>
                <example src="PERMUTATE" no="329">
                    <text>Quantitative electrophysiology of a single unit revealed that a homozygous mutation interrupts pulally by disrupts robust visual responses.</text>
                    <arg n="0">a homozygous mutation</arg>
                    <arg n="1">pulally</arg>
                </example>
                <example src="PERMUTATE" no="330">
                    <text>Quantitative electrophysiology of a single unit revealed that a homozygous mutation interrupts pulally while disrupts robust visual responses.</text>
                    <arg n="0">a homozygous mutation</arg>
                    <arg n="1">pulally</arg>
                </example>
                <example src="PERMUTATE" no="331">
                    <text>Quantitative electrophysiology of a single unit revealed that a homozygous mutation interrupts split by disrupts robust visual responses.</text>
                    <arg n="0">a homozygous mutation</arg>
                    <arg n="1">split</arg>
                </example>
                <example src="PERMUTATE" no="332">
                    <text>Quantitative electrophysiology of a single unit revealed that a homozygous mutation interrupts split while disrupts robust visual responses.</text>
                    <arg n="0">a homozygous mutation</arg>
                    <arg n="1">split</arg>
                </example>
                <example src="PERMUTATE" no="333">
                    <text>Quantitative electrophysiology of a single unit revealed that a homozygous mutation is able to detach pulally disrupt robust visual responses.</text>
                    <arg n="0">a homozygous mutation</arg>
                    <arg n="1">pulally</arg>
                </example>
                <example src="PERMUTATE" no="334">
                    <text>Quantitative electrophysiology of a single unit revealed that a homozygous mutation is able to detach split disrupt robust visual responses.</text>
                    <arg n="0">a homozygous mutation</arg>
                    <arg n="1">split</arg>
                </example>
                <example src="PERMUTATE" no="335">
                    <text>Quantitative electrophysiology of a single unit revealed that a homozygous mutation is capable of disrupt pulally by preserving robust visual responses.</text>
                    <arg n="0">a homozygous mutation</arg>
                    <arg n="1">pulally</arg>
                </example>
                <example src="PERMUTATE" no="336">
                    <text>Quantitative electrophysiology of a single unit revealed that a homozygous mutation is capable of disrupt split by preserving robust visual responses.</text>
                    <arg n="0">a homozygous mutation</arg>
                    <arg n="1">split</arg>
                </example>
                <example src="PERMUTATE" no="337">
                    <text>Quantitative electrophysiology of a single unit revealed that alcohol consumption exposure disrupted ocular dominance plasticity while retaining robust visual responses.</text>
                    <arg n="0">alcohol consumption exposure</arg>
                    <arg n="1">ocular dominance plasticity</arg>
                </example>
                <example src="PERMUTATE" no="338">
                    <text>Quantitative electrophysiology of a single unit revealed that alcohol consumption exposure has been able to disrupt ocular dominance plasticity preserving robust visual responses.</text>
                    <arg n="0">alcohol consumption exposure</arg>
                    <arg n="1">ocular dominance plasticity</arg>
                </example>
                <example src="PERMUTATE" no="339">
                    <text>Quantitative electrophysiology of a single unit revealed that alcohol consumption exposure has been shown to disrupt ocular dominance plasticity while preserving robust visual responses.</text>
                    <arg n="0">alcohol consumption exposure</arg>
                    <arg n="1">ocular dominance plasticity</arg>
                </example>
                <example src="PERMUTATE" no="340">
                    <text>Quantitative electrophysiology of a single unit revealed that alcohol consumption exposure has disrupted ocular dominance plasticity while preserving robust visual responses.</text>
                    <arg n="0">alcohol consumption exposure</arg>
                    <arg n="1">ocular dominance plasticity</arg>
                </example>
                <example src="PERMUTATE" no="341">
                    <text>Quantitative electrophysiology of a single unit revealed that alcohol consumption exposure interrupts ocular dominance plasticity while disrupts robust visual responses.</text>
                    <arg n="0">alcohol consumption exposure</arg>
                    <arg n="1">ocular dominance plasticity</arg>
                </example>
                <example src="PERMUTATE" no="342">
                    <text>Quantitative electrophysiology of a single unit revealed that alcohol consumption exposure is able to detach ocular dominance plasticity disrupt robust visual responses.</text>
                    <arg n="0">alcohol consumption exposure</arg>
                    <arg n="1">ocular dominance plasticity</arg>
                </example>
                <example src="PERMUTATE" no="343">
                    <text>Quantitative electrophysiology of a single unit revealed that alcohol consumption exposure is capable of disrupt ocular dominance plasticity by preserving robust visual responses.</text>
                    <arg n="0">alcohol consumption exposure</arg>
                    <arg n="1">ocular dominance plasticity</arg>
                </example>
                <example src="PERMUTATE" no="344">
                    <text>Quantitative electrophysiology of a single unit revealed that alcohol exposure disrupted ocular domain plasticity while retaining robust visual responses.</text>
                    <arg n="0">alcohol exposure</arg>
                    <arg n="1">ocular domain plasticity</arg>
                </example>
                <example src="PERMUTATE" no="345">
                    <text>Quantitative electrophysiology of a single unit revealed that alcohol exposure disrupted ocular dominance plasticity while retaining robust visual responses.</text>
                    <arg n="0">alcohol exposure</arg>
                    <arg n="1">ocular dominance plasticity</arg>
                </example>
                <example src="PERMUTATE" no="346">
                    <text>Quantitative electrophysiology of a single unit revealed that alcohol exposure has been able to disrupt ocular domain plasticity preserving robust visual responses.</text>
                    <arg n="0">alcohol exposure</arg>
                    <arg n="1">ocular domain plasticity</arg>
                </example>
                <example src="PERMUTATE" no="347">
                    <text>Quantitative electrophysiology of a single unit revealed that alcohol exposure has been shown to disrupt ocular domain plasticity while preserving robust visual responses.</text>
                    <arg n="0">alcohol exposure</arg>
                    <arg n="1">ocular domain plasticity</arg>
                </example>
                <example src="PERMUTATE" no="348">
                    <text>Quantitative electrophysiology of a single unit revealed that alcohol exposure has disrupted ocular domain plasticity while preserving robust visual responses.</text>
                    <arg n="0">alcohol exposure</arg>
                    <arg n="1">ocular domain plasticity</arg>
                </example>
                <example src="PERMUTATE" no="349">
                    <text>Quantitative electrophysiology of a single unit revealed that alcohol exposure interrupts ocular domain plasticity by disrupts robust visual responses.</text>
                    <arg n="0">alcohol exposure</arg>
                    <arg n="1">ocular domain plasticity</arg>
                </example>
                <example src="PERMUTATE" no="350">
                    <text>Quantitative electrophysiology of a single unit revealed that alcohol exposure interrupts ocular domain plasticity while disrupts robust visual responses.</text>
                    <arg n="0">alcohol exposure</arg>
                    <arg n="1">ocular domain plasticity</arg>
                </example>
                <example src="PERMUTATE" no="351">
                    <text>Quantitative electrophysiology of a single unit revealed that alcohol exposure interrupts ocular dominance plasticity by disrupts robust visual responses.</text>
                    <arg n="0">alcohol exposure</arg>
                    <arg n="1">ocular dominance plasticity</arg>
                </example>
                <example src="PERMUTATE" no="352">
                    <text>Quantitative electrophysiology of a single unit revealed that alcohol exposure is able to detach ocular dominance plasticity disrupt robust visual responses.</text>
                    <arg n="0">alcohol exposure</arg>
                    <arg n="1">ocular dominance plasticity</arg>
                </example>
                <example src="PERMUTATE" no="353">
                    <text>Quantitative electrophysiology of a single unit revealed that alcohol exposure is capable of disrupt ocular domain plasticity by preserving robust visual responses.</text>
                    <arg n="0">alcohol exposure</arg>
                    <arg n="1">ocular domain plasticity</arg>
                </example>
                <example src="PERMUTATE" no="354">
                    <text>Quantitative electrophysiology of a single unit revealed that alcohol exposure is capable of disrupt ocular dominance plasticity by preserving robust visual responses.</text>
                    <arg n="0">alcohol exposure</arg>
                    <arg n="1">ocular dominance plasticity</arg>
                </example>
                <example src="PERMUTATE" no="355">
                    <text>Quantitative electrophysiology of a single unit revealed that exposure to alcohol consumption disrupted ocular domain plasticity while retaining robust visual responses.</text>
                    <arg n="0">exposure to alcohol consumption</arg>
                    <arg n="1">ocular domain plasticity</arg>
                </example>
                <example src="PERMUTATE" no="356">
                    <text>Quantitative electrophysiology of a single unit revealed that exposure to alcohol consumption has been able to disrupt ocular domain plasticity preserving robust visual responses.</text>
                    <arg n="0">exposure to alcohol consumption</arg>
                    <arg n="1">ocular domain plasticity</arg>
                </example>
                <example src="PERMUTATE" no="357">
                    <text>Quantitative electrophysiology of a single unit revealed that exposure to alcohol consumption has been able to disrupt plasticity of eye dominance preserving robust visual responses.</text>
                    <arg n="0">exposure to alcohol consumption</arg>
                    <arg n="1">plasticity of eye dominance</arg>
                </example>
                <example src="PERMUTATE" no="358">
                    <text>Quantitative electrophysiology of a single unit revealed that exposure to alcohol consumption has been shown to disrupt ocular domain plasticity while preserving robust visual responses.</text>
                    <arg n="0">exposure to alcohol consumption</arg>
                    <arg n="1">ocular domain plasticity</arg>
                </example>
                <example src="PERMUTATE" no="359">
                    <text>Quantitative electrophysiology of a single unit revealed that exposure to alcohol consumption has been shown to disrupt plasticity of eye dominance while preserving robust visual responses.</text>
                    <arg n="0">exposure to alcohol consumption</arg>
                    <arg n="1">plasticity of eye dominance</arg>
                </example>
                <example src="PERMUTATE" no="360">
                    <text>Quantitative electrophysiology of a single unit revealed that exposure to alcohol consumption has disrupted ocular domain plasticity while preserving robust visual responses.</text>
                    <arg n="0">exposure to alcohol consumption</arg>
                    <arg n="1">ocular domain plasticity</arg>
                </example>
                <example src="PERMUTATE" no="361">
                    <text>Quantitative electrophysiology of a single unit revealed that exposure to alcohol consumption has disrupted plasticity of eye dominance while preserving robust visual responses.</text>
                    <arg n="0">exposure to alcohol consumption</arg>
                    <arg n="1">plasticity of eye dominance</arg>
                </example>
                <example src="PERMUTATE" no="362">
                    <text>Quantitative electrophysiology of a single unit revealed that exposure to alcohol consumption interrupts ocular domain plasticity by disrupts robust visual responses.</text>
                    <arg n="0">exposure to alcohol consumption</arg>
                    <arg n="1">ocular domain plasticity</arg>
                </example>
                <example src="PERMUTATE" no="363">
                    <text>Quantitative electrophysiology of a single unit revealed that exposure to alcohol consumption interrupts ocular domain plasticity while disrupts robust visual responses.</text>
                    <arg n="0">exposure to alcohol consumption</arg>
                    <arg n="1">ocular domain plasticity</arg>
                </example>
                <example src="PERMUTATE" no="364">
                    <text>Quantitative electrophysiology of a single unit revealed that exposure to alcohol consumption interrupts plasticity of eye dominance by disrupts robust visual responses.</text>
                    <arg n="0">exposure to alcohol consumption</arg>
                    <arg n="1">plasticity of eye dominance</arg>
                </example>
                <example src="PERMUTATE" no="365">
                    <text>Quantitative electrophysiology of a single unit revealed that exposure to alcohol consumption interrupts plasticity of eye dominance while disrupts robust visual responses.</text>
                    <arg n="0">exposure to alcohol consumption</arg>
                    <arg n="1">plasticity of eye dominance</arg>
                </example>
                <example src="PERMUTATE" no="366">
                    <text>Quantitative electrophysiology of a single unit revealed that exposure to alcohol consumption is able to detach ocular domain plasticity disrupt robust visual responses.</text>
                    <arg n="0">exposure to alcohol consumption</arg>
                    <arg n="1">ocular domain plasticity</arg>
                </example>
                <example src="PERMUTATE" no="367">
                    <text>Quantitative electrophysiology of a single unit revealed that exposure to alcohol consumption is able to detach plasticity of eye dominance disrupt robust visual responses.</text>
                    <arg n="0">exposure to alcohol consumption</arg>
                    <arg n="1">plasticity of eye dominance</arg>
                </example>
                <example src="PERMUTATE" no="368">
                    <text>Quantitative electrophysiology of a single unit revealed that exposure to alcohol consumption is capable of disrupt plasticity of eye dominance by preserving robust visual responses.</text>
                    <arg n="0">exposure to alcohol consumption</arg>
                    <arg n="1">plasticity of eye dominance</arg>
                </example>
                <example src="PERMUTATE" no="369">
                    <text>Quantitative electrophysiology of a single unit revealed that his retired expression MEKK1 or MEKK2 disrupted the overall integrity of MAPK pathway regulation while retaining robust visual responses.</text>
                    <arg n="0">his retired expression MEKK1 or MEKK2</arg>
                    <arg n="1">the overall integrity of MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="370">
                    <text>Quantitative electrophysiology of a single unit revealed that his retired expression MEKK1 or MEKK2 has been able to disrupt the overall integrity of MAPK pathway regulation preserving robust visual responses.</text>
                    <arg n="0">his retired expression MEKK1 or MEKK2</arg>
                    <arg n="1">the overall integrity of MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="371">
                    <text>Quantitative electrophysiology of a single unit revealed that his retired expression MEKK1 or MEKK2 has been shown to disrupt the overall integrity of MAPK pathway regulation while preserving robust visual responses.</text>
                    <arg n="0">his retired expression MEKK1 or MEKK2</arg>
                    <arg n="1">the overall integrity of MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="372">
                    <text>Quantitative electrophysiology of a single unit revealed that his retired expression MEKK1 or MEKK2 has disrupted the overall integrity of MAPK pathway regulation while preserving robust visual responses.</text>
                    <arg n="0">his retired expression MEKK1 or MEKK2</arg>
                    <arg n="1">the overall integrity of MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="373">
                    <text>Quantitative electrophysiology of a single unit revealed that his retired expression MEKK1 or MEKK2 interrupts the overall integrity of MAPK pathway regulation by disrupts robust visual responses.</text>
                    <arg n="0">his retired expression MEKK1 or MEKK2</arg>
                    <arg n="1">the overall integrity of MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="374">
                    <text>Quantitative electrophysiology of a single unit revealed that his retired expression MEKK1 or MEKK2 interrupts the overall integrity of MAPK pathway regulation while disrupts robust visual responses.</text>
                    <arg n="0">his retired expression MEKK1 or MEKK2</arg>
                    <arg n="1">the overall integrity of MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="375">
                    <text>Quantitative electrophysiology of a single unit revealed that his retired expression MEKK1 or MEKK2 is able to detach the overall integrity of MAPK pathway regulation disrupt robust visual responses.</text>
                    <arg n="0">his retired expression MEKK1 or MEKK2</arg>
                    <arg n="1">the overall integrity of MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="376">
                    <text>Quantitative electrophysiology of a single unit revealed that his retired expression MEKK1 or MEKK2 is capable of disrupt the overall integrity of MAPK pathway regulation by preserving robust visual responses.</text>
                    <arg n="0">his retired expression MEKK1 or MEKK2</arg>
                    <arg n="1">the overall integrity of MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="377">
                    <text>Quantitative electrophysiology of a single unit revealed that homozygous mutation disrupted spacing while retaining robust visual responses.</text>
                    <arg n="0">homozygous mutation</arg>
                    <arg n="1">spacing</arg>
                </example>
                <example src="PERMUTATE" no="378">
                    <text>Quantitative electrophysiology of a single unit revealed that homozygous mutation disrupted squirrel while retaining robust visual responses.</text>
                    <arg n="0">homozygous mutation</arg>
                    <arg n="1">squirrel</arg>
                </example>
                <example src="PERMUTATE" no="379">
                    <text>Quantitative electrophysiology of a single unit revealed that homozygous mutation has been able to disrupt spacing preserving robust visual responses.</text>
                    <arg n="0">homozygous mutation</arg>
                    <arg n="1">spacing</arg>
                </example>
                <example src="PERMUTATE" no="380">
                    <text>Quantitative electrophysiology of a single unit revealed that homozygous mutation has been able to disrupt squirrel preserving robust visual responses.</text>
                    <arg n="0">homozygous mutation</arg>
                    <arg n="1">squirrel</arg>
                </example>
                <example src="PERMUTATE" no="381">
                    <text>Quantitative electrophysiology of a single unit revealed that homozygous mutation has been shown to disrupt spacing while preserving robust visual responses.</text>
                    <arg n="0">homozygous mutation</arg>
                    <arg n="1">spacing</arg>
                </example>
                <example src="PERMUTATE" no="382">
                    <text>Quantitative electrophysiology of a single unit revealed that homozygous mutation has been shown to disrupt squirrel while preserving robust visual responses.</text>
                    <arg n="0">homozygous mutation</arg>
                    <arg n="1">squirrel</arg>
                </example>
                <example src="PERMUTATE" no="383">
                    <text>Quantitative electrophysiology of a single unit revealed that homozygous mutation has disrupted spacing while preserving robust visual responses.</text>
                    <arg n="0">homozygous mutation</arg>
                    <arg n="1">spacing</arg>
                </example>
                <example src="PERMUTATE" no="384">
                    <text>Quantitative electrophysiology of a single unit revealed that homozygous mutation has disrupted squirrel while preserving robust visual responses.</text>
                    <arg n="0">homozygous mutation</arg>
                    <arg n="1">squirrel</arg>
                </example>
                <example src="PERMUTATE" no="385">
                    <text>Quantitative electrophysiology of a single unit revealed that homozygous mutation interrupts spacing by disrupts robust visual responses.</text>
                    <arg n="0">homozygous mutation</arg>
                    <arg n="1">spacing</arg>
                </example>
                <example src="PERMUTATE" no="386">
                    <text>Quantitative electrophysiology of a single unit revealed that homozygous mutation interrupts spacing while disrupts robust visual responses.</text>
                    <arg n="0">homozygous mutation</arg>
                    <arg n="1">spacing</arg>
                </example>
                <example src="PERMUTATE" no="387">
                    <text>Quantitative electrophysiology of a single unit revealed that homozygous mutation interrupts squirrel by disrupts robust visual responses.</text>
                    <arg n="0">homozygous mutation</arg>
                    <arg n="1">squirrel</arg>
                </example>
                <example src="PERMUTATE" no="388">
                    <text>Quantitative electrophysiology of a single unit revealed that homozygous mutation interrupts squirrel while disrupts robust visual responses.</text>
                    <arg n="0">homozygous mutation</arg>
                    <arg n="1">squirrel</arg>
                </example>
                <example src="PERMUTATE" no="389">
                    <text>Quantitative electrophysiology of a single unit revealed that homozygous mutation is able to detach spacing disrupt robust visual responses.</text>
                    <arg n="0">homozygous mutation</arg>
                    <arg n="1">spacing</arg>
                </example>
                <example src="PERMUTATE" no="390">
                    <text>Quantitative electrophysiology of a single unit revealed that homozygous mutation is able to detach squirrel disrupt robust visual responses.</text>
                    <arg n="0">homozygous mutation</arg>
                    <arg n="1">squirrel</arg>
                </example>
                <example src="PERMUTATE" no="391">
                    <text>Quantitative electrophysiology of a single unit revealed that homozygous mutation is capable of disrupt spacing by preserving robust visual responses.</text>
                    <arg n="0">homozygous mutation</arg>
                    <arg n="1">spacing</arg>
                </example>
                <example src="PERMUTATE" no="392">
                    <text>Quantitative electrophysiology of a single unit revealed that homozygous mutation is capable of disrupt squirrel by preserving robust visual responses.</text>
                    <arg n="0">homozygous mutation</arg>
                    <arg n="1">squirrel</arg>
                </example>
                <example src="PERMUTATE" no="393">
                    <text>Quantitative electrophysiology of a single unit revealed that if retired from the expression MEKK1 or MEKK2 disrupted the overall integrity of MAPK pathway regulation while retaining robust visual responses.</text>
                    <arg n="0">if retired from the expression MEKK1 or MEKK2</arg>
                    <arg n="1">the overall integrity of MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="394">
                    <text>Quantitative electrophysiology of a single unit revealed that if retired from the expression MEKK1 or MEKK2 has been able to disrupt the overall integrity of MAPK pathway regulation preserving robust visual responses.</text>
                    <arg n="0">if retired from the expression MEKK1 or MEKK2</arg>
                    <arg n="1">the overall integrity of MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="395">
                    <text>Quantitative electrophysiology of a single unit revealed that if retired from the expression MEKK1 or MEKK2 has been shown to disrupt the overall integrity of MAPK pathway regulation while preserving robust visual responses.</text>
                    <arg n="0">if retired from the expression MEKK1 or MEKK2</arg>
                    <arg n="1">the overall integrity of MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="396">
                    <text>Quantitative electrophysiology of a single unit revealed that if retired from the expression MEKK1 or MEKK2 has disrupted the overall integrity of MAPK pathway regulation while preserving robust visual responses.</text>
                    <arg n="0">if retired from the expression MEKK1 or MEKK2</arg>
                    <arg n="1">the overall integrity of MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="397">
                    <text>Quantitative electrophysiology of a single unit revealed that if retired from the expression MEKK1 or MEKK2 interrupts the overall integrity of MAPK pathway regulation by disrupts robust visual responses.</text>
                    <arg n="0">if retired from the expression MEKK1 or MEKK2</arg>
                    <arg n="1">the overall integrity of MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="398">
                    <text>Quantitative electrophysiology of a single unit revealed that if retired from the expression MEKK1 or MEKK2 interrupts the overall integrity of MAPK pathway regulation while disrupts robust visual responses.</text>
                    <arg n="0">if retired from the expression MEKK1 or MEKK2</arg>
                    <arg n="1">the overall integrity of MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="399">
                    <text>Quantitative electrophysiology of a single unit revealed that if retired from the expression MEKK1 or MEKK2 is able to detach the overall integrity of MAPK pathway regulation disrupt robust visual responses.</text>
                    <arg n="0">if retired from the expression MEKK1 or MEKK2</arg>
                    <arg n="1">the overall integrity of MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="400">
                    <text>Quantitative electrophysiology of a single unit revealed that if retired from the expression MEKK1 or MEKK2 is capable of disrupt the overall integrity of MAPK pathway regulation by preserving robust visual responses.</text>
                    <arg n="0">if retired from the expression MEKK1 or MEKK2</arg>
                    <arg n="1">the overall integrity of MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="401">
                    <text>Quantitative electrophysiology of a single unit revealed that inhibition of inflammation disrupted physiological protective response while retaining robust visual responses.</text>
                    <arg n="0">inhibition of inflammation</arg>
                    <arg n="1">physiological protective response</arg>
                </example>
                <example src="PERMUTATE" no="402">
                    <text>Quantitative electrophysiology of a single unit revealed that inhibition of inflammation disrupted protective physiological responses while retaining robust visual responses.</text>
                    <arg n="0">inhibition of inflammation</arg>
                    <arg n="1">protective physiological responses</arg>
                </example>
                <example src="PERMUTATE" no="403">
                    <text>Quantitative electrophysiology of a single unit revealed that inhibition of inflammation has been able to disrupt physiological protective response preserving robust visual responses.</text>
                    <arg n="0">inhibition of inflammation</arg>
                    <arg n="1">physiological protective response</arg>
                </example>
                <example src="PERMUTATE" no="404">
                    <text>Quantitative electrophysiology of a single unit revealed that inhibition of inflammation has been able to disrupt protective physiological responses preserving robust visual responses.</text>
                    <arg n="0">inhibition of inflammation</arg>
                    <arg n="1">protective physiological responses</arg>
                </example>
                <example src="PERMUTATE" no="405">
                    <text>Quantitative electrophysiology of a single unit revealed that inhibition of inflammation has been shown to disrupt physiological protective response while preserving robust visual responses.</text>
                    <arg n="0">inhibition of inflammation</arg>
                    <arg n="1">physiological protective response</arg>
                </example>
                <example src="PERMUTATE" no="406">
                    <text>Quantitative electrophysiology of a single unit revealed that inhibition of inflammation has been shown to disrupt protective physiological responses while preserving robust visual responses.</text>
                    <arg n="0">inhibition of inflammation</arg>
                    <arg n="1">protective physiological responses</arg>
                </example>
                <example src="PERMUTATE" no="407">
                    <text>Quantitative electrophysiology of a single unit revealed that inhibition of inflammation has disrupted physiological protective response while preserving robust visual responses.</text>
                    <arg n="0">inhibition of inflammation</arg>
                    <arg n="1">physiological protective response</arg>
                </example>
                <example src="PERMUTATE" no="408">
                    <text>Quantitative electrophysiology of a single unit revealed that inhibition of inflammation has disrupted protective physiological responses while preserving robust visual responses.</text>
                    <arg n="0">inhibition of inflammation</arg>
                    <arg n="1">protective physiological responses</arg>
                </example>
                <example src="PERMUTATE" no="409">
                    <text>Quantitative electrophysiology of a single unit revealed that inhibition of inflammation interrupts physiological protective response by disrupts robust visual responses.</text>
                    <arg n="0">inhibition of inflammation</arg>
                    <arg n="1">physiological protective response</arg>
                </example>
                <example src="PERMUTATE" no="410">
                    <text>Quantitative electrophysiology of a single unit revealed that inhibition of inflammation interrupts physiological protective response while disrupts robust visual responses.</text>
                    <arg n="0">inhibition of inflammation</arg>
                    <arg n="1">physiological protective response</arg>
                </example>
                <example src="PERMUTATE" no="411">
                    <text>Quantitative electrophysiology of a single unit revealed that inhibition of inflammation interrupts protective physiological responses by disrupts robust visual responses.</text>
                    <arg n="0">inhibition of inflammation</arg>
                    <arg n="1">protective physiological responses</arg>
                </example>
                <example src="PERMUTATE" no="412">
                    <text>Quantitative electrophysiology of a single unit revealed that inhibition of inflammation interrupts protective physiological responses while disrupts robust visual responses.</text>
                    <arg n="0">inhibition of inflammation</arg>
                    <arg n="1">protective physiological responses</arg>
                </example>
                <example src="PERMUTATE" no="413">
                    <text>Quantitative electrophysiology of a single unit revealed that inhibition of inflammation is able to detach physiological protective response disrupt robust visual responses.</text>
                    <arg n="0">inhibition of inflammation</arg>
                    <arg n="1">physiological protective response</arg>
                </example>
                <example src="PERMUTATE" no="414">
                    <text>Quantitative electrophysiology of a single unit revealed that inhibition of inflammation is able to detach protective physiological responses disrupt robust visual responses.</text>
                    <arg n="0">inhibition of inflammation</arg>
                    <arg n="1">protective physiological responses</arg>
                </example>
                <example src="PERMUTATE" no="415">
                    <text>Quantitative electrophysiology of a single unit revealed that inhibition of inflammation is capable of disrupt physiological protective response by preserving robust visual responses.</text>
                    <arg n="0">inhibition of inflammation</arg>
                    <arg n="1">physiological protective response</arg>
                </example>
                <example src="PERMUTATE" no="416">
                    <text>Quantitative electrophysiology of a single unit revealed that inhibition of inflammation is capable of disrupt protective physiological responses by preserving robust visual responses.</text>
                    <arg n="0">inhibition of inflammation</arg>
                    <arg n="1">protective physiological responses</arg>
                </example>
                <example src="PERMUTATE" no="417">
                    <text>Quantitative electrophysiology of a single unit revealed that knockout of the expression MEKK1 or MEKK2 disrupted the overall integrity of MAPK pathway regulation while retaining robust visual responses.</text>
                    <arg n="0">knockout of the expression MEKK1 or MEKK2</arg>
                    <arg n="1">the overall integrity of MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="418">
                    <text>Quantitative electrophysiology of a single unit revealed that knockout of the expression MEKK1 or MEKK2 has been able to disrupt the overall integrity of MAPK pathway regulation preserving robust visual responses.</text>
                    <arg n="0">knockout of the expression MEKK1 or MEKK2</arg>
                    <arg n="1">the overall integrity of MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="419">
                    <text>Quantitative electrophysiology of a single unit revealed that knockout of the expression MEKK1 or MEKK2 has been shown to disrupt the overall integrity of MAPK pathway regulation while preserving robust visual responses.</text>
                    <arg n="0">knockout of the expression MEKK1 or MEKK2</arg>
                    <arg n="1">the overall integrity of MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="420">
                    <text>Quantitative electrophysiology of a single unit revealed that knockout of the expression MEKK1 or MEKK2 has disrupted the overall integrity of MAPK pathway regulation while preserving robust visual responses.</text>
                    <arg n="0">knockout of the expression MEKK1 or MEKK2</arg>
                    <arg n="1">the overall integrity of MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="421">
                    <text>Quantitative electrophysiology of a single unit revealed that knockout of the expression MEKK1 or MEKK2 interrupts the overall integrity of MAPK pathway regulation by disrupts robust visual responses.</text>
                    <arg n="0">knockout of the expression MEKK1 or MEKK2</arg>
                    <arg n="1">the overall integrity of MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="422">
                    <text>Quantitative electrophysiology of a single unit revealed that knockout of the expression MEKK1 or MEKK2 interrupts the overall integrity of MAPK pathway regulation while disrupts robust visual responses.</text>
                    <arg n="0">knockout of the expression MEKK1 or MEKK2</arg>
                    <arg n="1">the overall integrity of MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="423">
                    <text>Quantitative electrophysiology of a single unit revealed that knockout of the expression MEKK1 or MEKK2 is able to detach the overall integrity of MAPK pathway regulation disrupt robust visual responses.</text>
                    <arg n="0">knockout of the expression MEKK1 or MEKK2</arg>
                    <arg n="1">the overall integrity of MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="424">
                    <text>Quantitative electrophysiology of a single unit revealed that knockout of the expression MEKK1 or MEKK2 is capable of disrupt the overall integrity of MAPK pathway regulation by preserving robust visual responses.</text>
                    <arg n="0">knockout of the expression MEKK1 or MEKK2</arg>
                    <arg n="1">the overall integrity of MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="425">
                    <text>Quantitative electrophysiology of a single unit revealed that retired from the MEKK1 or MEKK2 expression disrupted the overall integrity of the MAPK pathway regulation while retaining robust visual responses.</text>
                    <arg n="0">retired from the MEKK1 or MEKK2 expression</arg>
                    <arg n="1">the overall integrity of the MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="426">
                    <text>Quantitative electrophysiology of a single unit revealed that retired from the MEKK1 or MEKK2 expression has been able to disrupt the overall integrity of the MAPK pathway regulation preserving robust visual responses.</text>
                    <arg n="0">retired from the MEKK1 or MEKK2 expression</arg>
                    <arg n="1">the overall integrity of the MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="427">
                    <text>Quantitative electrophysiology of a single unit revealed that retired from the MEKK1 or MEKK2 expression has been shown to disrupt the overall integrity of the MAPK pathway regulation while preserving robust visual responses.</text>
                    <arg n="0">retired from the MEKK1 or MEKK2 expression</arg>
                    <arg n="1">the overall integrity of the MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="428">
                    <text>Quantitative electrophysiology of a single unit revealed that retired from the MEKK1 or MEKK2 expression has disrupted the overall integrity of the MAPK pathway regulation while preserving robust visual responses.</text>
                    <arg n="0">retired from the MEKK1 or MEKK2 expression</arg>
                    <arg n="1">the overall integrity of the MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="429">
                    <text>Quantitative electrophysiology of a single unit revealed that retired from the MEKK1 or MEKK2 expression interrupts the overall integrity of the MAPK pathway regulation by disrupts robust visual responses.</text>
                    <arg n="0">retired from the MEKK1 or MEKK2 expression</arg>
                    <arg n="1">the overall integrity of the MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="430">
                    <text>Quantitative electrophysiology of a single unit revealed that retired from the MEKK1 or MEKK2 expression interrupts the overall integrity of the MAPK pathway regulation while disrupts robust visual responses.</text>
                    <arg n="0">retired from the MEKK1 or MEKK2 expression</arg>
                    <arg n="1">the overall integrity of the MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="431">
                    <text>Quantitative electrophysiology of a single unit revealed that retired from the MEKK1 or MEKK2 expression is able to detach the overall integrity of the MAPK pathway regulation disrupt robust visual responses.</text>
                    <arg n="0">retired from the MEKK1 or MEKK2 expression</arg>
                    <arg n="1">the overall integrity of the MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="432">
                    <text>Quantitative electrophysiology of a single unit revealed that retired from the MEKK1 or MEKK2 expression is capable of disrupt the overall integrity of the MAPK pathway regulation by preserving robust visual responses.</text>
                    <arg n="0">retired from the MEKK1 or MEKK2 expression</arg>
                    <arg n="1">the overall integrity of the MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="433">
                    <text>Quantitative electrophysiology of a single unit revealed that the Gly188--Glu mutation disrupted an Ava II site while retaining robust visual responses.</text>
                    <arg n="0">the Gly188--Glu mutation</arg>
                    <arg n="1">an Ava II site</arg>
                </example>
                <example src="PERMUTATE" no="434">
                    <text>Quantitative electrophysiology of a single unit revealed that the Gly188--Glu mutation has been able to disrupt an Ava II site preserving robust visual responses.</text>
                    <arg n="0">the Gly188--Glu mutation</arg>
                    <arg n="1">an Ava II site</arg>
                </example>
                <example src="PERMUTATE" no="435">
                    <text>Quantitative electrophysiology of a single unit revealed that the Gly188--Glu mutation has been shown to disrupt an Ava II site while preserving robust visual responses.</text>
                    <arg n="0">the Gly188--Glu mutation</arg>
                    <arg n="1">an Ava II site</arg>
                </example>
                <example src="PERMUTATE" no="436">
                    <text>Quantitative electrophysiology of a single unit revealed that the Gly188--Glu mutation has disrupted an Ava II site while preserving robust visual responses.</text>
                    <arg n="0">the Gly188--Glu mutation</arg>
                    <arg n="1">an Ava II site</arg>
                </example>
                <example src="PERMUTATE" no="437">
                    <text>Quantitative electrophysiology of a single unit revealed that the Gly188--Glu mutation interrupts an Ava II site by disrupts robust visual responses.</text>
                    <arg n="0">the Gly188--Glu mutation</arg>
                    <arg n="1">an Ava II site</arg>
                </example>
                <example src="PERMUTATE" no="438">
                    <text>Quantitative electrophysiology of a single unit revealed that the Gly188--Glu mutation interrupts an Ava II site while disrupts robust visual responses.</text>
                    <arg n="0">the Gly188--Glu mutation</arg>
                    <arg n="1">an Ava II site</arg>
                </example>
                <example src="PERMUTATE" no="439">
                    <text>Quantitative electrophysiology of a single unit revealed that the Gly188--Glu mutation is able to detach an Ava II site disrupt robust visual responses.</text>
                    <arg n="0">the Gly188--Glu mutation</arg>
                    <arg n="1">an Ava II site</arg>
                </example>
                <example src="PERMUTATE" no="440">
                    <text>Quantitative electrophysiology of a single unit revealed that the Gly188--Glu mutation is capable of disrupt an Ava II site by preserving robust visual responses.</text>
                    <arg n="0">the Gly188--Glu mutation</arg>
                    <arg n="1">an Ava II site</arg>
                </example>
                <example src="PERMUTATE" no="441">
                    <text>Quantitative electrophysiology of a single unit revealed that the knockout of the MEKK1 or MEKK2 expression disrupted the overall integrity of the MAPK pathway regulation while retaining robust visual responses.</text>
                    <arg n="0">the knockout of the MEKK1 or MEKK2 expression</arg>
                    <arg n="1">the overall integrity of the MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="442">
                    <text>Quantitative electrophysiology of a single unit revealed that the knockout of the MEKK1 or MEKK2 expression has been able to disrupt the overall integrity of the MAPK pathway regulation preserving robust visual responses.</text>
                    <arg n="0">the knockout of the MEKK1 or MEKK2 expression</arg>
                    <arg n="1">the overall integrity of the MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="443">
                    <text>Quantitative electrophysiology of a single unit revealed that the knockout of the MEKK1 or MEKK2 expression has been shown to disrupt the overall integrity of the MAPK pathway regulation while preserving robust visual responses.</text>
                    <arg n="0">the knockout of the MEKK1 or MEKK2 expression</arg>
                    <arg n="1">the overall integrity of the MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="444">
                    <text>Quantitative electrophysiology of a single unit revealed that the knockout of the MEKK1 or MEKK2 expression has disrupted the overall integrity of the MAPK pathway regulation while preserving robust visual responses.</text>
                    <arg n="0">the knockout of the MEKK1 or MEKK2 expression</arg>
                    <arg n="1">the overall integrity of the MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="445">
                    <text>Quantitative electrophysiology of a single unit revealed that the knockout of the MEKK1 or MEKK2 expression interrupts the overall integrity of the MAPK pathway regulation by disrupts robust visual responses.</text>
                    <arg n="0">the knockout of the MEKK1 or MEKK2 expression</arg>
                    <arg n="1">the overall integrity of the MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="446">
                    <text>Quantitative electrophysiology of a single unit revealed that the knockout of the MEKK1 or MEKK2 expression interrupts the overall integrity of the MAPK pathway regulation while disrupts robust visual responses.</text>
                    <arg n="0">the knockout of the MEKK1 or MEKK2 expression</arg>
                    <arg n="1">the overall integrity of the MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="447">
                    <text>Quantitative electrophysiology of a single unit revealed that the knockout of the MEKK1 or MEKK2 expression is able to detach the overall integrity of the MAPK pathway regulation disrupt robust visual responses.</text>
                    <arg n="0">the knockout of the MEKK1 or MEKK2 expression</arg>
                    <arg n="1">the overall integrity of the MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="448">
                    <text>Quantitative electrophysiology of a single unit revealed that the knockout of the MEKK1 or MEKK2 expression is capable of disrupt the overall integrity of the MAPK pathway regulation by preserving robust visual responses.</text>
                    <arg n="0">the knockout of the MEKK1 or MEKK2 expression</arg>
                    <arg n="1">the overall integrity of the MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="449">
                    <text>Quantitative electrophysiology of a single unit revealed that this deletion disrupted open reading frame while retaining robust visual responses.</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">open reading frame</arg>
                </example>
                <example src="PERMUTATE" no="450">
                    <text>Quantitative electrophysiology of a single unit revealed that this deletion disrupted the open reading frame while retaining robust visual responses.</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">the open reading frame</arg>
                </example>
                <example src="PERMUTATE" no="451">
                    <text>Quantitative electrophysiology of a single unit revealed that this deletion disrupted the open reading structure while retaining robust visual responses.</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">the open reading structure</arg>
                </example>
                <example src="PERMUTATE" no="452">
                    <text>Quantitative electrophysiology of a single unit revealed that this deletion has been able to disrupt open reading frame preserving robust visual responses.</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">open reading frame</arg>
                </example>
                <example src="PERMUTATE" no="453">
                    <text>Quantitative electrophysiology of a single unit revealed that this deletion has been able to disrupt the open reading frame preserving robust visual responses.</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">the open reading frame</arg>
                </example>
                <example src="PERMUTATE" no="454">
                    <text>Quantitative electrophysiology of a single unit revealed that this deletion has been able to disrupt the open reading structure preserving robust visual responses.</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">the open reading structure</arg>
                </example>
                <example src="PERMUTATE" no="455">
                    <text>Quantitative electrophysiology of a single unit revealed that this deletion has been shown to disrupt open reading frame while preserving robust visual responses.</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">open reading frame</arg>
                </example>
                <example src="PERMUTATE" no="456">
                    <text>Quantitative electrophysiology of a single unit revealed that this deletion has been shown to disrupt the open reading frame while preserving robust visual responses.</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">the open reading frame</arg>
                </example>
                <example src="PERMUTATE" no="457">
                    <text>Quantitative electrophysiology of a single unit revealed that this deletion has been shown to disrupt the open reading structure while preserving robust visual responses.</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">the open reading structure</arg>
                </example>
                <example src="PERMUTATE" no="458">
                    <text>Quantitative electrophysiology of a single unit revealed that this deletion has disrupted open reading frame while preserving robust visual responses.</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">open reading frame</arg>
                </example>
                <example src="PERMUTATE" no="459">
                    <text>Quantitative electrophysiology of a single unit revealed that this deletion has disrupted the open reading frame while preserving robust visual responses.</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">the open reading frame</arg>
                </example>
                <example src="PERMUTATE" no="460">
                    <text>Quantitative electrophysiology of a single unit revealed that this deletion has disrupted the open reading structure while preserving robust visual responses.</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">the open reading structure</arg>
                </example>
                <example src="PERMUTATE" no="461">
                    <text>Quantitative electrophysiology of a single unit revealed that this deletion interrupts open reading frame by disrupts robust visual responses.</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">open reading frame</arg>
                </example>
                <example src="PERMUTATE" no="462">
                    <text>Quantitative electrophysiology of a single unit revealed that this deletion interrupts open reading frame while disrupts robust visual responses.</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">open reading frame</arg>
                </example>
                <example src="PERMUTATE" no="463">
                    <text>Quantitative electrophysiology of a single unit revealed that this deletion interrupts the open reading frame by disrupts robust visual responses.</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">the open reading frame</arg>
                </example>
                <example src="PERMUTATE" no="464">
                    <text>Quantitative electrophysiology of a single unit revealed that this deletion interrupts the open reading frame while disrupts robust visual responses.</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">the open reading frame</arg>
                </example>
                <example src="PERMUTATE" no="465">
                    <text>Quantitative electrophysiology of a single unit revealed that this deletion interrupts the open reading structure by disrupts robust visual responses.</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">the open reading structure</arg>
                </example>
                <example src="PERMUTATE" no="466">
                    <text>Quantitative electrophysiology of a single unit revealed that this deletion interrupts the open reading structure while disrupts robust visual responses.</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">the open reading structure</arg>
                </example>
                <example src="PERMUTATE" no="467">
                    <text>Quantitative electrophysiology of a single unit revealed that this deletion is able to detach open reading frame disrupt robust visual responses.</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">open reading frame</arg>
                </example>
                <example src="PERMUTATE" no="468">
                    <text>Quantitative electrophysiology of a single unit revealed that this deletion is able to detach the open reading frame disrupt robust visual responses.</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">the open reading frame</arg>
                </example>
                <example src="PERMUTATE" no="469">
                    <text>Quantitative electrophysiology of a single unit revealed that this deletion is able to detach the open reading structure disrupt robust visual responses.</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">the open reading structure</arg>
                </example>
                <example src="PERMUTATE" no="470">
                    <text>Quantitative electrophysiology of a single unit revealed that this deletion is capable of disrupt open reading frame by preserving robust visual responses.</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">open reading frame</arg>
                </example>
                <example src="PERMUTATE" no="471">
                    <text>Quantitative electrophysiology of a single unit revealed that this deletion is capable of disrupt the open reading frame by preserving robust visual responses.</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">the open reading frame</arg>
                </example>
                <example src="PERMUTATE" no="472">
                    <text>Quantitative electrophysiology of a single unit revealed that this deletion is capable of disrupt the open reading structure by preserving robust visual responses.</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">the open reading structure</arg>
                </example>
                <example src="PERMUTATE" no="473">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (Arg99 and Arg253 after disrupted hydrogen bonds in the model, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">Arg99 and Arg253</arg>
                    <arg n="1">hydrogen bonds in the model</arg>
                </example>
                <example src="PERMUTATE" no="474">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (Arg99 and Arg253 being able to disrupt hydrogen bonds in the model, the Arg243----His mutation, one site Hha I and the Asp250----Asn mutation, one site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients</text>
                    <arg n="0">Arg99 and Arg253</arg>
                    <arg n="1">hydrogen bonds in the model</arg>
                </example>
                <example src="PERMUTATE" no="475">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (Arg99 and Arg253 that can disrupt hydrogen bonds in the model, the Arg243----His mutation, a site Hha I and the Asp250----Asn mutation, a site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients were indeed com</text>
                    <arg n="0">Arg99 and Arg253</arg>
                    <arg n="1">hydrogen bonds in the model</arg>
                </example>
                <example src="PERMUTATE" no="476">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (Arg99 and Arg253 that disrupted hydrogen bonds in the model, the Arg243----His mutation, a site Hha I and the Asp250----Asn mutation, a site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients were indeed composit</text>
                    <arg n="0">Arg99 and Arg253</arg>
                    <arg n="1">hydrogen bonds in the model</arg>
                </example>
                <example src="PERMUTATE" no="477">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (Arr99 and Arr253 after disrupted hydrogen bond pairing in the model, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">Arr99 and Arr253</arg>
                    <arg n="1">hydrogen bond pairing in the model</arg>
                </example>
                <example src="PERMUTATE" no="478">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (Arr99 and Arr253 after disrupted the hydrogen bonding pairing in the model, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">Arr99 and Arr253</arg>
                    <arg n="1">the hydrogen bonding pairing in the model</arg>
                </example>
                <example src="PERMUTATE" no="479">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (Arr99 and Arr253 being able to disrupt hydrogen bond pairing in the model, the Arg243----His mutation, one site Hha I and the Asp250----Asn mutation, one site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients</text>
                    <arg n="0">Arr99 and Arr253</arg>
                    <arg n="1">hydrogen bond pairing in the model</arg>
                </example>
                <example src="PERMUTATE" no="480">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (Arr99 and Arr253 being able to disrupt the hydrogen bonding pairing in the model, the Arg243----His mutation, one site Hha I and the Asp250----Asn mutation, one site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients</text>
                    <arg n="0">Arr99 and Arr253</arg>
                    <arg n="1">the hydrogen bonding pairing in the model</arg>
                </example>
                <example src="PERMUTATE" no="481">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (Arr99 and Arr253 that can disrupt hydrogen bond pairing in the model, the Arg243----His mutation, a site Hha I and the Asp250----Asn mutation, a site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients were indeed com</text>
                    <arg n="0">Arr99 and Arr253</arg>
                    <arg n="1">hydrogen bond pairing in the model</arg>
                </example>
                <example src="PERMUTATE" no="482">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (Arr99 and Arr253 that can disrupt the hydrogen bonding pairing in the model, the Arg243----His mutation, a site Hha I and the Asp250----Asn mutation, a site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients were indeed com</text>
                    <arg n="0">Arr99 and Arr253</arg>
                    <arg n="1">the hydrogen bonding pairing in the model</arg>
                </example>
                <example src="PERMUTATE" no="483">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (Arr99 and Arr253 that disrupted hydrogen bond pairing in the model, the Arg243----His mutation, a site Hha I and the Asp250----Asn mutation, a site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients were indeed composit</text>
                    <arg n="0">Arr99 and Arr253</arg>
                    <arg n="1">hydrogen bond pairing in the model</arg>
                </example>
                <example src="PERMUTATE" no="484">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (Arr99 and Arr253 that disrupted the hydrogen bonding pairing in the model, the Arg243----His mutation, a site Hha I and the Asp250----Asn mutation, a site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients were indeed composit</text>
                    <arg n="0">Arr99 and Arr253</arg>
                    <arg n="1">the hydrogen bonding pairing in the model</arg>
                </example>
                <example src="PERMUTATE" no="485">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (Gly188---Glu mutation after disrupted a site Ava II, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">Gly188---Glu mutation</arg>
                    <arg n="1">a site Ava II</arg>
                </example>
                <example src="PERMUTATE" no="486">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (Gly188---Glu mutation after disrupted one site Ava II, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">Gly188---Glu mutation</arg>
                    <arg n="1">one site Ava II</arg>
                </example>
                <example src="PERMUTATE" no="487">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (Gly188---Glu mutation being able to disrupt a site Ava II, the Arg243----His mutation, one site Hha I and the Asp250----Asn mutation, one site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients</text>
                    <arg n="0">Gly188---Glu mutation</arg>
                    <arg n="1">a site Ava II</arg>
                </example>
                <example src="PERMUTATE" no="488">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (Gly188---Glu mutation that can disrupt one site Ava II, the Arg243----His mutation, a site Hha I and the Asp250----Asn mutation, a site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients were indeed com</text>
                    <arg n="0">Gly188---Glu mutation</arg>
                    <arg n="1">one site Ava II</arg>
                </example>
                <example src="PERMUTATE" no="489">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (Gly188---Glu mutation that disrupted one site Ava II, the Arg243----His mutation, a site Hha I and the Asp250----Asn mutation, a site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients were indeed composit</text>
                    <arg n="0">Gly188---Glu mutation</arg>
                    <arg n="1">one site Ava II</arg>
                </example>
                <example src="PERMUTATE" no="490">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (Mutation 415G4 after disrupted potent spike: (GAR)n-(GAR)n, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">Mutation 415G4</arg>
                    <arg n="1">potent spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="PERMUTATE" no="491">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (Mutation 415G4 being able to disrupt potent spike: (GAR)n-(GAR)n, the Arg243----His mutation, one site Hha I and the Asp250----Asn mutation, one site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients</text>
                    <arg n="0">Mutation 415G4</arg>
                    <arg n="1">potent spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="PERMUTATE" no="492">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (Mutation 415G4 that can disrupt potent spike: (GAR)n-(GAR)n, the Arg243----His mutation, a site Hha I and the Asp250----Asn mutation, a site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients were indeed com</text>
                    <arg n="0">Mutation 415G4</arg>
                    <arg n="1">potent spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="PERMUTATE" no="493">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (Mutation 415G4 that disrupted potent spike: (GAR)n-(GAR)n, the Arg243----His mutation, a site Hha I and the Asp250----Asn mutation, a site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients were indeed composit</text>
                    <arg n="0">Mutation 415G4</arg>
                    <arg n="1">potent spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="PERMUTATE" no="494">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (a homozygous mutation after disrupted pulally, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">a homozygous mutation</arg>
                    <arg n="1">pulally</arg>
                </example>
                <example src="PERMUTATE" no="495">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (a homozygous mutation after disrupted split, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">a homozygous mutation</arg>
                    <arg n="1">split</arg>
                </example>
                <example src="PERMUTATE" no="496">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (a homozygous mutation being able to disrupt pulally, the Arg243----His mutation, one site Hha I and the Asp250----Asn mutation, one site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients</text>
                    <arg n="0">a homozygous mutation</arg>
                    <arg n="1">pulally</arg>
                </example>
                <example src="PERMUTATE" no="497">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (a homozygous mutation being able to disrupt split, the Arg243----His mutation, one site Hha I and the Asp250----Asn mutation, one site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients</text>
                    <arg n="0">a homozygous mutation</arg>
                    <arg n="1">split</arg>
                </example>
                <example src="PERMUTATE" no="498">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (a homozygous mutation that can disrupt pulally, the Arg243----His mutation, a site Hha I and the Asp250----Asn mutation, a site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients were indeed com</text>
                    <arg n="0">a homozygous mutation</arg>
                    <arg n="1">pulally</arg>
                </example>
                <example src="PERMUTATE" no="499">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (a homozygous mutation that can disrupt split, the Arg243----His mutation, a site Hha I and the Asp250----Asn mutation, a site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients were indeed com</text>
                    <arg n="0">a homozygous mutation</arg>
                    <arg n="1">split</arg>
                </example>
                <example src="PERMUTATE" no="500">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (a homozygous mutation that disrupted pulally, the Arg243----His mutation, a site Hha I and the Asp250----Asn mutation, a site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients were indeed composit</text>
                    <arg n="0">a homozygous mutation</arg>
                    <arg n="1">pulally</arg>
                </example>
                <example src="PERMUTATE" no="501">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (a homozygous mutation that disrupted split, the Arg243----His mutation, a site Hha I and the Asp250----Asn mutation, a site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients were indeed composit</text>
                    <arg n="0">a homozygous mutation</arg>
                    <arg n="1">split</arg>
                </example>
                <example src="PERMUTATE" no="502">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (a homozygous mutation with A1 rupture (one site Ava II), the Arg243----His mutation, one site Hha I and the Asp250----Asn mutation, one site Taq I) and hybridization of allele-specific oligonucleotides disrupted that the patients were indeed com</text>
                    <arg n="0">a homozygous mutation</arg>
                </example>
                <example src="PERMUTATE" no="503">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (alcohol consumption exposure after disrupted ocular dominance plasticity, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">alcohol consumption exposure</arg>
                    <arg n="1">ocular dominance plasticity</arg>
                </example>
                <example src="PERMUTATE" no="504">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (alcohol consumption exposure being able to disrupt ocular dominance plasticity, the Arg243----His mutation, one site Hha I and the Asp250----Asn mutation, one site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients</text>
                    <arg n="0">alcohol consumption exposure</arg>
                    <arg n="1">ocular dominance plasticity</arg>
                </example>
                <example src="PERMUTATE" no="505">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (alcohol consumption exposure that can disrupt ocular dominance plasticity, the Arg243----His mutation, a site Hha I and the Asp250----Asn mutation, a site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients were indeed com</text>
                    <arg n="0">alcohol consumption exposure</arg>
                    <arg n="1">ocular dominance plasticity</arg>
                </example>
                <example src="PERMUTATE" no="506">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (alcohol consumption exposure that disrupted ocular dominance plasticity, the Arg243----His mutation, a site Hha I and the Asp250----Asn mutation, a site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients were indeed composit</text>
                    <arg n="0">alcohol consumption exposure</arg>
                    <arg n="1">ocular dominance plasticity</arg>
                </example>
                <example src="PERMUTATE" no="507">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (alcohol exposure after disrupted ocular domain plasticity, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">alcohol exposure</arg>
                    <arg n="1">ocular domain plasticity</arg>
                </example>
                <example src="PERMUTATE" no="508">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (alcohol exposure after disrupted ocular dominance plasticity, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">alcohol exposure</arg>
                    <arg n="1">ocular dominance plasticity</arg>
                </example>
                <example src="PERMUTATE" no="509">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (alcohol exposure being able to disrupt ocular domain plasticity, the Arg243----His mutation, one site Hha I and the Asp250----Asn mutation, one site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients</text>
                    <arg n="0">alcohol exposure</arg>
                    <arg n="1">ocular domain plasticity</arg>
                </example>
                <example src="PERMUTATE" no="510">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (alcohol exposure being able to disrupt ocular dominance plasticity, the Arg243----His mutation, one site Hha I and the Asp250----Asn mutation, one site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients</text>
                    <arg n="0">alcohol exposure</arg>
                    <arg n="1">ocular dominance plasticity</arg>
                </example>
                <example src="PERMUTATE" no="511">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (alcohol exposure that can disrupt ocular domain plasticity, the Arg243----His mutation, a site Hha I and the Asp250----Asn mutation, a site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients were indeed com</text>
                    <arg n="0">alcohol exposure</arg>
                    <arg n="1">ocular domain plasticity</arg>
                </example>
                <example src="PERMUTATE" no="512">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (alcohol exposure that can disrupt ocular dominance plasticity, the Arg243----His mutation, a site Hha I and the Asp250----Asn mutation, a site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients were indeed com</text>
                    <arg n="0">alcohol exposure</arg>
                    <arg n="1">ocular dominance plasticity</arg>
                </example>
                <example src="PERMUTATE" no="513">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (alcohol exposure that disrupted ocular domain plasticity, the Arg243----His mutation, a site Hha I and the Asp250----Asn mutation, a site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients were indeed composit</text>
                    <arg n="0">alcohol exposure</arg>
                    <arg n="1">ocular domain plasticity</arg>
                </example>
                <example src="PERMUTATE" no="514">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (alcohol exposure that disrupted ocular dominance plasticity, the Arg243----His mutation, a site Hha I and the Asp250----Asn mutation, a site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients were indeed composit</text>
                    <arg n="0">alcohol exposure</arg>
                    <arg n="1">ocular dominance plasticity</arg>
                </example>
                <example src="PERMUTATE" no="515">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (exposure to alcohol consumption after disrupted ocular domain plasticity, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">exposure to alcohol consumption</arg>
                    <arg n="1">ocular domain plasticity</arg>
                </example>
                <example src="PERMUTATE" no="516">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (exposure to alcohol consumption after disrupted plasticity of eye dominance, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">exposure to alcohol consumption</arg>
                    <arg n="1">plasticity of eye dominance</arg>
                </example>
                <example src="PERMUTATE" no="517">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (exposure to alcohol consumption being able to disrupt ocular domain plasticity, the Arg243----His mutation, one site Hha I and the Asp250----Asn mutation, one site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients</text>
                    <arg n="0">exposure to alcohol consumption</arg>
                    <arg n="1">ocular domain plasticity</arg>
                </example>
                <example src="PERMUTATE" no="518">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (exposure to alcohol consumption being able to disrupt plasticity of eye dominance, the Arg243----His mutation, one site Hha I and the Asp250----Asn mutation, one site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients</text>
                    <arg n="0">exposure to alcohol consumption</arg>
                    <arg n="1">plasticity of eye dominance</arg>
                </example>
                <example src="PERMUTATE" no="519">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (exposure to alcohol consumption that can disrupt ocular domain plasticity, the Arg243----His mutation, a site Hha I and the Asp250----Asn mutation, a site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients were indeed com</text>
                    <arg n="0">exposure to alcohol consumption</arg>
                    <arg n="1">ocular domain plasticity</arg>
                </example>
                <example src="PERMUTATE" no="520">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (exposure to alcohol consumption that can disrupt plasticity of eye dominance, the Arg243----His mutation, a site Hha I and the Asp250----Asn mutation, a site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients were indeed com</text>
                    <arg n="0">exposure to alcohol consumption</arg>
                    <arg n="1">plasticity of eye dominance</arg>
                </example>
                <example src="PERMUTATE" no="521">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (exposure to alcohol consumption that disrupted ocular domain plasticity, the Arg243----His mutation, a site Hha I and the Asp250----Asn mutation, a site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients were indeed composit</text>
                    <arg n="0">exposure to alcohol consumption</arg>
                    <arg n="1">ocular domain plasticity</arg>
                </example>
                <example src="PERMUTATE" no="522">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (exposure to alcohol consumption that disrupted plasticity of eye dominance, the Arg243----His mutation, a site Hha I and the Asp250----Asn mutation, a site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients were indeed composit</text>
                    <arg n="0">exposure to alcohol consumption</arg>
                    <arg n="1">plasticity of eye dominance</arg>
                </example>
                <example src="PERMUTATE" no="523">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (his retired expression MEKK1 or MEKK2 after disrupted the overall integrity of MAPK pathway regulation, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">his retired expression MEKK1 or MEKK2</arg>
                    <arg n="1">the overall integrity of MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="524">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (his retired expression MEKK1 or MEKK2 being able to disrupt the overall integrity of MAPK pathway regulation, the Arg243----His mutation, one site Hha I and the Asp250----Asn mutation, one site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients</text>
                    <arg n="0">his retired expression MEKK1 or MEKK2</arg>
                    <arg n="1">the overall integrity of MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="525">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (his retired expression MEKK1 or MEKK2 that can disrupt the overall integrity of MAPK pathway regulation, the Arg243----His mutation, a site Hha I and the Asp250----Asn mutation, a site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients were indeed com</text>
                    <arg n="0">his retired expression MEKK1 or MEKK2</arg>
                    <arg n="1">the overall integrity of MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="526">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (his retired expression MEKK1 or MEKK2 that disrupted the overall integrity of MAPK pathway regulation, the Arg243----His mutation, a site Hha I and the Asp250----Asn mutation, a site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients were indeed composit</text>
                    <arg n="0">his retired expression MEKK1 or MEKK2</arg>
                    <arg n="1">the overall integrity of MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="527">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (homozygous mutation after disrupted spacing, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">homozygous mutation</arg>
                    <arg n="1">spacing</arg>
                </example>
                <example src="PERMUTATE" no="528">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (homozygous mutation after disrupted squirrel, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">homozygous mutation</arg>
                    <arg n="1">squirrel</arg>
                </example>
                <example src="PERMUTATE" no="529">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (homozygous mutation being able to disrupt spacing, the Arg243----His mutation, one site Hha I and the Asp250----Asn mutation, one site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients</text>
                    <arg n="0">homozygous mutation</arg>
                    <arg n="1">spacing</arg>
                </example>
                <example src="PERMUTATE" no="530">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (homozygous mutation being able to disrupt squirrel, the Arg243----His mutation, one site Hha I and the Asp250----Asn mutation, one site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients</text>
                    <arg n="0">homozygous mutation</arg>
                    <arg n="1">squirrel</arg>
                </example>
                <example src="PERMUTATE" no="531">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (homozygous mutation that can disrupt spacing, the Arg243----His mutation, a site Hha I and the Asp250----Asn mutation, a site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients were indeed com</text>
                    <arg n="0">homozygous mutation</arg>
                    <arg n="1">spacing</arg>
                </example>
                <example src="PERMUTATE" no="532">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (homozygous mutation that can disrupt squirrel, the Arg243----His mutation, a site Hha I and the Asp250----Asn mutation, a site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients were indeed com</text>
                    <arg n="0">homozygous mutation</arg>
                    <arg n="1">squirrel</arg>
                </example>
                <example src="PERMUTATE" no="533">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (homozygous mutation that disrupted spacing, the Arg243----His mutation, a site Hha I and the Asp250----Asn mutation, a site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients were indeed composit</text>
                    <arg n="0">homozygous mutation</arg>
                    <arg n="1">spacing</arg>
                </example>
                <example src="PERMUTATE" no="534">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (homozygous mutation that disrupted squirrel, the Arg243----His mutation, a site Hha I and the Asp250----Asn mutation, a site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients were indeed composit</text>
                    <arg n="0">homozygous mutation</arg>
                    <arg n="1">squirrel</arg>
                </example>
                <example src="PERMUTATE" no="535">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (homozygous mutation with A1 rupture (one site Ava II), the Arg243----His mutation, one site Hha I and the Asp250----Asn mutation, one site Taq I) and hybridization of allele-specific oligonucleotides disrupted that the patients were indeed com</text>
                    <arg n="0">homozygous mutation</arg>
                </example>
                <example src="PERMUTATE" no="536">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (if retired from the expression MEKK1 or MEKK2 after disrupted the overall integrity of MAPK pathway regulation, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">if retired from the expression MEKK1 or MEKK2</arg>
                    <arg n="1">the overall integrity of MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="537">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (if retired from the expression MEKK1 or MEKK2 being able to disrupt the overall integrity of MAPK pathway regulation, the Arg243----His mutation, one site Hha I and the Asp250----Asn mutation, one site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients</text>
                    <arg n="0">if retired from the expression MEKK1 or MEKK2</arg>
                    <arg n="1">the overall integrity of MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="538">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (if retired from the expression MEKK1 or MEKK2 that can disrupt the overall integrity of MAPK pathway regulation, the Arg243----His mutation, a site Hha I and the Asp250----Asn mutation, a site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients were indeed com</text>
                    <arg n="0">if retired from the expression MEKK1 or MEKK2</arg>
                    <arg n="1">the overall integrity of MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="539">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (if retired from the expression MEKK1 or MEKK2 that disrupted the overall integrity of MAPK pathway regulation, the Arg243----His mutation, a site Hha I and the Asp250----Asn mutation, a site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients were indeed composit</text>
                    <arg n="0">if retired from the expression MEKK1 or MEKK2</arg>
                    <arg n="1">the overall integrity of MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="540">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (inhibition of inflammation after disrupted physiological protective response, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">inhibition of inflammation</arg>
                    <arg n="1">physiological protective response</arg>
                </example>
                <example src="PERMUTATE" no="541">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (inhibition of inflammation after disrupted protective physiological responses, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">inhibition of inflammation</arg>
                    <arg n="1">protective physiological responses</arg>
                </example>
                <example src="PERMUTATE" no="542">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (inhibition of inflammation being able to disrupt physiological protective response, the Arg243----His mutation, one site Hha I and the Asp250----Asn mutation, one site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients</text>
                    <arg n="0">inhibition of inflammation</arg>
                    <arg n="1">physiological protective response</arg>
                </example>
                <example src="PERMUTATE" no="543">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (inhibition of inflammation being able to disrupt protective physiological responses, the Arg243----His mutation, one site Hha I and the Asp250----Asn mutation, one site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients</text>
                    <arg n="0">inhibition of inflammation</arg>
                    <arg n="1">protective physiological responses</arg>
                </example>
                <example src="PERMUTATE" no="544">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (inhibition of inflammation that can disrupt physiological protective response, the Arg243----His mutation, a site Hha I and the Asp250----Asn mutation, a site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients were indeed com</text>
                    <arg n="0">inhibition of inflammation</arg>
                    <arg n="1">physiological protective response</arg>
                </example>
                <example src="PERMUTATE" no="545">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (inhibition of inflammation that can disrupt protective physiological responses, the Arg243----His mutation, a site Hha I and the Asp250----Asn mutation, a site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients were indeed com</text>
                    <arg n="0">inhibition of inflammation</arg>
                    <arg n="1">protective physiological responses</arg>
                </example>
                <example src="PERMUTATE" no="546">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (inhibition of inflammation that disrupted physiological protective response, the Arg243----His mutation, a site Hha I and the Asp250----Asn mutation, a site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients were indeed composit</text>
                    <arg n="0">inhibition of inflammation</arg>
                    <arg n="1">physiological protective response</arg>
                </example>
                <example src="PERMUTATE" no="547">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (inhibition of inflammation that disrupted protective physiological responses, the Arg243----His mutation, a site Hha I and the Asp250----Asn mutation, a site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients were indeed composit</text>
                    <arg n="0">inhibition of inflammation</arg>
                    <arg n="1">protective physiological responses</arg>
                </example>
                <example src="PERMUTATE" no="548">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (knockout of the expression MEKK1 or MEKK2 after disrupted the overall integrity of MAPK pathway regulation, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">knockout of the expression MEKK1 or MEKK2</arg>
                    <arg n="1">the overall integrity of MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="549">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (knockout of the expression MEKK1 or MEKK2 being able to disrupt the overall integrity of MAPK pathway regulation, the Arg243----His mutation, one site Hha I and the Asp250----Asn mutation, one site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients</text>
                    <arg n="0">knockout of the expression MEKK1 or MEKK2</arg>
                    <arg n="1">the overall integrity of MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="550">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (knockout of the expression MEKK1 or MEKK2 that can disrupt the overall integrity of MAPK pathway regulation, the Arg243----His mutation, a site Hha I and the Asp250----Asn mutation, a site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients were indeed com</text>
                    <arg n="0">knockout of the expression MEKK1 or MEKK2</arg>
                    <arg n="1">the overall integrity of MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="551">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (knockout of the expression MEKK1 or MEKK2 that disrupted the overall integrity of MAPK pathway regulation, the Arg243----His mutation, a site Hha I and the Asp250----Asn mutation, a site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients were indeed composit</text>
                    <arg n="0">knockout of the expression MEKK1 or MEKK2</arg>
                    <arg n="1">the overall integrity of MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="552">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (retired from the MEKK1 or MEKK2 expression after disrupted the overall integrity of the MAPK pathway regulation, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">retired from the MEKK1 or MEKK2 expression</arg>
                    <arg n="1">the overall integrity of the MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="553">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (retired from the MEKK1 or MEKK2 expression being able to disrupt the overall integrity of the MAPK pathway regulation, the Arg243----His mutation, one site Hha I and the Asp250----Asn mutation, one site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients</text>
                    <arg n="0">retired from the MEKK1 or MEKK2 expression</arg>
                    <arg n="1">the overall integrity of the MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="554">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (retired from the MEKK1 or MEKK2 expression that can disrupt the overall integrity of the MAPK pathway regulation, the Arg243----His mutation, a site Hha I and the Asp250----Asn mutation, a site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients were indeed com</text>
                    <arg n="0">retired from the MEKK1 or MEKK2 expression</arg>
                    <arg n="1">the overall integrity of the MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="555">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (retired from the MEKK1 or MEKK2 expression that disrupted the overall integrity of the MAPK pathway regulation, the Arg243----His mutation, a site Hha I and the Asp250----Asn mutation, a site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients were indeed composit</text>
                    <arg n="0">retired from the MEKK1 or MEKK2 expression</arg>
                    <arg n="1">the overall integrity of the MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="556">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (the Gly188--Glu mutation being able to disrupt an Ava II site, the Arg243----His mutation, one site Hha I and the Asp250----Asn mutation, one site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients</text>
                    <arg n="0">the Gly188--Glu mutation</arg>
                    <arg n="1">an Ava II site</arg>
                </example>
                <example src="PERMUTATE" no="557">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (the Gly188--Glu mutation that can disrupt an Ava II site, the Arg243----His mutation, a site Hha I and the Asp250----Asn mutation, a site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients were indeed com</text>
                    <arg n="0">the Gly188--Glu mutation</arg>
                    <arg n="1">an Ava II site</arg>
                </example>
                <example src="PERMUTATE" no="558">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (the Gly188--Glu mutation that disrupted an Ava II site, the Arg243----His mutation, a site Hha I and the Asp250----Asn mutation, a site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients were indeed composit</text>
                    <arg n="0">the Gly188--Glu mutation</arg>
                    <arg n="1">an Ava II site</arg>
                </example>
                <example src="PERMUTATE" no="559">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (the knockout of the MEKK1 or MEKK2 expression after disrupted the overall integrity of the MAPK pathway regulation, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">the knockout of the MEKK1 or MEKK2 expression</arg>
                    <arg n="1">the overall integrity of the MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="560">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (the knockout of the MEKK1 or MEKK2 expression being able to disrupt the overall integrity of the MAPK pathway regulation, the Arg243----His mutation, one site Hha I and the Asp250----Asn mutation, one site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients</text>
                    <arg n="0">the knockout of the MEKK1 or MEKK2 expression</arg>
                    <arg n="1">the overall integrity of the MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="561">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (the knockout of the MEKK1 or MEKK2 expression that can disrupt the overall integrity of the MAPK pathway regulation, the Arg243----His mutation, a site Hha I and the Asp250----Asn mutation, a site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients were indeed com</text>
                    <arg n="0">the knockout of the MEKK1 or MEKK2 expression</arg>
                    <arg n="1">the overall integrity of the MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="562">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (the knockout of the MEKK1 or MEKK2 expression that disrupted the overall integrity of the MAPK pathway regulation, the Arg243----His mutation, a site Hha I and the Asp250----Asn mutation, a site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients were indeed composit</text>
                    <arg n="0">the knockout of the MEKK1 or MEKK2 expression</arg>
                    <arg n="1">the overall integrity of the MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="563">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (this deletion after disrupted open reading frame, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">open reading frame</arg>
                </example>
                <example src="PERMUTATE" no="564">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (this deletion after disrupted the open reading frame, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">the open reading frame</arg>
                </example>
                <example src="PERMUTATE" no="565">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (this deletion after disrupted the open reading structure, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">the open reading structure</arg>
                </example>
                <example src="PERMUTATE" no="566">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (this deletion being able to disrupt open reading frame, the Arg243----His mutation, one site Hha I and the Asp250----Asn mutation, one site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">open reading frame</arg>
                </example>
                <example src="PERMUTATE" no="567">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (this deletion being able to disrupt the open reading frame, the Arg243----His mutation, one site Hha I and the Asp250----Asn mutation, one site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">the open reading frame</arg>
                </example>
                <example src="PERMUTATE" no="568">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (this deletion being able to disrupt the open reading structure, the Arg243----His mutation, one site Hha I and the Asp250----Asn mutation, one site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">the open reading structure</arg>
                </example>
                <example src="PERMUTATE" no="569">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (this deletion that can disrupt open reading frame, the Arg243----His mutation, a site Hha I and the Asp250----Asn mutation, a site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients were indeed com</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">open reading frame</arg>
                </example>
                <example src="PERMUTATE" no="570">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (this deletion that can disrupt the open reading frame, the Arg243----His mutation, a site Hha I and the Asp250----Asn mutation, a site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients were indeed com</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">the open reading frame</arg>
                </example>
                <example src="PERMUTATE" no="571">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (this deletion that can disrupt the open reading structure, the Arg243----His mutation, a site Hha I and the Asp250----Asn mutation, a site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients were indeed com</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">the open reading structure</arg>
                </example>
                <example src="PERMUTATE" no="572">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (this deletion that disrupted open reading frame, the Arg243----His mutation, a site Hha I and the Asp250----Asn mutation, a site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients were indeed composit</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">open reading frame</arg>
                </example>
                <example src="PERMUTATE" no="573">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (this deletion that disrupted the open reading frame, the Arg243----His mutation, a site Hha I and the Asp250----Asn mutation, a site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients were indeed composit</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">the open reading frame</arg>
                </example>
                <example src="PERMUTATE" no="574">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (this deletion that disrupted the open reading structure, the Arg243----His mutation, a site Hha I and the Asp250----Asn mutation, a site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients were indeed composit</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">the open reading structure</arg>
                </example>
                <example src="PERMUTATE" no="575">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (Arg99 and Arg253 being able to disrupt hydrogen bonds in the model, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">Arg99 and Arg253</arg>
                    <arg n="1">hydrogen bonds in the model</arg>
                </example>
                <example src="PERMUTATE" no="576">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (Arg99 and Arg253 that can disrupt hydrogen bonds in the model, the Arg243--His mutation, a Hha I site, and the Asp250---Asn mutation, a Taq I site), and the allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">Arg99 and Arg253</arg>
                    <arg n="1">hydrogen bonds in the model</arg>
                </example>
                <example src="PERMUTATE" no="577">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (Arg99 and Arg253 that have disrupted hydrogen bonds in the model, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">Arg99 and Arg253</arg>
                    <arg n="1">hydrogen bonds in the model</arg>
                </example>
                <example src="PERMUTATE" no="578">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (Arr99 and Arr253 being able to disrupt hydrogen bond pairing in the model, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">Arr99 and Arr253</arg>
                    <arg n="1">hydrogen bond pairing in the model</arg>
                </example>
                <example src="PERMUTATE" no="579">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (Arr99 and Arr253 being able to disrupt the hydrogen bonding pairing in the model, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">Arr99 and Arr253</arg>
                    <arg n="1">the hydrogen bonding pairing in the model</arg>
                </example>
                <example src="PERMUTATE" no="580">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (Arr99 and Arr253 that can disrupt hydrogen bond pairing in the model, the Arg243--His mutation, a Hha I site, and the Asp250---Asn mutation, a Taq I site), and the allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">Arr99 and Arr253</arg>
                    <arg n="1">hydrogen bond pairing in the model</arg>
                </example>
                <example src="PERMUTATE" no="581">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (Arr99 and Arr253 that can disrupt the hydrogen bonding pairing in the model, the Arg243--His mutation, a Hha I site, and the Asp250---Asn mutation, a Taq I site), and the allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">Arr99 and Arr253</arg>
                    <arg n="1">the hydrogen bonding pairing in the model</arg>
                </example>
                <example src="PERMUTATE" no="582">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (Arr99 and Arr253 that have disrupted hydrogen bond pairing in the model, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">Arr99 and Arr253</arg>
                    <arg n="1">hydrogen bond pairing in the model</arg>
                </example>
                <example src="PERMUTATE" no="583">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (Arr99 and Arr253 that have disrupted the hydrogen bonding pairing in the model, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">Arr99 and Arr253</arg>
                    <arg n="1">the hydrogen bonding pairing in the model</arg>
                </example>
                <example src="PERMUTATE" no="584">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (Gly188---Glu mutation being able to disrupt a site Ava II, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">Gly188---Glu mutation</arg>
                    <arg n="1">a site Ava II</arg>
                </example>
                <example src="PERMUTATE" no="585">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (Gly188---Glu mutation being able to disrupt one site Ava II, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">Gly188---Glu mutation</arg>
                    <arg n="1">one site Ava II</arg>
                </example>
                <example src="PERMUTATE" no="586">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (Gly188---Glu mutation that can disrupt a site Ava II, the Arg243--His mutation, a Hha I site, and the Asp250---Asn mutation, a Taq I site), and the allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">Gly188---Glu mutation</arg>
                    <arg n="1">a site Ava II</arg>
                </example>
                <example src="PERMUTATE" no="587">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (Gly188---Glu mutation that can disrupt one site Ava II, the Arg243--His mutation, a Hha I site, and the Asp250---Asn mutation, a Taq I site), and the allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">Gly188---Glu mutation</arg>
                    <arg n="1">one site Ava II</arg>
                </example>
                <example src="PERMUTATE" no="588">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (Gly188---Glu mutation that have disrupted a site Ava II, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">Gly188---Glu mutation</arg>
                    <arg n="1">a site Ava II</arg>
                </example>
                <example src="PERMUTATE" no="589">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (Gly188---Glu mutation that have disrupted one site Ava II, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">Gly188---Glu mutation</arg>
                    <arg n="1">one site Ava II</arg>
                </example>
                <example src="PERMUTATE" no="590">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (Mutation 415G4 being able to disrupt potent spike: (GAR)n-(GAR)n, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">Mutation 415G4</arg>
                    <arg n="1">potent spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="PERMUTATE" no="591">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (Mutation 415G4 that can disrupt potent spike: (GAR)n-(GAR)n, the Arg243--His mutation, a Hha I site, and the Asp250---Asn mutation, a Taq I site), and the allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">Mutation 415G4</arg>
                    <arg n="1">potent spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="PERMUTATE" no="592">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (Mutation 415G4 that have disrupted potent spike: (GAR)n-(GAR)n, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">Mutation 415G4</arg>
                    <arg n="1">potent spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="PERMUTATE" no="593">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (a homozygous mutation being able to disrupt pulally, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">a homozygous mutation</arg>
                    <arg n="1">pulally</arg>
                </example>
                <example src="PERMUTATE" no="594">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (a homozygous mutation being able to disrupt split, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">a homozygous mutation</arg>
                    <arg n="1">split</arg>
                </example>
                <example src="PERMUTATE" no="595">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (a homozygous mutation that can disrupt pulally, the Arg243--His mutation, a Hha I site, and the Asp250---Asn mutation, a Taq I site), and the allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">a homozygous mutation</arg>
                    <arg n="1">pulally</arg>
                </example>
                <example src="PERMUTATE" no="596">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (a homozygous mutation that can disrupt split, the Arg243--His mutation, a Hha I site, and the Asp250---Asn mutation, a Taq I site), and the allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">a homozygous mutation</arg>
                    <arg n="1">split</arg>
                </example>
                <example src="PERMUTATE" no="597">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (a homozygous mutation that have disrupted pulally, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">a homozygous mutation</arg>
                    <arg n="1">pulally</arg>
                </example>
                <example src="PERMUTATE" no="598">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (a homozygous mutation that have disrupted split, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">a homozygous mutation</arg>
                    <arg n="1">split</arg>
                </example>
                <example src="PERMUTATE" no="599">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (alcohol consumption exposure being able to disrupt ocular dominance plasticity, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">alcohol consumption exposure</arg>
                    <arg n="1">ocular dominance plasticity</arg>
                </example>
                <example src="PERMUTATE" no="600">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (alcohol consumption exposure that can disrupt ocular dominance plasticity, the Arg243--His mutation, a Hha I site, and the Asp250---Asn mutation, a Taq I site), and the allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">alcohol consumption exposure</arg>
                    <arg n="1">ocular dominance plasticity</arg>
                </example>
                <example src="PERMUTATE" no="601">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (alcohol consumption exposure that have disrupted ocular dominance plasticity, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">alcohol consumption exposure</arg>
                    <arg n="1">ocular dominance plasticity</arg>
                </example>
                <example src="PERMUTATE" no="602">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (alcohol exposure being able to disrupt ocular domain plasticity, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">alcohol exposure</arg>
                    <arg n="1">ocular domain plasticity</arg>
                </example>
                <example src="PERMUTATE" no="603">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (alcohol exposure being able to disrupt ocular dominance plasticity, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">alcohol exposure</arg>
                    <arg n="1">ocular dominance plasticity</arg>
                </example>
                <example src="PERMUTATE" no="604">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (alcohol exposure that can disrupt ocular domain plasticity, the Arg243--His mutation, a Hha I site, and the Asp250---Asn mutation, a Taq I site), and the allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">alcohol exposure</arg>
                    <arg n="1">ocular domain plasticity</arg>
                </example>
                <example src="PERMUTATE" no="605">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (alcohol exposure that can disrupt ocular dominance plasticity, the Arg243--His mutation, a Hha I site, and the Asp250---Asn mutation, a Taq I site), and the allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">alcohol exposure</arg>
                    <arg n="1">ocular dominance plasticity</arg>
                </example>
                <example src="PERMUTATE" no="606">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (alcohol exposure that have disrupted ocular domain plasticity, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">alcohol exposure</arg>
                    <arg n="1">ocular domain plasticity</arg>
                </example>
                <example src="PERMUTATE" no="607">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (alcohol exposure that have disrupted ocular dominance plasticity, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">alcohol exposure</arg>
                    <arg n="1">ocular dominance plasticity</arg>
                </example>
                <example src="PERMUTATE" no="608">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (exposure to alcohol consumption being able to disrupt ocular domain plasticity, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">exposure to alcohol consumption</arg>
                    <arg n="1">ocular domain plasticity</arg>
                </example>
                <example src="PERMUTATE" no="609">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (exposure to alcohol consumption being able to disrupt plasticity of eye dominance, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">exposure to alcohol consumption</arg>
                    <arg n="1">plasticity of eye dominance</arg>
                </example>
                <example src="PERMUTATE" no="610">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (exposure to alcohol consumption that can disrupt ocular domain plasticity, the Arg243--His mutation, a Hha I site, and the Asp250---Asn mutation, a Taq I site), and the allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">exposure to alcohol consumption</arg>
                    <arg n="1">ocular domain plasticity</arg>
                </example>
                <example src="PERMUTATE" no="611">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (exposure to alcohol consumption that can disrupt plasticity of eye dominance, the Arg243--His mutation, a Hha I site, and the Asp250---Asn mutation, a Taq I site), and the allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">exposure to alcohol consumption</arg>
                    <arg n="1">plasticity of eye dominance</arg>
                </example>
                <example src="PERMUTATE" no="612">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (exposure to alcohol consumption that have disrupted ocular domain plasticity, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">exposure to alcohol consumption</arg>
                    <arg n="1">ocular domain plasticity</arg>
                </example>
                <example src="PERMUTATE" no="613">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (exposure to alcohol consumption that have disrupted plasticity of eye dominance, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">exposure to alcohol consumption</arg>
                    <arg n="1">plasticity of eye dominance</arg>
                </example>
                <example src="PERMUTATE" no="614">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (his retired expression MEKK1 or MEKK2 being able to disrupt the overall integrity of MAPK pathway regulation, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">his retired expression MEKK1 or MEKK2</arg>
                    <arg n="1">the overall integrity of MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="615">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (his retired expression MEKK1 or MEKK2 that can disrupt the overall integrity of MAPK pathway regulation, the Arg243--His mutation, a Hha I site, and the Asp250---Asn mutation, a Taq I site), and the allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">his retired expression MEKK1 or MEKK2</arg>
                    <arg n="1">the overall integrity of MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="616">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (his retired expression MEKK1 or MEKK2 that have disrupted the overall integrity of MAPK pathway regulation, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">his retired expression MEKK1 or MEKK2</arg>
                    <arg n="1">the overall integrity of MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="617">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (homozygous mutation being able to disrupt spacing, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">homozygous mutation</arg>
                    <arg n="1">spacing</arg>
                </example>
                <example src="PERMUTATE" no="618">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (homozygous mutation being able to disrupt squirrel, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">homozygous mutation</arg>
                    <arg n="1">squirrel</arg>
                </example>
                <example src="PERMUTATE" no="619">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (homozygous mutation that can disrupt spacing, the Arg243--His mutation, a Hha I site, and the Asp250---Asn mutation, a Taq I site), and the allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">homozygous mutation</arg>
                    <arg n="1">spacing</arg>
                </example>
                <example src="PERMUTATE" no="620">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (homozygous mutation that can disrupt squirrel, the Arg243--His mutation, a Hha I site, and the Asp250---Asn mutation, a Taq I site), and the allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">homozygous mutation</arg>
                    <arg n="1">squirrel</arg>
                </example>
                <example src="PERMUTATE" no="621">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (homozygous mutation that have disrupted spacing, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">homozygous mutation</arg>
                    <arg n="1">spacing</arg>
                </example>
                <example src="PERMUTATE" no="622">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (homozygous mutation that have disrupted squirrel, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">homozygous mutation</arg>
                    <arg n="1">squirrel</arg>
                </example>
                <example src="PERMUTATE" no="623">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (if retired from the expression MEKK1 or MEKK2 being able to disrupt the overall integrity of MAPK pathway regulation, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">if retired from the expression MEKK1 or MEKK2</arg>
                    <arg n="1">the overall integrity of MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="624">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (if retired from the expression MEKK1 or MEKK2 that can disrupt the overall integrity of MAPK pathway regulation, the Arg243--His mutation, a Hha I site, and the Asp250---Asn mutation, a Taq I site), and the allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">if retired from the expression MEKK1 or MEKK2</arg>
                    <arg n="1">the overall integrity of MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="625">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (if retired from the expression MEKK1 or MEKK2 that have disrupted the overall integrity of MAPK pathway regulation, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">if retired from the expression MEKK1 or MEKK2</arg>
                    <arg n="1">the overall integrity of MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="626">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (inhibition of inflammation being able to disrupt physiological protective response, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">inhibition of inflammation</arg>
                    <arg n="1">physiological protective response</arg>
                </example>
                <example src="PERMUTATE" no="627">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (inhibition of inflammation being able to disrupt protective physiological responses, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">inhibition of inflammation</arg>
                    <arg n="1">protective physiological responses</arg>
                </example>
                <example src="PERMUTATE" no="628">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (inhibition of inflammation that can disrupt physiological protective response, the Arg243--His mutation, a Hha I site, and the Asp250---Asn mutation, a Taq I site), and the allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">inhibition of inflammation</arg>
                    <arg n="1">physiological protective response</arg>
                </example>
                <example src="PERMUTATE" no="629">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (inhibition of inflammation that can disrupt protective physiological responses, the Arg243--His mutation, a Hha I site, and the Asp250---Asn mutation, a Taq I site), and the allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">inhibition of inflammation</arg>
                    <arg n="1">protective physiological responses</arg>
                </example>
                <example src="PERMUTATE" no="630">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (inhibition of inflammation that have disrupted physiological protective response, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">inhibition of inflammation</arg>
                    <arg n="1">physiological protective response</arg>
                </example>
                <example src="PERMUTATE" no="631">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (inhibition of inflammation that have disrupted protective physiological responses, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">inhibition of inflammation</arg>
                    <arg n="1">protective physiological responses</arg>
                </example>
                <example src="PERMUTATE" no="632">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (knockout of the expression MEKK1 or MEKK2 being able to disrupt the overall integrity of MAPK pathway regulation, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">knockout of the expression MEKK1 or MEKK2</arg>
                    <arg n="1">the overall integrity of MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="633">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (knockout of the expression MEKK1 or MEKK2 that can disrupt the overall integrity of MAPK pathway regulation, the Arg243--His mutation, a Hha I site, and the Asp250---Asn mutation, a Taq I site), and the allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">knockout of the expression MEKK1 or MEKK2</arg>
                    <arg n="1">the overall integrity of MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="634">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (knockout of the expression MEKK1 or MEKK2 that have disrupted the overall integrity of MAPK pathway regulation, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">knockout of the expression MEKK1 or MEKK2</arg>
                    <arg n="1">the overall integrity of MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="635">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (retired from the MEKK1 or MEKK2 expression being able to disrupt the overall integrity of the MAPK pathway regulation, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">retired from the MEKK1 or MEKK2 expression</arg>
                    <arg n="1">the overall integrity of the MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="636">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (retired from the MEKK1 or MEKK2 expression that can disrupt the overall integrity of the MAPK pathway regulation, the Arg243--His mutation, a Hha I site, and the Asp250---Asn mutation, a Taq I site), and the allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">retired from the MEKK1 or MEKK2 expression</arg>
                    <arg n="1">the overall integrity of the MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="637">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (retired from the MEKK1 or MEKK2 expression that have disrupted the overall integrity of the MAPK pathway regulation, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">retired from the MEKK1 or MEKK2 expression</arg>
                    <arg n="1">the overall integrity of the MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="638">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (the knockout of the MEKK1 or MEKK2 expression being able to disrupt the overall integrity of the MAPK pathway regulation, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">the knockout of the MEKK1 or MEKK2 expression</arg>
                    <arg n="1">the overall integrity of the MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="639">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (the knockout of the MEKK1 or MEKK2 expression that can disrupt the overall integrity of the MAPK pathway regulation, the Arg243--His mutation, a Hha I site, and the Asp250---Asn mutation, a Taq I site), and the allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">the knockout of the MEKK1 or MEKK2 expression</arg>
                    <arg n="1">the overall integrity of the MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="640">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (the knockout of the MEKK1 or MEKK2 expression that have disrupted the overall integrity of the MAPK pathway regulation, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">the knockout of the MEKK1 or MEKK2 expression</arg>
                    <arg n="1">the overall integrity of the MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="641">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (this deletion being able to disrupt open reading frame, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">open reading frame</arg>
                </example>
                <example src="PERMUTATE" no="642">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (this deletion being able to disrupt the open reading frame, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">the open reading frame</arg>
                </example>
                <example src="PERMUTATE" no="643">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (this deletion being able to disrupt the open reading structure, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">the open reading structure</arg>
                </example>
                <example src="PERMUTATE" no="644">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (this deletion that can disrupt open reading frame, the Arg243--His mutation, a Hha I site, and the Asp250---Asn mutation, a Taq I site), and the allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">open reading frame</arg>
                </example>
                <example src="PERMUTATE" no="645">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (this deletion that can disrupt the open reading frame, the Arg243--His mutation, a Hha I site, and the Asp250---Asn mutation, a Taq I site), and the allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">the open reading frame</arg>
                </example>
                <example src="PERMUTATE" no="646">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (this deletion that can disrupt the open reading structure, the Arg243--His mutation, a Hha I site, and the Asp250---Asn mutation, a Taq I site), and the allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">the open reading structure</arg>
                </example>
                <example src="PERMUTATE" no="647">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (this deletion that have disrupted open reading frame, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">open reading frame</arg>
                </example>
                <example src="PERMUTATE" no="648">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (this deletion that have disrupted the open reading frame, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">the open reading frame</arg>
                </example>
                <example src="PERMUTATE" no="649">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (this deletion that have disrupted the open reading structure, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">the open reading structure</arg>
                </example>
                <example src="PERMUTATE" no="650">
                    <text>The Arg99 and Arg253 that disrupted hydrogen bonds in the model was identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">Arg99 and Arg253</arg>
                    <arg n="1">hydrogen bonds in the model</arg>
                </example>
                <example src="PERMUTATE" no="651">
                    <text>The Arr99 and Arr253 that disrupted hydrogen bond pairing in the model was identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">Arr99 and Arr253</arg>
                    <arg n="1">hydrogen bond pairing in the model</arg>
                </example>
                <example src="PERMUTATE" no="652">
                    <text>The Arr99 and Arr253 that disrupted the hydrogen bonding pairing in the model was identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">Arr99 and Arr253</arg>
                    <arg n="1">the hydrogen bonding pairing in the model</arg>
                </example>
                <example src="PERMUTATE" no="653">
                    <text>The Gly188---Glu mutation that disrupted a site Ava II was identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">Gly188---Glu mutation</arg>
                    <arg n="1">a site Ava II</arg>
                </example>
                <example src="PERMUTATE" no="654">
                    <text>The Gly188---Glu mutation that disrupted one site Ava II was identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">Gly188---Glu mutation</arg>
                    <arg n="1">one site Ava II</arg>
                </example>
                <example src="PERMUTATE" no="655">
                    <text>The Mutation 415G4 that disrupted potent spike: (GAR)n-(GAR)n was identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">Mutation 415G4</arg>
                    <arg n="1">potent spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="PERMUTATE" no="656">
                    <text>The a homozygous mutation that disrupted pulally was identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">a homozygous mutation</arg>
                    <arg n="1">pulally</arg>
                </example>
                <example src="PERMUTATE" no="657">
                    <text>The a homozygous mutation that disrupted split was identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">a homozygous mutation</arg>
                    <arg n="1">split</arg>
                </example>
                <example src="PERMUTATE" no="658">
                    <text>The alcohol consumption exposure that disrupted ocular dominance plasticity was identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">alcohol consumption exposure</arg>
                    <arg n="1">ocular dominance plasticity</arg>
                </example>
                <example src="PERMUTATE" no="659">
                    <text>The alcohol exposure that disrupted ocular domain plasticity was identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">alcohol exposure</arg>
                    <arg n="1">ocular domain plasticity</arg>
                </example>
                <example src="PERMUTATE" no="660">
                    <text>The alcohol exposure that disrupted ocular dominance plasticity was identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">alcohol exposure</arg>
                    <arg n="1">ocular dominance plasticity</arg>
                </example>
                <example src="PERMUTATE" no="661">
                    <text>The exposure to alcohol consumption that disrupted ocular domain plasticity was identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">exposure to alcohol consumption</arg>
                    <arg n="1">ocular domain plasticity</arg>
                </example>
                <example src="PERMUTATE" no="662">
                    <text>The exposure to alcohol consumption that disrupted plasticity of eye dominance was identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">exposure to alcohol consumption</arg>
                    <arg n="1">plasticity of eye dominance</arg>
                </example>
                <example src="PERMUTATE" no="663">
                    <text>The his retired expression MEKK1 or MEKK2 that disrupted the overall integrity of MAPK pathway regulation was identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">his retired expression MEKK1 or MEKK2</arg>
                    <arg n="1">the overall integrity of MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="664">
                    <text>The homozygous mutation that disrupted squirrel was identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">homozygous mutation</arg>
                    <arg n="1">squirrel</arg>
                </example>
                <example src="PERMUTATE" no="665">
                    <text>The if retired from the expression MEKK1 or MEKK2 that disrupted the overall integrity of MAPK pathway regulation was identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">if retired from the expression MEKK1 or MEKK2</arg>
                    <arg n="1">the overall integrity of MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="666">
                    <text>The inhibition of inflammation that disrupted physiological protective response was identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">inhibition of inflammation</arg>
                    <arg n="1">physiological protective response</arg>
                </example>
                <example src="PERMUTATE" no="667">
                    <text>The inhibition of inflammation that disrupted protective physiological responses was identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">inhibition of inflammation</arg>
                    <arg n="1">protective physiological responses</arg>
                </example>
                <example src="PERMUTATE" no="668">
                    <text>The knockout of the expression MEKK1 or MEKK2 that disrupted the overall integrity of MAPK pathway regulation was identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">knockout of the expression MEKK1 or MEKK2</arg>
                    <arg n="1">the overall integrity of MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="669">
                    <text>The retired from the MEKK1 or MEKK2 expression that disrupted the overall integrity of the MAPK pathway regulation was identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">retired from the MEKK1 or MEKK2 expression</arg>
                    <arg n="1">the overall integrity of the MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="670">
                    <text>The sequence of amplified fragments of the cloned polymerase chain reaction of the AMH gene revealed a 14-bp deletion in the second exon of the maternal allele; Arg99 and Arg253 was shown to disrupt hydrogen bonds in the model.</text>
                    <arg n="0">Arg99 and Arg253</arg>
                    <arg n="1">hydrogen bonds in the model</arg>
                </example>
                <example src="PERMUTATE" no="671">
                    <text>The sequence of amplified fragments of the cloned polymerase chain reaction of the AMH gene revealed a 14-bp deletion in the second exon of the maternal allele; Arr99 and Arr253 was shown to disrupt hydrogen bond pairing in the model.</text>
                    <arg n="0">Arr99 and Arr253</arg>
                    <arg n="1">hydrogen bond pairing in the model</arg>
                </example>
                <example src="PERMUTATE" no="672">
                    <text>The sequence of amplified fragments of the cloned polymerase chain reaction of the AMH gene revealed a 14-bp deletion in the second exon of the maternal allele; Arr99 and Arr253 was shown to disrupt the hydrogen bonding pairing in the model.</text>
                    <arg n="0">Arr99 and Arr253</arg>
                    <arg n="1">the hydrogen bonding pairing in the model</arg>
                </example>
                <example src="PERMUTATE" no="673">
                    <text>The sequence of amplified fragments of the cloned polymerase chain reaction of the AMH gene revealed a 14-bp deletion in the second exon of the maternal allele; Gly188---Glu mutation was shown to disrupt a site Ava II.</text>
                    <arg n="0">Gly188---Glu mutation</arg>
                    <arg n="1">a site Ava II</arg>
                </example>
                <example src="PERMUTATE" no="674">
                    <text>The sequence of amplified fragments of the cloned polymerase chain reaction of the AMH gene revealed a 14-bp deletion in the second exon of the maternal allele; Gly188---Glu mutation was shown to disrupt one site Ava II.</text>
                    <arg n="0">Gly188---Glu mutation</arg>
                    <arg n="1">one site Ava II</arg>
                </example>
                <example src="PERMUTATE" no="675">
                    <text>The sequence of amplified fragments of the cloned polymerase chain reaction of the AMH gene revealed a 14-bp deletion in the second exon of the maternal allele; Mutation 415G4 was shown to disrupt potent spike: (GAR)n-(GAR)n.</text>
                    <arg n="0">Mutation 415G4</arg>
                    <arg n="1">potent spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="PERMUTATE" no="676">
                    <text>The sequence of amplified fragments of the cloned polymerase chain reaction of the AMH gene revealed a 14-bp deletion in the second exon of the maternal allele; a homozygous mutation was shown to disrupt pulally.</text>
                    <arg n="0">a homozygous mutation</arg>
                    <arg n="1">pulally</arg>
                </example>
                <example src="PERMUTATE" no="677">
                    <text>The sequence of amplified fragments of the cloned polymerase chain reaction of the AMH gene revealed a 14-bp deletion in the second exon of the maternal allele; a homozygous mutation was shown to disrupt split.</text>
                    <arg n="0">a homozygous mutation</arg>
                    <arg n="1">split</arg>
                </example>
                <example src="PERMUTATE" no="678">
                    <text>The sequence of amplified fragments of the cloned polymerase chain reaction of the AMH gene revealed a 14-bp deletion in the second exon of the maternal allele; alcohol consumption exposure was shown to disrupt ocular dominance plasticity.</text>
                    <arg n="0">alcohol consumption exposure</arg>
                    <arg n="1">ocular dominance plasticity</arg>
                </example>
                <example src="PERMUTATE" no="679">
                    <text>The sequence of amplified fragments of the cloned polymerase chain reaction of the AMH gene revealed a 14-bp deletion in the second exon of the maternal allele; alcohol exposure was shown to disrupt ocular domain plasticity.</text>
                    <arg n="0">alcohol exposure</arg>
                    <arg n="1">ocular domain plasticity</arg>
                </example>
                <example src="PERMUTATE" no="680">
                    <text>The sequence of amplified fragments of the cloned polymerase chain reaction of the AMH gene revealed a 14-bp deletion in the second exon of the maternal allele; alcohol exposure was shown to disrupt ocular dominance plasticity.</text>
                    <arg n="0">alcohol exposure</arg>
                    <arg n="1">ocular dominance plasticity</arg>
                </example>
                <example src="PERMUTATE" no="681">
                    <text>The sequence of amplified fragments of the cloned polymerase chain reaction of the AMH gene revealed a 14-bp deletion in the second exon of the maternal allele; exposure to alcohol consumption was shown to disrupt ocular domain plasticity.</text>
                    <arg n="0">exposure to alcohol consumption</arg>
                    <arg n="1">ocular domain plasticity</arg>
                </example>
                <example src="PERMUTATE" no="682">
                    <text>The sequence of amplified fragments of the cloned polymerase chain reaction of the AMH gene revealed a 14-bp deletion in the second exon of the maternal allele; exposure to alcohol consumption was shown to disrupt plasticity of eye dominance.</text>
                    <arg n="0">exposure to alcohol consumption</arg>
                    <arg n="1">plasticity of eye dominance</arg>
                </example>
                <example src="PERMUTATE" no="683">
                    <text>The sequence of amplified fragments of the cloned polymerase chain reaction of the AMH gene revealed a 14-bp deletion in the second exon of the maternal allele; his retired expression MEKK1 or MEKK2 was shown to disrupt the overall integrity of MAPK pathway regulation.</text>
                    <arg n="0">his retired expression MEKK1 or MEKK2</arg>
                    <arg n="1">the overall integrity of MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="684">
                    <text>The sequence of amplified fragments of the cloned polymerase chain reaction of the AMH gene revealed a 14-bp deletion in the second exon of the maternal allele; homozygous mutation was shown to disrupt spacing.</text>
                    <arg n="0">homozygous mutation</arg>
                    <arg n="1">spacing</arg>
                </example>
                <example src="PERMUTATE" no="685">
                    <text>The sequence of amplified fragments of the cloned polymerase chain reaction of the AMH gene revealed a 14-bp deletion in the second exon of the maternal allele; homozygous mutation was shown to disrupt squirrel.</text>
                    <arg n="0">homozygous mutation</arg>
                    <arg n="1">squirrel</arg>
                </example>
                <example src="PERMUTATE" no="686">
                    <text>The sequence of amplified fragments of the cloned polymerase chain reaction of the AMH gene revealed a 14-bp deletion in the second exon of the maternal allele; if retired from the expression MEKK1 or MEKK2 was shown to disrupt the overall integrity of MAPK pathway regulation.</text>
                    <arg n="0">if retired from the expression MEKK1 or MEKK2</arg>
                    <arg n="1">the overall integrity of MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="687">
                    <text>The sequence of amplified fragments of the cloned polymerase chain reaction of the AMH gene revealed a 14-bp deletion in the second exon of the maternal allele; inhibition of inflammation was shown to disrupt physiological protective response.</text>
                    <arg n="0">inhibition of inflammation</arg>
                    <arg n="1">physiological protective response</arg>
                </example>
                <example src="PERMUTATE" no="688">
                    <text>The sequence of amplified fragments of the cloned polymerase chain reaction of the AMH gene revealed a 14-bp deletion in the second exon of the maternal allele; inhibition of inflammation was shown to disrupt protective physiological responses.</text>
                    <arg n="0">inhibition of inflammation</arg>
                    <arg n="1">protective physiological responses</arg>
                </example>
                <example src="PERMUTATE" no="689">
                    <text>The sequence of amplified fragments of the cloned polymerase chain reaction of the AMH gene revealed a 14-bp deletion in the second exon of the maternal allele; knockout of the expression MEKK1 or MEKK2 was shown to disrupt the overall integrity of MAPK pathway regulation.</text>
                    <arg n="0">knockout of the expression MEKK1 or MEKK2</arg>
                    <arg n="1">the overall integrity of MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="690">
                    <text>The sequence of amplified fragments of the cloned polymerase chain reaction of the AMH gene revealed a 14-bp deletion in the second exon of the maternal allele; retired from the MEKK1 or MEKK2 expression was shown to disrupt the overall integrity of the MAPK pathway regulation.</text>
                    <arg n="0">retired from the MEKK1 or MEKK2 expression</arg>
                    <arg n="1">the overall integrity of the MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="691">
                    <text>The sequence of amplified fragments of the cloned polymerase chain reaction of the AMH gene revealed a 14-bp deletion in the second exon of the maternal allele; the Gly188--Glu mutation was shown to disrupt an Ava II site.</text>
                    <arg n="0">the Gly188--Glu mutation</arg>
                    <arg n="1">an Ava II site</arg>
                </example>
                <example src="PERMUTATE" no="692">
                    <text>The sequence of amplified fragments of the cloned polymerase chain reaction of the AMH gene revealed a 14-bp deletion in the second exon of the maternal allele; the knockout of the MEKK1 or MEKK2 expression was shown to disrupt the overall integrity of the MAPK pathway regulation.</text>
                    <arg n="0">the knockout of the MEKK1 or MEKK2 expression</arg>
                    <arg n="1">the overall integrity of the MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="693">
                    <text>The sequence of amplified fragments of the cloned polymerase chain reaction of the AMH gene revealed a 14-bp deletion in the second exon of the maternal allele; this deletion was shown to disrupt open reading frame.</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">open reading frame</arg>
                </example>
                <example src="PERMUTATE" no="694">
                    <text>The sequence of amplified fragments of the cloned polymerase chain reaction of the AMH gene revealed a 14-bp deletion in the second exon of the maternal allele; this deletion was shown to disrupt the open reading frame.</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">the open reading frame</arg>
                </example>
                <example src="PERMUTATE" no="695">
                    <text>The sequence of the cloned polymerase chain reaction amplified fragments of the AMH gene revealed a deletion of 14-bp in the second exon of the maternal allele; Arg99 and Arg253 is able to disrupt hydrogen bonds in the model.</text>
                    <arg n="0">Arg99 and Arg253</arg>
                    <arg n="1">hydrogen bonds in the model</arg>
                </example>
                <example src="PERMUTATE" no="696">
                    <text>The sequence of the cloned polymerase chain reaction amplified fragments of the AMH gene revealed a deletion of 14-bp in the second exon of the maternal allele; Arr99 and Arr253 is able to disrupt hydrogen bond pairing in the model.</text>
                    <arg n="0">Arr99 and Arr253</arg>
                    <arg n="1">hydrogen bond pairing in the model</arg>
                </example>
                <example src="PERMUTATE" no="697">
                    <text>The sequence of the cloned polymerase chain reaction amplified fragments of the AMH gene revealed a deletion of 14-bp in the second exon of the maternal allele; Arr99 and Arr253 is able to disrupt the hydrogen bonding pairing in the model.</text>
                    <arg n="0">Arr99 and Arr253</arg>
                    <arg n="1">the hydrogen bonding pairing in the model</arg>
                </example>
                <example src="PERMUTATE" no="698">
                    <text>The sequence of the cloned polymerase chain reaction amplified fragments of the AMH gene revealed a deletion of 14-bp in the second exon of the maternal allele; Gly188---Glu mutation is able to disrupt a site Ava II.</text>
                    <arg n="0">Gly188---Glu mutation</arg>
                    <arg n="1">a site Ava II</arg>
                </example>
                <example src="PERMUTATE" no="699">
                    <text>The sequence of the cloned polymerase chain reaction amplified fragments of the AMH gene revealed a deletion of 14-bp in the second exon of the maternal allele; Gly188---Glu mutation is able to disrupt one site Ava II.</text>
                    <arg n="0">Gly188---Glu mutation</arg>
                    <arg n="1">one site Ava II</arg>
                </example>
                <example src="PERMUTATE" no="700">
                    <text>The sequence of the cloned polymerase chain reaction amplified fragments of the AMH gene revealed a deletion of 14-bp in the second exon of the maternal allele; Mutation 415G4 is able to disrupt potent spike: (GAR)n-(GAR)n.</text>
                    <arg n="0">Mutation 415G4</arg>
                    <arg n="1">potent spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="PERMUTATE" no="701">
                    <text>The sequence of the cloned polymerase chain reaction amplified fragments of the AMH gene revealed a deletion of 14-bp in the second exon of the maternal allele; a homozygous mutation is able to disrupt pulally.</text>
                    <arg n="0">a homozygous mutation</arg>
                    <arg n="1">pulally</arg>
                </example>
                <example src="PERMUTATE" no="702">
                    <text>The sequence of the cloned polymerase chain reaction amplified fragments of the AMH gene revealed a deletion of 14-bp in the second exon of the maternal allele; a homozygous mutation is able to disrupt split.</text>
                    <arg n="0">a homozygous mutation</arg>
                    <arg n="1">split</arg>
                </example>
                <example src="PERMUTATE" no="703">
                    <text>The sequence of the cloned polymerase chain reaction amplified fragments of the AMH gene revealed a deletion of 14-bp in the second exon of the maternal allele; alcohol consumption exposure is able to disrupt ocular dominance plasticity.</text>
                    <arg n="0">alcohol consumption exposure</arg>
                    <arg n="1">ocular dominance plasticity</arg>
                </example>
                <example src="PERMUTATE" no="704">
                    <text>The sequence of the cloned polymerase chain reaction amplified fragments of the AMH gene revealed a deletion of 14-bp in the second exon of the maternal allele; alcohol exposure is able to disrupt ocular domain plasticity.</text>
                    <arg n="0">alcohol exposure</arg>
                    <arg n="1">ocular domain plasticity</arg>
                </example>
                <example src="PERMUTATE" no="705">
                    <text>The sequence of the cloned polymerase chain reaction amplified fragments of the AMH gene revealed a deletion of 14-bp in the second exon of the maternal allele; alcohol exposure is able to disrupt ocular dominance plasticity.</text>
                    <arg n="0">alcohol exposure</arg>
                    <arg n="1">ocular dominance plasticity</arg>
                </example>
                <example src="PERMUTATE" no="706">
                    <text>The sequence of the cloned polymerase chain reaction amplified fragments of the AMH gene revealed a deletion of 14-bp in the second exon of the maternal allele; exposure to alcohol consumption is able to disrupt ocular domain plasticity.</text>
                    <arg n="0">exposure to alcohol consumption</arg>
                    <arg n="1">ocular domain plasticity</arg>
                </example>
                <example src="PERMUTATE" no="707">
                    <text>The sequence of the cloned polymerase chain reaction amplified fragments of the AMH gene revealed a deletion of 14-bp in the second exon of the maternal allele; exposure to alcohol consumption is able to disrupt plasticity of eye dominance.</text>
                    <arg n="0">exposure to alcohol consumption</arg>
                    <arg n="1">plasticity of eye dominance</arg>
                </example>
                <example src="PERMUTATE" no="708">
                    <text>The sequence of the cloned polymerase chain reaction amplified fragments of the AMH gene revealed a deletion of 14-bp in the second exon of the maternal allele; his retired expression MEKK1 or MEKK2 is able to disrupt the overall integrity of MAPK pathway regulation.</text>
                    <arg n="0">his retired expression MEKK1 or MEKK2</arg>
                    <arg n="1">the overall integrity of MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="709">
                    <text>The sequence of the cloned polymerase chain reaction amplified fragments of the AMH gene revealed a deletion of 14-bp in the second exon of the maternal allele; homozygous mutation is able to disrupt spacing.</text>
                    <arg n="0">homozygous mutation</arg>
                    <arg n="1">spacing</arg>
                </example>
                <example src="PERMUTATE" no="710">
                    <text>The sequence of the cloned polymerase chain reaction amplified fragments of the AMH gene revealed a deletion of 14-bp in the second exon of the maternal allele; homozygous mutation is able to disrupt squirrel.</text>
                    <arg n="0">homozygous mutation</arg>
                    <arg n="1">squirrel</arg>
                </example>
                <example src="PERMUTATE" no="711">
                    <text>The sequence of the cloned polymerase chain reaction amplified fragments of the AMH gene revealed a deletion of 14-bp in the second exon of the maternal allele; if retired from the expression MEKK1 or MEKK2 is able to disrupt the overall integrity of MAPK pathway regulation.</text>
                    <arg n="0">if retired from the expression MEKK1 or MEKK2</arg>
                    <arg n="1">the overall integrity of MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="712">
                    <text>The sequence of the cloned polymerase chain reaction amplified fragments of the AMH gene revealed a deletion of 14-bp in the second exon of the maternal allele; inhibition of inflammation is able to disrupt physiological protective response.</text>
                    <arg n="0">inhibition of inflammation</arg>
                    <arg n="1">physiological protective response</arg>
                </example>
                <example src="PERMUTATE" no="713">
                    <text>The sequence of the cloned polymerase chain reaction amplified fragments of the AMH gene revealed a deletion of 14-bp in the second exon of the maternal allele; inhibition of inflammation is able to disrupt protective physiological responses.</text>
                    <arg n="0">inhibition of inflammation</arg>
                    <arg n="1">protective physiological responses</arg>
                </example>
                <example src="PERMUTATE" no="714">
                    <text>The sequence of the cloned polymerase chain reaction amplified fragments of the AMH gene revealed a deletion of 14-bp in the second exon of the maternal allele; knockout of the expression MEKK1 or MEKK2 is able to disrupt the overall integrity of MAPK pathway regulation.</text>
                    <arg n="0">knockout of the expression MEKK1 or MEKK2</arg>
                    <arg n="1">the overall integrity of MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="715">
                    <text>The sequence of the cloned polymerase chain reaction amplified fragments of the AMH gene revealed a deletion of 14-bp in the second exon of the maternal allele; retired from the MEKK1 or MEKK2 expression is able to disrupt the overall integrity of the MAPK pathway regulation.</text>
                    <arg n="0">retired from the MEKK1 or MEKK2 expression</arg>
                    <arg n="1">the overall integrity of the MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="716">
                    <text>The sequence of the cloned polymerase chain reaction amplified fragments of the AMH gene revealed a deletion of 14-bp in the second exon of the maternal allele; the Gly188--Glu mutation is able to disrupt an Ava II site.</text>
                    <arg n="0">the Gly188--Glu mutation</arg>
                    <arg n="1">an Ava II site</arg>
                </example>
                <example src="PERMUTATE" no="717">
                    <text>The sequence of the cloned polymerase chain reaction amplified fragments of the AMH gene revealed a deletion of 14-bp in the second exon of the maternal allele; the knockout of the MEKK1 or MEKK2 expression is able to disrupt the overall integrity of the MAPK pathway regulation.</text>
                    <arg n="0">the knockout of the MEKK1 or MEKK2 expression</arg>
                    <arg n="1">the overall integrity of the MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="718">
                    <text>The sequence of the cloned polymerase chain reaction amplified fragments of the AMH gene revealed a deletion of 14-bp in the second exon of the maternal allele; this deletion is able to disrupt open reading frame.</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">open reading frame</arg>
                </example>
                <example src="PERMUTATE" no="719">
                    <text>The sequence of the cloned polymerase chain reaction amplified fragments of the AMH gene revealed a deletion of 14-bp in the second exon of the maternal allele; this deletion is able to disrupt the open reading frame.</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">the open reading frame</arg>
                </example>
                <example src="PERMUTATE" no="720">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene disrupted a 14 bp deletion in the second exon of the maternal allele; Arg99 and Arg253 broke hydrogen bonds in the model.</text>
                    <arg n="0">Arg99 and Arg253</arg>
                    <arg n="1">hydrogen bonds in the model</arg>
                </example>
                <example src="PERMUTATE" no="721">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene disrupted a 14 bp deletion in the second exon of the maternal allele; Arr99 and Arr253 broke hydrogen bond pairing in the model.</text>
                    <arg n="0">Arr99 and Arr253</arg>
                    <arg n="1">hydrogen bond pairing in the model</arg>
                </example>
                <example src="PERMUTATE" no="722">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene disrupted a 14 bp deletion in the second exon of the maternal allele; Arr99 and Arr253 broke the hydrogen bonding pairing in the model.</text>
                    <arg n="0">Arr99 and Arr253</arg>
                    <arg n="1">the hydrogen bonding pairing in the model</arg>
                </example>
                <example src="PERMUTATE" no="723">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene disrupted a 14 bp deletion in the second exon of the maternal allele; Gly188---Glu mutation broke a site Ava II.</text>
                    <arg n="0">Gly188---Glu mutation</arg>
                    <arg n="1">a site Ava II</arg>
                </example>
                <example src="PERMUTATE" no="724">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene disrupted a 14 bp deletion in the second exon of the maternal allele; Gly188---Glu mutation broke one site Ava II.</text>
                    <arg n="0">Gly188---Glu mutation</arg>
                    <arg n="1">one site Ava II</arg>
                </example>
                <example src="PERMUTATE" no="725">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene disrupted a 14 bp deletion in the second exon of the maternal allele; Mutation 415G4 broke potent spike: (GAR)n-(GAR)n.</text>
                    <arg n="0">Mutation 415G4</arg>
                    <arg n="1">potent spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="PERMUTATE" no="726">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene disrupted a 14 bp deletion in the second exon of the maternal allele; a homozygous mutation broke pulally.</text>
                    <arg n="0">a homozygous mutation</arg>
                    <arg n="1">pulally</arg>
                </example>
                <example src="PERMUTATE" no="727">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene disrupted a 14 bp deletion in the second exon of the maternal allele; a homozygous mutation broke split.</text>
                    <arg n="0">a homozygous mutation</arg>
                    <arg n="1">split</arg>
                </example>
                <example src="PERMUTATE" no="728">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene disrupted a 14 bp deletion in the second exon of the maternal allele; alcohol consumption exposure broke ocular dominance plasticity.</text>
                    <arg n="0">alcohol consumption exposure</arg>
                    <arg n="1">ocular dominance plasticity</arg>
                </example>
                <example src="PERMUTATE" no="729">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene disrupted a 14 bp deletion in the second exon of the maternal allele; alcohol exposure broke ocular domain plasticity.</text>
                    <arg n="0">alcohol exposure</arg>
                    <arg n="1">ocular domain plasticity</arg>
                </example>
                <example src="PERMUTATE" no="730">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene disrupted a 14 bp deletion in the second exon of the maternal allele; alcohol exposure broke ocular dominance plasticity.</text>
                    <arg n="0">alcohol exposure</arg>
                    <arg n="1">ocular dominance plasticity</arg>
                </example>
                <example src="PERMUTATE" no="731">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene disrupted a 14 bp deletion in the second exon of the maternal allele; exposure to alcohol consumption broke ocular domain plasticity.</text>
                    <arg n="0">exposure to alcohol consumption</arg>
                    <arg n="1">ocular domain plasticity</arg>
                </example>
                <example src="PERMUTATE" no="732">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene disrupted a 14 bp deletion in the second exon of the maternal allele; exposure to alcohol consumption broke plasticity of eye dominance.</text>
                    <arg n="0">exposure to alcohol consumption</arg>
                    <arg n="1">plasticity of eye dominance</arg>
                </example>
                <example src="PERMUTATE" no="733">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene disrupted a 14 bp deletion in the second exon of the maternal allele; his retired expression MEKK1 or MEKK2 broke the overall integrity of MAPK pathway regulation.</text>
                    <arg n="0">his retired expression MEKK1 or MEKK2</arg>
                    <arg n="1">the overall integrity of MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="734">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene disrupted a 14 bp deletion in the second exon of the maternal allele; homozygous mutation broke spacing.</text>
                    <arg n="0">homozygous mutation</arg>
                    <arg n="1">spacing</arg>
                </example>
                <example src="PERMUTATE" no="735">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene disrupted a 14 bp deletion in the second exon of the maternal allele; homozygous mutation broke squirrel.</text>
                    <arg n="0">homozygous mutation</arg>
                    <arg n="1">squirrel</arg>
                </example>
                <example src="PERMUTATE" no="736">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene disrupted a 14 bp deletion in the second exon of the maternal allele; if retired from the expression MEKK1 or MEKK2 broke the overall integrity of MAPK pathway regulation.</text>
                    <arg n="0">if retired from the expression MEKK1 or MEKK2</arg>
                    <arg n="1">the overall integrity of MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="737">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene disrupted a 14 bp deletion in the second exon of the maternal allele; inhibition of inflammation broke physiological protective response.</text>
                    <arg n="0">inhibition of inflammation</arg>
                    <arg n="1">physiological protective response</arg>
                </example>
                <example src="PERMUTATE" no="738">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene disrupted a 14 bp deletion in the second exon of the maternal allele; inhibition of inflammation broke protective physiological responses.</text>
                    <arg n="0">inhibition of inflammation</arg>
                    <arg n="1">protective physiological responses</arg>
                </example>
                <example src="PERMUTATE" no="739">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene disrupted a 14 bp deletion in the second exon of the maternal allele; knockout of the expression MEKK1 or MEKK2 broke the overall integrity of MAPK pathway regulation.</text>
                    <arg n="0">knockout of the expression MEKK1 or MEKK2</arg>
                    <arg n="1">the overall integrity of MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="740">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene disrupted a 14 bp deletion in the second exon of the maternal allele; retired from the MEKK1 or MEKK2 expression broke the overall integrity of the MAPK pathway regulation.</text>
                    <arg n="0">retired from the MEKK1 or MEKK2 expression</arg>
                    <arg n="1">the overall integrity of the MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="741">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene disrupted a 14 bp deletion in the second exon of the maternal allele; the Gly188--Glu mutation broke an Ava II site.</text>
                    <arg n="0">the Gly188--Glu mutation</arg>
                    <arg n="1">an Ava II site</arg>
                </example>
                <example src="PERMUTATE" no="742">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene disrupted a 14 bp deletion in the second exon of the maternal allele; the knockout of the MEKK1 or MEKK2 expression broke the overall integrity of the MAPK pathway regulation.</text>
                    <arg n="0">the knockout of the MEKK1 or MEKK2 expression</arg>
                    <arg n="1">the overall integrity of the MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="743">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene disrupted a 14 bp deletion in the second exon of the maternal allele; this deletion broke open reading frame.</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">open reading frame</arg>
                </example>
                <example src="PERMUTATE" no="744">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene disrupted a 14 bp deletion in the second exon of the maternal allele; this deletion broke the open reading frame.</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">the open reading frame</arg>
                </example>
                <example src="PERMUTATE" no="745">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; Arg99 and Arg253 disrupts hydrogen bonds in the model.</text>
                    <arg n="0">Arg99 and Arg253</arg>
                    <arg n="1">hydrogen bonds in the model</arg>
                </example>
                <example src="PERMUTATE" no="746">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; Arg99 and Arg253 has been shown to disrupt hydrogen bonds in the model.</text>
                    <arg n="0">Arg99 and Arg253</arg>
                    <arg n="1">hydrogen bonds in the model</arg>
                </example>
                <example src="PERMUTATE" no="747">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; Arg99 and Arg253 has disrupted hydrogen bonds in the model.</text>
                    <arg n="0">Arg99 and Arg253</arg>
                    <arg n="1">hydrogen bonds in the model</arg>
                </example>
                <example src="PERMUTATE" no="748">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; Arg99 and Arg253 may have disrupted hydrogen bonds in the model.</text>
                    <arg n="0">Arg99 and Arg253</arg>
                    <arg n="1">hydrogen bonds in the model</arg>
                </example>
                <example src="PERMUTATE" no="749">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; Arr99 and Arr253 disrupts hydrogen bond pairing in the model.</text>
                    <arg n="0">Arr99 and Arr253</arg>
                    <arg n="1">hydrogen bond pairing in the model</arg>
                </example>
                <example src="PERMUTATE" no="750">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; Arr99 and Arr253 disrupts the hydrogen bonding pairing in the model.</text>
                    <arg n="0">Arr99 and Arr253</arg>
                    <arg n="1">the hydrogen bonding pairing in the model</arg>
                </example>
                <example src="PERMUTATE" no="751">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; Arr99 and Arr253 has been shown to disrupt hydrogen bond pairing in the model.</text>
                    <arg n="0">Arr99 and Arr253</arg>
                    <arg n="1">hydrogen bond pairing in the model</arg>
                </example>
                <example src="PERMUTATE" no="752">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; Arr99 and Arr253 has been shown to disrupt the hydrogen bonding pairing in the model.</text>
                    <arg n="0">Arr99 and Arr253</arg>
                    <arg n="1">the hydrogen bonding pairing in the model</arg>
                </example>
                <example src="PERMUTATE" no="753">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; Arr99 and Arr253 has disrupted hydrogen bond pairing in the model.</text>
                    <arg n="0">Arr99 and Arr253</arg>
                    <arg n="1">hydrogen bond pairing in the model</arg>
                </example>
                <example src="PERMUTATE" no="754">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; Arr99 and Arr253 has disrupted the hydrogen bonding pairing in the model.</text>
                    <arg n="0">Arr99 and Arr253</arg>
                    <arg n="1">the hydrogen bonding pairing in the model</arg>
                </example>
                <example src="PERMUTATE" no="755">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; Arr99 and Arr253 may have disrupted hydrogen bond pairing in the model.</text>
                    <arg n="0">Arr99 and Arr253</arg>
                    <arg n="1">hydrogen bond pairing in the model</arg>
                </example>
                <example src="PERMUTATE" no="756">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; Arr99 and Arr253 may have disrupted the hydrogen bonding pairing in the model.</text>
                    <arg n="0">Arr99 and Arr253</arg>
                    <arg n="1">the hydrogen bonding pairing in the model</arg>
                </example>
                <example src="PERMUTATE" no="757">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; Gly188---Glu mutation disrupts a site Ava II.</text>
                    <arg n="0">Gly188---Glu mutation</arg>
                    <arg n="1">a site Ava II</arg>
                </example>
                <example src="PERMUTATE" no="758">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; Gly188---Glu mutation disrupts one site Ava II.</text>
                    <arg n="0">Gly188---Glu mutation</arg>
                    <arg n="1">one site Ava II</arg>
                </example>
                <example src="PERMUTATE" no="759">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; Gly188---Glu mutation has been shown to disrupt a site Ava II.</text>
                    <arg n="0">Gly188---Glu mutation</arg>
                    <arg n="1">a site Ava II</arg>
                </example>
                <example src="PERMUTATE" no="760">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; Gly188---Glu mutation has been shown to disrupt one site Ava II.</text>
                    <arg n="0">Gly188---Glu mutation</arg>
                    <arg n="1">one site Ava II</arg>
                </example>
                <example src="PERMUTATE" no="761">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; Gly188---Glu mutation has disrupted a site Ava II.</text>
                    <arg n="0">Gly188---Glu mutation</arg>
                    <arg n="1">a site Ava II</arg>
                </example>
                <example src="PERMUTATE" no="762">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; Gly188---Glu mutation has disrupted one site Ava II.</text>
                    <arg n="0">Gly188---Glu mutation</arg>
                    <arg n="1">one site Ava II</arg>
                </example>
                <example src="PERMUTATE" no="763">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; Gly188---Glu mutation may have disrupted a site Ava II.</text>
                    <arg n="0">Gly188---Glu mutation</arg>
                    <arg n="1">a site Ava II</arg>
                </example>
                <example src="PERMUTATE" no="764">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; Gly188---Glu mutation may have disrupted one site Ava II.</text>
                    <arg n="0">Gly188---Glu mutation</arg>
                    <arg n="1">one site Ava II</arg>
                </example>
                <example src="PERMUTATE" no="765">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; Mutation 415G4 disrupts potent spike: (GAR)n-(GAR)n.</text>
                    <arg n="0">Mutation 415G4</arg>
                    <arg n="1">potent spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="PERMUTATE" no="766">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; Mutation 415G4 has been shown to disrupt potent spike: (GAR)n-(GAR)n.</text>
                    <arg n="0">Mutation 415G4</arg>
                    <arg n="1">potent spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="PERMUTATE" no="767">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; Mutation 415G4 has disrupted potent spike: (GAR)n-(GAR)n.</text>
                    <arg n="0">Mutation 415G4</arg>
                    <arg n="1">potent spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="PERMUTATE" no="768">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; Mutation 415G4 may have disrupted potent spike: (GAR)n-(GAR)n.</text>
                    <arg n="0">Mutation 415G4</arg>
                    <arg n="1">potent spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="PERMUTATE" no="769">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; a homozygous mutation disrupts pulally.</text>
                    <arg n="0">a homozygous mutation</arg>
                    <arg n="1">pulally</arg>
                </example>
                <example src="PERMUTATE" no="770">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; a homozygous mutation disrupts split.</text>
                    <arg n="0">a homozygous mutation</arg>
                    <arg n="1">split</arg>
                </example>
                <example src="PERMUTATE" no="771">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; a homozygous mutation has been shown to disrupt pulally.</text>
                    <arg n="0">a homozygous mutation</arg>
                    <arg n="1">pulally</arg>
                </example>
                <example src="PERMUTATE" no="772">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; a homozygous mutation has been shown to disrupt split.</text>
                    <arg n="0">a homozygous mutation</arg>
                    <arg n="1">split</arg>
                </example>
                <example src="PERMUTATE" no="773">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; a homozygous mutation has disrupted pulally.</text>
                    <arg n="0">a homozygous mutation</arg>
                    <arg n="1">pulally</arg>
                </example>
                <example src="PERMUTATE" no="774">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; a homozygous mutation has disrupted split.</text>
                    <arg n="0">a homozygous mutation</arg>
                    <arg n="1">split</arg>
                </example>
                <example src="PERMUTATE" no="775">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; a homozygous mutation may have disrupted pulally.</text>
                    <arg n="0">a homozygous mutation</arg>
                    <arg n="1">pulally</arg>
                </example>
                <example src="PERMUTATE" no="776">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; a homozygous mutation may have disrupted split.</text>
                    <arg n="0">a homozygous mutation</arg>
                    <arg n="1">split</arg>
                </example>
                <example src="PERMUTATE" no="777">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; alcohol consumption exposure disrupts ocular dominance plasticity.</text>
                    <arg n="0">alcohol consumption exposure</arg>
                    <arg n="1">ocular dominance plasticity</arg>
                </example>
                <example src="PERMUTATE" no="778">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; alcohol consumption exposure has been shown to disrupt ocular dominance plasticity.</text>
                    <arg n="0">alcohol consumption exposure</arg>
                    <arg n="1">ocular dominance plasticity</arg>
                </example>
                <example src="PERMUTATE" no="779">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; alcohol consumption exposure has disrupted ocular dominance plasticity.</text>
                    <arg n="0">alcohol consumption exposure</arg>
                    <arg n="1">ocular dominance plasticity</arg>
                </example>
                <example src="PERMUTATE" no="780">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; alcohol consumption exposure may have disrupted ocular dominance plasticity.</text>
                    <arg n="0">alcohol consumption exposure</arg>
                    <arg n="1">ocular dominance plasticity</arg>
                </example>
                <example src="PERMUTATE" no="781">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; alcohol exposure disrupts ocular domain plasticity.</text>
                    <arg n="0">alcohol exposure</arg>
                    <arg n="1">ocular domain plasticity</arg>
                </example>
                <example src="PERMUTATE" no="782">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; alcohol exposure disrupts ocular dominance plasticity.</text>
                    <arg n="0">alcohol exposure</arg>
                    <arg n="1">ocular dominance plasticity</arg>
                </example>
                <example src="PERMUTATE" no="783">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; alcohol exposure has been shown to disrupt ocular domain plasticity.</text>
                    <arg n="0">alcohol exposure</arg>
                    <arg n="1">ocular domain plasticity</arg>
                </example>
                <example src="PERMUTATE" no="784">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; alcohol exposure has been shown to disrupt ocular dominance plasticity.</text>
                    <arg n="0">alcohol exposure</arg>
                    <arg n="1">ocular dominance plasticity</arg>
                </example>
                <example src="PERMUTATE" no="785">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; alcohol exposure has disrupted ocular domain plasticity.</text>
                    <arg n="0">alcohol exposure</arg>
                    <arg n="1">ocular domain plasticity</arg>
                </example>
                <example src="PERMUTATE" no="786">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; alcohol exposure has disrupted ocular dominance plasticity.</text>
                    <arg n="0">alcohol exposure</arg>
                    <arg n="1">ocular dominance plasticity</arg>
                </example>
                <example src="PERMUTATE" no="787">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; alcohol exposure may have disrupted ocular domain plasticity.</text>
                    <arg n="0">alcohol exposure</arg>
                    <arg n="1">ocular domain plasticity</arg>
                </example>
                <example src="PERMUTATE" no="788">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; alcohol exposure may have disrupted ocular dominance plasticity.</text>
                    <arg n="0">alcohol exposure</arg>
                    <arg n="1">ocular dominance plasticity</arg>
                </example>
                <example src="PERMUTATE" no="789">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; exposure to alcohol consumption disrupts ocular domain plasticity.</text>
                    <arg n="0">exposure to alcohol consumption</arg>
                    <arg n="1">ocular domain plasticity</arg>
                </example>
                <example src="PERMUTATE" no="790">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; exposure to alcohol consumption disrupts plasticity of eye dominance.</text>
                    <arg n="0">exposure to alcohol consumption</arg>
                    <arg n="1">plasticity of eye dominance</arg>
                </example>
                <example src="PERMUTATE" no="791">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; exposure to alcohol consumption has been shown to disrupt ocular domain plasticity.</text>
                    <arg n="0">exposure to alcohol consumption</arg>
                    <arg n="1">ocular domain plasticity</arg>
                </example>
                <example src="PERMUTATE" no="792">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; exposure to alcohol consumption has been shown to disrupt plasticity of eye dominance.</text>
                    <arg n="0">exposure to alcohol consumption</arg>
                    <arg n="1">plasticity of eye dominance</arg>
                </example>
                <example src="PERMUTATE" no="793">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; exposure to alcohol consumption has disrupted ocular domain plasticity.</text>
                    <arg n="0">exposure to alcohol consumption</arg>
                    <arg n="1">ocular domain plasticity</arg>
                </example>
                <example src="PERMUTATE" no="794">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; exposure to alcohol consumption has disrupted plasticity of eye dominance.</text>
                    <arg n="0">exposure to alcohol consumption</arg>
                    <arg n="1">plasticity of eye dominance</arg>
                </example>
                <example src="PERMUTATE" no="795">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; exposure to alcohol consumption may have disrupted ocular domain plasticity.</text>
                    <arg n="0">exposure to alcohol consumption</arg>
                    <arg n="1">ocular domain plasticity</arg>
                </example>
                <example src="PERMUTATE" no="796">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; exposure to alcohol consumption may have disrupted plasticity of eye dominance.</text>
                    <arg n="0">exposure to alcohol consumption</arg>
                    <arg n="1">plasticity of eye dominance</arg>
                </example>
                <example src="PERMUTATE" no="797">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; his retired expression MEKK1 or MEKK2 disrupts the overall integrity of MAPK pathway regulation.</text>
                    <arg n="0">his retired expression MEKK1 or MEKK2</arg>
                    <arg n="1">the overall integrity of MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="798">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; his retired expression MEKK1 or MEKK2 has been shown to disrupt the overall integrity of MAPK pathway regulation.</text>
                    <arg n="0">his retired expression MEKK1 or MEKK2</arg>
                    <arg n="1">the overall integrity of MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="799">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; his retired expression MEKK1 or MEKK2 has disrupted the overall integrity of MAPK pathway regulation.</text>
                    <arg n="0">his retired expression MEKK1 or MEKK2</arg>
                    <arg n="1">the overall integrity of MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="800">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; his retired expression MEKK1 or MEKK2 may have disrupted the overall integrity of MAPK pathway regulation.</text>
                    <arg n="0">his retired expression MEKK1 or MEKK2</arg>
                    <arg n="1">the overall integrity of MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="801">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; homozygous mutation disrupts spacing.</text>
                    <arg n="0">homozygous mutation</arg>
                    <arg n="1">spacing</arg>
                </example>
                <example src="PERMUTATE" no="802">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; homozygous mutation disrupts squirrel.</text>
                    <arg n="0">homozygous mutation</arg>
                    <arg n="1">squirrel</arg>
                </example>
                <example src="PERMUTATE" no="803">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; homozygous mutation has been shown to disrupt spacing.</text>
                    <arg n="0">homozygous mutation</arg>
                    <arg n="1">spacing</arg>
                </example>
                <example src="PERMUTATE" no="804">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; homozygous mutation has been shown to disrupt squirrel.</text>
                    <arg n="0">homozygous mutation</arg>
                    <arg n="1">squirrel</arg>
                </example>
                <example src="PERMUTATE" no="805">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; homozygous mutation has disrupted spacing.</text>
                    <arg n="0">homozygous mutation</arg>
                    <arg n="1">spacing</arg>
                </example>
                <example src="PERMUTATE" no="806">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; homozygous mutation has disrupted squirrel.</text>
                    <arg n="0">homozygous mutation</arg>
                    <arg n="1">squirrel</arg>
                </example>
                <example src="PERMUTATE" no="807">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; homozygous mutation may have disrupted spacing.</text>
                    <arg n="0">homozygous mutation</arg>
                    <arg n="1">spacing</arg>
                </example>
                <example src="PERMUTATE" no="808">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; homozygous mutation may have disrupted squirrel.</text>
                    <arg n="0">homozygous mutation</arg>
                    <arg n="1">squirrel</arg>
                </example>
                <example src="PERMUTATE" no="809">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; if retired from the expression MEKK1 or MEKK2 disrupts the overall integrity of MAPK pathway regulation.</text>
                    <arg n="0">if retired from the expression MEKK1 or MEKK2</arg>
                    <arg n="1">the overall integrity of MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="810">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; if retired from the expression MEKK1 or MEKK2 has been shown to disrupt the overall integrity of MAPK pathway regulation.</text>
                    <arg n="0">if retired from the expression MEKK1 or MEKK2</arg>
                    <arg n="1">the overall integrity of MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="811">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; if retired from the expression MEKK1 or MEKK2 has disrupted the overall integrity of MAPK pathway regulation.</text>
                    <arg n="0">if retired from the expression MEKK1 or MEKK2</arg>
                    <arg n="1">the overall integrity of MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="812">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; if retired from the expression MEKK1 or MEKK2 may have disrupted the overall integrity of MAPK pathway regulation.</text>
                    <arg n="0">if retired from the expression MEKK1 or MEKK2</arg>
                    <arg n="1">the overall integrity of MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="813">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; inhibition of inflammation disrupts physiological protective response.</text>
                    <arg n="0">inhibition of inflammation</arg>
                    <arg n="1">physiological protective response</arg>
                </example>
                <example src="PERMUTATE" no="814">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; inhibition of inflammation disrupts protective physiological responses.</text>
                    <arg n="0">inhibition of inflammation</arg>
                    <arg n="1">protective physiological responses</arg>
                </example>
                <example src="PERMUTATE" no="815">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; inhibition of inflammation has been shown to disrupt physiological protective response.</text>
                    <arg n="0">inhibition of inflammation</arg>
                    <arg n="1">physiological protective response</arg>
                </example>
                <example src="PERMUTATE" no="816">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; inhibition of inflammation has been shown to disrupt protective physiological responses.</text>
                    <arg n="0">inhibition of inflammation</arg>
                    <arg n="1">protective physiological responses</arg>
                </example>
                <example src="PERMUTATE" no="817">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; inhibition of inflammation has disrupted physiological protective response.</text>
                    <arg n="0">inhibition of inflammation</arg>
                    <arg n="1">physiological protective response</arg>
                </example>
                <example src="PERMUTATE" no="818">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; inhibition of inflammation has disrupted protective physiological responses.</text>
                    <arg n="0">inhibition of inflammation</arg>
                    <arg n="1">protective physiological responses</arg>
                </example>
                <example src="PERMUTATE" no="819">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; inhibition of inflammation may have disrupted physiological protective response.</text>
                    <arg n="0">inhibition of inflammation</arg>
                    <arg n="1">physiological protective response</arg>
                </example>
                <example src="PERMUTATE" no="820">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; inhibition of inflammation may have disrupted protective physiological responses.</text>
                    <arg n="0">inhibition of inflammation</arg>
                    <arg n="1">protective physiological responses</arg>
                </example>
                <example src="PERMUTATE" no="821">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; knockout of the expression MEKK1 or MEKK2 disrupts the overall integrity of MAPK pathway regulation.</text>
                    <arg n="0">knockout of the expression MEKK1 or MEKK2</arg>
                    <arg n="1">the overall integrity of MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="822">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; knockout of the expression MEKK1 or MEKK2 has been shown to disrupt the overall integrity of MAPK pathway regulation.</text>
                    <arg n="0">knockout of the expression MEKK1 or MEKK2</arg>
                    <arg n="1">the overall integrity of MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="823">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; knockout of the expression MEKK1 or MEKK2 has disrupted the overall integrity of MAPK pathway regulation.</text>
                    <arg n="0">knockout of the expression MEKK1 or MEKK2</arg>
                    <arg n="1">the overall integrity of MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="824">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; knockout of the expression MEKK1 or MEKK2 may have disrupted the overall integrity of MAPK pathway regulation.</text>
                    <arg n="0">knockout of the expression MEKK1 or MEKK2</arg>
                    <arg n="1">the overall integrity of MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="825">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; retired from the MEKK1 or MEKK2 expression disrupts the overall integrity of the MAPK pathway regulation.</text>
                    <arg n="0">retired from the MEKK1 or MEKK2 expression</arg>
                    <arg n="1">the overall integrity of the MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="826">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; retired from the MEKK1 or MEKK2 expression has been shown to disrupt the overall integrity of the MAPK pathway regulation.</text>
                    <arg n="0">retired from the MEKK1 or MEKK2 expression</arg>
                    <arg n="1">the overall integrity of the MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="827">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; retired from the MEKK1 or MEKK2 expression has disrupted the overall integrity of the MAPK pathway regulation.</text>
                    <arg n="0">retired from the MEKK1 or MEKK2 expression</arg>
                    <arg n="1">the overall integrity of the MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="828">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; retired from the MEKK1 or MEKK2 expression may have disrupted the overall integrity of the MAPK pathway regulation.</text>
                    <arg n="0">retired from the MEKK1 or MEKK2 expression</arg>
                    <arg n="1">the overall integrity of the MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="829">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; the Gly188--Glu mutation disrupts an Ava II site.</text>
                    <arg n="0">the Gly188--Glu mutation</arg>
                    <arg n="1">an Ava II site</arg>
                </example>
                <example src="PERMUTATE" no="830">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; the Gly188--Glu mutation has been shown to disrupt an Ava II site.</text>
                    <arg n="0">the Gly188--Glu mutation</arg>
                    <arg n="1">an Ava II site</arg>
                </example>
                <example src="PERMUTATE" no="831">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; the Gly188--Glu mutation has disrupted an Ava II site.</text>
                    <arg n="0">the Gly188--Glu mutation</arg>
                    <arg n="1">an Ava II site</arg>
                </example>
                <example src="PERMUTATE" no="832">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; the Gly188--Glu mutation may have disrupted an Ava II site.</text>
                    <arg n="0">the Gly188--Glu mutation</arg>
                    <arg n="1">an Ava II site</arg>
                </example>
                <example src="PERMUTATE" no="833">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; the knockout of the MEKK1 or MEKK2 expression disrupts the overall integrity of the MAPK pathway regulation.</text>
                    <arg n="0">the knockout of the MEKK1 or MEKK2 expression</arg>
                    <arg n="1">the overall integrity of the MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="834">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; the knockout of the MEKK1 or MEKK2 expression has been shown to disrupt the overall integrity of the MAPK pathway regulation.</text>
                    <arg n="0">the knockout of the MEKK1 or MEKK2 expression</arg>
                    <arg n="1">the overall integrity of the MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="835">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; the knockout of the MEKK1 or MEKK2 expression has disrupted the overall integrity of the MAPK pathway regulation.</text>
                    <arg n="0">the knockout of the MEKK1 or MEKK2 expression</arg>
                    <arg n="1">the overall integrity of the MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="836">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; the knockout of the MEKK1 or MEKK2 expression may have disrupted the overall integrity of the MAPK pathway regulation.</text>
                    <arg n="0">the knockout of the MEKK1 or MEKK2 expression</arg>
                    <arg n="1">the overall integrity of the MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="837">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; this deletion disrupts open reading frame.</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">open reading frame</arg>
                </example>
                <example src="PERMUTATE" no="838">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; this deletion disrupts the open reading structure.</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">the open reading structure</arg>
                </example>
                <example src="PERMUTATE" no="839">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; this deletion has been shown to disrupt open reading frame.</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">open reading frame</arg>
                </example>
                <example src="PERMUTATE" no="840">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; this deletion has been shown to disrupt the open reading structure.</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">the open reading structure</arg>
                </example>
                <example src="PERMUTATE" no="841">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; this deletion has disrupted open reading frame.</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">open reading frame</arg>
                </example>
                <example src="PERMUTATE" no="842">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; this deletion has disrupted the open reading structure.</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">the open reading structure</arg>
                </example>
                <example src="PERMUTATE" no="843">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; this deletion may have disrupted open reading frame.</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">open reading frame</arg>
                </example>
                <example src="PERMUTATE" no="844">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; this deletion may have disrupted the open reading structure.</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">the open reading structure</arg>
                </example>
                <example src="PERMUTATE" no="845">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; Arg99 and Arg253 disrupts hydrogen bonds in the model.</text>
                    <arg n="0">Arg99 and Arg253</arg>
                    <arg n="1">hydrogen bonds in the model</arg>
                </example>
                <example src="PERMUTATE" no="846">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; Arg99 and Arg253 is able to disrupt hydrogen bonds in the model.</text>
                    <arg n="0">Arg99 and Arg253</arg>
                    <arg n="1">hydrogen bonds in the model</arg>
                </example>
                <example src="PERMUTATE" no="847">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; Arg99 and Arg253 may have disrupted hydrogen bonds in the model.</text>
                    <arg n="0">Arg99 and Arg253</arg>
                    <arg n="1">hydrogen bonds in the model</arg>
                </example>
                <example src="PERMUTATE" no="848">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; Arr99 and Arr253 disrupts hydrogen bond pairing in the model.</text>
                    <arg n="0">Arr99 and Arr253</arg>
                    <arg n="1">hydrogen bond pairing in the model</arg>
                </example>
                <example src="PERMUTATE" no="849">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; Arr99 and Arr253 disrupts the hydrogen bonding pairing in the model.</text>
                    <arg n="0">Arr99 and Arr253</arg>
                    <arg n="1">the hydrogen bonding pairing in the model</arg>
                </example>
                <example src="PERMUTATE" no="850">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; Arr99 and Arr253 is able to disrupt hydrogen bond pairing in the model.</text>
                    <arg n="0">Arr99 and Arr253</arg>
                    <arg n="1">hydrogen bond pairing in the model</arg>
                </example>
                <example src="PERMUTATE" no="851">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; Arr99 and Arr253 is able to disrupt the hydrogen bonding pairing in the model.</text>
                    <arg n="0">Arr99 and Arr253</arg>
                    <arg n="1">the hydrogen bonding pairing in the model</arg>
                </example>
                <example src="PERMUTATE" no="852">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; Arr99 and Arr253 may have disrupted hydrogen bond pairing in the model.</text>
                    <arg n="0">Arr99 and Arr253</arg>
                    <arg n="1">hydrogen bond pairing in the model</arg>
                </example>
                <example src="PERMUTATE" no="853">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; Arr99 and Arr253 may have disrupted the hydrogen bonding pairing in the model.</text>
                    <arg n="0">Arr99 and Arr253</arg>
                    <arg n="1">the hydrogen bonding pairing in the model</arg>
                </example>
                <example src="PERMUTATE" no="854">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; Gly188---Glu mutation disrupts a site Ava II.</text>
                    <arg n="0">Gly188---Glu mutation</arg>
                    <arg n="1">a site Ava II</arg>
                </example>
                <example src="PERMUTATE" no="855">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; Gly188---Glu mutation disrupts one site Ava II.</text>
                    <arg n="0">Gly188---Glu mutation</arg>
                    <arg n="1">one site Ava II</arg>
                </example>
                <example src="PERMUTATE" no="856">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; Gly188---Glu mutation is able to disrupt a site Ava II.</text>
                    <arg n="0">Gly188---Glu mutation</arg>
                    <arg n="1">a site Ava II</arg>
                </example>
                <example src="PERMUTATE" no="857">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; Gly188---Glu mutation is able to disrupt one site Ava II.</text>
                    <arg n="0">Gly188---Glu mutation</arg>
                    <arg n="1">one site Ava II</arg>
                </example>
                <example src="PERMUTATE" no="858">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; Gly188---Glu mutation may have disrupted a site Ava II.</text>
                    <arg n="0">Gly188---Glu mutation</arg>
                    <arg n="1">a site Ava II</arg>
                </example>
                <example src="PERMUTATE" no="859">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; Gly188---Glu mutation may have disrupted one site Ava II.</text>
                    <arg n="0">Gly188---Glu mutation</arg>
                    <arg n="1">one site Ava II</arg>
                </example>
                <example src="PERMUTATE" no="860">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; Mutation 415G4 disrupts potent spike: (GAR)n-(GAR)n.</text>
                    <arg n="0">Mutation 415G4</arg>
                    <arg n="1">potent spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="PERMUTATE" no="861">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; Mutation 415G4 is able to disrupt potent spike: (GAR)n-(GAR)n.</text>
                    <arg n="0">Mutation 415G4</arg>
                    <arg n="1">potent spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="PERMUTATE" no="862">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; Mutation 415G4 may have disrupted potent spike: (GAR)n-(GAR)n.</text>
                    <arg n="0">Mutation 415G4</arg>
                    <arg n="1">potent spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="PERMUTATE" no="863">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; a homozygous mutation disrupts pulally.</text>
                    <arg n="0">a homozygous mutation</arg>
                    <arg n="1">pulally</arg>
                </example>
                <example src="PERMUTATE" no="864">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; a homozygous mutation disrupts split.</text>
                    <arg n="0">a homozygous mutation</arg>
                    <arg n="1">split</arg>
                </example>
                <example src="PERMUTATE" no="865">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; a homozygous mutation is able to disrupt pulally.</text>
                    <arg n="0">a homozygous mutation</arg>
                    <arg n="1">pulally</arg>
                </example>
                <example src="PERMUTATE" no="866">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; a homozygous mutation is able to disrupt split.</text>
                    <arg n="0">a homozygous mutation</arg>
                    <arg n="1">split</arg>
                </example>
                <example src="PERMUTATE" no="867">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; a homozygous mutation may have disrupted pulally.</text>
                    <arg n="0">a homozygous mutation</arg>
                    <arg n="1">pulally</arg>
                </example>
                <example src="PERMUTATE" no="868">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; a homozygous mutation may have disrupted split.</text>
                    <arg n="0">a homozygous mutation</arg>
                    <arg n="1">split</arg>
                </example>
                <example src="PERMUTATE" no="869">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; alcohol consumption exposure disrupts ocular dominance plasticity.</text>
                    <arg n="0">alcohol consumption exposure</arg>
                    <arg n="1">ocular dominance plasticity</arg>
                </example>
                <example src="PERMUTATE" no="870">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; alcohol consumption exposure is able to disrupt ocular dominance plasticity.</text>
                    <arg n="0">alcohol consumption exposure</arg>
                    <arg n="1">ocular dominance plasticity</arg>
                </example>
                <example src="PERMUTATE" no="871">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; alcohol consumption exposure may have disrupted ocular dominance plasticity.</text>
                    <arg n="0">alcohol consumption exposure</arg>
                    <arg n="1">ocular dominance plasticity</arg>
                </example>
                <example src="PERMUTATE" no="872">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; alcohol exposure disrupts ocular domain plasticity.</text>
                    <arg n="0">alcohol exposure</arg>
                    <arg n="1">ocular domain plasticity</arg>
                </example>
                <example src="PERMUTATE" no="873">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; alcohol exposure disrupts ocular dominance plasticity.</text>
                    <arg n="0">alcohol exposure</arg>
                    <arg n="1">ocular dominance plasticity</arg>
                </example>
                <example src="PERMUTATE" no="874">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; alcohol exposure is able to disrupt ocular domain plasticity.</text>
                    <arg n="0">alcohol exposure</arg>
                    <arg n="1">ocular domain plasticity</arg>
                </example>
                <example src="PERMUTATE" no="875">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; alcohol exposure is able to disrupt ocular dominance plasticity.</text>
                    <arg n="0">alcohol exposure</arg>
                    <arg n="1">ocular dominance plasticity</arg>
                </example>
                <example src="PERMUTATE" no="876">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; alcohol exposure may have disrupted ocular domain plasticity.</text>
                    <arg n="0">alcohol exposure</arg>
                    <arg n="1">ocular domain plasticity</arg>
                </example>
                <example src="PERMUTATE" no="877">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; alcohol exposure may have disrupted ocular dominance plasticity.</text>
                    <arg n="0">alcohol exposure</arg>
                    <arg n="1">ocular dominance plasticity</arg>
                </example>
                <example src="PERMUTATE" no="878">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; exposure to alcohol consumption disrupts ocular domain plasticity.</text>
                    <arg n="0">exposure to alcohol consumption</arg>
                    <arg n="1">ocular domain plasticity</arg>
                </example>
                <example src="PERMUTATE" no="879">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; exposure to alcohol consumption disrupts plasticity of eye dominance.</text>
                    <arg n="0">exposure to alcohol consumption</arg>
                    <arg n="1">plasticity of eye dominance</arg>
                </example>
                <example src="PERMUTATE" no="880">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; exposure to alcohol consumption is able to disrupt ocular domain plasticity.</text>
                    <arg n="0">exposure to alcohol consumption</arg>
                    <arg n="1">ocular domain plasticity</arg>
                </example>
                <example src="PERMUTATE" no="881">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; exposure to alcohol consumption is able to disrupt plasticity of eye dominance.</text>
                    <arg n="0">exposure to alcohol consumption</arg>
                    <arg n="1">plasticity of eye dominance</arg>
                </example>
                <example src="PERMUTATE" no="882">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; exposure to alcohol consumption may have disrupted ocular domain plasticity.</text>
                    <arg n="0">exposure to alcohol consumption</arg>
                    <arg n="1">ocular domain plasticity</arg>
                </example>
                <example src="PERMUTATE" no="883">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; exposure to alcohol consumption may have disrupted plasticity of eye dominance.</text>
                    <arg n="0">exposure to alcohol consumption</arg>
                    <arg n="1">plasticity of eye dominance</arg>
                </example>
                <example src="PERMUTATE" no="884">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; his retired expression MEKK1 or MEKK2 disrupts the overall integrity of MAPK pathway regulation.</text>
                    <arg n="0">his retired expression MEKK1 or MEKK2</arg>
                    <arg n="1">the overall integrity of MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="885">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; his retired expression MEKK1 or MEKK2 is able to disrupt the overall integrity of MAPK pathway regulation.</text>
                    <arg n="0">his retired expression MEKK1 or MEKK2</arg>
                    <arg n="1">the overall integrity of MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="886">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; his retired expression MEKK1 or MEKK2 may have disrupted the overall integrity of MAPK pathway regulation.</text>
                    <arg n="0">his retired expression MEKK1 or MEKK2</arg>
                    <arg n="1">the overall integrity of MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="887">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; homozygous mutation disrupts spacing.</text>
                    <arg n="0">homozygous mutation</arg>
                    <arg n="1">spacing</arg>
                </example>
                <example src="PERMUTATE" no="888">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; homozygous mutation disrupts squirrel.</text>
                    <arg n="0">homozygous mutation</arg>
                    <arg n="1">squirrel</arg>
                </example>
                <example src="PERMUTATE" no="889">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; homozygous mutation is able to disrupt spacing.</text>
                    <arg n="0">homozygous mutation</arg>
                    <arg n="1">spacing</arg>
                </example>
                <example src="PERMUTATE" no="890">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; homozygous mutation is able to disrupt squirrel.</text>
                    <arg n="0">homozygous mutation</arg>
                    <arg n="1">squirrel</arg>
                </example>
                <example src="PERMUTATE" no="891">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; homozygous mutation may have disrupted spacing.</text>
                    <arg n="0">homozygous mutation</arg>
                    <arg n="1">spacing</arg>
                </example>
                <example src="PERMUTATE" no="892">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; homozygous mutation may have disrupted squirrel.</text>
                    <arg n="0">homozygous mutation</arg>
                    <arg n="1">squirrel</arg>
                </example>
                <example src="PERMUTATE" no="893">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; if retired from the expression MEKK1 or MEKK2 disrupts the overall integrity of MAPK pathway regulation.</text>
                    <arg n="0">if retired from the expression MEKK1 or MEKK2</arg>
                    <arg n="1">the overall integrity of MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="894">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; if retired from the expression MEKK1 or MEKK2 is able to disrupt the overall integrity of MAPK pathway regulation.</text>
                    <arg n="0">if retired from the expression MEKK1 or MEKK2</arg>
                    <arg n="1">the overall integrity of MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="895">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; if retired from the expression MEKK1 or MEKK2 may have disrupted the overall integrity of MAPK pathway regulation.</text>
                    <arg n="0">if retired from the expression MEKK1 or MEKK2</arg>
                    <arg n="1">the overall integrity of MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="896">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; inhibition of inflammation disrupts physiological protective response.</text>
                    <arg n="0">inhibition of inflammation</arg>
                    <arg n="1">physiological protective response</arg>
                </example>
                <example src="PERMUTATE" no="897">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; inhibition of inflammation disrupts protective physiological responses.</text>
                    <arg n="0">inhibition of inflammation</arg>
                    <arg n="1">protective physiological responses</arg>
                </example>
                <example src="PERMUTATE" no="898">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; inhibition of inflammation is able to disrupt physiological protective response.</text>
                    <arg n="0">inhibition of inflammation</arg>
                    <arg n="1">physiological protective response</arg>
                </example>
                <example src="PERMUTATE" no="899">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; inhibition of inflammation is able to disrupt protective physiological responses.</text>
                    <arg n="0">inhibition of inflammation</arg>
                    <arg n="1">protective physiological responses</arg>
                </example>
                <example src="PERMUTATE" no="900">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; inhibition of inflammation may have disrupted physiological protective response.</text>
                    <arg n="0">inhibition of inflammation</arg>
                    <arg n="1">physiological protective response</arg>
                </example>
                <example src="PERMUTATE" no="901">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; inhibition of inflammation may have disrupted protective physiological responses.</text>
                    <arg n="0">inhibition of inflammation</arg>
                    <arg n="1">protective physiological responses</arg>
                </example>
                <example src="PERMUTATE" no="902">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; knockout of the expression MEKK1 or MEKK2 disrupts the overall integrity of MAPK pathway regulation.</text>
                    <arg n="0">knockout of the expression MEKK1 or MEKK2</arg>
                    <arg n="1">the overall integrity of MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="903">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; knockout of the expression MEKK1 or MEKK2 is able to disrupt the overall integrity of MAPK pathway regulation.</text>
                    <arg n="0">knockout of the expression MEKK1 or MEKK2</arg>
                    <arg n="1">the overall integrity of MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="904">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; knockout of the expression MEKK1 or MEKK2 may have disrupted the overall integrity of MAPK pathway regulation.</text>
                    <arg n="0">knockout of the expression MEKK1 or MEKK2</arg>
                    <arg n="1">the overall integrity of MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="905">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; retired from the MEKK1 or MEKK2 expression disrupts the overall integrity of the MAPK pathway regulation.</text>
                    <arg n="0">retired from the MEKK1 or MEKK2 expression</arg>
                    <arg n="1">the overall integrity of the MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="906">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; retired from the MEKK1 or MEKK2 expression is able to disrupt the overall integrity of the MAPK pathway regulation.</text>
                    <arg n="0">retired from the MEKK1 or MEKK2 expression</arg>
                    <arg n="1">the overall integrity of the MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="907">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; retired from the MEKK1 or MEKK2 expression may have disrupted the overall integrity of the MAPK pathway regulation.</text>
                    <arg n="0">retired from the MEKK1 or MEKK2 expression</arg>
                    <arg n="1">the overall integrity of the MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="908">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; the Gly188--Glu mutation disrupts an Ava II site.</text>
                    <arg n="0">the Gly188--Glu mutation</arg>
                    <arg n="1">an Ava II site</arg>
                </example>
                <example src="PERMUTATE" no="909">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; the Gly188--Glu mutation is able to disrupt an Ava II site.</text>
                    <arg n="0">the Gly188--Glu mutation</arg>
                    <arg n="1">an Ava II site</arg>
                </example>
                <example src="PERMUTATE" no="910">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; the Gly188--Glu mutation may have disrupted an Ava II site.</text>
                    <arg n="0">the Gly188--Glu mutation</arg>
                    <arg n="1">an Ava II site</arg>
                </example>
                <example src="PERMUTATE" no="911">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; the knockout of the MEKK1 or MEKK2 expression disrupts the overall integrity of the MAPK pathway regulation.</text>
                    <arg n="0">the knockout of the MEKK1 or MEKK2 expression</arg>
                    <arg n="1">the overall integrity of the MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="912">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; the knockout of the MEKK1 or MEKK2 expression is able to disrupt the overall integrity of the MAPK pathway regulation.</text>
                    <arg n="0">the knockout of the MEKK1 or MEKK2 expression</arg>
                    <arg n="1">the overall integrity of the MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="913">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; the knockout of the MEKK1 or MEKK2 expression may have disrupted the overall integrity of the MAPK pathway regulation.</text>
                    <arg n="0">the knockout of the MEKK1 or MEKK2 expression</arg>
                    <arg n="1">the overall integrity of the MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="914">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; this deletion disrupts open reading frame.</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">open reading frame</arg>
                </example>
                <example src="PERMUTATE" no="915">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; this deletion disrupts the open reading frame.</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">the open reading frame</arg>
                </example>
                <example src="PERMUTATE" no="916">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; this deletion is able to disrupt open reading frame.</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">open reading frame</arg>
                </example>
                <example src="PERMUTATE" no="917">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; this deletion is able to disrupt the open reading frame.</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">the open reading frame</arg>
                </example>
                <example src="PERMUTATE" no="918">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; this deletion may have disrupted the open reading frame.</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">the open reading frame</arg>
                </example>
                <example src="PERMUTATE" no="919">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; this deletion may have disrupted the open reading structure.</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">the open reading structure</arg>
                </example>
                <example src="PERMUTATE" no="920">
                    <text>The the Gly188--Glu mutation that disrupted an Ava II site was identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">the Gly188--Glu mutation</arg>
                    <arg n="1">an Ava II site</arg>
                </example>
                <example src="PERMUTATE" no="921">
                    <text>The the knockout of the MEKK1 or MEKK2 expression that disrupted the overall integrity of the MAPK pathway regulation was identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">the knockout of the MEKK1 or MEKK2 expression</arg>
                    <arg n="1">the overall integrity of the MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="922">
                    <text>The this deletion that disrupted open reading frame was identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">open reading frame</arg>
                </example>
                <example src="PERMUTATE" no="923">
                    <text>The this deletion that disrupted the open reading frame was identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">the open reading frame</arg>
                </example>
                <example src="PERMUTATE" no="924">
                    <text>The this deletion that disrupted the open reading structure was identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">the open reading structure</arg>
                </example>
                <example src="PERMUTATE" no="925">
                    <text>The treatment of systemic inflammatory response to CPB is also confused by the fact that Arg99 and Arg253 has been shown to disrupt hydrogen bonds in the model or to produce immunosuppression.</text>
                    <arg n="0">Arg99 and Arg253</arg>
                    <arg n="1">hydrogen bonds in the model</arg>
                </example>
                <example src="PERMUTATE" no="926">
                    <text>The treatment of systemic inflammatory response to CPB is also confused by the fact that Arr99 and Arr253 has been shown to disrupt hydrogen bond pairing in the model or to produce immunosuppression.</text>
                    <arg n="0">Arr99 and Arr253</arg>
                    <arg n="1">hydrogen bond pairing in the model</arg>
                </example>
                <example src="PERMUTATE" no="927">
                    <text>The treatment of systemic inflammatory response to CPB is also confused by the fact that Arr99 and Arr253 has been shown to disrupt the hydrogen bonding pairing in the model or to produce immunosuppression.</text>
                    <arg n="0">Arr99 and Arr253</arg>
                    <arg n="1">the hydrogen bonding pairing in the model</arg>
                </example>
                <example src="PERMUTATE" no="928">
                    <text>The treatment of systemic inflammatory response to CPB is also confused by the fact that Gly188---Glu mutation has been shown to disrupt a site Ava II or to produce immunosuppression.</text>
                    <arg n="0">Gly188---Glu mutation</arg>
                    <arg n="1">a site Ava II</arg>
                </example>
                <example src="PERMUTATE" no="929">
                    <text>The treatment of systemic inflammatory response to CPB is also confused by the fact that Gly188---Glu mutation has been shown to disrupt one site Ava II or to produce immunosuppression.</text>
                    <arg n="0">Gly188---Glu mutation</arg>
                    <arg n="1">one site Ava II</arg>
                </example>
                <example src="PERMUTATE" no="930">
                    <text>The treatment of systemic inflammatory response to CPB is also confused by the fact that Mutation 415G4 has been shown to disrupt potent spike: (GAR)n-(GAR)n or to produce immunosuppression.</text>
                    <arg n="0">Mutation 415G4</arg>
                    <arg n="1">potent spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="PERMUTATE" no="931">
                    <text>The treatment of systemic inflammatory response to CPB is also confused by the fact that a homozygous mutation has been shown to disrupt pulally or to produce immunosuppression.</text>
                    <arg n="0">a homozygous mutation</arg>
                    <arg n="1">pulally</arg>
                </example>
                <example src="PERMUTATE" no="932">
                    <text>The treatment of systemic inflammatory response to CPB is also confused by the fact that a homozygous mutation has been shown to disrupt split or to produce immunosuppression.</text>
                    <arg n="0">a homozygous mutation</arg>
                    <arg n="1">split</arg>
                </example>
                <example src="PERMUTATE" no="933">
                    <text>The treatment of systemic inflammatory response to CPB is also confused by the fact that alcohol consumption exposure has been shown to disrupt ocular dominance plasticity or to produce immunosuppression.</text>
                    <arg n="0">alcohol consumption exposure</arg>
                    <arg n="1">ocular dominance plasticity</arg>
                </example>
                <example src="PERMUTATE" no="934">
                    <text>The treatment of systemic inflammatory response to CPB is also confused by the fact that alcohol exposure has been shown to disrupt ocular domain plasticity or to produce immunosuppression.</text>
                    <arg n="0">alcohol exposure</arg>
                    <arg n="1">ocular domain plasticity</arg>
                </example>
                <example src="PERMUTATE" no="935">
                    <text>The treatment of systemic inflammatory response to CPB is also confused by the fact that alcohol exposure has been shown to disrupt ocular dominance plasticity or to produce immunosuppression.</text>
                    <arg n="0">alcohol exposure</arg>
                    <arg n="1">ocular dominance plasticity</arg>
                </example>
                <example src="PERMUTATE" no="936">
                    <text>The treatment of systemic inflammatory response to CPB is also confused by the fact that exposure to alcohol consumption has been shown to disrupt ocular domain plasticity or to produce immunosuppression.</text>
                    <arg n="0">exposure to alcohol consumption</arg>
                    <arg n="1">ocular domain plasticity</arg>
                </example>
                <example src="PERMUTATE" no="937">
                    <text>The treatment of systemic inflammatory response to CPB is also confused by the fact that exposure to alcohol consumption has been shown to disrupt plasticity of eye dominance or to produce immunosuppression.</text>
                    <arg n="0">exposure to alcohol consumption</arg>
                    <arg n="1">plasticity of eye dominance</arg>
                </example>
                <example src="PERMUTATE" no="938">
                    <text>The treatment of systemic inflammatory response to CPB is also confused by the fact that his retired expression MEKK1 or MEKK2 has been shown to disrupt the overall integrity of MAPK pathway regulation or to produce immunosuppression.</text>
                    <arg n="0">his retired expression MEKK1 or MEKK2</arg>
                    <arg n="1">the overall integrity of MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="939">
                    <text>The treatment of systemic inflammatory response to CPB is also confused by the fact that homozygous mutation has been shown to disrupt spacing or to produce immunosuppression.</text>
                    <arg n="0">homozygous mutation</arg>
                    <arg n="1">spacing</arg>
                </example>
                <example src="PERMUTATE" no="940">
                    <text>The treatment of systemic inflammatory response to CPB is also confused by the fact that homozygous mutation has been shown to disrupt squirrel or to produce immunosuppression.</text>
                    <arg n="0">homozygous mutation</arg>
                    <arg n="1">squirrel</arg>
                </example>
                <example src="PERMUTATE" no="941">
                    <text>The treatment of systemic inflammatory response to CPB is also confused by the fact that if retired from the expression MEKK1 or MEKK2 has been shown to disrupt the overall integrity of MAPK pathway regulation or to produce immunosuppression.</text>
                    <arg n="0">if retired from the expression MEKK1 or MEKK2</arg>
                    <arg n="1">the overall integrity of MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="942">
                    <text>The treatment of systemic inflammatory response to CPB is also confused by the fact that inhibition of inflammation has been shown to disrupt physiological protective response or to produce immunosuppression.</text>
                    <arg n="0">inhibition of inflammation</arg>
                    <arg n="1">physiological protective response</arg>
                </example>
                <example src="PERMUTATE" no="943">
                    <text>The treatment of systemic inflammatory response to CPB is also confused by the fact that knockout of the expression MEKK1 or MEKK2 has been shown to disrupt the overall integrity of MAPK pathway regulation or to produce immunosuppression.</text>
                    <arg n="0">knockout of the expression MEKK1 or MEKK2</arg>
                    <arg n="1">the overall integrity of MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="944">
                    <text>The treatment of systemic inflammatory response to CPB is also confused by the fact that retired from the MEKK1 or MEKK2 expression has been shown to disrupt the overall integrity of the MAPK pathway regulation or to produce immunosuppression.</text>
                    <arg n="0">retired from the MEKK1 or MEKK2 expression</arg>
                    <arg n="1">the overall integrity of the MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="945">
                    <text>The treatment of systemic inflammatory response to CPB is also confused by the fact that the Gly188--Glu mutation has been shown to disrupt an Ava II site or to produce immunosuppression.</text>
                    <arg n="0">the Gly188--Glu mutation</arg>
                    <arg n="1">an Ava II site</arg>
                </example>
                <example src="PERMUTATE" no="946">
                    <text>The treatment of systemic inflammatory response to CPB is also confused by the fact that the knockout of the MEKK1 or MEKK2 expression has been shown to disrupt the overall integrity of the MAPK pathway regulation or to produce immunosuppression.</text>
                    <arg n="0">the knockout of the MEKK1 or MEKK2 expression</arg>
                    <arg n="1">the overall integrity of the MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="947">
                    <text>The treatment of systemic inflammatory response to CPB is also confused by the fact that this deletion has been shown to disrupt open reading frame or to produce immunosuppression.</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">open reading frame</arg>
                </example>
                <example src="PERMUTATE" no="948">
                    <text>The treatment of systemic inflammatory response to CPB is also confused by the fact that this deletion has been shown to disrupt the open reading frame or to produce immunosuppression.</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">the open reading frame</arg>
                </example>
                <example src="PERMUTATE" no="949">
                    <text>The treatment of systemic inflammatory response to CPB is also confused by the fact that this deletion has been shown to disrupt the open reading structure or to produce immunosuppression.</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">the open reading structure</arg>
                </example>
                <example src="PERMUTATE" no="950">
                    <text>The treatment of the systemic inflammatory response to CPB is also confused by the fact that Arg99 and Arg253 has deregulated hydrogen bonds in the model or disrupting in immunosuppression.</text>
                    <arg n="0">Arg99 and Arg253</arg>
                    <arg n="1">hydrogen bonds in the model</arg>
                </example>
                <example src="PERMUTATE" no="951">
                    <text>The treatment of the systemic inflammatory response to CPB is also confused by the fact that Arr99 and Arr253 has deregulated hydrogen bond pairing in the model or disrupting in immunosuppression.</text>
                    <arg n="0">Arr99 and Arr253</arg>
                    <arg n="1">hydrogen bond pairing in the model</arg>
                </example>
                <example src="PERMUTATE" no="952">
                    <text>The treatment of the systemic inflammatory response to CPB is also confused by the fact that Arr99 and Arr253 has deregulated the hydrogen bonding pairing in the model or disrupting in immunosuppression.</text>
                    <arg n="0">Arr99 and Arr253</arg>
                    <arg n="1">the hydrogen bonding pairing in the model</arg>
                </example>
                <example src="PERMUTATE" no="953">
                    <text>The treatment of the systemic inflammatory response to CPB is also confused by the fact that Gly188---Glu mutation has deregulated a site Ava II or disrupting in immunosuppression.</text>
                    <arg n="0">Gly188---Glu mutation</arg>
                    <arg n="1">a site Ava II</arg>
                </example>
                <example src="PERMUTATE" no="954">
                    <text>The treatment of the systemic inflammatory response to CPB is also confused by the fact that Gly188---Glu mutation has deregulated one site Ava II or disrupting in immunosuppression.</text>
                    <arg n="0">Gly188---Glu mutation</arg>
                    <arg n="1">one site Ava II</arg>
                </example>
                <example src="PERMUTATE" no="955">
                    <text>The treatment of the systemic inflammatory response to CPB is also confused by the fact that Mutation 415G4 has deregulated potent spike: (GAR)n-(GAR)n or disrupting in immunosuppression.</text>
                    <arg n="0">Mutation 415G4</arg>
                    <arg n="1">potent spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="PERMUTATE" no="956">
                    <text>The treatment of the systemic inflammatory response to CPB is also confused by the fact that a homozygous mutation has deregulated pulally or disrupting in immunosuppression.</text>
                    <arg n="0">a homozygous mutation</arg>
                    <arg n="1">pulally</arg>
                </example>
                <example src="PERMUTATE" no="957">
                    <text>The treatment of the systemic inflammatory response to CPB is also confused by the fact that a homozygous mutation has deregulated split or disrupting in immunosuppression.</text>
                    <arg n="0">a homozygous mutation</arg>
                    <arg n="1">split</arg>
                </example>
                <example src="PERMUTATE" no="958">
                    <text>The treatment of the systemic inflammatory response to CPB is also confused by the fact that alcohol consumption exposure has deregulated ocular dominance plasticity or disrupting in immunosuppression.</text>
                    <arg n="0">alcohol consumption exposure</arg>
                    <arg n="1">ocular dominance plasticity</arg>
                </example>
                <example src="PERMUTATE" no="959">
                    <text>The treatment of the systemic inflammatory response to CPB is also confused by the fact that alcohol exposure has deregulated ocular domain plasticity or disrupting in immunosuppression.</text>
                    <arg n="0">alcohol exposure</arg>
                    <arg n="1">ocular domain plasticity</arg>
                </example>
                <example src="PERMUTATE" no="960">
                    <text>The treatment of the systemic inflammatory response to CPB is also confused by the fact that alcohol exposure has deregulated ocular dominance plasticity or disrupting in immunosuppression.</text>
                    <arg n="0">alcohol exposure</arg>
                    <arg n="1">ocular dominance plasticity</arg>
                </example>
                <example src="PERMUTATE" no="961">
                    <text>The treatment of the systemic inflammatory response to CPB is also confused by the fact that exposure to alcohol consumption has deregulated ocular domain plasticity or disrupting in immunosuppression.</text>
                    <arg n="0">exposure to alcohol consumption</arg>
                    <arg n="1">ocular domain plasticity</arg>
                </example>
                <example src="PERMUTATE" no="962">
                    <text>The treatment of the systemic inflammatory response to CPB is also confused by the fact that exposure to alcohol consumption has deregulated plasticity of eye dominance or disrupting in immunosuppression.</text>
                    <arg n="0">exposure to alcohol consumption</arg>
                    <arg n="1">plasticity of eye dominance</arg>
                </example>
                <example src="PERMUTATE" no="963">
                    <text>The treatment of the systemic inflammatory response to CPB is also confused by the fact that his retired expression MEKK1 or MEKK2 has deregulated the overall integrity of MAPK pathway regulation or disrupting in immunosuppression.</text>
                    <arg n="0">his retired expression MEKK1 or MEKK2</arg>
                    <arg n="1">the overall integrity of MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="964">
                    <text>The treatment of the systemic inflammatory response to CPB is also confused by the fact that homozygous mutation has deregulated spacing or disrupting in immunosuppression.</text>
                    <arg n="0">homozygous mutation</arg>
                    <arg n="1">spacing</arg>
                </example>
                <example src="PERMUTATE" no="965">
                    <text>The treatment of the systemic inflammatory response to CPB is also confused by the fact that homozygous mutation has deregulated squirrel or disrupting in immunosuppression.</text>
                    <arg n="0">homozygous mutation</arg>
                    <arg n="1">squirrel</arg>
                </example>
                <example src="PERMUTATE" no="966">
                    <text>The treatment of the systemic inflammatory response to CPB is also confused by the fact that if retired from the expression MEKK1 or MEKK2 has deregulated the overall integrity of MAPK pathway regulation or disrupting in immunosuppression.</text>
                    <arg n="0">if retired from the expression MEKK1 or MEKK2</arg>
                    <arg n="1">the overall integrity of MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="967">
                    <text>The treatment of the systemic inflammatory response to CPB is also confused by the fact that inhibition of inflammation has deregulated protective physiological responses or disrupting in immunosuppression.</text>
                    <arg n="0">inhibition of inflammation</arg>
                    <arg n="1">protective physiological responses</arg>
                </example>
                <example src="PERMUTATE" no="968">
                    <text>The treatment of the systemic inflammatory response to CPB is also confused by the fact that knockout of the expression MEKK1 or MEKK2 has deregulated the overall integrity of MAPK pathway regulation or disrupting in immunosuppression.</text>
                    <arg n="0">knockout of the expression MEKK1 or MEKK2</arg>
                    <arg n="1">the overall integrity of MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="969">
                    <text>The treatment of the systemic inflammatory response to CPB is also confused by the fact that retired from the MEKK1 or MEKK2 expression has deregulated the overall integrity of the MAPK pathway regulation or disrupting in immunosuppression.</text>
                    <arg n="0">retired from the MEKK1 or MEKK2 expression</arg>
                    <arg n="1">the overall integrity of the MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="970">
                    <text>The treatment of the systemic inflammatory response to CPB is also confused by the fact that the Gly188--Glu mutation has deregulated an Ava II site or disrupting in immunosuppression.</text>
                    <arg n="0">the Gly188--Glu mutation</arg>
                    <arg n="1">an Ava II site</arg>
                </example>
                <example src="PERMUTATE" no="971">
                    <text>The treatment of the systemic inflammatory response to CPB is also confused by the fact that the knockout of the MEKK1 or MEKK2 expression has deregulated the overall integrity of the MAPK pathway regulation or disrupting in immunosuppression.</text>
                    <arg n="0">the knockout of the MEKK1 or MEKK2 expression</arg>
                    <arg n="1">the overall integrity of the MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="972">
                    <text>The treatment of the systemic inflammatory response to CPB is also confused by the fact that this deletion has deregulated open reading frame or disrupting in immunosuppression.</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">open reading frame</arg>
                </example>
                <example src="PERMUTATE" no="973">
                    <text>The treatment of the systemic inflammatory response to CPB is also confused by the fact that this deletion has deregulated the open reading frame or disrupting in immunosuppression.</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">the open reading frame</arg>
                </example>
                <example src="PERMUTATE" no="974">
                    <text>The treatment of the systemic inflammatory response to CPB is also confused by the fact that this deletion has deregulated the open reading structure or disrupting in immunosuppression.</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">the open reading structure</arg>
                </example>
                <example src="PERMUTATE" no="975">
                    <text>This suppression have perturbed consensus signal jump 5 and disrupted in exon exhaustion.</text>
                    <arg n="0">This suppression</arg>
                    <arg n="1">consensus signal jump 5</arg>
                    <arg n="R">exon exhaustion</arg>
                </example>
                <example src="PERMUTATE" no="976">
                    <text>This suppression rupture of consensus signal jump 5 may disrupting in exon exhaustion.</text>
                    <arg n="0">This suppression</arg>
                    <arg n="1">consensus signal jump 5</arg>
                    <arg n="R">exon exhaustion</arg>
                </example>
                <example src="PERMUTATE" no="977">
                    <text>Thus, the breakdown of checking points responses to DNA damage by p53 mutations can disrupting in genome destabilization potential.</text>
                    <arg n="0">p53 mutations</arg>
                    <arg n="1">checking points responses to DNA damage</arg>
                    <arg n="R">genome destabilization potential</arg>
                </example>
                <example src="PERMUTATE" no="978">
                    <text>Thus, the breakdown of consensus signal 5 by this suppression can disrupting in exon is omitted.</text>
                    <arg n="0">this suppression</arg>
                    <arg n="1">consensus signal 5</arg>
                    <arg n="R">exon is omitted</arg>
                </example>
                <example src="PERMUTATE" no="979">
                    <text>Thus, the breakdown of consensus signal jump 5 by This suppression can disrupting in exon exhaustion.</text>
                    <arg n="0">This suppression</arg>
                    <arg n="1">consensus signal jump 5</arg>
                    <arg n="R">exon exhaustion</arg>
                </example>
                <example src="PERMUTATE" no="980">
                    <text>Thus, the breakdown of responses of checkpoints to DNA damage by Mutations in p53 can disrupting in the potential for genome destabilization.</text>
                    <arg n="0">Mutations in p53</arg>
                    <arg n="1">responses of checkpoints to DNA damage</arg>
                    <arg n="R">the potential for genome destabilization</arg>
                </example>
                <example src="PERMUTATE" no="981">
                    <text>Thus, the breakdown of tumor vessels by manipulation of the binding system 2 in tumours can disrupting in similar effects on peripheral nerves.</text>
                    <arg n="0">manipulation of the binding system 2 in tumours</arg>
                    <arg n="1">tumor vessels</arg>
                    <arg n="R">similar effects on peripheral nerves</arg>
                </example>
                <example src="PERMUTATE" no="982">
                    <text>Thus, the rupture of checking points responses to DNA damage by p53 mutations may disrupting in genome destabilization potential.</text>
                    <arg n="0">p53 mutations</arg>
                    <arg n="1">checking points responses to DNA damage</arg>
                    <arg n="R">genome destabilization potential</arg>
                </example>
                <example src="PERMUTATE" no="983">
                    <text>Thus, the rupture of consensus signal 5 by this suppression may disrupting in exon is omitted.</text>
                    <arg n="0">this suppression</arg>
                    <arg n="1">consensus signal 5</arg>
                    <arg n="R">exon is omitted</arg>
                </example>
                <example src="PERMUTATE" no="984">
                    <text>Thus, the rupture of consensus signal jump 5 by This suppression may disrupting in exon exhaustion.</text>
                    <arg n="0">This suppression</arg>
                    <arg n="1">consensus signal jump 5</arg>
                    <arg n="R">exon exhaustion</arg>
                </example>
                <example src="PERMUTATE" no="985">
                    <text>Thus, the rupture of responses of checkpoints to DNA damage by Mutations in p53 may disrupting in the potential for genome destabilization.</text>
                    <arg n="0">Mutations in p53</arg>
                    <arg n="1">responses of checkpoints to DNA damage</arg>
                    <arg n="R">the potential for genome destabilization</arg>
                </example>
                <example src="PERMUTATE" no="986">
                    <text>Thus, the rupture of tumour vessels by manipulation of the 2-bonding system in tumors may disrupting in similar effects on peripheral nerves.</text>
                    <arg n="0">manipulation of the 2-bonding system in tumors</arg>
                    <arg n="1">tumour vessels</arg>
                    <arg n="R">similar effects on peripheral nerves</arg>
                </example>
                <example src="PERMUTATE" no="987">
                    <text>When both genes are disrupted, GalS.</text>
                    <arg n="1">both genes</arg>
                    <arg n="2">GalS</arg>
                </example>
                <example src="PERMUTATE" no="988">
                    <text>When both genes are disrupted, Galish expression is further increased.</text>
                    <arg n="1">both genes</arg>
                    <arg n="2">Galish expression is further increased</arg>
                </example>
                <example src="PERMUTATE" no="989">
                    <text>When both genes are disrupted, child expression was higher.</text>
                    <arg n="1">both genes</arg>
                    <arg n="2">child expression was higher</arg>
                </example>
                <example src="PERMUTATE" no="990">
                    <text>When both genes are disrupted, the Gaulish expression is raised even higher.</text>
                    <arg n="1">both genes</arg>
                    <arg n="2">the Gaulish expression is raised even higher</arg>
                </example>
                <example src="PERMUTATE" no="991">
                    <text>When both genes are disrupted, the Gaulish expression was higher.</text>
                    <arg n="1">both genes</arg>
                    <arg n="2">the Gaulish expression was higher</arg>
                </example>
                <example src="PERMUTATE" no="992">
                    <text>When both genes has already been disrupted, GalS.</text>
                    <arg n="1">both genes</arg>
                    <arg n="2">GalS</arg>
                </example>
                <example src="PERMUTATE" no="993">
                    <text>When both genes has already been disrupted, Galish expression is further increased.</text>
                    <arg n="1">both genes</arg>
                    <arg n="2">Galish expression is further increased</arg>
                </example>
                <example src="PERMUTATE" no="994">
                    <text>When both genes has already been disrupted, child expression is higher.</text>
                    <arg n="1">both genes</arg>
                    <arg n="2">child expression is higher</arg>
                </example>
                <example src="PERMUTATE" no="995">
                    <text>When both genes has already been disrupted, child expression was higher.</text>
                    <arg n="1">both genes</arg>
                    <arg n="2">child expression was higher</arg>
                </example>
                <example src="PERMUTATE" no="996">
                    <text>When both genes has already been disrupted, the Gaulish expression is higher.</text>
                    <arg n="1">both genes</arg>
                    <arg n="2">the Gaulish expression is higher</arg>
                </example>
                <example src="PERMUTATE" no="997">
                    <text>When both genes has already been disrupted, the Gaulish expression is raised even higher.</text>
                    <arg n="1">both genes</arg>
                    <arg n="2">the Gaulish expression is raised even higher</arg>
                </example>
                <example src="PERMUTATE" no="998">
                    <text>When both genes has been disrupted, GalS.</text>
                    <arg n="1">both genes</arg>
                    <arg n="2">GalS</arg>
                </example>
                <example src="PERMUTATE" no="999">
                    <text>When both genes has been disrupted, Galish expression is further increased.</text>
                    <arg n="1">both genes</arg>
                    <arg n="2">Galish expression is further increased</arg>
                </example>
                <example src="PERMUTATE" no="1000">
                    <text>When both genes has been disrupted, child expression is higher.</text>
                    <arg n="1">both genes</arg>
                    <arg n="2">child expression is higher</arg>
                </example>
                <example src="PERMUTATE" no="1001">
                    <text>When both genes has been disrupted, child expression was higher.</text>
                    <arg n="1">both genes</arg>
                    <arg n="2">child expression was higher</arg>
                </example>
                <example src="PERMUTATE" no="1002">
                    <text>When both genes has been disrupted, the Gaulish expression is higher.</text>
                    <arg n="1">both genes</arg>
                    <arg n="2">the Gaulish expression is higher</arg>
                </example>
                <example src="PERMUTATE" no="1003">
                    <text>When both genes has been disrupted, the Gaulish expression is raised even higher.</text>
                    <arg n="1">both genes</arg>
                    <arg n="2">the Gaulish expression is raised even higher</arg>
                </example>
                <example src="PERMUTATE" no="1004">
                    <text>When both genes is shown to be disrupted, GalS.</text>
                    <arg n="1">both genes</arg>
                    <arg n="2">GalS</arg>
                </example>
                <example src="PERMUTATE" no="1005">
                    <text>When both genes is shown to be disrupted, child expression is higher.</text>
                    <arg n="1">both genes</arg>
                    <arg n="2">child expression is higher</arg>
                </example>
                <example src="PERMUTATE" no="1006">
                    <text>When both genes is shown to be disrupted, child expression was higher.</text>
                    <arg n="1">both genes</arg>
                    <arg n="2">child expression was higher</arg>
                </example>
                <example src="PERMUTATE" no="1007">
                    <text>When both genes is shown to be disrupted, the Gaulish expression is higher.</text>
                    <arg n="1">both genes</arg>
                    <arg n="2">the Gaulish expression is higher</arg>
                </example>
                <example src="PERMUTATE" no="1008">
                    <text>When both genes is shown to be disrupted, the Gaulish expression is raised even higher.</text>
                    <arg n="1">both genes</arg>
                    <arg n="2">the Gaulish expression is raised even higher</arg>
                </example>
                <example src="PERMUTATE" no="1009">
                    <text>When both genes is shown to be disrupted, the Gaulish expression was higher.</text>
                    <arg n="1">both genes</arg>
                    <arg n="2">the Gaulish expression was higher</arg>
                </example>
                <example src="PERMUTATE" no="1010">
                    <text>When both genes was already disrupted, GalS.</text>
                    <arg n="1">both genes</arg>
                    <arg n="2">GalS</arg>
                </example>
                <example src="PERMUTATE" no="1011">
                    <text>When both genes was already disrupted, Galish expression is further increased.</text>
                    <arg n="1">both genes</arg>
                    <arg n="2">Galish expression is further increased</arg>
                </example>
                <example src="PERMUTATE" no="1012">
                    <text>When both genes was already disrupted, child expression is higher.</text>
                    <arg n="1">both genes</arg>
                    <arg n="2">child expression is higher</arg>
                </example>
                <example src="PERMUTATE" no="1013">
                    <text>When both genes was already disrupted, the Gaulish expression is higher.</text>
                    <arg n="1">both genes</arg>
                    <arg n="2">the Gaulish expression is higher</arg>
                </example>
                <example src="PERMUTATE" no="1014">
                    <text>When both genes was already disrupted, the Gaulish expression is raised even higher.</text>
                    <arg n="1">both genes</arg>
                    <arg n="2">the Gaulish expression is raised even higher</arg>
                </example>
                <example src="PERMUTATE" no="1015">
                    <text>When both genes was already disrupted, the Gaulish expression was higher.</text>
                    <arg n="1">both genes</arg>
                    <arg n="2">the Gaulish expression was higher</arg>
                </example>
                <example src="PERMUTATE" no="1016">
                    <text>When both genes was disrupted, GalS.</text>
                    <arg n="1">both genes</arg>
                    <arg n="2">GalS</arg>
                </example>
                <example src="PERMUTATE" no="1017">
                    <text>When both genes was disrupted, Galish expression is further increased.</text>
                    <arg n="1">both genes</arg>
                    <arg n="2">Galish expression is further increased</arg>
                </example>
                <example src="PERMUTATE" no="1018">
                    <text>When both genes was disrupted, child expression is higher.</text>
                    <arg n="1">both genes</arg>
                    <arg n="2">child expression is higher</arg>
                </example>
                <example src="PERMUTATE" no="1019">
                    <text>When both genes was disrupted, the Gaulish expression is higher.</text>
                    <arg n="1">both genes</arg>
                    <arg n="2">the Gaulish expression is higher</arg>
                </example>
                <example src="PERMUTATE" no="1020">
                    <text>When both genes was disrupted, the Gaulish expression is raised even higher.</text>
                    <arg n="1">both genes</arg>
                    <arg n="2">the Gaulish expression is raised even higher</arg>
                </example>
                <example src="PERMUTATE" no="1021">
                    <text>When both genes was disrupted, the Gaulish expression was higher.</text>
                    <arg n="1">both genes</arg>
                    <arg n="2">the Gaulish expression was higher</arg>
                </example>
                <example src="PERMUTATE" no="1022">
                    <text>When both genes was disrupted, the expression Galish expression is further increased was higher.</text>
                    <arg n="1">both genes</arg>
                    <arg n="2">Galish expression is further increased</arg>
                </example>
                <example src="PERMUTATE" no="1023">
                    <text>When both genes was disrupted, the expression child expression is higher was higher.</text>
                    <arg n="1">both genes</arg>
                    <arg n="2">child expression is higher</arg>
                </example>
                <example src="PERMUTATE" no="1024">
                    <text>When both genes was disrupted, the expression child expression was higher was higher.</text>
                    <arg n="1">both genes</arg>
                    <arg n="2">child expression was higher</arg>
                </example>
                <example src="PERMUTATE" no="1025">
                    <text>When both genes was disrupted, the expression the Gaulish expression is higher was higher.</text>
                    <arg n="1">both genes</arg>
                    <arg n="2">the Gaulish expression is higher</arg>
                </example>
                <example src="PERMUTATE" no="1026">
                    <text>When both genes was disrupted, the expression the Gaulish expression is raised even higher was higher.</text>
                    <arg n="1">both genes</arg>
                    <arg n="2">the Gaulish expression is raised even higher</arg>
                </example>
                <example src="PERMUTATE" no="1027">
                    <text>When both genes was disrupted, the expression the Gaulish expression was higher was higher.</text>
                    <arg n="1">both genes</arg>
                    <arg n="2">the Gaulish expression was higher</arg>
                </example>
                <example src="PERMUTATE" no="1028">
                    <text>When it has been disrupted that both genes is perturbed, GalS.</text>
                    <arg n="1">both genes</arg>
                    <arg n="2">GalS</arg>
                </example>
                <example src="PERMUTATE" no="1029">
                    <text>When it has been disrupted that both genes is perturbed, Galish expression is further increased.</text>
                    <arg n="1">both genes</arg>
                    <arg n="2">Galish expression is further increased</arg>
                </example>
                <example src="PERMUTATE" no="1030">
                    <text>When it has been disrupted that both genes is perturbed, child expression is higher.</text>
                    <arg n="1">both genes</arg>
                    <arg n="2">child expression is higher</arg>
                </example>
                <example src="PERMUTATE" no="1031">
                    <text>When it has been disrupted that both genes is perturbed, child expression was higher.</text>
                    <arg n="1">both genes</arg>
                    <arg n="2">child expression was higher</arg>
                </example>
                <example src="PERMUTATE" no="1032">
                    <text>When it has been disrupted that both genes is perturbed, the Gaulish expression is raised even higher.</text>
                    <arg n="1">both genes</arg>
                    <arg n="2">the Gaulish expression is raised even higher</arg>
                </example>
                <example src="PERMUTATE" no="1033">
                    <text>When it has been disrupted that both genes is perturbed, the Gaulish expression was higher.</text>
                    <arg n="1">both genes</arg>
                    <arg n="2">the Gaulish expression was higher</arg>
                </example>
                <example src="PERMUTATE" no="1034">
                    <text>When it is shown that both genes is disrupted, GalS.</text>
                    <arg n="1">both genes</arg>
                    <arg n="2">GalS</arg>
                </example>
                <example src="PERMUTATE" no="1035">
                    <text>When it is shown that both genes is disrupted, Galish expression is further increased.</text>
                    <arg n="1">both genes</arg>
                    <arg n="2">Galish expression is further increased</arg>
                </example>
                <example src="PERMUTATE" no="1036">
                    <text>When it is shown that both genes is disrupted, child expression is higher.</text>
                    <arg n="1">both genes</arg>
                    <arg n="2">child expression is higher</arg>
                </example>
                <example src="PERMUTATE" no="1037">
                    <text>When it is shown that both genes is disrupted, child expression was higher.</text>
                    <arg n="1">both genes</arg>
                    <arg n="2">child expression was higher</arg>
                </example>
                <example src="PERMUTATE" no="1038">
                    <text>When it is shown that both genes is disrupted, the Gaulish expression is higher.</text>
                    <arg n="1">both genes</arg>
                    <arg n="2">the Gaulish expression is higher</arg>
                </example>
                <example src="PERMUTATE" no="1039">
                    <text>When it is shown that both genes is disrupted, the Gaulish expression was higher.</text>
                    <arg n="1">both genes</arg>
                    <arg n="2">the Gaulish expression was higher</arg>
                </example>
                <example src="PERMUTATE" no="1040">
                    <text>a homozygous mutation broke a sequence of pulally disrupted in R (exon 5 spike).</text>
                    <arg n="0">a homozygous mutation</arg>
                    <arg n="1">pulally</arg>
                </example>
                <example src="PERMUTATE" no="1041">
                    <text>a homozygous mutation broke a sequence of split disrupted in R (exon 5 spike).</text>
                    <arg n="0">a homozygous mutation</arg>
                    <arg n="1">split</arg>
                </example>
                <example src="PERMUTATE" no="1042">
                    <text>a homozygous mutation can disrupt with the base groups ceto and C (blue) on both sides of the dsDNA DNA and interrupt pulally.</text>
                    <arg n="0">a homozygous mutation</arg>
                    <arg n="1">pulally</arg>
                </example>
                <example src="PERMUTATE" no="1043">
                    <text>a homozygous mutation can disrupt with the base groups ceto and C (blue) on both sides of the dsDNA DNA and interrupt split.</text>
                    <arg n="0">a homozygous mutation</arg>
                    <arg n="1">split</arg>
                </example>
                <example src="PERMUTATE" no="1044">
                    <text>a homozygous mutation that broke A1 will be identified in the siblings disrupted by classical abetalipoproteinemia.</text>
                    <arg n="0">a homozygous mutation</arg>
                </example>
                <example src="PERMUTATE" no="1045">
                    <text>a homozygous mutation that can disrupt pulally has been identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">a homozygous mutation</arg>
                    <arg n="1">pulally</arg>
                </example>
                <example src="PERMUTATE" no="1046">
                    <text>a homozygous mutation that can disrupt pulally that has been identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">a homozygous mutation</arg>
                    <arg n="1">pulally</arg>
                </example>
                <example src="PERMUTATE" no="1047">
                    <text>a homozygous mutation that can disrupt split that has been identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">a homozygous mutation</arg>
                    <arg n="1">split</arg>
                </example>
                <example src="PERMUTATE" no="1048">
                    <text>a homozygous mutation that has disrupted split was identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">a homozygous mutation</arg>
                    <arg n="1">split</arg>
                </example>
                <example src="PERMUTATE" no="1049">
                    <text>a homozygous mutation that interact with the keto groups of the base pair GO and C (blue) on either side of the dsDNA can disrupt pulally.</text>
                    <arg n="0">a homozygous mutation</arg>
                    <arg n="1">pulally</arg>
                </example>
                <example src="PERMUTATE" no="1050">
                    <text>a homozygous mutation that interact with the keto groups of the base pair GO and C (blue) on either side of the dsDNA can disrupt split.</text>
                    <arg n="0">a homozygous mutation</arg>
                    <arg n="1">split</arg>
                </example>
                <example src="PERMUTATE" no="1051">
                    <text>a homozygous mutation that interacts with the keto and C group pair (blue) on both sides of the dsDNA can disrupt pulally.</text>
                    <arg n="0">a homozygous mutation</arg>
                    <arg n="1">pulally</arg>
                </example>
                <example src="PERMUTATE" no="1052">
                    <text>a homozygous mutation that interacts with the keto and C group pair (blue) on both sides of the dsDNA can disrupt split.</text>
                    <arg n="0">a homozygous mutation</arg>
                    <arg n="1">split</arg>
                </example>
                <example src="PERMUTATE" no="1053">
                    <text>alcohol consumption exposure broke a sequence of ocular dominance plasticity disrupted in R (exon 5 spike).</text>
                    <arg n="0">alcohol consumption exposure</arg>
                    <arg n="1">ocular dominance plasticity</arg>
                </example>
                <example src="PERMUTATE" no="1054">
                    <text>alcohol consumption exposure can disrupt with the base groups ceto and C (blue) on both sides of the dsDNA DNA and interrupt ocular dominance plasticity.</text>
                    <arg n="0">alcohol consumption exposure</arg>
                    <arg n="1">ocular dominance plasticity</arg>
                </example>
                <example src="PERMUTATE" no="1055">
                    <text>alcohol consumption exposure that can disrupt ocular dominance plasticity has been identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">alcohol consumption exposure</arg>
                    <arg n="1">ocular dominance plasticity</arg>
                </example>
                <example src="PERMUTATE" no="1056">
                    <text>alcohol consumption exposure that can disrupt ocular dominance plasticity that has been identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">alcohol consumption exposure</arg>
                    <arg n="1">ocular dominance plasticity</arg>
                </example>
                <example src="PERMUTATE" no="1057">
                    <text>alcohol consumption exposure that has disrupted ocular dominance plasticity was identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">alcohol consumption exposure</arg>
                    <arg n="1">ocular dominance plasticity</arg>
                </example>
                <example src="PERMUTATE" no="1058">
                    <text>alcohol consumption exposure that interact with the keto groups of the base pair GO and C (blue) on either side of the dsDNA can disrupt ocular dominance plasticity.</text>
                    <arg n="0">alcohol consumption exposure</arg>
                    <arg n="1">ocular dominance plasticity</arg>
                </example>
                <example src="PERMUTATE" no="1059">
                    <text>alcohol consumption exposure that interacts with the keto and C group pair (blue) on both sides of the dsDNA can disrupt ocular dominance plasticity.</text>
                    <arg n="0">alcohol consumption exposure</arg>
                    <arg n="1">ocular dominance plasticity</arg>
                </example>
                <example src="PERMUTATE" no="1060">
                    <text>alcohol exposure broke a sequence of ocular domain plasticity disrupted in R (exon 5 spike).</text>
                    <arg n="0">alcohol exposure</arg>
                    <arg n="1">ocular domain plasticity</arg>
                </example>
                <example src="PERMUTATE" no="1061">
                    <text>alcohol exposure broke a sequence of ocular dominance plasticity disrupted in R (exon 5 spike).</text>
                    <arg n="0">alcohol exposure</arg>
                    <arg n="1">ocular dominance plasticity</arg>
                </example>
                <example src="PERMUTATE" no="1062">
                    <text>alcohol exposure can disrupt with the base groups ceto and C (blue) on both sides of the dsDNA DNA and interrupt ocular domain plasticity.</text>
                    <arg n="0">alcohol exposure</arg>
                    <arg n="1">ocular domain plasticity</arg>
                </example>
                <example src="PERMUTATE" no="1063">
                    <text>alcohol exposure can disrupt with the base groups ceto and C (blue) on both sides of the dsDNA DNA and interrupt ocular dominance plasticity.</text>
                    <arg n="0">alcohol exposure</arg>
                    <arg n="1">ocular dominance plasticity</arg>
                </example>
                <example src="PERMUTATE" no="1064">
                    <text>alcohol exposure that can disrupt ocular domain plasticity has been identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">alcohol exposure</arg>
                    <arg n="1">ocular domain plasticity</arg>
                </example>
                <example src="PERMUTATE" no="1065">
                    <text>alcohol exposure that can disrupt ocular domain plasticity that has been identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">alcohol exposure</arg>
                    <arg n="1">ocular domain plasticity</arg>
                </example>
                <example src="PERMUTATE" no="1066">
                    <text>alcohol exposure that can disrupt ocular dominance plasticity has been identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">alcohol exposure</arg>
                    <arg n="1">ocular dominance plasticity</arg>
                </example>
                <example src="PERMUTATE" no="1067">
                    <text>alcohol exposure that can disrupt ocular dominance plasticity that has been identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">alcohol exposure</arg>
                    <arg n="1">ocular dominance plasticity</arg>
                </example>
                <example src="PERMUTATE" no="1068">
                    <text>alcohol exposure that has disrupted ocular domain plasticity was identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">alcohol exposure</arg>
                    <arg n="1">ocular domain plasticity</arg>
                </example>
                <example src="PERMUTATE" no="1069">
                    <text>alcohol exposure that has disrupted ocular dominance plasticity was identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">alcohol exposure</arg>
                    <arg n="1">ocular dominance plasticity</arg>
                </example>
                <example src="PERMUTATE" no="1070">
                    <text>alcohol exposure that interact with the keto groups of the base pair GO and C (blue) on either side of the dsDNA can disrupt ocular domain plasticity.</text>
                    <arg n="0">alcohol exposure</arg>
                    <arg n="1">ocular domain plasticity</arg>
                </example>
                <example src="PERMUTATE" no="1071">
                    <text>alcohol exposure that interact with the keto groups of the base pair GO and C (blue) on either side of the dsDNA can disrupt ocular dominance plasticity.</text>
                    <arg n="0">alcohol exposure</arg>
                    <arg n="1">ocular dominance plasticity</arg>
                </example>
                <example src="PERMUTATE" no="1072">
                    <text>alcohol exposure that interacts with the keto and C group pair (blue) on both sides of the dsDNA can disrupt ocular domain plasticity.</text>
                    <arg n="0">alcohol exposure</arg>
                    <arg n="1">ocular domain plasticity</arg>
                </example>
                <example src="PERMUTATE" no="1073">
                    <text>alcohol exposure that interacts with the keto and C group pair (blue) on both sides of the dsDNA can disrupt ocular dominance plasticity.</text>
                    <arg n="0">alcohol exposure</arg>
                    <arg n="1">ocular dominance plasticity</arg>
                </example>
                <example src="PERMUTATE" no="1074">
                    <text>exposure to alcohol consumption broke a sequence of ocular domain plasticity disrupted in R (exon 5 spike).</text>
                    <arg n="0">exposure to alcohol consumption</arg>
                    <arg n="1">ocular domain plasticity</arg>
                </example>
                <example src="PERMUTATE" no="1075">
                    <text>exposure to alcohol consumption broke a sequence of plasticity of eye dominance disrupted in R (exon 5 spike).</text>
                    <arg n="0">exposure to alcohol consumption</arg>
                    <arg n="1">plasticity of eye dominance</arg>
                </example>
                <example src="PERMUTATE" no="1076">
                    <text>exposure to alcohol consumption can disrupt with the base groups ceto and C (blue) on both sides of the dsDNA DNA and interrupt ocular domain plasticity.</text>
                    <arg n="0">exposure to alcohol consumption</arg>
                    <arg n="1">ocular domain plasticity</arg>
                </example>
                <example src="PERMUTATE" no="1077">
                    <text>exposure to alcohol consumption can disrupt with the base groups ceto and C (blue) on both sides of the dsDNA DNA and interrupt plasticity of eye dominance.</text>
                    <arg n="0">exposure to alcohol consumption</arg>
                    <arg n="1">plasticity of eye dominance</arg>
                </example>
                <example src="PERMUTATE" no="1078">
                    <text>exposure to alcohol consumption that can disrupt ocular domain plasticity has been identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">exposure to alcohol consumption</arg>
                    <arg n="1">ocular domain plasticity</arg>
                </example>
                <example src="PERMUTATE" no="1079">
                    <text>exposure to alcohol consumption that can disrupt ocular domain plasticity that has been identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">exposure to alcohol consumption</arg>
                    <arg n="1">ocular domain plasticity</arg>
                </example>
                <example src="PERMUTATE" no="1080">
                    <text>exposure to alcohol consumption that can disrupt plasticity of eye dominance has been identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">exposure to alcohol consumption</arg>
                    <arg n="1">plasticity of eye dominance</arg>
                </example>
                <example src="PERMUTATE" no="1081">
                    <text>exposure to alcohol consumption that can disrupt plasticity of eye dominance that has been identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">exposure to alcohol consumption</arg>
                    <arg n="1">plasticity of eye dominance</arg>
                </example>
                <example src="PERMUTATE" no="1082">
                    <text>exposure to alcohol consumption that has disrupted ocular domain plasticity was identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">exposure to alcohol consumption</arg>
                    <arg n="1">ocular domain plasticity</arg>
                </example>
                <example src="PERMUTATE" no="1083">
                    <text>exposure to alcohol consumption that has disrupted plasticity of eye dominance was identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">exposure to alcohol consumption</arg>
                    <arg n="1">plasticity of eye dominance</arg>
                </example>
                <example src="PERMUTATE" no="1084">
                    <text>exposure to alcohol consumption that interact with the keto groups of the base pair GO and C (blue) on either side of the dsDNA can disrupt ocular domain plasticity.</text>
                    <arg n="0">exposure to alcohol consumption</arg>
                    <arg n="1">ocular domain plasticity</arg>
                </example>
                <example src="PERMUTATE" no="1085">
                    <text>exposure to alcohol consumption that interact with the keto groups of the base pair GO and C (blue) on either side of the dsDNA can disrupt plasticity of eye dominance.</text>
                    <arg n="0">exposure to alcohol consumption</arg>
                    <arg n="1">plasticity of eye dominance</arg>
                </example>
                <example src="PERMUTATE" no="1086">
                    <text>exposure to alcohol consumption that interacts with the keto and C group pair (blue) on both sides of the dsDNA can disrupt ocular domain plasticity.</text>
                    <arg n="0">exposure to alcohol consumption</arg>
                    <arg n="1">ocular domain plasticity</arg>
                </example>
                <example src="PERMUTATE" no="1087">
                    <text>exposure to alcohol consumption that interacts with the keto and C group pair (blue) on both sides of the dsDNA can disrupt plasticity of eye dominance.</text>
                    <arg n="0">exposure to alcohol consumption</arg>
                    <arg n="1">plasticity of eye dominance</arg>
                </example>
                <example src="PERMUTATE" no="1088">
                    <text>his retired expression MEKK1 or MEKK2 broke a sequence of the overall integrity of MAPK pathway regulation disrupted in R (exon 5 spike).</text>
                    <arg n="0">his retired expression MEKK1 or MEKK2</arg>
                    <arg n="1">the overall integrity of MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="1089">
                    <text>his retired expression MEKK1 or MEKK2 can disrupt with the base groups ceto and C (blue) on both sides of the dsDNA DNA and interrupt the overall integrity of MAPK pathway regulation.</text>
                    <arg n="0">his retired expression MEKK1 or MEKK2</arg>
                    <arg n="1">the overall integrity of MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="1090">
                    <text>his retired expression MEKK1 or MEKK2 that can disrupt the overall integrity of MAPK pathway regulation has been identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">his retired expression MEKK1 or MEKK2</arg>
                    <arg n="1">the overall integrity of MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="1091">
                    <text>his retired expression MEKK1 or MEKK2 that can disrupt the overall integrity of MAPK pathway regulation that has been identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">his retired expression MEKK1 or MEKK2</arg>
                    <arg n="1">the overall integrity of MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="1092">
                    <text>his retired expression MEKK1 or MEKK2 that has disrupted the overall integrity of MAPK pathway regulation was identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">his retired expression MEKK1 or MEKK2</arg>
                    <arg n="1">the overall integrity of MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="1093">
                    <text>his retired expression MEKK1 or MEKK2 that interact with the keto groups of the base pair GO and C (blue) on either side of the dsDNA can disrupt the overall integrity of MAPK pathway regulation.</text>
                    <arg n="0">his retired expression MEKK1 or MEKK2</arg>
                    <arg n="1">the overall integrity of MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="1094">
                    <text>his retired expression MEKK1 or MEKK2 that interacts with the keto and C group pair (blue) on both sides of the dsDNA can disrupt the overall integrity of MAPK pathway regulation.</text>
                    <arg n="0">his retired expression MEKK1 or MEKK2</arg>
                    <arg n="1">the overall integrity of MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="1095">
                    <text>homozygous mutation broke a sequence of spacing disrupted in R (exon 5 spike).</text>
                    <arg n="0">homozygous mutation</arg>
                    <arg n="1">spacing</arg>
                </example>
                <example src="PERMUTATE" no="1096">
                    <text>homozygous mutation broke a sequence of squirrel disrupted in R (exon 5 spike).</text>
                    <arg n="0">homozygous mutation</arg>
                    <arg n="1">squirrel</arg>
                </example>
                <example src="PERMUTATE" no="1097">
                    <text>homozygous mutation can disrupt with the base groups ceto and C (blue) on both sides of the dsDNA DNA and interrupt spacing.</text>
                    <arg n="0">homozygous mutation</arg>
                    <arg n="1">spacing</arg>
                </example>
                <example src="PERMUTATE" no="1098">
                    <text>homozygous mutation can disrupt with the base groups ceto and C (blue) on both sides of the dsDNA DNA and interrupt squirrel.</text>
                    <arg n="0">homozygous mutation</arg>
                    <arg n="1">squirrel</arg>
                </example>
                <example src="PERMUTATE" no="1099">
                    <text>homozygous mutation that can disrupt spacing has been identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">homozygous mutation</arg>
                    <arg n="1">spacing</arg>
                </example>
                <example src="PERMUTATE" no="1100">
                    <text>homozygous mutation that can disrupt spacing that has been identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">homozygous mutation</arg>
                    <arg n="1">spacing</arg>
                </example>
                <example src="PERMUTATE" no="1101">
                    <text>homozygous mutation that can disrupt squirrel has been identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">homozygous mutation</arg>
                    <arg n="1">squirrel</arg>
                </example>
                <example src="PERMUTATE" no="1102">
                    <text>homozygous mutation that has disrupted A1 will be identified in the affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">homozygous mutation</arg>
                </example>
                <example src="PERMUTATE" no="1103">
                    <text>homozygous mutation that has disrupted spacing was identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">homozygous mutation</arg>
                    <arg n="1">spacing</arg>
                </example>
                <example src="PERMUTATE" no="1104">
                    <text>homozygous mutation that has disrupted squirrel was identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">homozygous mutation</arg>
                    <arg n="1">squirrel</arg>
                </example>
                <example src="PERMUTATE" no="1105">
                    <text>homozygous mutation that interact with the keto groups of the base pair GO and C (blue) on either side of the dsDNA can disrupt spacing.</text>
                    <arg n="0">homozygous mutation</arg>
                    <arg n="1">spacing</arg>
                </example>
                <example src="PERMUTATE" no="1106">
                    <text>homozygous mutation that interact with the keto groups of the base pair GO and C (blue) on either side of the dsDNA can disrupt squirrel.</text>
                    <arg n="0">homozygous mutation</arg>
                    <arg n="1">squirrel</arg>
                </example>
                <example src="PERMUTATE" no="1107">
                    <text>homozygous mutation that interacts with the keto and C group pair (blue) on both sides of the dsDNA can disrupt spacing.</text>
                    <arg n="0">homozygous mutation</arg>
                    <arg n="1">spacing</arg>
                </example>
                <example src="PERMUTATE" no="1108">
                    <text>homozygous mutation that interacts with the keto and C group pair (blue) on both sides of the dsDNA can disrupt squirrel.</text>
                    <arg n="0">homozygous mutation</arg>
                    <arg n="1">squirrel</arg>
                </example>
                <example src="PERMUTATE" no="1109">
                    <text>if retired from the expression MEKK1 or MEKK2 broke a sequence of the overall integrity of MAPK pathway regulation disrupted in R (exon 5 spike).</text>
                    <arg n="0">if retired from the expression MEKK1 or MEKK2</arg>
                    <arg n="1">the overall integrity of MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="1110">
                    <text>if retired from the expression MEKK1 or MEKK2 can disrupt with the base groups ceto and C (blue) on both sides of the dsDNA DNA and interrupt the overall integrity of MAPK pathway regulation.</text>
                    <arg n="0">if retired from the expression MEKK1 or MEKK2</arg>
                    <arg n="1">the overall integrity of MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="1111">
                    <text>if retired from the expression MEKK1 or MEKK2 that can disrupt the overall integrity of MAPK pathway regulation has been identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">if retired from the expression MEKK1 or MEKK2</arg>
                    <arg n="1">the overall integrity of MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="1112">
                    <text>if retired from the expression MEKK1 or MEKK2 that can disrupt the overall integrity of MAPK pathway regulation that has been identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">if retired from the expression MEKK1 or MEKK2</arg>
                    <arg n="1">the overall integrity of MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="1113">
                    <text>if retired from the expression MEKK1 or MEKK2 that has disrupted the overall integrity of MAPK pathway regulation was identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">if retired from the expression MEKK1 or MEKK2</arg>
                    <arg n="1">the overall integrity of MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="1114">
                    <text>if retired from the expression MEKK1 or MEKK2 that interact with the keto groups of the base pair GO and C (blue) on either side of the dsDNA can disrupt the overall integrity of MAPK pathway regulation.</text>
                    <arg n="0">if retired from the expression MEKK1 or MEKK2</arg>
                    <arg n="1">the overall integrity of MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="1115">
                    <text>if retired from the expression MEKK1 or MEKK2 that interacts with the keto and C group pair (blue) on both sides of the dsDNA can disrupt the overall integrity of MAPK pathway regulation.</text>
                    <arg n="0">if retired from the expression MEKK1 or MEKK2</arg>
                    <arg n="1">the overall integrity of MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="1116">
                    <text>inhibition of inflammation broke a sequence of physiological protective response disrupted in R (exon 5 spike).</text>
                    <arg n="0">inhibition of inflammation</arg>
                    <arg n="1">physiological protective response</arg>
                </example>
                <example src="PERMUTATE" no="1117">
                    <text>inhibition of inflammation broke a sequence of protective physiological responses disrupted in R (exon 5 spike).</text>
                    <arg n="0">inhibition of inflammation</arg>
                    <arg n="1">protective physiological responses</arg>
                </example>
                <example src="PERMUTATE" no="1118">
                    <text>inhibition of inflammation can disrupt with the base groups ceto and C (blue) on both sides of the dsDNA DNA and interrupt physiological protective response.</text>
                    <arg n="0">inhibition of inflammation</arg>
                    <arg n="1">physiological protective response</arg>
                </example>
                <example src="PERMUTATE" no="1119">
                    <text>inhibition of inflammation can disrupt with the base groups ceto and C (blue) on both sides of the dsDNA DNA and interrupt protective physiological responses.</text>
                    <arg n="0">inhibition of inflammation</arg>
                    <arg n="1">protective physiological responses</arg>
                </example>
                <example src="PERMUTATE" no="1120">
                    <text>inhibition of inflammation that can disrupt physiological protective response has been identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">inhibition of inflammation</arg>
                    <arg n="1">physiological protective response</arg>
                </example>
                <example src="PERMUTATE" no="1121">
                    <text>inhibition of inflammation that can disrupt physiological protective response that has been identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">inhibition of inflammation</arg>
                    <arg n="1">physiological protective response</arg>
                </example>
                <example src="PERMUTATE" no="1122">
                    <text>inhibition of inflammation that can disrupt protective physiological responses has been identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">inhibition of inflammation</arg>
                    <arg n="1">protective physiological responses</arg>
                </example>
                <example src="PERMUTATE" no="1123">
                    <text>inhibition of inflammation that can disrupt protective physiological responses that has been identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">inhibition of inflammation</arg>
                    <arg n="1">protective physiological responses</arg>
                </example>
                <example src="PERMUTATE" no="1124">
                    <text>inhibition of inflammation that has disrupted physiological protective response was identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">inhibition of inflammation</arg>
                    <arg n="1">physiological protective response</arg>
                </example>
                <example src="PERMUTATE" no="1125">
                    <text>inhibition of inflammation that has disrupted protective physiological responses was identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">inhibition of inflammation</arg>
                    <arg n="1">protective physiological responses</arg>
                </example>
                <example src="PERMUTATE" no="1126">
                    <text>inhibition of inflammation that interact with the keto groups of the base pair GO and C (blue) on either side of the dsDNA can disrupt physiological protective response.</text>
                    <arg n="0">inhibition of inflammation</arg>
                    <arg n="1">physiological protective response</arg>
                </example>
                <example src="PERMUTATE" no="1127">
                    <text>inhibition of inflammation that interact with the keto groups of the base pair GO and C (blue) on either side of the dsDNA can disrupt protective physiological responses.</text>
                    <arg n="0">inhibition of inflammation</arg>
                    <arg n="1">protective physiological responses</arg>
                </example>
                <example src="PERMUTATE" no="1128">
                    <text>inhibition of inflammation that interacts with the keto and C group pair (blue) on both sides of the dsDNA can disrupt physiological protective response.</text>
                    <arg n="0">inhibition of inflammation</arg>
                    <arg n="1">physiological protective response</arg>
                </example>
                <example src="PERMUTATE" no="1129">
                    <text>inhibition of inflammation that interacts with the keto and C group pair (blue) on both sides of the dsDNA can disrupt protective physiological responses.</text>
                    <arg n="0">inhibition of inflammation</arg>
                    <arg n="1">protective physiological responses</arg>
                </example>
                <example src="PERMUTATE" no="1130">
                    <text>knockout of the expression MEKK1 or MEKK2 broke a sequence of the overall integrity of MAPK pathway regulation disrupted in R (exon 5 spike).</text>
                    <arg n="0">knockout of the expression MEKK1 or MEKK2</arg>
                    <arg n="1">the overall integrity of MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="1131">
                    <text>knockout of the expression MEKK1 or MEKK2 can disrupt with the base groups ceto and C (blue) on both sides of the dsDNA DNA and interrupt the overall integrity of MAPK pathway regulation.</text>
                    <arg n="0">knockout of the expression MEKK1 or MEKK2</arg>
                    <arg n="1">the overall integrity of MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="1132">
                    <text>knockout of the expression MEKK1 or MEKK2 that can disrupt the overall integrity of MAPK pathway regulation has been identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">knockout of the expression MEKK1 or MEKK2</arg>
                    <arg n="1">the overall integrity of MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="1133">
                    <text>knockout of the expression MEKK1 or MEKK2 that can disrupt the overall integrity of MAPK pathway regulation that has been identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">knockout of the expression MEKK1 or MEKK2</arg>
                    <arg n="1">the overall integrity of MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="1134">
                    <text>knockout of the expression MEKK1 or MEKK2 that has disrupted the overall integrity of MAPK pathway regulation was identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">knockout of the expression MEKK1 or MEKK2</arg>
                    <arg n="1">the overall integrity of MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="1135">
                    <text>knockout of the expression MEKK1 or MEKK2 that interact with the keto groups of the base pair GO and C (blue) on either side of the dsDNA can disrupt the overall integrity of MAPK pathway regulation.</text>
                    <arg n="0">knockout of the expression MEKK1 or MEKK2</arg>
                    <arg n="1">the overall integrity of MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="1136">
                    <text>knockout of the expression MEKK1 or MEKK2 that interacts with the keto and C group pair (blue) on both sides of the dsDNA can disrupt the overall integrity of MAPK pathway regulation.</text>
                    <arg n="0">knockout of the expression MEKK1 or MEKK2</arg>
                    <arg n="1">the overall integrity of MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="1137">
                    <text>manipulation of the 2-bonding system in tumors broke the tumour vessels and disrupted to the similar effects on peripheral nerves.</text>
                    <arg n="0">manipulation of the 2-bonding system in tumors</arg>
                    <arg n="1">tumour vessels</arg>
                    <arg n="R">similar effects on peripheral nerves</arg>
                </example>
                <example src="PERMUTATE" no="1138">
                    <text>manipulation of the 2-bonding system in tumors have perturbed tumour vessels and disrupted in similar effects on peripheral nerves.</text>
                    <arg n="0">manipulation of the 2-bonding system in tumors</arg>
                    <arg n="1">tumour vessels</arg>
                    <arg n="R">similar effects on peripheral nerves</arg>
                </example>
                <example src="PERMUTATE" no="1139">
                    <text>manipulation of the 2-bonding system in tumors rupture of tumour vessels may disrupting in similar effects on peripheral nerves.</text>
                    <arg n="0">manipulation of the 2-bonding system in tumors</arg>
                    <arg n="1">tumour vessels</arg>
                    <arg n="R">similar effects on peripheral nerves</arg>
                </example>
                <example src="PERMUTATE" no="1140">
                    <text>manipulation of the binding system 2 in tumours broke the tumor vessels and disrupted to the similar effects on peripheral nerves.</text>
                    <arg n="0">manipulation of the binding system 2 in tumours</arg>
                    <arg n="1">tumor vessels</arg>
                    <arg n="R">similar effects on peripheral nerves</arg>
                </example>
                <example src="PERMUTATE" no="1141">
                    <text>manipulation of the binding system 2 in tumours have perturbed tumor vessels and disrupted in similar effects on peripheral nerves.</text>
                    <arg n="0">manipulation of the binding system 2 in tumours</arg>
                    <arg n="1">tumor vessels</arg>
                    <arg n="R">similar effects on peripheral nerves</arg>
                </example>
                <example src="PERMUTATE" no="1142">
                    <text>manipulation of the binding system 2 in tumours rupture of tumor vessels may disrupting in similar effects on peripheral nerves.</text>
                    <arg n="0">manipulation of the binding system 2 in tumours</arg>
                    <arg n="1">tumor vessels</arg>
                    <arg n="R">similar effects on peripheral nerves</arg>
                </example>
                <example src="PERMUTATE" no="1143">
                    <text>p53 mutations broke the checking points responses to DNA damage and disrupted to the genome destabilization potential.</text>
                    <arg n="0">p53 mutations</arg>
                    <arg n="1">checking points responses to DNA damage</arg>
                    <arg n="R">genome destabilization potential</arg>
                </example>
                <example src="PERMUTATE" no="1144">
                    <text>p53 mutations have perturbed checking points responses to DNA damage and disrupted in genome destabilization potential.</text>
                    <arg n="0">p53 mutations</arg>
                    <arg n="1">checking points responses to DNA damage</arg>
                    <arg n="R">genome destabilization potential</arg>
                </example>
                <example src="PERMUTATE" no="1145">
                    <text>retired from the MEKK1 or MEKK2 expression broke a sequence of the overall integrity of the MAPK pathway regulation disrupted in R (exon 5 spike).</text>
                    <arg n="0">retired from the MEKK1 or MEKK2 expression</arg>
                    <arg n="1">the overall integrity of the MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="1146">
                    <text>retired from the MEKK1 or MEKK2 expression can disrupt with the base groups ceto and C (blue) on both sides of the dsDNA DNA and interrupt the overall integrity of the MAPK pathway regulation.</text>
                    <arg n="0">retired from the MEKK1 or MEKK2 expression</arg>
                    <arg n="1">the overall integrity of the MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="1147">
                    <text>retired from the MEKK1 or MEKK2 expression that can disrupt the overall integrity of the MAPK pathway regulation has been identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">retired from the MEKK1 or MEKK2 expression</arg>
                    <arg n="1">the overall integrity of the MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="1148">
                    <text>retired from the MEKK1 or MEKK2 expression that can disrupt the overall integrity of the MAPK pathway regulation that has been identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">retired from the MEKK1 or MEKK2 expression</arg>
                    <arg n="1">the overall integrity of the MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="1149">
                    <text>retired from the MEKK1 or MEKK2 expression that has disrupted the overall integrity of the MAPK pathway regulation was identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">retired from the MEKK1 or MEKK2 expression</arg>
                    <arg n="1">the overall integrity of the MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="1150">
                    <text>retired from the MEKK1 or MEKK2 expression that interact with the keto groups of the base pair GO and C (blue) on either side of the dsDNA can disrupt the overall integrity of the MAPK pathway regulation.</text>
                    <arg n="0">retired from the MEKK1 or MEKK2 expression</arg>
                    <arg n="1">the overall integrity of the MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="1151">
                    <text>retired from the MEKK1 or MEKK2 expression that interacts with the keto and C group pair (blue) on both sides of the dsDNA can disrupt the overall integrity of the MAPK pathway regulation.</text>
                    <arg n="0">retired from the MEKK1 or MEKK2 expression</arg>
                    <arg n="1">the overall integrity of the MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="1152">
                    <text>the Gly188--Glu mutation broke a sequence of an Ava II site disrupted in R (exon 5 spike).</text>
                    <arg n="0">the Gly188--Glu mutation</arg>
                    <arg n="1">an Ava II site</arg>
                </example>
                <example src="PERMUTATE" no="1153">
                    <text>the Gly188--Glu mutation can disrupt with the base groups ceto and C (blue) on both sides of the dsDNA DNA and interrupt an Ava II site.</text>
                    <arg n="0">the Gly188--Glu mutation</arg>
                    <arg n="1">an Ava II site</arg>
                </example>
                <example src="PERMUTATE" no="1154">
                    <text>the Gly188--Glu mutation that can disrupt an Ava II site has been identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">the Gly188--Glu mutation</arg>
                    <arg n="1">an Ava II site</arg>
                </example>
                <example src="PERMUTATE" no="1155">
                    <text>the Gly188--Glu mutation that can disrupt an Ava II site that has been identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">the Gly188--Glu mutation</arg>
                    <arg n="1">an Ava II site</arg>
                </example>
                <example src="PERMUTATE" no="1156">
                    <text>the Gly188--Glu mutation that has disrupted an Ava II site was identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">the Gly188--Glu mutation</arg>
                    <arg n="1">an Ava II site</arg>
                </example>
                <example src="PERMUTATE" no="1157">
                    <text>the Gly188--Glu mutation that interact with the keto groups of the base pair GO and C (blue) on either side of the dsDNA can disrupt an Ava II site.</text>
                    <arg n="0">the Gly188--Glu mutation</arg>
                    <arg n="1">an Ava II site</arg>
                </example>
                <example src="PERMUTATE" no="1158">
                    <text>the Gly188--Glu mutation that interacts with the keto and C group pair (blue) on both sides of the dsDNA can disrupt an Ava II site.</text>
                    <arg n="0">the Gly188--Glu mutation</arg>
                    <arg n="1">an Ava II site</arg>
                </example>
                <example src="PERMUTATE" no="1159">
                    <text>the knockout of the MEKK1 or MEKK2 expression broke a sequence of the overall integrity of the MAPK pathway regulation disrupted in R (exon 5 spike).</text>
                    <arg n="0">the knockout of the MEKK1 or MEKK2 expression</arg>
                    <arg n="1">the overall integrity of the MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="1160">
                    <text>the knockout of the MEKK1 or MEKK2 expression can disrupt with the base groups ceto and C (blue) on both sides of the dsDNA DNA and interrupt the overall integrity of the MAPK pathway regulation.</text>
                    <arg n="0">the knockout of the MEKK1 or MEKK2 expression</arg>
                    <arg n="1">the overall integrity of the MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="1161">
                    <text>the knockout of the MEKK1 or MEKK2 expression that can disrupt the overall integrity of the MAPK pathway regulation has been identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">the knockout of the MEKK1 or MEKK2 expression</arg>
                    <arg n="1">the overall integrity of the MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="1162">
                    <text>the knockout of the MEKK1 or MEKK2 expression that can disrupt the overall integrity of the MAPK pathway regulation that has been identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">the knockout of the MEKK1 or MEKK2 expression</arg>
                    <arg n="1">the overall integrity of the MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="1163">
                    <text>the knockout of the MEKK1 or MEKK2 expression that has disrupted the overall integrity of the MAPK pathway regulation was identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">the knockout of the MEKK1 or MEKK2 expression</arg>
                    <arg n="1">the overall integrity of the MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="1164">
                    <text>the knockout of the MEKK1 or MEKK2 expression that interact with the keto groups of the base pair GO and C (blue) on either side of the dsDNA can disrupt the overall integrity of the MAPK pathway regulation.</text>
                    <arg n="0">the knockout of the MEKK1 or MEKK2 expression</arg>
                    <arg n="1">the overall integrity of the MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="1165">
                    <text>the knockout of the MEKK1 or MEKK2 expression that interacts with the keto and C group pair (blue) on both sides of the dsDNA can disrupt the overall integrity of the MAPK pathway regulation.</text>
                    <arg n="0">the knockout of the MEKK1 or MEKK2 expression</arg>
                    <arg n="1">the overall integrity of the MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="1166">
                    <text>this deletion broke a sequence of open reading frame disrupted in R (exon 5 spike).</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">open reading frame</arg>
                </example>
                <example src="PERMUTATE" no="1167">
                    <text>this deletion broke a sequence of the open reading frame disrupted in R (exon 5 spike).</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">the open reading frame</arg>
                </example>
                <example src="PERMUTATE" no="1168">
                    <text>this deletion broke a sequence of the open reading structure disrupted in R (exon 5 spike).</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">the open reading structure</arg>
                </example>
                <example src="PERMUTATE" no="1169">
                    <text>this deletion can disrupt with the base groups ceto and C (blue) on both sides of the dsDNA DNA and interrupt open reading frame.</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">open reading frame</arg>
                </example>
                <example src="PERMUTATE" no="1170">
                    <text>this deletion can disrupt with the base groups ceto and C (blue) on both sides of the dsDNA DNA and interrupt the open reading frame.</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">the open reading frame</arg>
                </example>
                <example src="PERMUTATE" no="1171">
                    <text>this deletion can disrupt with the base groups ceto and C (blue) on both sides of the dsDNA DNA and interrupt the open reading structure.</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">the open reading structure</arg>
                </example>
                <example src="PERMUTATE" no="1172">
                    <text>this deletion that can disrupt open reading frame has been identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">open reading frame</arg>
                </example>
                <example src="PERMUTATE" no="1173">
                    <text>this deletion that can disrupt open reading frame that has been identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">open reading frame</arg>
                </example>
                <example src="PERMUTATE" no="1174">
                    <text>this deletion that can disrupt the open reading frame has been identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">the open reading frame</arg>
                </example>
                <example src="PERMUTATE" no="1175">
                    <text>this deletion that can disrupt the open reading frame that has been identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">the open reading frame</arg>
                </example>
                <example src="PERMUTATE" no="1176">
                    <text>this deletion that can disrupt the open reading structure has been identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">the open reading structure</arg>
                </example>
                <example src="PERMUTATE" no="1177">
                    <text>this deletion that can disrupt the open reading structure that has been identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">the open reading structure</arg>
                </example>
                <example src="PERMUTATE" no="1178">
                    <text>this deletion that has disrupted open reading frame was identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">open reading frame</arg>
                </example>
                <example src="PERMUTATE" no="1179">
                    <text>this deletion that has disrupted the open reading frame was identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">the open reading frame</arg>
                </example>
                <example src="PERMUTATE" no="1180">
                    <text>this deletion that has disrupted the open reading structure was identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">the open reading structure</arg>
                </example>
                <example src="PERMUTATE" no="1181">
                    <text>this deletion that interact with the keto groups of the base pair GO and C (blue) on either side of the dsDNA can disrupt open reading frame.</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">open reading frame</arg>
                </example>
                <example src="PERMUTATE" no="1182">
                    <text>this deletion that interact with the keto groups of the base pair GO and C (blue) on either side of the dsDNA can disrupt the open reading frame.</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">the open reading frame</arg>
                </example>
                <example src="PERMUTATE" no="1183">
                    <text>this deletion that interact with the keto groups of the base pair GO and C (blue) on either side of the dsDNA can disrupt the open reading structure.</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">the open reading structure</arg>
                </example>
                <example src="PERMUTATE" no="1184">
                    <text>this deletion that interacts with the keto and C group pair (blue) on both sides of the dsDNA can disrupt open reading frame.</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">open reading frame</arg>
                </example>
                <example src="PERMUTATE" no="1185">
                    <text>this deletion that interacts with the keto and C group pair (blue) on both sides of the dsDNA can disrupt the open reading frame.</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">the open reading frame</arg>
                </example>
                <example src="PERMUTATE" no="1186">
                    <text>this deletion that interacts with the keto and C group pair (blue) on both sides of the dsDNA can disrupt the open reading structure.</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">the open reading structure</arg>
                </example>
                <example src="PERMUTATE" no="1187">
                    <text>this suppression broke the consensus signal 5 and disrupted to the exon is omitted.</text>
                    <arg n="0">this suppression</arg>
                    <arg n="1">consensus signal 5</arg>
                    <arg n="R">exon is omitted</arg>
                </example>
                <example src="PERMUTATE" no="1188">
                    <text>this suppression have perturbed consensus signal 5 and disrupted in exon is omitted.</text>
                    <arg n="0">this suppression</arg>
                    <arg n="1">consensus signal 5</arg>
                    <arg n="R">exon is omitted</arg>
                </example>
                <example src="PERMUTATE" no="1189">
                    <text>this suppression rupture of consensus signal 5 may disrupting in exon is omitted.</text>
                    <arg n="0">this suppression</arg>
                    <arg n="1">consensus signal 5</arg>
                    <arg n="R">exon is omitted</arg>
                </example>
                <example src="REPLACE" no="1">
                    <text>A mutation 415G4 broke a sequence of slicing enhancer sequnce: (GAR)n-(GAR)n disrupted in R (exon 5 spike).</text>
                    <arg n="0">A mutation 415G4</arg>
                    <arg n="1">slicing enhancer sequnce: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="2">
                    <text>A mutation 415G4 can disrupt with the base groups ceto and C (blue) on both sides of the dsDNA DNA and interrupt slicing enhancer sequnce: (GAR)n-(GAR)n.</text>
                    <arg n="0">A mutation 415G4</arg>
                    <arg n="1">slicing enhancer sequnce: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="3">
                    <text>A mutation 415G4 that broke A1 will be identified in the siblings disrupted by classical abetalipoproteinemia.</text>
                    <arg n="0">A mutation 415G4</arg>
                </example>
                <example src="REPLACE" no="4">
                    <text>A mutation 415G4 that can disrupt slicing enhancer sequnce: (GAR)n-(GAR)n has been identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">A mutation 415G4</arg>
                    <arg n="1">slicing enhancer sequnce: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="5">
                    <text>A mutation 415G4 that can disrupt slicing enhancer sequnce: (GAR)n-(GAR)n that has been identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">A mutation 415G4</arg>
                    <arg n="1">slicing enhancer sequnce: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="6">
                    <text>A mutation 415G4 that has disrupted A1 will be identified in the affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">A mutation 415G4</arg>
                </example>
                <example src="REPLACE" no="7">
                    <text>A mutation 415G4 that has disrupted slicing enhancer sequnce: (GAR)n-(GAR)n was identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">A mutation 415G4</arg>
                    <arg n="1">slicing enhancer sequnce: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="8">
                    <text>A mutation 415G4 that interact with the keto groups of the base pair GO and C (blue) on either side of the dsDNA can disrupt slicing enhancer sequnce: (GAR)n-(GAR)n.</text>
                    <arg n="0">A mutation 415G4</arg>
                    <arg n="1">slicing enhancer sequnce: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="9">
                    <text>A mutation 415G4 that interacts with the keto and C group pair (blue) on both sides of the dsDNA can disrupt slicing enhancer sequnce: (GAR)n-(GAR)n.</text>
                    <arg n="0">A mutation 415G4</arg>
                    <arg n="1">slicing enhancer sequnce: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="10">
                    <text>Arg99 and Arg253 that broke A1 will be identified in the siblings disrupted by classical abetalipoproteinemia.</text>
                    <arg n="0">Arg99 and Arg253</arg>
                </example>
                <example src="REPLACE" no="11">
                    <text>Arg99 and Arg253 that has disrupted A1 will be identified in the affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">Arg99 and Arg253</arg>
                </example>
                <example src="REPLACE" no="12">
                    <text>It has been shown that Lys147Ala substitution interrupts interaction and disrupt to a drastic drop of activity against GO:C substrates.</text>
                    <arg n="0">Lys147Ala substitution</arg>
                    <arg n="1">interaction</arg>
                    <arg n="R">a drastic drop of activity against GO:C substrates</arg>
                </example>
                <example src="REPLACE" no="13">
                    <text>It has been shown that Multations in p53 interrupts posts of checkpoints to DNA damage and disrupt to the potential for genome destabilization.</text>
                    <arg n="0">Multations in p53</arg>
                    <arg n="1">posts of checkpoints to DNA damage</arg>
                    <arg n="R">the potential for genome destabilization</arg>
                </example>
                <example src="REPLACE" no="14">
                    <text>It has been shown that Multations in p53 interrupts responses of checkpoints to DNA damage and disrupt to the potential for genome destabilization.</text>
                    <arg n="0">Multations in p53</arg>
                    <arg n="1">responses of checkpoints to DNA damage</arg>
                    <arg n="R">the potential for genome destabilization</arg>
                </example>
                <example src="REPLACE" no="15">
                    <text>It has been shown that These mutations interrupts ubiquitin binding function and disrupt to abnormal NF-kappaB pathway activation and subsequent osteoclast activation.</text>
                    <arg n="0">These mutations</arg>
                    <arg n="1">ubiquitin binding function</arg>
                    <arg n="R">abnormal NF-kappaB pathway activation and subsequent osteoclast activation</arg>
                </example>
                <example src="REPLACE" no="16">
                    <text>It has been shown that This deletion interrupts consensus coupling signal 5 and disrupt to exon exhaustion.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">consensus coupling signal 5</arg>
                    <arg n="R">exon exhaustion</arg>
                </example>
                <example src="REPLACE" no="17">
                    <text>It has been shown that This deletion interrupts the 5 consensus of splice signal and disrupt to exon exhaustion.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">the 5 consensus of splice signal</arg>
                    <arg n="R">exon exhaustion</arg>
                </example>
                <example src="REPLACE" no="18">
                    <text>It has been shown that This deletion interrupts the 5th consensus of the cut signal and disrupt to exon exhaustion.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">the 5th consensus of the cut signal</arg>
                    <arg n="R">exon exhaustion</arg>
                </example>
                <example src="REPLACE" no="19">
                    <text>It has been shown that This deletion interrupts the splice signal consensus 5 and disrupt to exon exhaustion.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">the splice signal consensus 5</arg>
                    <arg n="R">exon exhaustion</arg>
                </example>
                <example src="REPLACE" no="20">
                    <text>It has been shown that manipulation of the Tie-2 system in tumors interrupts tumour vessels and disrupt to lateral effects on peripheral nerves.</text>
                    <arg n="0">manipulation of the Tie-2 system in tumors</arg>
                    <arg n="1">tumour vessels</arg>
                    <arg n="R">lateral effects on peripheral nerves</arg>
                </example>
                <example src="REPLACE" no="21">
                    <text>It has been shown that multations at p53 interrupts post-checking points for DNA damage and disrupt to the potential for destabilization of the genome.</text>
                    <arg n="0">multations at p53</arg>
                    <arg n="1">post-checking points for DNA damage</arg>
                    <arg n="R">the potential for destabilization of the genome</arg>
                </example>
                <example src="REPLACE" no="22">
                    <text>It has been shown that mutations in this region interrupts assembly of keratin filaments and disrupt to degeneration or cytolysis of keratinocytes.</text>
                    <arg n="0">mutations in this region</arg>
                    <arg n="1">assembly of keratin filaments</arg>
                    <arg n="R">degeneration or cytolysis of keratinocytes</arg>
                </example>
                <example src="REPLACE" no="23">
                    <text>It has been shown that mutations in this region interrupts assembly of keratin filaments and disrupt to degeneration or keratinocyte cytolysis.</text>
                    <arg n="0">mutations in this region</arg>
                    <arg n="1">assembly of keratin filaments</arg>
                    <arg n="R">degeneration or keratinocyte cytolysis</arg>
                </example>
                <example src="REPLACE" no="24">
                    <text>It has been shown that p53 mutations interrupts checking point responses for DNA damage and disrupt to the potential for destabilization of the genome.</text>
                    <arg n="0">p53 mutations</arg>
                    <arg n="1">checking point responses for DNA damage</arg>
                    <arg n="R">the potential for destabilization of the genome</arg>
                </example>
                <example src="REPLACE" no="25">
                    <text>It has been shown that such mutations interrupts the ubiquitin binding function and disrupt to abnormal activation of the NF-kappaB pathway and subsequent activation of the.</text>
                    <arg n="0">such mutations</arg>
                    <arg n="1">the ubiquitin binding function</arg>
                    <arg n="R">abnormal activation of the NF-kappaB pathway and subsequent activation of the</arg>
                </example>
                <example src="REPLACE" no="26">
                    <text>It has been shown that such mutations interrupts the ubiquitin-binding function and disrupt to abnormal activation of the NF-kappaB pathway and subsequent activation of the.</text>
                    <arg n="0">such mutations</arg>
                    <arg n="1">the ubiquitin-binding function</arg>
                    <arg n="R">abnormal activation of the NF-kappaB pathway and subsequent activation of the</arg>
                </example>
                <example src="REPLACE" no="27">
                    <text>It has been shown that the Lys147Ala substitution interrupts the interaction and disrupt to a drastic decrease in activity against GO:C substrates.</text>
                    <arg n="0">the Lys147Ala substitution</arg>
                    <arg n="1">the interaction</arg>
                    <arg n="R">a drastic decrease in activity against GO:C substrates</arg>
                </example>
                <example src="REPLACE" no="28">
                    <text>It has been shown that the Lys147Ala substitution interrupts the interaction and disrupt to a drastic decrease of activity against GO:C substrates.</text>
                    <arg n="0">the Lys147Ala substitution</arg>
                    <arg n="1">the interaction</arg>
                    <arg n="R">a drastic decrease of activity against GO:C substrates</arg>
                </example>
                <example src="REPLACE" no="29">
                    <text>It has been shown that this deletion interrupts consensus signal 5 and disrupt to exon skipping.</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">consensus signal 5</arg>
                    <arg n="R">exon skipping</arg>
                </example>
                <example src="REPLACE" no="30">
                    <text>It has been shown that this suppression interrupts consensus signal 5 and disrupt to exon signal.</text>
                    <arg n="0">this suppression</arg>
                    <arg n="1">consensus signal 5</arg>
                    <arg n="R">exon signal</arg>
                </example>
                <example src="REPLACE" no="31">
                    <text>It has been shown that tumour binding system 2 maneuver interrupts tumour vessels and disrupt to similar effects on peripheral nerves.</text>
                    <arg n="0">tumour binding system 2 maneuver</arg>
                    <arg n="1">tumour vessels</arg>
                    <arg n="R">similar effects on peripheral nerves</arg>
                </example>
                <example src="REPLACE" no="32">
                    <text>It is important to note that A mutation 415G4 disrupt slicing enhancer sequnce: (GAR)n-(GAR)n.</text>
                    <arg n="0">A mutation 415G4</arg>
                    <arg n="1">slicing enhancer sequnce: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="33">
                    <text>It is important to note that Lys147Ala substitution disrupt interaction.</text>
                    <arg n="0">Lys147Ala substitution</arg>
                    <arg n="1">interaction</arg>
                </example>
                <example src="REPLACE" no="34">
                    <text>It is important to note that Multations in p53 disrupt posts of checkpoints to DNA damage.</text>
                    <arg n="0">Multations in p53</arg>
                    <arg n="1">posts of checkpoints to DNA damage</arg>
                </example>
                <example src="REPLACE" no="35">
                    <text>It is important to note that Multations in p53 disrupt responses of checkpoints to DNA damage.</text>
                    <arg n="0">Multations in p53</arg>
                    <arg n="1">responses of checkpoints to DNA damage</arg>
                </example>
                <example src="REPLACE" no="36">
                    <text>It is important to note that Mutation 415G4 disrupt licensing improvement sequence: (GAR)n-(GAR)n.</text>
                    <arg n="0">Mutation 415G4</arg>
                    <arg n="1">licensing improvement sequence: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="37">
                    <text>It is important to note that Mutations in p53 disrupt responses of checkpoints to DNA damage.</text>
                    <arg n="0">Mutations in p53</arg>
                    <arg n="1">responses of checkpoints to DNA damage</arg>
                </example>
                <example src="REPLACE" no="38">
                    <text>It is important to note that R142X disrupt a splicing enhancer.</text>
                    <arg n="0">R142X</arg>
                    <arg n="1">a splicing enhancer</arg>
                </example>
                <example src="REPLACE" no="39">
                    <text>It is important to note that R142X disrupt a splicing power.</text>
                    <arg n="0">R142X</arg>
                    <arg n="1">a splicing power</arg>
                </example>
                <example src="REPLACE" no="40">
                    <text>It is important to note that The 415G4 mutation disrupt enhancer spike: (GAR)n-(GAR)n.</text>
                    <arg n="0">The 415G4 mutation</arg>
                    <arg n="1">enhancer spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="41">
                    <text>It is important to note that The 415G4 mutation disrupt powerers spike: (GAR)n-(GAR)n.</text>
                    <arg n="0">The 415G4 mutation</arg>
                    <arg n="1">powerers spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="42">
                    <text>It is important to note that The mutation 415G4 disrupt enhancement brush: (GAR)n-(GAR)n.</text>
                    <arg n="0">The mutation 415G4</arg>
                    <arg n="1">enhancement brush: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="43">
                    <text>It is important to note that The mutation 415G4 disrupt potent spike: (GAR)n-(GAR)n.</text>
                    <arg n="0">The mutation 415G4</arg>
                    <arg n="1">potent spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="44">
                    <text>It is important to note that These mutations disrupt ubiquitin binding function.</text>
                    <arg n="0">These mutations</arg>
                    <arg n="1">ubiquitin binding function</arg>
                </example>
                <example src="REPLACE" no="45">
                    <text>It is important to note that This deletion disrupt consensus coupling signal 5.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">consensus coupling signal 5</arg>
                </example>
                <example src="REPLACE" no="46">
                    <text>It is important to note that This deletion disrupt the 5 consensus of splice signal.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">the 5 consensus of splice signal</arg>
                </example>
                <example src="REPLACE" no="47">
                    <text>It is important to note that This deletion disrupt the 5th consensus of the cut signal.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">the 5th consensus of the cut signal</arg>
                </example>
                <example src="REPLACE" no="48">
                    <text>It is important to note that This deletion disrupt the splice signal consensus 5.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">the splice signal consensus 5</arg>
                </example>
                <example src="REPLACE" no="49">
                    <text>It is important to note that a 415G4 mutation disrupt licensing improvement sequence: (GAR)n-(GAR)n.</text>
                    <arg n="0">a 415G4 mutation</arg>
                    <arg n="1">licensing improvement sequence: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="50">
                    <text>It is important to note that a homozygotic mutation disrupt splicing.</text>
                    <arg n="0">a homozygotic mutation</arg>
                    <arg n="1">splicing</arg>
                </example>
                <example src="REPLACE" no="51">
                    <text>It is important to note that blocking the expression MEKK1 or MEKK2 disrupt the overall integrity of the MAPK route regulation.</text>
                    <arg n="0">blocking the expression MEKK1 or MEKK2</arg>
                    <arg n="1">the overall integrity of the MAPK route regulation</arg>
                </example>
                <example src="REPLACE" no="52">
                    <text>It is important to note that homozygous mutation disrupt splicing.</text>
                    <arg n="0">homozygous mutation</arg>
                    <arg n="1">splicing</arg>
                </example>
                <example src="REPLACE" no="53">
                    <text>It is important to note that inhibition of inflammation disrupt physiological protective responses.</text>
                    <arg n="0">inhibition of inflammation</arg>
                    <arg n="1">physiological protective responses</arg>
                </example>
                <example src="REPLACE" no="54">
                    <text>It is important to note that inhibition of inflammation disrupt protective physiological response.</text>
                    <arg n="0">inhibition of inflammation</arg>
                    <arg n="1">protective physiological response</arg>
                </example>
                <example src="REPLACE" no="55">
                    <text>It is important to note that manipulation of the Tie-2 system in tumors disrupt tumour vessels.</text>
                    <arg n="0">manipulation of the Tie-2 system in tumors</arg>
                    <arg n="1">tumour vessels</arg>
                </example>
                <example src="REPLACE" no="56">
                    <text>It is important to note that manipulation of the binding system 2 in tumours disrupt tumor vessels.</text>
                    <arg n="0">manipulation of the binding system 2 in tumours</arg>
                    <arg n="1">tumor vessels</arg>
                </example>
                <example src="REPLACE" no="57">
                    <text>It is important to note that multations at p53 disrupt post-checking points for DNA damage.</text>
                    <arg n="0">multations at p53</arg>
                    <arg n="1">post-checking points for DNA damage</arg>
                </example>
                <example src="REPLACE" no="58">
                    <text>It is important to note that mutation 415G4 disrupt pulling enhancement sequence: (GAR)n-(GAR)n.</text>
                    <arg n="0">mutation 415G4</arg>
                    <arg n="1">pulling enhancement sequence: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="59">
                    <text>It is important to note that mutation 415G4 disrupt splicing sequencer: (GAR)n-(GAR)n.</text>
                    <arg n="0">mutation 415G4</arg>
                    <arg n="1">splicing sequencer: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="60">
                    <text>It is important to note that mutations in this region disrupt assembly of keratin filaments.</text>
                    <arg n="0">mutations in this region</arg>
                    <arg n="1">assembly of keratin filaments</arg>
                </example>
                <example src="REPLACE" no="61">
                    <text>It is important to note that p53 mutations disrupt checking point responses for DNA damage.</text>
                    <arg n="0">p53 mutations</arg>
                    <arg n="1">checking point responses for DNA damage</arg>
                </example>
                <example src="REPLACE" no="62">
                    <text>It is important to note that such mutations disrupt the ubiquitin binding function.</text>
                    <arg n="0">such mutations</arg>
                    <arg n="1">the ubiquitin binding function</arg>
                </example>
                <example src="REPLACE" no="63">
                    <text>It is important to note that such mutations disrupt the ubiquitin-binding function.</text>
                    <arg n="0">such mutations</arg>
                    <arg n="1">the ubiquitin-binding function</arg>
                </example>
                <example src="REPLACE" no="64">
                    <text>It is important to note that the Lys147Ala substitution disrupt the interaction.</text>
                    <arg n="0">the Lys147Ala substitution</arg>
                    <arg n="1">the interaction</arg>
                </example>
                <example src="REPLACE" no="65">
                    <text>It is important to note that the findings disrupt that A mutation 415G4 has not interrupts slicing enhancer sequnce: (GAR)n-(GAR)n.</text>
                    <arg n="0">A mutation 415G4</arg>
                    <arg n="1">slicing enhancer sequnce: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="66">
                    <text>It is important to note that the findings disrupt that Lys147Ala substitution has not interrupts interaction.</text>
                    <arg n="0">Lys147Ala substitution</arg>
                    <arg n="1">interaction</arg>
                </example>
                <example src="REPLACE" no="67">
                    <text>It is important to note that the findings disrupt that Multations in p53 has not interrupts posts of checkpoints to DNA damage.</text>
                    <arg n="0">Multations in p53</arg>
                    <arg n="1">posts of checkpoints to DNA damage</arg>
                </example>
                <example src="REPLACE" no="68">
                    <text>It is important to note that the findings disrupt that Multations in p53 has not interrupts responses of checkpoints to DNA damage.</text>
                    <arg n="0">Multations in p53</arg>
                    <arg n="1">responses of checkpoints to DNA damage</arg>
                </example>
                <example src="REPLACE" no="69">
                    <text>It is important to note that the findings disrupt that Mutation 415G4 has not interrupts licensing improvement sequence: (GAR)n-(GAR)n.</text>
                    <arg n="0">Mutation 415G4</arg>
                    <arg n="1">licensing improvement sequence: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="70">
                    <text>It is important to note that the findings disrupt that Mutations in p53 has not interrupts responses of checkpoints to DNA damage.</text>
                    <arg n="0">Mutations in p53</arg>
                    <arg n="1">responses of checkpoints to DNA damage</arg>
                </example>
                <example src="REPLACE" no="71">
                    <text>It is important to note that the findings disrupt that R142X has not interrupts a splicing enhancer.</text>
                    <arg n="0">R142X</arg>
                    <arg n="1">a splicing enhancer</arg>
                </example>
                <example src="REPLACE" no="72">
                    <text>It is important to note that the findings disrupt that R142X has not interrupts a splicing power.</text>
                    <arg n="0">R142X</arg>
                    <arg n="1">a splicing power</arg>
                </example>
                <example src="REPLACE" no="73">
                    <text>It is important to note that the findings disrupt that The 415G4 mutation has not interrupts enhancer spike: (GAR)n-(GAR)n.</text>
                    <arg n="0">The 415G4 mutation</arg>
                    <arg n="1">enhancer spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="74">
                    <text>It is important to note that the findings disrupt that The 415G4 mutation has not interrupts powerers spike: (GAR)n-(GAR)n.</text>
                    <arg n="0">The 415G4 mutation</arg>
                    <arg n="1">powerers spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="75">
                    <text>It is important to note that the findings disrupt that The mutation 415G4 has not interrupts enhancement brush: (GAR)n-(GAR)n.</text>
                    <arg n="0">The mutation 415G4</arg>
                    <arg n="1">enhancement brush: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="76">
                    <text>It is important to note that the findings disrupt that The mutation 415G4 has not interrupts potent spike: (GAR)n-(GAR)n.</text>
                    <arg n="0">The mutation 415G4</arg>
                    <arg n="1">potent spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="77">
                    <text>It is important to note that the findings disrupt that These mutations has not interrupts ubiquitin binding function.</text>
                    <arg n="0">These mutations</arg>
                    <arg n="1">ubiquitin binding function</arg>
                </example>
                <example src="REPLACE" no="78">
                    <text>It is important to note that the findings disrupt that This deletion has not interrupts consensus coupling signal 5.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">consensus coupling signal 5</arg>
                </example>
                <example src="REPLACE" no="79">
                    <text>It is important to note that the findings disrupt that This deletion has not interrupts the 5 consensus of splice signal.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">the 5 consensus of splice signal</arg>
                </example>
                <example src="REPLACE" no="80">
                    <text>It is important to note that the findings disrupt that This deletion has not interrupts the 5th consensus of the cut signal.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">the 5th consensus of the cut signal</arg>
                </example>
                <example src="REPLACE" no="81">
                    <text>It is important to note that the findings disrupt that This deletion has not interrupts the splice signal consensus 5.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">the splice signal consensus 5</arg>
                </example>
                <example src="REPLACE" no="82">
                    <text>It is important to note that the findings disrupt that a 415G4 mutation has not interrupts licensing improvement sequence: (GAR)n-(GAR)n.</text>
                    <arg n="0">a 415G4 mutation</arg>
                    <arg n="1">licensing improvement sequence: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="83">
                    <text>It is important to note that the findings disrupt that a homozygotic mutation has not interrupts splicing.</text>
                    <arg n="0">a homozygotic mutation</arg>
                    <arg n="1">splicing</arg>
                </example>
                <example src="REPLACE" no="84">
                    <text>It is important to note that the findings disrupt that blocking the expression MEKK1 or MEKK2 has not interrupts the overall integrity of the MAPK route regulation.</text>
                    <arg n="0">blocking the expression MEKK1 or MEKK2</arg>
                    <arg n="1">the overall integrity of the MAPK route regulation</arg>
                </example>
                <example src="REPLACE" no="85">
                    <text>It is important to note that the findings disrupt that homozygous mutation has not interrupts splicing.</text>
                    <arg n="0">homozygous mutation</arg>
                    <arg n="1">splicing</arg>
                </example>
                <example src="REPLACE" no="86">
                    <text>It is important to note that the findings disrupt that inhibition of inflammation has not interrupts physiological protective responses.</text>
                    <arg n="0">inhibition of inflammation</arg>
                    <arg n="1">physiological protective responses</arg>
                </example>
                <example src="REPLACE" no="87">
                    <text>It is important to note that the findings disrupt that inhibition of inflammation has not interrupts protective physiological response.</text>
                    <arg n="0">inhibition of inflammation</arg>
                    <arg n="1">protective physiological response</arg>
                </example>
                <example src="REPLACE" no="88">
                    <text>It is important to note that the findings disrupt that manipulation of the Tie-2 system in tumors has not interrupts tumour vessels.</text>
                    <arg n="0">manipulation of the Tie-2 system in tumors</arg>
                    <arg n="1">tumour vessels</arg>
                </example>
                <example src="REPLACE" no="89">
                    <text>It is important to note that the findings disrupt that manipulation of the binding system 2 in tumours has not interrupts tumor vessels.</text>
                    <arg n="0">manipulation of the binding system 2 in tumours</arg>
                    <arg n="1">tumor vessels</arg>
                </example>
                <example src="REPLACE" no="90">
                    <text>It is important to note that the findings disrupt that multations at p53 has not interrupts post-checking points for DNA damage.</text>
                    <arg n="0">multations at p53</arg>
                    <arg n="1">post-checking points for DNA damage</arg>
                </example>
                <example src="REPLACE" no="91">
                    <text>It is important to note that the findings disrupt that mutation 415G4 has not interrupts pulling enhancement sequence: (GAR)n-(GAR)n.</text>
                    <arg n="0">mutation 415G4</arg>
                    <arg n="1">pulling enhancement sequence: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="92">
                    <text>It is important to note that the findings disrupt that mutation 415G4 has not interrupts splicing sequencer: (GAR)n-(GAR)n.</text>
                    <arg n="0">mutation 415G4</arg>
                    <arg n="1">splicing sequencer: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="93">
                    <text>It is important to note that the findings disrupt that mutations in this region has not interrupts assembly of keratin filaments.</text>
                    <arg n="0">mutations in this region</arg>
                    <arg n="1">assembly of keratin filaments</arg>
                </example>
                <example src="REPLACE" no="94">
                    <text>It is important to note that the findings disrupt that p53 mutations has not interrupts checking point responses for DNA damage.</text>
                    <arg n="0">p53 mutations</arg>
                    <arg n="1">checking point responses for DNA damage</arg>
                </example>
                <example src="REPLACE" no="95">
                    <text>It is important to note that the findings disrupt that such mutations has not interrupts the ubiquitin binding function.</text>
                    <arg n="0">such mutations</arg>
                    <arg n="1">the ubiquitin binding function</arg>
                </example>
                <example src="REPLACE" no="96">
                    <text>It is important to note that the findings disrupt that such mutations has not interrupts the ubiquitin-binding function.</text>
                    <arg n="0">such mutations</arg>
                    <arg n="1">the ubiquitin-binding function</arg>
                </example>
                <example src="REPLACE" no="97">
                    <text>It is important to note that the findings disrupt that the Lys147Ala substitution has not interrupts the interaction.</text>
                    <arg n="0">the Lys147Ala substitution</arg>
                    <arg n="1">the interaction</arg>
                </example>
                <example src="REPLACE" no="98">
                    <text>It is important to note that the findings disrupt that these mutations has not interrupts biquitin binding function.</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">biquitin binding function</arg>
                </example>
                <example src="REPLACE" no="99">
                    <text>It is important to note that the findings disrupt that this deletion has not interrupts consensus signal 5.</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">consensus signal 5</arg>
                </example>
                <example src="REPLACE" no="100">
                    <text>It is important to note that the findings disrupt that this suppression has not interrupts consensus signal 5.</text>
                    <arg n="0">this suppression</arg>
                    <arg n="1">consensus signal 5</arg>
                </example>
                <example src="REPLACE" no="101">
                    <text>It is important to note that the findings disrupt that tumour binding system 2 maneuver has not interrupts tumour vessels.</text>
                    <arg n="0">tumour binding system 2 maneuver</arg>
                    <arg n="1">tumour vessels</arg>
                </example>
                <example src="REPLACE" no="102">
                    <text>It is important to note that the findings show that A mutation 415G4 will disrupt no slicing enhancer sequnce: (GAR)n-(GAR)n.</text>
                    <arg n="0">A mutation 415G4</arg>
                    <arg n="1">slicing enhancer sequnce: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="103">
                    <text>It is important to note that the findings show that Lys147Ala substitution will disrupt no interaction.</text>
                    <arg n="0">Lys147Ala substitution</arg>
                    <arg n="1">interaction</arg>
                </example>
                <example src="REPLACE" no="104">
                    <text>It is important to note that the findings show that Multations in p53 will disrupt no posts of checkpoints to DNA damage.</text>
                    <arg n="0">Multations in p53</arg>
                    <arg n="1">posts of checkpoints to DNA damage</arg>
                </example>
                <example src="REPLACE" no="105">
                    <text>It is important to note that the findings show that Multations in p53 will disrupt no responses of checkpoints to DNA damage.</text>
                    <arg n="0">Multations in p53</arg>
                    <arg n="1">responses of checkpoints to DNA damage</arg>
                </example>
                <example src="REPLACE" no="106">
                    <text>It is important to note that the findings show that Mutation 415G4 will disrupt no licensing improvement sequence: (GAR)n-(GAR)n.</text>
                    <arg n="0">Mutation 415G4</arg>
                    <arg n="1">licensing improvement sequence: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="107">
                    <text>It is important to note that the findings show that Mutations in p53 will disrupt no responses of checkpoints to DNA damage.</text>
                    <arg n="0">Mutations in p53</arg>
                    <arg n="1">responses of checkpoints to DNA damage</arg>
                </example>
                <example src="REPLACE" no="108">
                    <text>It is important to note that the findings show that R142X will disrupt no a splicing enhancer.</text>
                    <arg n="0">R142X</arg>
                    <arg n="1">a splicing enhancer</arg>
                </example>
                <example src="REPLACE" no="109">
                    <text>It is important to note that the findings show that R142X will disrupt no a splicing power.</text>
                    <arg n="0">R142X</arg>
                    <arg n="1">a splicing power</arg>
                </example>
                <example src="REPLACE" no="110">
                    <text>It is important to note that the findings show that The 415G4 mutation will disrupt no enhancer spike: (GAR)n-(GAR)n.</text>
                    <arg n="0">The 415G4 mutation</arg>
                    <arg n="1">enhancer spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="111">
                    <text>It is important to note that the findings show that The 415G4 mutation will disrupt no powerers spike: (GAR)n-(GAR)n.</text>
                    <arg n="0">The 415G4 mutation</arg>
                    <arg n="1">powerers spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="112">
                    <text>It is important to note that the findings show that The mutation 415G4 will disrupt no enhancement brush: (GAR)n-(GAR)n.</text>
                    <arg n="0">The mutation 415G4</arg>
                    <arg n="1">enhancement brush: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="113">
                    <text>It is important to note that the findings show that The mutation 415G4 will disrupt no potent spike: (GAR)n-(GAR)n.</text>
                    <arg n="0">The mutation 415G4</arg>
                    <arg n="1">potent spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="114">
                    <text>It is important to note that the findings show that These mutations will disrupt no ubiquitin binding function.</text>
                    <arg n="0">These mutations</arg>
                    <arg n="1">ubiquitin binding function</arg>
                </example>
                <example src="REPLACE" no="115">
                    <text>It is important to note that the findings show that This deletion will disrupt no consensus coupling signal 5.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">consensus coupling signal 5</arg>
                </example>
                <example src="REPLACE" no="116">
                    <text>It is important to note that the findings show that This deletion will disrupt no the 5 consensus of splice signal.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">the 5 consensus of splice signal</arg>
                </example>
                <example src="REPLACE" no="117">
                    <text>It is important to note that the findings show that This deletion will disrupt no the 5th consensus of the cut signal.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">the 5th consensus of the cut signal</arg>
                </example>
                <example src="REPLACE" no="118">
                    <text>It is important to note that the findings show that This deletion will disrupt no the splice signal consensus 5.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">the splice signal consensus 5</arg>
                </example>
                <example src="REPLACE" no="119">
                    <text>It is important to note that the findings show that a 415G4 mutation will disrupt no licensing improvement sequence: (GAR)n-(GAR)n.</text>
                    <arg n="0">a 415G4 mutation</arg>
                    <arg n="1">licensing improvement sequence: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="120">
                    <text>It is important to note that the findings show that a homozygotic mutation will disrupt no splicing.</text>
                    <arg n="0">a homozygotic mutation</arg>
                    <arg n="1">splicing</arg>
                </example>
                <example src="REPLACE" no="121">
                    <text>It is important to note that the findings show that blocking the expression MEKK1 or MEKK2 will disrupt no the overall integrity of the MAPK route regulation.</text>
                    <arg n="0">blocking the expression MEKK1 or MEKK2</arg>
                    <arg n="1">the overall integrity of the MAPK route regulation</arg>
                </example>
                <example src="REPLACE" no="122">
                    <text>It is important to note that the findings show that homozygous mutation will disrupt no splicing.</text>
                    <arg n="0">homozygous mutation</arg>
                    <arg n="1">splicing</arg>
                </example>
                <example src="REPLACE" no="123">
                    <text>It is important to note that the findings show that inhibition of inflammation will disrupt no physiological protective responses.</text>
                    <arg n="0">inhibition of inflammation</arg>
                    <arg n="1">physiological protective responses</arg>
                </example>
                <example src="REPLACE" no="124">
                    <text>It is important to note that the findings show that inhibition of inflammation will disrupt no protective physiological response.</text>
                    <arg n="0">inhibition of inflammation</arg>
                    <arg n="1">protective physiological response</arg>
                </example>
                <example src="REPLACE" no="125">
                    <text>It is important to note that the findings show that manipulation of the Tie-2 system in tumors will disrupt no tumour vessels.</text>
                    <arg n="0">manipulation of the Tie-2 system in tumors</arg>
                    <arg n="1">tumour vessels</arg>
                </example>
                <example src="REPLACE" no="126">
                    <text>It is important to note that the findings show that manipulation of the binding system 2 in tumours will disrupt no tumor vessels.</text>
                    <arg n="0">manipulation of the binding system 2 in tumours</arg>
                    <arg n="1">tumor vessels</arg>
                </example>
                <example src="REPLACE" no="127">
                    <text>It is important to note that the findings show that multations at p53 will disrupt no post-checking points for DNA damage.</text>
                    <arg n="0">multations at p53</arg>
                    <arg n="1">post-checking points for DNA damage</arg>
                </example>
                <example src="REPLACE" no="128">
                    <text>It is important to note that the findings show that mutation 415G4 will disrupt no pulling enhancement sequence: (GAR)n-(GAR)n.</text>
                    <arg n="0">mutation 415G4</arg>
                    <arg n="1">pulling enhancement sequence: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="129">
                    <text>It is important to note that the findings show that mutation 415G4 will disrupt no splicing sequencer: (GAR)n-(GAR)n.</text>
                    <arg n="0">mutation 415G4</arg>
                    <arg n="1">splicing sequencer: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="130">
                    <text>It is important to note that the findings show that mutations in this region will disrupt no assembly of keratin filaments.</text>
                    <arg n="0">mutations in this region</arg>
                    <arg n="1">assembly of keratin filaments</arg>
                </example>
                <example src="REPLACE" no="131">
                    <text>It is important to note that the findings show that p53 mutations will disrupt no checking point responses for DNA damage.</text>
                    <arg n="0">p53 mutations</arg>
                    <arg n="1">checking point responses for DNA damage</arg>
                </example>
                <example src="REPLACE" no="132">
                    <text>It is important to note that the findings show that such mutations will disrupt no the ubiquitin binding function.</text>
                    <arg n="0">such mutations</arg>
                    <arg n="1">the ubiquitin binding function</arg>
                </example>
                <example src="REPLACE" no="133">
                    <text>It is important to note that the findings show that such mutations will disrupt no the ubiquitin-binding function.</text>
                    <arg n="0">such mutations</arg>
                    <arg n="1">the ubiquitin-binding function</arg>
                </example>
                <example src="REPLACE" no="134">
                    <text>It is important to note that the findings show that the Lys147Ala substitution will disrupt no the interaction.</text>
                    <arg n="0">the Lys147Ala substitution</arg>
                    <arg n="1">the interaction</arg>
                </example>
                <example src="REPLACE" no="135">
                    <text>It is important to note that the findings show that these mutations will disrupt no biquitin binding function.</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">biquitin binding function</arg>
                </example>
                <example src="REPLACE" no="136">
                    <text>It is important to note that the findings show that this deletion will disrupt no consensus signal 5.</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">consensus signal 5</arg>
                </example>
                <example src="REPLACE" no="137">
                    <text>It is important to note that the findings show that this suppression will disrupt no consensus signal 5.</text>
                    <arg n="0">this suppression</arg>
                    <arg n="1">consensus signal 5</arg>
                </example>
                <example src="REPLACE" no="138">
                    <text>It is important to note that the findings show that tumour binding system 2 maneuver will disrupt no tumour vessels.</text>
                    <arg n="0">tumour binding system 2 maneuver</arg>
                    <arg n="1">tumour vessels</arg>
                </example>
                <example src="REPLACE" no="139">
                    <text>It is important to note that these mutations disrupt biquitin binding function.</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">biquitin binding function</arg>
                </example>
                <example src="REPLACE" no="140">
                    <text>It is important to note that this deletion disrupt consensus signal 5.</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">consensus signal 5</arg>
                </example>
                <example src="REPLACE" no="141">
                    <text>It is important to note that this suppression disrupt consensus signal 5.</text>
                    <arg n="0">this suppression</arg>
                    <arg n="1">consensus signal 5</arg>
                </example>
                <example src="REPLACE" no="142">
                    <text>It is important to note that tumour binding system 2 maneuver disrupt tumour vessels.</text>
                    <arg n="0">tumour binding system 2 maneuver</arg>
                    <arg n="1">tumour vessels</arg>
                </example>
                <example src="REPLACE" no="143">
                    <text>It is important to point out that A mutation 415G4 disrupt slicing enhancer sequnce: (GAR)n-(GAR)n.</text>
                    <arg n="0">A mutation 415G4</arg>
                    <arg n="1">slicing enhancer sequnce: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="144">
                    <text>It is important to point out that Lys147Ala substitution disrupt interaction.</text>
                    <arg n="0">Lys147Ala substitution</arg>
                    <arg n="1">interaction</arg>
                </example>
                <example src="REPLACE" no="145">
                    <text>It is important to point out that Multations in p53 disrupt posts of checkpoints to DNA damage.</text>
                    <arg n="0">Multations in p53</arg>
                    <arg n="1">posts of checkpoints to DNA damage</arg>
                </example>
                <example src="REPLACE" no="146">
                    <text>It is important to point out that Multations in p53 disrupt responses of checkpoints to DNA damage.</text>
                    <arg n="0">Multations in p53</arg>
                    <arg n="1">responses of checkpoints to DNA damage</arg>
                </example>
                <example src="REPLACE" no="147">
                    <text>It is important to point out that Mutation 415G4 disrupt licensing improvement sequence: (GAR)n-(GAR)n.</text>
                    <arg n="0">Mutation 415G4</arg>
                    <arg n="1">licensing improvement sequence: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="148">
                    <text>It is important to point out that Mutations in p53 disrupt responses of checkpoints to DNA damage.</text>
                    <arg n="0">Mutations in p53</arg>
                    <arg n="1">responses of checkpoints to DNA damage</arg>
                </example>
                <example src="REPLACE" no="149">
                    <text>It is important to point out that R142X disrupt a splicing enhancer.</text>
                    <arg n="0">R142X</arg>
                    <arg n="1">a splicing enhancer</arg>
                </example>
                <example src="REPLACE" no="150">
                    <text>It is important to point out that R142X disrupt a splicing power.</text>
                    <arg n="0">R142X</arg>
                    <arg n="1">a splicing power</arg>
                </example>
                <example src="REPLACE" no="151">
                    <text>It is important to point out that The 415G4 mutation disrupt enhancer spike: (GAR)n-(GAR)n.</text>
                    <arg n="0">The 415G4 mutation</arg>
                    <arg n="1">enhancer spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="152">
                    <text>It is important to point out that The 415G4 mutation disrupt powerers spike: (GAR)n-(GAR)n.</text>
                    <arg n="0">The 415G4 mutation</arg>
                    <arg n="1">powerers spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="153">
                    <text>It is important to point out that The mutation 415G4 disrupt enhancement brush: (GAR)n-(GAR)n.</text>
                    <arg n="0">The mutation 415G4</arg>
                    <arg n="1">enhancement brush: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="154">
                    <text>It is important to point out that The mutation 415G4 disrupt potent spike: (GAR)n-(GAR)n.</text>
                    <arg n="0">The mutation 415G4</arg>
                    <arg n="1">potent spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="155">
                    <text>It is important to point out that These mutations disrupt ubiquitin binding function.</text>
                    <arg n="0">These mutations</arg>
                    <arg n="1">ubiquitin binding function</arg>
                </example>
                <example src="REPLACE" no="156">
                    <text>It is important to point out that This deletion disrupt consensus coupling signal 5.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">consensus coupling signal 5</arg>
                </example>
                <example src="REPLACE" no="157">
                    <text>It is important to point out that This deletion disrupt the 5 consensus of splice signal.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">the 5 consensus of splice signal</arg>
                </example>
                <example src="REPLACE" no="158">
                    <text>It is important to point out that This deletion disrupt the 5th consensus of the cut signal.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">the 5th consensus of the cut signal</arg>
                </example>
                <example src="REPLACE" no="159">
                    <text>It is important to point out that This deletion disrupt the splice signal consensus 5.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">the splice signal consensus 5</arg>
                </example>
                <example src="REPLACE" no="160">
                    <text>It is important to point out that a 415G4 mutation disrupt licensing improvement sequence: (GAR)n-(GAR)n.</text>
                    <arg n="0">a 415G4 mutation</arg>
                    <arg n="1">licensing improvement sequence: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="161">
                    <text>It is important to point out that a homozygotic mutation disrupt splicing.</text>
                    <arg n="0">a homozygotic mutation</arg>
                    <arg n="1">splicing</arg>
                </example>
                <example src="REPLACE" no="162">
                    <text>It is important to point out that blocking the expression MEKK1 or MEKK2 disrupt the overall integrity of the MAPK route regulation.</text>
                    <arg n="0">blocking the expression MEKK1 or MEKK2</arg>
                    <arg n="1">the overall integrity of the MAPK route regulation</arg>
                </example>
                <example src="REPLACE" no="163">
                    <text>It is important to point out that homozygous mutation disrupt splicing.</text>
                    <arg n="0">homozygous mutation</arg>
                    <arg n="1">splicing</arg>
                </example>
                <example src="REPLACE" no="164">
                    <text>It is important to point out that inhibition of inflammation disrupt physiological protective responses.</text>
                    <arg n="0">inhibition of inflammation</arg>
                    <arg n="1">physiological protective responses</arg>
                </example>
                <example src="REPLACE" no="165">
                    <text>It is important to point out that inhibition of inflammation disrupt protective physiological response.</text>
                    <arg n="0">inhibition of inflammation</arg>
                    <arg n="1">protective physiological response</arg>
                </example>
                <example src="REPLACE" no="166">
                    <text>It is important to point out that manipulation of the Tie-2 system in tumors disrupt tumour vessels.</text>
                    <arg n="0">manipulation of the Tie-2 system in tumors</arg>
                    <arg n="1">tumour vessels</arg>
                </example>
                <example src="REPLACE" no="167">
                    <text>It is important to point out that manipulation of the binding system 2 in tumours disrupt tumor vessels.</text>
                    <arg n="0">manipulation of the binding system 2 in tumours</arg>
                    <arg n="1">tumor vessels</arg>
                </example>
                <example src="REPLACE" no="168">
                    <text>It is important to point out that multations at p53 disrupt post-checking points for DNA damage.</text>
                    <arg n="0">multations at p53</arg>
                    <arg n="1">post-checking points for DNA damage</arg>
                </example>
                <example src="REPLACE" no="169">
                    <text>It is important to point out that mutation 415G4 disrupt pulling enhancement sequence: (GAR)n-(GAR)n.</text>
                    <arg n="0">mutation 415G4</arg>
                    <arg n="1">pulling enhancement sequence: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="170">
                    <text>It is important to point out that mutation 415G4 disrupt splicing sequencer: (GAR)n-(GAR)n.</text>
                    <arg n="0">mutation 415G4</arg>
                    <arg n="1">splicing sequencer: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="171">
                    <text>It is important to point out that mutations in this region disrupt assembly of keratin filaments.</text>
                    <arg n="0">mutations in this region</arg>
                    <arg n="1">assembly of keratin filaments</arg>
                </example>
                <example src="REPLACE" no="172">
                    <text>It is important to point out that p53 mutations disrupt checking point responses for DNA damage.</text>
                    <arg n="0">p53 mutations</arg>
                    <arg n="1">checking point responses for DNA damage</arg>
                </example>
                <example src="REPLACE" no="173">
                    <text>It is important to point out that such mutations disrupt the ubiquitin binding function.</text>
                    <arg n="0">such mutations</arg>
                    <arg n="1">the ubiquitin binding function</arg>
                </example>
                <example src="REPLACE" no="174">
                    <text>It is important to point out that such mutations disrupt the ubiquitin-binding function.</text>
                    <arg n="0">such mutations</arg>
                    <arg n="1">the ubiquitin-binding function</arg>
                </example>
                <example src="REPLACE" no="175">
                    <text>It is important to point out that the Lys147Ala substitution disrupt the interaction.</text>
                    <arg n="0">the Lys147Ala substitution</arg>
                    <arg n="1">the interaction</arg>
                </example>
                <example src="REPLACE" no="176">
                    <text>It is important to point out that these mutations disrupt biquitin binding function.</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">biquitin binding function</arg>
                </example>
                <example src="REPLACE" no="177">
                    <text>It is important to point out that this deletion disrupt consensus signal 5.</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">consensus signal 5</arg>
                </example>
                <example src="REPLACE" no="178">
                    <text>It is important to point out that this suppression disrupt consensus signal 5.</text>
                    <arg n="0">this suppression</arg>
                    <arg n="1">consensus signal 5</arg>
                </example>
                <example src="REPLACE" no="179">
                    <text>It is important to point out that tumour binding system 2 maneuver disrupt tumour vessels.</text>
                    <arg n="0">tumour binding system 2 maneuver</arg>
                    <arg n="1">tumour vessels</arg>
                </example>
                <example src="REPLACE" no="180">
                    <text>It is important to stress that A mutation 415G4 could disrupt with slicing enhancer sequnce: (GAR)n-(GAR)n.</text>
                    <arg n="0">A mutation 415G4</arg>
                    <arg n="1">slicing enhancer sequnce: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="181">
                    <text>It is important to stress that A mutation 415G4 has the no that disrupt slicing enhancer sequnce: (GAR)n-(GAR)n.</text>
                    <arg n="0">A mutation 415G4</arg>
                    <arg n="1">slicing enhancer sequnce: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="182">
                    <text>It is important to stress that A mutation 415G4 is able to disrupt slicing enhancer sequnce: (GAR)n-(GAR)n.</text>
                    <arg n="0">A mutation 415G4</arg>
                    <arg n="1">slicing enhancer sequnce: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="183">
                    <text>It is important to stress that Lys147Ala substitution could disrupt with interaction.</text>
                    <arg n="0">Lys147Ala substitution</arg>
                    <arg n="1">interaction</arg>
                </example>
                <example src="REPLACE" no="184">
                    <text>It is important to stress that Lys147Ala substitution has the no that disrupt interaction.</text>
                    <arg n="0">Lys147Ala substitution</arg>
                    <arg n="1">interaction</arg>
                </example>
                <example src="REPLACE" no="185">
                    <text>It is important to stress that Lys147Ala substitution is able to disrupt interaction.</text>
                    <arg n="0">Lys147Ala substitution</arg>
                    <arg n="1">interaction</arg>
                </example>
                <example src="REPLACE" no="186">
                    <text>It is important to stress that Multations in p53 could disrupt with posts of checkpoints to DNA damage.</text>
                    <arg n="0">Multations in p53</arg>
                    <arg n="1">posts of checkpoints to DNA damage</arg>
                </example>
                <example src="REPLACE" no="187">
                    <text>It is important to stress that Multations in p53 could disrupt with responses of checkpoints to DNA damage.</text>
                    <arg n="0">Multations in p53</arg>
                    <arg n="1">responses of checkpoints to DNA damage</arg>
                </example>
                <example src="REPLACE" no="188">
                    <text>It is important to stress that Multations in p53 has the no that disrupt posts of checkpoints to DNA damage.</text>
                    <arg n="0">Multations in p53</arg>
                    <arg n="1">posts of checkpoints to DNA damage</arg>
                </example>
                <example src="REPLACE" no="189">
                    <text>It is important to stress that Multations in p53 has the no that disrupt responses of checkpoints to DNA damage.</text>
                    <arg n="0">Multations in p53</arg>
                    <arg n="1">responses of checkpoints to DNA damage</arg>
                </example>
                <example src="REPLACE" no="190">
                    <text>It is important to stress that Multations in p53 is able to disrupt posts of checkpoints to DNA damage.</text>
                    <arg n="0">Multations in p53</arg>
                    <arg n="1">posts of checkpoints to DNA damage</arg>
                </example>
                <example src="REPLACE" no="191">
                    <text>It is important to stress that Multations in p53 is able to disrupt responses of checkpoints to DNA damage.</text>
                    <arg n="0">Multations in p53</arg>
                    <arg n="1">responses of checkpoints to DNA damage</arg>
                </example>
                <example src="REPLACE" no="192">
                    <text>It is important to stress that Mutation 415G4 could disrupt with licensing improvement sequence: (GAR)n-(GAR)n.</text>
                    <arg n="0">Mutation 415G4</arg>
                    <arg n="1">licensing improvement sequence: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="193">
                    <text>It is important to stress that Mutation 415G4 has the no that disrupt licensing improvement sequence: (GAR)n-(GAR)n.</text>
                    <arg n="0">Mutation 415G4</arg>
                    <arg n="1">licensing improvement sequence: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="194">
                    <text>It is important to stress that Mutation 415G4 is able to disrupt licensing improvement sequence: (GAR)n-(GAR)n.</text>
                    <arg n="0">Mutation 415G4</arg>
                    <arg n="1">licensing improvement sequence: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="195">
                    <text>It is important to stress that Mutations in p53 could disrupt with responses of checkpoints to DNA damage.</text>
                    <arg n="0">Mutations in p53</arg>
                    <arg n="1">responses of checkpoints to DNA damage</arg>
                </example>
                <example src="REPLACE" no="196">
                    <text>It is important to stress that Mutations in p53 has the no that disrupt responses of checkpoints to DNA damage.</text>
                    <arg n="0">Mutations in p53</arg>
                    <arg n="1">responses of checkpoints to DNA damage</arg>
                </example>
                <example src="REPLACE" no="197">
                    <text>It is important to stress that Mutations in p53 is able to disrupt responses of checkpoints to DNA damage.</text>
                    <arg n="0">Mutations in p53</arg>
                    <arg n="1">responses of checkpoints to DNA damage</arg>
                </example>
                <example src="REPLACE" no="198">
                    <text>It is important to stress that R142X could disrupt with a splicing enhancer.</text>
                    <arg n="0">R142X</arg>
                    <arg n="1">a splicing enhancer</arg>
                </example>
                <example src="REPLACE" no="199">
                    <text>It is important to stress that R142X could disrupt with a splicing power.</text>
                    <arg n="0">R142X</arg>
                    <arg n="1">a splicing power</arg>
                </example>
                <example src="REPLACE" no="200">
                    <text>It is important to stress that R142X has the no that disrupt a splicing enhancer.</text>
                    <arg n="0">R142X</arg>
                    <arg n="1">a splicing enhancer</arg>
                </example>
                <example src="REPLACE" no="201">
                    <text>It is important to stress that R142X has the no that disrupt a splicing power.</text>
                    <arg n="0">R142X</arg>
                    <arg n="1">a splicing power</arg>
                </example>
                <example src="REPLACE" no="202">
                    <text>It is important to stress that R142X is able to disrupt a splicing enhancer.</text>
                    <arg n="0">R142X</arg>
                    <arg n="1">a splicing enhancer</arg>
                </example>
                <example src="REPLACE" no="203">
                    <text>It is important to stress that R142X is able to disrupt a splicing power.</text>
                    <arg n="0">R142X</arg>
                    <arg n="1">a splicing power</arg>
                </example>
                <example src="REPLACE" no="204">
                    <text>It is important to stress that The 415G4 mutation could disrupt with enhancer spike: (GAR)n-(GAR)n.</text>
                    <arg n="0">The 415G4 mutation</arg>
                    <arg n="1">enhancer spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="205">
                    <text>It is important to stress that The 415G4 mutation could disrupt with powerers spike: (GAR)n-(GAR)n.</text>
                    <arg n="0">The 415G4 mutation</arg>
                    <arg n="1">powerers spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="206">
                    <text>It is important to stress that The 415G4 mutation has the no that disrupt enhancer spike: (GAR)n-(GAR)n.</text>
                    <arg n="0">The 415G4 mutation</arg>
                    <arg n="1">enhancer spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="207">
                    <text>It is important to stress that The 415G4 mutation has the no that disrupt powerers spike: (GAR)n-(GAR)n.</text>
                    <arg n="0">The 415G4 mutation</arg>
                    <arg n="1">powerers spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="208">
                    <text>It is important to stress that The 415G4 mutation is able to disrupt enhancer spike: (GAR)n-(GAR)n.</text>
                    <arg n="0">The 415G4 mutation</arg>
                    <arg n="1">enhancer spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="209">
                    <text>It is important to stress that The 415G4 mutation is able to disrupt powerers spike: (GAR)n-(GAR)n.</text>
                    <arg n="0">The 415G4 mutation</arg>
                    <arg n="1">powerers spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="210">
                    <text>It is important to stress that The mutation 415G4 could disrupt with enhancement brush: (GAR)n-(GAR)n.</text>
                    <arg n="0">The mutation 415G4</arg>
                    <arg n="1">enhancement brush: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="211">
                    <text>It is important to stress that The mutation 415G4 could disrupt with potent spike: (GAR)n-(GAR)n.</text>
                    <arg n="0">The mutation 415G4</arg>
                    <arg n="1">potent spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="212">
                    <text>It is important to stress that The mutation 415G4 has the no that disrupt enhancement brush: (GAR)n-(GAR)n.</text>
                    <arg n="0">The mutation 415G4</arg>
                    <arg n="1">enhancement brush: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="213">
                    <text>It is important to stress that The mutation 415G4 has the no that disrupt potent spike: (GAR)n-(GAR)n.</text>
                    <arg n="0">The mutation 415G4</arg>
                    <arg n="1">potent spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="214">
                    <text>It is important to stress that The mutation 415G4 is able to disrupt enhancement brush: (GAR)n-(GAR)n.</text>
                    <arg n="0">The mutation 415G4</arg>
                    <arg n="1">enhancement brush: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="215">
                    <text>It is important to stress that The mutation 415G4 is able to disrupt potent spike: (GAR)n-(GAR)n.</text>
                    <arg n="0">The mutation 415G4</arg>
                    <arg n="1">potent spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="216">
                    <text>It is important to stress that These mutations could disrupt with ubiquitin binding function.</text>
                    <arg n="0">These mutations</arg>
                    <arg n="1">ubiquitin binding function</arg>
                </example>
                <example src="REPLACE" no="217">
                    <text>It is important to stress that These mutations has the no that disrupt ubiquitin binding function.</text>
                    <arg n="0">These mutations</arg>
                    <arg n="1">ubiquitin binding function</arg>
                </example>
                <example src="REPLACE" no="218">
                    <text>It is important to stress that These mutations is able to disrupt ubiquitin binding function.</text>
                    <arg n="0">These mutations</arg>
                    <arg n="1">ubiquitin binding function</arg>
                </example>
                <example src="REPLACE" no="219">
                    <text>It is important to stress that This deletion could disrupt with consensus coupling signal 5.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">consensus coupling signal 5</arg>
                </example>
                <example src="REPLACE" no="220">
                    <text>It is important to stress that This deletion could disrupt with the 5 consensus of splice signal.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">the 5 consensus of splice signal</arg>
                </example>
                <example src="REPLACE" no="221">
                    <text>It is important to stress that This deletion could disrupt with the 5th consensus of the cut signal.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">the 5th consensus of the cut signal</arg>
                </example>
                <example src="REPLACE" no="222">
                    <text>It is important to stress that This deletion could disrupt with the splice signal consensus 5.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">the splice signal consensus 5</arg>
                </example>
                <example src="REPLACE" no="223">
                    <text>It is important to stress that This deletion has the no that disrupt consensus coupling signal 5.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">consensus coupling signal 5</arg>
                </example>
                <example src="REPLACE" no="224">
                    <text>It is important to stress that This deletion has the no that disrupt the 5 consensus of splice signal.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">the 5 consensus of splice signal</arg>
                </example>
                <example src="REPLACE" no="225">
                    <text>It is important to stress that This deletion has the no that disrupt the 5th consensus of the cut signal.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">the 5th consensus of the cut signal</arg>
                </example>
                <example src="REPLACE" no="226">
                    <text>It is important to stress that This deletion has the no that disrupt the splice signal consensus 5.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">the splice signal consensus 5</arg>
                </example>
                <example src="REPLACE" no="227">
                    <text>It is important to stress that This deletion is able to disrupt consensus coupling signal 5.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">consensus coupling signal 5</arg>
                </example>
                <example src="REPLACE" no="228">
                    <text>It is important to stress that This deletion is able to disrupt the 5 consensus of splice signal.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">the 5 consensus of splice signal</arg>
                </example>
                <example src="REPLACE" no="229">
                    <text>It is important to stress that This deletion is able to disrupt the 5th consensus of the cut signal.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">the 5th consensus of the cut signal</arg>
                </example>
                <example src="REPLACE" no="230">
                    <text>It is important to stress that This deletion is able to disrupt the splice signal consensus 5.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">the splice signal consensus 5</arg>
                </example>
                <example src="REPLACE" no="231">
                    <text>It is important to stress that a 415G4 mutation could disrupt with licensing improvement sequence: (GAR)n-(GAR)n.</text>
                    <arg n="0">a 415G4 mutation</arg>
                    <arg n="1">licensing improvement sequence: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="232">
                    <text>It is important to stress that a 415G4 mutation has the no that disrupt licensing improvement sequence: (GAR)n-(GAR)n.</text>
                    <arg n="0">a 415G4 mutation</arg>
                    <arg n="1">licensing improvement sequence: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="233">
                    <text>It is important to stress that a 415G4 mutation is able to disrupt licensing improvement sequence: (GAR)n-(GAR)n.</text>
                    <arg n="0">a 415G4 mutation</arg>
                    <arg n="1">licensing improvement sequence: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="234">
                    <text>It is important to stress that a homozygotic mutation could disrupt with splicing.</text>
                    <arg n="0">a homozygotic mutation</arg>
                    <arg n="1">splicing</arg>
                </example>
                <example src="REPLACE" no="235">
                    <text>It is important to stress that a homozygotic mutation has the no that disrupt splicing.</text>
                    <arg n="0">a homozygotic mutation</arg>
                    <arg n="1">splicing</arg>
                </example>
                <example src="REPLACE" no="236">
                    <text>It is important to stress that a homozygotic mutation is able to disrupt splicing.</text>
                    <arg n="0">a homozygotic mutation</arg>
                    <arg n="1">splicing</arg>
                </example>
                <example src="REPLACE" no="237">
                    <text>It is important to stress that blocking the expression MEKK1 or MEKK2 could disrupt with the overall integrity of the MAPK route regulation.</text>
                    <arg n="0">blocking the expression MEKK1 or MEKK2</arg>
                    <arg n="1">the overall integrity of the MAPK route regulation</arg>
                </example>
                <example src="REPLACE" no="238">
                    <text>It is important to stress that blocking the expression MEKK1 or MEKK2 has the no that disrupt the overall integrity of the MAPK route regulation.</text>
                    <arg n="0">blocking the expression MEKK1 or MEKK2</arg>
                    <arg n="1">the overall integrity of the MAPK route regulation</arg>
                </example>
                <example src="REPLACE" no="239">
                    <text>It is important to stress that blocking the expression MEKK1 or MEKK2 is able to disrupt the overall integrity of the MAPK route regulation.</text>
                    <arg n="0">blocking the expression MEKK1 or MEKK2</arg>
                    <arg n="1">the overall integrity of the MAPK route regulation</arg>
                </example>
                <example src="REPLACE" no="240">
                    <text>It is important to stress that homozygous mutation could disrupt with splicing.</text>
                    <arg n="0">homozygous mutation</arg>
                    <arg n="1">splicing</arg>
                </example>
                <example src="REPLACE" no="241">
                    <text>It is important to stress that homozygous mutation has the no that disrupt splicing.</text>
                    <arg n="0">homozygous mutation</arg>
                    <arg n="1">splicing</arg>
                </example>
                <example src="REPLACE" no="242">
                    <text>It is important to stress that homozygous mutation is able to disrupt splicing.</text>
                    <arg n="0">homozygous mutation</arg>
                    <arg n="1">splicing</arg>
                </example>
                <example src="REPLACE" no="243">
                    <text>It is important to stress that inhibition of inflammation could disrupt with physiological protective responses.</text>
                    <arg n="0">inhibition of inflammation</arg>
                    <arg n="1">physiological protective responses</arg>
                </example>
                <example src="REPLACE" no="244">
                    <text>It is important to stress that inhibition of inflammation could disrupt with protective physiological response.</text>
                    <arg n="0">inhibition of inflammation</arg>
                    <arg n="1">protective physiological response</arg>
                </example>
                <example src="REPLACE" no="245">
                    <text>It is important to stress that inhibition of inflammation has the no that disrupt physiological protective responses.</text>
                    <arg n="0">inhibition of inflammation</arg>
                    <arg n="1">physiological protective responses</arg>
                </example>
                <example src="REPLACE" no="246">
                    <text>It is important to stress that inhibition of inflammation has the no that disrupt protective physiological response.</text>
                    <arg n="0">inhibition of inflammation</arg>
                    <arg n="1">protective physiological response</arg>
                </example>
                <example src="REPLACE" no="247">
                    <text>It is important to stress that inhibition of inflammation is able to disrupt physiological protective responses.</text>
                    <arg n="0">inhibition of inflammation</arg>
                    <arg n="1">physiological protective responses</arg>
                </example>
                <example src="REPLACE" no="248">
                    <text>It is important to stress that inhibition of inflammation is able to disrupt protective physiological response.</text>
                    <arg n="0">inhibition of inflammation</arg>
                    <arg n="1">protective physiological response</arg>
                </example>
                <example src="REPLACE" no="249">
                    <text>It is important to stress that manipulation of the Tie-2 system in tumors could disrupt with tumour vessels.</text>
                    <arg n="0">manipulation of the Tie-2 system in tumors</arg>
                    <arg n="1">tumour vessels</arg>
                </example>
                <example src="REPLACE" no="250">
                    <text>It is important to stress that manipulation of the Tie-2 system in tumors has the no that disrupt tumour vessels.</text>
                    <arg n="0">manipulation of the Tie-2 system in tumors</arg>
                    <arg n="1">tumour vessels</arg>
                </example>
                <example src="REPLACE" no="251">
                    <text>It is important to stress that manipulation of the Tie-2 system in tumors is able to disrupt tumour vessels.</text>
                    <arg n="0">manipulation of the Tie-2 system in tumors</arg>
                    <arg n="1">tumour vessels</arg>
                </example>
                <example src="REPLACE" no="252">
                    <text>It is important to stress that manipulation of the binding system 2 in tumours could disrupt with tumor vessels.</text>
                    <arg n="0">manipulation of the binding system 2 in tumours</arg>
                    <arg n="1">tumor vessels</arg>
                </example>
                <example src="REPLACE" no="253">
                    <text>It is important to stress that manipulation of the binding system 2 in tumours has the no that disrupt tumor vessels.</text>
                    <arg n="0">manipulation of the binding system 2 in tumours</arg>
                    <arg n="1">tumor vessels</arg>
                </example>
                <example src="REPLACE" no="254">
                    <text>It is important to stress that manipulation of the binding system 2 in tumours is able to disrupt tumor vessels.</text>
                    <arg n="0">manipulation of the binding system 2 in tumours</arg>
                    <arg n="1">tumor vessels</arg>
                </example>
                <example src="REPLACE" no="255">
                    <text>It is important to stress that multations at p53 could disrupt with post-checking points for DNA damage.</text>
                    <arg n="0">multations at p53</arg>
                    <arg n="1">post-checking points for DNA damage</arg>
                </example>
                <example src="REPLACE" no="256">
                    <text>It is important to stress that multations at p53 has the no that disrupt post-checking points for DNA damage.</text>
                    <arg n="0">multations at p53</arg>
                    <arg n="1">post-checking points for DNA damage</arg>
                </example>
                <example src="REPLACE" no="257">
                    <text>It is important to stress that multations at p53 is able to disrupt post-checking points for DNA damage.</text>
                    <arg n="0">multations at p53</arg>
                    <arg n="1">post-checking points for DNA damage</arg>
                </example>
                <example src="REPLACE" no="258">
                    <text>It is important to stress that mutation 415G4 could disrupt with pulling enhancement sequence: (GAR)n-(GAR)n.</text>
                    <arg n="0">mutation 415G4</arg>
                    <arg n="1">pulling enhancement sequence: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="259">
                    <text>It is important to stress that mutation 415G4 could disrupt with splicing sequencer: (GAR)n-(GAR)n.</text>
                    <arg n="0">mutation 415G4</arg>
                    <arg n="1">splicing sequencer: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="260">
                    <text>It is important to stress that mutation 415G4 has the no that disrupt pulling enhancement sequence: (GAR)n-(GAR)n.</text>
                    <arg n="0">mutation 415G4</arg>
                    <arg n="1">pulling enhancement sequence: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="261">
                    <text>It is important to stress that mutation 415G4 has the no that disrupt splicing sequencer: (GAR)n-(GAR)n.</text>
                    <arg n="0">mutation 415G4</arg>
                    <arg n="1">splicing sequencer: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="262">
                    <text>It is important to stress that mutation 415G4 is able to disrupt pulling enhancement sequence: (GAR)n-(GAR)n.</text>
                    <arg n="0">mutation 415G4</arg>
                    <arg n="1">pulling enhancement sequence: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="263">
                    <text>It is important to stress that mutation 415G4 is able to disrupt splicing sequencer: (GAR)n-(GAR)n.</text>
                    <arg n="0">mutation 415G4</arg>
                    <arg n="1">splicing sequencer: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="264">
                    <text>It is important to stress that mutations in this region could disrupt with assembly of keratin filaments.</text>
                    <arg n="0">mutations in this region</arg>
                    <arg n="1">assembly of keratin filaments</arg>
                </example>
                <example src="REPLACE" no="265">
                    <text>It is important to stress that mutations in this region has the no that disrupt assembly of keratin filaments.</text>
                    <arg n="0">mutations in this region</arg>
                    <arg n="1">assembly of keratin filaments</arg>
                </example>
                <example src="REPLACE" no="266">
                    <text>It is important to stress that mutations in this region is able to disrupt assembly of keratin filaments.</text>
                    <arg n="0">mutations in this region</arg>
                    <arg n="1">assembly of keratin filaments</arg>
                </example>
                <example src="REPLACE" no="267">
                    <text>It is important to stress that p53 mutations could disrupt with checking point responses for DNA damage.</text>
                    <arg n="0">p53 mutations</arg>
                    <arg n="1">checking point responses for DNA damage</arg>
                </example>
                <example src="REPLACE" no="268">
                    <text>It is important to stress that p53 mutations has the no that disrupt checking point responses for DNA damage.</text>
                    <arg n="0">p53 mutations</arg>
                    <arg n="1">checking point responses for DNA damage</arg>
                </example>
                <example src="REPLACE" no="269">
                    <text>It is important to stress that p53 mutations is able to disrupt checking point responses for DNA damage.</text>
                    <arg n="0">p53 mutations</arg>
                    <arg n="1">checking point responses for DNA damage</arg>
                </example>
                <example src="REPLACE" no="270">
                    <text>It is important to stress that such mutations could disrupt with the ubiquitin binding function.</text>
                    <arg n="0">such mutations</arg>
                    <arg n="1">the ubiquitin binding function</arg>
                </example>
                <example src="REPLACE" no="271">
                    <text>It is important to stress that such mutations could disrupt with the ubiquitin-binding function.</text>
                    <arg n="0">such mutations</arg>
                    <arg n="1">the ubiquitin-binding function</arg>
                </example>
                <example src="REPLACE" no="272">
                    <text>It is important to stress that such mutations has the no that disrupt the ubiquitin binding function.</text>
                    <arg n="0">such mutations</arg>
                    <arg n="1">the ubiquitin binding function</arg>
                </example>
                <example src="REPLACE" no="273">
                    <text>It is important to stress that such mutations has the no that disrupt the ubiquitin-binding function.</text>
                    <arg n="0">such mutations</arg>
                    <arg n="1">the ubiquitin-binding function</arg>
                </example>
                <example src="REPLACE" no="274">
                    <text>It is important to stress that such mutations is able to disrupt the ubiquitin binding function.</text>
                    <arg n="0">such mutations</arg>
                    <arg n="1">the ubiquitin binding function</arg>
                </example>
                <example src="REPLACE" no="275">
                    <text>It is important to stress that such mutations is able to disrupt the ubiquitin-binding function.</text>
                    <arg n="0">such mutations</arg>
                    <arg n="1">the ubiquitin-binding function</arg>
                </example>
                <example src="REPLACE" no="276">
                    <text>It is important to stress that the Lys147Ala substitution could disrupt with the interaction.</text>
                    <arg n="0">the Lys147Ala substitution</arg>
                    <arg n="1">the interaction</arg>
                </example>
                <example src="REPLACE" no="277">
                    <text>It is important to stress that the Lys147Ala substitution has the no that disrupt the interaction.</text>
                    <arg n="0">the Lys147Ala substitution</arg>
                    <arg n="1">the interaction</arg>
                </example>
                <example src="REPLACE" no="278">
                    <text>It is important to stress that the Lys147Ala substitution is able to disrupt the interaction.</text>
                    <arg n="0">the Lys147Ala substitution</arg>
                    <arg n="1">the interaction</arg>
                </example>
                <example src="REPLACE" no="279">
                    <text>It is important to stress that the findings show that A mutation 415G4 could disrupt slicing enhancer sequnce: (GAR)n-(GAR)n.</text>
                    <arg n="0">A mutation 415G4</arg>
                    <arg n="1">slicing enhancer sequnce: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="280">
                    <text>It is important to stress that the findings show that A mutation 415G4 disrupt the expression no slicing enhancer sequnce: (GAR)n-(GAR)n.</text>
                    <arg n="0">A mutation 415G4</arg>
                    <arg n="1">slicing enhancer sequnce: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="281">
                    <text>It is important to stress that the findings show that Lys147Ala substitution could disrupt interaction.</text>
                    <arg n="0">Lys147Ala substitution</arg>
                    <arg n="1">interaction</arg>
                </example>
                <example src="REPLACE" no="282">
                    <text>It is important to stress that the findings show that Lys147Ala substitution disrupt the expression no interaction.</text>
                    <arg n="0">Lys147Ala substitution</arg>
                    <arg n="1">interaction</arg>
                </example>
                <example src="REPLACE" no="283">
                    <text>It is important to stress that the findings show that Multations in p53 could disrupt posts of checkpoints to DNA damage.</text>
                    <arg n="0">Multations in p53</arg>
                    <arg n="1">posts of checkpoints to DNA damage</arg>
                </example>
                <example src="REPLACE" no="284">
                    <text>It is important to stress that the findings show that Multations in p53 could disrupt responses of checkpoints to DNA damage.</text>
                    <arg n="0">Multations in p53</arg>
                    <arg n="1">responses of checkpoints to DNA damage</arg>
                </example>
                <example src="REPLACE" no="285">
                    <text>It is important to stress that the findings show that Multations in p53 disrupt the expression no posts of checkpoints to DNA damage.</text>
                    <arg n="0">Multations in p53</arg>
                    <arg n="1">posts of checkpoints to DNA damage</arg>
                </example>
                <example src="REPLACE" no="286">
                    <text>It is important to stress that the findings show that Multations in p53 disrupt the expression no responses of checkpoints to DNA damage.</text>
                    <arg n="0">Multations in p53</arg>
                    <arg n="1">responses of checkpoints to DNA damage</arg>
                </example>
                <example src="REPLACE" no="287">
                    <text>It is important to stress that the findings show that Mutation 415G4 could disrupt licensing improvement sequence: (GAR)n-(GAR)n.</text>
                    <arg n="0">Mutation 415G4</arg>
                    <arg n="1">licensing improvement sequence: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="288">
                    <text>It is important to stress that the findings show that Mutation 415G4 disrupt the expression no licensing improvement sequence: (GAR)n-(GAR)n.</text>
                    <arg n="0">Mutation 415G4</arg>
                    <arg n="1">licensing improvement sequence: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="289">
                    <text>It is important to stress that the findings show that Mutations in p53 could disrupt responses of checkpoints to DNA damage.</text>
                    <arg n="0">Mutations in p53</arg>
                    <arg n="1">responses of checkpoints to DNA damage</arg>
                </example>
                <example src="REPLACE" no="290">
                    <text>It is important to stress that the findings show that Mutations in p53 disrupt the expression no responses of checkpoints to DNA damage.</text>
                    <arg n="0">Mutations in p53</arg>
                    <arg n="1">responses of checkpoints to DNA damage</arg>
                </example>
                <example src="REPLACE" no="291">
                    <text>It is important to stress that the findings show that R142X could disrupt a splicing enhancer.</text>
                    <arg n="0">R142X</arg>
                    <arg n="1">a splicing enhancer</arg>
                </example>
                <example src="REPLACE" no="292">
                    <text>It is important to stress that the findings show that R142X could disrupt a splicing power.</text>
                    <arg n="0">R142X</arg>
                    <arg n="1">a splicing power</arg>
                </example>
                <example src="REPLACE" no="293">
                    <text>It is important to stress that the findings show that R142X disrupt the expression no a splicing enhancer.</text>
                    <arg n="0">R142X</arg>
                    <arg n="1">a splicing enhancer</arg>
                </example>
                <example src="REPLACE" no="294">
                    <text>It is important to stress that the findings show that R142X disrupt the expression no a splicing power.</text>
                    <arg n="0">R142X</arg>
                    <arg n="1">a splicing power</arg>
                </example>
                <example src="REPLACE" no="295">
                    <text>It is important to stress that the findings show that The 415G4 mutation could disrupt enhancer spike: (GAR)n-(GAR)n.</text>
                    <arg n="0">The 415G4 mutation</arg>
                    <arg n="1">enhancer spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="296">
                    <text>It is important to stress that the findings show that The 415G4 mutation could disrupt powerers spike: (GAR)n-(GAR)n.</text>
                    <arg n="0">The 415G4 mutation</arg>
                    <arg n="1">powerers spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="297">
                    <text>It is important to stress that the findings show that The 415G4 mutation disrupt the expression no enhancer spike: (GAR)n-(GAR)n.</text>
                    <arg n="0">The 415G4 mutation</arg>
                    <arg n="1">enhancer spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="298">
                    <text>It is important to stress that the findings show that The 415G4 mutation disrupt the expression no powerers spike: (GAR)n-(GAR)n.</text>
                    <arg n="0">The 415G4 mutation</arg>
                    <arg n="1">powerers spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="299">
                    <text>It is important to stress that the findings show that The mutation 415G4 could disrupt enhancement brush: (GAR)n-(GAR)n.</text>
                    <arg n="0">The mutation 415G4</arg>
                    <arg n="1">enhancement brush: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="300">
                    <text>It is important to stress that the findings show that The mutation 415G4 could disrupt potent spike: (GAR)n-(GAR)n.</text>
                    <arg n="0">The mutation 415G4</arg>
                    <arg n="1">potent spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="301">
                    <text>It is important to stress that the findings show that The mutation 415G4 disrupt the expression no enhancement brush: (GAR)n-(GAR)n.</text>
                    <arg n="0">The mutation 415G4</arg>
                    <arg n="1">enhancement brush: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="302">
                    <text>It is important to stress that the findings show that The mutation 415G4 disrupt the expression no potent spike: (GAR)n-(GAR)n.</text>
                    <arg n="0">The mutation 415G4</arg>
                    <arg n="1">potent spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="303">
                    <text>It is important to stress that the findings show that These mutations could disrupt ubiquitin binding function.</text>
                    <arg n="0">These mutations</arg>
                    <arg n="1">ubiquitin binding function</arg>
                </example>
                <example src="REPLACE" no="304">
                    <text>It is important to stress that the findings show that These mutations disrupt the expression no ubiquitin binding function.</text>
                    <arg n="0">These mutations</arg>
                    <arg n="1">ubiquitin binding function</arg>
                </example>
                <example src="REPLACE" no="305">
                    <text>It is important to stress that the findings show that This deletion could disrupt consensus coupling signal 5.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">consensus coupling signal 5</arg>
                </example>
                <example src="REPLACE" no="306">
                    <text>It is important to stress that the findings show that This deletion could disrupt the 5 consensus of splice signal.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">the 5 consensus of splice signal</arg>
                </example>
                <example src="REPLACE" no="307">
                    <text>It is important to stress that the findings show that This deletion could disrupt the 5th consensus of the cut signal.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">the 5th consensus of the cut signal</arg>
                </example>
                <example src="REPLACE" no="308">
                    <text>It is important to stress that the findings show that This deletion could disrupt the splice signal consensus 5.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">the splice signal consensus 5</arg>
                </example>
                <example src="REPLACE" no="309">
                    <text>It is important to stress that the findings show that This deletion disrupt the expression no consensus coupling signal 5.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">consensus coupling signal 5</arg>
                </example>
                <example src="REPLACE" no="310">
                    <text>It is important to stress that the findings show that This deletion disrupt the expression no the 5 consensus of splice signal.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">the 5 consensus of splice signal</arg>
                </example>
                <example src="REPLACE" no="311">
                    <text>It is important to stress that the findings show that This deletion disrupt the expression no the 5th consensus of the cut signal.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">the 5th consensus of the cut signal</arg>
                </example>
                <example src="REPLACE" no="312">
                    <text>It is important to stress that the findings show that This deletion disrupt the expression no the splice signal consensus 5.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">the splice signal consensus 5</arg>
                </example>
                <example src="REPLACE" no="313">
                    <text>It is important to stress that the findings show that a 415G4 mutation could disrupt licensing improvement sequence: (GAR)n-(GAR)n.</text>
                    <arg n="0">a 415G4 mutation</arg>
                    <arg n="1">licensing improvement sequence: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="314">
                    <text>It is important to stress that the findings show that a 415G4 mutation disrupt the expression no licensing improvement sequence: (GAR)n-(GAR)n.</text>
                    <arg n="0">a 415G4 mutation</arg>
                    <arg n="1">licensing improvement sequence: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="315">
                    <text>It is important to stress that the findings show that a homozygotic mutation could disrupt splicing.</text>
                    <arg n="0">a homozygotic mutation</arg>
                    <arg n="1">splicing</arg>
                </example>
                <example src="REPLACE" no="316">
                    <text>It is important to stress that the findings show that a homozygotic mutation disrupt the expression no splicing.</text>
                    <arg n="0">a homozygotic mutation</arg>
                    <arg n="1">splicing</arg>
                </example>
                <example src="REPLACE" no="317">
                    <text>It is important to stress that the findings show that blocking the expression MEKK1 or MEKK2 could disrupt the overall integrity of the MAPK route regulation.</text>
                    <arg n="0">blocking the expression MEKK1 or MEKK2</arg>
                    <arg n="1">the overall integrity of the MAPK route regulation</arg>
                </example>
                <example src="REPLACE" no="318">
                    <text>It is important to stress that the findings show that blocking the expression MEKK1 or MEKK2 disrupt the expression no the overall integrity of the MAPK route regulation.</text>
                    <arg n="0">blocking the expression MEKK1 or MEKK2</arg>
                    <arg n="1">the overall integrity of the MAPK route regulation</arg>
                </example>
                <example src="REPLACE" no="319">
                    <text>It is important to stress that the findings show that homozygous mutation could disrupt splicing.</text>
                    <arg n="0">homozygous mutation</arg>
                    <arg n="1">splicing</arg>
                </example>
                <example src="REPLACE" no="320">
                    <text>It is important to stress that the findings show that homozygous mutation disrupt the expression no splicing.</text>
                    <arg n="0">homozygous mutation</arg>
                    <arg n="1">splicing</arg>
                </example>
                <example src="REPLACE" no="321">
                    <text>It is important to stress that the findings show that inhibition of inflammation could disrupt physiological protective responses.</text>
                    <arg n="0">inhibition of inflammation</arg>
                    <arg n="1">physiological protective responses</arg>
                </example>
                <example src="REPLACE" no="322">
                    <text>It is important to stress that the findings show that inhibition of inflammation could disrupt protective physiological response.</text>
                    <arg n="0">inhibition of inflammation</arg>
                    <arg n="1">protective physiological response</arg>
                </example>
                <example src="REPLACE" no="323">
                    <text>It is important to stress that the findings show that inhibition of inflammation disrupt the expression no physiological protective responses.</text>
                    <arg n="0">inhibition of inflammation</arg>
                    <arg n="1">physiological protective responses</arg>
                </example>
                <example src="REPLACE" no="324">
                    <text>It is important to stress that the findings show that inhibition of inflammation disrupt the expression no protective physiological response.</text>
                    <arg n="0">inhibition of inflammation</arg>
                    <arg n="1">protective physiological response</arg>
                </example>
                <example src="REPLACE" no="325">
                    <text>It is important to stress that the findings show that manipulation of the Tie-2 system in tumors could disrupt tumour vessels.</text>
                    <arg n="0">manipulation of the Tie-2 system in tumors</arg>
                    <arg n="1">tumour vessels</arg>
                </example>
                <example src="REPLACE" no="326">
                    <text>It is important to stress that the findings show that manipulation of the Tie-2 system in tumors disrupt the expression no tumour vessels.</text>
                    <arg n="0">manipulation of the Tie-2 system in tumors</arg>
                    <arg n="1">tumour vessels</arg>
                </example>
                <example src="REPLACE" no="327">
                    <text>It is important to stress that the findings show that manipulation of the binding system 2 in tumours could disrupt tumor vessels.</text>
                    <arg n="0">manipulation of the binding system 2 in tumours</arg>
                    <arg n="1">tumor vessels</arg>
                </example>
                <example src="REPLACE" no="328">
                    <text>It is important to stress that the findings show that manipulation of the binding system 2 in tumours disrupt the expression no tumor vessels.</text>
                    <arg n="0">manipulation of the binding system 2 in tumours</arg>
                    <arg n="1">tumor vessels</arg>
                </example>
                <example src="REPLACE" no="329">
                    <text>It is important to stress that the findings show that multations at p53 could disrupt post-checking points for DNA damage.</text>
                    <arg n="0">multations at p53</arg>
                    <arg n="1">post-checking points for DNA damage</arg>
                </example>
                <example src="REPLACE" no="330">
                    <text>It is important to stress that the findings show that multations at p53 disrupt the expression no post-checking points for DNA damage.</text>
                    <arg n="0">multations at p53</arg>
                    <arg n="1">post-checking points for DNA damage</arg>
                </example>
                <example src="REPLACE" no="331">
                    <text>It is important to stress that the findings show that mutation 415G4 could disrupt pulling enhancement sequence: (GAR)n-(GAR)n.</text>
                    <arg n="0">mutation 415G4</arg>
                    <arg n="1">pulling enhancement sequence: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="332">
                    <text>It is important to stress that the findings show that mutation 415G4 could disrupt splicing sequencer: (GAR)n-(GAR)n.</text>
                    <arg n="0">mutation 415G4</arg>
                    <arg n="1">splicing sequencer: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="333">
                    <text>It is important to stress that the findings show that mutation 415G4 disrupt the expression no pulling enhancement sequence: (GAR)n-(GAR)n.</text>
                    <arg n="0">mutation 415G4</arg>
                    <arg n="1">pulling enhancement sequence: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="334">
                    <text>It is important to stress that the findings show that mutation 415G4 disrupt the expression no splicing sequencer: (GAR)n-(GAR)n.</text>
                    <arg n="0">mutation 415G4</arg>
                    <arg n="1">splicing sequencer: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="335">
                    <text>It is important to stress that the findings show that mutations in this region could disrupt assembly of keratin filaments.</text>
                    <arg n="0">mutations in this region</arg>
                    <arg n="1">assembly of keratin filaments</arg>
                </example>
                <example src="REPLACE" no="336">
                    <text>It is important to stress that the findings show that mutations in this region disrupt the expression no assembly of keratin filaments.</text>
                    <arg n="0">mutations in this region</arg>
                    <arg n="1">assembly of keratin filaments</arg>
                </example>
                <example src="REPLACE" no="337">
                    <text>It is important to stress that the findings show that p53 mutations could disrupt checking point responses for DNA damage.</text>
                    <arg n="0">p53 mutations</arg>
                    <arg n="1">checking point responses for DNA damage</arg>
                </example>
                <example src="REPLACE" no="338">
                    <text>It is important to stress that the findings show that p53 mutations disrupt the expression no checking point responses for DNA damage.</text>
                    <arg n="0">p53 mutations</arg>
                    <arg n="1">checking point responses for DNA damage</arg>
                </example>
                <example src="REPLACE" no="339">
                    <text>It is important to stress that the findings show that such mutations could disrupt the ubiquitin binding function.</text>
                    <arg n="0">such mutations</arg>
                    <arg n="1">the ubiquitin binding function</arg>
                </example>
                <example src="REPLACE" no="340">
                    <text>It is important to stress that the findings show that such mutations could disrupt the ubiquitin-binding function.</text>
                    <arg n="0">such mutations</arg>
                    <arg n="1">the ubiquitin-binding function</arg>
                </example>
                <example src="REPLACE" no="341">
                    <text>It is important to stress that the findings show that such mutations disrupt the expression no the ubiquitin binding function.</text>
                    <arg n="0">such mutations</arg>
                    <arg n="1">the ubiquitin binding function</arg>
                </example>
                <example src="REPLACE" no="342">
                    <text>It is important to stress that the findings show that such mutations disrupt the expression no the ubiquitin-binding function.</text>
                    <arg n="0">such mutations</arg>
                    <arg n="1">the ubiquitin-binding function</arg>
                </example>
                <example src="REPLACE" no="343">
                    <text>It is important to stress that the findings show that the Lys147Ala substitution could disrupt the interaction.</text>
                    <arg n="0">the Lys147Ala substitution</arg>
                    <arg n="1">the interaction</arg>
                </example>
                <example src="REPLACE" no="344">
                    <text>It is important to stress that the findings show that the Lys147Ala substitution disrupt the expression no the interaction.</text>
                    <arg n="0">the Lys147Ala substitution</arg>
                    <arg n="1">the interaction</arg>
                </example>
                <example src="REPLACE" no="345">
                    <text>It is important to stress that the findings show that these mutations could disrupt biquitin binding function.</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">biquitin binding function</arg>
                </example>
                <example src="REPLACE" no="346">
                    <text>It is important to stress that the findings show that these mutations disrupt the expression no biquitin binding function.</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">biquitin binding function</arg>
                </example>
                <example src="REPLACE" no="347">
                    <text>It is important to stress that the findings show that this deletion could disrupt consensus signal 5.</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">consensus signal 5</arg>
                </example>
                <example src="REPLACE" no="348">
                    <text>It is important to stress that the findings show that this deletion disrupt the expression no consensus signal 5.</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">consensus signal 5</arg>
                </example>
                <example src="REPLACE" no="349">
                    <text>It is important to stress that the findings show that this suppression could disrupt consensus signal 5.</text>
                    <arg n="0">this suppression</arg>
                    <arg n="1">consensus signal 5</arg>
                </example>
                <example src="REPLACE" no="350">
                    <text>It is important to stress that the findings show that this suppression disrupt the expression no consensus signal 5.</text>
                    <arg n="0">this suppression</arg>
                    <arg n="1">consensus signal 5</arg>
                </example>
                <example src="REPLACE" no="351">
                    <text>It is important to stress that the findings show that tumour binding system 2 maneuver could disrupt tumour vessels.</text>
                    <arg n="0">tumour binding system 2 maneuver</arg>
                    <arg n="1">tumour vessels</arg>
                </example>
                <example src="REPLACE" no="352">
                    <text>It is important to stress that the findings show that tumour binding system 2 maneuver disrupt the expression no tumour vessels.</text>
                    <arg n="0">tumour binding system 2 maneuver</arg>
                    <arg n="1">tumour vessels</arg>
                </example>
                <example src="REPLACE" no="353">
                    <text>It is important to stress that these mutations could disrupt with biquitin binding function.</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">biquitin binding function</arg>
                </example>
                <example src="REPLACE" no="354">
                    <text>It is important to stress that these mutations has the no that disrupt biquitin binding function.</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">biquitin binding function</arg>
                </example>
                <example src="REPLACE" no="355">
                    <text>It is important to stress that these mutations is able to disrupt biquitin binding function.</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">biquitin binding function</arg>
                </example>
                <example src="REPLACE" no="356">
                    <text>It is important to stress that this deletion could disrupt with consensus signal 5.</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">consensus signal 5</arg>
                </example>
                <example src="REPLACE" no="357">
                    <text>It is important to stress that this deletion has the no that disrupt consensus signal 5.</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">consensus signal 5</arg>
                </example>
                <example src="REPLACE" no="358">
                    <text>It is important to stress that this deletion is able to disrupt consensus signal 5.</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">consensus signal 5</arg>
                </example>
                <example src="REPLACE" no="359">
                    <text>It is important to stress that this suppression could disrupt with consensus signal 5.</text>
                    <arg n="0">this suppression</arg>
                    <arg n="1">consensus signal 5</arg>
                </example>
                <example src="REPLACE" no="360">
                    <text>It is important to stress that this suppression has the no that disrupt consensus signal 5.</text>
                    <arg n="0">this suppression</arg>
                    <arg n="1">consensus signal 5</arg>
                </example>
                <example src="REPLACE" no="361">
                    <text>It is important to stress that this suppression is able to disrupt consensus signal 5.</text>
                    <arg n="0">this suppression</arg>
                    <arg n="1">consensus signal 5</arg>
                </example>
                <example src="REPLACE" no="362">
                    <text>It is important to stress that tumour binding system 2 maneuver could disrupt with tumour vessels.</text>
                    <arg n="0">tumour binding system 2 maneuver</arg>
                    <arg n="1">tumour vessels</arg>
                </example>
                <example src="REPLACE" no="363">
                    <text>It is important to stress that tumour binding system 2 maneuver has the no that disrupt tumour vessels.</text>
                    <arg n="0">tumour binding system 2 maneuver</arg>
                    <arg n="1">tumour vessels</arg>
                </example>
                <example src="REPLACE" no="364">
                    <text>It is important to stress that tumour binding system 2 maneuver is able to disrupt tumour vessels.</text>
                    <arg n="0">tumour binding system 2 maneuver</arg>
                    <arg n="1">tumour vessels</arg>
                </example>
                <example src="REPLACE" no="365">
                    <text>Lys147Ala substitution broke a sequence of interaction disrupted in R (exon 5 spike).</text>
                    <arg n="0">Lys147Ala substitution</arg>
                    <arg n="1">interaction</arg>
                </example>
                <example src="REPLACE" no="366">
                    <text>Lys147Ala substitution broke the interaction and disrupted to the a drastic drop of activity against GO:C substrates.</text>
                    <arg n="0">Lys147Ala substitution</arg>
                    <arg n="1">interaction</arg>
                    <arg n="R">a drastic drop of activity against GO:C substrates</arg>
                </example>
                <example src="REPLACE" no="367">
                    <text>Lys147Ala substitution can disrupt with the base groups ceto and C (blue) on both sides of the dsDNA DNA and interrupt interaction.</text>
                    <arg n="0">Lys147Ala substitution</arg>
                    <arg n="1">interaction</arg>
                </example>
                <example src="REPLACE" no="368">
                    <text>Lys147Ala substitution have perturbed interaction and disrupted in a drastic drop of activity against GO:C substrates.</text>
                    <arg n="0">Lys147Ala substitution</arg>
                    <arg n="1">interaction</arg>
                    <arg n="R">a drastic drop of activity against GO:C substrates</arg>
                </example>
                <example src="REPLACE" no="369">
                    <text>Lys147Ala substitution rupture of interaction may disrupting in a drastic drop of activity against GO:C substrates.</text>
                    <arg n="0">Lys147Ala substitution</arg>
                    <arg n="1">interaction</arg>
                    <arg n="R">a drastic drop of activity against GO:C substrates</arg>
                </example>
                <example src="REPLACE" no="370">
                    <text>Lys147Ala substitution that broke A1 will be identified in the siblings disrupted by classical abetalipoproteinemia.</text>
                    <arg n="0">Lys147Ala substitution</arg>
                </example>
                <example src="REPLACE" no="371">
                    <text>Lys147Ala substitution that can disrupt interaction has been identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">Lys147Ala substitution</arg>
                    <arg n="1">interaction</arg>
                </example>
                <example src="REPLACE" no="372">
                    <text>Lys147Ala substitution that can disrupt interaction that has been identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">Lys147Ala substitution</arg>
                    <arg n="1">interaction</arg>
                </example>
                <example src="REPLACE" no="373">
                    <text>Lys147Ala substitution that has disrupted A1 will be identified in the affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">Lys147Ala substitution</arg>
                </example>
                <example src="REPLACE" no="374">
                    <text>Lys147Ala substitution that has disrupted interaction was identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">Lys147Ala substitution</arg>
                    <arg n="1">interaction</arg>
                </example>
                <example src="REPLACE" no="375">
                    <text>Lys147Ala substitution that interact with the keto groups of the base pair GO and C (blue) on either side of the dsDNA can disrupt interaction.</text>
                    <arg n="0">Lys147Ala substitution</arg>
                    <arg n="1">interaction</arg>
                </example>
                <example src="REPLACE" no="376">
                    <text>Lys147Ala substitution that interacts with the keto and C group pair (blue) on both sides of the dsDNA can disrupt interaction.</text>
                    <arg n="0">Lys147Ala substitution</arg>
                    <arg n="1">interaction</arg>
                </example>
                <example src="REPLACE" no="377">
                    <text>Multations in p53 broke a sequence of posts of checkpoints to DNA damage disrupted in R (exon 5 spike).</text>
                    <arg n="0">Multations in p53</arg>
                    <arg n="1">posts of checkpoints to DNA damage</arg>
                </example>
                <example src="REPLACE" no="378">
                    <text>Multations in p53 broke a sequence of responses of checkpoints to DNA damage disrupted in R (exon 5 spike).</text>
                    <arg n="0">Multations in p53</arg>
                    <arg n="1">responses of checkpoints to DNA damage</arg>
                </example>
                <example src="REPLACE" no="379">
                    <text>Multations in p53 broke the posts of checkpoints to DNA damage and disrupted to the the potential for genome destabilization.</text>
                    <arg n="0">Multations in p53</arg>
                    <arg n="1">posts of checkpoints to DNA damage</arg>
                    <arg n="R">the potential for genome destabilization</arg>
                </example>
                <example src="REPLACE" no="380">
                    <text>Multations in p53 broke the responses of checkpoints to DNA damage and disrupted to the the potential for genome destabilization.</text>
                    <arg n="0">Multations in p53</arg>
                    <arg n="1">responses of checkpoints to DNA damage</arg>
                    <arg n="R">the potential for genome destabilization</arg>
                </example>
                <example src="REPLACE" no="381">
                    <text>Multations in p53 can disrupt with the base groups ceto and C (blue) on both sides of the dsDNA DNA and interrupt posts of checkpoints to DNA damage.</text>
                    <arg n="0">Multations in p53</arg>
                    <arg n="1">posts of checkpoints to DNA damage</arg>
                </example>
                <example src="REPLACE" no="382">
                    <text>Multations in p53 can disrupt with the base groups ceto and C (blue) on both sides of the dsDNA DNA and interrupt responses of checkpoints to DNA damage.</text>
                    <arg n="0">Multations in p53</arg>
                    <arg n="1">responses of checkpoints to DNA damage</arg>
                </example>
                <example src="REPLACE" no="383">
                    <text>Multations in p53 have perturbed posts of checkpoints to DNA damage and disrupted in the potential for genome destabilization.</text>
                    <arg n="0">Multations in p53</arg>
                    <arg n="1">posts of checkpoints to DNA damage</arg>
                    <arg n="R">the potential for genome destabilization</arg>
                </example>
                <example src="REPLACE" no="384">
                    <text>Multations in p53 have perturbed responses of checkpoints to DNA damage and disrupted in the potential for genome destabilization.</text>
                    <arg n="0">Multations in p53</arg>
                    <arg n="1">responses of checkpoints to DNA damage</arg>
                    <arg n="R">the potential for genome destabilization</arg>
                </example>
                <example src="REPLACE" no="385">
                    <text>Multations in p53 rupture of posts of checkpoints to DNA damage may disrupting in the potential for genome destabilization.</text>
                    <arg n="0">Multations in p53</arg>
                    <arg n="1">posts of checkpoints to DNA damage</arg>
                    <arg n="R">the potential for genome destabilization</arg>
                </example>
                <example src="REPLACE" no="386">
                    <text>Multations in p53 rupture of responses of checkpoints to DNA damage may disrupting in the potential for genome destabilization.</text>
                    <arg n="0">Multations in p53</arg>
                    <arg n="1">responses of checkpoints to DNA damage</arg>
                    <arg n="R">the potential for genome destabilization</arg>
                </example>
                <example src="REPLACE" no="387">
                    <text>Multations in p53 that broke A1 will be identified in the siblings disrupted by classical abetalipoproteinemia.</text>
                    <arg n="0">Multations in p53</arg>
                </example>
                <example src="REPLACE" no="388">
                    <text>Multations in p53 that can disrupt posts of checkpoints to DNA damage has been identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">Multations in p53</arg>
                    <arg n="1">posts of checkpoints to DNA damage</arg>
                </example>
                <example src="REPLACE" no="389">
                    <text>Multations in p53 that can disrupt posts of checkpoints to DNA damage that has been identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">Multations in p53</arg>
                    <arg n="1">posts of checkpoints to DNA damage</arg>
                </example>
                <example src="REPLACE" no="390">
                    <text>Multations in p53 that can disrupt responses of checkpoints to DNA damage has been identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">Multations in p53</arg>
                    <arg n="1">responses of checkpoints to DNA damage</arg>
                </example>
                <example src="REPLACE" no="391">
                    <text>Multations in p53 that can disrupt responses of checkpoints to DNA damage that has been identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">Multations in p53</arg>
                    <arg n="1">responses of checkpoints to DNA damage</arg>
                </example>
                <example src="REPLACE" no="392">
                    <text>Multations in p53 that has disrupted A1 will be identified in the affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">Multations in p53</arg>
                </example>
                <example src="REPLACE" no="393">
                    <text>Multations in p53 that has disrupted posts of checkpoints to DNA damage was identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">Multations in p53</arg>
                    <arg n="1">posts of checkpoints to DNA damage</arg>
                </example>
                <example src="REPLACE" no="394">
                    <text>Multations in p53 that has disrupted responses of checkpoints to DNA damage was identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">Multations in p53</arg>
                    <arg n="1">responses of checkpoints to DNA damage</arg>
                </example>
                <example src="REPLACE" no="395">
                    <text>Multations in p53 that interact with the keto groups of the base pair GO and C (blue) on either side of the dsDNA can disrupt posts of checkpoints to DNA damage.</text>
                    <arg n="0">Multations in p53</arg>
                    <arg n="1">posts of checkpoints to DNA damage</arg>
                </example>
                <example src="REPLACE" no="396">
                    <text>Multations in p53 that interact with the keto groups of the base pair GO and C (blue) on either side of the dsDNA can disrupt responses of checkpoints to DNA damage.</text>
                    <arg n="0">Multations in p53</arg>
                    <arg n="1">responses of checkpoints to DNA damage</arg>
                </example>
                <example src="REPLACE" no="397">
                    <text>Multations in p53 that interacts with the keto and C group pair (blue) on both sides of the dsDNA can disrupt posts of checkpoints to DNA damage.</text>
                    <arg n="0">Multations in p53</arg>
                    <arg n="1">posts of checkpoints to DNA damage</arg>
                </example>
                <example src="REPLACE" no="398">
                    <text>Multations in p53 that interacts with the keto and C group pair (blue) on both sides of the dsDNA can disrupt responses of checkpoints to DNA damage.</text>
                    <arg n="0">Multations in p53</arg>
                    <arg n="1">responses of checkpoints to DNA damage</arg>
                </example>
                <example src="REPLACE" no="399">
                    <text>Mutation 415G4 broke a sequence of licensing improvement sequence: (GAR)n-(GAR)n disrupted in R (exon 5 spike).</text>
                    <arg n="0">Mutation 415G4</arg>
                    <arg n="1">licensing improvement sequence: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="400">
                    <text>Mutation 415G4 can disrupt with the base groups ceto and C (blue) on both sides of the dsDNA DNA and interrupt licensing improvement sequence: (GAR)n-(GAR)n.</text>
                    <arg n="0">Mutation 415G4</arg>
                    <arg n="1">licensing improvement sequence: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="401">
                    <text>Mutation 415G4 that broke A1 will be identified in the siblings disrupted by classical abetalipoproteinemia.</text>
                    <arg n="0">Mutation 415G4</arg>
                </example>
                <example src="REPLACE" no="402">
                    <text>Mutation 415G4 that can disrupt licensing improvement sequence: (GAR)n-(GAR)n has been identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">Mutation 415G4</arg>
                    <arg n="1">licensing improvement sequence: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="403">
                    <text>Mutation 415G4 that can disrupt licensing improvement sequence: (GAR)n-(GAR)n that has been identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">Mutation 415G4</arg>
                    <arg n="1">licensing improvement sequence: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="404">
                    <text>Mutation 415G4 that has disrupted A1 will be identified in the affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">Mutation 415G4</arg>
                </example>
                <example src="REPLACE" no="405">
                    <text>Mutation 415G4 that has disrupted licensing improvement sequence: (GAR)n-(GAR)n was identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">Mutation 415G4</arg>
                    <arg n="1">licensing improvement sequence: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="406">
                    <text>Mutation 415G4 that interact with the keto groups of the base pair GO and C (blue) on either side of the dsDNA can disrupt licensing improvement sequence: (GAR)n-(GAR)n.</text>
                    <arg n="0">Mutation 415G4</arg>
                    <arg n="1">licensing improvement sequence: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="407">
                    <text>Mutation 415G4 that interacts with the keto and C group pair (blue) on both sides of the dsDNA can disrupt licensing improvement sequence: (GAR)n-(GAR)n.</text>
                    <arg n="0">Mutation 415G4</arg>
                    <arg n="1">licensing improvement sequence: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="408">
                    <text>Mutations in p53 broke a sequence of responses of checkpoints to DNA damage disrupted in R (exon 5 spike).</text>
                    <arg n="0">Mutations in p53</arg>
                    <arg n="1">responses of checkpoints to DNA damage</arg>
                </example>
                <example src="REPLACE" no="409">
                    <text>Mutations in p53 can disrupt with the base groups ceto and C (blue) on both sides of the dsDNA DNA and interrupt responses of checkpoints to DNA damage.</text>
                    <arg n="0">Mutations in p53</arg>
                    <arg n="1">responses of checkpoints to DNA damage</arg>
                </example>
                <example src="REPLACE" no="410">
                    <text>Mutations in p53 that broke A1 will be identified in the siblings disrupted by classical abetalipoproteinemia.</text>
                    <arg n="0">Mutations in p53</arg>
                </example>
                <example src="REPLACE" no="411">
                    <text>Mutations in p53 that can disrupt responses of checkpoints to DNA damage has been identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">Mutations in p53</arg>
                    <arg n="1">responses of checkpoints to DNA damage</arg>
                </example>
                <example src="REPLACE" no="412">
                    <text>Mutations in p53 that can disrupt responses of checkpoints to DNA damage that has been identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">Mutations in p53</arg>
                    <arg n="1">responses of checkpoints to DNA damage</arg>
                </example>
                <example src="REPLACE" no="413">
                    <text>Mutations in p53 that has disrupted A1 will be identified in the affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">Mutations in p53</arg>
                </example>
                <example src="REPLACE" no="414">
                    <text>Mutations in p53 that has disrupted responses of checkpoints to DNA damage was identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">Mutations in p53</arg>
                    <arg n="1">responses of checkpoints to DNA damage</arg>
                </example>
                <example src="REPLACE" no="415">
                    <text>Mutations in p53 that interact with the keto groups of the base pair GO and C (blue) on either side of the dsDNA can disrupt responses of checkpoints to DNA damage.</text>
                    <arg n="0">Mutations in p53</arg>
                    <arg n="1">responses of checkpoints to DNA damage</arg>
                </example>
                <example src="REPLACE" no="416">
                    <text>Mutations in p53 that interacts with the keto and C group pair (blue) on both sides of the dsDNA can disrupt responses of checkpoints to DNA damage.</text>
                    <arg n="0">Mutations in p53</arg>
                    <arg n="1">responses of checkpoints to DNA damage</arg>
                </example>
                <example src="REPLACE" no="417">
                    <text>Quantitative electrophysiology of a single unit revealed that A mutation 415G4 disrupted slicing enhancer sequnce: (GAR)n-(GAR)n while retaining robust visual responses.</text>
                    <arg n="0">A mutation 415G4</arg>
                    <arg n="1">slicing enhancer sequnce: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="418">
                    <text>Quantitative electrophysiology of a single unit revealed that A mutation 415G4 has been able to disrupt slicing enhancer sequnce: (GAR)n-(GAR)n preserving robust visual responses.</text>
                    <arg n="0">A mutation 415G4</arg>
                    <arg n="1">slicing enhancer sequnce: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="419">
                    <text>Quantitative electrophysiology of a single unit revealed that A mutation 415G4 has been shown to disrupt slicing enhancer sequnce: (GAR)n-(GAR)n while preserving robust visual responses.</text>
                    <arg n="0">A mutation 415G4</arg>
                    <arg n="1">slicing enhancer sequnce: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="420">
                    <text>Quantitative electrophysiology of a single unit revealed that A mutation 415G4 has disrupted slicing enhancer sequnce: (GAR)n-(GAR)n while preserving robust visual responses.</text>
                    <arg n="0">A mutation 415G4</arg>
                    <arg n="1">slicing enhancer sequnce: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="421">
                    <text>Quantitative electrophysiology of a single unit revealed that A mutation 415G4 interrupts slicing enhancer sequnce: (GAR)n-(GAR)n by disrupts robust visual responses.</text>
                    <arg n="0">A mutation 415G4</arg>
                    <arg n="1">slicing enhancer sequnce: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="422">
                    <text>Quantitative electrophysiology of a single unit revealed that A mutation 415G4 interrupts slicing enhancer sequnce: (GAR)n-(GAR)n while disrupts robust visual responses.</text>
                    <arg n="0">A mutation 415G4</arg>
                    <arg n="1">slicing enhancer sequnce: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="423">
                    <text>Quantitative electrophysiology of a single unit revealed that A mutation 415G4 is able to detach slicing enhancer sequnce: (GAR)n-(GAR)n disrupt robust visual responses.</text>
                    <arg n="0">A mutation 415G4</arg>
                    <arg n="1">slicing enhancer sequnce: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="424">
                    <text>Quantitative electrophysiology of a single unit revealed that A mutation 415G4 is capable of disrupt slicing enhancer sequnce: (GAR)n-(GAR)n by preserving robust visual responses.</text>
                    <arg n="0">A mutation 415G4</arg>
                    <arg n="1">slicing enhancer sequnce: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="425">
                    <text>Quantitative electrophysiology of a single unit revealed that Lys147Ala substitution disrupted interaction while retaining robust visual responses.</text>
                    <arg n="0">Lys147Ala substitution</arg>
                    <arg n="1">interaction</arg>
                </example>
                <example src="REPLACE" no="426">
                    <text>Quantitative electrophysiology of a single unit revealed that Lys147Ala substitution has been able to disrupt interaction preserving robust visual responses.</text>
                    <arg n="0">Lys147Ala substitution</arg>
                    <arg n="1">interaction</arg>
                </example>
                <example src="REPLACE" no="427">
                    <text>Quantitative electrophysiology of a single unit revealed that Lys147Ala substitution has been shown to disrupt interaction while preserving robust visual responses.</text>
                    <arg n="0">Lys147Ala substitution</arg>
                    <arg n="1">interaction</arg>
                </example>
                <example src="REPLACE" no="428">
                    <text>Quantitative electrophysiology of a single unit revealed that Lys147Ala substitution has disrupted interaction while preserving robust visual responses.</text>
                    <arg n="0">Lys147Ala substitution</arg>
                    <arg n="1">interaction</arg>
                </example>
                <example src="REPLACE" no="429">
                    <text>Quantitative electrophysiology of a single unit revealed that Lys147Ala substitution interrupts interaction by disrupts robust visual responses.</text>
                    <arg n="0">Lys147Ala substitution</arg>
                    <arg n="1">interaction</arg>
                </example>
                <example src="REPLACE" no="430">
                    <text>Quantitative electrophysiology of a single unit revealed that Lys147Ala substitution interrupts interaction while disrupts robust visual responses.</text>
                    <arg n="0">Lys147Ala substitution</arg>
                    <arg n="1">interaction</arg>
                </example>
                <example src="REPLACE" no="431">
                    <text>Quantitative electrophysiology of a single unit revealed that Lys147Ala substitution is able to detach interaction disrupt robust visual responses.</text>
                    <arg n="0">Lys147Ala substitution</arg>
                    <arg n="1">interaction</arg>
                </example>
                <example src="REPLACE" no="432">
                    <text>Quantitative electrophysiology of a single unit revealed that Lys147Ala substitution is capable of disrupt interaction by preserving robust visual responses.</text>
                    <arg n="0">Lys147Ala substitution</arg>
                    <arg n="1">interaction</arg>
                </example>
                <example src="REPLACE" no="433">
                    <text>Quantitative electrophysiology of a single unit revealed that Multations in p53 disrupted posts of checkpoints to DNA damage while retaining robust visual responses.</text>
                    <arg n="0">Multations in p53</arg>
                    <arg n="1">posts of checkpoints to DNA damage</arg>
                </example>
                <example src="REPLACE" no="434">
                    <text>Quantitative electrophysiology of a single unit revealed that Multations in p53 disrupted responses of checkpoints to DNA damage while retaining robust visual responses.</text>
                    <arg n="0">Multations in p53</arg>
                    <arg n="1">responses of checkpoints to DNA damage</arg>
                </example>
                <example src="REPLACE" no="435">
                    <text>Quantitative electrophysiology of a single unit revealed that Multations in p53 has been able to disrupt posts of checkpoints to DNA damage preserving robust visual responses.</text>
                    <arg n="0">Multations in p53</arg>
                    <arg n="1">posts of checkpoints to DNA damage</arg>
                </example>
                <example src="REPLACE" no="436">
                    <text>Quantitative electrophysiology of a single unit revealed that Multations in p53 has been able to disrupt responses of checkpoints to DNA damage preserving robust visual responses.</text>
                    <arg n="0">Multations in p53</arg>
                    <arg n="1">responses of checkpoints to DNA damage</arg>
                </example>
                <example src="REPLACE" no="437">
                    <text>Quantitative electrophysiology of a single unit revealed that Multations in p53 has been shown to disrupt posts of checkpoints to DNA damage while preserving robust visual responses.</text>
                    <arg n="0">Multations in p53</arg>
                    <arg n="1">posts of checkpoints to DNA damage</arg>
                </example>
                <example src="REPLACE" no="438">
                    <text>Quantitative electrophysiology of a single unit revealed that Multations in p53 has been shown to disrupt responses of checkpoints to DNA damage while preserving robust visual responses.</text>
                    <arg n="0">Multations in p53</arg>
                    <arg n="1">responses of checkpoints to DNA damage</arg>
                </example>
                <example src="REPLACE" no="439">
                    <text>Quantitative electrophysiology of a single unit revealed that Multations in p53 has disrupted posts of checkpoints to DNA damage while preserving robust visual responses.</text>
                    <arg n="0">Multations in p53</arg>
                    <arg n="1">posts of checkpoints to DNA damage</arg>
                </example>
                <example src="REPLACE" no="440">
                    <text>Quantitative electrophysiology of a single unit revealed that Multations in p53 has disrupted responses of checkpoints to DNA damage while preserving robust visual responses.</text>
                    <arg n="0">Multations in p53</arg>
                    <arg n="1">responses of checkpoints to DNA damage</arg>
                </example>
                <example src="REPLACE" no="441">
                    <text>Quantitative electrophysiology of a single unit revealed that Multations in p53 interrupts posts of checkpoints to DNA damage by disrupts robust visual responses.</text>
                    <arg n="0">Multations in p53</arg>
                    <arg n="1">posts of checkpoints to DNA damage</arg>
                </example>
                <example src="REPLACE" no="442">
                    <text>Quantitative electrophysiology of a single unit revealed that Multations in p53 interrupts posts of checkpoints to DNA damage while disrupts robust visual responses.</text>
                    <arg n="0">Multations in p53</arg>
                    <arg n="1">posts of checkpoints to DNA damage</arg>
                </example>
                <example src="REPLACE" no="443">
                    <text>Quantitative electrophysiology of a single unit revealed that Multations in p53 interrupts responses of checkpoints to DNA damage by disrupts robust visual responses.</text>
                    <arg n="0">Multations in p53</arg>
                    <arg n="1">responses of checkpoints to DNA damage</arg>
                </example>
                <example src="REPLACE" no="444">
                    <text>Quantitative electrophysiology of a single unit revealed that Multations in p53 interrupts responses of checkpoints to DNA damage while disrupts robust visual responses.</text>
                    <arg n="0">Multations in p53</arg>
                    <arg n="1">responses of checkpoints to DNA damage</arg>
                </example>
                <example src="REPLACE" no="445">
                    <text>Quantitative electrophysiology of a single unit revealed that Multations in p53 is able to detach posts of checkpoints to DNA damage disrupt robust visual responses.</text>
                    <arg n="0">Multations in p53</arg>
                    <arg n="1">posts of checkpoints to DNA damage</arg>
                </example>
                <example src="REPLACE" no="446">
                    <text>Quantitative electrophysiology of a single unit revealed that Multations in p53 is able to detach responses of checkpoints to DNA damage disrupt robust visual responses.</text>
                    <arg n="0">Multations in p53</arg>
                    <arg n="1">responses of checkpoints to DNA damage</arg>
                </example>
                <example src="REPLACE" no="447">
                    <text>Quantitative electrophysiology of a single unit revealed that Multations in p53 is capable of disrupt posts of checkpoints to DNA damage by preserving robust visual responses.</text>
                    <arg n="0">Multations in p53</arg>
                    <arg n="1">posts of checkpoints to DNA damage</arg>
                </example>
                <example src="REPLACE" no="448">
                    <text>Quantitative electrophysiology of a single unit revealed that Multations in p53 is capable of disrupt responses of checkpoints to DNA damage by preserving robust visual responses.</text>
                    <arg n="0">Multations in p53</arg>
                    <arg n="1">responses of checkpoints to DNA damage</arg>
                </example>
                <example src="REPLACE" no="449">
                    <text>Quantitative electrophysiology of a single unit revealed that Mutation 415G4 disrupted licensing improvement sequence: (GAR)n-(GAR)n while retaining robust visual responses.</text>
                    <arg n="0">Mutation 415G4</arg>
                    <arg n="1">licensing improvement sequence: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="450">
                    <text>Quantitative electrophysiology of a single unit revealed that Mutation 415G4 has been able to disrupt licensing improvement sequence: (GAR)n-(GAR)n preserving robust visual responses.</text>
                    <arg n="0">Mutation 415G4</arg>
                    <arg n="1">licensing improvement sequence: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="451">
                    <text>Quantitative electrophysiology of a single unit revealed that Mutation 415G4 has been shown to disrupt licensing improvement sequence: (GAR)n-(GAR)n while preserving robust visual responses.</text>
                    <arg n="0">Mutation 415G4</arg>
                    <arg n="1">licensing improvement sequence: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="452">
                    <text>Quantitative electrophysiology of a single unit revealed that Mutation 415G4 has disrupted licensing improvement sequence: (GAR)n-(GAR)n while preserving robust visual responses.</text>
                    <arg n="0">Mutation 415G4</arg>
                    <arg n="1">licensing improvement sequence: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="453">
                    <text>Quantitative electrophysiology of a single unit revealed that Mutation 415G4 interrupts licensing improvement sequence: (GAR)n-(GAR)n by disrupts robust visual responses.</text>
                    <arg n="0">Mutation 415G4</arg>
                    <arg n="1">licensing improvement sequence: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="454">
                    <text>Quantitative electrophysiology of a single unit revealed that Mutation 415G4 interrupts licensing improvement sequence: (GAR)n-(GAR)n while disrupts robust visual responses.</text>
                    <arg n="0">Mutation 415G4</arg>
                    <arg n="1">licensing improvement sequence: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="455">
                    <text>Quantitative electrophysiology of a single unit revealed that Mutation 415G4 is able to detach licensing improvement sequence: (GAR)n-(GAR)n disrupt robust visual responses.</text>
                    <arg n="0">Mutation 415G4</arg>
                    <arg n="1">licensing improvement sequence: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="456">
                    <text>Quantitative electrophysiology of a single unit revealed that Mutation 415G4 is capable of disrupt licensing improvement sequence: (GAR)n-(GAR)n by preserving robust visual responses.</text>
                    <arg n="0">Mutation 415G4</arg>
                    <arg n="1">licensing improvement sequence: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="457">
                    <text>Quantitative electrophysiology of a single unit revealed that Mutations in p53 disrupted responses of checkpoints to DNA damage while retaining robust visual responses.</text>
                    <arg n="0">Mutations in p53</arg>
                    <arg n="1">responses of checkpoints to DNA damage</arg>
                </example>
                <example src="REPLACE" no="458">
                    <text>Quantitative electrophysiology of a single unit revealed that Mutations in p53 has been able to disrupt responses of checkpoints to DNA damage preserving robust visual responses.</text>
                    <arg n="0">Mutations in p53</arg>
                    <arg n="1">responses of checkpoints to DNA damage</arg>
                </example>
                <example src="REPLACE" no="459">
                    <text>Quantitative electrophysiology of a single unit revealed that Mutations in p53 has been shown to disrupt responses of checkpoints to DNA damage while preserving robust visual responses.</text>
                    <arg n="0">Mutations in p53</arg>
                    <arg n="1">responses of checkpoints to DNA damage</arg>
                </example>
                <example src="REPLACE" no="460">
                    <text>Quantitative electrophysiology of a single unit revealed that Mutations in p53 has disrupted responses of checkpoints to DNA damage while preserving robust visual responses.</text>
                    <arg n="0">Mutations in p53</arg>
                    <arg n="1">responses of checkpoints to DNA damage</arg>
                </example>
                <example src="REPLACE" no="461">
                    <text>Quantitative electrophysiology of a single unit revealed that Mutations in p53 interrupts responses of checkpoints to DNA damage by disrupts robust visual responses.</text>
                    <arg n="0">Mutations in p53</arg>
                    <arg n="1">responses of checkpoints to DNA damage</arg>
                </example>
                <example src="REPLACE" no="462">
                    <text>Quantitative electrophysiology of a single unit revealed that Mutations in p53 interrupts responses of checkpoints to DNA damage while disrupts robust visual responses.</text>
                    <arg n="0">Mutations in p53</arg>
                    <arg n="1">responses of checkpoints to DNA damage</arg>
                </example>
                <example src="REPLACE" no="463">
                    <text>Quantitative electrophysiology of a single unit revealed that Mutations in p53 is able to detach responses of checkpoints to DNA damage disrupt robust visual responses.</text>
                    <arg n="0">Mutations in p53</arg>
                    <arg n="1">responses of checkpoints to DNA damage</arg>
                </example>
                <example src="REPLACE" no="464">
                    <text>Quantitative electrophysiology of a single unit revealed that Mutations in p53 is capable of disrupt responses of checkpoints to DNA damage by preserving robust visual responses.</text>
                    <arg n="0">Mutations in p53</arg>
                    <arg n="1">responses of checkpoints to DNA damage</arg>
                </example>
                <example src="REPLACE" no="465">
                    <text>Quantitative electrophysiology of a single unit revealed that R142X disrupted a splicing enhancer while retaining robust visual responses.</text>
                    <arg n="0">R142X</arg>
                    <arg n="1">a splicing enhancer</arg>
                </example>
                <example src="REPLACE" no="466">
                    <text>Quantitative electrophysiology of a single unit revealed that R142X disrupted a splicing power while retaining robust visual responses.</text>
                    <arg n="0">R142X</arg>
                    <arg n="1">a splicing power</arg>
                </example>
                <example src="REPLACE" no="467">
                    <text>Quantitative electrophysiology of a single unit revealed that R142X has been able to disrupt a splicing enhancer preserving robust visual responses.</text>
                    <arg n="0">R142X</arg>
                    <arg n="1">a splicing enhancer</arg>
                </example>
                <example src="REPLACE" no="468">
                    <text>Quantitative electrophysiology of a single unit revealed that R142X has been able to disrupt a splicing power preserving robust visual responses.</text>
                    <arg n="0">R142X</arg>
                    <arg n="1">a splicing power</arg>
                </example>
                <example src="REPLACE" no="469">
                    <text>Quantitative electrophysiology of a single unit revealed that R142X has been shown to disrupt a splicing enhancer while preserving robust visual responses.</text>
                    <arg n="0">R142X</arg>
                    <arg n="1">a splicing enhancer</arg>
                </example>
                <example src="REPLACE" no="470">
                    <text>Quantitative electrophysiology of a single unit revealed that R142X has been shown to disrupt a splicing power while preserving robust visual responses.</text>
                    <arg n="0">R142X</arg>
                    <arg n="1">a splicing power</arg>
                </example>
                <example src="REPLACE" no="471">
                    <text>Quantitative electrophysiology of a single unit revealed that R142X has disrupted a splicing enhancer while preserving robust visual responses.</text>
                    <arg n="0">R142X</arg>
                    <arg n="1">a splicing enhancer</arg>
                </example>
                <example src="REPLACE" no="472">
                    <text>Quantitative electrophysiology of a single unit revealed that R142X has disrupted a splicing power while preserving robust visual responses.</text>
                    <arg n="0">R142X</arg>
                    <arg n="1">a splicing power</arg>
                </example>
                <example src="REPLACE" no="473">
                    <text>Quantitative electrophysiology of a single unit revealed that R142X interrupts a splicing enhancer by disrupts robust visual responses.</text>
                    <arg n="0">R142X</arg>
                    <arg n="1">a splicing enhancer</arg>
                </example>
                <example src="REPLACE" no="474">
                    <text>Quantitative electrophysiology of a single unit revealed that R142X interrupts a splicing enhancer while disrupts robust visual responses.</text>
                    <arg n="0">R142X</arg>
                    <arg n="1">a splicing enhancer</arg>
                </example>
                <example src="REPLACE" no="475">
                    <text>Quantitative electrophysiology of a single unit revealed that R142X interrupts a splicing power by disrupts robust visual responses.</text>
                    <arg n="0">R142X</arg>
                    <arg n="1">a splicing power</arg>
                </example>
                <example src="REPLACE" no="476">
                    <text>Quantitative electrophysiology of a single unit revealed that R142X interrupts a splicing power while disrupts robust visual responses.</text>
                    <arg n="0">R142X</arg>
                    <arg n="1">a splicing power</arg>
                </example>
                <example src="REPLACE" no="477">
                    <text>Quantitative electrophysiology of a single unit revealed that R142X is able to detach a splicing enhancer disrupt robust visual responses.</text>
                    <arg n="0">R142X</arg>
                    <arg n="1">a splicing enhancer</arg>
                </example>
                <example src="REPLACE" no="478">
                    <text>Quantitative electrophysiology of a single unit revealed that R142X is able to detach a splicing power disrupt robust visual responses.</text>
                    <arg n="0">R142X</arg>
                    <arg n="1">a splicing power</arg>
                </example>
                <example src="REPLACE" no="479">
                    <text>Quantitative electrophysiology of a single unit revealed that R142X is capable of disrupt a splicing enhancer by preserving robust visual responses.</text>
                    <arg n="0">R142X</arg>
                    <arg n="1">a splicing enhancer</arg>
                </example>
                <example src="REPLACE" no="480">
                    <text>Quantitative electrophysiology of a single unit revealed that R142X is capable of disrupt a splicing power by preserving robust visual responses.</text>
                    <arg n="0">R142X</arg>
                    <arg n="1">a splicing power</arg>
                </example>
                <example src="REPLACE" no="481">
                    <text>Quantitative electrophysiology of a single unit revealed that The 415G4 mutation disrupted enhancer spike: (GAR)n-(GAR)n while retaining robust visual responses.</text>
                    <arg n="0">The 415G4 mutation</arg>
                    <arg n="1">enhancer spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="482">
                    <text>Quantitative electrophysiology of a single unit revealed that The 415G4 mutation disrupted powerers spike: (GAR)n-(GAR)n while retaining robust visual responses.</text>
                    <arg n="0">The 415G4 mutation</arg>
                    <arg n="1">powerers spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="483">
                    <text>Quantitative electrophysiology of a single unit revealed that The 415G4 mutation has been able to disrupt enhancer spike: (GAR)n-(GAR)n preserving robust visual responses.</text>
                    <arg n="0">The 415G4 mutation</arg>
                    <arg n="1">enhancer spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="484">
                    <text>Quantitative electrophysiology of a single unit revealed that The 415G4 mutation has been able to disrupt powerers spike: (GAR)n-(GAR)n preserving robust visual responses.</text>
                    <arg n="0">The 415G4 mutation</arg>
                    <arg n="1">powerers spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="485">
                    <text>Quantitative electrophysiology of a single unit revealed that The 415G4 mutation has been shown to disrupt enhancer spike: (GAR)n-(GAR)n while preserving robust visual responses.</text>
                    <arg n="0">The 415G4 mutation</arg>
                    <arg n="1">enhancer spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="486">
                    <text>Quantitative electrophysiology of a single unit revealed that The 415G4 mutation has been shown to disrupt powerers spike: (GAR)n-(GAR)n while preserving robust visual responses.</text>
                    <arg n="0">The 415G4 mutation</arg>
                    <arg n="1">powerers spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="487">
                    <text>Quantitative electrophysiology of a single unit revealed that The 415G4 mutation has disrupted enhancer spike: (GAR)n-(GAR)n while preserving robust visual responses.</text>
                    <arg n="0">The 415G4 mutation</arg>
                    <arg n="1">enhancer spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="488">
                    <text>Quantitative electrophysiology of a single unit revealed that The 415G4 mutation has disrupted powerers spike: (GAR)n-(GAR)n while preserving robust visual responses.</text>
                    <arg n="0">The 415G4 mutation</arg>
                    <arg n="1">powerers spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="489">
                    <text>Quantitative electrophysiology of a single unit revealed that The 415G4 mutation interrupts enhancer spike: (GAR)n-(GAR)n by disrupts robust visual responses.</text>
                    <arg n="0">The 415G4 mutation</arg>
                    <arg n="1">enhancer spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="490">
                    <text>Quantitative electrophysiology of a single unit revealed that The 415G4 mutation interrupts enhancer spike: (GAR)n-(GAR)n while disrupts robust visual responses.</text>
                    <arg n="0">The 415G4 mutation</arg>
                    <arg n="1">enhancer spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="491">
                    <text>Quantitative electrophysiology of a single unit revealed that The 415G4 mutation interrupts powerers spike: (GAR)n-(GAR)n by disrupts robust visual responses.</text>
                    <arg n="0">The 415G4 mutation</arg>
                    <arg n="1">powerers spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="492">
                    <text>Quantitative electrophysiology of a single unit revealed that The 415G4 mutation interrupts powerers spike: (GAR)n-(GAR)n while disrupts robust visual responses.</text>
                    <arg n="0">The 415G4 mutation</arg>
                    <arg n="1">powerers spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="493">
                    <text>Quantitative electrophysiology of a single unit revealed that The 415G4 mutation is able to detach enhancer spike: (GAR)n-(GAR)n disrupt robust visual responses.</text>
                    <arg n="0">The 415G4 mutation</arg>
                    <arg n="1">enhancer spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="494">
                    <text>Quantitative electrophysiology of a single unit revealed that The 415G4 mutation is able to detach powerers spike: (GAR)n-(GAR)n disrupt robust visual responses.</text>
                    <arg n="0">The 415G4 mutation</arg>
                    <arg n="1">powerers spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="495">
                    <text>Quantitative electrophysiology of a single unit revealed that The 415G4 mutation is capable of disrupt enhancer spike: (GAR)n-(GAR)n by preserving robust visual responses.</text>
                    <arg n="0">The 415G4 mutation</arg>
                    <arg n="1">enhancer spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="496">
                    <text>Quantitative electrophysiology of a single unit revealed that The 415G4 mutation is capable of disrupt powerers spike: (GAR)n-(GAR)n by preserving robust visual responses.</text>
                    <arg n="0">The 415G4 mutation</arg>
                    <arg n="1">powerers spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="497">
                    <text>Quantitative electrophysiology of a single unit revealed that The mutation 415G4 disrupted enhancement brush: (GAR)n-(GAR)n while retaining robust visual responses.</text>
                    <arg n="0">The mutation 415G4</arg>
                    <arg n="1">enhancement brush: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="498">
                    <text>Quantitative electrophysiology of a single unit revealed that The mutation 415G4 disrupted potent spike: (GAR)n-(GAR)n while retaining robust visual responses.</text>
                    <arg n="0">The mutation 415G4</arg>
                    <arg n="1">potent spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="499">
                    <text>Quantitative electrophysiology of a single unit revealed that The mutation 415G4 has been able to disrupt enhancement brush: (GAR)n-(GAR)n preserving robust visual responses.</text>
                    <arg n="0">The mutation 415G4</arg>
                    <arg n="1">enhancement brush: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="500">
                    <text>Quantitative electrophysiology of a single unit revealed that The mutation 415G4 has been able to disrupt potent spike: (GAR)n-(GAR)n preserving robust visual responses.</text>
                    <arg n="0">The mutation 415G4</arg>
                    <arg n="1">potent spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="501">
                    <text>Quantitative electrophysiology of a single unit revealed that The mutation 415G4 has been shown to disrupt enhancement brush: (GAR)n-(GAR)n while preserving robust visual responses.</text>
                    <arg n="0">The mutation 415G4</arg>
                    <arg n="1">enhancement brush: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="502">
                    <text>Quantitative electrophysiology of a single unit revealed that The mutation 415G4 has been shown to disrupt potent spike: (GAR)n-(GAR)n while preserving robust visual responses.</text>
                    <arg n="0">The mutation 415G4</arg>
                    <arg n="1">potent spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="503">
                    <text>Quantitative electrophysiology of a single unit revealed that The mutation 415G4 has disrupted enhancement brush: (GAR)n-(GAR)n while preserving robust visual responses.</text>
                    <arg n="0">The mutation 415G4</arg>
                    <arg n="1">enhancement brush: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="504">
                    <text>Quantitative electrophysiology of a single unit revealed that The mutation 415G4 has disrupted potent spike: (GAR)n-(GAR)n while preserving robust visual responses.</text>
                    <arg n="0">The mutation 415G4</arg>
                    <arg n="1">potent spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="505">
                    <text>Quantitative electrophysiology of a single unit revealed that The mutation 415G4 interrupts enhancement brush: (GAR)n-(GAR)n by disrupts robust visual responses.</text>
                    <arg n="0">The mutation 415G4</arg>
                    <arg n="1">enhancement brush: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="506">
                    <text>Quantitative electrophysiology of a single unit revealed that The mutation 415G4 interrupts enhancement brush: (GAR)n-(GAR)n while disrupts robust visual responses.</text>
                    <arg n="0">The mutation 415G4</arg>
                    <arg n="1">enhancement brush: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="507">
                    <text>Quantitative electrophysiology of a single unit revealed that The mutation 415G4 interrupts potent spike: (GAR)n-(GAR)n by disrupts robust visual responses.</text>
                    <arg n="0">The mutation 415G4</arg>
                    <arg n="1">potent spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="508">
                    <text>Quantitative electrophysiology of a single unit revealed that The mutation 415G4 interrupts potent spike: (GAR)n-(GAR)n while disrupts robust visual responses.</text>
                    <arg n="0">The mutation 415G4</arg>
                    <arg n="1">potent spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="509">
                    <text>Quantitative electrophysiology of a single unit revealed that The mutation 415G4 is able to detach enhancement brush: (GAR)n-(GAR)n disrupt robust visual responses.</text>
                    <arg n="0">The mutation 415G4</arg>
                    <arg n="1">enhancement brush: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="510">
                    <text>Quantitative electrophysiology of a single unit revealed that The mutation 415G4 is able to detach potent spike: (GAR)n-(GAR)n disrupt robust visual responses.</text>
                    <arg n="0">The mutation 415G4</arg>
                    <arg n="1">potent spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="511">
                    <text>Quantitative electrophysiology of a single unit revealed that The mutation 415G4 is capable of disrupt enhancement brush: (GAR)n-(GAR)n by preserving robust visual responses.</text>
                    <arg n="0">The mutation 415G4</arg>
                    <arg n="1">enhancement brush: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="512">
                    <text>Quantitative electrophysiology of a single unit revealed that The mutation 415G4 is capable of disrupt potent spike: (GAR)n-(GAR)n by preserving robust visual responses.</text>
                    <arg n="0">The mutation 415G4</arg>
                    <arg n="1">potent spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="513">
                    <text>Quantitative electrophysiology of a single unit revealed that These mutations disrupted ubiquitin binding function while retaining robust visual responses.</text>
                    <arg n="0">These mutations</arg>
                    <arg n="1">ubiquitin binding function</arg>
                </example>
                <example src="REPLACE" no="514">
                    <text>Quantitative electrophysiology of a single unit revealed that These mutations has been able to disrupt ubiquitin binding function preserving robust visual responses.</text>
                    <arg n="0">These mutations</arg>
                    <arg n="1">ubiquitin binding function</arg>
                </example>
                <example src="REPLACE" no="515">
                    <text>Quantitative electrophysiology of a single unit revealed that These mutations has been shown to disrupt ubiquitin binding function while preserving robust visual responses.</text>
                    <arg n="0">These mutations</arg>
                    <arg n="1">ubiquitin binding function</arg>
                </example>
                <example src="REPLACE" no="516">
                    <text>Quantitative electrophysiology of a single unit revealed that These mutations has disrupted ubiquitin binding function while preserving robust visual responses.</text>
                    <arg n="0">These mutations</arg>
                    <arg n="1">ubiquitin binding function</arg>
                </example>
                <example src="REPLACE" no="517">
                    <text>Quantitative electrophysiology of a single unit revealed that These mutations interrupts ubiquitin binding function by disrupts robust visual responses.</text>
                    <arg n="0">These mutations</arg>
                    <arg n="1">ubiquitin binding function</arg>
                </example>
                <example src="REPLACE" no="518">
                    <text>Quantitative electrophysiology of a single unit revealed that These mutations interrupts ubiquitin binding function while disrupts robust visual responses.</text>
                    <arg n="0">These mutations</arg>
                    <arg n="1">ubiquitin binding function</arg>
                </example>
                <example src="REPLACE" no="519">
                    <text>Quantitative electrophysiology of a single unit revealed that These mutations is able to detach ubiquitin binding function disrupt robust visual responses.</text>
                    <arg n="0">These mutations</arg>
                    <arg n="1">ubiquitin binding function</arg>
                </example>
                <example src="REPLACE" no="520">
                    <text>Quantitative electrophysiology of a single unit revealed that These mutations is capable of disrupt ubiquitin binding function by preserving robust visual responses.</text>
                    <arg n="0">These mutations</arg>
                    <arg n="1">ubiquitin binding function</arg>
                </example>
                <example src="REPLACE" no="521">
                    <text>Quantitative electrophysiology of a single unit revealed that This deletion disrupted consensus coupling signal 5 while retaining robust visual responses.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">consensus coupling signal 5</arg>
                </example>
                <example src="REPLACE" no="522">
                    <text>Quantitative electrophysiology of a single unit revealed that This deletion disrupted the 5 consensus of splice signal while retaining robust visual responses.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">the 5 consensus of splice signal</arg>
                </example>
                <example src="REPLACE" no="523">
                    <text>Quantitative electrophysiology of a single unit revealed that This deletion disrupted the 5th consensus of the cut signal while retaining robust visual responses.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">the 5th consensus of the cut signal</arg>
                </example>
                <example src="REPLACE" no="524">
                    <text>Quantitative electrophysiology of a single unit revealed that This deletion disrupted the splice signal consensus 5 while retaining robust visual responses.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">the splice signal consensus 5</arg>
                </example>
                <example src="REPLACE" no="525">
                    <text>Quantitative electrophysiology of a single unit revealed that This deletion has been able to disrupt consensus coupling signal 5 preserving robust visual responses.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">consensus coupling signal 5</arg>
                </example>
                <example src="REPLACE" no="526">
                    <text>Quantitative electrophysiology of a single unit revealed that This deletion has been able to disrupt the 5 consensus of splice signal preserving robust visual responses.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">the 5 consensus of splice signal</arg>
                </example>
                <example src="REPLACE" no="527">
                    <text>Quantitative electrophysiology of a single unit revealed that This deletion has been able to disrupt the 5th consensus of the cut signal preserving robust visual responses.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">the 5th consensus of the cut signal</arg>
                </example>
                <example src="REPLACE" no="528">
                    <text>Quantitative electrophysiology of a single unit revealed that This deletion has been able to disrupt the splice signal consensus 5 preserving robust visual responses.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">the splice signal consensus 5</arg>
                </example>
                <example src="REPLACE" no="529">
                    <text>Quantitative electrophysiology of a single unit revealed that This deletion has been shown to disrupt consensus coupling signal 5 while preserving robust visual responses.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">consensus coupling signal 5</arg>
                </example>
                <example src="REPLACE" no="530">
                    <text>Quantitative electrophysiology of a single unit revealed that This deletion has been shown to disrupt the 5 consensus of splice signal while preserving robust visual responses.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">the 5 consensus of splice signal</arg>
                </example>
                <example src="REPLACE" no="531">
                    <text>Quantitative electrophysiology of a single unit revealed that This deletion has been shown to disrupt the 5th consensus of the cut signal while preserving robust visual responses.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">the 5th consensus of the cut signal</arg>
                </example>
                <example src="REPLACE" no="532">
                    <text>Quantitative electrophysiology of a single unit revealed that This deletion has been shown to disrupt the splice signal consensus 5 while preserving robust visual responses.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">the splice signal consensus 5</arg>
                </example>
                <example src="REPLACE" no="533">
                    <text>Quantitative electrophysiology of a single unit revealed that This deletion has disrupted consensus coupling signal 5 while preserving robust visual responses.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">consensus coupling signal 5</arg>
                </example>
                <example src="REPLACE" no="534">
                    <text>Quantitative electrophysiology of a single unit revealed that This deletion has disrupted the 5 consensus of splice signal while preserving robust visual responses.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">the 5 consensus of splice signal</arg>
                </example>
                <example src="REPLACE" no="535">
                    <text>Quantitative electrophysiology of a single unit revealed that This deletion has disrupted the 5th consensus of the cut signal while preserving robust visual responses.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">the 5th consensus of the cut signal</arg>
                </example>
                <example src="REPLACE" no="536">
                    <text>Quantitative electrophysiology of a single unit revealed that This deletion has disrupted the splice signal consensus 5 while preserving robust visual responses.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">the splice signal consensus 5</arg>
                </example>
                <example src="REPLACE" no="537">
                    <text>Quantitative electrophysiology of a single unit revealed that This deletion interrupts consensus coupling signal 5 by disrupts robust visual responses.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">consensus coupling signal 5</arg>
                </example>
                <example src="REPLACE" no="538">
                    <text>Quantitative electrophysiology of a single unit revealed that This deletion interrupts consensus coupling signal 5 while disrupts robust visual responses.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">consensus coupling signal 5</arg>
                </example>
                <example src="REPLACE" no="539">
                    <text>Quantitative electrophysiology of a single unit revealed that This deletion interrupts the 5 consensus of splice signal by disrupts robust visual responses.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">the 5 consensus of splice signal</arg>
                </example>
                <example src="REPLACE" no="540">
                    <text>Quantitative electrophysiology of a single unit revealed that This deletion interrupts the 5 consensus of splice signal while disrupts robust visual responses.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">the 5 consensus of splice signal</arg>
                </example>
                <example src="REPLACE" no="541">
                    <text>Quantitative electrophysiology of a single unit revealed that This deletion interrupts the 5th consensus of the cut signal by disrupts robust visual responses.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">the 5th consensus of the cut signal</arg>
                </example>
                <example src="REPLACE" no="542">
                    <text>Quantitative electrophysiology of a single unit revealed that This deletion interrupts the 5th consensus of the cut signal while disrupts robust visual responses.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">the 5th consensus of the cut signal</arg>
                </example>
                <example src="REPLACE" no="543">
                    <text>Quantitative electrophysiology of a single unit revealed that This deletion interrupts the splice signal consensus 5 by disrupts robust visual responses.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">the splice signal consensus 5</arg>
                </example>
                <example src="REPLACE" no="544">
                    <text>Quantitative electrophysiology of a single unit revealed that This deletion interrupts the splice signal consensus 5 while disrupts robust visual responses.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">the splice signal consensus 5</arg>
                </example>
                <example src="REPLACE" no="545">
                    <text>Quantitative electrophysiology of a single unit revealed that This deletion is able to detach consensus coupling signal 5 disrupt robust visual responses.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">consensus coupling signal 5</arg>
                </example>
                <example src="REPLACE" no="546">
                    <text>Quantitative electrophysiology of a single unit revealed that This deletion is able to detach the 5 consensus of splice signal disrupt robust visual responses.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">the 5 consensus of splice signal</arg>
                </example>
                <example src="REPLACE" no="547">
                    <text>Quantitative electrophysiology of a single unit revealed that This deletion is able to detach the 5th consensus of the cut signal disrupt robust visual responses.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">the 5th consensus of the cut signal</arg>
                </example>
                <example src="REPLACE" no="548">
                    <text>Quantitative electrophysiology of a single unit revealed that This deletion is able to detach the splice signal consensus 5 disrupt robust visual responses.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">the splice signal consensus 5</arg>
                </example>
                <example src="REPLACE" no="549">
                    <text>Quantitative electrophysiology of a single unit revealed that This deletion is capable of disrupt consensus coupling signal 5 by preserving robust visual responses.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">consensus coupling signal 5</arg>
                </example>
                <example src="REPLACE" no="550">
                    <text>Quantitative electrophysiology of a single unit revealed that This deletion is capable of disrupt the 5 consensus of splice signal by preserving robust visual responses.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">the 5 consensus of splice signal</arg>
                </example>
                <example src="REPLACE" no="551">
                    <text>Quantitative electrophysiology of a single unit revealed that This deletion is capable of disrupt the 5th consensus of the cut signal by preserving robust visual responses.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">the 5th consensus of the cut signal</arg>
                </example>
                <example src="REPLACE" no="552">
                    <text>Quantitative electrophysiology of a single unit revealed that This deletion is capable of disrupt the splice signal consensus 5 by preserving robust visual responses.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">the splice signal consensus 5</arg>
                </example>
                <example src="REPLACE" no="553">
                    <text>Quantitative electrophysiology of a single unit revealed that a 415G4 mutation disrupted licensing improvement sequence: (GAR)n-(GAR)n while retaining robust visual responses.</text>
                    <arg n="0">a 415G4 mutation</arg>
                    <arg n="1">licensing improvement sequence: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="554">
                    <text>Quantitative electrophysiology of a single unit revealed that a 415G4 mutation has been able to disrupt licensing improvement sequence: (GAR)n-(GAR)n preserving robust visual responses.</text>
                    <arg n="0">a 415G4 mutation</arg>
                    <arg n="1">licensing improvement sequence: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="555">
                    <text>Quantitative electrophysiology of a single unit revealed that a 415G4 mutation has been shown to disrupt licensing improvement sequence: (GAR)n-(GAR)n while preserving robust visual responses.</text>
                    <arg n="0">a 415G4 mutation</arg>
                    <arg n="1">licensing improvement sequence: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="556">
                    <text>Quantitative electrophysiology of a single unit revealed that a 415G4 mutation has disrupted licensing improvement sequence: (GAR)n-(GAR)n while preserving robust visual responses.</text>
                    <arg n="0">a 415G4 mutation</arg>
                    <arg n="1">licensing improvement sequence: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="557">
                    <text>Quantitative electrophysiology of a single unit revealed that a 415G4 mutation interrupts licensing improvement sequence: (GAR)n-(GAR)n by disrupts robust visual responses.</text>
                    <arg n="0">a 415G4 mutation</arg>
                    <arg n="1">licensing improvement sequence: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="558">
                    <text>Quantitative electrophysiology of a single unit revealed that a 415G4 mutation interrupts licensing improvement sequence: (GAR)n-(GAR)n while disrupts robust visual responses.</text>
                    <arg n="0">a 415G4 mutation</arg>
                    <arg n="1">licensing improvement sequence: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="559">
                    <text>Quantitative electrophysiology of a single unit revealed that a 415G4 mutation is able to detach licensing improvement sequence: (GAR)n-(GAR)n disrupt robust visual responses.</text>
                    <arg n="0">a 415G4 mutation</arg>
                    <arg n="1">licensing improvement sequence: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="560">
                    <text>Quantitative electrophysiology of a single unit revealed that a 415G4 mutation is capable of disrupt licensing improvement sequence: (GAR)n-(GAR)n by preserving robust visual responses.</text>
                    <arg n="0">a 415G4 mutation</arg>
                    <arg n="1">licensing improvement sequence: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="561">
                    <text>Quantitative electrophysiology of a single unit revealed that a homozygotic mutation disrupted splicing while retaining robust visual responses.</text>
                    <arg n="0">a homozygotic mutation</arg>
                    <arg n="1">splicing</arg>
                </example>
                <example src="REPLACE" no="562">
                    <text>Quantitative electrophysiology of a single unit revealed that a homozygotic mutation has been able to disrupt splicing preserving robust visual responses.</text>
                    <arg n="0">a homozygotic mutation</arg>
                    <arg n="1">splicing</arg>
                </example>
                <example src="REPLACE" no="563">
                    <text>Quantitative electrophysiology of a single unit revealed that a homozygotic mutation has been shown to disrupt splicing while preserving robust visual responses.</text>
                    <arg n="0">a homozygotic mutation</arg>
                    <arg n="1">splicing</arg>
                </example>
                <example src="REPLACE" no="564">
                    <text>Quantitative electrophysiology of a single unit revealed that a homozygotic mutation has disrupted splicing while preserving robust visual responses.</text>
                    <arg n="0">a homozygotic mutation</arg>
                    <arg n="1">splicing</arg>
                </example>
                <example src="REPLACE" no="565">
                    <text>Quantitative electrophysiology of a single unit revealed that a homozygotic mutation interrupts splicing by disrupts robust visual responses.</text>
                    <arg n="0">a homozygotic mutation</arg>
                    <arg n="1">splicing</arg>
                </example>
                <example src="REPLACE" no="566">
                    <text>Quantitative electrophysiology of a single unit revealed that a homozygotic mutation interrupts splicing while disrupts robust visual responses.</text>
                    <arg n="0">a homozygotic mutation</arg>
                    <arg n="1">splicing</arg>
                </example>
                <example src="REPLACE" no="567">
                    <text>Quantitative electrophysiology of a single unit revealed that a homozygotic mutation is able to detach splicing disrupt robust visual responses.</text>
                    <arg n="0">a homozygotic mutation</arg>
                    <arg n="1">splicing</arg>
                </example>
                <example src="REPLACE" no="568">
                    <text>Quantitative electrophysiology of a single unit revealed that a homozygotic mutation is capable of disrupt splicing by preserving robust visual responses.</text>
                    <arg n="0">a homozygotic mutation</arg>
                    <arg n="1">splicing</arg>
                </example>
                <example src="REPLACE" no="569">
                    <text>Quantitative electrophysiology of a single unit revealed that blocking the expression MEKK1 or MEKK2 disrupted the overall integrity of the MAPK route regulation while retaining robust visual responses.</text>
                    <arg n="0">blocking the expression MEKK1 or MEKK2</arg>
                    <arg n="1">the overall integrity of the MAPK route regulation</arg>
                </example>
                <example src="REPLACE" no="570">
                    <text>Quantitative electrophysiology of a single unit revealed that blocking the expression MEKK1 or MEKK2 has been able to disrupt the overall integrity of the MAPK route regulation preserving robust visual responses.</text>
                    <arg n="0">blocking the expression MEKK1 or MEKK2</arg>
                    <arg n="1">the overall integrity of the MAPK route regulation</arg>
                </example>
                <example src="REPLACE" no="571">
                    <text>Quantitative electrophysiology of a single unit revealed that blocking the expression MEKK1 or MEKK2 has been shown to disrupt the overall integrity of the MAPK route regulation while preserving robust visual responses.</text>
                    <arg n="0">blocking the expression MEKK1 or MEKK2</arg>
                    <arg n="1">the overall integrity of the MAPK route regulation</arg>
                </example>
                <example src="REPLACE" no="572">
                    <text>Quantitative electrophysiology of a single unit revealed that blocking the expression MEKK1 or MEKK2 has disrupted the overall integrity of the MAPK route regulation while preserving robust visual responses.</text>
                    <arg n="0">blocking the expression MEKK1 or MEKK2</arg>
                    <arg n="1">the overall integrity of the MAPK route regulation</arg>
                </example>
                <example src="REPLACE" no="573">
                    <text>Quantitative electrophysiology of a single unit revealed that blocking the expression MEKK1 or MEKK2 interrupts the overall integrity of the MAPK route regulation by disrupts robust visual responses.</text>
                    <arg n="0">blocking the expression MEKK1 or MEKK2</arg>
                    <arg n="1">the overall integrity of the MAPK route regulation</arg>
                </example>
                <example src="REPLACE" no="574">
                    <text>Quantitative electrophysiology of a single unit revealed that blocking the expression MEKK1 or MEKK2 interrupts the overall integrity of the MAPK route regulation while disrupts robust visual responses.</text>
                    <arg n="0">blocking the expression MEKK1 or MEKK2</arg>
                    <arg n="1">the overall integrity of the MAPK route regulation</arg>
                </example>
                <example src="REPLACE" no="575">
                    <text>Quantitative electrophysiology of a single unit revealed that blocking the expression MEKK1 or MEKK2 is able to detach the overall integrity of the MAPK route regulation disrupt robust visual responses.</text>
                    <arg n="0">blocking the expression MEKK1 or MEKK2</arg>
                    <arg n="1">the overall integrity of the MAPK route regulation</arg>
                </example>
                <example src="REPLACE" no="576">
                    <text>Quantitative electrophysiology of a single unit revealed that blocking the expression MEKK1 or MEKK2 is capable of disrupt the overall integrity of the MAPK route regulation by preserving robust visual responses.</text>
                    <arg n="0">blocking the expression MEKK1 or MEKK2</arg>
                    <arg n="1">the overall integrity of the MAPK route regulation</arg>
                </example>
                <example src="REPLACE" no="577">
                    <text>Quantitative electrophysiology of a single unit revealed that homozygous mutation disrupted splicing while retaining robust visual responses.</text>
                    <arg n="0">homozygous mutation</arg>
                    <arg n="1">splicing</arg>
                </example>
                <example src="REPLACE" no="578">
                    <text>Quantitative electrophysiology of a single unit revealed that homozygous mutation has been able to disrupt splicing preserving robust visual responses.</text>
                    <arg n="0">homozygous mutation</arg>
                    <arg n="1">splicing</arg>
                </example>
                <example src="REPLACE" no="579">
                    <text>Quantitative electrophysiology of a single unit revealed that homozygous mutation has been shown to disrupt splicing while preserving robust visual responses.</text>
                    <arg n="0">homozygous mutation</arg>
                    <arg n="1">splicing</arg>
                </example>
                <example src="REPLACE" no="580">
                    <text>Quantitative electrophysiology of a single unit revealed that homozygous mutation has disrupted splicing while preserving robust visual responses.</text>
                    <arg n="0">homozygous mutation</arg>
                    <arg n="1">splicing</arg>
                </example>
                <example src="REPLACE" no="581">
                    <text>Quantitative electrophysiology of a single unit revealed that homozygous mutation interrupts splicing by disrupts robust visual responses.</text>
                    <arg n="0">homozygous mutation</arg>
                    <arg n="1">splicing</arg>
                </example>
                <example src="REPLACE" no="582">
                    <text>Quantitative electrophysiology of a single unit revealed that homozygous mutation interrupts splicing while disrupts robust visual responses.</text>
                    <arg n="0">homozygous mutation</arg>
                    <arg n="1">splicing</arg>
                </example>
                <example src="REPLACE" no="583">
                    <text>Quantitative electrophysiology of a single unit revealed that homozygous mutation is able to detach splicing disrupt robust visual responses.</text>
                    <arg n="0">homozygous mutation</arg>
                    <arg n="1">splicing</arg>
                </example>
                <example src="REPLACE" no="584">
                    <text>Quantitative electrophysiology of a single unit revealed that homozygous mutation is capable of disrupt splicing by preserving robust visual responses.</text>
                    <arg n="0">homozygous mutation</arg>
                    <arg n="1">splicing</arg>
                </example>
                <example src="REPLACE" no="585">
                    <text>Quantitative electrophysiology of a single unit revealed that inhibition of inflammation disrupted physiological protective responses while retaining robust visual responses.</text>
                    <arg n="0">inhibition of inflammation</arg>
                    <arg n="1">physiological protective responses</arg>
                </example>
                <example src="REPLACE" no="586">
                    <text>Quantitative electrophysiology of a single unit revealed that inhibition of inflammation disrupted protective physiological response while retaining robust visual responses.</text>
                    <arg n="0">inhibition of inflammation</arg>
                    <arg n="1">protective physiological response</arg>
                </example>
                <example src="REPLACE" no="587">
                    <text>Quantitative electrophysiology of a single unit revealed that inhibition of inflammation has been able to disrupt physiological protective responses preserving robust visual responses.</text>
                    <arg n="0">inhibition of inflammation</arg>
                    <arg n="1">physiological protective responses</arg>
                </example>
                <example src="REPLACE" no="588">
                    <text>Quantitative electrophysiology of a single unit revealed that inhibition of inflammation has been able to disrupt protective physiological response preserving robust visual responses.</text>
                    <arg n="0">inhibition of inflammation</arg>
                    <arg n="1">protective physiological response</arg>
                </example>
                <example src="REPLACE" no="589">
                    <text>Quantitative electrophysiology of a single unit revealed that inhibition of inflammation has been shown to disrupt physiological protective responses while preserving robust visual responses.</text>
                    <arg n="0">inhibition of inflammation</arg>
                    <arg n="1">physiological protective responses</arg>
                </example>
                <example src="REPLACE" no="590">
                    <text>Quantitative electrophysiology of a single unit revealed that inhibition of inflammation has been shown to disrupt protective physiological response while preserving robust visual responses.</text>
                    <arg n="0">inhibition of inflammation</arg>
                    <arg n="1">protective physiological response</arg>
                </example>
                <example src="REPLACE" no="591">
                    <text>Quantitative electrophysiology of a single unit revealed that inhibition of inflammation has disrupted physiological protective responses while preserving robust visual responses.</text>
                    <arg n="0">inhibition of inflammation</arg>
                    <arg n="1">physiological protective responses</arg>
                </example>
                <example src="REPLACE" no="592">
                    <text>Quantitative electrophysiology of a single unit revealed that inhibition of inflammation has disrupted protective physiological response while preserving robust visual responses.</text>
                    <arg n="0">inhibition of inflammation</arg>
                    <arg n="1">protective physiological response</arg>
                </example>
                <example src="REPLACE" no="593">
                    <text>Quantitative electrophysiology of a single unit revealed that inhibition of inflammation interrupts physiological protective responses by disrupts robust visual responses.</text>
                    <arg n="0">inhibition of inflammation</arg>
                    <arg n="1">physiological protective responses</arg>
                </example>
                <example src="REPLACE" no="594">
                    <text>Quantitative electrophysiology of a single unit revealed that inhibition of inflammation interrupts physiological protective responses while disrupts robust visual responses.</text>
                    <arg n="0">inhibition of inflammation</arg>
                    <arg n="1">physiological protective responses</arg>
                </example>
                <example src="REPLACE" no="595">
                    <text>Quantitative electrophysiology of a single unit revealed that inhibition of inflammation interrupts protective physiological response by disrupts robust visual responses.</text>
                    <arg n="0">inhibition of inflammation</arg>
                    <arg n="1">protective physiological response</arg>
                </example>
                <example src="REPLACE" no="596">
                    <text>Quantitative electrophysiology of a single unit revealed that inhibition of inflammation interrupts protective physiological response while disrupts robust visual responses.</text>
                    <arg n="0">inhibition of inflammation</arg>
                    <arg n="1">protective physiological response</arg>
                </example>
                <example src="REPLACE" no="597">
                    <text>Quantitative electrophysiology of a single unit revealed that inhibition of inflammation is able to detach physiological protective responses disrupt robust visual responses.</text>
                    <arg n="0">inhibition of inflammation</arg>
                    <arg n="1">physiological protective responses</arg>
                </example>
                <example src="REPLACE" no="598">
                    <text>Quantitative electrophysiology of a single unit revealed that inhibition of inflammation is able to detach protective physiological response disrupt robust visual responses.</text>
                    <arg n="0">inhibition of inflammation</arg>
                    <arg n="1">protective physiological response</arg>
                </example>
                <example src="REPLACE" no="599">
                    <text>Quantitative electrophysiology of a single unit revealed that inhibition of inflammation is capable of disrupt physiological protective responses by preserving robust visual responses.</text>
                    <arg n="0">inhibition of inflammation</arg>
                    <arg n="1">physiological protective responses</arg>
                </example>
                <example src="REPLACE" no="600">
                    <text>Quantitative electrophysiology of a single unit revealed that inhibition of inflammation is capable of disrupt protective physiological response by preserving robust visual responses.</text>
                    <arg n="0">inhibition of inflammation</arg>
                    <arg n="1">protective physiological response</arg>
                </example>
                <example src="REPLACE" no="601">
                    <text>Quantitative electrophysiology of a single unit revealed that manipulation of the Tie-2 system in tumors disrupted tumour vessels while retaining robust visual responses.</text>
                    <arg n="0">manipulation of the Tie-2 system in tumors</arg>
                    <arg n="1">tumour vessels</arg>
                </example>
                <example src="REPLACE" no="602">
                    <text>Quantitative electrophysiology of a single unit revealed that manipulation of the Tie-2 system in tumors has been able to disrupt tumour vessels preserving robust visual responses.</text>
                    <arg n="0">manipulation of the Tie-2 system in tumors</arg>
                    <arg n="1">tumour vessels</arg>
                </example>
                <example src="REPLACE" no="603">
                    <text>Quantitative electrophysiology of a single unit revealed that manipulation of the Tie-2 system in tumors has been shown to disrupt tumour vessels while preserving robust visual responses.</text>
                    <arg n="0">manipulation of the Tie-2 system in tumors</arg>
                    <arg n="1">tumour vessels</arg>
                </example>
                <example src="REPLACE" no="604">
                    <text>Quantitative electrophysiology of a single unit revealed that manipulation of the Tie-2 system in tumors has disrupted tumour vessels while preserving robust visual responses.</text>
                    <arg n="0">manipulation of the Tie-2 system in tumors</arg>
                    <arg n="1">tumour vessels</arg>
                </example>
                <example src="REPLACE" no="605">
                    <text>Quantitative electrophysiology of a single unit revealed that manipulation of the Tie-2 system in tumors interrupts tumour vessels by disrupts robust visual responses.</text>
                    <arg n="0">manipulation of the Tie-2 system in tumors</arg>
                    <arg n="1">tumour vessels</arg>
                </example>
                <example src="REPLACE" no="606">
                    <text>Quantitative electrophysiology of a single unit revealed that manipulation of the Tie-2 system in tumors interrupts tumour vessels while disrupts robust visual responses.</text>
                    <arg n="0">manipulation of the Tie-2 system in tumors</arg>
                    <arg n="1">tumour vessels</arg>
                </example>
                <example src="REPLACE" no="607">
                    <text>Quantitative electrophysiology of a single unit revealed that manipulation of the Tie-2 system in tumors is able to detach tumour vessels disrupt robust visual responses.</text>
                    <arg n="0">manipulation of the Tie-2 system in tumors</arg>
                    <arg n="1">tumour vessels</arg>
                </example>
                <example src="REPLACE" no="608">
                    <text>Quantitative electrophysiology of a single unit revealed that manipulation of the Tie-2 system in tumors is capable of disrupt tumour vessels by preserving robust visual responses.</text>
                    <arg n="0">manipulation of the Tie-2 system in tumors</arg>
                    <arg n="1">tumour vessels</arg>
                </example>
                <example src="REPLACE" no="609">
                    <text>Quantitative electrophysiology of a single unit revealed that manipulation of the binding system 2 in tumours disrupted tumor vessels while retaining robust visual responses.</text>
                    <arg n="0">manipulation of the binding system 2 in tumours</arg>
                    <arg n="1">tumor vessels</arg>
                </example>
                <example src="REPLACE" no="610">
                    <text>Quantitative electrophysiology of a single unit revealed that manipulation of the binding system 2 in tumours has been able to disrupt tumor vessels preserving robust visual responses.</text>
                    <arg n="0">manipulation of the binding system 2 in tumours</arg>
                    <arg n="1">tumor vessels</arg>
                </example>
                <example src="REPLACE" no="611">
                    <text>Quantitative electrophysiology of a single unit revealed that manipulation of the binding system 2 in tumours has been shown to disrupt tumor vessels while preserving robust visual responses.</text>
                    <arg n="0">manipulation of the binding system 2 in tumours</arg>
                    <arg n="1">tumor vessels</arg>
                </example>
                <example src="REPLACE" no="612">
                    <text>Quantitative electrophysiology of a single unit revealed that manipulation of the binding system 2 in tumours has disrupted tumor vessels while preserving robust visual responses.</text>
                    <arg n="0">manipulation of the binding system 2 in tumours</arg>
                    <arg n="1">tumor vessels</arg>
                </example>
                <example src="REPLACE" no="613">
                    <text>Quantitative electrophysiology of a single unit revealed that manipulation of the binding system 2 in tumours interrupts tumor vessels by disrupts robust visual responses.</text>
                    <arg n="0">manipulation of the binding system 2 in tumours</arg>
                    <arg n="1">tumor vessels</arg>
                </example>
                <example src="REPLACE" no="614">
                    <text>Quantitative electrophysiology of a single unit revealed that manipulation of the binding system 2 in tumours interrupts tumor vessels while disrupts robust visual responses.</text>
                    <arg n="0">manipulation of the binding system 2 in tumours</arg>
                    <arg n="1">tumor vessels</arg>
                </example>
                <example src="REPLACE" no="615">
                    <text>Quantitative electrophysiology of a single unit revealed that manipulation of the binding system 2 in tumours is able to detach tumor vessels disrupt robust visual responses.</text>
                    <arg n="0">manipulation of the binding system 2 in tumours</arg>
                    <arg n="1">tumor vessels</arg>
                </example>
                <example src="REPLACE" no="616">
                    <text>Quantitative electrophysiology of a single unit revealed that manipulation of the binding system 2 in tumours is capable of disrupt tumor vessels by preserving robust visual responses.</text>
                    <arg n="0">manipulation of the binding system 2 in tumours</arg>
                    <arg n="1">tumor vessels</arg>
                </example>
                <example src="REPLACE" no="617">
                    <text>Quantitative electrophysiology of a single unit revealed that multations at p53 disrupted post-checking points for DNA damage while retaining robust visual responses.</text>
                    <arg n="0">multations at p53</arg>
                    <arg n="1">post-checking points for DNA damage</arg>
                </example>
                <example src="REPLACE" no="618">
                    <text>Quantitative electrophysiology of a single unit revealed that multations at p53 has been able to disrupt post-checking points for DNA damage preserving robust visual responses.</text>
                    <arg n="0">multations at p53</arg>
                    <arg n="1">post-checking points for DNA damage</arg>
                </example>
                <example src="REPLACE" no="619">
                    <text>Quantitative electrophysiology of a single unit revealed that multations at p53 has been shown to disrupt post-checking points for DNA damage while preserving robust visual responses.</text>
                    <arg n="0">multations at p53</arg>
                    <arg n="1">post-checking points for DNA damage</arg>
                </example>
                <example src="REPLACE" no="620">
                    <text>Quantitative electrophysiology of a single unit revealed that multations at p53 has disrupted post-checking points for DNA damage while preserving robust visual responses.</text>
                    <arg n="0">multations at p53</arg>
                    <arg n="1">post-checking points for DNA damage</arg>
                </example>
                <example src="REPLACE" no="621">
                    <text>Quantitative electrophysiology of a single unit revealed that multations at p53 interrupts post-checking points for DNA damage by disrupts robust visual responses.</text>
                    <arg n="0">multations at p53</arg>
                    <arg n="1">post-checking points for DNA damage</arg>
                </example>
                <example src="REPLACE" no="622">
                    <text>Quantitative electrophysiology of a single unit revealed that multations at p53 interrupts post-checking points for DNA damage while disrupts robust visual responses.</text>
                    <arg n="0">multations at p53</arg>
                    <arg n="1">post-checking points for DNA damage</arg>
                </example>
                <example src="REPLACE" no="623">
                    <text>Quantitative electrophysiology of a single unit revealed that multations at p53 is able to detach post-checking points for DNA damage disrupt robust visual responses.</text>
                    <arg n="0">multations at p53</arg>
                    <arg n="1">post-checking points for DNA damage</arg>
                </example>
                <example src="REPLACE" no="624">
                    <text>Quantitative electrophysiology of a single unit revealed that multations at p53 is capable of disrupt post-checking points for DNA damage by preserving robust visual responses.</text>
                    <arg n="0">multations at p53</arg>
                    <arg n="1">post-checking points for DNA damage</arg>
                </example>
                <example src="REPLACE" no="625">
                    <text>Quantitative electrophysiology of a single unit revealed that mutation 415G4 disrupted pulling enhancement sequence: (GAR)n-(GAR)n while retaining robust visual responses.</text>
                    <arg n="0">mutation 415G4</arg>
                    <arg n="1">pulling enhancement sequence: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="626">
                    <text>Quantitative electrophysiology of a single unit revealed that mutation 415G4 disrupted splicing sequencer: (GAR)n-(GAR)n while retaining robust visual responses.</text>
                    <arg n="0">mutation 415G4</arg>
                    <arg n="1">splicing sequencer: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="627">
                    <text>Quantitative electrophysiology of a single unit revealed that mutation 415G4 has been able to disrupt pulling enhancement sequence: (GAR)n-(GAR)n preserving robust visual responses.</text>
                    <arg n="0">mutation 415G4</arg>
                    <arg n="1">pulling enhancement sequence: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="628">
                    <text>Quantitative electrophysiology of a single unit revealed that mutation 415G4 has been able to disrupt splicing sequencer: (GAR)n-(GAR)n preserving robust visual responses.</text>
                    <arg n="0">mutation 415G4</arg>
                    <arg n="1">splicing sequencer: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="629">
                    <text>Quantitative electrophysiology of a single unit revealed that mutation 415G4 has been shown to disrupt pulling enhancement sequence: (GAR)n-(GAR)n while preserving robust visual responses.</text>
                    <arg n="0">mutation 415G4</arg>
                    <arg n="1">pulling enhancement sequence: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="630">
                    <text>Quantitative electrophysiology of a single unit revealed that mutation 415G4 has been shown to disrupt splicing sequencer: (GAR)n-(GAR)n while preserving robust visual responses.</text>
                    <arg n="0">mutation 415G4</arg>
                    <arg n="1">splicing sequencer: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="631">
                    <text>Quantitative electrophysiology of a single unit revealed that mutation 415G4 has disrupted pulling enhancement sequence: (GAR)n-(GAR)n while preserving robust visual responses.</text>
                    <arg n="0">mutation 415G4</arg>
                    <arg n="1">pulling enhancement sequence: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="632">
                    <text>Quantitative electrophysiology of a single unit revealed that mutation 415G4 has disrupted splicing sequencer: (GAR)n-(GAR)n while preserving robust visual responses.</text>
                    <arg n="0">mutation 415G4</arg>
                    <arg n="1">splicing sequencer: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="633">
                    <text>Quantitative electrophysiology of a single unit revealed that mutation 415G4 interrupts pulling enhancement sequence: (GAR)n-(GAR)n by disrupts robust visual responses.</text>
                    <arg n="0">mutation 415G4</arg>
                    <arg n="1">pulling enhancement sequence: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="634">
                    <text>Quantitative electrophysiology of a single unit revealed that mutation 415G4 interrupts pulling enhancement sequence: (GAR)n-(GAR)n while disrupts robust visual responses.</text>
                    <arg n="0">mutation 415G4</arg>
                    <arg n="1">pulling enhancement sequence: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="635">
                    <text>Quantitative electrophysiology of a single unit revealed that mutation 415G4 interrupts splicing sequencer: (GAR)n-(GAR)n by disrupts robust visual responses.</text>
                    <arg n="0">mutation 415G4</arg>
                    <arg n="1">splicing sequencer: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="636">
                    <text>Quantitative electrophysiology of a single unit revealed that mutation 415G4 interrupts splicing sequencer: (GAR)n-(GAR)n while disrupts robust visual responses.</text>
                    <arg n="0">mutation 415G4</arg>
                    <arg n="1">splicing sequencer: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="637">
                    <text>Quantitative electrophysiology of a single unit revealed that mutation 415G4 is able to detach pulling enhancement sequence: (GAR)n-(GAR)n disrupt robust visual responses.</text>
                    <arg n="0">mutation 415G4</arg>
                    <arg n="1">pulling enhancement sequence: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="638">
                    <text>Quantitative electrophysiology of a single unit revealed that mutation 415G4 is able to detach splicing sequencer: (GAR)n-(GAR)n disrupt robust visual responses.</text>
                    <arg n="0">mutation 415G4</arg>
                    <arg n="1">splicing sequencer: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="639">
                    <text>Quantitative electrophysiology of a single unit revealed that mutation 415G4 is capable of disrupt pulling enhancement sequence: (GAR)n-(GAR)n by preserving robust visual responses.</text>
                    <arg n="0">mutation 415G4</arg>
                    <arg n="1">pulling enhancement sequence: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="640">
                    <text>Quantitative electrophysiology of a single unit revealed that mutation 415G4 is capable of disrupt splicing sequencer: (GAR)n-(GAR)n by preserving robust visual responses.</text>
                    <arg n="0">mutation 415G4</arg>
                    <arg n="1">splicing sequencer: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="641">
                    <text>Quantitative electrophysiology of a single unit revealed that mutations in this region disrupted assembly of keratin filaments while retaining robust visual responses.</text>
                    <arg n="0">mutations in this region</arg>
                    <arg n="1">assembly of keratin filaments</arg>
                </example>
                <example src="REPLACE" no="642">
                    <text>Quantitative electrophysiology of a single unit revealed that mutations in this region has been able to disrupt assembly of keratin filaments preserving robust visual responses.</text>
                    <arg n="0">mutations in this region</arg>
                    <arg n="1">assembly of keratin filaments</arg>
                </example>
                <example src="REPLACE" no="643">
                    <text>Quantitative electrophysiology of a single unit revealed that mutations in this region has been shown to disrupt assembly of keratin filaments while preserving robust visual responses.</text>
                    <arg n="0">mutations in this region</arg>
                    <arg n="1">assembly of keratin filaments</arg>
                </example>
                <example src="REPLACE" no="644">
                    <text>Quantitative electrophysiology of a single unit revealed that mutations in this region has disrupted assembly of keratin filaments while preserving robust visual responses.</text>
                    <arg n="0">mutations in this region</arg>
                    <arg n="1">assembly of keratin filaments</arg>
                </example>
                <example src="REPLACE" no="645">
                    <text>Quantitative electrophysiology of a single unit revealed that mutations in this region interrupts assembly of keratin filaments by disrupts robust visual responses.</text>
                    <arg n="0">mutations in this region</arg>
                    <arg n="1">assembly of keratin filaments</arg>
                </example>
                <example src="REPLACE" no="646">
                    <text>Quantitative electrophysiology of a single unit revealed that mutations in this region interrupts assembly of keratin filaments while disrupts robust visual responses.</text>
                    <arg n="0">mutations in this region</arg>
                    <arg n="1">assembly of keratin filaments</arg>
                </example>
                <example src="REPLACE" no="647">
                    <text>Quantitative electrophysiology of a single unit revealed that mutations in this region is able to detach assembly of keratin filaments disrupt robust visual responses.</text>
                    <arg n="0">mutations in this region</arg>
                    <arg n="1">assembly of keratin filaments</arg>
                </example>
                <example src="REPLACE" no="648">
                    <text>Quantitative electrophysiology of a single unit revealed that mutations in this region is capable of disrupt assembly of keratin filaments by preserving robust visual responses.</text>
                    <arg n="0">mutations in this region</arg>
                    <arg n="1">assembly of keratin filaments</arg>
                </example>
                <example src="REPLACE" no="649">
                    <text>Quantitative electrophysiology of a single unit revealed that p53 mutations disrupted checking point responses for DNA damage while retaining robust visual responses.</text>
                    <arg n="0">p53 mutations</arg>
                    <arg n="1">checking point responses for DNA damage</arg>
                </example>
                <example src="REPLACE" no="650">
                    <text>Quantitative electrophysiology of a single unit revealed that p53 mutations has been able to disrupt checking point responses for DNA damage preserving robust visual responses.</text>
                    <arg n="0">p53 mutations</arg>
                    <arg n="1">checking point responses for DNA damage</arg>
                </example>
                <example src="REPLACE" no="651">
                    <text>Quantitative electrophysiology of a single unit revealed that p53 mutations has been shown to disrupt checking point responses for DNA damage while preserving robust visual responses.</text>
                    <arg n="0">p53 mutations</arg>
                    <arg n="1">checking point responses for DNA damage</arg>
                </example>
                <example src="REPLACE" no="652">
                    <text>Quantitative electrophysiology of a single unit revealed that p53 mutations has disrupted checking point responses for DNA damage while preserving robust visual responses.</text>
                    <arg n="0">p53 mutations</arg>
                    <arg n="1">checking point responses for DNA damage</arg>
                </example>
                <example src="REPLACE" no="653">
                    <text>Quantitative electrophysiology of a single unit revealed that p53 mutations interrupts checking point responses for DNA damage by disrupts robust visual responses.</text>
                    <arg n="0">p53 mutations</arg>
                    <arg n="1">checking point responses for DNA damage</arg>
                </example>
                <example src="REPLACE" no="654">
                    <text>Quantitative electrophysiology of a single unit revealed that p53 mutations interrupts checking point responses for DNA damage while disrupts robust visual responses.</text>
                    <arg n="0">p53 mutations</arg>
                    <arg n="1">checking point responses for DNA damage</arg>
                </example>
                <example src="REPLACE" no="655">
                    <text>Quantitative electrophysiology of a single unit revealed that p53 mutations is able to detach checking point responses for DNA damage disrupt robust visual responses.</text>
                    <arg n="0">p53 mutations</arg>
                    <arg n="1">checking point responses for DNA damage</arg>
                </example>
                <example src="REPLACE" no="656">
                    <text>Quantitative electrophysiology of a single unit revealed that p53 mutations is capable of disrupt checking point responses for DNA damage by preserving robust visual responses.</text>
                    <arg n="0">p53 mutations</arg>
                    <arg n="1">checking point responses for DNA damage</arg>
                </example>
                <example src="REPLACE" no="657">
                    <text>Quantitative electrophysiology of a single unit revealed that such mutations disrupted the ubiquitin binding function while retaining robust visual responses.</text>
                    <arg n="0">such mutations</arg>
                    <arg n="1">the ubiquitin binding function</arg>
                </example>
                <example src="REPLACE" no="658">
                    <text>Quantitative electrophysiology of a single unit revealed that such mutations disrupted the ubiquitin-binding function while retaining robust visual responses.</text>
                    <arg n="0">such mutations</arg>
                    <arg n="1">the ubiquitin-binding function</arg>
                </example>
                <example src="REPLACE" no="659">
                    <text>Quantitative electrophysiology of a single unit revealed that such mutations has been able to disrupt the ubiquitin binding function preserving robust visual responses.</text>
                    <arg n="0">such mutations</arg>
                    <arg n="1">the ubiquitin binding function</arg>
                </example>
                <example src="REPLACE" no="660">
                    <text>Quantitative electrophysiology of a single unit revealed that such mutations has been able to disrupt the ubiquitin-binding function preserving robust visual responses.</text>
                    <arg n="0">such mutations</arg>
                    <arg n="1">the ubiquitin-binding function</arg>
                </example>
                <example src="REPLACE" no="661">
                    <text>Quantitative electrophysiology of a single unit revealed that such mutations has been shown to disrupt the ubiquitin binding function while preserving robust visual responses.</text>
                    <arg n="0">such mutations</arg>
                    <arg n="1">the ubiquitin binding function</arg>
                </example>
                <example src="REPLACE" no="662">
                    <text>Quantitative electrophysiology of a single unit revealed that such mutations has been shown to disrupt the ubiquitin-binding function while preserving robust visual responses.</text>
                    <arg n="0">such mutations</arg>
                    <arg n="1">the ubiquitin-binding function</arg>
                </example>
                <example src="REPLACE" no="663">
                    <text>Quantitative electrophysiology of a single unit revealed that such mutations has disrupted the ubiquitin binding function while preserving robust visual responses.</text>
                    <arg n="0">such mutations</arg>
                    <arg n="1">the ubiquitin binding function</arg>
                </example>
                <example src="REPLACE" no="664">
                    <text>Quantitative electrophysiology of a single unit revealed that such mutations has disrupted the ubiquitin-binding function while preserving robust visual responses.</text>
                    <arg n="0">such mutations</arg>
                    <arg n="1">the ubiquitin-binding function</arg>
                </example>
                <example src="REPLACE" no="665">
                    <text>Quantitative electrophysiology of a single unit revealed that such mutations interrupts the ubiquitin binding function by disrupts robust visual responses.</text>
                    <arg n="0">such mutations</arg>
                    <arg n="1">the ubiquitin binding function</arg>
                </example>
                <example src="REPLACE" no="666">
                    <text>Quantitative electrophysiology of a single unit revealed that such mutations interrupts the ubiquitin binding function while disrupts robust visual responses.</text>
                    <arg n="0">such mutations</arg>
                    <arg n="1">the ubiquitin binding function</arg>
                </example>
                <example src="REPLACE" no="667">
                    <text>Quantitative electrophysiology of a single unit revealed that such mutations interrupts the ubiquitin-binding function by disrupts robust visual responses.</text>
                    <arg n="0">such mutations</arg>
                    <arg n="1">the ubiquitin-binding function</arg>
                </example>
                <example src="REPLACE" no="668">
                    <text>Quantitative electrophysiology of a single unit revealed that such mutations interrupts the ubiquitin-binding function while disrupts robust visual responses.</text>
                    <arg n="0">such mutations</arg>
                    <arg n="1">the ubiquitin-binding function</arg>
                </example>
                <example src="REPLACE" no="669">
                    <text>Quantitative electrophysiology of a single unit revealed that such mutations is able to detach the ubiquitin binding function disrupt robust visual responses.</text>
                    <arg n="0">such mutations</arg>
                    <arg n="1">the ubiquitin binding function</arg>
                </example>
                <example src="REPLACE" no="670">
                    <text>Quantitative electrophysiology of a single unit revealed that such mutations is able to detach the ubiquitin-binding function disrupt robust visual responses.</text>
                    <arg n="0">such mutations</arg>
                    <arg n="1">the ubiquitin-binding function</arg>
                </example>
                <example src="REPLACE" no="671">
                    <text>Quantitative electrophysiology of a single unit revealed that such mutations is capable of disrupt the ubiquitin binding function by preserving robust visual responses.</text>
                    <arg n="0">such mutations</arg>
                    <arg n="1">the ubiquitin binding function</arg>
                </example>
                <example src="REPLACE" no="672">
                    <text>Quantitative electrophysiology of a single unit revealed that such mutations is capable of disrupt the ubiquitin-binding function by preserving robust visual responses.</text>
                    <arg n="0">such mutations</arg>
                    <arg n="1">the ubiquitin-binding function</arg>
                </example>
                <example src="REPLACE" no="673">
                    <text>Quantitative electrophysiology of a single unit revealed that the Lys147Ala substitution disrupted the interaction while retaining robust visual responses.</text>
                    <arg n="0">the Lys147Ala substitution</arg>
                    <arg n="1">the interaction</arg>
                </example>
                <example src="REPLACE" no="674">
                    <text>Quantitative electrophysiology of a single unit revealed that the Lys147Ala substitution has been able to disrupt the interaction preserving robust visual responses.</text>
                    <arg n="0">the Lys147Ala substitution</arg>
                    <arg n="1">the interaction</arg>
                </example>
                <example src="REPLACE" no="675">
                    <text>Quantitative electrophysiology of a single unit revealed that the Lys147Ala substitution has been shown to disrupt the interaction while preserving robust visual responses.</text>
                    <arg n="0">the Lys147Ala substitution</arg>
                    <arg n="1">the interaction</arg>
                </example>
                <example src="REPLACE" no="676">
                    <text>Quantitative electrophysiology of a single unit revealed that the Lys147Ala substitution has disrupted the interaction while preserving robust visual responses.</text>
                    <arg n="0">the Lys147Ala substitution</arg>
                    <arg n="1">the interaction</arg>
                </example>
                <example src="REPLACE" no="677">
                    <text>Quantitative electrophysiology of a single unit revealed that the Lys147Ala substitution interrupts the interaction by disrupts robust visual responses.</text>
                    <arg n="0">the Lys147Ala substitution</arg>
                    <arg n="1">the interaction</arg>
                </example>
                <example src="REPLACE" no="678">
                    <text>Quantitative electrophysiology of a single unit revealed that the Lys147Ala substitution interrupts the interaction while disrupts robust visual responses.</text>
                    <arg n="0">the Lys147Ala substitution</arg>
                    <arg n="1">the interaction</arg>
                </example>
                <example src="REPLACE" no="679">
                    <text>Quantitative electrophysiology of a single unit revealed that the Lys147Ala substitution is able to detach the interaction disrupt robust visual responses.</text>
                    <arg n="0">the Lys147Ala substitution</arg>
                    <arg n="1">the interaction</arg>
                </example>
                <example src="REPLACE" no="680">
                    <text>Quantitative electrophysiology of a single unit revealed that the Lys147Ala substitution is capable of disrupt the interaction by preserving robust visual responses.</text>
                    <arg n="0">the Lys147Ala substitution</arg>
                    <arg n="1">the interaction</arg>
                </example>
                <example src="REPLACE" no="681">
                    <text>Quantitative electrophysiology of a single unit revealed that these mutations disrupted biquitin binding function while retaining robust visual responses.</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">biquitin binding function</arg>
                </example>
                <example src="REPLACE" no="682">
                    <text>Quantitative electrophysiology of a single unit revealed that these mutations has been able to disrupt biquitin binding function preserving robust visual responses.</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">biquitin binding function</arg>
                </example>
                <example src="REPLACE" no="683">
                    <text>Quantitative electrophysiology of a single unit revealed that these mutations has been shown to disrupt biquitin binding function while preserving robust visual responses.</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">biquitin binding function</arg>
                </example>
                <example src="REPLACE" no="684">
                    <text>Quantitative electrophysiology of a single unit revealed that these mutations has disrupted biquitin binding function while preserving robust visual responses.</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">biquitin binding function</arg>
                </example>
                <example src="REPLACE" no="685">
                    <text>Quantitative electrophysiology of a single unit revealed that these mutations interrupts biquitin binding function by disrupts robust visual responses.</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">biquitin binding function</arg>
                </example>
                <example src="REPLACE" no="686">
                    <text>Quantitative electrophysiology of a single unit revealed that these mutations interrupts biquitin binding function while disrupts robust visual responses.</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">biquitin binding function</arg>
                </example>
                <example src="REPLACE" no="687">
                    <text>Quantitative electrophysiology of a single unit revealed that these mutations is able to detach biquitin binding function disrupt robust visual responses.</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">biquitin binding function</arg>
                </example>
                <example src="REPLACE" no="688">
                    <text>Quantitative electrophysiology of a single unit revealed that these mutations is capable of disrupt biquitin binding function by preserving robust visual responses.</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">biquitin binding function</arg>
                </example>
                <example src="REPLACE" no="689">
                    <text>Quantitative electrophysiology of a single unit revealed that this deletion disrupted consensus signal 5 while retaining robust visual responses.</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">consensus signal 5</arg>
                </example>
                <example src="REPLACE" no="690">
                    <text>Quantitative electrophysiology of a single unit revealed that this deletion has been able to disrupt consensus signal 5 preserving robust visual responses.</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">consensus signal 5</arg>
                </example>
                <example src="REPLACE" no="691">
                    <text>Quantitative electrophysiology of a single unit revealed that this deletion has been shown to disrupt consensus signal 5 while preserving robust visual responses.</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">consensus signal 5</arg>
                </example>
                <example src="REPLACE" no="692">
                    <text>Quantitative electrophysiology of a single unit revealed that this deletion has disrupted consensus signal 5 while preserving robust visual responses.</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">consensus signal 5</arg>
                </example>
                <example src="REPLACE" no="693">
                    <text>Quantitative electrophysiology of a single unit revealed that this deletion interrupts consensus signal 5 by disrupts robust visual responses.</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">consensus signal 5</arg>
                </example>
                <example src="REPLACE" no="694">
                    <text>Quantitative electrophysiology of a single unit revealed that this deletion interrupts consensus signal 5 while disrupts robust visual responses.</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">consensus signal 5</arg>
                </example>
                <example src="REPLACE" no="695">
                    <text>Quantitative electrophysiology of a single unit revealed that this deletion is able to detach consensus signal 5 disrupt robust visual responses.</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">consensus signal 5</arg>
                </example>
                <example src="REPLACE" no="696">
                    <text>Quantitative electrophysiology of a single unit revealed that this deletion is capable of disrupt consensus signal 5 by preserving robust visual responses.</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">consensus signal 5</arg>
                </example>
                <example src="REPLACE" no="697">
                    <text>Quantitative electrophysiology of a single unit revealed that this suppression disrupted consensus signal 5 while retaining robust visual responses.</text>
                    <arg n="0">this suppression</arg>
                    <arg n="1">consensus signal 5</arg>
                </example>
                <example src="REPLACE" no="698">
                    <text>Quantitative electrophysiology of a single unit revealed that this suppression has been able to disrupt consensus signal 5 preserving robust visual responses.</text>
                    <arg n="0">this suppression</arg>
                    <arg n="1">consensus signal 5</arg>
                </example>
                <example src="REPLACE" no="699">
                    <text>Quantitative electrophysiology of a single unit revealed that this suppression has been shown to disrupt consensus signal 5 while preserving robust visual responses.</text>
                    <arg n="0">this suppression</arg>
                    <arg n="1">consensus signal 5</arg>
                </example>
                <example src="REPLACE" no="700">
                    <text>Quantitative electrophysiology of a single unit revealed that this suppression has disrupted consensus signal 5 while preserving robust visual responses.</text>
                    <arg n="0">this suppression</arg>
                    <arg n="1">consensus signal 5</arg>
                </example>
                <example src="REPLACE" no="701">
                    <text>Quantitative electrophysiology of a single unit revealed that this suppression interrupts consensus signal 5 by disrupts robust visual responses.</text>
                    <arg n="0">this suppression</arg>
                    <arg n="1">consensus signal 5</arg>
                </example>
                <example src="REPLACE" no="702">
                    <text>Quantitative electrophysiology of a single unit revealed that this suppression interrupts consensus signal 5 while disrupts robust visual responses.</text>
                    <arg n="0">this suppression</arg>
                    <arg n="1">consensus signal 5</arg>
                </example>
                <example src="REPLACE" no="703">
                    <text>Quantitative electrophysiology of a single unit revealed that this suppression is able to detach consensus signal 5 disrupt robust visual responses.</text>
                    <arg n="0">this suppression</arg>
                    <arg n="1">consensus signal 5</arg>
                </example>
                <example src="REPLACE" no="704">
                    <text>Quantitative electrophysiology of a single unit revealed that this suppression is capable of disrupt consensus signal 5 by preserving robust visual responses.</text>
                    <arg n="0">this suppression</arg>
                    <arg n="1">consensus signal 5</arg>
                </example>
                <example src="REPLACE" no="705">
                    <text>Quantitative electrophysiology of a single unit revealed that tumour binding system 2 maneuver disrupted tumour vessels while retaining robust visual responses.</text>
                    <arg n="0">tumour binding system 2 maneuver</arg>
                    <arg n="1">tumour vessels</arg>
                </example>
                <example src="REPLACE" no="706">
                    <text>Quantitative electrophysiology of a single unit revealed that tumour binding system 2 maneuver has been able to disrupt tumour vessels preserving robust visual responses.</text>
                    <arg n="0">tumour binding system 2 maneuver</arg>
                    <arg n="1">tumour vessels</arg>
                </example>
                <example src="REPLACE" no="707">
                    <text>Quantitative electrophysiology of a single unit revealed that tumour binding system 2 maneuver has been shown to disrupt tumour vessels while preserving robust visual responses.</text>
                    <arg n="0">tumour binding system 2 maneuver</arg>
                    <arg n="1">tumour vessels</arg>
                </example>
                <example src="REPLACE" no="708">
                    <text>Quantitative electrophysiology of a single unit revealed that tumour binding system 2 maneuver has disrupted tumour vessels while preserving robust visual responses.</text>
                    <arg n="0">tumour binding system 2 maneuver</arg>
                    <arg n="1">tumour vessels</arg>
                </example>
                <example src="REPLACE" no="709">
                    <text>Quantitative electrophysiology of a single unit revealed that tumour binding system 2 maneuver interrupts tumour vessels by disrupts robust visual responses.</text>
                    <arg n="0">tumour binding system 2 maneuver</arg>
                    <arg n="1">tumour vessels</arg>
                </example>
                <example src="REPLACE" no="710">
                    <text>Quantitative electrophysiology of a single unit revealed that tumour binding system 2 maneuver interrupts tumour vessels while disrupts robust visual responses.</text>
                    <arg n="0">tumour binding system 2 maneuver</arg>
                    <arg n="1">tumour vessels</arg>
                </example>
                <example src="REPLACE" no="711">
                    <text>Quantitative electrophysiology of a single unit revealed that tumour binding system 2 maneuver is able to detach tumour vessels disrupt robust visual responses.</text>
                    <arg n="0">tumour binding system 2 maneuver</arg>
                    <arg n="1">tumour vessels</arg>
                </example>
                <example src="REPLACE" no="712">
                    <text>Quantitative electrophysiology of a single unit revealed that tumour binding system 2 maneuver is capable of disrupt tumour vessels by preserving robust visual responses.</text>
                    <arg n="0">tumour binding system 2 maneuver</arg>
                    <arg n="1">tumour vessels</arg>
                </example>
                <example src="REPLACE" no="713">
                    <text>R142X broke a sequence of a splicing enhancer disrupted in R (exon 5 spike).</text>
                    <arg n="0">R142X</arg>
                    <arg n="1">a splicing enhancer</arg>
                </example>
                <example src="REPLACE" no="714">
                    <text>R142X broke a sequence of a splicing power disrupted in R (exon 5 spike).</text>
                    <arg n="0">R142X</arg>
                    <arg n="1">a splicing power</arg>
                </example>
                <example src="REPLACE" no="715">
                    <text>R142X can disrupt with the base groups ceto and C (blue) on both sides of the dsDNA DNA and interrupt a splicing enhancer.</text>
                    <arg n="0">R142X</arg>
                    <arg n="1">a splicing enhancer</arg>
                </example>
                <example src="REPLACE" no="716">
                    <text>R142X can disrupt with the base groups ceto and C (blue) on both sides of the dsDNA DNA and interrupt a splicing power.</text>
                    <arg n="0">R142X</arg>
                    <arg n="1">a splicing power</arg>
                </example>
                <example src="REPLACE" no="717">
                    <text>R142X that broke A1 will be identified in the siblings disrupted by classical abetalipoproteinemia.</text>
                    <arg n="0">R142X</arg>
                </example>
                <example src="REPLACE" no="718">
                    <text>R142X that can disrupt a splicing enhancer has been identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">R142X</arg>
                    <arg n="1">a splicing enhancer</arg>
                </example>
                <example src="REPLACE" no="719">
                    <text>R142X that can disrupt a splicing enhancer that has been identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">R142X</arg>
                    <arg n="1">a splicing enhancer</arg>
                </example>
                <example src="REPLACE" no="720">
                    <text>R142X that can disrupt a splicing power has been identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">R142X</arg>
                    <arg n="1">a splicing power</arg>
                </example>
                <example src="REPLACE" no="721">
                    <text>R142X that can disrupt a splicing power that has been identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">R142X</arg>
                    <arg n="1">a splicing power</arg>
                </example>
                <example src="REPLACE" no="722">
                    <text>R142X that has disrupted A1 will be identified in the affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">R142X</arg>
                </example>
                <example src="REPLACE" no="723">
                    <text>R142X that has disrupted a splicing enhancer was identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">R142X</arg>
                    <arg n="1">a splicing enhancer</arg>
                </example>
                <example src="REPLACE" no="724">
                    <text>R142X that has disrupted a splicing power was identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">R142X</arg>
                    <arg n="1">a splicing power</arg>
                </example>
                <example src="REPLACE" no="725">
                    <text>R142X that interact with the keto groups of the base pair GO and C (blue) on either side of the dsDNA can disrupt a splicing enhancer.</text>
                    <arg n="0">R142X</arg>
                    <arg n="1">a splicing enhancer</arg>
                </example>
                <example src="REPLACE" no="726">
                    <text>R142X that interact with the keto groups of the base pair GO and C (blue) on either side of the dsDNA can disrupt a splicing power.</text>
                    <arg n="0">R142X</arg>
                    <arg n="1">a splicing power</arg>
                </example>
                <example src="REPLACE" no="727">
                    <text>R142X that interacts with the keto and C group pair (blue) on both sides of the dsDNA can disrupt a splicing enhancer.</text>
                    <arg n="0">R142X</arg>
                    <arg n="1">a splicing enhancer</arg>
                </example>
                <example src="REPLACE" no="728">
                    <text>R142X that interacts with the keto and C group pair (blue) on both sides of the dsDNA can disrupt a splicing power.</text>
                    <arg n="0">R142X</arg>
                    <arg n="1">a splicing power</arg>
                </example>
                <example src="REPLACE" no="729">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (A mutation 415G4 after disrupted slicing enhancer sequnce: (GAR)n-(GAR)n, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">A mutation 415G4</arg>
                    <arg n="1">slicing enhancer sequnce: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="730">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (A mutation 415G4 being able to disrupt slicing enhancer sequnce: (GAR)n-(GAR)n, the Arg243----His mutation, one site Hha I and the Asp250----Asn mutation, one site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients</text>
                    <arg n="0">A mutation 415G4</arg>
                    <arg n="1">slicing enhancer sequnce: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="731">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (A mutation 415G4 that can disrupt slicing enhancer sequnce: (GAR)n-(GAR)n, the Arg243----His mutation, a site Hha I and the Asp250----Asn mutation, a site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients were indeed com</text>
                    <arg n="0">A mutation 415G4</arg>
                    <arg n="1">slicing enhancer sequnce: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="732">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (A mutation 415G4 that disrupted slicing enhancer sequnce: (GAR)n-(GAR)n, the Arg243----His mutation, a site Hha I and the Asp250----Asn mutation, a site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients were indeed composit</text>
                    <arg n="0">A mutation 415G4</arg>
                    <arg n="1">slicing enhancer sequnce: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="733">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (A mutation 415G4 with A1 rupture (one site Ava II), the Arg243----His mutation, one site Hha I and the Asp250----Asn mutation, one site Taq I) and hybridization of allele-specific oligonucleotides disrupted that the patients were indeed com</text>
                    <arg n="0">A mutation 415G4</arg>
                </example>
                <example src="REPLACE" no="734">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (Arg99 and Arg253 with A1 rupture (one site Ava II), the Arg243----His mutation, one site Hha I and the Asp250----Asn mutation, one site Taq I) and hybridization of allele-specific oligonucleotides disrupted that the patients were indeed com</text>
                    <arg n="0">Arg99 and Arg253</arg>
                </example>
                <example src="REPLACE" no="735">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (Lys147Ala substitution after disrupted interaction, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">Lys147Ala substitution</arg>
                    <arg n="1">interaction</arg>
                </example>
                <example src="REPLACE" no="736">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (Lys147Ala substitution being able to disrupt interaction, the Arg243----His mutation, one site Hha I and the Asp250----Asn mutation, one site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients</text>
                    <arg n="0">Lys147Ala substitution</arg>
                    <arg n="1">interaction</arg>
                </example>
                <example src="REPLACE" no="737">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (Lys147Ala substitution that can disrupt interaction, the Arg243----His mutation, a site Hha I and the Asp250----Asn mutation, a site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients were indeed com</text>
                    <arg n="0">Lys147Ala substitution</arg>
                    <arg n="1">interaction</arg>
                </example>
                <example src="REPLACE" no="738">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (Lys147Ala substitution that disrupted interaction, the Arg243----His mutation, a site Hha I and the Asp250----Asn mutation, a site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients were indeed composit</text>
                    <arg n="0">Lys147Ala substitution</arg>
                    <arg n="1">interaction</arg>
                </example>
                <example src="REPLACE" no="739">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (Lys147Ala substitution with A1 rupture (one site Ava II), the Arg243----His mutation, one site Hha I and the Asp250----Asn mutation, one site Taq I) and hybridization of allele-specific oligonucleotides disrupted that the patients were indeed com</text>
                    <arg n="0">Lys147Ala substitution</arg>
                </example>
                <example src="REPLACE" no="740">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (Multations in p53 after disrupted posts of checkpoints to DNA damage, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">Multations in p53</arg>
                    <arg n="1">posts of checkpoints to DNA damage</arg>
                </example>
                <example src="REPLACE" no="741">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (Multations in p53 after disrupted responses of checkpoints to DNA damage, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">Multations in p53</arg>
                    <arg n="1">responses of checkpoints to DNA damage</arg>
                </example>
                <example src="REPLACE" no="742">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (Multations in p53 being able to disrupt posts of checkpoints to DNA damage, the Arg243----His mutation, one site Hha I and the Asp250----Asn mutation, one site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients</text>
                    <arg n="0">Multations in p53</arg>
                    <arg n="1">posts of checkpoints to DNA damage</arg>
                </example>
                <example src="REPLACE" no="743">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (Multations in p53 being able to disrupt responses of checkpoints to DNA damage, the Arg243----His mutation, one site Hha I and the Asp250----Asn mutation, one site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients</text>
                    <arg n="0">Multations in p53</arg>
                    <arg n="1">responses of checkpoints to DNA damage</arg>
                </example>
                <example src="REPLACE" no="744">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (Multations in p53 that can disrupt posts of checkpoints to DNA damage, the Arg243----His mutation, a site Hha I and the Asp250----Asn mutation, a site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients were indeed com</text>
                    <arg n="0">Multations in p53</arg>
                    <arg n="1">posts of checkpoints to DNA damage</arg>
                </example>
                <example src="REPLACE" no="745">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (Multations in p53 that can disrupt responses of checkpoints to DNA damage, the Arg243----His mutation, a site Hha I and the Asp250----Asn mutation, a site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients were indeed com</text>
                    <arg n="0">Multations in p53</arg>
                    <arg n="1">responses of checkpoints to DNA damage</arg>
                </example>
                <example src="REPLACE" no="746">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (Multations in p53 that disrupted posts of checkpoints to DNA damage, the Arg243----His mutation, a site Hha I and the Asp250----Asn mutation, a site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients were indeed composit</text>
                    <arg n="0">Multations in p53</arg>
                    <arg n="1">posts of checkpoints to DNA damage</arg>
                </example>
                <example src="REPLACE" no="747">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (Multations in p53 that disrupted responses of checkpoints to DNA damage, the Arg243----His mutation, a site Hha I and the Asp250----Asn mutation, a site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients were indeed composit</text>
                    <arg n="0">Multations in p53</arg>
                    <arg n="1">responses of checkpoints to DNA damage</arg>
                </example>
                <example src="REPLACE" no="748">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (Multations in p53 with A1 rupture (one site Ava II), the Arg243----His mutation, one site Hha I and the Asp250----Asn mutation, one site Taq I) and hybridization of allele-specific oligonucleotides disrupted that the patients were indeed com</text>
                    <arg n="0">Multations in p53</arg>
                </example>
                <example src="REPLACE" no="749">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (Mutation 415G4 after disrupted licensing improvement sequence: (GAR)n-(GAR)n, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">Mutation 415G4</arg>
                    <arg n="1">licensing improvement sequence: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="750">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (Mutation 415G4 being able to disrupt licensing improvement sequence: (GAR)n-(GAR)n, the Arg243----His mutation, one site Hha I and the Asp250----Asn mutation, one site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients</text>
                    <arg n="0">Mutation 415G4</arg>
                    <arg n="1">licensing improvement sequence: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="751">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (Mutation 415G4 that can disrupt licensing improvement sequence: (GAR)n-(GAR)n, the Arg243----His mutation, a site Hha I and the Asp250----Asn mutation, a site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients were indeed com</text>
                    <arg n="0">Mutation 415G4</arg>
                    <arg n="1">licensing improvement sequence: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="752">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (Mutation 415G4 that disrupted licensing improvement sequence: (GAR)n-(GAR)n, the Arg243----His mutation, a site Hha I and the Asp250----Asn mutation, a site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients were indeed composit</text>
                    <arg n="0">Mutation 415G4</arg>
                    <arg n="1">licensing improvement sequence: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="753">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (Mutation 415G4 with A1 rupture (one site Ava II), the Arg243----His mutation, one site Hha I and the Asp250----Asn mutation, one site Taq I) and hybridization of allele-specific oligonucleotides disrupted that the patients were indeed com</text>
                    <arg n="0">Mutation 415G4</arg>
                </example>
                <example src="REPLACE" no="754">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (Mutations in p53 after disrupted responses of checkpoints to DNA damage, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">Mutations in p53</arg>
                    <arg n="1">responses of checkpoints to DNA damage</arg>
                </example>
                <example src="REPLACE" no="755">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (Mutations in p53 being able to disrupt responses of checkpoints to DNA damage, the Arg243----His mutation, one site Hha I and the Asp250----Asn mutation, one site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients</text>
                    <arg n="0">Mutations in p53</arg>
                    <arg n="1">responses of checkpoints to DNA damage</arg>
                </example>
                <example src="REPLACE" no="756">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (Mutations in p53 that can disrupt responses of checkpoints to DNA damage, the Arg243----His mutation, a site Hha I and the Asp250----Asn mutation, a site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients were indeed com</text>
                    <arg n="0">Mutations in p53</arg>
                    <arg n="1">responses of checkpoints to DNA damage</arg>
                </example>
                <example src="REPLACE" no="757">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (Mutations in p53 that disrupted responses of checkpoints to DNA damage, the Arg243----His mutation, a site Hha I and the Asp250----Asn mutation, a site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients were indeed composit</text>
                    <arg n="0">Mutations in p53</arg>
                    <arg n="1">responses of checkpoints to DNA damage</arg>
                </example>
                <example src="REPLACE" no="758">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (Mutations in p53 with A1 rupture (one site Ava II), the Arg243----His mutation, one site Hha I and the Asp250----Asn mutation, one site Taq I) and hybridization of allele-specific oligonucleotides disrupted that the patients were indeed com</text>
                    <arg n="0">Mutations in p53</arg>
                </example>
                <example src="REPLACE" no="759">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (R142X after disrupted a splicing enhancer, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">R142X</arg>
                    <arg n="1">a splicing enhancer</arg>
                </example>
                <example src="REPLACE" no="760">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (R142X after disrupted a splicing power, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">R142X</arg>
                    <arg n="1">a splicing power</arg>
                </example>
                <example src="REPLACE" no="761">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (R142X being able to disrupt a splicing enhancer, the Arg243----His mutation, one site Hha I and the Asp250----Asn mutation, one site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients</text>
                    <arg n="0">R142X</arg>
                    <arg n="1">a splicing enhancer</arg>
                </example>
                <example src="REPLACE" no="762">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (R142X being able to disrupt a splicing power, the Arg243----His mutation, one site Hha I and the Asp250----Asn mutation, one site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients</text>
                    <arg n="0">R142X</arg>
                    <arg n="1">a splicing power</arg>
                </example>
                <example src="REPLACE" no="763">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (R142X that can disrupt a splicing enhancer, the Arg243----His mutation, a site Hha I and the Asp250----Asn mutation, a site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients were indeed com</text>
                    <arg n="0">R142X</arg>
                    <arg n="1">a splicing enhancer</arg>
                </example>
                <example src="REPLACE" no="764">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (R142X that can disrupt a splicing power, the Arg243----His mutation, a site Hha I and the Asp250----Asn mutation, a site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients were indeed com</text>
                    <arg n="0">R142X</arg>
                    <arg n="1">a splicing power</arg>
                </example>
                <example src="REPLACE" no="765">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (R142X that disrupted a splicing enhancer, the Arg243----His mutation, a site Hha I and the Asp250----Asn mutation, a site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients were indeed composit</text>
                    <arg n="0">R142X</arg>
                    <arg n="1">a splicing enhancer</arg>
                </example>
                <example src="REPLACE" no="766">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (R142X that disrupted a splicing power, the Arg243----His mutation, a site Hha I and the Asp250----Asn mutation, a site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients were indeed composit</text>
                    <arg n="0">R142X</arg>
                    <arg n="1">a splicing power</arg>
                </example>
                <example src="REPLACE" no="767">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (R142X with A1 rupture (one site Ava II), the Arg243----His mutation, one site Hha I and the Asp250----Asn mutation, one site Taq I) and hybridization of allele-specific oligonucleotides disrupted that the patients were indeed com</text>
                    <arg n="0">R142X</arg>
                </example>
                <example src="REPLACE" no="768">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (The 415G4 mutation after disrupted enhancer spike: (GAR)n-(GAR)n, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">The 415G4 mutation</arg>
                    <arg n="1">enhancer spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="769">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (The 415G4 mutation after disrupted powerers spike: (GAR)n-(GAR)n, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">The 415G4 mutation</arg>
                    <arg n="1">powerers spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="770">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (The 415G4 mutation being able to disrupt enhancer spike: (GAR)n-(GAR)n, the Arg243----His mutation, one site Hha I and the Asp250----Asn mutation, one site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients</text>
                    <arg n="0">The 415G4 mutation</arg>
                    <arg n="1">enhancer spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="771">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (The 415G4 mutation being able to disrupt powerers spike: (GAR)n-(GAR)n, the Arg243----His mutation, one site Hha I and the Asp250----Asn mutation, one site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients</text>
                    <arg n="0">The 415G4 mutation</arg>
                    <arg n="1">powerers spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="772">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (The 415G4 mutation that can disrupt enhancer spike: (GAR)n-(GAR)n, the Arg243----His mutation, a site Hha I and the Asp250----Asn mutation, a site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients were indeed com</text>
                    <arg n="0">The 415G4 mutation</arg>
                    <arg n="1">enhancer spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="773">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (The 415G4 mutation that can disrupt powerers spike: (GAR)n-(GAR)n, the Arg243----His mutation, a site Hha I and the Asp250----Asn mutation, a site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients were indeed com</text>
                    <arg n="0">The 415G4 mutation</arg>
                    <arg n="1">powerers spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="774">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (The 415G4 mutation that disrupted enhancer spike: (GAR)n-(GAR)n, the Arg243----His mutation, a site Hha I and the Asp250----Asn mutation, a site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients were indeed composit</text>
                    <arg n="0">The 415G4 mutation</arg>
                    <arg n="1">enhancer spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="775">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (The 415G4 mutation that disrupted powerers spike: (GAR)n-(GAR)n, the Arg243----His mutation, a site Hha I and the Asp250----Asn mutation, a site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients were indeed composit</text>
                    <arg n="0">The 415G4 mutation</arg>
                    <arg n="1">powerers spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="776">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (The 415G4 mutation with A1 rupture (one site Ava II), the Arg243----His mutation, one site Hha I and the Asp250----Asn mutation, one site Taq I) and hybridization of allele-specific oligonucleotides disrupted that the patients were indeed com</text>
                    <arg n="0">The 415G4 mutation</arg>
                </example>
                <example src="REPLACE" no="777">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (The mutation 415G4 after disrupted enhancement brush: (GAR)n-(GAR)n, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">The mutation 415G4</arg>
                    <arg n="1">enhancement brush: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="778">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (The mutation 415G4 after disrupted potent spike: (GAR)n-(GAR)n, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">The mutation 415G4</arg>
                    <arg n="1">potent spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="779">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (The mutation 415G4 being able to disrupt enhancement brush: (GAR)n-(GAR)n, the Arg243----His mutation, one site Hha I and the Asp250----Asn mutation, one site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients</text>
                    <arg n="0">The mutation 415G4</arg>
                    <arg n="1">enhancement brush: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="780">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (The mutation 415G4 being able to disrupt potent spike: (GAR)n-(GAR)n, the Arg243----His mutation, one site Hha I and the Asp250----Asn mutation, one site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients</text>
                    <arg n="0">The mutation 415G4</arg>
                    <arg n="1">potent spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="781">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (The mutation 415G4 that can disrupt enhancement brush: (GAR)n-(GAR)n, the Arg243----His mutation, a site Hha I and the Asp250----Asn mutation, a site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients were indeed com</text>
                    <arg n="0">The mutation 415G4</arg>
                    <arg n="1">enhancement brush: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="782">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (The mutation 415G4 that can disrupt potent spike: (GAR)n-(GAR)n, the Arg243----His mutation, a site Hha I and the Asp250----Asn mutation, a site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients were indeed com</text>
                    <arg n="0">The mutation 415G4</arg>
                    <arg n="1">potent spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="783">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (The mutation 415G4 that disrupted enhancement brush: (GAR)n-(GAR)n, the Arg243----His mutation, a site Hha I and the Asp250----Asn mutation, a site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients were indeed composit</text>
                    <arg n="0">The mutation 415G4</arg>
                    <arg n="1">enhancement brush: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="784">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (The mutation 415G4 that disrupted potent spike: (GAR)n-(GAR)n, the Arg243----His mutation, a site Hha I and the Asp250----Asn mutation, a site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients were indeed composit</text>
                    <arg n="0">The mutation 415G4</arg>
                    <arg n="1">potent spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="785">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (The mutation 415G4 with A1 rupture (one site Ava II), the Arg243----His mutation, one site Hha I and the Asp250----Asn mutation, one site Taq I) and hybridization of allele-specific oligonucleotides disrupted that the patients were indeed com</text>
                    <arg n="0">The mutation 415G4</arg>
                </example>
                <example src="REPLACE" no="786">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (These mutations after disrupted ubiquitin binding function, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">These mutations</arg>
                    <arg n="1">ubiquitin binding function</arg>
                </example>
                <example src="REPLACE" no="787">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (These mutations being able to disrupt ubiquitin binding function, the Arg243----His mutation, one site Hha I and the Asp250----Asn mutation, one site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients</text>
                    <arg n="0">These mutations</arg>
                    <arg n="1">ubiquitin binding function</arg>
                </example>
                <example src="REPLACE" no="788">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (These mutations that can disrupt ubiquitin binding function, the Arg243----His mutation, a site Hha I and the Asp250----Asn mutation, a site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients were indeed com</text>
                    <arg n="0">These mutations</arg>
                    <arg n="1">ubiquitin binding function</arg>
                </example>
                <example src="REPLACE" no="789">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (These mutations that disrupted ubiquitin binding function, the Arg243----His mutation, a site Hha I and the Asp250----Asn mutation, a site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients were indeed composit</text>
                    <arg n="0">These mutations</arg>
                    <arg n="1">ubiquitin binding function</arg>
                </example>
                <example src="REPLACE" no="790">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (These mutations with A1 rupture (one site Ava II), the Arg243----His mutation, one site Hha I and the Asp250----Asn mutation, one site Taq I) and hybridization of allele-specific oligonucleotides disrupted that the patients were indeed com</text>
                    <arg n="0">These mutations</arg>
                </example>
                <example src="REPLACE" no="791">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (This deletion after disrupted consensus coupling signal 5, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">consensus coupling signal 5</arg>
                </example>
                <example src="REPLACE" no="792">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (This deletion after disrupted the 5 consensus of splice signal, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">the 5 consensus of splice signal</arg>
                </example>
                <example src="REPLACE" no="793">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (This deletion after disrupted the 5th consensus of the cut signal, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">the 5th consensus of the cut signal</arg>
                </example>
                <example src="REPLACE" no="794">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (This deletion after disrupted the splice signal consensus 5, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">the splice signal consensus 5</arg>
                </example>
                <example src="REPLACE" no="795">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (This deletion being able to disrupt consensus coupling signal 5, the Arg243----His mutation, one site Hha I and the Asp250----Asn mutation, one site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">consensus coupling signal 5</arg>
                </example>
                <example src="REPLACE" no="796">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (This deletion being able to disrupt the 5 consensus of splice signal, the Arg243----His mutation, one site Hha I and the Asp250----Asn mutation, one site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">the 5 consensus of splice signal</arg>
                </example>
                <example src="REPLACE" no="797">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (This deletion being able to disrupt the 5th consensus of the cut signal, the Arg243----His mutation, one site Hha I and the Asp250----Asn mutation, one site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">the 5th consensus of the cut signal</arg>
                </example>
                <example src="REPLACE" no="798">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (This deletion being able to disrupt the splice signal consensus 5, the Arg243----His mutation, one site Hha I and the Asp250----Asn mutation, one site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">the splice signal consensus 5</arg>
                </example>
                <example src="REPLACE" no="799">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (This deletion that can disrupt consensus coupling signal 5, the Arg243----His mutation, a site Hha I and the Asp250----Asn mutation, a site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients were indeed com</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">consensus coupling signal 5</arg>
                </example>
                <example src="REPLACE" no="800">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (This deletion that can disrupt the 5 consensus of splice signal, the Arg243----His mutation, a site Hha I and the Asp250----Asn mutation, a site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients were indeed com</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">the 5 consensus of splice signal</arg>
                </example>
                <example src="REPLACE" no="801">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (This deletion that can disrupt the 5th consensus of the cut signal, the Arg243----His mutation, a site Hha I and the Asp250----Asn mutation, a site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients were indeed com</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">the 5th consensus of the cut signal</arg>
                </example>
                <example src="REPLACE" no="802">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (This deletion that can disrupt the splice signal consensus 5, the Arg243----His mutation, a site Hha I and the Asp250----Asn mutation, a site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients were indeed com</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">the splice signal consensus 5</arg>
                </example>
                <example src="REPLACE" no="803">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (This deletion that disrupted consensus coupling signal 5, the Arg243----His mutation, a site Hha I and the Asp250----Asn mutation, a site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients were indeed composit</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">consensus coupling signal 5</arg>
                </example>
                <example src="REPLACE" no="804">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (This deletion that disrupted the 5 consensus of splice signal, the Arg243----His mutation, a site Hha I and the Asp250----Asn mutation, a site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients were indeed composit</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">the 5 consensus of splice signal</arg>
                </example>
                <example src="REPLACE" no="805">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (This deletion that disrupted the 5th consensus of the cut signal, the Arg243----His mutation, a site Hha I and the Asp250----Asn mutation, a site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients were indeed composit</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">the 5th consensus of the cut signal</arg>
                </example>
                <example src="REPLACE" no="806">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (This deletion that disrupted the splice signal consensus 5, the Arg243----His mutation, a site Hha I and the Asp250----Asn mutation, a site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients were indeed composit</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">the splice signal consensus 5</arg>
                </example>
                <example src="REPLACE" no="807">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (This deletion with A1 rupture (one site Ava II), the Arg243----His mutation, one site Hha I and the Asp250----Asn mutation, one site Taq I) and hybridization of allele-specific oligonucleotides disrupted that the patients were indeed com</text>
                    <arg n="0">This deletion</arg>
                </example>
                <example src="REPLACE" no="808">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (a 415G4 mutation after disrupted licensing improvement sequence: (GAR)n-(GAR)n, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">a 415G4 mutation</arg>
                    <arg n="1">licensing improvement sequence: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="809">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (a 415G4 mutation being able to disrupt licensing improvement sequence: (GAR)n-(GAR)n, the Arg243----His mutation, one site Hha I and the Asp250----Asn mutation, one site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients</text>
                    <arg n="0">a 415G4 mutation</arg>
                    <arg n="1">licensing improvement sequence: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="810">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (a 415G4 mutation that can disrupt licensing improvement sequence: (GAR)n-(GAR)n, the Arg243----His mutation, a site Hha I and the Asp250----Asn mutation, a site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients were indeed com</text>
                    <arg n="0">a 415G4 mutation</arg>
                    <arg n="1">licensing improvement sequence: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="811">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (a 415G4 mutation that disrupted licensing improvement sequence: (GAR)n-(GAR)n, the Arg243----His mutation, a site Hha I and the Asp250----Asn mutation, a site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients were indeed composit</text>
                    <arg n="0">a 415G4 mutation</arg>
                    <arg n="1">licensing improvement sequence: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="812">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (a 415G4 mutation with A1 rupture (one site Ava II), the Arg243----His mutation, one site Hha I and the Asp250----Asn mutation, one site Taq I) and hybridization of allele-specific oligonucleotides disrupted that the patients were indeed com</text>
                    <arg n="0">a 415G4 mutation</arg>
                </example>
                <example src="REPLACE" no="813">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (a homozygotic mutation after disrupted splicing, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">a homozygotic mutation</arg>
                    <arg n="1">splicing</arg>
                </example>
                <example src="REPLACE" no="814">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (a homozygotic mutation being able to disrupt splicing, the Arg243----His mutation, one site Hha I and the Asp250----Asn mutation, one site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients</text>
                    <arg n="0">a homozygotic mutation</arg>
                    <arg n="1">splicing</arg>
                </example>
                <example src="REPLACE" no="815">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (a homozygotic mutation that can disrupt splicing, the Arg243----His mutation, a site Hha I and the Asp250----Asn mutation, a site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients were indeed com</text>
                    <arg n="0">a homozygotic mutation</arg>
                    <arg n="1">splicing</arg>
                </example>
                <example src="REPLACE" no="816">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (a homozygotic mutation that disrupted splicing, the Arg243----His mutation, a site Hha I and the Asp250----Asn mutation, a site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients were indeed composit</text>
                    <arg n="0">a homozygotic mutation</arg>
                    <arg n="1">splicing</arg>
                </example>
                <example src="REPLACE" no="817">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (a homozygotic mutation with A1 rupture (one site Ava II), the Arg243----His mutation, one site Hha I and the Asp250----Asn mutation, one site Taq I) and hybridization of allele-specific oligonucleotides disrupted that the patients were indeed com</text>
                    <arg n="0">a homozygotic mutation</arg>
                </example>
                <example src="REPLACE" no="818">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (blocking the expression MEKK1 or MEKK2 after disrupted the overall integrity of the MAPK route regulation, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">blocking the expression MEKK1 or MEKK2</arg>
                    <arg n="1">the overall integrity of the MAPK route regulation</arg>
                </example>
                <example src="REPLACE" no="819">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (blocking the expression MEKK1 or MEKK2 being able to disrupt the overall integrity of the MAPK route regulation, the Arg243----His mutation, one site Hha I and the Asp250----Asn mutation, one site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients</text>
                    <arg n="0">blocking the expression MEKK1 or MEKK2</arg>
                    <arg n="1">the overall integrity of the MAPK route regulation</arg>
                </example>
                <example src="REPLACE" no="820">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (blocking the expression MEKK1 or MEKK2 that can disrupt the overall integrity of the MAPK route regulation, the Arg243----His mutation, a site Hha I and the Asp250----Asn mutation, a site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients were indeed com</text>
                    <arg n="0">blocking the expression MEKK1 or MEKK2</arg>
                    <arg n="1">the overall integrity of the MAPK route regulation</arg>
                </example>
                <example src="REPLACE" no="821">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (blocking the expression MEKK1 or MEKK2 that disrupted the overall integrity of the MAPK route regulation, the Arg243----His mutation, a site Hha I and the Asp250----Asn mutation, a site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients were indeed composit</text>
                    <arg n="0">blocking the expression MEKK1 or MEKK2</arg>
                    <arg n="1">the overall integrity of the MAPK route regulation</arg>
                </example>
                <example src="REPLACE" no="822">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (blocking the expression MEKK1 or MEKK2 with A1 rupture (one site Ava II), the Arg243----His mutation, one site Hha I and the Asp250----Asn mutation, one site Taq I) and hybridization of allele-specific oligonucleotides disrupted that the patients were indeed com</text>
                    <arg n="0">blocking the expression MEKK1 or MEKK2</arg>
                </example>
                <example src="REPLACE" no="823">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (homozygous mutation after disrupted splicing, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">homozygous mutation</arg>
                    <arg n="1">splicing</arg>
                </example>
                <example src="REPLACE" no="824">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (homozygous mutation being able to disrupt splicing, the Arg243----His mutation, one site Hha I and the Asp250----Asn mutation, one site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients</text>
                    <arg n="0">homozygous mutation</arg>
                    <arg n="1">splicing</arg>
                </example>
                <example src="REPLACE" no="825">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (homozygous mutation that can disrupt splicing, the Arg243----His mutation, a site Hha I and the Asp250----Asn mutation, a site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients were indeed com</text>
                    <arg n="0">homozygous mutation</arg>
                    <arg n="1">splicing</arg>
                </example>
                <example src="REPLACE" no="826">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (homozygous mutation that disrupted splicing, the Arg243----His mutation, a site Hha I and the Asp250----Asn mutation, a site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients were indeed composit</text>
                    <arg n="0">homozygous mutation</arg>
                    <arg n="1">splicing</arg>
                </example>
                <example src="REPLACE" no="827">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (inhibition of inflammation after disrupted physiological protective responses, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">inhibition of inflammation</arg>
                    <arg n="1">physiological protective responses</arg>
                </example>
                <example src="REPLACE" no="828">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (inhibition of inflammation after disrupted protective physiological response, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">inhibition of inflammation</arg>
                    <arg n="1">protective physiological response</arg>
                </example>
                <example src="REPLACE" no="829">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (inhibition of inflammation being able to disrupt physiological protective responses, the Arg243----His mutation, one site Hha I and the Asp250----Asn mutation, one site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients</text>
                    <arg n="0">inhibition of inflammation</arg>
                    <arg n="1">physiological protective responses</arg>
                </example>
                <example src="REPLACE" no="830">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (inhibition of inflammation being able to disrupt protective physiological response, the Arg243----His mutation, one site Hha I and the Asp250----Asn mutation, one site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients</text>
                    <arg n="0">inhibition of inflammation</arg>
                    <arg n="1">protective physiological response</arg>
                </example>
                <example src="REPLACE" no="831">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (inhibition of inflammation that can disrupt physiological protective responses, the Arg243----His mutation, a site Hha I and the Asp250----Asn mutation, a site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients were indeed com</text>
                    <arg n="0">inhibition of inflammation</arg>
                    <arg n="1">physiological protective responses</arg>
                </example>
                <example src="REPLACE" no="832">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (inhibition of inflammation that can disrupt protective physiological response, the Arg243----His mutation, a site Hha I and the Asp250----Asn mutation, a site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients were indeed com</text>
                    <arg n="0">inhibition of inflammation</arg>
                    <arg n="1">protective physiological response</arg>
                </example>
                <example src="REPLACE" no="833">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (inhibition of inflammation that disrupted physiological protective responses, the Arg243----His mutation, a site Hha I and the Asp250----Asn mutation, a site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients were indeed composit</text>
                    <arg n="0">inhibition of inflammation</arg>
                    <arg n="1">physiological protective responses</arg>
                </example>
                <example src="REPLACE" no="834">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (inhibition of inflammation that disrupted protective physiological response, the Arg243----His mutation, a site Hha I and the Asp250----Asn mutation, a site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients were indeed composit</text>
                    <arg n="0">inhibition of inflammation</arg>
                    <arg n="1">protective physiological response</arg>
                </example>
                <example src="REPLACE" no="835">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (inhibition of inflammation with A1 rupture (one site Ava II), the Arg243----His mutation, one site Hha I and the Asp250----Asn mutation, one site Taq I) and hybridization of allele-specific oligonucleotides disrupted that the patients were indeed com</text>
                    <arg n="0">inhibition of inflammation</arg>
                </example>
                <example src="REPLACE" no="836">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (manipulation of the Tie-2 system in tumors after disrupted tumour vessels, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">manipulation of the Tie-2 system in tumors</arg>
                    <arg n="1">tumour vessels</arg>
                </example>
                <example src="REPLACE" no="837">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (manipulation of the Tie-2 system in tumors being able to disrupt tumour vessels, the Arg243----His mutation, one site Hha I and the Asp250----Asn mutation, one site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients</text>
                    <arg n="0">manipulation of the Tie-2 system in tumors</arg>
                    <arg n="1">tumour vessels</arg>
                </example>
                <example src="REPLACE" no="838">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (manipulation of the Tie-2 system in tumors that can disrupt tumour vessels, the Arg243----His mutation, a site Hha I and the Asp250----Asn mutation, a site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients were indeed com</text>
                    <arg n="0">manipulation of the Tie-2 system in tumors</arg>
                    <arg n="1">tumour vessels</arg>
                </example>
                <example src="REPLACE" no="839">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (manipulation of the Tie-2 system in tumors that disrupted tumour vessels, the Arg243----His mutation, a site Hha I and the Asp250----Asn mutation, a site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients were indeed composit</text>
                    <arg n="0">manipulation of the Tie-2 system in tumors</arg>
                    <arg n="1">tumour vessels</arg>
                </example>
                <example src="REPLACE" no="840">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (manipulation of the Tie-2 system in tumors with A1 rupture (one site Ava II), the Arg243----His mutation, one site Hha I and the Asp250----Asn mutation, one site Taq I) and hybridization of allele-specific oligonucleotides disrupted that the patients were indeed com</text>
                    <arg n="0">manipulation of the Tie-2 system in tumors</arg>
                </example>
                <example src="REPLACE" no="841">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (manipulation of the binding system 2 in tumours after disrupted tumor vessels, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">manipulation of the binding system 2 in tumours</arg>
                    <arg n="1">tumor vessels</arg>
                </example>
                <example src="REPLACE" no="842">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (manipulation of the binding system 2 in tumours being able to disrupt tumor vessels, the Arg243----His mutation, one site Hha I and the Asp250----Asn mutation, one site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients</text>
                    <arg n="0">manipulation of the binding system 2 in tumours</arg>
                    <arg n="1">tumor vessels</arg>
                </example>
                <example src="REPLACE" no="843">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (manipulation of the binding system 2 in tumours that can disrupt tumor vessels, the Arg243----His mutation, a site Hha I and the Asp250----Asn mutation, a site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients were indeed com</text>
                    <arg n="0">manipulation of the binding system 2 in tumours</arg>
                    <arg n="1">tumor vessels</arg>
                </example>
                <example src="REPLACE" no="844">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (manipulation of the binding system 2 in tumours that disrupted tumor vessels, the Arg243----His mutation, a site Hha I and the Asp250----Asn mutation, a site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients were indeed composit</text>
                    <arg n="0">manipulation of the binding system 2 in tumours</arg>
                    <arg n="1">tumor vessels</arg>
                </example>
                <example src="REPLACE" no="845">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (manipulation of the binding system 2 in tumours with A1 rupture (one site Ava II), the Arg243----His mutation, one site Hha I and the Asp250----Asn mutation, one site Taq I) and hybridization of allele-specific oligonucleotides disrupted that the patients were indeed com</text>
                    <arg n="0">manipulation of the binding system 2 in tumours</arg>
                </example>
                <example src="REPLACE" no="846">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (multations at p53 after disrupted post-checking points for DNA damage, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">multations at p53</arg>
                    <arg n="1">post-checking points for DNA damage</arg>
                </example>
                <example src="REPLACE" no="847">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (multations at p53 being able to disrupt post-checking points for DNA damage, the Arg243----His mutation, one site Hha I and the Asp250----Asn mutation, one site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients</text>
                    <arg n="0">multations at p53</arg>
                    <arg n="1">post-checking points for DNA damage</arg>
                </example>
                <example src="REPLACE" no="848">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (multations at p53 that can disrupt post-checking points for DNA damage, the Arg243----His mutation, a site Hha I and the Asp250----Asn mutation, a site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients were indeed com</text>
                    <arg n="0">multations at p53</arg>
                    <arg n="1">post-checking points for DNA damage</arg>
                </example>
                <example src="REPLACE" no="849">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (multations at p53 that disrupted post-checking points for DNA damage, the Arg243----His mutation, a site Hha I and the Asp250----Asn mutation, a site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients were indeed composit</text>
                    <arg n="0">multations at p53</arg>
                    <arg n="1">post-checking points for DNA damage</arg>
                </example>
                <example src="REPLACE" no="850">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (multations at p53 with A1 rupture (one site Ava II), the Arg243----His mutation, one site Hha I and the Asp250----Asn mutation, one site Taq I) and hybridization of allele-specific oligonucleotides disrupted that the patients were indeed com</text>
                    <arg n="0">multations at p53</arg>
                </example>
                <example src="REPLACE" no="851">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (mutation 415G4 after disrupted pulling enhancement sequence: (GAR)n-(GAR)n, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">mutation 415G4</arg>
                    <arg n="1">pulling enhancement sequence: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="852">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (mutation 415G4 after disrupted splicing sequencer: (GAR)n-(GAR)n, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">mutation 415G4</arg>
                    <arg n="1">splicing sequencer: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="853">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (mutation 415G4 being able to disrupt pulling enhancement sequence: (GAR)n-(GAR)n, the Arg243----His mutation, one site Hha I and the Asp250----Asn mutation, one site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients</text>
                    <arg n="0">mutation 415G4</arg>
                    <arg n="1">pulling enhancement sequence: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="854">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (mutation 415G4 being able to disrupt splicing sequencer: (GAR)n-(GAR)n, the Arg243----His mutation, one site Hha I and the Asp250----Asn mutation, one site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients</text>
                    <arg n="0">mutation 415G4</arg>
                    <arg n="1">splicing sequencer: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="855">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (mutation 415G4 that can disrupt pulling enhancement sequence: (GAR)n-(GAR)n, the Arg243----His mutation, a site Hha I and the Asp250----Asn mutation, a site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients were indeed com</text>
                    <arg n="0">mutation 415G4</arg>
                    <arg n="1">pulling enhancement sequence: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="856">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (mutation 415G4 that can disrupt splicing sequencer: (GAR)n-(GAR)n, the Arg243----His mutation, a site Hha I and the Asp250----Asn mutation, a site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients were indeed com</text>
                    <arg n="0">mutation 415G4</arg>
                    <arg n="1">splicing sequencer: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="857">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (mutation 415G4 that disrupted pulling enhancement sequence: (GAR)n-(GAR)n, the Arg243----His mutation, a site Hha I and the Asp250----Asn mutation, a site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients were indeed composit</text>
                    <arg n="0">mutation 415G4</arg>
                    <arg n="1">pulling enhancement sequence: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="858">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (mutation 415G4 that disrupted splicing sequencer: (GAR)n-(GAR)n, the Arg243----His mutation, a site Hha I and the Asp250----Asn mutation, a site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients were indeed composit</text>
                    <arg n="0">mutation 415G4</arg>
                    <arg n="1">splicing sequencer: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="859">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (mutation 415G4 with A1 rupture (one site Ava II), the Arg243----His mutation, one site Hha I and the Asp250----Asn mutation, one site Taq I) and hybridization of allele-specific oligonucleotides disrupted that the patients were indeed com</text>
                    <arg n="0">mutation 415G4</arg>
                </example>
                <example src="REPLACE" no="860">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (mutations in this region after disrupted assembly of keratin filaments, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">mutations in this region</arg>
                    <arg n="1">assembly of keratin filaments</arg>
                </example>
                <example src="REPLACE" no="861">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (mutations in this region being able to disrupt assembly of keratin filaments, the Arg243----His mutation, one site Hha I and the Asp250----Asn mutation, one site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients</text>
                    <arg n="0">mutations in this region</arg>
                    <arg n="1">assembly of keratin filaments</arg>
                </example>
                <example src="REPLACE" no="862">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (mutations in this region that can disrupt assembly of keratin filaments, the Arg243----His mutation, a site Hha I and the Asp250----Asn mutation, a site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients were indeed com</text>
                    <arg n="0">mutations in this region</arg>
                    <arg n="1">assembly of keratin filaments</arg>
                </example>
                <example src="REPLACE" no="863">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (mutations in this region that disrupted assembly of keratin filaments, the Arg243----His mutation, a site Hha I and the Asp250----Asn mutation, a site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients were indeed composit</text>
                    <arg n="0">mutations in this region</arg>
                    <arg n="1">assembly of keratin filaments</arg>
                </example>
                <example src="REPLACE" no="864">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (mutations in this region with A1 rupture (one site Ava II), the Arg243----His mutation, one site Hha I and the Asp250----Asn mutation, one site Taq I) and hybridization of allele-specific oligonucleotides disrupted that the patients were indeed com</text>
                    <arg n="0">mutations in this region</arg>
                </example>
                <example src="REPLACE" no="865">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (p53 mutations after disrupted checking point responses for DNA damage, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">p53 mutations</arg>
                    <arg n="1">checking point responses for DNA damage</arg>
                </example>
                <example src="REPLACE" no="866">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (p53 mutations being able to disrupt checking point responses for DNA damage, the Arg243----His mutation, one site Hha I and the Asp250----Asn mutation, one site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients</text>
                    <arg n="0">p53 mutations</arg>
                    <arg n="1">checking point responses for DNA damage</arg>
                </example>
                <example src="REPLACE" no="867">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (p53 mutations that can disrupt checking point responses for DNA damage, the Arg243----His mutation, a site Hha I and the Asp250----Asn mutation, a site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients were indeed com</text>
                    <arg n="0">p53 mutations</arg>
                    <arg n="1">checking point responses for DNA damage</arg>
                </example>
                <example src="REPLACE" no="868">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (p53 mutations that disrupted checking point responses for DNA damage, the Arg243----His mutation, a site Hha I and the Asp250----Asn mutation, a site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients were indeed composit</text>
                    <arg n="0">p53 mutations</arg>
                    <arg n="1">checking point responses for DNA damage</arg>
                </example>
                <example src="REPLACE" no="869">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (p53 mutations with A1 rupture (one site Ava II), the Arg243----His mutation, one site Hha I and the Asp250----Asn mutation, one site Taq I) and hybridization of allele-specific oligonucleotides disrupted that the patients were indeed com</text>
                    <arg n="0">p53 mutations</arg>
                </example>
                <example src="REPLACE" no="870">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (such mutations after disrupted the ubiquitin binding function, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">such mutations</arg>
                    <arg n="1">the ubiquitin binding function</arg>
                </example>
                <example src="REPLACE" no="871">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (such mutations after disrupted the ubiquitin-binding function, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">such mutations</arg>
                    <arg n="1">the ubiquitin-binding function</arg>
                </example>
                <example src="REPLACE" no="872">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (such mutations being able to disrupt the ubiquitin binding function, the Arg243----His mutation, one site Hha I and the Asp250----Asn mutation, one site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients</text>
                    <arg n="0">such mutations</arg>
                    <arg n="1">the ubiquitin binding function</arg>
                </example>
                <example src="REPLACE" no="873">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (such mutations being able to disrupt the ubiquitin-binding function, the Arg243----His mutation, one site Hha I and the Asp250----Asn mutation, one site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients</text>
                    <arg n="0">such mutations</arg>
                    <arg n="1">the ubiquitin-binding function</arg>
                </example>
                <example src="REPLACE" no="874">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (such mutations that can disrupt the ubiquitin binding function, the Arg243----His mutation, a site Hha I and the Asp250----Asn mutation, a site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients were indeed com</text>
                    <arg n="0">such mutations</arg>
                    <arg n="1">the ubiquitin binding function</arg>
                </example>
                <example src="REPLACE" no="875">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (such mutations that can disrupt the ubiquitin-binding function, the Arg243----His mutation, a site Hha I and the Asp250----Asn mutation, a site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients were indeed com</text>
                    <arg n="0">such mutations</arg>
                    <arg n="1">the ubiquitin-binding function</arg>
                </example>
                <example src="REPLACE" no="876">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (such mutations that disrupted the ubiquitin binding function, the Arg243----His mutation, a site Hha I and the Asp250----Asn mutation, a site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients were indeed composit</text>
                    <arg n="0">such mutations</arg>
                    <arg n="1">the ubiquitin binding function</arg>
                </example>
                <example src="REPLACE" no="877">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (such mutations that disrupted the ubiquitin-binding function, the Arg243----His mutation, a site Hha I and the Asp250----Asn mutation, a site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients were indeed composit</text>
                    <arg n="0">such mutations</arg>
                    <arg n="1">the ubiquitin-binding function</arg>
                </example>
                <example src="REPLACE" no="878">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (such mutations with A1 rupture (one site Ava II), the Arg243----His mutation, one site Hha I and the Asp250----Asn mutation, one site Taq I) and hybridization of allele-specific oligonucleotides disrupted that the patients were indeed com</text>
                    <arg n="0">such mutations</arg>
                </example>
                <example src="REPLACE" no="879">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (the Lys147Ala substitution after disrupted the interaction, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">the Lys147Ala substitution</arg>
                    <arg n="1">the interaction</arg>
                </example>
                <example src="REPLACE" no="880">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (the Lys147Ala substitution being able to disrupt the interaction, the Arg243----His mutation, one site Hha I and the Asp250----Asn mutation, one site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients</text>
                    <arg n="0">the Lys147Ala substitution</arg>
                    <arg n="1">the interaction</arg>
                </example>
                <example src="REPLACE" no="881">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (the Lys147Ala substitution that can disrupt the interaction, the Arg243----His mutation, a site Hha I and the Asp250----Asn mutation, a site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients were indeed com</text>
                    <arg n="0">the Lys147Ala substitution</arg>
                    <arg n="1">the interaction</arg>
                </example>
                <example src="REPLACE" no="882">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (the Lys147Ala substitution that disrupted the interaction, the Arg243----His mutation, a site Hha I and the Asp250----Asn mutation, a site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients were indeed composit</text>
                    <arg n="0">the Lys147Ala substitution</arg>
                    <arg n="1">the interaction</arg>
                </example>
                <example src="REPLACE" no="883">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (the Lys147Ala substitution with A1 rupture (one site Ava II), the Arg243----His mutation, one site Hha I and the Asp250----Asn mutation, one site Taq I) and hybridization of allele-specific oligonucleotides disrupted that the patients were indeed com</text>
                    <arg n="0">the Lys147Ala substitution</arg>
                </example>
                <example src="REPLACE" no="884">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (these mutations after disrupted biquitin binding function, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">biquitin binding function</arg>
                </example>
                <example src="REPLACE" no="885">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (these mutations being able to disrupt biquitin binding function, the Arg243----His mutation, one site Hha I and the Asp250----Asn mutation, one site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">biquitin binding function</arg>
                </example>
                <example src="REPLACE" no="886">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (these mutations that can disrupt biquitin binding function, the Arg243----His mutation, a site Hha I and the Asp250----Asn mutation, a site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients were indeed com</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">biquitin binding function</arg>
                </example>
                <example src="REPLACE" no="887">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (these mutations that disrupted biquitin binding function, the Arg243----His mutation, a site Hha I and the Asp250----Asn mutation, a site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients were indeed composit</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">biquitin binding function</arg>
                </example>
                <example src="REPLACE" no="888">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (these mutations with A1 rupture (one site Ava II), the Arg243----His mutation, one site Hha I and the Asp250----Asn mutation, one site Taq I) and hybridization of allele-specific oligonucleotides disrupted that the patients were indeed com</text>
                    <arg n="0">these mutations</arg>
                </example>
                <example src="REPLACE" no="889">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (this deletion after disrupted consensus signal 5, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">consensus signal 5</arg>
                </example>
                <example src="REPLACE" no="890">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (this deletion being able to disrupt consensus signal 5, the Arg243----His mutation, one site Hha I and the Asp250----Asn mutation, one site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">consensus signal 5</arg>
                </example>
                <example src="REPLACE" no="891">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (this deletion that can disrupt consensus signal 5, the Arg243----His mutation, a site Hha I and the Asp250----Asn mutation, a site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients were indeed com</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">consensus signal 5</arg>
                </example>
                <example src="REPLACE" no="892">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (this deletion that disrupted consensus signal 5, the Arg243----His mutation, a site Hha I and the Asp250----Asn mutation, a site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients were indeed composit</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">consensus signal 5</arg>
                </example>
                <example src="REPLACE" no="893">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (this deletion with A1 rupture (one site Ava II), the Arg243----His mutation, one site Hha I and the Asp250----Asn mutation, one site Taq I) and hybridization of allele-specific oligonucleotides disrupted that the patients were indeed com</text>
                    <arg n="0">this deletion</arg>
                </example>
                <example src="REPLACE" no="894">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (this suppression after disrupted consensus signal 5, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">this suppression</arg>
                    <arg n="1">consensus signal 5</arg>
                </example>
                <example src="REPLACE" no="895">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (this suppression being able to disrupt consensus signal 5, the Arg243----His mutation, one site Hha I and the Asp250----Asn mutation, one site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients</text>
                    <arg n="0">this suppression</arg>
                    <arg n="1">consensus signal 5</arg>
                </example>
                <example src="REPLACE" no="896">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (this suppression that can disrupt consensus signal 5, the Arg243----His mutation, a site Hha I and the Asp250----Asn mutation, a site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients were indeed com</text>
                    <arg n="0">this suppression</arg>
                    <arg n="1">consensus signal 5</arg>
                </example>
                <example src="REPLACE" no="897">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (this suppression that disrupted consensus signal 5, the Arg243----His mutation, a site Hha I and the Asp250----Asn mutation, a site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients were indeed composit</text>
                    <arg n="0">this suppression</arg>
                    <arg n="1">consensus signal 5</arg>
                </example>
                <example src="REPLACE" no="898">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (this suppression with A1 rupture (one site Ava II), the Arg243----His mutation, one site Hha I and the Asp250----Asn mutation, one site Taq I) and hybridization of allele-specific oligonucleotides disrupted that the patients were indeed com</text>
                    <arg n="0">this suppression</arg>
                </example>
                <example src="REPLACE" no="899">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (tumour binding system 2 maneuver after disrupted tumour vessels, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">tumour binding system 2 maneuver</arg>
                    <arg n="1">tumour vessels</arg>
                </example>
                <example src="REPLACE" no="900">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (tumour binding system 2 maneuver being able to disrupt tumour vessels, the Arg243----His mutation, one site Hha I and the Asp250----Asn mutation, one site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients</text>
                    <arg n="0">tumour binding system 2 maneuver</arg>
                    <arg n="1">tumour vessels</arg>
                </example>
                <example src="REPLACE" no="901">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (tumour binding system 2 maneuver that can disrupt tumour vessels, the Arg243----His mutation, a site Hha I and the Asp250----Asn mutation, a site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients were indeed com</text>
                    <arg n="0">tumour binding system 2 maneuver</arg>
                    <arg n="1">tumour vessels</arg>
                </example>
                <example src="REPLACE" no="902">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (tumour binding system 2 maneuver that disrupted tumour vessels, the Arg243----His mutation, a site Hha I and the Asp250----Asn mutation, a site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients were indeed composit</text>
                    <arg n="0">tumour binding system 2 maneuver</arg>
                    <arg n="1">tumour vessels</arg>
                </example>
                <example src="REPLACE" no="903">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (tumour binding system 2 maneuver with A1 rupture (one site Ava II), the Arg243----His mutation, one site Hha I and the Asp250----Asn mutation, one site Taq I) and hybridization of allele-specific oligonucleotides disrupted that the patients were indeed com</text>
                    <arg n="0">tumour binding system 2 maneuver</arg>
                </example>
                <example src="REPLACE" no="904">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (A mutation 415G4 being able to disrupt slicing enhancer sequnce: (GAR)n-(GAR)n, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">A mutation 415G4</arg>
                    <arg n="1">slicing enhancer sequnce: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="905">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (A mutation 415G4 that can disrupt slicing enhancer sequnce: (GAR)n-(GAR)n, the Arg243--His mutation, a Hha I site, and the Asp250---Asn mutation, a Taq I site), and the allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">A mutation 415G4</arg>
                    <arg n="1">slicing enhancer sequnce: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="906">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (A mutation 415G4 that have disrupted slicing enhancer sequnce: (GAR)n-(GAR)n, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">A mutation 415G4</arg>
                    <arg n="1">slicing enhancer sequnce: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="907">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (Lys147Ala substitution being able to disrupt interaction, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">Lys147Ala substitution</arg>
                    <arg n="1">interaction</arg>
                </example>
                <example src="REPLACE" no="908">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (Lys147Ala substitution that can disrupt interaction, the Arg243--His mutation, a Hha I site, and the Asp250---Asn mutation, a Taq I site), and the allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">Lys147Ala substitution</arg>
                    <arg n="1">interaction</arg>
                </example>
                <example src="REPLACE" no="909">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (Lys147Ala substitution that have disrupted interaction, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">Lys147Ala substitution</arg>
                    <arg n="1">interaction</arg>
                </example>
                <example src="REPLACE" no="910">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (Multations in p53 being able to disrupt posts of checkpoints to DNA damage, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">Multations in p53</arg>
                    <arg n="1">posts of checkpoints to DNA damage</arg>
                </example>
                <example src="REPLACE" no="911">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (Multations in p53 being able to disrupt responses of checkpoints to DNA damage, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">Multations in p53</arg>
                    <arg n="1">responses of checkpoints to DNA damage</arg>
                </example>
                <example src="REPLACE" no="912">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (Multations in p53 that can disrupt posts of checkpoints to DNA damage, the Arg243--His mutation, a Hha I site, and the Asp250---Asn mutation, a Taq I site), and the allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">Multations in p53</arg>
                    <arg n="1">posts of checkpoints to DNA damage</arg>
                </example>
                <example src="REPLACE" no="913">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (Multations in p53 that can disrupt responses of checkpoints to DNA damage, the Arg243--His mutation, a Hha I site, and the Asp250---Asn mutation, a Taq I site), and the allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">Multations in p53</arg>
                    <arg n="1">responses of checkpoints to DNA damage</arg>
                </example>
                <example src="REPLACE" no="914">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (Multations in p53 that have disrupted posts of checkpoints to DNA damage, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">Multations in p53</arg>
                    <arg n="1">posts of checkpoints to DNA damage</arg>
                </example>
                <example src="REPLACE" no="915">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (Multations in p53 that have disrupted responses of checkpoints to DNA damage, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">Multations in p53</arg>
                    <arg n="1">responses of checkpoints to DNA damage</arg>
                </example>
                <example src="REPLACE" no="916">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (Mutation 415G4 being able to disrupt licensing improvement sequence: (GAR)n-(GAR)n, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">Mutation 415G4</arg>
                    <arg n="1">licensing improvement sequence: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="917">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (Mutation 415G4 that can disrupt licensing improvement sequence: (GAR)n-(GAR)n, the Arg243--His mutation, a Hha I site, and the Asp250---Asn mutation, a Taq I site), and the allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">Mutation 415G4</arg>
                    <arg n="1">licensing improvement sequence: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="918">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (Mutation 415G4 that have disrupted licensing improvement sequence: (GAR)n-(GAR)n, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">Mutation 415G4</arg>
                    <arg n="1">licensing improvement sequence: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="919">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (Mutations in p53 being able to disrupt responses of checkpoints to DNA damage, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">Mutations in p53</arg>
                    <arg n="1">responses of checkpoints to DNA damage</arg>
                </example>
                <example src="REPLACE" no="920">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (Mutations in p53 that can disrupt responses of checkpoints to DNA damage, the Arg243--His mutation, a Hha I site, and the Asp250---Asn mutation, a Taq I site), and the allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">Mutations in p53</arg>
                    <arg n="1">responses of checkpoints to DNA damage</arg>
                </example>
                <example src="REPLACE" no="921">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (Mutations in p53 that have disrupted responses of checkpoints to DNA damage, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">Mutations in p53</arg>
                    <arg n="1">responses of checkpoints to DNA damage</arg>
                </example>
                <example src="REPLACE" no="922">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (R142X being able to disrupt a splicing enhancer, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">R142X</arg>
                    <arg n="1">a splicing enhancer</arg>
                </example>
                <example src="REPLACE" no="923">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (R142X being able to disrupt a splicing power, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">R142X</arg>
                    <arg n="1">a splicing power</arg>
                </example>
                <example src="REPLACE" no="924">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (R142X that can disrupt a splicing enhancer, the Arg243--His mutation, a Hha I site, and the Asp250---Asn mutation, a Taq I site), and the allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">R142X</arg>
                    <arg n="1">a splicing enhancer</arg>
                </example>
                <example src="REPLACE" no="925">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (R142X that can disrupt a splicing power, the Arg243--His mutation, a Hha I site, and the Asp250---Asn mutation, a Taq I site), and the allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">R142X</arg>
                    <arg n="1">a splicing power</arg>
                </example>
                <example src="REPLACE" no="926">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (R142X that have disrupted a splicing enhancer, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">R142X</arg>
                    <arg n="1">a splicing enhancer</arg>
                </example>
                <example src="REPLACE" no="927">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (R142X that have disrupted a splicing power, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">R142X</arg>
                    <arg n="1">a splicing power</arg>
                </example>
                <example src="REPLACE" no="928">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (The 415G4 mutation being able to disrupt enhancer spike: (GAR)n-(GAR)n, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">The 415G4 mutation</arg>
                    <arg n="1">enhancer spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="929">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (The 415G4 mutation being able to disrupt powerers spike: (GAR)n-(GAR)n, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">The 415G4 mutation</arg>
                    <arg n="1">powerers spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="930">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (The 415G4 mutation that can disrupt enhancer spike: (GAR)n-(GAR)n, the Arg243--His mutation, a Hha I site, and the Asp250---Asn mutation, a Taq I site), and the allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">The 415G4 mutation</arg>
                    <arg n="1">enhancer spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="931">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (The 415G4 mutation that can disrupt powerers spike: (GAR)n-(GAR)n, the Arg243--His mutation, a Hha I site, and the Asp250---Asn mutation, a Taq I site), and the allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">The 415G4 mutation</arg>
                    <arg n="1">powerers spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="932">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (The 415G4 mutation that have disrupted enhancer spike: (GAR)n-(GAR)n, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">The 415G4 mutation</arg>
                    <arg n="1">enhancer spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="933">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (The 415G4 mutation that have disrupted powerers spike: (GAR)n-(GAR)n, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">The 415G4 mutation</arg>
                    <arg n="1">powerers spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="934">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (The mutation 415G4 being able to disrupt enhancement brush: (GAR)n-(GAR)n, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">The mutation 415G4</arg>
                    <arg n="1">enhancement brush: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="935">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (The mutation 415G4 being able to disrupt potent spike: (GAR)n-(GAR)n, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">The mutation 415G4</arg>
                    <arg n="1">potent spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="936">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (The mutation 415G4 that can disrupt enhancement brush: (GAR)n-(GAR)n, the Arg243--His mutation, a Hha I site, and the Asp250---Asn mutation, a Taq I site), and the allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">The mutation 415G4</arg>
                    <arg n="1">enhancement brush: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="937">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (The mutation 415G4 that can disrupt potent spike: (GAR)n-(GAR)n, the Arg243--His mutation, a Hha I site, and the Asp250---Asn mutation, a Taq I site), and the allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">The mutation 415G4</arg>
                    <arg n="1">potent spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="938">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (The mutation 415G4 that have disrupted enhancement brush: (GAR)n-(GAR)n, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">The mutation 415G4</arg>
                    <arg n="1">enhancement brush: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="939">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (The mutation 415G4 that have disrupted potent spike: (GAR)n-(GAR)n, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">The mutation 415G4</arg>
                    <arg n="1">potent spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="940">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (These mutations being able to disrupt ubiquitin binding function, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">These mutations</arg>
                    <arg n="1">ubiquitin binding function</arg>
                </example>
                <example src="REPLACE" no="941">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (These mutations that can disrupt ubiquitin binding function, the Arg243--His mutation, a Hha I site, and the Asp250---Asn mutation, a Taq I site), and the allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">These mutations</arg>
                    <arg n="1">ubiquitin binding function</arg>
                </example>
                <example src="REPLACE" no="942">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (These mutations that have disrupted ubiquitin binding function, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">These mutations</arg>
                    <arg n="1">ubiquitin binding function</arg>
                </example>
                <example src="REPLACE" no="943">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (This deletion being able to disrupt consensus coupling signal 5, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">consensus coupling signal 5</arg>
                </example>
                <example src="REPLACE" no="944">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (This deletion being able to disrupt the 5 consensus of splice signal, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">the 5 consensus of splice signal</arg>
                </example>
                <example src="REPLACE" no="945">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (This deletion being able to disrupt the 5th consensus of the cut signal, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">the 5th consensus of the cut signal</arg>
                </example>
                <example src="REPLACE" no="946">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (This deletion being able to disrupt the splice signal consensus 5, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">the splice signal consensus 5</arg>
                </example>
                <example src="REPLACE" no="947">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (This deletion that can disrupt consensus coupling signal 5, the Arg243--His mutation, a Hha I site, and the Asp250---Asn mutation, a Taq I site), and the allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">consensus coupling signal 5</arg>
                </example>
                <example src="REPLACE" no="948">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (This deletion that can disrupt the 5 consensus of splice signal, the Arg243--His mutation, a Hha I site, and the Asp250---Asn mutation, a Taq I site), and the allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">the 5 consensus of splice signal</arg>
                </example>
                <example src="REPLACE" no="949">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (This deletion that can disrupt the 5th consensus of the cut signal, the Arg243--His mutation, a Hha I site, and the Asp250---Asn mutation, a Taq I site), and the allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">the 5th consensus of the cut signal</arg>
                </example>
                <example src="REPLACE" no="950">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (This deletion that can disrupt the splice signal consensus 5, the Arg243--His mutation, a Hha I site, and the Asp250---Asn mutation, a Taq I site), and the allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">the splice signal consensus 5</arg>
                </example>
                <example src="REPLACE" no="951">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (This deletion that have disrupted consensus coupling signal 5, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">consensus coupling signal 5</arg>
                </example>
                <example src="REPLACE" no="952">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (This deletion that have disrupted the 5 consensus of splice signal, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">the 5 consensus of splice signal</arg>
                </example>
                <example src="REPLACE" no="953">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (This deletion that have disrupted the 5th consensus of the cut signal, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">the 5th consensus of the cut signal</arg>
                </example>
                <example src="REPLACE" no="954">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (This deletion that have disrupted the splice signal consensus 5, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">the splice signal consensus 5</arg>
                </example>
                <example src="REPLACE" no="955">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (a 415G4 mutation being able to disrupt licensing improvement sequence: (GAR)n-(GAR)n, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">a 415G4 mutation</arg>
                    <arg n="1">licensing improvement sequence: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="956">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (a 415G4 mutation that can disrupt licensing improvement sequence: (GAR)n-(GAR)n, the Arg243--His mutation, a Hha I site, and the Asp250---Asn mutation, a Taq I site), and the allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">a 415G4 mutation</arg>
                    <arg n="1">licensing improvement sequence: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="957">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (a 415G4 mutation that have disrupted licensing improvement sequence: (GAR)n-(GAR)n, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">a 415G4 mutation</arg>
                    <arg n="1">licensing improvement sequence: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="958">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (a homozygotic mutation being able to disrupt splicing, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">a homozygotic mutation</arg>
                    <arg n="1">splicing</arg>
                </example>
                <example src="REPLACE" no="959">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (a homozygotic mutation that can disrupt splicing, the Arg243--His mutation, a Hha I site, and the Asp250---Asn mutation, a Taq I site), and the allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">a homozygotic mutation</arg>
                    <arg n="1">splicing</arg>
                </example>
                <example src="REPLACE" no="960">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (a homozygotic mutation that have disrupted splicing, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">a homozygotic mutation</arg>
                    <arg n="1">splicing</arg>
                </example>
                <example src="REPLACE" no="961">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (blocking the expression MEKK1 or MEKK2 being able to disrupt the overall integrity of the MAPK route regulation, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">blocking the expression MEKK1 or MEKK2</arg>
                    <arg n="1">the overall integrity of the MAPK route regulation</arg>
                </example>
                <example src="REPLACE" no="962">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (blocking the expression MEKK1 or MEKK2 that can disrupt the overall integrity of the MAPK route regulation, the Arg243--His mutation, a Hha I site, and the Asp250---Asn mutation, a Taq I site), and the allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">blocking the expression MEKK1 or MEKK2</arg>
                    <arg n="1">the overall integrity of the MAPK route regulation</arg>
                </example>
                <example src="REPLACE" no="963">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (blocking the expression MEKK1 or MEKK2 that have disrupted the overall integrity of the MAPK route regulation, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">blocking the expression MEKK1 or MEKK2</arg>
                    <arg n="1">the overall integrity of the MAPK route regulation</arg>
                </example>
                <example src="REPLACE" no="964">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (homozygous mutation being able to disrupt splicing, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">homozygous mutation</arg>
                    <arg n="1">splicing</arg>
                </example>
                <example src="REPLACE" no="965">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (homozygous mutation that can disrupt splicing, the Arg243--His mutation, a Hha I site, and the Asp250---Asn mutation, a Taq I site), and the allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">homozygous mutation</arg>
                    <arg n="1">splicing</arg>
                </example>
                <example src="REPLACE" no="966">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (homozygous mutation that have disrupted splicing, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">homozygous mutation</arg>
                    <arg n="1">splicing</arg>
                </example>
                <example src="REPLACE" no="967">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (inhibition of inflammation being able to disrupt physiological protective responses, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">inhibition of inflammation</arg>
                    <arg n="1">physiological protective responses</arg>
                </example>
                <example src="REPLACE" no="968">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (inhibition of inflammation being able to disrupt protective physiological response, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">inhibition of inflammation</arg>
                    <arg n="1">protective physiological response</arg>
                </example>
                <example src="REPLACE" no="969">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (inhibition of inflammation that can disrupt physiological protective responses, the Arg243--His mutation, a Hha I site, and the Asp250---Asn mutation, a Taq I site), and the allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">inhibition of inflammation</arg>
                    <arg n="1">physiological protective responses</arg>
                </example>
                <example src="REPLACE" no="970">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (inhibition of inflammation that can disrupt protective physiological response, the Arg243--His mutation, a Hha I site, and the Asp250---Asn mutation, a Taq I site), and the allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">inhibition of inflammation</arg>
                    <arg n="1">protective physiological response</arg>
                </example>
                <example src="REPLACE" no="971">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (inhibition of inflammation that have disrupted physiological protective responses, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">inhibition of inflammation</arg>
                    <arg n="1">physiological protective responses</arg>
                </example>
                <example src="REPLACE" no="972">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (inhibition of inflammation that have disrupted protective physiological response, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">inhibition of inflammation</arg>
                    <arg n="1">protective physiological response</arg>
                </example>
                <example src="REPLACE" no="973">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (manipulation of the Tie-2 system in tumors being able to disrupt tumour vessels, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">manipulation of the Tie-2 system in tumors</arg>
                    <arg n="1">tumour vessels</arg>
                </example>
                <example src="REPLACE" no="974">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (manipulation of the Tie-2 system in tumors that can disrupt tumour vessels, the Arg243--His mutation, a Hha I site, and the Asp250---Asn mutation, a Taq I site), and the allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">manipulation of the Tie-2 system in tumors</arg>
                    <arg n="1">tumour vessels</arg>
                </example>
                <example src="REPLACE" no="975">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (manipulation of the Tie-2 system in tumors that have disrupted tumour vessels, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">manipulation of the Tie-2 system in tumors</arg>
                    <arg n="1">tumour vessels</arg>
                </example>
                <example src="REPLACE" no="976">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (manipulation of the binding system 2 in tumours being able to disrupt tumor vessels, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">manipulation of the binding system 2 in tumours</arg>
                    <arg n="1">tumor vessels</arg>
                </example>
                <example src="REPLACE" no="977">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (manipulation of the binding system 2 in tumours that can disrupt tumor vessels, the Arg243--His mutation, a Hha I site, and the Asp250---Asn mutation, a Taq I site), and the allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">manipulation of the binding system 2 in tumours</arg>
                    <arg n="1">tumor vessels</arg>
                </example>
                <example src="REPLACE" no="978">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (manipulation of the binding system 2 in tumours that have disrupted tumor vessels, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">manipulation of the binding system 2 in tumours</arg>
                    <arg n="1">tumor vessels</arg>
                </example>
                <example src="REPLACE" no="979">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (multations at p53 being able to disrupt post-checking points for DNA damage, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">multations at p53</arg>
                    <arg n="1">post-checking points for DNA damage</arg>
                </example>
                <example src="REPLACE" no="980">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (multations at p53 that can disrupt post-checking points for DNA damage, the Arg243--His mutation, a Hha I site, and the Asp250---Asn mutation, a Taq I site), and the allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">multations at p53</arg>
                    <arg n="1">post-checking points for DNA damage</arg>
                </example>
                <example src="REPLACE" no="981">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (multations at p53 that have disrupted post-checking points for DNA damage, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">multations at p53</arg>
                    <arg n="1">post-checking points for DNA damage</arg>
                </example>
                <example src="REPLACE" no="982">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (mutation 415G4 being able to disrupt pulling enhancement sequence: (GAR)n-(GAR)n, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">mutation 415G4</arg>
                    <arg n="1">pulling enhancement sequence: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="983">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (mutation 415G4 being able to disrupt splicing sequencer: (GAR)n-(GAR)n, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">mutation 415G4</arg>
                    <arg n="1">splicing sequencer: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="984">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (mutation 415G4 that can disrupt pulling enhancement sequence: (GAR)n-(GAR)n, the Arg243--His mutation, a Hha I site, and the Asp250---Asn mutation, a Taq I site), and the allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">mutation 415G4</arg>
                    <arg n="1">pulling enhancement sequence: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="985">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (mutation 415G4 that can disrupt splicing sequencer: (GAR)n-(GAR)n, the Arg243--His mutation, a Hha I site, and the Asp250---Asn mutation, a Taq I site), and the allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">mutation 415G4</arg>
                    <arg n="1">splicing sequencer: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="986">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (mutation 415G4 that have disrupted pulling enhancement sequence: (GAR)n-(GAR)n, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">mutation 415G4</arg>
                    <arg n="1">pulling enhancement sequence: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="987">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (mutation 415G4 that have disrupted splicing sequencer: (GAR)n-(GAR)n, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">mutation 415G4</arg>
                    <arg n="1">splicing sequencer: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="988">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (mutations in this region being able to disrupt assembly of keratin filaments, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">mutations in this region</arg>
                    <arg n="1">assembly of keratin filaments</arg>
                </example>
                <example src="REPLACE" no="989">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (mutations in this region that can disrupt assembly of keratin filaments, the Arg243--His mutation, a Hha I site, and the Asp250---Asn mutation, a Taq I site), and the allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">mutations in this region</arg>
                    <arg n="1">assembly of keratin filaments</arg>
                </example>
                <example src="REPLACE" no="990">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (mutations in this region that have disrupted assembly of keratin filaments, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">mutations in this region</arg>
                    <arg n="1">assembly of keratin filaments</arg>
                </example>
                <example src="REPLACE" no="991">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (p53 mutations being able to disrupt checking point responses for DNA damage, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">p53 mutations</arg>
                    <arg n="1">checking point responses for DNA damage</arg>
                </example>
                <example src="REPLACE" no="992">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (p53 mutations that can disrupt checking point responses for DNA damage, the Arg243--His mutation, a Hha I site, and the Asp250---Asn mutation, a Taq I site), and the allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">p53 mutations</arg>
                    <arg n="1">checking point responses for DNA damage</arg>
                </example>
                <example src="REPLACE" no="993">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (p53 mutations that have disrupted checking point responses for DNA damage, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">p53 mutations</arg>
                    <arg n="1">checking point responses for DNA damage</arg>
                </example>
                <example src="REPLACE" no="994">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (such mutations being able to disrupt the ubiquitin binding function, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">such mutations</arg>
                    <arg n="1">the ubiquitin binding function</arg>
                </example>
                <example src="REPLACE" no="995">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (such mutations being able to disrupt the ubiquitin-binding function, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">such mutations</arg>
                    <arg n="1">the ubiquitin-binding function</arg>
                </example>
                <example src="REPLACE" no="996">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (such mutations that can disrupt the ubiquitin binding function, the Arg243--His mutation, a Hha I site, and the Asp250---Asn mutation, a Taq I site), and the allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">such mutations</arg>
                    <arg n="1">the ubiquitin binding function</arg>
                </example>
                <example src="REPLACE" no="997">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (such mutations that can disrupt the ubiquitin-binding function, the Arg243--His mutation, a Hha I site, and the Asp250---Asn mutation, a Taq I site), and the allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">such mutations</arg>
                    <arg n="1">the ubiquitin-binding function</arg>
                </example>
                <example src="REPLACE" no="998">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (such mutations that have disrupted the ubiquitin binding function, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">such mutations</arg>
                    <arg n="1">the ubiquitin binding function</arg>
                </example>
                <example src="REPLACE" no="999">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (such mutations that have disrupted the ubiquitin-binding function, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">such mutations</arg>
                    <arg n="1">the ubiquitin-binding function</arg>
                </example>
                <example src="REPLACE" no="1000">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (the Lys147Ala substitution being able to disrupt the interaction, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">the Lys147Ala substitution</arg>
                    <arg n="1">the interaction</arg>
                </example>
                <example src="REPLACE" no="1001">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (the Lys147Ala substitution that can disrupt the interaction, the Arg243--His mutation, a Hha I site, and the Asp250---Asn mutation, a Taq I site), and the allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">the Lys147Ala substitution</arg>
                    <arg n="1">the interaction</arg>
                </example>
                <example src="REPLACE" no="1002">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (the Lys147Ala substitution that have disrupted the interaction, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">the Lys147Ala substitution</arg>
                    <arg n="1">the interaction</arg>
                </example>
                <example src="REPLACE" no="1003">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (these mutations being able to disrupt biquitin binding function, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">biquitin binding function</arg>
                </example>
                <example src="REPLACE" no="1004">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (these mutations that can disrupt biquitin binding function, the Arg243--His mutation, a Hha I site, and the Asp250---Asn mutation, a Taq I site), and the allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">biquitin binding function</arg>
                </example>
                <example src="REPLACE" no="1005">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (these mutations that have disrupted biquitin binding function, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">biquitin binding function</arg>
                </example>
                <example src="REPLACE" no="1006">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (this deletion being able to disrupt consensus signal 5, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">consensus signal 5</arg>
                </example>
                <example src="REPLACE" no="1007">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (this deletion that can disrupt consensus signal 5, the Arg243--His mutation, a Hha I site, and the Asp250---Asn mutation, a Taq I site), and the allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">consensus signal 5</arg>
                </example>
                <example src="REPLACE" no="1008">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (this deletion that have disrupted consensus signal 5, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">consensus signal 5</arg>
                </example>
                <example src="REPLACE" no="1009">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (this suppression being able to disrupt consensus signal 5, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">this suppression</arg>
                    <arg n="1">consensus signal 5</arg>
                </example>
                <example src="REPLACE" no="1010">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (this suppression that can disrupt consensus signal 5, the Arg243--His mutation, a Hha I site, and the Asp250---Asn mutation, a Taq I site), and the allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">this suppression</arg>
                    <arg n="1">consensus signal 5</arg>
                </example>
                <example src="REPLACE" no="1011">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (this suppression that have disrupted consensus signal 5, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">this suppression</arg>
                    <arg n="1">consensus signal 5</arg>
                </example>
                <example src="REPLACE" no="1012">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (tumour binding system 2 maneuver being able to disrupt tumour vessels, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">tumour binding system 2 maneuver</arg>
                    <arg n="1">tumour vessels</arg>
                </example>
                <example src="REPLACE" no="1013">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (tumour binding system 2 maneuver that can disrupt tumour vessels, the Arg243--His mutation, a Hha I site, and the Asp250---Asn mutation, a Taq I site), and the allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">tumour binding system 2 maneuver</arg>
                    <arg n="1">tumour vessels</arg>
                </example>
                <example src="REPLACE" no="1014">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (tumour binding system 2 maneuver that have disrupted tumour vessels, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">tumour binding system 2 maneuver</arg>
                    <arg n="1">tumour vessels</arg>
                </example>
                <example src="REPLACE" no="1015">
                    <text>The 415G4 mutation broke a sequence of enhancer spike: (GAR)n-(GAR)n disrupted in R (exon 5 spike).</text>
                    <arg n="0">The 415G4 mutation</arg>
                    <arg n="1">enhancer spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="1016">
                    <text>The 415G4 mutation broke a sequence of powerers spike: (GAR)n-(GAR)n disrupted in R (exon 5 spike).</text>
                    <arg n="0">The 415G4 mutation</arg>
                    <arg n="1">powerers spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="1017">
                    <text>The 415G4 mutation can disrupt with the base groups ceto and C (blue) on both sides of the dsDNA DNA and interrupt enhancer spike: (GAR)n-(GAR)n.</text>
                    <arg n="0">The 415G4 mutation</arg>
                    <arg n="1">enhancer spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="1018">
                    <text>The 415G4 mutation can disrupt with the base groups ceto and C (blue) on both sides of the dsDNA DNA and interrupt powerers spike: (GAR)n-(GAR)n.</text>
                    <arg n="0">The 415G4 mutation</arg>
                    <arg n="1">powerers spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="1019">
                    <text>The 415G4 mutation that broke A1 will be identified in the siblings disrupted by classical abetalipoproteinemia.</text>
                    <arg n="0">The 415G4 mutation</arg>
                </example>
                <example src="REPLACE" no="1020">
                    <text>The 415G4 mutation that can disrupt enhancer spike: (GAR)n-(GAR)n has been identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">The 415G4 mutation</arg>
                    <arg n="1">enhancer spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="1021">
                    <text>The 415G4 mutation that can disrupt enhancer spike: (GAR)n-(GAR)n that has been identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">The 415G4 mutation</arg>
                    <arg n="1">enhancer spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="1022">
                    <text>The 415G4 mutation that can disrupt powerers spike: (GAR)n-(GAR)n has been identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">The 415G4 mutation</arg>
                    <arg n="1">powerers spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="1023">
                    <text>The 415G4 mutation that can disrupt powerers spike: (GAR)n-(GAR)n that has been identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">The 415G4 mutation</arg>
                    <arg n="1">powerers spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="1024">
                    <text>The 415G4 mutation that has disrupted A1 will be identified in the affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">The 415G4 mutation</arg>
                </example>
                <example src="REPLACE" no="1025">
                    <text>The 415G4 mutation that has disrupted enhancer spike: (GAR)n-(GAR)n was identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">The 415G4 mutation</arg>
                    <arg n="1">enhancer spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="1026">
                    <text>The 415G4 mutation that has disrupted powerers spike: (GAR)n-(GAR)n was identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">The 415G4 mutation</arg>
                    <arg n="1">powerers spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="1027">
                    <text>The 415G4 mutation that interact with the keto groups of the base pair GO and C (blue) on either side of the dsDNA can disrupt enhancer spike: (GAR)n-(GAR)n.</text>
                    <arg n="0">The 415G4 mutation</arg>
                    <arg n="1">enhancer spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="1028">
                    <text>The 415G4 mutation that interact with the keto groups of the base pair GO and C (blue) on either side of the dsDNA can disrupt powerers spike: (GAR)n-(GAR)n.</text>
                    <arg n="0">The 415G4 mutation</arg>
                    <arg n="1">powerers spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="1029">
                    <text>The 415G4 mutation that interacts with the keto and C group pair (blue) on both sides of the dsDNA can disrupt enhancer spike: (GAR)n-(GAR)n.</text>
                    <arg n="0">The 415G4 mutation</arg>
                    <arg n="1">enhancer spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="1030">
                    <text>The 415G4 mutation that interacts with the keto and C group pair (blue) on both sides of the dsDNA can disrupt powerers spike: (GAR)n-(GAR)n.</text>
                    <arg n="0">The 415G4 mutation</arg>
                    <arg n="1">powerers spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="1031">
                    <text>The A mutation 415G4 that disrupted slicing enhancer sequnce: (GAR)n-(GAR)n was identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">A mutation 415G4</arg>
                    <arg n="1">slicing enhancer sequnce: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="1032">
                    <text>The Lys147Ala substitution that disrupted interaction was identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">Lys147Ala substitution</arg>
                    <arg n="1">interaction</arg>
                </example>
                <example src="REPLACE" no="1033">
                    <text>The Multations in p53 that disrupted posts of checkpoints to DNA damage was identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">Multations in p53</arg>
                    <arg n="1">posts of checkpoints to DNA damage</arg>
                </example>
                <example src="REPLACE" no="1034">
                    <text>The Multations in p53 that disrupted responses of checkpoints to DNA damage was identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">Multations in p53</arg>
                    <arg n="1">responses of checkpoints to DNA damage</arg>
                </example>
                <example src="REPLACE" no="1035">
                    <text>The Mutation 415G4 that disrupted licensing improvement sequence: (GAR)n-(GAR)n was identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">Mutation 415G4</arg>
                    <arg n="1">licensing improvement sequence: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="1036">
                    <text>The Mutations in p53 that disrupted responses of checkpoints to DNA damage was identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">Mutations in p53</arg>
                    <arg n="1">responses of checkpoints to DNA damage</arg>
                </example>
                <example src="REPLACE" no="1037">
                    <text>The R142X that disrupted a splicing enhancer was identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">R142X</arg>
                    <arg n="1">a splicing enhancer</arg>
                </example>
                <example src="REPLACE" no="1038">
                    <text>The R142X that disrupted a splicing power was identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">R142X</arg>
                    <arg n="1">a splicing power</arg>
                </example>
                <example src="REPLACE" no="1039">
                    <text>The The 415G4 mutation that disrupted enhancer spike: (GAR)n-(GAR)n was identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">The 415G4 mutation</arg>
                    <arg n="1">enhancer spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="1040">
                    <text>The The 415G4 mutation that disrupted powerers spike: (GAR)n-(GAR)n was identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">The 415G4 mutation</arg>
                    <arg n="1">powerers spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="1041">
                    <text>The The mutation 415G4 that disrupted enhancement brush: (GAR)n-(GAR)n was identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">The mutation 415G4</arg>
                    <arg n="1">enhancement brush: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="1042">
                    <text>The The mutation 415G4 that disrupted potent spike: (GAR)n-(GAR)n was identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">The mutation 415G4</arg>
                    <arg n="1">potent spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="1043">
                    <text>The These mutations that disrupted ubiquitin binding function was identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">These mutations</arg>
                    <arg n="1">ubiquitin binding function</arg>
                </example>
                <example src="REPLACE" no="1044">
                    <text>The This deletion that disrupted consensus coupling signal 5 was identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">consensus coupling signal 5</arg>
                </example>
                <example src="REPLACE" no="1045">
                    <text>The This deletion that disrupted the 5 consensus of splice signal was identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">the 5 consensus of splice signal</arg>
                </example>
                <example src="REPLACE" no="1046">
                    <text>The This deletion that disrupted the 5th consensus of the cut signal was identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">the 5th consensus of the cut signal</arg>
                </example>
                <example src="REPLACE" no="1047">
                    <text>The This deletion that disrupted the splice signal consensus 5 was identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">the splice signal consensus 5</arg>
                </example>
                <example src="REPLACE" no="1048">
                    <text>The a 415G4 mutation that disrupted licensing improvement sequence: (GAR)n-(GAR)n was identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">a 415G4 mutation</arg>
                    <arg n="1">licensing improvement sequence: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="1049">
                    <text>The a homozygotic mutation that disrupted splicing was identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">a homozygotic mutation</arg>
                    <arg n="1">splicing</arg>
                </example>
                <example src="REPLACE" no="1050">
                    <text>The blocking the expression MEKK1 or MEKK2 that disrupted the overall integrity of the MAPK route regulation was identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">blocking the expression MEKK1 or MEKK2</arg>
                    <arg n="1">the overall integrity of the MAPK route regulation</arg>
                </example>
                <example src="REPLACE" no="1051">
                    <text>The homozygous mutation that disrupted splicing was identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">homozygous mutation</arg>
                    <arg n="1">splicing</arg>
                </example>
                <example src="REPLACE" no="1052">
                    <text>The inhibition of inflammation that disrupted physiological protective responses was identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">inhibition of inflammation</arg>
                    <arg n="1">physiological protective responses</arg>
                </example>
                <example src="REPLACE" no="1053">
                    <text>The inhibition of inflammation that disrupted protective physiological response was identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">inhibition of inflammation</arg>
                    <arg n="1">protective physiological response</arg>
                </example>
                <example src="REPLACE" no="1054">
                    <text>The manipulation of the Tie-2 system in tumors that disrupted tumour vessels was identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">manipulation of the Tie-2 system in tumors</arg>
                    <arg n="1">tumour vessels</arg>
                </example>
                <example src="REPLACE" no="1055">
                    <text>The manipulation of the binding system 2 in tumours that disrupted tumor vessels was identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">manipulation of the binding system 2 in tumours</arg>
                    <arg n="1">tumor vessels</arg>
                </example>
                <example src="REPLACE" no="1056">
                    <text>The multations at p53 that disrupted post-checking points for DNA damage was identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">multations at p53</arg>
                    <arg n="1">post-checking points for DNA damage</arg>
                </example>
                <example src="REPLACE" no="1057">
                    <text>The mutation 415G4 broke a sequence of enhancement brush: (GAR)n-(GAR)n disrupted in R (exon 5 spike).</text>
                    <arg n="0">The mutation 415G4</arg>
                    <arg n="1">enhancement brush: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="1058">
                    <text>The mutation 415G4 broke a sequence of potent spike: (GAR)n-(GAR)n disrupted in R (exon 5 spike).</text>
                    <arg n="0">The mutation 415G4</arg>
                    <arg n="1">potent spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="1059">
                    <text>The mutation 415G4 can disrupt with the base groups ceto and C (blue) on both sides of the dsDNA DNA and interrupt enhancement brush: (GAR)n-(GAR)n.</text>
                    <arg n="0">The mutation 415G4</arg>
                    <arg n="1">enhancement brush: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="1060">
                    <text>The mutation 415G4 can disrupt with the base groups ceto and C (blue) on both sides of the dsDNA DNA and interrupt potent spike: (GAR)n-(GAR)n.</text>
                    <arg n="0">The mutation 415G4</arg>
                    <arg n="1">potent spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="1061">
                    <text>The mutation 415G4 that broke A1 will be identified in the siblings disrupted by classical abetalipoproteinemia.</text>
                    <arg n="0">The mutation 415G4</arg>
                </example>
                <example src="REPLACE" no="1062">
                    <text>The mutation 415G4 that can disrupt enhancement brush: (GAR)n-(GAR)n has been identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">The mutation 415G4</arg>
                    <arg n="1">enhancement brush: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="1063">
                    <text>The mutation 415G4 that can disrupt enhancement brush: (GAR)n-(GAR)n that has been identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">The mutation 415G4</arg>
                    <arg n="1">enhancement brush: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="1064">
                    <text>The mutation 415G4 that can disrupt potent spike: (GAR)n-(GAR)n has been identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">The mutation 415G4</arg>
                    <arg n="1">potent spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="1065">
                    <text>The mutation 415G4 that can disrupt potent spike: (GAR)n-(GAR)n that has been identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">The mutation 415G4</arg>
                    <arg n="1">potent spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="1066">
                    <text>The mutation 415G4 that disrupted pulling enhancement sequence: (GAR)n-(GAR)n was identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">mutation 415G4</arg>
                    <arg n="1">pulling enhancement sequence: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="1067">
                    <text>The mutation 415G4 that disrupted splicing sequencer: (GAR)n-(GAR)n was identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">mutation 415G4</arg>
                    <arg n="1">splicing sequencer: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="1068">
                    <text>The mutation 415G4 that has disrupted A1 will be identified in the affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">The mutation 415G4</arg>
                </example>
                <example src="REPLACE" no="1069">
                    <text>The mutation 415G4 that has disrupted enhancement brush: (GAR)n-(GAR)n was identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">The mutation 415G4</arg>
                    <arg n="1">enhancement brush: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="1070">
                    <text>The mutation 415G4 that has disrupted potent spike: (GAR)n-(GAR)n was identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">The mutation 415G4</arg>
                    <arg n="1">potent spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="1071">
                    <text>The mutation 415G4 that interact with the keto groups of the base pair GO and C (blue) on either side of the dsDNA can disrupt enhancement brush: (GAR)n-(GAR)n.</text>
                    <arg n="0">The mutation 415G4</arg>
                    <arg n="1">enhancement brush: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="1072">
                    <text>The mutation 415G4 that interact with the keto groups of the base pair GO and C (blue) on either side of the dsDNA can disrupt potent spike: (GAR)n-(GAR)n.</text>
                    <arg n="0">The mutation 415G4</arg>
                    <arg n="1">potent spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="1073">
                    <text>The mutation 415G4 that interacts with the keto and C group pair (blue) on both sides of the dsDNA can disrupt enhancement brush: (GAR)n-(GAR)n.</text>
                    <arg n="0">The mutation 415G4</arg>
                    <arg n="1">enhancement brush: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="1074">
                    <text>The mutation 415G4 that interacts with the keto and C group pair (blue) on both sides of the dsDNA can disrupt potent spike: (GAR)n-(GAR)n.</text>
                    <arg n="0">The mutation 415G4</arg>
                    <arg n="1">potent spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="1075">
                    <text>The mutations in this region that disrupted assembly of keratin filaments was identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">mutations in this region</arg>
                    <arg n="1">assembly of keratin filaments</arg>
                </example>
                <example src="REPLACE" no="1076">
                    <text>The p53 mutations that disrupted checking point responses for DNA damage was identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">p53 mutations</arg>
                    <arg n="1">checking point responses for DNA damage</arg>
                </example>
                <example src="REPLACE" no="1077">
                    <text>The sequence of amplified fragments of the cloned polymerase chain reaction of the AMH gene revealed a 14-bp deletion in the second exon of the maternal allele; A mutation 415G4 was shown to disrupt slicing enhancer sequnce: (GAR)n-(GAR)n.</text>
                    <arg n="0">A mutation 415G4</arg>
                    <arg n="1">slicing enhancer sequnce: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="1078">
                    <text>The sequence of amplified fragments of the cloned polymerase chain reaction of the AMH gene revealed a 14-bp deletion in the second exon of the maternal allele; Lys147Ala substitution was shown to disrupt interaction.</text>
                    <arg n="0">Lys147Ala substitution</arg>
                    <arg n="1">interaction</arg>
                </example>
                <example src="REPLACE" no="1079">
                    <text>The sequence of amplified fragments of the cloned polymerase chain reaction of the AMH gene revealed a 14-bp deletion in the second exon of the maternal allele; Multations in p53 was shown to disrupt posts of checkpoints to DNA damage.</text>
                    <arg n="0">Multations in p53</arg>
                    <arg n="1">posts of checkpoints to DNA damage</arg>
                </example>
                <example src="REPLACE" no="1080">
                    <text>The sequence of amplified fragments of the cloned polymerase chain reaction of the AMH gene revealed a 14-bp deletion in the second exon of the maternal allele; Multations in p53 was shown to disrupt responses of checkpoints to DNA damage.</text>
                    <arg n="0">Multations in p53</arg>
                    <arg n="1">responses of checkpoints to DNA damage</arg>
                </example>
                <example src="REPLACE" no="1081">
                    <text>The sequence of amplified fragments of the cloned polymerase chain reaction of the AMH gene revealed a 14-bp deletion in the second exon of the maternal allele; Mutation 415G4 was shown to disrupt licensing improvement sequence: (GAR)n-(GAR)n.</text>
                    <arg n="0">Mutation 415G4</arg>
                    <arg n="1">licensing improvement sequence: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="1082">
                    <text>The sequence of amplified fragments of the cloned polymerase chain reaction of the AMH gene revealed a 14-bp deletion in the second exon of the maternal allele; Mutations in p53 was shown to disrupt responses of checkpoints to DNA damage.</text>
                    <arg n="0">Mutations in p53</arg>
                    <arg n="1">responses of checkpoints to DNA damage</arg>
                </example>
                <example src="REPLACE" no="1083">
                    <text>The sequence of amplified fragments of the cloned polymerase chain reaction of the AMH gene revealed a 14-bp deletion in the second exon of the maternal allele; R142X was shown to disrupt a splicing enhancer.</text>
                    <arg n="0">R142X</arg>
                    <arg n="1">a splicing enhancer</arg>
                </example>
                <example src="REPLACE" no="1084">
                    <text>The sequence of amplified fragments of the cloned polymerase chain reaction of the AMH gene revealed a 14-bp deletion in the second exon of the maternal allele; R142X was shown to disrupt a splicing power.</text>
                    <arg n="0">R142X</arg>
                    <arg n="1">a splicing power</arg>
                </example>
                <example src="REPLACE" no="1085">
                    <text>The sequence of amplified fragments of the cloned polymerase chain reaction of the AMH gene revealed a 14-bp deletion in the second exon of the maternal allele; The 415G4 mutation was shown to disrupt enhancer spike: (GAR)n-(GAR)n.</text>
                    <arg n="0">The 415G4 mutation</arg>
                    <arg n="1">enhancer spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="1086">
                    <text>The sequence of amplified fragments of the cloned polymerase chain reaction of the AMH gene revealed a 14-bp deletion in the second exon of the maternal allele; The 415G4 mutation was shown to disrupt powerers spike: (GAR)n-(GAR)n.</text>
                    <arg n="0">The 415G4 mutation</arg>
                    <arg n="1">powerers spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="1087">
                    <text>The sequence of amplified fragments of the cloned polymerase chain reaction of the AMH gene revealed a 14-bp deletion in the second exon of the maternal allele; The mutation 415G4 was shown to disrupt enhancement brush: (GAR)n-(GAR)n.</text>
                    <arg n="0">The mutation 415G4</arg>
                    <arg n="1">enhancement brush: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="1088">
                    <text>The sequence of amplified fragments of the cloned polymerase chain reaction of the AMH gene revealed a 14-bp deletion in the second exon of the maternal allele; The mutation 415G4 was shown to disrupt potent spike: (GAR)n-(GAR)n.</text>
                    <arg n="0">The mutation 415G4</arg>
                    <arg n="1">potent spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="1089">
                    <text>The sequence of amplified fragments of the cloned polymerase chain reaction of the AMH gene revealed a 14-bp deletion in the second exon of the maternal allele; These mutations was shown to disrupt ubiquitin binding function.</text>
                    <arg n="0">These mutations</arg>
                    <arg n="1">ubiquitin binding function</arg>
                </example>
                <example src="REPLACE" no="1090">
                    <text>The sequence of amplified fragments of the cloned polymerase chain reaction of the AMH gene revealed a 14-bp deletion in the second exon of the maternal allele; This deletion was shown to disrupt consensus coupling signal 5.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">consensus coupling signal 5</arg>
                </example>
                <example src="REPLACE" no="1091">
                    <text>The sequence of amplified fragments of the cloned polymerase chain reaction of the AMH gene revealed a 14-bp deletion in the second exon of the maternal allele; This deletion was shown to disrupt the 5 consensus of splice signal.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">the 5 consensus of splice signal</arg>
                </example>
                <example src="REPLACE" no="1092">
                    <text>The sequence of amplified fragments of the cloned polymerase chain reaction of the AMH gene revealed a 14-bp deletion in the second exon of the maternal allele; This deletion was shown to disrupt the 5th consensus of the cut signal.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">the 5th consensus of the cut signal</arg>
                </example>
                <example src="REPLACE" no="1093">
                    <text>The sequence of amplified fragments of the cloned polymerase chain reaction of the AMH gene revealed a 14-bp deletion in the second exon of the maternal allele; This deletion was shown to disrupt the splice signal consensus 5.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">the splice signal consensus 5</arg>
                </example>
                <example src="REPLACE" no="1094">
                    <text>The sequence of amplified fragments of the cloned polymerase chain reaction of the AMH gene revealed a 14-bp deletion in the second exon of the maternal allele; a 415G4 mutation was shown to disrupt licensing improvement sequence: (GAR)n-(GAR)n.</text>
                    <arg n="0">a 415G4 mutation</arg>
                    <arg n="1">licensing improvement sequence: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="1095">
                    <text>The sequence of amplified fragments of the cloned polymerase chain reaction of the AMH gene revealed a 14-bp deletion in the second exon of the maternal allele; a homozygotic mutation was shown to disrupt splicing.</text>
                    <arg n="0">a homozygotic mutation</arg>
                    <arg n="1">splicing</arg>
                </example>
                <example src="REPLACE" no="1096">
                    <text>The sequence of amplified fragments of the cloned polymerase chain reaction of the AMH gene revealed a 14-bp deletion in the second exon of the maternal allele; blocking the expression MEKK1 or MEKK2 was shown to disrupt the overall integrity of the MAPK route regulation.</text>
                    <arg n="0">blocking the expression MEKK1 or MEKK2</arg>
                    <arg n="1">the overall integrity of the MAPK route regulation</arg>
                </example>
                <example src="REPLACE" no="1097">
                    <text>The sequence of amplified fragments of the cloned polymerase chain reaction of the AMH gene revealed a 14-bp deletion in the second exon of the maternal allele; homozygous mutation was shown to disrupt splicing.</text>
                    <arg n="0">homozygous mutation</arg>
                    <arg n="1">splicing</arg>
                </example>
                <example src="REPLACE" no="1098">
                    <text>The sequence of amplified fragments of the cloned polymerase chain reaction of the AMH gene revealed a 14-bp deletion in the second exon of the maternal allele; inhibition of inflammation was shown to disrupt physiological protective responses.</text>
                    <arg n="0">inhibition of inflammation</arg>
                    <arg n="1">physiological protective responses</arg>
                </example>
                <example src="REPLACE" no="1099">
                    <text>The sequence of amplified fragments of the cloned polymerase chain reaction of the AMH gene revealed a 14-bp deletion in the second exon of the maternal allele; inhibition of inflammation was shown to disrupt protective physiological response.</text>
                    <arg n="0">inhibition of inflammation</arg>
                    <arg n="1">protective physiological response</arg>
                </example>
                <example src="REPLACE" no="1100">
                    <text>The sequence of amplified fragments of the cloned polymerase chain reaction of the AMH gene revealed a 14-bp deletion in the second exon of the maternal allele; manipulation of the Tie-2 system in tumors was shown to disrupt tumour vessels.</text>
                    <arg n="0">manipulation of the Tie-2 system in tumors</arg>
                    <arg n="1">tumour vessels</arg>
                </example>
                <example src="REPLACE" no="1101">
                    <text>The sequence of amplified fragments of the cloned polymerase chain reaction of the AMH gene revealed a 14-bp deletion in the second exon of the maternal allele; manipulation of the binding system 2 in tumours was shown to disrupt tumor vessels.</text>
                    <arg n="0">manipulation of the binding system 2 in tumours</arg>
                    <arg n="1">tumor vessels</arg>
                </example>
                <example src="REPLACE" no="1102">
                    <text>The sequence of amplified fragments of the cloned polymerase chain reaction of the AMH gene revealed a 14-bp deletion in the second exon of the maternal allele; multations at p53 was shown to disrupt post-checking points for DNA damage.</text>
                    <arg n="0">multations at p53</arg>
                    <arg n="1">post-checking points for DNA damage</arg>
                </example>
                <example src="REPLACE" no="1103">
                    <text>The sequence of amplified fragments of the cloned polymerase chain reaction of the AMH gene revealed a 14-bp deletion in the second exon of the maternal allele; mutation 415G4 was shown to disrupt pulling enhancement sequence: (GAR)n-(GAR)n.</text>
                    <arg n="0">mutation 415G4</arg>
                    <arg n="1">pulling enhancement sequence: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="1104">
                    <text>The sequence of amplified fragments of the cloned polymerase chain reaction of the AMH gene revealed a 14-bp deletion in the second exon of the maternal allele; mutation 415G4 was shown to disrupt splicing sequencer: (GAR)n-(GAR)n.</text>
                    <arg n="0">mutation 415G4</arg>
                    <arg n="1">splicing sequencer: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="1105">
                    <text>The sequence of amplified fragments of the cloned polymerase chain reaction of the AMH gene revealed a 14-bp deletion in the second exon of the maternal allele; mutations in this region was shown to disrupt assembly of keratin filaments.</text>
                    <arg n="0">mutations in this region</arg>
                    <arg n="1">assembly of keratin filaments</arg>
                </example>
                <example src="REPLACE" no="1106">
                    <text>The sequence of amplified fragments of the cloned polymerase chain reaction of the AMH gene revealed a 14-bp deletion in the second exon of the maternal allele; p53 mutations was shown to disrupt checking point responses for DNA damage.</text>
                    <arg n="0">p53 mutations</arg>
                    <arg n="1">checking point responses for DNA damage</arg>
                </example>
                <example src="REPLACE" no="1107">
                    <text>The sequence of amplified fragments of the cloned polymerase chain reaction of the AMH gene revealed a 14-bp deletion in the second exon of the maternal allele; such mutations was shown to disrupt the ubiquitin binding function.</text>
                    <arg n="0">such mutations</arg>
                    <arg n="1">the ubiquitin binding function</arg>
                </example>
                <example src="REPLACE" no="1108">
                    <text>The sequence of amplified fragments of the cloned polymerase chain reaction of the AMH gene revealed a 14-bp deletion in the second exon of the maternal allele; such mutations was shown to disrupt the ubiquitin-binding function.</text>
                    <arg n="0">such mutations</arg>
                    <arg n="1">the ubiquitin-binding function</arg>
                </example>
                <example src="REPLACE" no="1109">
                    <text>The sequence of amplified fragments of the cloned polymerase chain reaction of the AMH gene revealed a 14-bp deletion in the second exon of the maternal allele; the Lys147Ala substitution was shown to disrupt the interaction.</text>
                    <arg n="0">the Lys147Ala substitution</arg>
                    <arg n="1">the interaction</arg>
                </example>
                <example src="REPLACE" no="1110">
                    <text>The sequence of amplified fragments of the cloned polymerase chain reaction of the AMH gene revealed a 14-bp deletion in the second exon of the maternal allele; these mutations was shown to disrupt biquitin binding function.</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">biquitin binding function</arg>
                </example>
                <example src="REPLACE" no="1111">
                    <text>The sequence of amplified fragments of the cloned polymerase chain reaction of the AMH gene revealed a 14-bp deletion in the second exon of the maternal allele; this deletion was shown to disrupt consensus signal 5.</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">consensus signal 5</arg>
                </example>
                <example src="REPLACE" no="1112">
                    <text>The sequence of amplified fragments of the cloned polymerase chain reaction of the AMH gene revealed a 14-bp deletion in the second exon of the maternal allele; this suppression was shown to disrupt consensus signal 5.</text>
                    <arg n="0">this suppression</arg>
                    <arg n="1">consensus signal 5</arg>
                </example>
                <example src="REPLACE" no="1113">
                    <text>The sequence of amplified fragments of the cloned polymerase chain reaction of the AMH gene revealed a 14-bp deletion in the second exon of the maternal allele; tumour binding system 2 maneuver was shown to disrupt tumour vessels.</text>
                    <arg n="0">tumour binding system 2 maneuver</arg>
                    <arg n="1">tumour vessels</arg>
                </example>
                <example src="REPLACE" no="1114">
                    <text>The sequence of the cloned polymerase chain reaction amplified fragments of the AMH gene revealed a deletion of 14-bp in the second exon of the maternal allele; A mutation 415G4 is able to disrupt slicing enhancer sequnce: (GAR)n-(GAR)n.</text>
                    <arg n="0">A mutation 415G4</arg>
                    <arg n="1">slicing enhancer sequnce: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="1115">
                    <text>The sequence of the cloned polymerase chain reaction amplified fragments of the AMH gene revealed a deletion of 14-bp in the second exon of the maternal allele; Lys147Ala substitution is able to disrupt interaction.</text>
                    <arg n="0">Lys147Ala substitution</arg>
                    <arg n="1">interaction</arg>
                </example>
                <example src="REPLACE" no="1116">
                    <text>The sequence of the cloned polymerase chain reaction amplified fragments of the AMH gene revealed a deletion of 14-bp in the second exon of the maternal allele; Multations in p53 is able to disrupt posts of checkpoints to DNA damage.</text>
                    <arg n="0">Multations in p53</arg>
                    <arg n="1">posts of checkpoints to DNA damage</arg>
                </example>
                <example src="REPLACE" no="1117">
                    <text>The sequence of the cloned polymerase chain reaction amplified fragments of the AMH gene revealed a deletion of 14-bp in the second exon of the maternal allele; Multations in p53 is able to disrupt responses of checkpoints to DNA damage.</text>
                    <arg n="0">Multations in p53</arg>
                    <arg n="1">responses of checkpoints to DNA damage</arg>
                </example>
                <example src="REPLACE" no="1118">
                    <text>The sequence of the cloned polymerase chain reaction amplified fragments of the AMH gene revealed a deletion of 14-bp in the second exon of the maternal allele; Mutation 415G4 is able to disrupt licensing improvement sequence: (GAR)n-(GAR)n.</text>
                    <arg n="0">Mutation 415G4</arg>
                    <arg n="1">licensing improvement sequence: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="1119">
                    <text>The sequence of the cloned polymerase chain reaction amplified fragments of the AMH gene revealed a deletion of 14-bp in the second exon of the maternal allele; Mutations in p53 is able to disrupt responses of checkpoints to DNA damage.</text>
                    <arg n="0">Mutations in p53</arg>
                    <arg n="1">responses of checkpoints to DNA damage</arg>
                </example>
                <example src="REPLACE" no="1120">
                    <text>The sequence of the cloned polymerase chain reaction amplified fragments of the AMH gene revealed a deletion of 14-bp in the second exon of the maternal allele; R142X is able to disrupt a splicing enhancer.</text>
                    <arg n="0">R142X</arg>
                    <arg n="1">a splicing enhancer</arg>
                </example>
                <example src="REPLACE" no="1121">
                    <text>The sequence of the cloned polymerase chain reaction amplified fragments of the AMH gene revealed a deletion of 14-bp in the second exon of the maternal allele; R142X is able to disrupt a splicing power.</text>
                    <arg n="0">R142X</arg>
                    <arg n="1">a splicing power</arg>
                </example>
                <example src="REPLACE" no="1122">
                    <text>The sequence of the cloned polymerase chain reaction amplified fragments of the AMH gene revealed a deletion of 14-bp in the second exon of the maternal allele; The 415G4 mutation is able to disrupt enhancer spike: (GAR)n-(GAR)n.</text>
                    <arg n="0">The 415G4 mutation</arg>
                    <arg n="1">enhancer spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="1123">
                    <text>The sequence of the cloned polymerase chain reaction amplified fragments of the AMH gene revealed a deletion of 14-bp in the second exon of the maternal allele; The 415G4 mutation is able to disrupt powerers spike: (GAR)n-(GAR)n.</text>
                    <arg n="0">The 415G4 mutation</arg>
                    <arg n="1">powerers spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="1124">
                    <text>The sequence of the cloned polymerase chain reaction amplified fragments of the AMH gene revealed a deletion of 14-bp in the second exon of the maternal allele; The mutation 415G4 is able to disrupt enhancement brush: (GAR)n-(GAR)n.</text>
                    <arg n="0">The mutation 415G4</arg>
                    <arg n="1">enhancement brush: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="1125">
                    <text>The sequence of the cloned polymerase chain reaction amplified fragments of the AMH gene revealed a deletion of 14-bp in the second exon of the maternal allele; The mutation 415G4 is able to disrupt potent spike: (GAR)n-(GAR)n.</text>
                    <arg n="0">The mutation 415G4</arg>
                    <arg n="1">potent spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="1126">
                    <text>The sequence of the cloned polymerase chain reaction amplified fragments of the AMH gene revealed a deletion of 14-bp in the second exon of the maternal allele; These mutations is able to disrupt ubiquitin binding function.</text>
                    <arg n="0">These mutations</arg>
                    <arg n="1">ubiquitin binding function</arg>
                </example>
                <example src="REPLACE" no="1127">
                    <text>The sequence of the cloned polymerase chain reaction amplified fragments of the AMH gene revealed a deletion of 14-bp in the second exon of the maternal allele; This deletion is able to disrupt consensus coupling signal 5.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">consensus coupling signal 5</arg>
                </example>
                <example src="REPLACE" no="1128">
                    <text>The sequence of the cloned polymerase chain reaction amplified fragments of the AMH gene revealed a deletion of 14-bp in the second exon of the maternal allele; This deletion is able to disrupt the 5 consensus of splice signal.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">the 5 consensus of splice signal</arg>
                </example>
                <example src="REPLACE" no="1129">
                    <text>The sequence of the cloned polymerase chain reaction amplified fragments of the AMH gene revealed a deletion of 14-bp in the second exon of the maternal allele; This deletion is able to disrupt the 5th consensus of the cut signal.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">the 5th consensus of the cut signal</arg>
                </example>
                <example src="REPLACE" no="1130">
                    <text>The sequence of the cloned polymerase chain reaction amplified fragments of the AMH gene revealed a deletion of 14-bp in the second exon of the maternal allele; This deletion is able to disrupt the splice signal consensus 5.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">the splice signal consensus 5</arg>
                </example>
                <example src="REPLACE" no="1131">
                    <text>The sequence of the cloned polymerase chain reaction amplified fragments of the AMH gene revealed a deletion of 14-bp in the second exon of the maternal allele; a 415G4 mutation is able to disrupt licensing improvement sequence: (GAR)n-(GAR)n.</text>
                    <arg n="0">a 415G4 mutation</arg>
                    <arg n="1">licensing improvement sequence: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="1132">
                    <text>The sequence of the cloned polymerase chain reaction amplified fragments of the AMH gene revealed a deletion of 14-bp in the second exon of the maternal allele; a homozygotic mutation is able to disrupt splicing.</text>
                    <arg n="0">a homozygotic mutation</arg>
                    <arg n="1">splicing</arg>
                </example>
                <example src="REPLACE" no="1133">
                    <text>The sequence of the cloned polymerase chain reaction amplified fragments of the AMH gene revealed a deletion of 14-bp in the second exon of the maternal allele; blocking the expression MEKK1 or MEKK2 is able to disrupt the overall integrity of the MAPK route regulation.</text>
                    <arg n="0">blocking the expression MEKK1 or MEKK2</arg>
                    <arg n="1">the overall integrity of the MAPK route regulation</arg>
                </example>
                <example src="REPLACE" no="1134">
                    <text>The sequence of the cloned polymerase chain reaction amplified fragments of the AMH gene revealed a deletion of 14-bp in the second exon of the maternal allele; homozygous mutation is able to disrupt splicing.</text>
                    <arg n="0">homozygous mutation</arg>
                    <arg n="1">splicing</arg>
                </example>
                <example src="REPLACE" no="1135">
                    <text>The sequence of the cloned polymerase chain reaction amplified fragments of the AMH gene revealed a deletion of 14-bp in the second exon of the maternal allele; inhibition of inflammation is able to disrupt physiological protective responses.</text>
                    <arg n="0">inhibition of inflammation</arg>
                    <arg n="1">physiological protective responses</arg>
                </example>
                <example src="REPLACE" no="1136">
                    <text>The sequence of the cloned polymerase chain reaction amplified fragments of the AMH gene revealed a deletion of 14-bp in the second exon of the maternal allele; inhibition of inflammation is able to disrupt protective physiological response.</text>
                    <arg n="0">inhibition of inflammation</arg>
                    <arg n="1">protective physiological response</arg>
                </example>
                <example src="REPLACE" no="1137">
                    <text>The sequence of the cloned polymerase chain reaction amplified fragments of the AMH gene revealed a deletion of 14-bp in the second exon of the maternal allele; manipulation of the Tie-2 system in tumors is able to disrupt tumour vessels.</text>
                    <arg n="0">manipulation of the Tie-2 system in tumors</arg>
                    <arg n="1">tumour vessels</arg>
                </example>
                <example src="REPLACE" no="1138">
                    <text>The sequence of the cloned polymerase chain reaction amplified fragments of the AMH gene revealed a deletion of 14-bp in the second exon of the maternal allele; manipulation of the binding system 2 in tumours is able to disrupt tumor vessels.</text>
                    <arg n="0">manipulation of the binding system 2 in tumours</arg>
                    <arg n="1">tumor vessels</arg>
                </example>
                <example src="REPLACE" no="1139">
                    <text>The sequence of the cloned polymerase chain reaction amplified fragments of the AMH gene revealed a deletion of 14-bp in the second exon of the maternal allele; multations at p53 is able to disrupt post-checking points for DNA damage.</text>
                    <arg n="0">multations at p53</arg>
                    <arg n="1">post-checking points for DNA damage</arg>
                </example>
                <example src="REPLACE" no="1140">
                    <text>The sequence of the cloned polymerase chain reaction amplified fragments of the AMH gene revealed a deletion of 14-bp in the second exon of the maternal allele; mutation 415G4 is able to disrupt pulling enhancement sequence: (GAR)n-(GAR)n.</text>
                    <arg n="0">mutation 415G4</arg>
                    <arg n="1">pulling enhancement sequence: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="1141">
                    <text>The sequence of the cloned polymerase chain reaction amplified fragments of the AMH gene revealed a deletion of 14-bp in the second exon of the maternal allele; mutation 415G4 is able to disrupt splicing sequencer: (GAR)n-(GAR)n.</text>
                    <arg n="0">mutation 415G4</arg>
                    <arg n="1">splicing sequencer: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="1142">
                    <text>The sequence of the cloned polymerase chain reaction amplified fragments of the AMH gene revealed a deletion of 14-bp in the second exon of the maternal allele; mutations in this region is able to disrupt assembly of keratin filaments.</text>
                    <arg n="0">mutations in this region</arg>
                    <arg n="1">assembly of keratin filaments</arg>
                </example>
                <example src="REPLACE" no="1143">
                    <text>The sequence of the cloned polymerase chain reaction amplified fragments of the AMH gene revealed a deletion of 14-bp in the second exon of the maternal allele; p53 mutations is able to disrupt checking point responses for DNA damage.</text>
                    <arg n="0">p53 mutations</arg>
                    <arg n="1">checking point responses for DNA damage</arg>
                </example>
                <example src="REPLACE" no="1144">
                    <text>The sequence of the cloned polymerase chain reaction amplified fragments of the AMH gene revealed a deletion of 14-bp in the second exon of the maternal allele; such mutations is able to disrupt the ubiquitin binding function.</text>
                    <arg n="0">such mutations</arg>
                    <arg n="1">the ubiquitin binding function</arg>
                </example>
                <example src="REPLACE" no="1145">
                    <text>The sequence of the cloned polymerase chain reaction amplified fragments of the AMH gene revealed a deletion of 14-bp in the second exon of the maternal allele; such mutations is able to disrupt the ubiquitin-binding function.</text>
                    <arg n="0">such mutations</arg>
                    <arg n="1">the ubiquitin-binding function</arg>
                </example>
                <example src="REPLACE" no="1146">
                    <text>The sequence of the cloned polymerase chain reaction amplified fragments of the AMH gene revealed a deletion of 14-bp in the second exon of the maternal allele; the Lys147Ala substitution is able to disrupt the interaction.</text>
                    <arg n="0">the Lys147Ala substitution</arg>
                    <arg n="1">the interaction</arg>
                </example>
                <example src="REPLACE" no="1147">
                    <text>The sequence of the cloned polymerase chain reaction amplified fragments of the AMH gene revealed a deletion of 14-bp in the second exon of the maternal allele; these mutations is able to disrupt biquitin binding function.</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">biquitin binding function</arg>
                </example>
                <example src="REPLACE" no="1148">
                    <text>The sequence of the cloned polymerase chain reaction amplified fragments of the AMH gene revealed a deletion of 14-bp in the second exon of the maternal allele; this deletion is able to disrupt consensus signal 5.</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">consensus signal 5</arg>
                </example>
                <example src="REPLACE" no="1149">
                    <text>The sequence of the cloned polymerase chain reaction amplified fragments of the AMH gene revealed a deletion of 14-bp in the second exon of the maternal allele; this suppression is able to disrupt consensus signal 5.</text>
                    <arg n="0">this suppression</arg>
                    <arg n="1">consensus signal 5</arg>
                </example>
                <example src="REPLACE" no="1150">
                    <text>The sequence of the cloned polymerase chain reaction amplified fragments of the AMH gene revealed a deletion of 14-bp in the second exon of the maternal allele; tumour binding system 2 maneuver is able to disrupt tumour vessels.</text>
                    <arg n="0">tumour binding system 2 maneuver</arg>
                    <arg n="1">tumour vessels</arg>
                </example>
                <example src="REPLACE" no="1151">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene disrupted a 14 bp deletion in the second exon of the maternal allele; A mutation 415G4 broke slicing enhancer sequnce: (GAR)n-(GAR)n.</text>
                    <arg n="0">A mutation 415G4</arg>
                    <arg n="1">slicing enhancer sequnce: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="1152">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene disrupted a 14 bp deletion in the second exon of the maternal allele; Lys147Ala substitution broke interaction.</text>
                    <arg n="0">Lys147Ala substitution</arg>
                    <arg n="1">interaction</arg>
                </example>
                <example src="REPLACE" no="1153">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene disrupted a 14 bp deletion in the second exon of the maternal allele; Multations in p53 broke posts of checkpoints to DNA damage.</text>
                    <arg n="0">Multations in p53</arg>
                    <arg n="1">posts of checkpoints to DNA damage</arg>
                </example>
                <example src="REPLACE" no="1154">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene disrupted a 14 bp deletion in the second exon of the maternal allele; Multations in p53 broke responses of checkpoints to DNA damage.</text>
                    <arg n="0">Multations in p53</arg>
                    <arg n="1">responses of checkpoints to DNA damage</arg>
                </example>
                <example src="REPLACE" no="1155">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene disrupted a 14 bp deletion in the second exon of the maternal allele; Mutation 415G4 broke licensing improvement sequence: (GAR)n-(GAR)n.</text>
                    <arg n="0">Mutation 415G4</arg>
                    <arg n="1">licensing improvement sequence: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="1156">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene disrupted a 14 bp deletion in the second exon of the maternal allele; Mutations in p53 broke responses of checkpoints to DNA damage.</text>
                    <arg n="0">Mutations in p53</arg>
                    <arg n="1">responses of checkpoints to DNA damage</arg>
                </example>
                <example src="REPLACE" no="1157">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene disrupted a 14 bp deletion in the second exon of the maternal allele; R142X broke a splicing enhancer.</text>
                    <arg n="0">R142X</arg>
                    <arg n="1">a splicing enhancer</arg>
                </example>
                <example src="REPLACE" no="1158">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene disrupted a 14 bp deletion in the second exon of the maternal allele; R142X broke a splicing power.</text>
                    <arg n="0">R142X</arg>
                    <arg n="1">a splicing power</arg>
                </example>
                <example src="REPLACE" no="1159">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene disrupted a 14 bp deletion in the second exon of the maternal allele; The 415G4 mutation broke enhancer spike: (GAR)n-(GAR)n.</text>
                    <arg n="0">The 415G4 mutation</arg>
                    <arg n="1">enhancer spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="1160">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene disrupted a 14 bp deletion in the second exon of the maternal allele; The 415G4 mutation broke powerers spike: (GAR)n-(GAR)n.</text>
                    <arg n="0">The 415G4 mutation</arg>
                    <arg n="1">powerers spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="1161">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene disrupted a 14 bp deletion in the second exon of the maternal allele; The mutation 415G4 broke enhancement brush: (GAR)n-(GAR)n.</text>
                    <arg n="0">The mutation 415G4</arg>
                    <arg n="1">enhancement brush: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="1162">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene disrupted a 14 bp deletion in the second exon of the maternal allele; The mutation 415G4 broke potent spike: (GAR)n-(GAR)n.</text>
                    <arg n="0">The mutation 415G4</arg>
                    <arg n="1">potent spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="1163">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene disrupted a 14 bp deletion in the second exon of the maternal allele; These mutations broke ubiquitin binding function.</text>
                    <arg n="0">These mutations</arg>
                    <arg n="1">ubiquitin binding function</arg>
                </example>
                <example src="REPLACE" no="1164">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene disrupted a 14 bp deletion in the second exon of the maternal allele; This deletion broke consensus coupling signal 5.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">consensus coupling signal 5</arg>
                </example>
                <example src="REPLACE" no="1165">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene disrupted a 14 bp deletion in the second exon of the maternal allele; This deletion broke the 5 consensus of splice signal.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">the 5 consensus of splice signal</arg>
                </example>
                <example src="REPLACE" no="1166">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene disrupted a 14 bp deletion in the second exon of the maternal allele; This deletion broke the 5th consensus of the cut signal.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">the 5th consensus of the cut signal</arg>
                </example>
                <example src="REPLACE" no="1167">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene disrupted a 14 bp deletion in the second exon of the maternal allele; This deletion broke the splice signal consensus 5.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">the splice signal consensus 5</arg>
                </example>
                <example src="REPLACE" no="1168">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene disrupted a 14 bp deletion in the second exon of the maternal allele; a 415G4 mutation broke licensing improvement sequence: (GAR)n-(GAR)n.</text>
                    <arg n="0">a 415G4 mutation</arg>
                    <arg n="1">licensing improvement sequence: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="1169">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene disrupted a 14 bp deletion in the second exon of the maternal allele; a homozygotic mutation broke splicing.</text>
                    <arg n="0">a homozygotic mutation</arg>
                    <arg n="1">splicing</arg>
                </example>
                <example src="REPLACE" no="1170">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene disrupted a 14 bp deletion in the second exon of the maternal allele; blocking the expression MEKK1 or MEKK2 broke the overall integrity of the MAPK route regulation.</text>
                    <arg n="0">blocking the expression MEKK1 or MEKK2</arg>
                    <arg n="1">the overall integrity of the MAPK route regulation</arg>
                </example>
                <example src="REPLACE" no="1171">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene disrupted a 14 bp deletion in the second exon of the maternal allele; homozygous mutation broke splicing.</text>
                    <arg n="0">homozygous mutation</arg>
                    <arg n="1">splicing</arg>
                </example>
                <example src="REPLACE" no="1172">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene disrupted a 14 bp deletion in the second exon of the maternal allele; inhibition of inflammation broke physiological protective responses.</text>
                    <arg n="0">inhibition of inflammation</arg>
                    <arg n="1">physiological protective responses</arg>
                </example>
                <example src="REPLACE" no="1173">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene disrupted a 14 bp deletion in the second exon of the maternal allele; inhibition of inflammation broke protective physiological response.</text>
                    <arg n="0">inhibition of inflammation</arg>
                    <arg n="1">protective physiological response</arg>
                </example>
                <example src="REPLACE" no="1174">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene disrupted a 14 bp deletion in the second exon of the maternal allele; manipulation of the Tie-2 system in tumors broke tumour vessels.</text>
                    <arg n="0">manipulation of the Tie-2 system in tumors</arg>
                    <arg n="1">tumour vessels</arg>
                </example>
                <example src="REPLACE" no="1175">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene disrupted a 14 bp deletion in the second exon of the maternal allele; manipulation of the binding system 2 in tumours broke tumor vessels.</text>
                    <arg n="0">manipulation of the binding system 2 in tumours</arg>
                    <arg n="1">tumor vessels</arg>
                </example>
                <example src="REPLACE" no="1176">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene disrupted a 14 bp deletion in the second exon of the maternal allele; multations at p53 broke post-checking points for DNA damage.</text>
                    <arg n="0">multations at p53</arg>
                    <arg n="1">post-checking points for DNA damage</arg>
                </example>
                <example src="REPLACE" no="1177">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene disrupted a 14 bp deletion in the second exon of the maternal allele; mutation 415G4 broke pulling enhancement sequence: (GAR)n-(GAR)n.</text>
                    <arg n="0">mutation 415G4</arg>
                    <arg n="1">pulling enhancement sequence: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="1178">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene disrupted a 14 bp deletion in the second exon of the maternal allele; mutation 415G4 broke splicing sequencer: (GAR)n-(GAR)n.</text>
                    <arg n="0">mutation 415G4</arg>
                    <arg n="1">splicing sequencer: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="1179">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene disrupted a 14 bp deletion in the second exon of the maternal allele; mutations in this region broke assembly of keratin filaments.</text>
                    <arg n="0">mutations in this region</arg>
                    <arg n="1">assembly of keratin filaments</arg>
                </example>
                <example src="REPLACE" no="1180">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene disrupted a 14 bp deletion in the second exon of the maternal allele; p53 mutations broke checking point responses for DNA damage.</text>
                    <arg n="0">p53 mutations</arg>
                    <arg n="1">checking point responses for DNA damage</arg>
                </example>
                <example src="REPLACE" no="1181">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene disrupted a 14 bp deletion in the second exon of the maternal allele; such mutations broke the ubiquitin binding function.</text>
                    <arg n="0">such mutations</arg>
                    <arg n="1">the ubiquitin binding function</arg>
                </example>
                <example src="REPLACE" no="1182">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene disrupted a 14 bp deletion in the second exon of the maternal allele; such mutations broke the ubiquitin-binding function.</text>
                    <arg n="0">such mutations</arg>
                    <arg n="1">the ubiquitin-binding function</arg>
                </example>
                <example src="REPLACE" no="1183">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene disrupted a 14 bp deletion in the second exon of the maternal allele; the Lys147Ala substitution broke the interaction.</text>
                    <arg n="0">the Lys147Ala substitution</arg>
                    <arg n="1">the interaction</arg>
                </example>
                <example src="REPLACE" no="1184">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene disrupted a 14 bp deletion in the second exon of the maternal allele; these mutations broke biquitin binding function.</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">biquitin binding function</arg>
                </example>
                <example src="REPLACE" no="1185">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene disrupted a 14 bp deletion in the second exon of the maternal allele; this deletion broke consensus signal 5.</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">consensus signal 5</arg>
                </example>
                <example src="REPLACE" no="1186">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene disrupted a 14 bp deletion in the second exon of the maternal allele; this suppression broke consensus signal 5.</text>
                    <arg n="0">this suppression</arg>
                    <arg n="1">consensus signal 5</arg>
                </example>
                <example src="REPLACE" no="1187">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene disrupted a 14 bp deletion in the second exon of the maternal allele; tumour binding system 2 maneuver broke tumour vessels.</text>
                    <arg n="0">tumour binding system 2 maneuver</arg>
                    <arg n="1">tumour vessels</arg>
                </example>
                <example src="REPLACE" no="1188">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; A mutation 415G4 disrupts slicing enhancer sequnce: (GAR)n-(GAR)n.</text>
                    <arg n="0">A mutation 415G4</arg>
                    <arg n="1">slicing enhancer sequnce: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="1189">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; A mutation 415G4 has been shown to disrupt slicing enhancer sequnce: (GAR)n-(GAR)n.</text>
                    <arg n="0">A mutation 415G4</arg>
                    <arg n="1">slicing enhancer sequnce: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="1190">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; A mutation 415G4 has disrupted slicing enhancer sequnce: (GAR)n-(GAR)n.</text>
                    <arg n="0">A mutation 415G4</arg>
                    <arg n="1">slicing enhancer sequnce: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="1191">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; A mutation 415G4 may have disrupted slicing enhancer sequnce: (GAR)n-(GAR)n.</text>
                    <arg n="0">A mutation 415G4</arg>
                    <arg n="1">slicing enhancer sequnce: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="1192">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; Lys147Ala substitution disrupts interaction.</text>
                    <arg n="0">Lys147Ala substitution</arg>
                    <arg n="1">interaction</arg>
                </example>
                <example src="REPLACE" no="1193">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; Lys147Ala substitution has been shown to disrupt interaction.</text>
                    <arg n="0">Lys147Ala substitution</arg>
                    <arg n="1">interaction</arg>
                </example>
                <example src="REPLACE" no="1194">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; Lys147Ala substitution has disrupted interaction.</text>
                    <arg n="0">Lys147Ala substitution</arg>
                    <arg n="1">interaction</arg>
                </example>
                <example src="REPLACE" no="1195">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; Lys147Ala substitution may have disrupted interaction.</text>
                    <arg n="0">Lys147Ala substitution</arg>
                    <arg n="1">interaction</arg>
                </example>
                <example src="REPLACE" no="1196">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; Multations in p53 disrupts posts of checkpoints to DNA damage.</text>
                    <arg n="0">Multations in p53</arg>
                    <arg n="1">posts of checkpoints to DNA damage</arg>
                </example>
                <example src="REPLACE" no="1197">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; Multations in p53 disrupts responses of checkpoints to DNA damage.</text>
                    <arg n="0">Multations in p53</arg>
                    <arg n="1">responses of checkpoints to DNA damage</arg>
                </example>
                <example src="REPLACE" no="1198">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; Multations in p53 has been shown to disrupt posts of checkpoints to DNA damage.</text>
                    <arg n="0">Multations in p53</arg>
                    <arg n="1">posts of checkpoints to DNA damage</arg>
                </example>
                <example src="REPLACE" no="1199">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; Multations in p53 has been shown to disrupt responses of checkpoints to DNA damage.</text>
                    <arg n="0">Multations in p53</arg>
                    <arg n="1">responses of checkpoints to DNA damage</arg>
                </example>
                <example src="REPLACE" no="1200">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; Multations in p53 has disrupted posts of checkpoints to DNA damage.</text>
                    <arg n="0">Multations in p53</arg>
                    <arg n="1">posts of checkpoints to DNA damage</arg>
                </example>
                <example src="REPLACE" no="1201">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; Multations in p53 has disrupted responses of checkpoints to DNA damage.</text>
                    <arg n="0">Multations in p53</arg>
                    <arg n="1">responses of checkpoints to DNA damage</arg>
                </example>
                <example src="REPLACE" no="1202">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; Multations in p53 may have disrupted posts of checkpoints to DNA damage.</text>
                    <arg n="0">Multations in p53</arg>
                    <arg n="1">posts of checkpoints to DNA damage</arg>
                </example>
                <example src="REPLACE" no="1203">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; Multations in p53 may have disrupted responses of checkpoints to DNA damage.</text>
                    <arg n="0">Multations in p53</arg>
                    <arg n="1">responses of checkpoints to DNA damage</arg>
                </example>
                <example src="REPLACE" no="1204">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; Mutation 415G4 disrupts licensing improvement sequence: (GAR)n-(GAR)n.</text>
                    <arg n="0">Mutation 415G4</arg>
                    <arg n="1">licensing improvement sequence: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="1205">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; Mutation 415G4 has been shown to disrupt licensing improvement sequence: (GAR)n-(GAR)n.</text>
                    <arg n="0">Mutation 415G4</arg>
                    <arg n="1">licensing improvement sequence: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="1206">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; Mutation 415G4 has disrupted licensing improvement sequence: (GAR)n-(GAR)n.</text>
                    <arg n="0">Mutation 415G4</arg>
                    <arg n="1">licensing improvement sequence: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="1207">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; Mutation 415G4 may have disrupted licensing improvement sequence: (GAR)n-(GAR)n.</text>
                    <arg n="0">Mutation 415G4</arg>
                    <arg n="1">licensing improvement sequence: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="1208">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; Mutations in p53 disrupts responses of checkpoints to DNA damage.</text>
                    <arg n="0">Mutations in p53</arg>
                    <arg n="1">responses of checkpoints to DNA damage</arg>
                </example>
                <example src="REPLACE" no="1209">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; Mutations in p53 has been shown to disrupt responses of checkpoints to DNA damage.</text>
                    <arg n="0">Mutations in p53</arg>
                    <arg n="1">responses of checkpoints to DNA damage</arg>
                </example>
                <example src="REPLACE" no="1210">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; Mutations in p53 has disrupted responses of checkpoints to DNA damage.</text>
                    <arg n="0">Mutations in p53</arg>
                    <arg n="1">responses of checkpoints to DNA damage</arg>
                </example>
                <example src="REPLACE" no="1211">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; Mutations in p53 may have disrupted responses of checkpoints to DNA damage.</text>
                    <arg n="0">Mutations in p53</arg>
                    <arg n="1">responses of checkpoints to DNA damage</arg>
                </example>
                <example src="REPLACE" no="1212">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; R142X disrupts a splicing enhancer.</text>
                    <arg n="0">R142X</arg>
                    <arg n="1">a splicing enhancer</arg>
                </example>
                <example src="REPLACE" no="1213">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; R142X disrupts a splicing power.</text>
                    <arg n="0">R142X</arg>
                    <arg n="1">a splicing power</arg>
                </example>
                <example src="REPLACE" no="1214">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; R142X has been shown to disrupt a splicing enhancer.</text>
                    <arg n="0">R142X</arg>
                    <arg n="1">a splicing enhancer</arg>
                </example>
                <example src="REPLACE" no="1215">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; R142X has been shown to disrupt a splicing power.</text>
                    <arg n="0">R142X</arg>
                    <arg n="1">a splicing power</arg>
                </example>
                <example src="REPLACE" no="1216">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; R142X has disrupted a splicing enhancer.</text>
                    <arg n="0">R142X</arg>
                    <arg n="1">a splicing enhancer</arg>
                </example>
                <example src="REPLACE" no="1217">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; R142X has disrupted a splicing power.</text>
                    <arg n="0">R142X</arg>
                    <arg n="1">a splicing power</arg>
                </example>
                <example src="REPLACE" no="1218">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; R142X may have disrupted a splicing enhancer.</text>
                    <arg n="0">R142X</arg>
                    <arg n="1">a splicing enhancer</arg>
                </example>
                <example src="REPLACE" no="1219">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; R142X may have disrupted a splicing power.</text>
                    <arg n="0">R142X</arg>
                    <arg n="1">a splicing power</arg>
                </example>
                <example src="REPLACE" no="1220">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; The 415G4 mutation disrupts enhancer spike: (GAR)n-(GAR)n.</text>
                    <arg n="0">The 415G4 mutation</arg>
                    <arg n="1">enhancer spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="1221">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; The 415G4 mutation disrupts powerers spike: (GAR)n-(GAR)n.</text>
                    <arg n="0">The 415G4 mutation</arg>
                    <arg n="1">powerers spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="1222">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; The 415G4 mutation has been shown to disrupt enhancer spike: (GAR)n-(GAR)n.</text>
                    <arg n="0">The 415G4 mutation</arg>
                    <arg n="1">enhancer spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="1223">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; The 415G4 mutation has been shown to disrupt powerers spike: (GAR)n-(GAR)n.</text>
                    <arg n="0">The 415G4 mutation</arg>
                    <arg n="1">powerers spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="1224">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; The 415G4 mutation has disrupted enhancer spike: (GAR)n-(GAR)n.</text>
                    <arg n="0">The 415G4 mutation</arg>
                    <arg n="1">enhancer spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="1225">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; The 415G4 mutation has disrupted powerers spike: (GAR)n-(GAR)n.</text>
                    <arg n="0">The 415G4 mutation</arg>
                    <arg n="1">powerers spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="1226">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; The 415G4 mutation may have disrupted enhancer spike: (GAR)n-(GAR)n.</text>
                    <arg n="0">The 415G4 mutation</arg>
                    <arg n="1">enhancer spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="1227">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; The 415G4 mutation may have disrupted powerers spike: (GAR)n-(GAR)n.</text>
                    <arg n="0">The 415G4 mutation</arg>
                    <arg n="1">powerers spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="1228">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; The mutation 415G4 disrupts enhancement brush: (GAR)n-(GAR)n.</text>
                    <arg n="0">The mutation 415G4</arg>
                    <arg n="1">enhancement brush: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="1229">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; The mutation 415G4 disrupts potent spike: (GAR)n-(GAR)n.</text>
                    <arg n="0">The mutation 415G4</arg>
                    <arg n="1">potent spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="1230">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; The mutation 415G4 has been shown to disrupt enhancement brush: (GAR)n-(GAR)n.</text>
                    <arg n="0">The mutation 415G4</arg>
                    <arg n="1">enhancement brush: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="1231">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; The mutation 415G4 has been shown to disrupt potent spike: (GAR)n-(GAR)n.</text>
                    <arg n="0">The mutation 415G4</arg>
                    <arg n="1">potent spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="1232">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; The mutation 415G4 has disrupted enhancement brush: (GAR)n-(GAR)n.</text>
                    <arg n="0">The mutation 415G4</arg>
                    <arg n="1">enhancement brush: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="1233">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; The mutation 415G4 has disrupted potent spike: (GAR)n-(GAR)n.</text>
                    <arg n="0">The mutation 415G4</arg>
                    <arg n="1">potent spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="1234">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; The mutation 415G4 may have disrupted enhancement brush: (GAR)n-(GAR)n.</text>
                    <arg n="0">The mutation 415G4</arg>
                    <arg n="1">enhancement brush: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="1235">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; The mutation 415G4 may have disrupted potent spike: (GAR)n-(GAR)n.</text>
                    <arg n="0">The mutation 415G4</arg>
                    <arg n="1">potent spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="1236">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; These mutations disrupts ubiquitin binding function.</text>
                    <arg n="0">These mutations</arg>
                    <arg n="1">ubiquitin binding function</arg>
                </example>
                <example src="REPLACE" no="1237">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; These mutations has been shown to disrupt ubiquitin binding function.</text>
                    <arg n="0">These mutations</arg>
                    <arg n="1">ubiquitin binding function</arg>
                </example>
                <example src="REPLACE" no="1238">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; These mutations has disrupted ubiquitin binding function.</text>
                    <arg n="0">These mutations</arg>
                    <arg n="1">ubiquitin binding function</arg>
                </example>
                <example src="REPLACE" no="1239">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; These mutations may have disrupted ubiquitin binding function.</text>
                    <arg n="0">These mutations</arg>
                    <arg n="1">ubiquitin binding function</arg>
                </example>
                <example src="REPLACE" no="1240">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; This deletion disrupts consensus coupling signal 5.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">consensus coupling signal 5</arg>
                </example>
                <example src="REPLACE" no="1241">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; This deletion disrupts the 5 consensus of splice signal.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">the 5 consensus of splice signal</arg>
                </example>
                <example src="REPLACE" no="1242">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; This deletion disrupts the 5th consensus of the cut signal.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">the 5th consensus of the cut signal</arg>
                </example>
                <example src="REPLACE" no="1243">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; This deletion disrupts the splice signal consensus 5.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">the splice signal consensus 5</arg>
                </example>
                <example src="REPLACE" no="1244">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; This deletion has been shown to disrupt consensus coupling signal 5.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">consensus coupling signal 5</arg>
                </example>
                <example src="REPLACE" no="1245">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; This deletion has been shown to disrupt the 5 consensus of splice signal.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">the 5 consensus of splice signal</arg>
                </example>
                <example src="REPLACE" no="1246">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; This deletion has been shown to disrupt the 5th consensus of the cut signal.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">the 5th consensus of the cut signal</arg>
                </example>
                <example src="REPLACE" no="1247">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; This deletion has been shown to disrupt the splice signal consensus 5.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">the splice signal consensus 5</arg>
                </example>
                <example src="REPLACE" no="1248">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; This deletion has disrupted consensus coupling signal 5.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">consensus coupling signal 5</arg>
                </example>
                <example src="REPLACE" no="1249">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; This deletion has disrupted the 5 consensus of splice signal.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">the 5 consensus of splice signal</arg>
                </example>
                <example src="REPLACE" no="1250">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; This deletion has disrupted the 5th consensus of the cut signal.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">the 5th consensus of the cut signal</arg>
                </example>
                <example src="REPLACE" no="1251">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; This deletion has disrupted the splice signal consensus 5.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">the splice signal consensus 5</arg>
                </example>
                <example src="REPLACE" no="1252">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; This deletion may have disrupted consensus coupling signal 5.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">consensus coupling signal 5</arg>
                </example>
                <example src="REPLACE" no="1253">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; This deletion may have disrupted the 5 consensus of splice signal.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">the 5 consensus of splice signal</arg>
                </example>
                <example src="REPLACE" no="1254">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; This deletion may have disrupted the 5th consensus of the cut signal.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">the 5th consensus of the cut signal</arg>
                </example>
                <example src="REPLACE" no="1255">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; This deletion may have disrupted the splice signal consensus 5.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">the splice signal consensus 5</arg>
                </example>
                <example src="REPLACE" no="1256">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; a 415G4 mutation disrupts licensing improvement sequence: (GAR)n-(GAR)n.</text>
                    <arg n="0">a 415G4 mutation</arg>
                    <arg n="1">licensing improvement sequence: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="1257">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; a 415G4 mutation has been shown to disrupt licensing improvement sequence: (GAR)n-(GAR)n.</text>
                    <arg n="0">a 415G4 mutation</arg>
                    <arg n="1">licensing improvement sequence: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="1258">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; a 415G4 mutation has disrupted licensing improvement sequence: (GAR)n-(GAR)n.</text>
                    <arg n="0">a 415G4 mutation</arg>
                    <arg n="1">licensing improvement sequence: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="1259">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; a 415G4 mutation may have disrupted licensing improvement sequence: (GAR)n-(GAR)n.</text>
                    <arg n="0">a 415G4 mutation</arg>
                    <arg n="1">licensing improvement sequence: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="1260">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; a homozygotic mutation disrupts splicing.</text>
                    <arg n="0">a homozygotic mutation</arg>
                    <arg n="1">splicing</arg>
                </example>
                <example src="REPLACE" no="1261">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; a homozygotic mutation has been shown to disrupt splicing.</text>
                    <arg n="0">a homozygotic mutation</arg>
                    <arg n="1">splicing</arg>
                </example>
                <example src="REPLACE" no="1262">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; a homozygotic mutation has disrupted splicing.</text>
                    <arg n="0">a homozygotic mutation</arg>
                    <arg n="1">splicing</arg>
                </example>
                <example src="REPLACE" no="1263">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; a homozygotic mutation may have disrupted splicing.</text>
                    <arg n="0">a homozygotic mutation</arg>
                    <arg n="1">splicing</arg>
                </example>
                <example src="REPLACE" no="1264">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; blocking the expression MEKK1 or MEKK2 disrupts the overall integrity of the MAPK route regulation.</text>
                    <arg n="0">blocking the expression MEKK1 or MEKK2</arg>
                    <arg n="1">the overall integrity of the MAPK route regulation</arg>
                </example>
                <example src="REPLACE" no="1265">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; blocking the expression MEKK1 or MEKK2 has been shown to disrupt the overall integrity of the MAPK route regulation.</text>
                    <arg n="0">blocking the expression MEKK1 or MEKK2</arg>
                    <arg n="1">the overall integrity of the MAPK route regulation</arg>
                </example>
                <example src="REPLACE" no="1266">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; blocking the expression MEKK1 or MEKK2 has disrupted the overall integrity of the MAPK route regulation.</text>
                    <arg n="0">blocking the expression MEKK1 or MEKK2</arg>
                    <arg n="1">the overall integrity of the MAPK route regulation</arg>
                </example>
                <example src="REPLACE" no="1267">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; blocking the expression MEKK1 or MEKK2 may have disrupted the overall integrity of the MAPK route regulation.</text>
                    <arg n="0">blocking the expression MEKK1 or MEKK2</arg>
                    <arg n="1">the overall integrity of the MAPK route regulation</arg>
                </example>
                <example src="REPLACE" no="1268">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; homozygous mutation disrupts splicing.</text>
                    <arg n="0">homozygous mutation</arg>
                    <arg n="1">splicing</arg>
                </example>
                <example src="REPLACE" no="1269">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; homozygous mutation has been shown to disrupt splicing.</text>
                    <arg n="0">homozygous mutation</arg>
                    <arg n="1">splicing</arg>
                </example>
                <example src="REPLACE" no="1270">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; homozygous mutation has disrupted splicing.</text>
                    <arg n="0">homozygous mutation</arg>
                    <arg n="1">splicing</arg>
                </example>
                <example src="REPLACE" no="1271">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; homozygous mutation may have disrupted splicing.</text>
                    <arg n="0">homozygous mutation</arg>
                    <arg n="1">splicing</arg>
                </example>
                <example src="REPLACE" no="1272">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; inhibition of inflammation disrupts physiological protective responses.</text>
                    <arg n="0">inhibition of inflammation</arg>
                    <arg n="1">physiological protective responses</arg>
                </example>
                <example src="REPLACE" no="1273">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; inhibition of inflammation disrupts protective physiological response.</text>
                    <arg n="0">inhibition of inflammation</arg>
                    <arg n="1">protective physiological response</arg>
                </example>
                <example src="REPLACE" no="1274">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; inhibition of inflammation has been shown to disrupt physiological protective responses.</text>
                    <arg n="0">inhibition of inflammation</arg>
                    <arg n="1">physiological protective responses</arg>
                </example>
                <example src="REPLACE" no="1275">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; inhibition of inflammation has been shown to disrupt protective physiological response.</text>
                    <arg n="0">inhibition of inflammation</arg>
                    <arg n="1">protective physiological response</arg>
                </example>
                <example src="REPLACE" no="1276">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; inhibition of inflammation has disrupted physiological protective responses.</text>
                    <arg n="0">inhibition of inflammation</arg>
                    <arg n="1">physiological protective responses</arg>
                </example>
                <example src="REPLACE" no="1277">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; inhibition of inflammation has disrupted protective physiological response.</text>
                    <arg n="0">inhibition of inflammation</arg>
                    <arg n="1">protective physiological response</arg>
                </example>
                <example src="REPLACE" no="1278">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; inhibition of inflammation may have disrupted physiological protective responses.</text>
                    <arg n="0">inhibition of inflammation</arg>
                    <arg n="1">physiological protective responses</arg>
                </example>
                <example src="REPLACE" no="1279">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; inhibition of inflammation may have disrupted protective physiological response.</text>
                    <arg n="0">inhibition of inflammation</arg>
                    <arg n="1">protective physiological response</arg>
                </example>
                <example src="REPLACE" no="1280">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; manipulation of the Tie-2 system in tumors disrupts tumour vessels.</text>
                    <arg n="0">manipulation of the Tie-2 system in tumors</arg>
                    <arg n="1">tumour vessels</arg>
                </example>
                <example src="REPLACE" no="1281">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; manipulation of the Tie-2 system in tumors has been shown to disrupt tumour vessels.</text>
                    <arg n="0">manipulation of the Tie-2 system in tumors</arg>
                    <arg n="1">tumour vessels</arg>
                </example>
                <example src="REPLACE" no="1282">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; manipulation of the Tie-2 system in tumors has disrupted tumour vessels.</text>
                    <arg n="0">manipulation of the Tie-2 system in tumors</arg>
                    <arg n="1">tumour vessels</arg>
                </example>
                <example src="REPLACE" no="1283">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; manipulation of the Tie-2 system in tumors may have disrupted tumour vessels.</text>
                    <arg n="0">manipulation of the Tie-2 system in tumors</arg>
                    <arg n="1">tumour vessels</arg>
                </example>
                <example src="REPLACE" no="1284">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; manipulation of the binding system 2 in tumours disrupts tumor vessels.</text>
                    <arg n="0">manipulation of the binding system 2 in tumours</arg>
                    <arg n="1">tumor vessels</arg>
                </example>
                <example src="REPLACE" no="1285">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; manipulation of the binding system 2 in tumours has been shown to disrupt tumor vessels.</text>
                    <arg n="0">manipulation of the binding system 2 in tumours</arg>
                    <arg n="1">tumor vessels</arg>
                </example>
                <example src="REPLACE" no="1286">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; manipulation of the binding system 2 in tumours has disrupted tumor vessels.</text>
                    <arg n="0">manipulation of the binding system 2 in tumours</arg>
                    <arg n="1">tumor vessels</arg>
                </example>
                <example src="REPLACE" no="1287">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; manipulation of the binding system 2 in tumours may have disrupted tumor vessels.</text>
                    <arg n="0">manipulation of the binding system 2 in tumours</arg>
                    <arg n="1">tumor vessels</arg>
                </example>
                <example src="REPLACE" no="1288">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; multations at p53 disrupts post-checking points for DNA damage.</text>
                    <arg n="0">multations at p53</arg>
                    <arg n="1">post-checking points for DNA damage</arg>
                </example>
                <example src="REPLACE" no="1289">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; multations at p53 has been shown to disrupt post-checking points for DNA damage.</text>
                    <arg n="0">multations at p53</arg>
                    <arg n="1">post-checking points for DNA damage</arg>
                </example>
                <example src="REPLACE" no="1290">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; multations at p53 has disrupted post-checking points for DNA damage.</text>
                    <arg n="0">multations at p53</arg>
                    <arg n="1">post-checking points for DNA damage</arg>
                </example>
                <example src="REPLACE" no="1291">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; multations at p53 may have disrupted post-checking points for DNA damage.</text>
                    <arg n="0">multations at p53</arg>
                    <arg n="1">post-checking points for DNA damage</arg>
                </example>
                <example src="REPLACE" no="1292">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; mutation 415G4 disrupts pulling enhancement sequence: (GAR)n-(GAR)n.</text>
                    <arg n="0">mutation 415G4</arg>
                    <arg n="1">pulling enhancement sequence: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="1293">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; mutation 415G4 disrupts splicing sequencer: (GAR)n-(GAR)n.</text>
                    <arg n="0">mutation 415G4</arg>
                    <arg n="1">splicing sequencer: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="1294">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; mutation 415G4 has been shown to disrupt pulling enhancement sequence: (GAR)n-(GAR)n.</text>
                    <arg n="0">mutation 415G4</arg>
                    <arg n="1">pulling enhancement sequence: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="1295">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; mutation 415G4 has been shown to disrupt splicing sequencer: (GAR)n-(GAR)n.</text>
                    <arg n="0">mutation 415G4</arg>
                    <arg n="1">splicing sequencer: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="1296">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; mutation 415G4 has disrupted pulling enhancement sequence: (GAR)n-(GAR)n.</text>
                    <arg n="0">mutation 415G4</arg>
                    <arg n="1">pulling enhancement sequence: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="1297">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; mutation 415G4 has disrupted splicing sequencer: (GAR)n-(GAR)n.</text>
                    <arg n="0">mutation 415G4</arg>
                    <arg n="1">splicing sequencer: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="1298">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; mutation 415G4 may have disrupted pulling enhancement sequence: (GAR)n-(GAR)n.</text>
                    <arg n="0">mutation 415G4</arg>
                    <arg n="1">pulling enhancement sequence: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="1299">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; mutation 415G4 may have disrupted splicing sequencer: (GAR)n-(GAR)n.</text>
                    <arg n="0">mutation 415G4</arg>
                    <arg n="1">splicing sequencer: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="1300">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; mutations in this region disrupts assembly of keratin filaments.</text>
                    <arg n="0">mutations in this region</arg>
                    <arg n="1">assembly of keratin filaments</arg>
                </example>
                <example src="REPLACE" no="1301">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; mutations in this region has been shown to disrupt assembly of keratin filaments.</text>
                    <arg n="0">mutations in this region</arg>
                    <arg n="1">assembly of keratin filaments</arg>
                </example>
                <example src="REPLACE" no="1302">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; mutations in this region has disrupted assembly of keratin filaments.</text>
                    <arg n="0">mutations in this region</arg>
                    <arg n="1">assembly of keratin filaments</arg>
                </example>
                <example src="REPLACE" no="1303">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; mutations in this region may have disrupted assembly of keratin filaments.</text>
                    <arg n="0">mutations in this region</arg>
                    <arg n="1">assembly of keratin filaments</arg>
                </example>
                <example src="REPLACE" no="1304">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; p53 mutations disrupts checking point responses for DNA damage.</text>
                    <arg n="0">p53 mutations</arg>
                    <arg n="1">checking point responses for DNA damage</arg>
                </example>
                <example src="REPLACE" no="1305">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; p53 mutations has been shown to disrupt checking point responses for DNA damage.</text>
                    <arg n="0">p53 mutations</arg>
                    <arg n="1">checking point responses for DNA damage</arg>
                </example>
                <example src="REPLACE" no="1306">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; p53 mutations has disrupted checking point responses for DNA damage.</text>
                    <arg n="0">p53 mutations</arg>
                    <arg n="1">checking point responses for DNA damage</arg>
                </example>
                <example src="REPLACE" no="1307">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; p53 mutations may have disrupted checking point responses for DNA damage.</text>
                    <arg n="0">p53 mutations</arg>
                    <arg n="1">checking point responses for DNA damage</arg>
                </example>
                <example src="REPLACE" no="1308">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; such mutations disrupts the ubiquitin binding function.</text>
                    <arg n="0">such mutations</arg>
                    <arg n="1">the ubiquitin binding function</arg>
                </example>
                <example src="REPLACE" no="1309">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; such mutations disrupts the ubiquitin-binding function.</text>
                    <arg n="0">such mutations</arg>
                    <arg n="1">the ubiquitin-binding function</arg>
                </example>
                <example src="REPLACE" no="1310">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; such mutations has been shown to disrupt the ubiquitin binding function.</text>
                    <arg n="0">such mutations</arg>
                    <arg n="1">the ubiquitin binding function</arg>
                </example>
                <example src="REPLACE" no="1311">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; such mutations has been shown to disrupt the ubiquitin-binding function.</text>
                    <arg n="0">such mutations</arg>
                    <arg n="1">the ubiquitin-binding function</arg>
                </example>
                <example src="REPLACE" no="1312">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; such mutations has disrupted the ubiquitin binding function.</text>
                    <arg n="0">such mutations</arg>
                    <arg n="1">the ubiquitin binding function</arg>
                </example>
                <example src="REPLACE" no="1313">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; such mutations has disrupted the ubiquitin-binding function.</text>
                    <arg n="0">such mutations</arg>
                    <arg n="1">the ubiquitin-binding function</arg>
                </example>
                <example src="REPLACE" no="1314">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; such mutations may have disrupted the ubiquitin binding function.</text>
                    <arg n="0">such mutations</arg>
                    <arg n="1">the ubiquitin binding function</arg>
                </example>
                <example src="REPLACE" no="1315">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; such mutations may have disrupted the ubiquitin-binding function.</text>
                    <arg n="0">such mutations</arg>
                    <arg n="1">the ubiquitin-binding function</arg>
                </example>
                <example src="REPLACE" no="1316">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; the Lys147Ala substitution disrupts the interaction.</text>
                    <arg n="0">the Lys147Ala substitution</arg>
                    <arg n="1">the interaction</arg>
                </example>
                <example src="REPLACE" no="1317">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; the Lys147Ala substitution has been shown to disrupt the interaction.</text>
                    <arg n="0">the Lys147Ala substitution</arg>
                    <arg n="1">the interaction</arg>
                </example>
                <example src="REPLACE" no="1318">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; the Lys147Ala substitution has disrupted the interaction.</text>
                    <arg n="0">the Lys147Ala substitution</arg>
                    <arg n="1">the interaction</arg>
                </example>
                <example src="REPLACE" no="1319">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; the Lys147Ala substitution may have disrupted the interaction.</text>
                    <arg n="0">the Lys147Ala substitution</arg>
                    <arg n="1">the interaction</arg>
                </example>
                <example src="REPLACE" no="1320">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; these mutations disrupts biquitin binding function.</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">biquitin binding function</arg>
                </example>
                <example src="REPLACE" no="1321">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; these mutations has been shown to disrupt biquitin binding function.</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">biquitin binding function</arg>
                </example>
                <example src="REPLACE" no="1322">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; these mutations has disrupted biquitin binding function.</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">biquitin binding function</arg>
                </example>
                <example src="REPLACE" no="1323">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; these mutations may have disrupted biquitin binding function.</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">biquitin binding function</arg>
                </example>
                <example src="REPLACE" no="1324">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; this deletion disrupts consensus signal 5.</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">consensus signal 5</arg>
                </example>
                <example src="REPLACE" no="1325">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; this deletion has been shown to disrupt consensus signal 5.</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">consensus signal 5</arg>
                </example>
                <example src="REPLACE" no="1326">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; this deletion has disrupted consensus signal 5.</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">consensus signal 5</arg>
                </example>
                <example src="REPLACE" no="1327">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; this deletion may have disrupted consensus signal 5.</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">consensus signal 5</arg>
                </example>
                <example src="REPLACE" no="1328">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; this suppression disrupts consensus signal 5.</text>
                    <arg n="0">this suppression</arg>
                    <arg n="1">consensus signal 5</arg>
                </example>
                <example src="REPLACE" no="1329">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; this suppression has been shown to disrupt consensus signal 5.</text>
                    <arg n="0">this suppression</arg>
                    <arg n="1">consensus signal 5</arg>
                </example>
                <example src="REPLACE" no="1330">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; this suppression has disrupted consensus signal 5.</text>
                    <arg n="0">this suppression</arg>
                    <arg n="1">consensus signal 5</arg>
                </example>
                <example src="REPLACE" no="1331">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; this suppression may have disrupted consensus signal 5.</text>
                    <arg n="0">this suppression</arg>
                    <arg n="1">consensus signal 5</arg>
                </example>
                <example src="REPLACE" no="1332">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; tumour binding system 2 maneuver disrupts tumour vessels.</text>
                    <arg n="0">tumour binding system 2 maneuver</arg>
                    <arg n="1">tumour vessels</arg>
                </example>
                <example src="REPLACE" no="1333">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; tumour binding system 2 maneuver has been shown to disrupt tumour vessels.</text>
                    <arg n="0">tumour binding system 2 maneuver</arg>
                    <arg n="1">tumour vessels</arg>
                </example>
                <example src="REPLACE" no="1334">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; tumour binding system 2 maneuver has disrupted tumour vessels.</text>
                    <arg n="0">tumour binding system 2 maneuver</arg>
                    <arg n="1">tumour vessels</arg>
                </example>
                <example src="REPLACE" no="1335">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; tumour binding system 2 maneuver may have disrupted tumour vessels.</text>
                    <arg n="0">tumour binding system 2 maneuver</arg>
                    <arg n="1">tumour vessels</arg>
                </example>
                <example src="REPLACE" no="1336">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; A mutation 415G4 disrupts slicing enhancer sequnce: (GAR)n-(GAR)n.</text>
                    <arg n="0">A mutation 415G4</arg>
                    <arg n="1">slicing enhancer sequnce: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="1337">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; A mutation 415G4 is able to disrupt slicing enhancer sequnce: (GAR)n-(GAR)n.</text>
                    <arg n="0">A mutation 415G4</arg>
                    <arg n="1">slicing enhancer sequnce: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="1338">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; A mutation 415G4 may have disrupted slicing enhancer sequnce: (GAR)n-(GAR)n.</text>
                    <arg n="0">A mutation 415G4</arg>
                    <arg n="1">slicing enhancer sequnce: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="1339">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; Lys147Ala substitution disrupts interaction.</text>
                    <arg n="0">Lys147Ala substitution</arg>
                    <arg n="1">interaction</arg>
                </example>
                <example src="REPLACE" no="1340">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; Lys147Ala substitution is able to disrupt interaction.</text>
                    <arg n="0">Lys147Ala substitution</arg>
                    <arg n="1">interaction</arg>
                </example>
                <example src="REPLACE" no="1341">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; Lys147Ala substitution may have disrupted interaction.</text>
                    <arg n="0">Lys147Ala substitution</arg>
                    <arg n="1">interaction</arg>
                </example>
                <example src="REPLACE" no="1342">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; Multations in p53 disrupts posts of checkpoints to DNA damage.</text>
                    <arg n="0">Multations in p53</arg>
                    <arg n="1">posts of checkpoints to DNA damage</arg>
                </example>
                <example src="REPLACE" no="1343">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; Multations in p53 disrupts responses of checkpoints to DNA damage.</text>
                    <arg n="0">Multations in p53</arg>
                    <arg n="1">responses of checkpoints to DNA damage</arg>
                </example>
                <example src="REPLACE" no="1344">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; Multations in p53 is able to disrupt posts of checkpoints to DNA damage.</text>
                    <arg n="0">Multations in p53</arg>
                    <arg n="1">posts of checkpoints to DNA damage</arg>
                </example>
                <example src="REPLACE" no="1345">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; Multations in p53 is able to disrupt responses of checkpoints to DNA damage.</text>
                    <arg n="0">Multations in p53</arg>
                    <arg n="1">responses of checkpoints to DNA damage</arg>
                </example>
                <example src="REPLACE" no="1346">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; Multations in p53 may have disrupted posts of checkpoints to DNA damage.</text>
                    <arg n="0">Multations in p53</arg>
                    <arg n="1">posts of checkpoints to DNA damage</arg>
                </example>
                <example src="REPLACE" no="1347">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; Multations in p53 may have disrupted responses of checkpoints to DNA damage.</text>
                    <arg n="0">Multations in p53</arg>
                    <arg n="1">responses of checkpoints to DNA damage</arg>
                </example>
                <example src="REPLACE" no="1348">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; Mutation 415G4 disrupts licensing improvement sequence: (GAR)n-(GAR)n.</text>
                    <arg n="0">Mutation 415G4</arg>
                    <arg n="1">licensing improvement sequence: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="1349">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; Mutation 415G4 is able to disrupt licensing improvement sequence: (GAR)n-(GAR)n.</text>
                    <arg n="0">Mutation 415G4</arg>
                    <arg n="1">licensing improvement sequence: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="1350">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; Mutation 415G4 may have disrupted licensing improvement sequence: (GAR)n-(GAR)n.</text>
                    <arg n="0">Mutation 415G4</arg>
                    <arg n="1">licensing improvement sequence: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="1351">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; Mutations in p53 disrupts responses of checkpoints to DNA damage.</text>
                    <arg n="0">Mutations in p53</arg>
                    <arg n="1">responses of checkpoints to DNA damage</arg>
                </example>
                <example src="REPLACE" no="1352">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; Mutations in p53 is able to disrupt responses of checkpoints to DNA damage.</text>
                    <arg n="0">Mutations in p53</arg>
                    <arg n="1">responses of checkpoints to DNA damage</arg>
                </example>
                <example src="REPLACE" no="1353">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; Mutations in p53 may have disrupted responses of checkpoints to DNA damage.</text>
                    <arg n="0">Mutations in p53</arg>
                    <arg n="1">responses of checkpoints to DNA damage</arg>
                </example>
                <example src="REPLACE" no="1354">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; R142X disrupts a splicing enhancer.</text>
                    <arg n="0">R142X</arg>
                    <arg n="1">a splicing enhancer</arg>
                </example>
                <example src="REPLACE" no="1355">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; R142X disrupts a splicing power.</text>
                    <arg n="0">R142X</arg>
                    <arg n="1">a splicing power</arg>
                </example>
                <example src="REPLACE" no="1356">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; R142X is able to disrupt a splicing enhancer.</text>
                    <arg n="0">R142X</arg>
                    <arg n="1">a splicing enhancer</arg>
                </example>
                <example src="REPLACE" no="1357">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; R142X is able to disrupt a splicing power.</text>
                    <arg n="0">R142X</arg>
                    <arg n="1">a splicing power</arg>
                </example>
                <example src="REPLACE" no="1358">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; R142X may have disrupted a splicing enhancer.</text>
                    <arg n="0">R142X</arg>
                    <arg n="1">a splicing enhancer</arg>
                </example>
                <example src="REPLACE" no="1359">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; R142X may have disrupted a splicing power.</text>
                    <arg n="0">R142X</arg>
                    <arg n="1">a splicing power</arg>
                </example>
                <example src="REPLACE" no="1360">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; The 415G4 mutation disrupts enhancer spike: (GAR)n-(GAR)n.</text>
                    <arg n="0">The 415G4 mutation</arg>
                    <arg n="1">enhancer spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="1361">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; The 415G4 mutation disrupts powerers spike: (GAR)n-(GAR)n.</text>
                    <arg n="0">The 415G4 mutation</arg>
                    <arg n="1">powerers spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="1362">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; The 415G4 mutation is able to disrupt enhancer spike: (GAR)n-(GAR)n.</text>
                    <arg n="0">The 415G4 mutation</arg>
                    <arg n="1">enhancer spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="1363">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; The 415G4 mutation is able to disrupt powerers spike: (GAR)n-(GAR)n.</text>
                    <arg n="0">The 415G4 mutation</arg>
                    <arg n="1">powerers spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="1364">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; The 415G4 mutation may have disrupted enhancer spike: (GAR)n-(GAR)n.</text>
                    <arg n="0">The 415G4 mutation</arg>
                    <arg n="1">enhancer spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="1365">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; The 415G4 mutation may have disrupted powerers spike: (GAR)n-(GAR)n.</text>
                    <arg n="0">The 415G4 mutation</arg>
                    <arg n="1">powerers spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="1366">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; The mutation 415G4 disrupts enhancement brush: (GAR)n-(GAR)n.</text>
                    <arg n="0">The mutation 415G4</arg>
                    <arg n="1">enhancement brush: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="1367">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; The mutation 415G4 disrupts potent spike: (GAR)n-(GAR)n.</text>
                    <arg n="0">The mutation 415G4</arg>
                    <arg n="1">potent spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="1368">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; The mutation 415G4 is able to disrupt enhancement brush: (GAR)n-(GAR)n.</text>
                    <arg n="0">The mutation 415G4</arg>
                    <arg n="1">enhancement brush: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="1369">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; The mutation 415G4 is able to disrupt potent spike: (GAR)n-(GAR)n.</text>
                    <arg n="0">The mutation 415G4</arg>
                    <arg n="1">potent spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="1370">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; The mutation 415G4 may have disrupted enhancement brush: (GAR)n-(GAR)n.</text>
                    <arg n="0">The mutation 415G4</arg>
                    <arg n="1">enhancement brush: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="1371">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; The mutation 415G4 may have disrupted potent spike: (GAR)n-(GAR)n.</text>
                    <arg n="0">The mutation 415G4</arg>
                    <arg n="1">potent spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="1372">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; These mutations disrupts ubiquitin binding function.</text>
                    <arg n="0">These mutations</arg>
                    <arg n="1">ubiquitin binding function</arg>
                </example>
                <example src="REPLACE" no="1373">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; These mutations is able to disrupt ubiquitin binding function.</text>
                    <arg n="0">These mutations</arg>
                    <arg n="1">ubiquitin binding function</arg>
                </example>
                <example src="REPLACE" no="1374">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; These mutations may have disrupted ubiquitin binding function.</text>
                    <arg n="0">These mutations</arg>
                    <arg n="1">ubiquitin binding function</arg>
                </example>
                <example src="REPLACE" no="1375">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; This deletion disrupts consensus coupling signal 5.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">consensus coupling signal 5</arg>
                </example>
                <example src="REPLACE" no="1376">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; This deletion disrupts the 5 consensus of splice signal.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">the 5 consensus of splice signal</arg>
                </example>
                <example src="REPLACE" no="1377">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; This deletion disrupts the 5th consensus of the cut signal.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">the 5th consensus of the cut signal</arg>
                </example>
                <example src="REPLACE" no="1378">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; This deletion disrupts the splice signal consensus 5.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">the splice signal consensus 5</arg>
                </example>
                <example src="REPLACE" no="1379">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; This deletion is able to disrupt consensus coupling signal 5.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">consensus coupling signal 5</arg>
                </example>
                <example src="REPLACE" no="1380">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; This deletion is able to disrupt the 5 consensus of splice signal.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">the 5 consensus of splice signal</arg>
                </example>
                <example src="REPLACE" no="1381">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; This deletion is able to disrupt the 5th consensus of the cut signal.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">the 5th consensus of the cut signal</arg>
                </example>
                <example src="REPLACE" no="1382">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; This deletion is able to disrupt the splice signal consensus 5.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">the splice signal consensus 5</arg>
                </example>
                <example src="REPLACE" no="1383">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; This deletion may have disrupted consensus coupling signal 5.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">consensus coupling signal 5</arg>
                </example>
                <example src="REPLACE" no="1384">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; This deletion may have disrupted the 5 consensus of splice signal.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">the 5 consensus of splice signal</arg>
                </example>
                <example src="REPLACE" no="1385">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; This deletion may have disrupted the 5th consensus of the cut signal.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">the 5th consensus of the cut signal</arg>
                </example>
                <example src="REPLACE" no="1386">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; This deletion may have disrupted the splice signal consensus 5.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">the splice signal consensus 5</arg>
                </example>
                <example src="REPLACE" no="1387">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; a 415G4 mutation disrupts licensing improvement sequence: (GAR)n-(GAR)n.</text>
                    <arg n="0">a 415G4 mutation</arg>
                    <arg n="1">licensing improvement sequence: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="1388">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; a 415G4 mutation is able to disrupt licensing improvement sequence: (GAR)n-(GAR)n.</text>
                    <arg n="0">a 415G4 mutation</arg>
                    <arg n="1">licensing improvement sequence: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="1389">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; a 415G4 mutation may have disrupted licensing improvement sequence: (GAR)n-(GAR)n.</text>
                    <arg n="0">a 415G4 mutation</arg>
                    <arg n="1">licensing improvement sequence: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="1390">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; a homozygotic mutation disrupts splicing.</text>
                    <arg n="0">a homozygotic mutation</arg>
                    <arg n="1">splicing</arg>
                </example>
                <example src="REPLACE" no="1391">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; a homozygotic mutation is able to disrupt splicing.</text>
                    <arg n="0">a homozygotic mutation</arg>
                    <arg n="1">splicing</arg>
                </example>
                <example src="REPLACE" no="1392">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; a homozygotic mutation may have disrupted splicing.</text>
                    <arg n="0">a homozygotic mutation</arg>
                    <arg n="1">splicing</arg>
                </example>
                <example src="REPLACE" no="1393">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; blocking the expression MEKK1 or MEKK2 disrupts the overall integrity of the MAPK route regulation.</text>
                    <arg n="0">blocking the expression MEKK1 or MEKK2</arg>
                    <arg n="1">the overall integrity of the MAPK route regulation</arg>
                </example>
                <example src="REPLACE" no="1394">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; blocking the expression MEKK1 or MEKK2 is able to disrupt the overall integrity of the MAPK route regulation.</text>
                    <arg n="0">blocking the expression MEKK1 or MEKK2</arg>
                    <arg n="1">the overall integrity of the MAPK route regulation</arg>
                </example>
                <example src="REPLACE" no="1395">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; blocking the expression MEKK1 or MEKK2 may have disrupted the overall integrity of the MAPK route regulation.</text>
                    <arg n="0">blocking the expression MEKK1 or MEKK2</arg>
                    <arg n="1">the overall integrity of the MAPK route regulation</arg>
                </example>
                <example src="REPLACE" no="1396">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; homozygous mutation disrupts splicing.</text>
                    <arg n="0">homozygous mutation</arg>
                    <arg n="1">splicing</arg>
                </example>
                <example src="REPLACE" no="1397">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; homozygous mutation is able to disrupt splicing.</text>
                    <arg n="0">homozygous mutation</arg>
                    <arg n="1">splicing</arg>
                </example>
                <example src="REPLACE" no="1398">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; homozygous mutation may have disrupted splicing.</text>
                    <arg n="0">homozygous mutation</arg>
                    <arg n="1">splicing</arg>
                </example>
                <example src="REPLACE" no="1399">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; inhibition of inflammation disrupts physiological protective responses.</text>
                    <arg n="0">inhibition of inflammation</arg>
                    <arg n="1">physiological protective responses</arg>
                </example>
                <example src="REPLACE" no="1400">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; inhibition of inflammation disrupts protective physiological response.</text>
                    <arg n="0">inhibition of inflammation</arg>
                    <arg n="1">protective physiological response</arg>
                </example>
                <example src="REPLACE" no="1401">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; inhibition of inflammation is able to disrupt physiological protective responses.</text>
                    <arg n="0">inhibition of inflammation</arg>
                    <arg n="1">physiological protective responses</arg>
                </example>
                <example src="REPLACE" no="1402">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; inhibition of inflammation is able to disrupt protective physiological response.</text>
                    <arg n="0">inhibition of inflammation</arg>
                    <arg n="1">protective physiological response</arg>
                </example>
                <example src="REPLACE" no="1403">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; inhibition of inflammation may have disrupted physiological protective responses.</text>
                    <arg n="0">inhibition of inflammation</arg>
                    <arg n="1">physiological protective responses</arg>
                </example>
                <example src="REPLACE" no="1404">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; inhibition of inflammation may have disrupted protective physiological response.</text>
                    <arg n="0">inhibition of inflammation</arg>
                    <arg n="1">protective physiological response</arg>
                </example>
                <example src="REPLACE" no="1405">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; manipulation of the Tie-2 system in tumors disrupts tumour vessels.</text>
                    <arg n="0">manipulation of the Tie-2 system in tumors</arg>
                    <arg n="1">tumour vessels</arg>
                </example>
                <example src="REPLACE" no="1406">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; manipulation of the Tie-2 system in tumors is able to disrupt tumour vessels.</text>
                    <arg n="0">manipulation of the Tie-2 system in tumors</arg>
                    <arg n="1">tumour vessels</arg>
                </example>
                <example src="REPLACE" no="1407">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; manipulation of the Tie-2 system in tumors may have disrupted tumour vessels.</text>
                    <arg n="0">manipulation of the Tie-2 system in tumors</arg>
                    <arg n="1">tumour vessels</arg>
                </example>
                <example src="REPLACE" no="1408">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; manipulation of the binding system 2 in tumours disrupts tumor vessels.</text>
                    <arg n="0">manipulation of the binding system 2 in tumours</arg>
                    <arg n="1">tumor vessels</arg>
                </example>
                <example src="REPLACE" no="1409">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; manipulation of the binding system 2 in tumours is able to disrupt tumor vessels.</text>
                    <arg n="0">manipulation of the binding system 2 in tumours</arg>
                    <arg n="1">tumor vessels</arg>
                </example>
                <example src="REPLACE" no="1410">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; manipulation of the binding system 2 in tumours may have disrupted tumor vessels.</text>
                    <arg n="0">manipulation of the binding system 2 in tumours</arg>
                    <arg n="1">tumor vessels</arg>
                </example>
                <example src="REPLACE" no="1411">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; multations at p53 disrupts post-checking points for DNA damage.</text>
                    <arg n="0">multations at p53</arg>
                    <arg n="1">post-checking points for DNA damage</arg>
                </example>
                <example src="REPLACE" no="1412">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; multations at p53 is able to disrupt post-checking points for DNA damage.</text>
                    <arg n="0">multations at p53</arg>
                    <arg n="1">post-checking points for DNA damage</arg>
                </example>
                <example src="REPLACE" no="1413">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; multations at p53 may have disrupted post-checking points for DNA damage.</text>
                    <arg n="0">multations at p53</arg>
                    <arg n="1">post-checking points for DNA damage</arg>
                </example>
                <example src="REPLACE" no="1414">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; mutation 415G4 disrupts pulling enhancement sequence: (GAR)n-(GAR)n.</text>
                    <arg n="0">mutation 415G4</arg>
                    <arg n="1">pulling enhancement sequence: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="1415">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; mutation 415G4 disrupts splicing sequencer: (GAR)n-(GAR)n.</text>
                    <arg n="0">mutation 415G4</arg>
                    <arg n="1">splicing sequencer: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="1416">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; mutation 415G4 is able to disrupt pulling enhancement sequence: (GAR)n-(GAR)n.</text>
                    <arg n="0">mutation 415G4</arg>
                    <arg n="1">pulling enhancement sequence: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="1417">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; mutation 415G4 is able to disrupt splicing sequencer: (GAR)n-(GAR)n.</text>
                    <arg n="0">mutation 415G4</arg>
                    <arg n="1">splicing sequencer: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="1418">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; mutation 415G4 may have disrupted pulling enhancement sequence: (GAR)n-(GAR)n.</text>
                    <arg n="0">mutation 415G4</arg>
                    <arg n="1">pulling enhancement sequence: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="1419">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; mutation 415G4 may have disrupted splicing sequencer: (GAR)n-(GAR)n.</text>
                    <arg n="0">mutation 415G4</arg>
                    <arg n="1">splicing sequencer: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="1420">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; mutations in this region disrupts assembly of keratin filaments.</text>
                    <arg n="0">mutations in this region</arg>
                    <arg n="1">assembly of keratin filaments</arg>
                </example>
                <example src="REPLACE" no="1421">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; mutations in this region is able to disrupt assembly of keratin filaments.</text>
                    <arg n="0">mutations in this region</arg>
                    <arg n="1">assembly of keratin filaments</arg>
                </example>
                <example src="REPLACE" no="1422">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; mutations in this region may have disrupted assembly of keratin filaments.</text>
                    <arg n="0">mutations in this region</arg>
                    <arg n="1">assembly of keratin filaments</arg>
                </example>
                <example src="REPLACE" no="1423">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; p53 mutations disrupts checking point responses for DNA damage.</text>
                    <arg n="0">p53 mutations</arg>
                    <arg n="1">checking point responses for DNA damage</arg>
                </example>
                <example src="REPLACE" no="1424">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; p53 mutations is able to disrupt checking point responses for DNA damage.</text>
                    <arg n="0">p53 mutations</arg>
                    <arg n="1">checking point responses for DNA damage</arg>
                </example>
                <example src="REPLACE" no="1425">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; p53 mutations may have disrupted checking point responses for DNA damage.</text>
                    <arg n="0">p53 mutations</arg>
                    <arg n="1">checking point responses for DNA damage</arg>
                </example>
                <example src="REPLACE" no="1426">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; such mutations disrupts the ubiquitin binding function.</text>
                    <arg n="0">such mutations</arg>
                    <arg n="1">the ubiquitin binding function</arg>
                </example>
                <example src="REPLACE" no="1427">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; such mutations disrupts the ubiquitin-binding function.</text>
                    <arg n="0">such mutations</arg>
                    <arg n="1">the ubiquitin-binding function</arg>
                </example>
                <example src="REPLACE" no="1428">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; such mutations is able to disrupt the ubiquitin binding function.</text>
                    <arg n="0">such mutations</arg>
                    <arg n="1">the ubiquitin binding function</arg>
                </example>
                <example src="REPLACE" no="1429">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; such mutations is able to disrupt the ubiquitin-binding function.</text>
                    <arg n="0">such mutations</arg>
                    <arg n="1">the ubiquitin-binding function</arg>
                </example>
                <example src="REPLACE" no="1430">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; such mutations may have disrupted the ubiquitin binding function.</text>
                    <arg n="0">such mutations</arg>
                    <arg n="1">the ubiquitin binding function</arg>
                </example>
                <example src="REPLACE" no="1431">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; such mutations may have disrupted the ubiquitin-binding function.</text>
                    <arg n="0">such mutations</arg>
                    <arg n="1">the ubiquitin-binding function</arg>
                </example>
                <example src="REPLACE" no="1432">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; the Lys147Ala substitution disrupts the interaction.</text>
                    <arg n="0">the Lys147Ala substitution</arg>
                    <arg n="1">the interaction</arg>
                </example>
                <example src="REPLACE" no="1433">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; the Lys147Ala substitution is able to disrupt the interaction.</text>
                    <arg n="0">the Lys147Ala substitution</arg>
                    <arg n="1">the interaction</arg>
                </example>
                <example src="REPLACE" no="1434">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; the Lys147Ala substitution may have disrupted the interaction.</text>
                    <arg n="0">the Lys147Ala substitution</arg>
                    <arg n="1">the interaction</arg>
                </example>
                <example src="REPLACE" no="1435">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; these mutations disrupts biquitin binding function.</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">biquitin binding function</arg>
                </example>
                <example src="REPLACE" no="1436">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; these mutations is able to disrupt biquitin binding function.</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">biquitin binding function</arg>
                </example>
                <example src="REPLACE" no="1437">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; these mutations may have disrupted biquitin binding function.</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">biquitin binding function</arg>
                </example>
                <example src="REPLACE" no="1438">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; this deletion disrupts consensus signal 5.</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">consensus signal 5</arg>
                </example>
                <example src="REPLACE" no="1439">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; this deletion is able to disrupt consensus signal 5.</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">consensus signal 5</arg>
                </example>
                <example src="REPLACE" no="1440">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; this deletion may have disrupted consensus signal 5.</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">consensus signal 5</arg>
                </example>
                <example src="REPLACE" no="1441">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; this suppression disrupts consensus signal 5.</text>
                    <arg n="0">this suppression</arg>
                    <arg n="1">consensus signal 5</arg>
                </example>
                <example src="REPLACE" no="1442">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; this suppression is able to disrupt consensus signal 5.</text>
                    <arg n="0">this suppression</arg>
                    <arg n="1">consensus signal 5</arg>
                </example>
                <example src="REPLACE" no="1443">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; this suppression may have disrupted consensus signal 5.</text>
                    <arg n="0">this suppression</arg>
                    <arg n="1">consensus signal 5</arg>
                </example>
                <example src="REPLACE" no="1444">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; tumour binding system 2 maneuver disrupts tumour vessels.</text>
                    <arg n="0">tumour binding system 2 maneuver</arg>
                    <arg n="1">tumour vessels</arg>
                </example>
                <example src="REPLACE" no="1445">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; tumour binding system 2 maneuver is able to disrupt tumour vessels.</text>
                    <arg n="0">tumour binding system 2 maneuver</arg>
                    <arg n="1">tumour vessels</arg>
                </example>
                <example src="REPLACE" no="1446">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; tumour binding system 2 maneuver may have disrupted tumour vessels.</text>
                    <arg n="0">tumour binding system 2 maneuver</arg>
                    <arg n="1">tumour vessels</arg>
                </example>
                <example src="REPLACE" no="1447">
                    <text>The such mutations that disrupted the ubiquitin binding function was identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">such mutations</arg>
                    <arg n="1">the ubiquitin binding function</arg>
                </example>
                <example src="REPLACE" no="1448">
                    <text>The such mutations that disrupted the ubiquitin-binding function was identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">such mutations</arg>
                    <arg n="1">the ubiquitin-binding function</arg>
                </example>
                <example src="REPLACE" no="1449">
                    <text>The the Lys147Ala substitution that disrupted the interaction was identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">the Lys147Ala substitution</arg>
                    <arg n="1">the interaction</arg>
                </example>
                <example src="REPLACE" no="1450">
                    <text>The these mutations that disrupted biquitin binding function was identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">biquitin binding function</arg>
                </example>
                <example src="REPLACE" no="1451">
                    <text>The this deletion that disrupted consensus signal 5 was identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">consensus signal 5</arg>
                </example>
                <example src="REPLACE" no="1452">
                    <text>The this suppression that disrupted consensus signal 5 was identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">this suppression</arg>
                    <arg n="1">consensus signal 5</arg>
                </example>
                <example src="REPLACE" no="1453">
                    <text>The treatment of systemic inflammatory response to CPB is also confused by the fact that A mutation 415G4 has been shown to disrupt slicing enhancer sequnce: (GAR)n-(GAR)n or to produce immunosuppression.</text>
                    <arg n="0">A mutation 415G4</arg>
                    <arg n="1">slicing enhancer sequnce: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="1454">
                    <text>The treatment of systemic inflammatory response to CPB is also confused by the fact that Lys147Ala substitution has been shown to disrupt interaction or to produce immunosuppression.</text>
                    <arg n="0">Lys147Ala substitution</arg>
                    <arg n="1">interaction</arg>
                </example>
                <example src="REPLACE" no="1455">
                    <text>The treatment of systemic inflammatory response to CPB is also confused by the fact that Multations in p53 has been shown to disrupt posts of checkpoints to DNA damage or to produce immunosuppression.</text>
                    <arg n="0">Multations in p53</arg>
                    <arg n="1">posts of checkpoints to DNA damage</arg>
                </example>
                <example src="REPLACE" no="1456">
                    <text>The treatment of systemic inflammatory response to CPB is also confused by the fact that Multations in p53 has been shown to disrupt responses of checkpoints to DNA damage or to produce immunosuppression.</text>
                    <arg n="0">Multations in p53</arg>
                    <arg n="1">responses of checkpoints to DNA damage</arg>
                </example>
                <example src="REPLACE" no="1457">
                    <text>The treatment of systemic inflammatory response to CPB is also confused by the fact that Mutation 415G4 has been shown to disrupt licensing improvement sequence: (GAR)n-(GAR)n or to produce immunosuppression.</text>
                    <arg n="0">Mutation 415G4</arg>
                    <arg n="1">licensing improvement sequence: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="1458">
                    <text>The treatment of systemic inflammatory response to CPB is also confused by the fact that Mutations in p53 has been shown to disrupt responses of checkpoints to DNA damage or to produce immunosuppression.</text>
                    <arg n="0">Mutations in p53</arg>
                    <arg n="1">responses of checkpoints to DNA damage</arg>
                </example>
                <example src="REPLACE" no="1459">
                    <text>The treatment of systemic inflammatory response to CPB is also confused by the fact that R142X has been shown to disrupt a splicing enhancer or to produce immunosuppression.</text>
                    <arg n="0">R142X</arg>
                    <arg n="1">a splicing enhancer</arg>
                </example>
                <example src="REPLACE" no="1460">
                    <text>The treatment of systemic inflammatory response to CPB is also confused by the fact that R142X has been shown to disrupt a splicing power or to produce immunosuppression.</text>
                    <arg n="0">R142X</arg>
                    <arg n="1">a splicing power</arg>
                </example>
                <example src="REPLACE" no="1461">
                    <text>The treatment of systemic inflammatory response to CPB is also confused by the fact that The 415G4 mutation has been shown to disrupt enhancer spike: (GAR)n-(GAR)n or to produce immunosuppression.</text>
                    <arg n="0">The 415G4 mutation</arg>
                    <arg n="1">enhancer spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="1462">
                    <text>The treatment of systemic inflammatory response to CPB is also confused by the fact that The 415G4 mutation has been shown to disrupt powerers spike: (GAR)n-(GAR)n or to produce immunosuppression.</text>
                    <arg n="0">The 415G4 mutation</arg>
                    <arg n="1">powerers spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="1463">
                    <text>The treatment of systemic inflammatory response to CPB is also confused by the fact that The mutation 415G4 has been shown to disrupt enhancement brush: (GAR)n-(GAR)n or to produce immunosuppression.</text>
                    <arg n="0">The mutation 415G4</arg>
                    <arg n="1">enhancement brush: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="1464">
                    <text>The treatment of systemic inflammatory response to CPB is also confused by the fact that The mutation 415G4 has been shown to disrupt potent spike: (GAR)n-(GAR)n or to produce immunosuppression.</text>
                    <arg n="0">The mutation 415G4</arg>
                    <arg n="1">potent spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="1465">
                    <text>The treatment of systemic inflammatory response to CPB is also confused by the fact that These mutations has been shown to disrupt ubiquitin binding function or to produce immunosuppression.</text>
                    <arg n="0">These mutations</arg>
                    <arg n="1">ubiquitin binding function</arg>
                </example>
                <example src="REPLACE" no="1466">
                    <text>The treatment of systemic inflammatory response to CPB is also confused by the fact that This deletion has been shown to disrupt consensus coupling signal 5 or to produce immunosuppression.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">consensus coupling signal 5</arg>
                </example>
                <example src="REPLACE" no="1467">
                    <text>The treatment of systemic inflammatory response to CPB is also confused by the fact that This deletion has been shown to disrupt the 5 consensus of splice signal or to produce immunosuppression.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">the 5 consensus of splice signal</arg>
                </example>
                <example src="REPLACE" no="1468">
                    <text>The treatment of systemic inflammatory response to CPB is also confused by the fact that This deletion has been shown to disrupt the 5th consensus of the cut signal or to produce immunosuppression.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">the 5th consensus of the cut signal</arg>
                </example>
                <example src="REPLACE" no="1469">
                    <text>The treatment of systemic inflammatory response to CPB is also confused by the fact that This deletion has been shown to disrupt the splice signal consensus 5 or to produce immunosuppression.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">the splice signal consensus 5</arg>
                </example>
                <example src="REPLACE" no="1470">
                    <text>The treatment of systemic inflammatory response to CPB is also confused by the fact that a 415G4 mutation has been shown to disrupt licensing improvement sequence: (GAR)n-(GAR)n or to produce immunosuppression.</text>
                    <arg n="0">a 415G4 mutation</arg>
                    <arg n="1">licensing improvement sequence: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="1471">
                    <text>The treatment of systemic inflammatory response to CPB is also confused by the fact that a homozygotic mutation has been shown to disrupt splicing or to produce immunosuppression.</text>
                    <arg n="0">a homozygotic mutation</arg>
                    <arg n="1">splicing</arg>
                </example>
                <example src="REPLACE" no="1472">
                    <text>The treatment of systemic inflammatory response to CPB is also confused by the fact that blocking the expression MEKK1 or MEKK2 has been shown to disrupt the overall integrity of the MAPK route regulation or to produce immunosuppression.</text>
                    <arg n="0">blocking the expression MEKK1 or MEKK2</arg>
                    <arg n="1">the overall integrity of the MAPK route regulation</arg>
                </example>
                <example src="REPLACE" no="1473">
                    <text>The treatment of systemic inflammatory response to CPB is also confused by the fact that homozygous mutation has been shown to disrupt splicing or to produce immunosuppression.</text>
                    <arg n="0">homozygous mutation</arg>
                    <arg n="1">splicing</arg>
                </example>
                <example src="REPLACE" no="1474">
                    <text>The treatment of systemic inflammatory response to CPB is also confused by the fact that inhibition of inflammation has been shown to disrupt physiological protective responses or to produce immunosuppression.</text>
                    <arg n="0">inhibition of inflammation</arg>
                    <arg n="1">physiological protective responses</arg>
                </example>
                <example src="REPLACE" no="1475">
                    <text>The treatment of systemic inflammatory response to CPB is also confused by the fact that inhibition of inflammation has been shown to disrupt protective physiological response or to produce immunosuppression.</text>
                    <arg n="0">inhibition of inflammation</arg>
                    <arg n="1">protective physiological response</arg>
                </example>
                <example src="REPLACE" no="1476">
                    <text>The treatment of systemic inflammatory response to CPB is also confused by the fact that manipulation of the Tie-2 system in tumors has been shown to disrupt tumour vessels or to produce immunosuppression.</text>
                    <arg n="0">manipulation of the Tie-2 system in tumors</arg>
                    <arg n="1">tumour vessels</arg>
                </example>
                <example src="REPLACE" no="1477">
                    <text>The treatment of systemic inflammatory response to CPB is also confused by the fact that manipulation of the binding system 2 in tumours has been shown to disrupt tumor vessels or to produce immunosuppression.</text>
                    <arg n="0">manipulation of the binding system 2 in tumours</arg>
                    <arg n="1">tumor vessels</arg>
                </example>
                <example src="REPLACE" no="1478">
                    <text>The treatment of systemic inflammatory response to CPB is also confused by the fact that multations at p53 has been shown to disrupt post-checking points for DNA damage or to produce immunosuppression.</text>
                    <arg n="0">multations at p53</arg>
                    <arg n="1">post-checking points for DNA damage</arg>
                </example>
                <example src="REPLACE" no="1479">
                    <text>The treatment of systemic inflammatory response to CPB is also confused by the fact that mutation 415G4 has been shown to disrupt pulling enhancement sequence: (GAR)n-(GAR)n or to produce immunosuppression.</text>
                    <arg n="0">mutation 415G4</arg>
                    <arg n="1">pulling enhancement sequence: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="1480">
                    <text>The treatment of systemic inflammatory response to CPB is also confused by the fact that mutation 415G4 has been shown to disrupt splicing sequencer: (GAR)n-(GAR)n or to produce immunosuppression.</text>
                    <arg n="0">mutation 415G4</arg>
                    <arg n="1">splicing sequencer: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="1481">
                    <text>The treatment of systemic inflammatory response to CPB is also confused by the fact that mutations in this region has been shown to disrupt assembly of keratin filaments or to produce immunosuppression.</text>
                    <arg n="0">mutations in this region</arg>
                    <arg n="1">assembly of keratin filaments</arg>
                </example>
                <example src="REPLACE" no="1482">
                    <text>The treatment of systemic inflammatory response to CPB is also confused by the fact that p53 mutations has been shown to disrupt checking point responses for DNA damage or to produce immunosuppression.</text>
                    <arg n="0">p53 mutations</arg>
                    <arg n="1">checking point responses for DNA damage</arg>
                </example>
                <example src="REPLACE" no="1483">
                    <text>The treatment of systemic inflammatory response to CPB is also confused by the fact that such mutations has been shown to disrupt the ubiquitin binding function or to produce immunosuppression.</text>
                    <arg n="0">such mutations</arg>
                    <arg n="1">the ubiquitin binding function</arg>
                </example>
                <example src="REPLACE" no="1484">
                    <text>The treatment of systemic inflammatory response to CPB is also confused by the fact that such mutations has been shown to disrupt the ubiquitin-binding function or to produce immunosuppression.</text>
                    <arg n="0">such mutations</arg>
                    <arg n="1">the ubiquitin-binding function</arg>
                </example>
                <example src="REPLACE" no="1485">
                    <text>The treatment of systemic inflammatory response to CPB is also confused by the fact that the Lys147Ala substitution has been shown to disrupt the interaction or to produce immunosuppression.</text>
                    <arg n="0">the Lys147Ala substitution</arg>
                    <arg n="1">the interaction</arg>
                </example>
                <example src="REPLACE" no="1486">
                    <text>The treatment of systemic inflammatory response to CPB is also confused by the fact that these mutations has been shown to disrupt biquitin binding function or to produce immunosuppression.</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">biquitin binding function</arg>
                </example>
                <example src="REPLACE" no="1487">
                    <text>The treatment of systemic inflammatory response to CPB is also confused by the fact that this deletion has been shown to disrupt consensus signal 5 or to produce immunosuppression.</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">consensus signal 5</arg>
                </example>
                <example src="REPLACE" no="1488">
                    <text>The treatment of systemic inflammatory response to CPB is also confused by the fact that this suppression has been shown to disrupt consensus signal 5 or to produce immunosuppression.</text>
                    <arg n="0">this suppression</arg>
                    <arg n="1">consensus signal 5</arg>
                </example>
                <example src="REPLACE" no="1489">
                    <text>The treatment of systemic inflammatory response to CPB is also confused by the fact that tumour binding system 2 maneuver has been shown to disrupt tumour vessels or to produce immunosuppression.</text>
                    <arg n="0">tumour binding system 2 maneuver</arg>
                    <arg n="1">tumour vessels</arg>
                </example>
                <example src="REPLACE" no="1490">
                    <text>The treatment of the systemic inflammatory response to CPB is also confused by the fact that A mutation 415G4 has deregulated slicing enhancer sequnce: (GAR)n-(GAR)n or disrupting in immunosuppression.</text>
                    <arg n="0">A mutation 415G4</arg>
                    <arg n="1">slicing enhancer sequnce: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="1491">
                    <text>The treatment of the systemic inflammatory response to CPB is also confused by the fact that Lys147Ala substitution has deregulated interaction or disrupting in immunosuppression.</text>
                    <arg n="0">Lys147Ala substitution</arg>
                    <arg n="1">interaction</arg>
                </example>
                <example src="REPLACE" no="1492">
                    <text>The treatment of the systemic inflammatory response to CPB is also confused by the fact that Multations in p53 has deregulated posts of checkpoints to DNA damage or disrupting in immunosuppression.</text>
                    <arg n="0">Multations in p53</arg>
                    <arg n="1">posts of checkpoints to DNA damage</arg>
                </example>
                <example src="REPLACE" no="1493">
                    <text>The treatment of the systemic inflammatory response to CPB is also confused by the fact that Multations in p53 has deregulated responses of checkpoints to DNA damage or disrupting in immunosuppression.</text>
                    <arg n="0">Multations in p53</arg>
                    <arg n="1">responses of checkpoints to DNA damage</arg>
                </example>
                <example src="REPLACE" no="1494">
                    <text>The treatment of the systemic inflammatory response to CPB is also confused by the fact that Mutation 415G4 has deregulated licensing improvement sequence: (GAR)n-(GAR)n or disrupting in immunosuppression.</text>
                    <arg n="0">Mutation 415G4</arg>
                    <arg n="1">licensing improvement sequence: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="1495">
                    <text>The treatment of the systemic inflammatory response to CPB is also confused by the fact that Mutations in p53 has deregulated responses of checkpoints to DNA damage or disrupting in immunosuppression.</text>
                    <arg n="0">Mutations in p53</arg>
                    <arg n="1">responses of checkpoints to DNA damage</arg>
                </example>
                <example src="REPLACE" no="1496">
                    <text>The treatment of the systemic inflammatory response to CPB is also confused by the fact that R142X has deregulated a splicing enhancer or disrupting in immunosuppression.</text>
                    <arg n="0">R142X</arg>
                    <arg n="1">a splicing enhancer</arg>
                </example>
                <example src="REPLACE" no="1497">
                    <text>The treatment of the systemic inflammatory response to CPB is also confused by the fact that R142X has deregulated a splicing power or disrupting in immunosuppression.</text>
                    <arg n="0">R142X</arg>
                    <arg n="1">a splicing power</arg>
                </example>
                <example src="REPLACE" no="1498">
                    <text>The treatment of the systemic inflammatory response to CPB is also confused by the fact that The 415G4 mutation has deregulated enhancer spike: (GAR)n-(GAR)n or disrupting in immunosuppression.</text>
                    <arg n="0">The 415G4 mutation</arg>
                    <arg n="1">enhancer spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="1499">
                    <text>The treatment of the systemic inflammatory response to CPB is also confused by the fact that The 415G4 mutation has deregulated powerers spike: (GAR)n-(GAR)n or disrupting in immunosuppression.</text>
                    <arg n="0">The 415G4 mutation</arg>
                    <arg n="1">powerers spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="1500">
                    <text>The treatment of the systemic inflammatory response to CPB is also confused by the fact that The mutation 415G4 has deregulated enhancement brush: (GAR)n-(GAR)n or disrupting in immunosuppression.</text>
                    <arg n="0">The mutation 415G4</arg>
                    <arg n="1">enhancement brush: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="1501">
                    <text>The treatment of the systemic inflammatory response to CPB is also confused by the fact that The mutation 415G4 has deregulated potent spike: (GAR)n-(GAR)n or disrupting in immunosuppression.</text>
                    <arg n="0">The mutation 415G4</arg>
                    <arg n="1">potent spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="1502">
                    <text>The treatment of the systemic inflammatory response to CPB is also confused by the fact that These mutations has deregulated ubiquitin binding function or disrupting in immunosuppression.</text>
                    <arg n="0">These mutations</arg>
                    <arg n="1">ubiquitin binding function</arg>
                </example>
                <example src="REPLACE" no="1503">
                    <text>The treatment of the systemic inflammatory response to CPB is also confused by the fact that This deletion has deregulated consensus coupling signal 5 or disrupting in immunosuppression.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">consensus coupling signal 5</arg>
                </example>
                <example src="REPLACE" no="1504">
                    <text>The treatment of the systemic inflammatory response to CPB is also confused by the fact that This deletion has deregulated the 5 consensus of splice signal or disrupting in immunosuppression.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">the 5 consensus of splice signal</arg>
                </example>
                <example src="REPLACE" no="1505">
                    <text>The treatment of the systemic inflammatory response to CPB is also confused by the fact that This deletion has deregulated the 5th consensus of the cut signal or disrupting in immunosuppression.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">the 5th consensus of the cut signal</arg>
                </example>
                <example src="REPLACE" no="1506">
                    <text>The treatment of the systemic inflammatory response to CPB is also confused by the fact that This deletion has deregulated the splice signal consensus 5 or disrupting in immunosuppression.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">the splice signal consensus 5</arg>
                </example>
                <example src="REPLACE" no="1507">
                    <text>The treatment of the systemic inflammatory response to CPB is also confused by the fact that a 415G4 mutation has deregulated licensing improvement sequence: (GAR)n-(GAR)n or disrupting in immunosuppression.</text>
                    <arg n="0">a 415G4 mutation</arg>
                    <arg n="1">licensing improvement sequence: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="1508">
                    <text>The treatment of the systemic inflammatory response to CPB is also confused by the fact that a homozygotic mutation has deregulated splicing or disrupting in immunosuppression.</text>
                    <arg n="0">a homozygotic mutation</arg>
                    <arg n="1">splicing</arg>
                </example>
                <example src="REPLACE" no="1509">
                    <text>The treatment of the systemic inflammatory response to CPB is also confused by the fact that blocking the expression MEKK1 or MEKK2 has deregulated the overall integrity of the MAPK route regulation or disrupting in immunosuppression.</text>
                    <arg n="0">blocking the expression MEKK1 or MEKK2</arg>
                    <arg n="1">the overall integrity of the MAPK route regulation</arg>
                </example>
                <example src="REPLACE" no="1510">
                    <text>The treatment of the systemic inflammatory response to CPB is also confused by the fact that homozygous mutation has deregulated splicing or disrupting in immunosuppression.</text>
                    <arg n="0">homozygous mutation</arg>
                    <arg n="1">splicing</arg>
                </example>
                <example src="REPLACE" no="1511">
                    <text>The treatment of the systemic inflammatory response to CPB is also confused by the fact that inhibition of inflammation has deregulated physiological protective responses or disrupting in immunosuppression.</text>
                    <arg n="0">inhibition of inflammation</arg>
                    <arg n="1">physiological protective responses</arg>
                </example>
                <example src="REPLACE" no="1512">
                    <text>The treatment of the systemic inflammatory response to CPB is also confused by the fact that inhibition of inflammation has deregulated protective physiological response or disrupting in immunosuppression.</text>
                    <arg n="0">inhibition of inflammation</arg>
                    <arg n="1">protective physiological response</arg>
                </example>
                <example src="REPLACE" no="1513">
                    <text>The treatment of the systemic inflammatory response to CPB is also confused by the fact that manipulation of the Tie-2 system in tumors has deregulated tumour vessels or disrupting in immunosuppression.</text>
                    <arg n="0">manipulation of the Tie-2 system in tumors</arg>
                    <arg n="1">tumour vessels</arg>
                </example>
                <example src="REPLACE" no="1514">
                    <text>The treatment of the systemic inflammatory response to CPB is also confused by the fact that manipulation of the binding system 2 in tumours has deregulated tumor vessels or disrupting in immunosuppression.</text>
                    <arg n="0">manipulation of the binding system 2 in tumours</arg>
                    <arg n="1">tumor vessels</arg>
                </example>
                <example src="REPLACE" no="1515">
                    <text>The treatment of the systemic inflammatory response to CPB is also confused by the fact that multations at p53 has deregulated post-checking points for DNA damage or disrupting in immunosuppression.</text>
                    <arg n="0">multations at p53</arg>
                    <arg n="1">post-checking points for DNA damage</arg>
                </example>
                <example src="REPLACE" no="1516">
                    <text>The treatment of the systemic inflammatory response to CPB is also confused by the fact that mutation 415G4 has deregulated pulling enhancement sequence: (GAR)n-(GAR)n or disrupting in immunosuppression.</text>
                    <arg n="0">mutation 415G4</arg>
                    <arg n="1">pulling enhancement sequence: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="1517">
                    <text>The treatment of the systemic inflammatory response to CPB is also confused by the fact that mutation 415G4 has deregulated splicing sequencer: (GAR)n-(GAR)n or disrupting in immunosuppression.</text>
                    <arg n="0">mutation 415G4</arg>
                    <arg n="1">splicing sequencer: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="1518">
                    <text>The treatment of the systemic inflammatory response to CPB is also confused by the fact that mutations in this region has deregulated assembly of keratin filaments or disrupting in immunosuppression.</text>
                    <arg n="0">mutations in this region</arg>
                    <arg n="1">assembly of keratin filaments</arg>
                </example>
                <example src="REPLACE" no="1519">
                    <text>The treatment of the systemic inflammatory response to CPB is also confused by the fact that p53 mutations has deregulated checking point responses for DNA damage or disrupting in immunosuppression.</text>
                    <arg n="0">p53 mutations</arg>
                    <arg n="1">checking point responses for DNA damage</arg>
                </example>
                <example src="REPLACE" no="1520">
                    <text>The treatment of the systemic inflammatory response to CPB is also confused by the fact that such mutations has deregulated the ubiquitin binding function or disrupting in immunosuppression.</text>
                    <arg n="0">such mutations</arg>
                    <arg n="1">the ubiquitin binding function</arg>
                </example>
                <example src="REPLACE" no="1521">
                    <text>The treatment of the systemic inflammatory response to CPB is also confused by the fact that such mutations has deregulated the ubiquitin-binding function or disrupting in immunosuppression.</text>
                    <arg n="0">such mutations</arg>
                    <arg n="1">the ubiquitin-binding function</arg>
                </example>
                <example src="REPLACE" no="1522">
                    <text>The treatment of the systemic inflammatory response to CPB is also confused by the fact that the Lys147Ala substitution has deregulated the interaction or disrupting in immunosuppression.</text>
                    <arg n="0">the Lys147Ala substitution</arg>
                    <arg n="1">the interaction</arg>
                </example>
                <example src="REPLACE" no="1523">
                    <text>The treatment of the systemic inflammatory response to CPB is also confused by the fact that these mutations has deregulated biquitin binding function or disrupting in immunosuppression.</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">biquitin binding function</arg>
                </example>
                <example src="REPLACE" no="1524">
                    <text>The treatment of the systemic inflammatory response to CPB is also confused by the fact that this deletion has deregulated consensus signal 5 or disrupting in immunosuppression.</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">consensus signal 5</arg>
                </example>
                <example src="REPLACE" no="1525">
                    <text>The treatment of the systemic inflammatory response to CPB is also confused by the fact that this suppression has deregulated consensus signal 5 or disrupting in immunosuppression.</text>
                    <arg n="0">this suppression</arg>
                    <arg n="1">consensus signal 5</arg>
                </example>
                <example src="REPLACE" no="1526">
                    <text>The treatment of the systemic inflammatory response to CPB is also confused by the fact that tumour binding system 2 maneuver has deregulated tumour vessels or disrupting in immunosuppression.</text>
                    <arg n="0">tumour binding system 2 maneuver</arg>
                    <arg n="1">tumour vessels</arg>
                </example>
                <example src="REPLACE" no="1527">
                    <text>The tumour binding system 2 maneuver that disrupted tumour vessels was identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">tumour binding system 2 maneuver</arg>
                    <arg n="1">tumour vessels</arg>
                </example>
                <example src="REPLACE" no="1528">
                    <text>These mutations broke a sequence of ubiquitin binding function disrupted in R (exon 5 spike).</text>
                    <arg n="0">These mutations</arg>
                    <arg n="1">ubiquitin binding function</arg>
                </example>
                <example src="REPLACE" no="1529">
                    <text>These mutations broke the ubiquitin binding function and disrupted to the abnormal NF-kappaB pathway activation and subsequent osteoclast activation.</text>
                    <arg n="0">These mutations</arg>
                    <arg n="1">ubiquitin binding function</arg>
                    <arg n="R">abnormal NF-kappaB pathway activation and subsequent osteoclast activation</arg>
                </example>
                <example src="REPLACE" no="1530">
                    <text>These mutations can disrupt with the base groups ceto and C (blue) on both sides of the dsDNA DNA and interrupt ubiquitin binding function.</text>
                    <arg n="0">These mutations</arg>
                    <arg n="1">ubiquitin binding function</arg>
                </example>
                <example src="REPLACE" no="1531">
                    <text>These mutations have perturbed ubiquitin binding function and disrupted in abnormal NF-kappaB pathway activation and subsequent osteoclast activation.</text>
                    <arg n="0">These mutations</arg>
                    <arg n="1">ubiquitin binding function</arg>
                    <arg n="R">abnormal NF-kappaB pathway activation and subsequent osteoclast activation</arg>
                </example>
                <example src="REPLACE" no="1532">
                    <text>These mutations rupture of ubiquitin binding function may disrupting in abnormal NF-kappaB pathway activation and subsequent osteoclast activation.</text>
                    <arg n="0">These mutations</arg>
                    <arg n="1">ubiquitin binding function</arg>
                    <arg n="R">abnormal NF-kappaB pathway activation and subsequent osteoclast activation</arg>
                </example>
                <example src="REPLACE" no="1533">
                    <text>These mutations that broke A1 will be identified in the siblings disrupted by classical abetalipoproteinemia.</text>
                    <arg n="0">These mutations</arg>
                </example>
                <example src="REPLACE" no="1534">
                    <text>These mutations that can disrupt ubiquitin binding function has been identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">These mutations</arg>
                    <arg n="1">ubiquitin binding function</arg>
                </example>
                <example src="REPLACE" no="1535">
                    <text>These mutations that can disrupt ubiquitin binding function that has been identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">These mutations</arg>
                    <arg n="1">ubiquitin binding function</arg>
                </example>
                <example src="REPLACE" no="1536">
                    <text>These mutations that has disrupted A1 will be identified in the affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">These mutations</arg>
                </example>
                <example src="REPLACE" no="1537">
                    <text>These mutations that has disrupted ubiquitin binding function was identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">These mutations</arg>
                    <arg n="1">ubiquitin binding function</arg>
                </example>
                <example src="REPLACE" no="1538">
                    <text>These mutations that interact with the keto groups of the base pair GO and C (blue) on either side of the dsDNA can disrupt ubiquitin binding function.</text>
                    <arg n="0">These mutations</arg>
                    <arg n="1">ubiquitin binding function</arg>
                </example>
                <example src="REPLACE" no="1539">
                    <text>These mutations that interacts with the keto and C group pair (blue) on both sides of the dsDNA can disrupt ubiquitin binding function.</text>
                    <arg n="0">These mutations</arg>
                    <arg n="1">ubiquitin binding function</arg>
                </example>
                <example src="REPLACE" no="1540">
                    <text>This deletion broke a sequence of consensus coupling signal 5 disrupted in R (exon 5 spike).</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">consensus coupling signal 5</arg>
                </example>
                <example src="REPLACE" no="1541">
                    <text>This deletion broke a sequence of the 5 consensus of splice signal disrupted in R (exon 5 spike).</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">the 5 consensus of splice signal</arg>
                </example>
                <example src="REPLACE" no="1542">
                    <text>This deletion broke a sequence of the 5th consensus of the cut signal disrupted in R (exon 5 spike).</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">the 5th consensus of the cut signal</arg>
                </example>
                <example src="REPLACE" no="1543">
                    <text>This deletion broke a sequence of the splice signal consensus 5 disrupted in R (exon 5 spike).</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">the splice signal consensus 5</arg>
                </example>
                <example src="REPLACE" no="1544">
                    <text>This deletion broke the consensus coupling signal 5 and disrupted to the exon exhaustion.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">consensus coupling signal 5</arg>
                    <arg n="R">exon exhaustion</arg>
                </example>
                <example src="REPLACE" no="1545">
                    <text>This deletion broke the the 5 consensus of splice signal and disrupted to the exon exhaustion.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">the 5 consensus of splice signal</arg>
                    <arg n="R">exon exhaustion</arg>
                </example>
                <example src="REPLACE" no="1546">
                    <text>This deletion broke the the 5th consensus of the cut signal and disrupted to the exon exhaustion.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">the 5th consensus of the cut signal</arg>
                    <arg n="R">exon exhaustion</arg>
                </example>
                <example src="REPLACE" no="1547">
                    <text>This deletion broke the the splice signal consensus 5 and disrupted to the exon exhaustion.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">the splice signal consensus 5</arg>
                    <arg n="R">exon exhaustion</arg>
                </example>
                <example src="REPLACE" no="1548">
                    <text>This deletion can disrupt with the base groups ceto and C (blue) on both sides of the dsDNA DNA and interrupt consensus coupling signal 5.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">consensus coupling signal 5</arg>
                </example>
                <example src="REPLACE" no="1549">
                    <text>This deletion can disrupt with the base groups ceto and C (blue) on both sides of the dsDNA DNA and interrupt the 5 consensus of splice signal.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">the 5 consensus of splice signal</arg>
                </example>
                <example src="REPLACE" no="1550">
                    <text>This deletion can disrupt with the base groups ceto and C (blue) on both sides of the dsDNA DNA and interrupt the 5th consensus of the cut signal.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">the 5th consensus of the cut signal</arg>
                </example>
                <example src="REPLACE" no="1551">
                    <text>This deletion can disrupt with the base groups ceto and C (blue) on both sides of the dsDNA DNA and interrupt the splice signal consensus 5.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">the splice signal consensus 5</arg>
                </example>
                <example src="REPLACE" no="1552">
                    <text>This deletion have perturbed consensus coupling signal 5 and disrupted in exon exhaustion.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">consensus coupling signal 5</arg>
                    <arg n="R">exon exhaustion</arg>
                </example>
                <example src="REPLACE" no="1553">
                    <text>This deletion have perturbed the 5 consensus of splice signal and disrupted in exon exhaustion.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">the 5 consensus of splice signal</arg>
                    <arg n="R">exon exhaustion</arg>
                </example>
                <example src="REPLACE" no="1554">
                    <text>This deletion have perturbed the 5th consensus of the cut signal and disrupted in exon exhaustion.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">the 5th consensus of the cut signal</arg>
                    <arg n="R">exon exhaustion</arg>
                </example>
                <example src="REPLACE" no="1555">
                    <text>This deletion have perturbed the splice signal consensus 5 and disrupted in exon exhaustion.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">the splice signal consensus 5</arg>
                    <arg n="R">exon exhaustion</arg>
                </example>
                <example src="REPLACE" no="1556">
                    <text>This deletion rupture of consensus coupling signal 5 may disrupting in exon exhaustion.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">consensus coupling signal 5</arg>
                    <arg n="R">exon exhaustion</arg>
                </example>
                <example src="REPLACE" no="1557">
                    <text>This deletion rupture of the 5 consensus of splice signal may disrupting in exon exhaustion.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">the 5 consensus of splice signal</arg>
                    <arg n="R">exon exhaustion</arg>
                </example>
                <example src="REPLACE" no="1558">
                    <text>This deletion rupture of the 5th consensus of the cut signal may disrupting in exon exhaustion.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">the 5th consensus of the cut signal</arg>
                    <arg n="R">exon exhaustion</arg>
                </example>
                <example src="REPLACE" no="1559">
                    <text>This deletion rupture of the splice signal consensus 5 may disrupting in exon exhaustion.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">the splice signal consensus 5</arg>
                    <arg n="R">exon exhaustion</arg>
                </example>
                <example src="REPLACE" no="1560">
                    <text>This deletion that broke A1 will be identified in the siblings disrupted by classical abetalipoproteinemia.</text>
                    <arg n="0">This deletion</arg>
                </example>
                <example src="REPLACE" no="1561">
                    <text>This deletion that can disrupt consensus coupling signal 5 has been identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">consensus coupling signal 5</arg>
                </example>
                <example src="REPLACE" no="1562">
                    <text>This deletion that can disrupt consensus coupling signal 5 that has been identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">consensus coupling signal 5</arg>
                </example>
                <example src="REPLACE" no="1563">
                    <text>This deletion that can disrupt the 5 consensus of splice signal has been identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">the 5 consensus of splice signal</arg>
                </example>
                <example src="REPLACE" no="1564">
                    <text>This deletion that can disrupt the 5 consensus of splice signal that has been identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">the 5 consensus of splice signal</arg>
                </example>
                <example src="REPLACE" no="1565">
                    <text>This deletion that can disrupt the 5th consensus of the cut signal has been identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">the 5th consensus of the cut signal</arg>
                </example>
                <example src="REPLACE" no="1566">
                    <text>This deletion that can disrupt the 5th consensus of the cut signal that has been identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">the 5th consensus of the cut signal</arg>
                </example>
                <example src="REPLACE" no="1567">
                    <text>This deletion that can disrupt the splice signal consensus 5 has been identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">the splice signal consensus 5</arg>
                </example>
                <example src="REPLACE" no="1568">
                    <text>This deletion that can disrupt the splice signal consensus 5 that has been identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">the splice signal consensus 5</arg>
                </example>
                <example src="REPLACE" no="1569">
                    <text>This deletion that has disrupted A1 will be identified in the affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">This deletion</arg>
                </example>
                <example src="REPLACE" no="1570">
                    <text>This deletion that has disrupted consensus coupling signal 5 was identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">consensus coupling signal 5</arg>
                </example>
                <example src="REPLACE" no="1571">
                    <text>This deletion that has disrupted the 5 consensus of splice signal was identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">the 5 consensus of splice signal</arg>
                </example>
                <example src="REPLACE" no="1572">
                    <text>This deletion that has disrupted the 5th consensus of the cut signal was identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">the 5th consensus of the cut signal</arg>
                </example>
                <example src="REPLACE" no="1573">
                    <text>This deletion that has disrupted the splice signal consensus 5 was identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">the splice signal consensus 5</arg>
                </example>
                <example src="REPLACE" no="1574">
                    <text>This deletion that interact with the keto groups of the base pair GO and C (blue) on either side of the dsDNA can disrupt consensus coupling signal 5.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">consensus coupling signal 5</arg>
                </example>
                <example src="REPLACE" no="1575">
                    <text>This deletion that interact with the keto groups of the base pair GO and C (blue) on either side of the dsDNA can disrupt the 5 consensus of splice signal.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">the 5 consensus of splice signal</arg>
                </example>
                <example src="REPLACE" no="1576">
                    <text>This deletion that interact with the keto groups of the base pair GO and C (blue) on either side of the dsDNA can disrupt the 5th consensus of the cut signal.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">the 5th consensus of the cut signal</arg>
                </example>
                <example src="REPLACE" no="1577">
                    <text>This deletion that interact with the keto groups of the base pair GO and C (blue) on either side of the dsDNA can disrupt the splice signal consensus 5.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">the splice signal consensus 5</arg>
                </example>
                <example src="REPLACE" no="1578">
                    <text>This deletion that interacts with the keto and C group pair (blue) on both sides of the dsDNA can disrupt consensus coupling signal 5.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">consensus coupling signal 5</arg>
                </example>
                <example src="REPLACE" no="1579">
                    <text>This deletion that interacts with the keto and C group pair (blue) on both sides of the dsDNA can disrupt the 5 consensus of splice signal.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">the 5 consensus of splice signal</arg>
                </example>
                <example src="REPLACE" no="1580">
                    <text>This deletion that interacts with the keto and C group pair (blue) on both sides of the dsDNA can disrupt the 5th consensus of the cut signal.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">the 5th consensus of the cut signal</arg>
                </example>
                <example src="REPLACE" no="1581">
                    <text>This deletion that interacts with the keto and C group pair (blue) on both sides of the dsDNA can disrupt the splice signal consensus 5.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">the splice signal consensus 5</arg>
                </example>
                <example src="REPLACE" no="1582">
                    <text>Thus, the breakdown of assembly of keratin filaments by mutations in this region can disrupting in degeneration or cytolysis of keratinocytes.</text>
                    <arg n="0">mutations in this region</arg>
                    <arg n="1">assembly of keratin filaments</arg>
                    <arg n="R">degeneration or cytolysis of keratinocytes</arg>
                </example>
                <example src="REPLACE" no="1583">
                    <text>Thus, the breakdown of assembly of keratin filaments by mutations in this region can disrupting in degeneration or keratinocyte cytolysis.</text>
                    <arg n="0">mutations in this region</arg>
                    <arg n="1">assembly of keratin filaments</arg>
                    <arg n="R">degeneration or keratinocyte cytolysis</arg>
                </example>
                <example src="REPLACE" no="1584">
                    <text>Thus, the breakdown of checking point responses for DNA damage by p53 mutations can disrupting in the potential for destabilization of the genome.</text>
                    <arg n="0">p53 mutations</arg>
                    <arg n="1">checking point responses for DNA damage</arg>
                    <arg n="R">the potential for destabilization of the genome</arg>
                </example>
                <example src="REPLACE" no="1585">
                    <text>Thus, the breakdown of consensus coupling signal 5 by This deletion can disrupting in exon exhaustion.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">consensus coupling signal 5</arg>
                    <arg n="R">exon exhaustion</arg>
                </example>
                <example src="REPLACE" no="1586">
                    <text>Thus, the breakdown of consensus signal 5 by this deletion can disrupting in exon skipping.</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">consensus signal 5</arg>
                    <arg n="R">exon skipping</arg>
                </example>
                <example src="REPLACE" no="1587">
                    <text>Thus, the breakdown of consensus signal 5 by this suppression can disrupting in exon signal.</text>
                    <arg n="0">this suppression</arg>
                    <arg n="1">consensus signal 5</arg>
                    <arg n="R">exon signal</arg>
                </example>
                <example src="REPLACE" no="1588">
                    <text>Thus, the breakdown of interaction by Lys147Ala substitution can disrupting in a drastic drop of activity against GO:C substrates.</text>
                    <arg n="0">Lys147Ala substitution</arg>
                    <arg n="1">interaction</arg>
                    <arg n="R">a drastic drop of activity against GO:C substrates</arg>
                </example>
                <example src="REPLACE" no="1589">
                    <text>Thus, the breakdown of post-checking points for DNA damage by multations at p53 can disrupting in the potential for destabilization of the genome.</text>
                    <arg n="0">multations at p53</arg>
                    <arg n="1">post-checking points for DNA damage</arg>
                    <arg n="R">the potential for destabilization of the genome</arg>
                </example>
                <example src="REPLACE" no="1590">
                    <text>Thus, the breakdown of posts of checkpoints to DNA damage by Multations in p53 can disrupting in the potential for genome destabilization.</text>
                    <arg n="0">Multations in p53</arg>
                    <arg n="1">posts of checkpoints to DNA damage</arg>
                    <arg n="R">the potential for genome destabilization</arg>
                </example>
                <example src="REPLACE" no="1591">
                    <text>Thus, the breakdown of responses of checkpoints to DNA damage by Multations in p53 can disrupting in the potential for genome destabilization.</text>
                    <arg n="0">Multations in p53</arg>
                    <arg n="1">responses of checkpoints to DNA damage</arg>
                    <arg n="R">the potential for genome destabilization</arg>
                </example>
                <example src="REPLACE" no="1592">
                    <text>Thus, the breakdown of the 5 consensus of splice signal by This deletion can disrupting in exon exhaustion.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">the 5 consensus of splice signal</arg>
                    <arg n="R">exon exhaustion</arg>
                </example>
                <example src="REPLACE" no="1593">
                    <text>Thus, the breakdown of the 5th consensus of the cut signal by This deletion can disrupting in exon exhaustion.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">the 5th consensus of the cut signal</arg>
                    <arg n="R">exon exhaustion</arg>
                </example>
                <example src="REPLACE" no="1594">
                    <text>Thus, the breakdown of the interaction by the Lys147Ala substitution can disrupting in a drastic decrease in activity against GO:C substrates.</text>
                    <arg n="0">the Lys147Ala substitution</arg>
                    <arg n="1">the interaction</arg>
                    <arg n="R">a drastic decrease in activity against GO:C substrates</arg>
                </example>
                <example src="REPLACE" no="1595">
                    <text>Thus, the breakdown of the interaction by the Lys147Ala substitution can disrupting in a drastic decrease of activity against GO:C substrates.</text>
                    <arg n="0">the Lys147Ala substitution</arg>
                    <arg n="1">the interaction</arg>
                    <arg n="R">a drastic decrease of activity against GO:C substrates</arg>
                </example>
                <example src="REPLACE" no="1596">
                    <text>Thus, the breakdown of the splice signal consensus 5 by This deletion can disrupting in exon exhaustion.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">the splice signal consensus 5</arg>
                    <arg n="R">exon exhaustion</arg>
                </example>
                <example src="REPLACE" no="1597">
                    <text>Thus, the breakdown of the ubiquitin binding function by such mutations can disrupting in abnormal activation of the NF-kappaB pathway and subsequent activation of the.</text>
                    <arg n="0">such mutations</arg>
                    <arg n="1">the ubiquitin binding function</arg>
                    <arg n="R">abnormal activation of the NF-kappaB pathway and subsequent activation of the</arg>
                </example>
                <example src="REPLACE" no="1598">
                    <text>Thus, the breakdown of the ubiquitin-binding function by such mutations can disrupting in abnormal activation of the NF-kappaB pathway and subsequent activation of the.</text>
                    <arg n="0">such mutations</arg>
                    <arg n="1">the ubiquitin-binding function</arg>
                    <arg n="R">abnormal activation of the NF-kappaB pathway and subsequent activation of the</arg>
                </example>
                <example src="REPLACE" no="1599">
                    <text>Thus, the breakdown of tumour vessels by manipulation of the Tie-2 system in tumors can disrupting in lateral effects on peripheral nerves.</text>
                    <arg n="0">manipulation of the Tie-2 system in tumors</arg>
                    <arg n="1">tumour vessels</arg>
                    <arg n="R">lateral effects on peripheral nerves</arg>
                </example>
                <example src="REPLACE" no="1600">
                    <text>Thus, the breakdown of tumour vessels by tumour binding system 2 maneuver can disrupting in similar effects on peripheral nerves.</text>
                    <arg n="0">tumour binding system 2 maneuver</arg>
                    <arg n="1">tumour vessels</arg>
                    <arg n="R">similar effects on peripheral nerves</arg>
                </example>
                <example src="REPLACE" no="1601">
                    <text>Thus, the breakdown of ubiquitin binding function by These mutations can disrupting in abnormal NF-kappaB pathway activation and subsequent osteoclast activation.</text>
                    <arg n="0">These mutations</arg>
                    <arg n="1">ubiquitin binding function</arg>
                    <arg n="R">abnormal NF-kappaB pathway activation and subsequent osteoclast activation</arg>
                </example>
                <example src="REPLACE" no="1602">
                    <text>Thus, the rupture of assembly of keratin filaments by mutations in this region may disrupting in degeneration or cytolysis of keratinocytes.</text>
                    <arg n="0">mutations in this region</arg>
                    <arg n="1">assembly of keratin filaments</arg>
                    <arg n="R">degeneration or cytolysis of keratinocytes</arg>
                </example>
                <example src="REPLACE" no="1603">
                    <text>Thus, the rupture of assembly of keratin filaments by mutations in this region may disrupting in degeneration or keratinocyte cytolysis.</text>
                    <arg n="0">mutations in this region</arg>
                    <arg n="1">assembly of keratin filaments</arg>
                    <arg n="R">degeneration or keratinocyte cytolysis</arg>
                </example>
                <example src="REPLACE" no="1604">
                    <text>Thus, the rupture of checking point responses for DNA damage by p53 mutations may disrupting in the potential for destabilization of the genome.</text>
                    <arg n="0">p53 mutations</arg>
                    <arg n="1">checking point responses for DNA damage</arg>
                    <arg n="R">the potential for destabilization of the genome</arg>
                </example>
                <example src="REPLACE" no="1605">
                    <text>Thus, the rupture of consensus coupling signal 5 by This deletion may disrupting in exon exhaustion.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">consensus coupling signal 5</arg>
                    <arg n="R">exon exhaustion</arg>
                </example>
                <example src="REPLACE" no="1606">
                    <text>Thus, the rupture of consensus signal 5 by this deletion may disrupting in exon skipping.</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">consensus signal 5</arg>
                    <arg n="R">exon skipping</arg>
                </example>
                <example src="REPLACE" no="1607">
                    <text>Thus, the rupture of consensus signal 5 by this suppression may disrupting in exon signal.</text>
                    <arg n="0">this suppression</arg>
                    <arg n="1">consensus signal 5</arg>
                    <arg n="R">exon signal</arg>
                </example>
                <example src="REPLACE" no="1608">
                    <text>Thus, the rupture of interaction by Lys147Ala substitution may disrupting in a drastic drop of activity against GO:C substrates.</text>
                    <arg n="0">Lys147Ala substitution</arg>
                    <arg n="1">interaction</arg>
                    <arg n="R">a drastic drop of activity against GO:C substrates</arg>
                </example>
                <example src="REPLACE" no="1609">
                    <text>Thus, the rupture of post-checking points for DNA damage by multations at p53 may disrupting in the potential for destabilization of the genome.</text>
                    <arg n="0">multations at p53</arg>
                    <arg n="1">post-checking points for DNA damage</arg>
                    <arg n="R">the potential for destabilization of the genome</arg>
                </example>
                <example src="REPLACE" no="1610">
                    <text>Thus, the rupture of posts of checkpoints to DNA damage by Multations in p53 may disrupting in the potential for genome destabilization.</text>
                    <arg n="0">Multations in p53</arg>
                    <arg n="1">posts of checkpoints to DNA damage</arg>
                    <arg n="R">the potential for genome destabilization</arg>
                </example>
                <example src="REPLACE" no="1611">
                    <text>Thus, the rupture of responses of checkpoints to DNA damage by Multations in p53 may disrupting in the potential for genome destabilization.</text>
                    <arg n="0">Multations in p53</arg>
                    <arg n="1">responses of checkpoints to DNA damage</arg>
                    <arg n="R">the potential for genome destabilization</arg>
                </example>
                <example src="REPLACE" no="1612">
                    <text>Thus, the rupture of the 5 consensus of splice signal by This deletion may disrupting in exon exhaustion.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">the 5 consensus of splice signal</arg>
                    <arg n="R">exon exhaustion</arg>
                </example>
                <example src="REPLACE" no="1613">
                    <text>Thus, the rupture of the 5th consensus of the cut signal by This deletion may disrupting in exon exhaustion.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">the 5th consensus of the cut signal</arg>
                    <arg n="R">exon exhaustion</arg>
                </example>
                <example src="REPLACE" no="1614">
                    <text>Thus, the rupture of the interaction by the Lys147Ala substitution may disrupting in a drastic decrease in activity against GO:C substrates.</text>
                    <arg n="0">the Lys147Ala substitution</arg>
                    <arg n="1">the interaction</arg>
                    <arg n="R">a drastic decrease in activity against GO:C substrates</arg>
                </example>
                <example src="REPLACE" no="1615">
                    <text>Thus, the rupture of the interaction by the Lys147Ala substitution may disrupting in a drastic decrease of activity against GO:C substrates.</text>
                    <arg n="0">the Lys147Ala substitution</arg>
                    <arg n="1">the interaction</arg>
                    <arg n="R">a drastic decrease of activity against GO:C substrates</arg>
                </example>
                <example src="REPLACE" no="1616">
                    <text>Thus, the rupture of the splice signal consensus 5 by This deletion may disrupting in exon exhaustion.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">the splice signal consensus 5</arg>
                    <arg n="R">exon exhaustion</arg>
                </example>
                <example src="REPLACE" no="1617">
                    <text>Thus, the rupture of the ubiquitin binding function by such mutations may disrupting in abnormal activation of the NF-kappaB pathway and subsequent activation of the.</text>
                    <arg n="0">such mutations</arg>
                    <arg n="1">the ubiquitin binding function</arg>
                    <arg n="R">abnormal activation of the NF-kappaB pathway and subsequent activation of the</arg>
                </example>
                <example src="REPLACE" no="1618">
                    <text>Thus, the rupture of the ubiquitin-binding function by such mutations may disrupting in abnormal activation of the NF-kappaB pathway and subsequent activation of the.</text>
                    <arg n="0">such mutations</arg>
                    <arg n="1">the ubiquitin-binding function</arg>
                    <arg n="R">abnormal activation of the NF-kappaB pathway and subsequent activation of the</arg>
                </example>
                <example src="REPLACE" no="1619">
                    <text>Thus, the rupture of tumour vessels by manipulation of the Tie-2 system in tumors may disrupting in lateral effects on peripheral nerves.</text>
                    <arg n="0">manipulation of the Tie-2 system in tumors</arg>
                    <arg n="1">tumour vessels</arg>
                    <arg n="R">lateral effects on peripheral nerves</arg>
                </example>
                <example src="REPLACE" no="1620">
                    <text>Thus, the rupture of tumour vessels by tumour binding system 2 maneuver may disrupting in similar effects on peripheral nerves.</text>
                    <arg n="0">tumour binding system 2 maneuver</arg>
                    <arg n="1">tumour vessels</arg>
                    <arg n="R">similar effects on peripheral nerves</arg>
                </example>
                <example src="REPLACE" no="1621">
                    <text>Thus, the rupture of ubiquitin binding function by These mutations may disrupting in abnormal NF-kappaB pathway activation and subsequent osteoclast activation.</text>
                    <arg n="0">These mutations</arg>
                    <arg n="1">ubiquitin binding function</arg>
                    <arg n="R">abnormal NF-kappaB pathway activation and subsequent osteoclast activation</arg>
                </example>
                <example src="REPLACE" no="1622">
                    <text>a 415G4 mutation broke a sequence of licensing improvement sequence: (GAR)n-(GAR)n disrupted in R (exon 5 spike).</text>
                    <arg n="0">a 415G4 mutation</arg>
                    <arg n="1">licensing improvement sequence: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="1623">
                    <text>a 415G4 mutation can disrupt with the base groups ceto and C (blue) on both sides of the dsDNA DNA and interrupt licensing improvement sequence: (GAR)n-(GAR)n.</text>
                    <arg n="0">a 415G4 mutation</arg>
                    <arg n="1">licensing improvement sequence: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="1624">
                    <text>a 415G4 mutation that broke A1 will be identified in the siblings disrupted by classical abetalipoproteinemia.</text>
                    <arg n="0">a 415G4 mutation</arg>
                </example>
                <example src="REPLACE" no="1625">
                    <text>a 415G4 mutation that can disrupt licensing improvement sequence: (GAR)n-(GAR)n has been identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">a 415G4 mutation</arg>
                    <arg n="1">licensing improvement sequence: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="1626">
                    <text>a 415G4 mutation that can disrupt licensing improvement sequence: (GAR)n-(GAR)n that has been identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">a 415G4 mutation</arg>
                    <arg n="1">licensing improvement sequence: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="1627">
                    <text>a 415G4 mutation that has disrupted A1 will be identified in the affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">a 415G4 mutation</arg>
                </example>
                <example src="REPLACE" no="1628">
                    <text>a 415G4 mutation that has disrupted licensing improvement sequence: (GAR)n-(GAR)n was identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">a 415G4 mutation</arg>
                    <arg n="1">licensing improvement sequence: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="1629">
                    <text>a 415G4 mutation that interact with the keto groups of the base pair GO and C (blue) on either side of the dsDNA can disrupt licensing improvement sequence: (GAR)n-(GAR)n.</text>
                    <arg n="0">a 415G4 mutation</arg>
                    <arg n="1">licensing improvement sequence: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="1630">
                    <text>a 415G4 mutation that interacts with the keto and C group pair (blue) on both sides of the dsDNA can disrupt licensing improvement sequence: (GAR)n-(GAR)n.</text>
                    <arg n="0">a 415G4 mutation</arg>
                    <arg n="1">licensing improvement sequence: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="1631">
                    <text>a homozygotic mutation broke a sequence of splicing disrupted in R (exon 5 spike).</text>
                    <arg n="0">a homozygotic mutation</arg>
                    <arg n="1">splicing</arg>
                </example>
                <example src="REPLACE" no="1632">
                    <text>a homozygotic mutation can disrupt with the base groups ceto and C (blue) on both sides of the dsDNA DNA and interrupt splicing.</text>
                    <arg n="0">a homozygotic mutation</arg>
                    <arg n="1">splicing</arg>
                </example>
                <example src="REPLACE" no="1633">
                    <text>a homozygotic mutation that broke A1 will be identified in the siblings disrupted by classical abetalipoproteinemia.</text>
                    <arg n="0">a homozygotic mutation</arg>
                </example>
                <example src="REPLACE" no="1634">
                    <text>a homozygotic mutation that can disrupt splicing has been identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">a homozygotic mutation</arg>
                    <arg n="1">splicing</arg>
                </example>
                <example src="REPLACE" no="1635">
                    <text>a homozygotic mutation that can disrupt splicing that has been identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">a homozygotic mutation</arg>
                    <arg n="1">splicing</arg>
                </example>
                <example src="REPLACE" no="1636">
                    <text>a homozygotic mutation that has disrupted A1 will be identified in the affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">a homozygotic mutation</arg>
                </example>
                <example src="REPLACE" no="1637">
                    <text>a homozygotic mutation that has disrupted splicing was identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">a homozygotic mutation</arg>
                    <arg n="1">splicing</arg>
                </example>
                <example src="REPLACE" no="1638">
                    <text>a homozygotic mutation that interact with the keto groups of the base pair GO and C (blue) on either side of the dsDNA can disrupt splicing.</text>
                    <arg n="0">a homozygotic mutation</arg>
                    <arg n="1">splicing</arg>
                </example>
                <example src="REPLACE" no="1639">
                    <text>a homozygotic mutation that interacts with the keto and C group pair (blue) on both sides of the dsDNA can disrupt splicing.</text>
                    <arg n="0">a homozygotic mutation</arg>
                    <arg n="1">splicing</arg>
                </example>
                <example src="REPLACE" no="1640">
                    <text>blocking the expression MEKK1 or MEKK2 broke a sequence of the overall integrity of the MAPK route regulation disrupted in R (exon 5 spike).</text>
                    <arg n="0">blocking the expression MEKK1 or MEKK2</arg>
                    <arg n="1">the overall integrity of the MAPK route regulation</arg>
                </example>
                <example src="REPLACE" no="1641">
                    <text>blocking the expression MEKK1 or MEKK2 can disrupt with the base groups ceto and C (blue) on both sides of the dsDNA DNA and interrupt the overall integrity of the MAPK route regulation.</text>
                    <arg n="0">blocking the expression MEKK1 or MEKK2</arg>
                    <arg n="1">the overall integrity of the MAPK route regulation</arg>
                </example>
                <example src="REPLACE" no="1642">
                    <text>blocking the expression MEKK1 or MEKK2 that broke A1 will be identified in the siblings disrupted by classical abetalipoproteinemia.</text>
                    <arg n="0">blocking the expression MEKK1 or MEKK2</arg>
                </example>
                <example src="REPLACE" no="1643">
                    <text>blocking the expression MEKK1 or MEKK2 that can disrupt the overall integrity of the MAPK route regulation has been identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">blocking the expression MEKK1 or MEKK2</arg>
                    <arg n="1">the overall integrity of the MAPK route regulation</arg>
                </example>
                <example src="REPLACE" no="1644">
                    <text>blocking the expression MEKK1 or MEKK2 that can disrupt the overall integrity of the MAPK route regulation that has been identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">blocking the expression MEKK1 or MEKK2</arg>
                    <arg n="1">the overall integrity of the MAPK route regulation</arg>
                </example>
                <example src="REPLACE" no="1645">
                    <text>blocking the expression MEKK1 or MEKK2 that has disrupted A1 will be identified in the affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">blocking the expression MEKK1 or MEKK2</arg>
                </example>
                <example src="REPLACE" no="1646">
                    <text>blocking the expression MEKK1 or MEKK2 that has disrupted the overall integrity of the MAPK route regulation was identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">blocking the expression MEKK1 or MEKK2</arg>
                    <arg n="1">the overall integrity of the MAPK route regulation</arg>
                </example>
                <example src="REPLACE" no="1647">
                    <text>blocking the expression MEKK1 or MEKK2 that interact with the keto groups of the base pair GO and C (blue) on either side of the dsDNA can disrupt the overall integrity of the MAPK route regulation.</text>
                    <arg n="0">blocking the expression MEKK1 or MEKK2</arg>
                    <arg n="1">the overall integrity of the MAPK route regulation</arg>
                </example>
                <example src="REPLACE" no="1648">
                    <text>blocking the expression MEKK1 or MEKK2 that interacts with the keto and C group pair (blue) on both sides of the dsDNA can disrupt the overall integrity of the MAPK route regulation.</text>
                    <arg n="0">blocking the expression MEKK1 or MEKK2</arg>
                    <arg n="1">the overall integrity of the MAPK route regulation</arg>
                </example>
                <example src="REPLACE" no="1649">
                    <text>homozygous mutation broke a sequence of splicing disrupted in R (exon 5 spike).</text>
                    <arg n="0">homozygous mutation</arg>
                    <arg n="1">splicing</arg>
                </example>
                <example src="REPLACE" no="1650">
                    <text>homozygous mutation can disrupt with the base groups ceto and C (blue) on both sides of the dsDNA DNA and interrupt splicing.</text>
                    <arg n="0">homozygous mutation</arg>
                    <arg n="1">splicing</arg>
                </example>
                <example src="REPLACE" no="1651">
                    <text>homozygous mutation that can disrupt splicing has been identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">homozygous mutation</arg>
                    <arg n="1">splicing</arg>
                </example>
                <example src="REPLACE" no="1652">
                    <text>homozygous mutation that can disrupt splicing that has been identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">homozygous mutation</arg>
                    <arg n="1">splicing</arg>
                </example>
                <example src="REPLACE" no="1653">
                    <text>homozygous mutation that has disrupted splicing was identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">homozygous mutation</arg>
                    <arg n="1">splicing</arg>
                </example>
                <example src="REPLACE" no="1654">
                    <text>homozygous mutation that interact with the keto groups of the base pair GO and C (blue) on either side of the dsDNA can disrupt splicing.</text>
                    <arg n="0">homozygous mutation</arg>
                    <arg n="1">splicing</arg>
                </example>
                <example src="REPLACE" no="1655">
                    <text>homozygous mutation that interacts with the keto and C group pair (blue) on both sides of the dsDNA can disrupt splicing.</text>
                    <arg n="0">homozygous mutation</arg>
                    <arg n="1">splicing</arg>
                </example>
                <example src="REPLACE" no="1656">
                    <text>inhibition of inflammation broke a sequence of physiological protective responses disrupted in R (exon 5 spike).</text>
                    <arg n="0">inhibition of inflammation</arg>
                    <arg n="1">physiological protective responses</arg>
                </example>
                <example src="REPLACE" no="1657">
                    <text>inhibition of inflammation broke a sequence of protective physiological response disrupted in R (exon 5 spike).</text>
                    <arg n="0">inhibition of inflammation</arg>
                    <arg n="1">protective physiological response</arg>
                </example>
                <example src="REPLACE" no="1658">
                    <text>inhibition of inflammation can disrupt with the base groups ceto and C (blue) on both sides of the dsDNA DNA and interrupt physiological protective responses.</text>
                    <arg n="0">inhibition of inflammation</arg>
                    <arg n="1">physiological protective responses</arg>
                </example>
                <example src="REPLACE" no="1659">
                    <text>inhibition of inflammation can disrupt with the base groups ceto and C (blue) on both sides of the dsDNA DNA and interrupt protective physiological response.</text>
                    <arg n="0">inhibition of inflammation</arg>
                    <arg n="1">protective physiological response</arg>
                </example>
                <example src="REPLACE" no="1660">
                    <text>inhibition of inflammation that broke A1 will be identified in the siblings disrupted by classical abetalipoproteinemia.</text>
                    <arg n="0">inhibition of inflammation</arg>
                </example>
                <example src="REPLACE" no="1661">
                    <text>inhibition of inflammation that can disrupt physiological protective responses has been identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">inhibition of inflammation</arg>
                    <arg n="1">physiological protective responses</arg>
                </example>
                <example src="REPLACE" no="1662">
                    <text>inhibition of inflammation that can disrupt physiological protective responses that has been identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">inhibition of inflammation</arg>
                    <arg n="1">physiological protective responses</arg>
                </example>
                <example src="REPLACE" no="1663">
                    <text>inhibition of inflammation that can disrupt protective physiological response has been identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">inhibition of inflammation</arg>
                    <arg n="1">protective physiological response</arg>
                </example>
                <example src="REPLACE" no="1664">
                    <text>inhibition of inflammation that can disrupt protective physiological response that has been identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">inhibition of inflammation</arg>
                    <arg n="1">protective physiological response</arg>
                </example>
                <example src="REPLACE" no="1665">
                    <text>inhibition of inflammation that has disrupted A1 will be identified in the affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">inhibition of inflammation</arg>
                </example>
                <example src="REPLACE" no="1666">
                    <text>inhibition of inflammation that has disrupted physiological protective responses was identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">inhibition of inflammation</arg>
                    <arg n="1">physiological protective responses</arg>
                </example>
                <example src="REPLACE" no="1667">
                    <text>inhibition of inflammation that has disrupted protective physiological response was identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">inhibition of inflammation</arg>
                    <arg n="1">protective physiological response</arg>
                </example>
                <example src="REPLACE" no="1668">
                    <text>inhibition of inflammation that interact with the keto groups of the base pair GO and C (blue) on either side of the dsDNA can disrupt physiological protective responses.</text>
                    <arg n="0">inhibition of inflammation</arg>
                    <arg n="1">physiological protective responses</arg>
                </example>
                <example src="REPLACE" no="1669">
                    <text>inhibition of inflammation that interact with the keto groups of the base pair GO and C (blue) on either side of the dsDNA can disrupt protective physiological response.</text>
                    <arg n="0">inhibition of inflammation</arg>
                    <arg n="1">protective physiological response</arg>
                </example>
                <example src="REPLACE" no="1670">
                    <text>inhibition of inflammation that interacts with the keto and C group pair (blue) on both sides of the dsDNA can disrupt physiological protective responses.</text>
                    <arg n="0">inhibition of inflammation</arg>
                    <arg n="1">physiological protective responses</arg>
                </example>
                <example src="REPLACE" no="1671">
                    <text>inhibition of inflammation that interacts with the keto and C group pair (blue) on both sides of the dsDNA can disrupt protective physiological response.</text>
                    <arg n="0">inhibition of inflammation</arg>
                    <arg n="1">protective physiological response</arg>
                </example>
                <example src="REPLACE" no="1672">
                    <text>manipulation of the Tie-2 system in tumors broke a sequence of tumour vessels disrupted in R (exon 5 spike).</text>
                    <arg n="0">manipulation of the Tie-2 system in tumors</arg>
                    <arg n="1">tumour vessels</arg>
                </example>
                <example src="REPLACE" no="1673">
                    <text>manipulation of the Tie-2 system in tumors broke the tumour vessels and disrupted to the lateral effects on peripheral nerves.</text>
                    <arg n="0">manipulation of the Tie-2 system in tumors</arg>
                    <arg n="1">tumour vessels</arg>
                    <arg n="R">lateral effects on peripheral nerves</arg>
                </example>
                <example src="REPLACE" no="1674">
                    <text>manipulation of the Tie-2 system in tumors can disrupt with the base groups ceto and C (blue) on both sides of the dsDNA DNA and interrupt tumour vessels.</text>
                    <arg n="0">manipulation of the Tie-2 system in tumors</arg>
                    <arg n="1">tumour vessels</arg>
                </example>
                <example src="REPLACE" no="1675">
                    <text>manipulation of the Tie-2 system in tumors have perturbed tumour vessels and disrupted in lateral effects on peripheral nerves.</text>
                    <arg n="0">manipulation of the Tie-2 system in tumors</arg>
                    <arg n="1">tumour vessels</arg>
                    <arg n="R">lateral effects on peripheral nerves</arg>
                </example>
                <example src="REPLACE" no="1676">
                    <text>manipulation of the Tie-2 system in tumors rupture of tumour vessels may disrupting in lateral effects on peripheral nerves.</text>
                    <arg n="0">manipulation of the Tie-2 system in tumors</arg>
                    <arg n="1">tumour vessels</arg>
                    <arg n="R">lateral effects on peripheral nerves</arg>
                </example>
                <example src="REPLACE" no="1677">
                    <text>manipulation of the Tie-2 system in tumors that broke A1 will be identified in the siblings disrupted by classical abetalipoproteinemia.</text>
                    <arg n="0">manipulation of the Tie-2 system in tumors</arg>
                </example>
                <example src="REPLACE" no="1678">
                    <text>manipulation of the Tie-2 system in tumors that can disrupt tumour vessels has been identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">manipulation of the Tie-2 system in tumors</arg>
                    <arg n="1">tumour vessels</arg>
                </example>
                <example src="REPLACE" no="1679">
                    <text>manipulation of the Tie-2 system in tumors that can disrupt tumour vessels that has been identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">manipulation of the Tie-2 system in tumors</arg>
                    <arg n="1">tumour vessels</arg>
                </example>
                <example src="REPLACE" no="1680">
                    <text>manipulation of the Tie-2 system in tumors that has disrupted A1 will be identified in the affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">manipulation of the Tie-2 system in tumors</arg>
                </example>
                <example src="REPLACE" no="1681">
                    <text>manipulation of the Tie-2 system in tumors that has disrupted tumour vessels was identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">manipulation of the Tie-2 system in tumors</arg>
                    <arg n="1">tumour vessels</arg>
                </example>
                <example src="REPLACE" no="1682">
                    <text>manipulation of the Tie-2 system in tumors that interact with the keto groups of the base pair GO and C (blue) on either side of the dsDNA can disrupt tumour vessels.</text>
                    <arg n="0">manipulation of the Tie-2 system in tumors</arg>
                    <arg n="1">tumour vessels</arg>
                </example>
                <example src="REPLACE" no="1683">
                    <text>manipulation of the Tie-2 system in tumors that interacts with the keto and C group pair (blue) on both sides of the dsDNA can disrupt tumour vessels.</text>
                    <arg n="0">manipulation of the Tie-2 system in tumors</arg>
                    <arg n="1">tumour vessels</arg>
                </example>
                <example src="REPLACE" no="1684">
                    <text>manipulation of the binding system 2 in tumours broke a sequence of tumor vessels disrupted in R (exon 5 spike).</text>
                    <arg n="0">manipulation of the binding system 2 in tumours</arg>
                    <arg n="1">tumor vessels</arg>
                </example>
                <example src="REPLACE" no="1685">
                    <text>manipulation of the binding system 2 in tumours can disrupt with the base groups ceto and C (blue) on both sides of the dsDNA DNA and interrupt tumor vessels.</text>
                    <arg n="0">manipulation of the binding system 2 in tumours</arg>
                    <arg n="1">tumor vessels</arg>
                </example>
                <example src="REPLACE" no="1686">
                    <text>manipulation of the binding system 2 in tumours that broke A1 will be identified in the siblings disrupted by classical abetalipoproteinemia.</text>
                    <arg n="0">manipulation of the binding system 2 in tumours</arg>
                </example>
                <example src="REPLACE" no="1687">
                    <text>manipulation of the binding system 2 in tumours that can disrupt tumor vessels has been identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">manipulation of the binding system 2 in tumours</arg>
                    <arg n="1">tumor vessels</arg>
                </example>
                <example src="REPLACE" no="1688">
                    <text>manipulation of the binding system 2 in tumours that can disrupt tumor vessels that has been identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">manipulation of the binding system 2 in tumours</arg>
                    <arg n="1">tumor vessels</arg>
                </example>
                <example src="REPLACE" no="1689">
                    <text>manipulation of the binding system 2 in tumours that has disrupted A1 will be identified in the affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">manipulation of the binding system 2 in tumours</arg>
                </example>
                <example src="REPLACE" no="1690">
                    <text>manipulation of the binding system 2 in tumours that has disrupted tumor vessels was identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">manipulation of the binding system 2 in tumours</arg>
                    <arg n="1">tumor vessels</arg>
                </example>
                <example src="REPLACE" no="1691">
                    <text>manipulation of the binding system 2 in tumours that interact with the keto groups of the base pair GO and C (blue) on either side of the dsDNA can disrupt tumor vessels.</text>
                    <arg n="0">manipulation of the binding system 2 in tumours</arg>
                    <arg n="1">tumor vessels</arg>
                </example>
                <example src="REPLACE" no="1692">
                    <text>manipulation of the binding system 2 in tumours that interacts with the keto and C group pair (blue) on both sides of the dsDNA can disrupt tumor vessels.</text>
                    <arg n="0">manipulation of the binding system 2 in tumours</arg>
                    <arg n="1">tumor vessels</arg>
                </example>
                <example src="REPLACE" no="1693">
                    <text>multations at p53 broke a sequence of post-checking points for DNA damage disrupted in R (exon 5 spike).</text>
                    <arg n="0">multations at p53</arg>
                    <arg n="1">post-checking points for DNA damage</arg>
                </example>
                <example src="REPLACE" no="1694">
                    <text>multations at p53 broke the post-checking points for DNA damage and disrupted to the the potential for destabilization of the genome.</text>
                    <arg n="0">multations at p53</arg>
                    <arg n="1">post-checking points for DNA damage</arg>
                    <arg n="R">the potential for destabilization of the genome</arg>
                </example>
                <example src="REPLACE" no="1695">
                    <text>multations at p53 can disrupt with the base groups ceto and C (blue) on both sides of the dsDNA DNA and interrupt post-checking points for DNA damage.</text>
                    <arg n="0">multations at p53</arg>
                    <arg n="1">post-checking points for DNA damage</arg>
                </example>
                <example src="REPLACE" no="1696">
                    <text>multations at p53 have perturbed post-checking points for DNA damage and disrupted in the potential for destabilization of the genome.</text>
                    <arg n="0">multations at p53</arg>
                    <arg n="1">post-checking points for DNA damage</arg>
                    <arg n="R">the potential for destabilization of the genome</arg>
                </example>
                <example src="REPLACE" no="1697">
                    <text>multations at p53 rupture of post-checking points for DNA damage may disrupting in the potential for destabilization of the genome.</text>
                    <arg n="0">multations at p53</arg>
                    <arg n="1">post-checking points for DNA damage</arg>
                    <arg n="R">the potential for destabilization of the genome</arg>
                </example>
                <example src="REPLACE" no="1698">
                    <text>multations at p53 that broke A1 will be identified in the siblings disrupted by classical abetalipoproteinemia.</text>
                    <arg n="0">multations at p53</arg>
                </example>
                <example src="REPLACE" no="1699">
                    <text>multations at p53 that can disrupt post-checking points for DNA damage has been identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">multations at p53</arg>
                    <arg n="1">post-checking points for DNA damage</arg>
                </example>
                <example src="REPLACE" no="1700">
                    <text>multations at p53 that can disrupt post-checking points for DNA damage that has been identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">multations at p53</arg>
                    <arg n="1">post-checking points for DNA damage</arg>
                </example>
                <example src="REPLACE" no="1701">
                    <text>multations at p53 that has disrupted A1 will be identified in the affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">multations at p53</arg>
                </example>
                <example src="REPLACE" no="1702">
                    <text>multations at p53 that has disrupted post-checking points for DNA damage was identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">multations at p53</arg>
                    <arg n="1">post-checking points for DNA damage</arg>
                </example>
                <example src="REPLACE" no="1703">
                    <text>multations at p53 that interact with the keto groups of the base pair GO and C (blue) on either side of the dsDNA can disrupt post-checking points for DNA damage.</text>
                    <arg n="0">multations at p53</arg>
                    <arg n="1">post-checking points for DNA damage</arg>
                </example>
                <example src="REPLACE" no="1704">
                    <text>multations at p53 that interacts with the keto and C group pair (blue) on both sides of the dsDNA can disrupt post-checking points for DNA damage.</text>
                    <arg n="0">multations at p53</arg>
                    <arg n="1">post-checking points for DNA damage</arg>
                </example>
                <example src="REPLACE" no="1705">
                    <text>mutation 415G4 broke a sequence of pulling enhancement sequence: (GAR)n-(GAR)n disrupted in R (exon 5 spike).</text>
                    <arg n="0">mutation 415G4</arg>
                    <arg n="1">pulling enhancement sequence: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="1706">
                    <text>mutation 415G4 broke a sequence of splicing sequencer: (GAR)n-(GAR)n disrupted in R (exon 5 spike).</text>
                    <arg n="0">mutation 415G4</arg>
                    <arg n="1">splicing sequencer: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="1707">
                    <text>mutation 415G4 can disrupt with the base groups ceto and C (blue) on both sides of the dsDNA DNA and interrupt pulling enhancement sequence: (GAR)n-(GAR)n.</text>
                    <arg n="0">mutation 415G4</arg>
                    <arg n="1">pulling enhancement sequence: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="1708">
                    <text>mutation 415G4 can disrupt with the base groups ceto and C (blue) on both sides of the dsDNA DNA and interrupt splicing sequencer: (GAR)n-(GAR)n.</text>
                    <arg n="0">mutation 415G4</arg>
                    <arg n="1">splicing sequencer: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="1709">
                    <text>mutation 415G4 that broke A1 will be identified in the siblings disrupted by classical abetalipoproteinemia.</text>
                    <arg n="0">mutation 415G4</arg>
                </example>
                <example src="REPLACE" no="1710">
                    <text>mutation 415G4 that can disrupt pulling enhancement sequence: (GAR)n-(GAR)n has been identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">mutation 415G4</arg>
                    <arg n="1">pulling enhancement sequence: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="1711">
                    <text>mutation 415G4 that can disrupt pulling enhancement sequence: (GAR)n-(GAR)n that has been identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">mutation 415G4</arg>
                    <arg n="1">pulling enhancement sequence: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="1712">
                    <text>mutation 415G4 that can disrupt splicing sequencer: (GAR)n-(GAR)n has been identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">mutation 415G4</arg>
                    <arg n="1">splicing sequencer: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="1713">
                    <text>mutation 415G4 that can disrupt splicing sequencer: (GAR)n-(GAR)n that has been identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">mutation 415G4</arg>
                    <arg n="1">splicing sequencer: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="1714">
                    <text>mutation 415G4 that has disrupted A1 will be identified in the affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">mutation 415G4</arg>
                </example>
                <example src="REPLACE" no="1715">
                    <text>mutation 415G4 that has disrupted pulling enhancement sequence: (GAR)n-(GAR)n was identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">mutation 415G4</arg>
                    <arg n="1">pulling enhancement sequence: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="1716">
                    <text>mutation 415G4 that has disrupted splicing sequencer: (GAR)n-(GAR)n was identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">mutation 415G4</arg>
                    <arg n="1">splicing sequencer: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="1717">
                    <text>mutation 415G4 that interact with the keto groups of the base pair GO and C (blue) on either side of the dsDNA can disrupt pulling enhancement sequence: (GAR)n-(GAR)n.</text>
                    <arg n="0">mutation 415G4</arg>
                    <arg n="1">pulling enhancement sequence: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="1718">
                    <text>mutation 415G4 that interact with the keto groups of the base pair GO and C (blue) on either side of the dsDNA can disrupt splicing sequencer: (GAR)n-(GAR)n.</text>
                    <arg n="0">mutation 415G4</arg>
                    <arg n="1">splicing sequencer: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="1719">
                    <text>mutation 415G4 that interacts with the keto and C group pair (blue) on both sides of the dsDNA can disrupt pulling enhancement sequence: (GAR)n-(GAR)n.</text>
                    <arg n="0">mutation 415G4</arg>
                    <arg n="1">pulling enhancement sequence: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="1720">
                    <text>mutation 415G4 that interacts with the keto and C group pair (blue) on both sides of the dsDNA can disrupt splicing sequencer: (GAR)n-(GAR)n.</text>
                    <arg n="0">mutation 415G4</arg>
                    <arg n="1">splicing sequencer: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="1721">
                    <text>mutations in this region broke a sequence of assembly of keratin filaments disrupted in R (exon 5 spike).</text>
                    <arg n="0">mutations in this region</arg>
                    <arg n="1">assembly of keratin filaments</arg>
                </example>
                <example src="REPLACE" no="1722">
                    <text>mutations in this region broke the assembly of keratin filaments and disrupted to the degeneration or cytolysis of keratinocytes.</text>
                    <arg n="0">mutations in this region</arg>
                    <arg n="1">assembly of keratin filaments</arg>
                    <arg n="R">degeneration or cytolysis of keratinocytes</arg>
                </example>
                <example src="REPLACE" no="1723">
                    <text>mutations in this region broke the assembly of keratin filaments and disrupted to the degeneration or keratinocyte cytolysis.</text>
                    <arg n="0">mutations in this region</arg>
                    <arg n="1">assembly of keratin filaments</arg>
                    <arg n="R">degeneration or keratinocyte cytolysis</arg>
                </example>
                <example src="REPLACE" no="1724">
                    <text>mutations in this region can disrupt with the base groups ceto and C (blue) on both sides of the dsDNA DNA and interrupt assembly of keratin filaments.</text>
                    <arg n="0">mutations in this region</arg>
                    <arg n="1">assembly of keratin filaments</arg>
                </example>
                <example src="REPLACE" no="1725">
                    <text>mutations in this region have perturbed assembly of keratin filaments and disrupted in degeneration or cytolysis of keratinocytes.</text>
                    <arg n="0">mutations in this region</arg>
                    <arg n="1">assembly of keratin filaments</arg>
                    <arg n="R">degeneration or cytolysis of keratinocytes</arg>
                </example>
                <example src="REPLACE" no="1726">
                    <text>mutations in this region have perturbed assembly of keratin filaments and disrupted in degeneration or keratinocyte cytolysis.</text>
                    <arg n="0">mutations in this region</arg>
                    <arg n="1">assembly of keratin filaments</arg>
                    <arg n="R">degeneration or keratinocyte cytolysis</arg>
                </example>
                <example src="REPLACE" no="1727">
                    <text>mutations in this region rupture of assembly of keratin filaments may disrupting in degeneration or cytolysis of keratinocytes.</text>
                    <arg n="0">mutations in this region</arg>
                    <arg n="1">assembly of keratin filaments</arg>
                    <arg n="R">degeneration or cytolysis of keratinocytes</arg>
                </example>
                <example src="REPLACE" no="1728">
                    <text>mutations in this region rupture of assembly of keratin filaments may disrupting in degeneration or keratinocyte cytolysis.</text>
                    <arg n="0">mutations in this region</arg>
                    <arg n="1">assembly of keratin filaments</arg>
                    <arg n="R">degeneration or keratinocyte cytolysis</arg>
                </example>
                <example src="REPLACE" no="1729">
                    <text>mutations in this region that broke A1 will be identified in the siblings disrupted by classical abetalipoproteinemia.</text>
                    <arg n="0">mutations in this region</arg>
                </example>
                <example src="REPLACE" no="1730">
                    <text>mutations in this region that can disrupt assembly of keratin filaments has been identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">mutations in this region</arg>
                    <arg n="1">assembly of keratin filaments</arg>
                </example>
                <example src="REPLACE" no="1731">
                    <text>mutations in this region that can disrupt assembly of keratin filaments that has been identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">mutations in this region</arg>
                    <arg n="1">assembly of keratin filaments</arg>
                </example>
                <example src="REPLACE" no="1732">
                    <text>mutations in this region that has disrupted A1 will be identified in the affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">mutations in this region</arg>
                </example>
                <example src="REPLACE" no="1733">
                    <text>mutations in this region that has disrupted assembly of keratin filaments was identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">mutations in this region</arg>
                    <arg n="1">assembly of keratin filaments</arg>
                </example>
                <example src="REPLACE" no="1734">
                    <text>mutations in this region that interact with the keto groups of the base pair GO and C (blue) on either side of the dsDNA can disrupt assembly of keratin filaments.</text>
                    <arg n="0">mutations in this region</arg>
                    <arg n="1">assembly of keratin filaments</arg>
                </example>
                <example src="REPLACE" no="1735">
                    <text>mutations in this region that interacts with the keto and C group pair (blue) on both sides of the dsDNA can disrupt assembly of keratin filaments.</text>
                    <arg n="0">mutations in this region</arg>
                    <arg n="1">assembly of keratin filaments</arg>
                </example>
                <example src="REPLACE" no="1736">
                    <text>p53 mutations broke a sequence of checking point responses for DNA damage disrupted in R (exon 5 spike).</text>
                    <arg n="0">p53 mutations</arg>
                    <arg n="1">checking point responses for DNA damage</arg>
                </example>
                <example src="REPLACE" no="1737">
                    <text>p53 mutations broke the checking point responses for DNA damage and disrupted to the the potential for destabilization of the genome.</text>
                    <arg n="0">p53 mutations</arg>
                    <arg n="1">checking point responses for DNA damage</arg>
                    <arg n="R">the potential for destabilization of the genome</arg>
                </example>
                <example src="REPLACE" no="1738">
                    <text>p53 mutations can disrupt with the base groups ceto and C (blue) on both sides of the dsDNA DNA and interrupt checking point responses for DNA damage.</text>
                    <arg n="0">p53 mutations</arg>
                    <arg n="1">checking point responses for DNA damage</arg>
                </example>
                <example src="REPLACE" no="1739">
                    <text>p53 mutations have perturbed checking point responses for DNA damage and disrupted in the potential for destabilization of the genome.</text>
                    <arg n="0">p53 mutations</arg>
                    <arg n="1">checking point responses for DNA damage</arg>
                    <arg n="R">the potential for destabilization of the genome</arg>
                </example>
                <example src="REPLACE" no="1740">
                    <text>p53 mutations rupture of checking point responses for DNA damage may disrupting in the potential for destabilization of the genome.</text>
                    <arg n="0">p53 mutations</arg>
                    <arg n="1">checking point responses for DNA damage</arg>
                    <arg n="R">the potential for destabilization of the genome</arg>
                </example>
                <example src="REPLACE" no="1741">
                    <text>p53 mutations that broke A1 will be identified in the siblings disrupted by classical abetalipoproteinemia.</text>
                    <arg n="0">p53 mutations</arg>
                </example>
                <example src="REPLACE" no="1742">
                    <text>p53 mutations that can disrupt checking point responses for DNA damage has been identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">p53 mutations</arg>
                    <arg n="1">checking point responses for DNA damage</arg>
                </example>
                <example src="REPLACE" no="1743">
                    <text>p53 mutations that can disrupt checking point responses for DNA damage that has been identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">p53 mutations</arg>
                    <arg n="1">checking point responses for DNA damage</arg>
                </example>
                <example src="REPLACE" no="1744">
                    <text>p53 mutations that has disrupted A1 will be identified in the affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">p53 mutations</arg>
                </example>
                <example src="REPLACE" no="1745">
                    <text>p53 mutations that has disrupted checking point responses for DNA damage was identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">p53 mutations</arg>
                    <arg n="1">checking point responses for DNA damage</arg>
                </example>
                <example src="REPLACE" no="1746">
                    <text>p53 mutations that interact with the keto groups of the base pair GO and C (blue) on either side of the dsDNA can disrupt checking point responses for DNA damage.</text>
                    <arg n="0">p53 mutations</arg>
                    <arg n="1">checking point responses for DNA damage</arg>
                </example>
                <example src="REPLACE" no="1747">
                    <text>p53 mutations that interacts with the keto and C group pair (blue) on both sides of the dsDNA can disrupt checking point responses for DNA damage.</text>
                    <arg n="0">p53 mutations</arg>
                    <arg n="1">checking point responses for DNA damage</arg>
                </example>
                <example src="REPLACE" no="1748">
                    <text>such mutations broke a sequence of the ubiquitin binding function disrupted in R (exon 5 spike).</text>
                    <arg n="0">such mutations</arg>
                    <arg n="1">the ubiquitin binding function</arg>
                </example>
                <example src="REPLACE" no="1749">
                    <text>such mutations broke a sequence of the ubiquitin-binding function disrupted in R (exon 5 spike).</text>
                    <arg n="0">such mutations</arg>
                    <arg n="1">the ubiquitin-binding function</arg>
                </example>
                <example src="REPLACE" no="1750">
                    <text>such mutations broke the the ubiquitin binding function and disrupted to the abnormal activation of the NF-kappaB pathway and subsequent activation of the.</text>
                    <arg n="0">such mutations</arg>
                    <arg n="1">the ubiquitin binding function</arg>
                    <arg n="R">abnormal activation of the NF-kappaB pathway and subsequent activation of the</arg>
                </example>
                <example src="REPLACE" no="1751">
                    <text>such mutations broke the the ubiquitin-binding function and disrupted to the abnormal activation of the NF-kappaB pathway and subsequent activation of the.</text>
                    <arg n="0">such mutations</arg>
                    <arg n="1">the ubiquitin-binding function</arg>
                    <arg n="R">abnormal activation of the NF-kappaB pathway and subsequent activation of the</arg>
                </example>
                <example src="REPLACE" no="1752">
                    <text>such mutations can disrupt with the base groups ceto and C (blue) on both sides of the dsDNA DNA and interrupt the ubiquitin binding function.</text>
                    <arg n="0">such mutations</arg>
                    <arg n="1">the ubiquitin binding function</arg>
                </example>
                <example src="REPLACE" no="1753">
                    <text>such mutations can disrupt with the base groups ceto and C (blue) on both sides of the dsDNA DNA and interrupt the ubiquitin-binding function.</text>
                    <arg n="0">such mutations</arg>
                    <arg n="1">the ubiquitin-binding function</arg>
                </example>
                <example src="REPLACE" no="1754">
                    <text>such mutations have perturbed the ubiquitin binding function and disrupted in abnormal activation of the NF-kappaB pathway and subsequent activation of the.</text>
                    <arg n="0">such mutations</arg>
                    <arg n="1">the ubiquitin binding function</arg>
                    <arg n="R">abnormal activation of the NF-kappaB pathway and subsequent activation of the</arg>
                </example>
                <example src="REPLACE" no="1755">
                    <text>such mutations have perturbed the ubiquitin-binding function and disrupted in abnormal activation of the NF-kappaB pathway and subsequent activation of the.</text>
                    <arg n="0">such mutations</arg>
                    <arg n="1">the ubiquitin-binding function</arg>
                    <arg n="R">abnormal activation of the NF-kappaB pathway and subsequent activation of the</arg>
                </example>
                <example src="REPLACE" no="1756">
                    <text>such mutations rupture of the ubiquitin binding function may disrupting in abnormal activation of the NF-kappaB pathway and subsequent activation of the.</text>
                    <arg n="0">such mutations</arg>
                    <arg n="1">the ubiquitin binding function</arg>
                    <arg n="R">abnormal activation of the NF-kappaB pathway and subsequent activation of the</arg>
                </example>
                <example src="REPLACE" no="1757">
                    <text>such mutations rupture of the ubiquitin-binding function may disrupting in abnormal activation of the NF-kappaB pathway and subsequent activation of the.</text>
                    <arg n="0">such mutations</arg>
                    <arg n="1">the ubiquitin-binding function</arg>
                    <arg n="R">abnormal activation of the NF-kappaB pathway and subsequent activation of the</arg>
                </example>
                <example src="REPLACE" no="1758">
                    <text>such mutations that broke A1 will be identified in the siblings disrupted by classical abetalipoproteinemia.</text>
                    <arg n="0">such mutations</arg>
                </example>
                <example src="REPLACE" no="1759">
                    <text>such mutations that can disrupt the ubiquitin binding function has been identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">such mutations</arg>
                    <arg n="1">the ubiquitin binding function</arg>
                </example>
                <example src="REPLACE" no="1760">
                    <text>such mutations that can disrupt the ubiquitin binding function that has been identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">such mutations</arg>
                    <arg n="1">the ubiquitin binding function</arg>
                </example>
                <example src="REPLACE" no="1761">
                    <text>such mutations that can disrupt the ubiquitin-binding function has been identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">such mutations</arg>
                    <arg n="1">the ubiquitin-binding function</arg>
                </example>
                <example src="REPLACE" no="1762">
                    <text>such mutations that can disrupt the ubiquitin-binding function that has been identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">such mutations</arg>
                    <arg n="1">the ubiquitin-binding function</arg>
                </example>
                <example src="REPLACE" no="1763">
                    <text>such mutations that has disrupted A1 will be identified in the affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">such mutations</arg>
                </example>
                <example src="REPLACE" no="1764">
                    <text>such mutations that has disrupted the ubiquitin binding function was identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">such mutations</arg>
                    <arg n="1">the ubiquitin binding function</arg>
                </example>
                <example src="REPLACE" no="1765">
                    <text>such mutations that has disrupted the ubiquitin-binding function was identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">such mutations</arg>
                    <arg n="1">the ubiquitin-binding function</arg>
                </example>
                <example src="REPLACE" no="1766">
                    <text>such mutations that interact with the keto groups of the base pair GO and C (blue) on either side of the dsDNA can disrupt the ubiquitin binding function.</text>
                    <arg n="0">such mutations</arg>
                    <arg n="1">the ubiquitin binding function</arg>
                </example>
                <example src="REPLACE" no="1767">
                    <text>such mutations that interact with the keto groups of the base pair GO and C (blue) on either side of the dsDNA can disrupt the ubiquitin-binding function.</text>
                    <arg n="0">such mutations</arg>
                    <arg n="1">the ubiquitin-binding function</arg>
                </example>
                <example src="REPLACE" no="1768">
                    <text>such mutations that interacts with the keto and C group pair (blue) on both sides of the dsDNA can disrupt the ubiquitin binding function.</text>
                    <arg n="0">such mutations</arg>
                    <arg n="1">the ubiquitin binding function</arg>
                </example>
                <example src="REPLACE" no="1769">
                    <text>such mutations that interacts with the keto and C group pair (blue) on both sides of the dsDNA can disrupt the ubiquitin-binding function.</text>
                    <arg n="0">such mutations</arg>
                    <arg n="1">the ubiquitin-binding function</arg>
                </example>
                <example src="REPLACE" no="1770">
                    <text>the Lys147Ala substitution broke a sequence of the interaction disrupted in R (exon 5 spike).</text>
                    <arg n="0">the Lys147Ala substitution</arg>
                    <arg n="1">the interaction</arg>
                </example>
                <example src="REPLACE" no="1771">
                    <text>the Lys147Ala substitution broke the the interaction and disrupted to the a drastic decrease in activity against GO:C substrates.</text>
                    <arg n="0">the Lys147Ala substitution</arg>
                    <arg n="1">the interaction</arg>
                    <arg n="R">a drastic decrease in activity against GO:C substrates</arg>
                </example>
                <example src="REPLACE" no="1772">
                    <text>the Lys147Ala substitution broke the the interaction and disrupted to the a drastic decrease of activity against GO:C substrates.</text>
                    <arg n="0">the Lys147Ala substitution</arg>
                    <arg n="1">the interaction</arg>
                    <arg n="R">a drastic decrease of activity against GO:C substrates</arg>
                </example>
                <example src="REPLACE" no="1773">
                    <text>the Lys147Ala substitution can disrupt with the base groups ceto and C (blue) on both sides of the dsDNA DNA and interrupt the interaction.</text>
                    <arg n="0">the Lys147Ala substitution</arg>
                    <arg n="1">the interaction</arg>
                </example>
                <example src="REPLACE" no="1774">
                    <text>the Lys147Ala substitution have perturbed the interaction and disrupted in a drastic decrease in activity against GO:C substrates.</text>
                    <arg n="0">the Lys147Ala substitution</arg>
                    <arg n="1">the interaction</arg>
                    <arg n="R">a drastic decrease in activity against GO:C substrates</arg>
                </example>
                <example src="REPLACE" no="1775">
                    <text>the Lys147Ala substitution have perturbed the interaction and disrupted in a drastic decrease of activity against GO:C substrates.</text>
                    <arg n="0">the Lys147Ala substitution</arg>
                    <arg n="1">the interaction</arg>
                    <arg n="R">a drastic decrease of activity against GO:C substrates</arg>
                </example>
                <example src="REPLACE" no="1776">
                    <text>the Lys147Ala substitution rupture of the interaction may disrupting in a drastic decrease in activity against GO:C substrates.</text>
                    <arg n="0">the Lys147Ala substitution</arg>
                    <arg n="1">the interaction</arg>
                    <arg n="R">a drastic decrease in activity against GO:C substrates</arg>
                </example>
                <example src="REPLACE" no="1777">
                    <text>the Lys147Ala substitution rupture of the interaction may disrupting in a drastic decrease of activity against GO:C substrates.</text>
                    <arg n="0">the Lys147Ala substitution</arg>
                    <arg n="1">the interaction</arg>
                    <arg n="R">a drastic decrease of activity against GO:C substrates</arg>
                </example>
                <example src="REPLACE" no="1778">
                    <text>the Lys147Ala substitution that broke A1 will be identified in the siblings disrupted by classical abetalipoproteinemia.</text>
                    <arg n="0">the Lys147Ala substitution</arg>
                </example>
                <example src="REPLACE" no="1779">
                    <text>the Lys147Ala substitution that can disrupt the interaction has been identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">the Lys147Ala substitution</arg>
                    <arg n="1">the interaction</arg>
                </example>
                <example src="REPLACE" no="1780">
                    <text>the Lys147Ala substitution that can disrupt the interaction that has been identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">the Lys147Ala substitution</arg>
                    <arg n="1">the interaction</arg>
                </example>
                <example src="REPLACE" no="1781">
                    <text>the Lys147Ala substitution that has disrupted A1 will be identified in the affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">the Lys147Ala substitution</arg>
                </example>
                <example src="REPLACE" no="1782">
                    <text>the Lys147Ala substitution that has disrupted the interaction was identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">the Lys147Ala substitution</arg>
                    <arg n="1">the interaction</arg>
                </example>
                <example src="REPLACE" no="1783">
                    <text>the Lys147Ala substitution that interact with the keto groups of the base pair GO and C (blue) on either side of the dsDNA can disrupt the interaction.</text>
                    <arg n="0">the Lys147Ala substitution</arg>
                    <arg n="1">the interaction</arg>
                </example>
                <example src="REPLACE" no="1784">
                    <text>the Lys147Ala substitution that interacts with the keto and C group pair (blue) on both sides of the dsDNA can disrupt the interaction.</text>
                    <arg n="0">the Lys147Ala substitution</arg>
                    <arg n="1">the interaction</arg>
                </example>
                <example src="REPLACE" no="1785">
                    <text>these mutations broke a sequence of biquitin binding function disrupted in R (exon 5 spike).</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">biquitin binding function</arg>
                </example>
                <example src="REPLACE" no="1786">
                    <text>these mutations can disrupt with the base groups ceto and C (blue) on both sides of the dsDNA DNA and interrupt biquitin binding function.</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">biquitin binding function</arg>
                </example>
                <example src="REPLACE" no="1787">
                    <text>these mutations that broke A1 will be identified in the siblings disrupted by classical abetalipoproteinemia.</text>
                    <arg n="0">these mutations</arg>
                </example>
                <example src="REPLACE" no="1788">
                    <text>these mutations that can disrupt biquitin binding function has been identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">biquitin binding function</arg>
                </example>
                <example src="REPLACE" no="1789">
                    <text>these mutations that can disrupt biquitin binding function that has been identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">biquitin binding function</arg>
                </example>
                <example src="REPLACE" no="1790">
                    <text>these mutations that has disrupted A1 will be identified in the affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">these mutations</arg>
                </example>
                <example src="REPLACE" no="1791">
                    <text>these mutations that has disrupted biquitin binding function was identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">biquitin binding function</arg>
                </example>
                <example src="REPLACE" no="1792">
                    <text>these mutations that interact with the keto groups of the base pair GO and C (blue) on either side of the dsDNA can disrupt biquitin binding function.</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">biquitin binding function</arg>
                </example>
                <example src="REPLACE" no="1793">
                    <text>these mutations that interacts with the keto and C group pair (blue) on both sides of the dsDNA can disrupt biquitin binding function.</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">biquitin binding function</arg>
                </example>
                <example src="REPLACE" no="1794">
                    <text>this deletion broke a sequence of consensus signal 5 disrupted in R (exon 5 spike).</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">consensus signal 5</arg>
                </example>
                <example src="REPLACE" no="1795">
                    <text>this deletion broke the consensus signal 5 and disrupted to the exon skipping.</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">consensus signal 5</arg>
                    <arg n="R">exon skipping</arg>
                </example>
                <example src="REPLACE" no="1796">
                    <text>this deletion can disrupt with the base groups ceto and C (blue) on both sides of the dsDNA DNA and interrupt consensus signal 5.</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">consensus signal 5</arg>
                </example>
                <example src="REPLACE" no="1797">
                    <text>this deletion have perturbed consensus signal 5 and disrupted in exon skipping.</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">consensus signal 5</arg>
                    <arg n="R">exon skipping</arg>
                </example>
                <example src="REPLACE" no="1798">
                    <text>this deletion rupture of consensus signal 5 may disrupting in exon skipping.</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">consensus signal 5</arg>
                    <arg n="R">exon skipping</arg>
                </example>
                <example src="REPLACE" no="1799">
                    <text>this deletion that broke A1 will be identified in the siblings disrupted by classical abetalipoproteinemia.</text>
                    <arg n="0">this deletion</arg>
                </example>
                <example src="REPLACE" no="1800">
                    <text>this deletion that can disrupt consensus signal 5 has been identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">consensus signal 5</arg>
                </example>
                <example src="REPLACE" no="1801">
                    <text>this deletion that can disrupt consensus signal 5 that has been identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">consensus signal 5</arg>
                </example>
                <example src="REPLACE" no="1802">
                    <text>this deletion that has disrupted A1 will be identified in the affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">this deletion</arg>
                </example>
                <example src="REPLACE" no="1803">
                    <text>this deletion that has disrupted consensus signal 5 was identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">consensus signal 5</arg>
                </example>
                <example src="REPLACE" no="1804">
                    <text>this deletion that interact with the keto groups of the base pair GO and C (blue) on either side of the dsDNA can disrupt consensus signal 5.</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">consensus signal 5</arg>
                </example>
                <example src="REPLACE" no="1805">
                    <text>this deletion that interacts with the keto and C group pair (blue) on both sides of the dsDNA can disrupt consensus signal 5.</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">consensus signal 5</arg>
                </example>
                <example src="REPLACE" no="1806">
                    <text>this suppression broke a sequence of consensus signal 5 disrupted in R (exon 5 spike).</text>
                    <arg n="0">this suppression</arg>
                    <arg n="1">consensus signal 5</arg>
                </example>
                <example src="REPLACE" no="1807">
                    <text>this suppression broke the consensus signal 5 and disrupted to the exon signal.</text>
                    <arg n="0">this suppression</arg>
                    <arg n="1">consensus signal 5</arg>
                    <arg n="R">exon signal</arg>
                </example>
                <example src="REPLACE" no="1808">
                    <text>this suppression can disrupt with the base groups ceto and C (blue) on both sides of the dsDNA DNA and interrupt consensus signal 5.</text>
                    <arg n="0">this suppression</arg>
                    <arg n="1">consensus signal 5</arg>
                </example>
                <example src="REPLACE" no="1809">
                    <text>this suppression have perturbed consensus signal 5 and disrupted in exon signal.</text>
                    <arg n="0">this suppression</arg>
                    <arg n="1">consensus signal 5</arg>
                    <arg n="R">exon signal</arg>
                </example>
                <example src="REPLACE" no="1810">
                    <text>this suppression rupture of consensus signal 5 may disrupting in exon signal.</text>
                    <arg n="0">this suppression</arg>
                    <arg n="1">consensus signal 5</arg>
                    <arg n="R">exon signal</arg>
                </example>
                <example src="REPLACE" no="1811">
                    <text>this suppression that broke A1 will be identified in the siblings disrupted by classical abetalipoproteinemia.</text>
                    <arg n="0">this suppression</arg>
                </example>
                <example src="REPLACE" no="1812">
                    <text>this suppression that can disrupt consensus signal 5 has been identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">this suppression</arg>
                    <arg n="1">consensus signal 5</arg>
                </example>
                <example src="REPLACE" no="1813">
                    <text>this suppression that can disrupt consensus signal 5 that has been identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">this suppression</arg>
                    <arg n="1">consensus signal 5</arg>
                </example>
                <example src="REPLACE" no="1814">
                    <text>this suppression that has disrupted A1 will be identified in the affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">this suppression</arg>
                </example>
                <example src="REPLACE" no="1815">
                    <text>this suppression that has disrupted consensus signal 5 was identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">this suppression</arg>
                    <arg n="1">consensus signal 5</arg>
                </example>
                <example src="REPLACE" no="1816">
                    <text>this suppression that interact with the keto groups of the base pair GO and C (blue) on either side of the dsDNA can disrupt consensus signal 5.</text>
                    <arg n="0">this suppression</arg>
                    <arg n="1">consensus signal 5</arg>
                </example>
                <example src="REPLACE" no="1817">
                    <text>this suppression that interacts with the keto and C group pair (blue) on both sides of the dsDNA can disrupt consensus signal 5.</text>
                    <arg n="0">this suppression</arg>
                    <arg n="1">consensus signal 5</arg>
                </example>
                <example src="REPLACE" no="1818">
                    <text>tumour binding system 2 maneuver broke a sequence of tumour vessels disrupted in R (exon 5 spike).</text>
                    <arg n="0">tumour binding system 2 maneuver</arg>
                    <arg n="1">tumour vessels</arg>
                </example>
                <example src="REPLACE" no="1819">
                    <text>tumour binding system 2 maneuver broke the tumour vessels and disrupted to the similar effects on peripheral nerves.</text>
                    <arg n="0">tumour binding system 2 maneuver</arg>
                    <arg n="1">tumour vessels</arg>
                    <arg n="R">similar effects on peripheral nerves</arg>
                </example>
                <example src="REPLACE" no="1820">
                    <text>tumour binding system 2 maneuver can disrupt with the base groups ceto and C (blue) on both sides of the dsDNA DNA and interrupt tumour vessels.</text>
                    <arg n="0">tumour binding system 2 maneuver</arg>
                    <arg n="1">tumour vessels</arg>
                </example>
                <example src="REPLACE" no="1821">
                    <text>tumour binding system 2 maneuver have perturbed tumour vessels and disrupted in similar effects on peripheral nerves.</text>
                    <arg n="0">tumour binding system 2 maneuver</arg>
                    <arg n="1">tumour vessels</arg>
                    <arg n="R">similar effects on peripheral nerves</arg>
                </example>
                <example src="REPLACE" no="1822">
                    <text>tumour binding system 2 maneuver rupture of tumour vessels may disrupting in similar effects on peripheral nerves.</text>
                    <arg n="0">tumour binding system 2 maneuver</arg>
                    <arg n="1">tumour vessels</arg>
                    <arg n="R">similar effects on peripheral nerves</arg>
                </example>
                <example src="REPLACE" no="1823">
                    <text>tumour binding system 2 maneuver that broke A1 will be identified in the siblings disrupted by classical abetalipoproteinemia.</text>
                    <arg n="0">tumour binding system 2 maneuver</arg>
                </example>
                <example src="REPLACE" no="1824">
                    <text>tumour binding system 2 maneuver that can disrupt tumour vessels has been identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">tumour binding system 2 maneuver</arg>
                    <arg n="1">tumour vessels</arg>
                </example>
                <example src="REPLACE" no="1825">
                    <text>tumour binding system 2 maneuver that can disrupt tumour vessels that has been identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">tumour binding system 2 maneuver</arg>
                    <arg n="1">tumour vessels</arg>
                </example>
                <example src="REPLACE" no="1826">
                    <text>tumour binding system 2 maneuver that has disrupted A1 will be identified in the affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">tumour binding system 2 maneuver</arg>
                </example>
                <example src="REPLACE" no="1827">
                    <text>tumour binding system 2 maneuver that has disrupted tumour vessels was identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">tumour binding system 2 maneuver</arg>
                    <arg n="1">tumour vessels</arg>
                </example>
                <example src="REPLACE" no="1828">
                    <text>tumour binding system 2 maneuver that interact with the keto groups of the base pair GO and C (blue) on either side of the dsDNA can disrupt tumour vessels.</text>
                    <arg n="0">tumour binding system 2 maneuver</arg>
                    <arg n="1">tumour vessels</arg>
                </example>
                <example src="REPLACE" no="1829">
                    <text>tumour binding system 2 maneuver that interacts with the keto and C group pair (blue) on both sides of the dsDNA can disrupt tumour vessels.</text>
                    <arg n="0">tumour binding system 2 maneuver</arg>
                    <arg n="1">tumour vessels</arg>
                </example>
            </roleset>
        </predicate>
    </framesest>
</PASBIO>
